<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:GENE="http://gtglabs.com/20230630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_IFRS%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_GENE_gtglabs.com_20230630 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20220701_20230630 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0001166272 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_07A_XDX_form20%2Df.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_077_SO_form20%2Df.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_065_USD_0_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_064_AUD_1_iso4217%2D%2DAUD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_AUDPShares_0_iso4217%2D%2DAUD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_064_Integer_5_Integer -->
<!-- Field: Set; Name: xdx; ID: xdx_06E_CAD_0_iso4217%2D%2DCAD -->
<!-- Field: Set; Name: xdx; ID: xdx_065_EUR_0_iso4217%2D%2DEUR -->
<!-- Field: Set; Name: xdx; ID: xdx_061_GBP_0_iso4217%2D%2DGBP -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:EntityCentralIndexKey">0001166272</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionIncomeExpense" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl0078" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl0118" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="AsOf2023-06-30" id="xdx2ixbrl0198" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherNoncurrentAssets" contextRef="AsOf2022-06-30" id="xdx2ixbrl0199" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2022-06-30" id="xdx2ixbrl0202" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl0295" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl0297" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl0301" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:PaymentForPurchaseOfBusinessNetOfCashAcquired" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl0305" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl0316" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl0327" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl0328" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-07-012021-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0356" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-07-012021-06-30_ifrs-full_OtherReservesMember" id="xdx2ixbrl0357" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2020-07-012021-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0361" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2020-07-012021-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0363" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2020-07-012021-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0366" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2020-07-012021-06-30_ifrs-full_OtherReservesMember" id="xdx2ixbrl0377" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2020-07-012021-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0378" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ExerciseOfOptionsWarrants" contextRef="From2020-07-012021-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0383" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:IssueOfPerformanceRights" contextRef="From2020-07-012021-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0386" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:IssueOfPerformanceRights" contextRef="From2020-07-012021-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0388" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:OptionsWarrantsExpired" contextRef="From2020-07-012021-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0391" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:OptionsWarrantsExpired" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl0394" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:IssueOfOptionsWarrants" contextRef="From2020-07-012021-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0406" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:IssueOfOptionsWarrants" contextRef="From2020-07-012021-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0408" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-07-012022-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0421" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-07-012022-06-30_ifrs-full_OtherReservesMember" id="xdx2ixbrl0422" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2021-07-012022-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0426" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2021-07-012022-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0428" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-07-012022-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0431" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2021-07-012022-06-30_ifrs-full_OtherReservesMember" id="xdx2ixbrl0442" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2021-07-012022-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0443" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:IssueOfPerformanceRights" contextRef="From2021-07-012022-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0446" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:IssueOfPerformanceRights" contextRef="From2021-07-012022-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0448" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="From2021-07-012022-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0453" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2022-07-012023-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0466" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2022-07-012023-06-30_ifrs-full_OtherReservesMember" id="xdx2ixbrl0467" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2022-07-012023-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0471" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2022-07-012023-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0473" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2022-07-012023-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0476" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2022-07-012023-06-30_ifrs-full_OtherReservesMember" id="xdx2ixbrl0487" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2022-07-012023-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0488" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ValuationOfWarrants" contextRef="From2022-07-012023-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0493" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ValuationOfWarrants" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl0494" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ExerciseOfPerformanceRights" contextRef="From2022-07-012023-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0498" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ExerciseOfPerformanceRights" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl0499" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:OptionsWarrantsExpired" contextRef="From2022-07-012023-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0501" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:OptionsWarrantsExpired" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl0504" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:IssueOfPerformanceRights" contextRef="From2022-07-012023-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0506" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:IssueOfPerformanceRights" contextRef="From2022-07-012023-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0508" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_EasyDNABrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" id="xdx2ixbrl0621" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_AffinityDNABrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" id="xdx2ixbrl0625" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_AffinityDNABrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" id="xdx2ixbrl0627" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_LicenseFeesMember_ifrs-full_GoodsOrServicesTransferredOverTimeMember" id="xdx2ixbrl0634" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_EuropeMiddleEastAndAfricaMember" id="xdx2ixbrl0647" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_LatinAmericasMember" id="xdx2ixbrl0650" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_AsiaPacificsMember" id="xdx2ixbrl0653" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ContractAssets" contextRef="AsOf2022-06-30" id="xdx2ixbrl0666" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl0668" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:PerformanceObligations" contextRef="AsOf2022-06-30" id="xdx2ixbrl0670" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:PerformanceObligations" contextRef="AsOf2021-06-30" id="xdx2ixbrl0672" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ExportMarketingAndDevelopmentGrant" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl0682" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ExportMarketingAndDevelopmentGrant" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl0683" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:RevenueFromGovernmentGrants" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl0690" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:RevenueFromGovernmentGrants" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl0691" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:NetUnrealisedForeignExchangeGain" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl0696" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:NetUnrealisedForeignExchangeLoss" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl0767" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NetForeignExchangeLoss" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl0770" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NetForeignExchangeLoss" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl0771" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NetForeignExchangeLoss" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl0772" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TaxEffectOfImpairmentOfGoodwill" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl0846" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TaxEffectOfImpairmentOfGoodwill" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl0847" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:TaxEffectFromOtherAssessableItems" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl0849" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:TaxEffectFromOtherAssessableItems" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl0850" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:TaxEffectFromOtherAssessableItems" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl0851" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:UtilizationOfTaxLossesNotPreviouslyRecognized" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl0878" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:UtilizationOfTaxLossesNotPreviouslyRecognized" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl0879" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl0883" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="AsOf2021-06-30_ifrs-full_BrandNamesMember" id="xdx2ixbrl0889" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="AsOf2021-06-30" id="xdx2ixbrl0893" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:TaxEffectOfTaxLoss" contextRef="AsOf2022-06-30" id="xdx2ixbrl0896" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:TaxEffectOfTaxLoss" contextRef="AsOf2021-06-30" id="xdx2ixbrl0897" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2022-06-30" id="xdx2ixbrl0900" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2021-06-30" id="xdx2ixbrl0901" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2023-06-30_ifrs-full_PropertyPlantAndEquipmentMember" id="xdx2ixbrl0903" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2022-06-30_ifrs-full_PropertyPlantAndEquipmentMember" id="xdx2ixbrl0904" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2021-06-30_custom_TradeDebtorMember" id="xdx2ixbrl0909" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NetDeferredTaxAssets" contextRef="AsOf2023-06-30" id="xdx2ixbrl0939" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NetDeferredTaxAssets" contextRef="AsOf2021-06-30" id="xdx2ixbrl0941" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2021-06-30_custom_MTMember" id="xdx2ixbrl0985" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2022-06-30_custom_UKMember" id="xdx2ixbrl0995" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2021-06-30_custom_UKMember" id="xdx2ixbrl0997" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TaxEffectOfTaxLosses" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl1025" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" contextRef="AsOf2023-06-30" id="xdx2ixbrl1039" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl1081" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossTradeReceivables" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl1097" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl1100" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl1101" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AdjustmentsForInventoryWrittenoff" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl1107" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AdjustmentsForDecreaseIncreaseInNonCurrentAssets" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl1139" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AdjustmentsForDecreaseIncreaseInNonCurrentAssets" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl1141" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:FinancingFacilityUsedUnderCreditCards" contextRef="AsOf2022-06-30" id="xdx2ixbrl1163" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" contextRef="AsOf2023-06-30" id="xdx2ixbrl1206" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:LessCostWrittenoffDuringYear" contextRef="From2021-07-012022-06-30_custom_LaboratoryEquipmentMember" id="xdx2ixbrl1222" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AccumulatedDepreciationWrittenoff" contextRef="From2021-07-012022-06-30_custom_LaboratoryEquipmentMember" id="xdx2ixbrl1234" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:LessCostWrittenoffDuringYear" contextRef="From2021-07-012022-06-30_ifrs-full_ComputerEquipmentMember" id="xdx2ixbrl1246" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:LessCostTransferred" contextRef="From2021-07-012022-06-30_ifrs-full_ComputerEquipmentMember" id="xdx2ixbrl1250" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:PropertyEquipmentAccumulatedDepreciationTransferred" contextRef="From2021-07-012022-06-30_ifrs-full_ComputerEquipmentMember" id="xdx2ixbrl1262" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AccumulatedDepreciationWrittenoff" contextRef="From2021-07-012022-06-30_ifrs-full_ComputerEquipmentMember" id="xdx2ixbrl1266" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:LessCostWrittenoffDuringYear" contextRef="From2022-07-012023-06-30_ifrs-full_OfficeEquipmentMember" id="xdx2ixbrl1276" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:LessCostWrittenoffDuringYear" contextRef="From2021-07-012022-06-30_ifrs-full_OfficeEquipmentMember" id="xdx2ixbrl1278" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AddCostTransferred" contextRef="From2021-07-012022-06-30_ifrs-full_OfficeEquipmentMember" id="xdx2ixbrl1282" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2022-07-012023-06-30_ifrs-full_OfficeEquipmentMember" id="xdx2ixbrl1284" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:PropertyEquipmentAccumulatedDepreciationTransferred" contextRef="From2021-07-012022-06-30_ifrs-full_OfficeEquipmentMember" id="xdx2ixbrl1294" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AccumulatedDepreciationWrittenoff" contextRef="From2022-07-012023-06-30_ifrs-full_OfficeEquipmentMember" id="xdx2ixbrl1296" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AccumulatedDepreciationWrittenoff" contextRef="From2021-07-012022-06-30_ifrs-full_OfficeEquipmentMember" id="xdx2ixbrl1298" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:LessCostWrittenoffDuringYear" contextRef="From2021-07-012022-06-30_ifrs-full_GrossCarryingAmountMember" id="xdx2ixbrl1318" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AccumulatedDepreciationWrittenoff" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl1330" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AddForeignCurrencyTranslation" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl1338" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" contextRef="From2022-07-012023-06-30_custom_LaboratoryEquipmentsMember" id="xdx2ixbrl1354" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ForeignCurrencyTranslation" contextRef="From2022-07-012023-06-30_custom_ComputerEquipmentsMember" id="xdx2ixbrl1370" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2022-07-012023-06-30_ifrs-full_OfficeEquipmentMember" id="xdx2ixbrl1376" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl1390" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="From2021-07-012022-06-30_custom_LaboratoryEquipmentsMember" id="xdx2ixbrl1402" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="From2021-07-012022-06-30_custom_ComputerEquipmentsMember" id="xdx2ixbrl1412" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="From2021-07-012022-06-30_ifrs-full_OfficeEquipmentMember" id="xdx2ixbrl1422" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl1432" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2021-06-30_ifrs-full_GrossCarryingAmountMember" id="xdx2ixbrl1443" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2022-06-30_ifrs-full_AccumulatedImpairmentMember" id="xdx2ixbrl1451" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2021-06-30_ifrs-full_AccumulatedImpairmentMember" id="xdx2ixbrl1452" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill" contextRef="From2021-07-012022-06-30_ifrs-full_AccumulatedImpairmentMember" id="xdx2ixbrl1455" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2022-06-30_ifrs-full_AccumulatedImpairmentMember" id="xdx2ixbrl1458" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl1471" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember" id="xdx2ixbrl1498" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherIntangibleAssets" contextRef="AsOf2021-06-30_ifrs-full_GrossCarryingAmountMember" id="xdx2ixbrl1509" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="From2022-07-012023-06-30_ifrs-full_GrossCarryingAmountMember_custom_DomainNamesMember" id="xdx2ixbrl1514" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherIntangibleAssets" contextRef="AsOf2021-06-30_ifrs-full_AccumulatedImpairmentMember" id="xdx2ixbrl1521" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-07-142022-07-14_custom_AffinityDNAMember" id="xdx2ixbrl1569" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">P5Y</ix:nonNumeric>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" contextRef="From2021-07-012022-06-30_custom_AnnualLeaveProvisionMember" id="xdx2ixbrl1670" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:UnusedProvisionReversedOtherProvisions" contextRef="From2021-07-012022-06-30_custom_LongServiceLeaveProvisionMember" id="xdx2ixbrl1682" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ProvisionsPaidoffOtherProvisions" contextRef="From2021-07-012022-06-30_custom_LongServiceLeaveProvisionMember" id="xdx2ixbrl1685" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ExerciseOfPerformanceRightsShares" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl1743" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ShareIssueRelatedCostShares" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl1747" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ValuationOfWarrantsToBeIssuedShares" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl1751" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ShareIssueRelatedCostShares" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl1767" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:IncreaseDecreaseThroughSharebasedPaymentExpense" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl1828" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:IncreaseDecreaseThroughSharebasedPaymentExpense" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl1829" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AddValuationOfWarrants" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl1835" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ShareBasedPaymentReseveExerciseOfOptionswarrants" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl1838" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ShareBasedPaymentsReserveExerciseOfPerformanceRights" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl1841" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2020-07-012021-06-30_custom_EmployeeOptionPlanMember" id="xdx2ixbrl1936" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2022-07-012023-06-30_custom_AdamKramerMember" id="xdx2ixbrl1980" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2022-07-012023-06-30_custom_MikeTonroeMember" id="xdx2ixbrl1982" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2022-07-012023-06-30_custom_CarlStubbingsMember" id="xdx2ixbrl1984" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2022-07-012023-06-30_custom_KevinCamilleriMember" id="xdx2ixbrl1986" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:OptionsExpiration" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl2063" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2021-07-012022-06-30_custom_EmployeeOptionPlanMember" id="xdx2ixbrl2072" decimals="INF" unitRef="Shares">0</ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="From2021-07-012022-06-30_custom_EmployeeOptionPlanMember" id="xdx2ixbrl2096" unitRef="AUDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="From2021-07-012022-06-30_custom_EmployeeOptionPlanMember" id="xdx2ixbrl2098" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="From2022-07-012023-06-30_custom_EmployeeSharePlansMember" id="xdx2ixbrl2118" unitRef="AUDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2022-07-012023-06-30_custom_EmployeeSharePlansMember" id="xdx2ixbrl2120" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="From2021-07-012022-06-30_custom_EmployeeSharePlansMember" id="xdx2ixbrl2122" unitRef="AUDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2021-07-012022-06-30_custom_EmployeeSharePlansMember" id="xdx2ixbrl2124" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" contextRef="From2022-07-012023-06-30_custom_EmployeeSharePlansMember" id="xdx2ixbrl2126" unitRef="AUDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="From2022-07-012023-06-30_custom_EmployeeSharePlansMember" id="xdx2ixbrl2128" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="From2021-07-012022-06-30_custom_EmployeeSharePlansMember" id="xdx2ixbrl2138" unitRef="AUDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="From2021-07-012022-06-30_custom_EmployeeSharePlansMember" id="xdx2ixbrl2140" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2023-06-30_custom_UnlistedOptionsToVariousUnderwritersMember" id="xdx2ixbrl2152" unitRef="AUDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2023-06-30_custom_UnlistedOptionsToVariousUnderwritersMember" id="xdx2ixbrl2154" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2023-06-30_custom_UnlistedOptionsToDirectorsMember" id="xdx2ixbrl2160" unitRef="AUDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2023-06-30_custom_UnlistedOptionsToDirectorsMember" id="xdx2ixbrl2162" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2023-06-30_custom_UnlistedOptionsOptionsIssuedLodgeCorporatePtyLtdMember" id="xdx2ixbrl2168" unitRef="AUDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2023-06-30_custom_UnlistedOptionsOptionsIssuedLodgeCorporatePtyLtdMember" id="xdx2ixbrl2170" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" id="xdx2ixbrl2213" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" id="xdx2ixbrl2218" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" id="xdx2ixbrl2219" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" id="xdx2ixbrl2245" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" id="xdx2ixbrl2263" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" id="xdx2ixbrl2264" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" id="xdx2ixbrl2268" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" id="xdx2ixbrl2270" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" id="xdx2ixbrl2283" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" id="xdx2ixbrl2284" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2309" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2314" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" id="xdx2ixbrl2315" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2319" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" id="xdx2ixbrl2320" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:RevenuesAndOtherIncome" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2324" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2329" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" id="xdx2ixbrl2330" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2334" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" id="xdx2ixbrl2335" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ChangesInInventoriesOfFinishedGoodsAndWorkInProgress" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2339" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2344" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" id="xdx2ixbrl2346" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2349" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2354" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2359" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2364" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" id="xdx2ixbrl2365" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2369" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" id="xdx2ixbrl2370" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:OtherSegmentExpenses" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2374" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:SegmentExpenses" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2379" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2384" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" id="xdx2ixbrl2385" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2389" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2022-06-30_custom_AffinityDNAMember90603468" id="xdx2ixbrl2394" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2022-06-30_custom_AffinityDNAMember90603468" id="xdx2ixbrl2402" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2410" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2411" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2415" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2416" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2420" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2421" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:RevenuesAndOtherIncome" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2425" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:RevenuesAndOtherIncome" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2426" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2430" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2431" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2435" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2436" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ChangesInInventoriesOfFinishedGoodsAndWorkInProgress" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2440" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ChangesInInventoriesOfFinishedGoodsAndWorkInProgress" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2441" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2445" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2446" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" id="xdx2ixbrl2447" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl2448" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2450" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2451" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2455" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2456" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2460" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2461" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2465" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2466" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2470" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2471" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:OtherSegmentExpenses" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2475" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:OtherSegmentExpenses" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2476" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:SegmentExpenses" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2480" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:SegmentExpenses" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2481" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2485" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2486" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" id="xdx2ixbrl2487" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl2488" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2490" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2491" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2495" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2497" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2503" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2505" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember_custom_EuropeMiddleEastAndAfricaMember" id="xdx2ixbrl2520" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember_custom_LatinAmericaContinentMember" id="xdx2ixbrl2525" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember_custom_AmericaAndCanadaMember" id="xdx2ixbrl2538" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember_custom_EuropeMiddleEastAndAfricaMember" id="xdx2ixbrl2543" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember_custom_EuropeMiddleEastAndAfricaMember" id="xdx2ixbrl2545" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember_custom_LatinAmericaContinentMember" id="xdx2ixbrl2548" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember_custom_LatinAmericaContinentMember" id="xdx2ixbrl2550" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember_custom_AsiaPacificContinentMember" id="xdx2ixbrl2553" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2558" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember_custom_AmericaAndCanadaMember" id="xdx2ixbrl2563" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember_custom_AmericaAndCanadaMember" id="xdx2ixbrl2564" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember_custom_EuropeMiddleEastAndAfricaMember" id="xdx2ixbrl2568" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember_custom_EuropeMiddleEastAndAfricaMember" id="xdx2ixbrl2569" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember_custom_EuropeMiddleEastAndAfricaMember" id="xdx2ixbrl2570" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_EuropeMiddleEastAndAfricaMember" id="xdx2ixbrl2571" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember_custom_LatinAmericaContinentMember" id="xdx2ixbrl2573" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember_custom_LatinAmericaContinentMember" id="xdx2ixbrl2574" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember_custom_LatinAmericaContinentMember" id="xdx2ixbrl2575" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_LatinAmericaContinentMember" id="xdx2ixbrl2576" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember_custom_AsiaPacificContinentMember" id="xdx2ixbrl2578" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember_custom_AsiaPacificContinentMember" id="xdx2ixbrl2579" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember_custom_AsiaPacificContinentMember" id="xdx2ixbrl2580" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_AsiaPacificContinentMember" id="xdx2ixbrl2581" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_AffinityDNAMember" id="xdx2ixbrl2583" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_EasyDNAMember" id="xdx2ixbrl2584" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2022-07-012023-06-30_custom_ClassEPerformanceRightsMember_custom_MrStanleySackMember" id="xdx2ixbrl2691" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2022-07-012023-06-30_custom_KentgroveCapitalPtyLtdMember" id="xdx2ixbrl2771" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2021-07-012022-06-30_custom_KentgroveCapitalPtyLtdMember" id="xdx2ixbrl2772" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2021-07-012022-06-30_custom_WarrantstobeIssuedHCWainwrightMember" id="xdx2ixbrl2776" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2020-07-012021-06-30_custom_WarrantstobeIssuedHCWainwrightMember" id="xdx2ixbrl2777" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2022-07-012023-06-30_custom_ReversalOfForfeitedPerformanceRightsMember" id="xdx2ixbrl2783" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2021-07-012022-06-30_custom_ReversalOfForfeitedPerformanceRightsMember" id="xdx2ixbrl2784" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2020-07-012021-06-30_custom_ReversalOfForfeitedPerformanceRightsMember" id="xdx2ixbrl2785" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2022-07-012023-06-30_custom_EmployeeStocksOptionsMember" id="xdx2ixbrl2787" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="From2022-07-012023-06-30_custom_PriceWaterHouseCoopersMember" id="xdx2ixbrl2801" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AuditorsRemunerationForAuditRelatedServices" contextRef="From2022-07-012023-06-30_custom_PriceWaterHouseCoopersMember" id="xdx2ixbrl2805" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AuditorsRemunerationForAuditRelatedServices" contextRef="From2021-07-012022-06-30_custom_PriceWaterHouseCoopersMember" id="xdx2ixbrl2806" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AuditorsRemunerationForAuditRelatedServices" contextRef="From2020-07-012021-06-30_custom_PriceWaterHouseCoopersMember" id="xdx2ixbrl2807" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AuditorsRemunerationForOtherServices" contextRef="From2022-07-012023-06-30_custom_PriceWaterHouseCoopersMember" id="xdx2ixbrl2809" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AuditorsRemunerationForOtherServices" contextRef="From2021-07-012022-06-30_custom_PriceWaterHouseCoopersMember" id="xdx2ixbrl2810" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AuditorsRemunerationForOtherServices" contextRef="From2020-07-012021-06-30_custom_PriceWaterHouseCoopersMember" id="xdx2ixbrl2811" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AuditorsRemunerationForAuditRelatedServices" contextRef="From2022-07-012023-06-30_custom_GrantThorntonAuditPtyLtdMember" id="xdx2ixbrl2817" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AuditorsRemunerationForAuditRelatedServices" contextRef="From2021-07-012022-06-30_custom_GrantThorntonAuditPtyLtdMember" id="xdx2ixbrl2818" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AuditorsRemunerationForAuditRelatedServices" contextRef="From2020-07-012021-06-30_custom_GrantThorntonAuditPtyLtdMember" id="xdx2ixbrl2819" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AuditorsRemunerationForOtherServices" contextRef="From2022-07-012023-06-30_custom_GrantThorntonAuditPtyLtdMember" id="xdx2ixbrl2821" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AuditOfFinancialReportsOfSubsidiaries" contextRef="From2022-07-012023-06-30_custom_GrantThorntonAuditPtyLtdMember" id="xdx2ixbrl2825" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AuditOfFinancialReportsOfSubsidiaries" contextRef="From2021-07-012022-06-30_custom_GrantThorntonAuditPtyLtdMember" id="xdx2ixbrl2826" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GENE:AuditOfFinancialReportsOfSubsidiaries" contextRef="From2020-07-012021-06-30_custom_GrantThorntonAuditPtyLtdMember" id="xdx2ixbrl2827" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ServicesReceivedRelatedPartyTransactions" contextRef="From2020-07-012021-06-30_custom_DrJerzyMuchnickisMember" id="xdx2ixbrl2890" decimals="0" scale="0" unitRef="AUD">0</ix:nonFraction>
  <ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl2910" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl2911" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" contextRef="From2020-07-012021-06-30" id="xdx2ixbrl2912" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2023-06-30_custom_GeneTypePtyLtdMember" id="xdx2ixbrl2930" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2022-06-30_custom_GeneTypePtyLtdMember" id="xdx2ixbrl2932" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2023-06-30_custom_GeneTypeCorporationMember" id="xdx2ixbrl2966" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2022-06-30_custom_GeneTypeCorporationMember" id="xdx2ixbrl2968" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2023-06-30_custom_HainanAochengGeneticTechnologiesCoLtdMember" id="xdx2ixbrl2990" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2022-06-30_custom_HainanAochengGeneticTechnologiesCoLtdMember" id="xdx2ixbrl2992" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2023-06-30_custom_GeneticTechnologiesHKLtdMember" id="xdx2ixbrl3002" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2022-06-30_custom_GeneticTechnologiesHKLtdMember" id="xdx2ixbrl3004" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2022-06-30_custom_HelixGeneticsMember" id="xdx2ixbrl3016" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2022-06-30_custom_GenetypeUKLimitedMember" id="xdx2ixbrl3028" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2022-06-30_custom_TradeAndOtherReceivablesMember" id="xdx2ixbrl3064" unitRef="CAD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2023-06-30_custom_SixAndTwelveMonthsMember" id="xdx2ixbrl3097" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2023-06-30_custom_BetweenOneAndTwoYearsMember" id="xdx2ixbrl3098" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2023-06-30_custom_BetweenTwoAndFiveYearsMember" id="xdx2ixbrl3099" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2023-06-30_custom_OverFiveYearsMember" id="xdx2ixbrl3100" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2022-06-30_custom_SixAndTwelveMonthsMember" id="xdx2ixbrl3121" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2022-06-30_custom_BetweenOneAndTwoYearsMember" id="xdx2ixbrl3122" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2022-06-30_custom_BetweenTwoAndFiveYearsMember" id="xdx2ixbrl3123" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2022-06-30_custom_OverFiveYearsMember" id="xdx2ixbrl3124" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2022-06-30_custom_OverFiveYearsMember" id="xdx2ixbrl3132" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_custom_OverFiveYearsMember" id="xdx2ixbrl3140" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2023-06-30_custom_PerformanceBondAndDepositsMember_ifrs-full_FloatingInterestRateMember" id="xdx2ixbrl3165" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2022-06-30_custom_PerformanceBondAndDepositsMember_ifrs-full_FloatingInterestRateMember" id="xdx2ixbrl3169" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_custom_BorrowingMember_ifrs-full_FloatingInterestRateMember" id="xdx2ixbrl3180" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_custom_BorrowingMember_ifrs-full_FixedInterestRateMember" id="xdx2ixbrl3181" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_custom_BorrowingMember" id="xdx2ixbrl3182" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_custom_BorrowingMember_ifrs-full_FloatingInterestRateMember" id="xdx2ixbrl3184" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_custom_BorrowingMember_ifrs-full_FixedInterestRateMember" id="xdx2ixbrl3185" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_custom_BorrowingMember" id="xdx2ixbrl3186" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_custom_LeasesMember_ifrs-full_FloatingInterestRateMember" id="xdx2ixbrl3187" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_custom_LeasesMember_ifrs-full_FloatingInterestRateMember" id="xdx2ixbrl3192" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_ifrs-full_FloatingInterestRateMember" id="xdx2ixbrl3197" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_ifrs-full_FixedInterestRateMember" id="xdx2ixbrl3198" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30" id="xdx2ixbrl3199" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_ifrs-full_FloatingInterestRateMember" id="xdx2ixbrl3200" unitRef="AUD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl3208" decimals="0" scale="0" unitRef="AUD">0</ix:nonFraction>
  <ix:nonFraction name="GENE:FrankingAccountBalance" contextRef="From2022-07-01to2023-06-30" id="xdx2ixbrl3210" decimals="0" scale="0" unitRef="AUD">0</ix:nonFraction>
  <ix:nonFraction name="GENE:FrankingAccountBalance" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl3212" decimals="0" scale="0" unitRef="AUD">0</ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="From2021-07-012022-06-30" id="xdx2ixbrl3268" decimals="0" scale="0" unitRef="AUD">0</ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="gene-20230630.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-07-01to2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_dei_BusinessContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AustralianGovernmentTaxIncentiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">GENE:AustralianGovernmentTaxIncentiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_BrandTradeMarkTradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:BrandTradeMarkTradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_PropertyPlantAndEquipmentsMember_ifrs-full_BottomOfRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:PropertyPlantAndEquipmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_PropertyPlantAndEquipmentsMember_ifrs-full_TopOfRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:PropertyPlantAndEquipmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_ifrs-full_FixturesAndFittingsMember_ifrs-full_BottomOfRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_ifrs-full_FixturesAndFittingsMember_ifrs-full_TopOfRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_ifrs-full_LeaseholdImprovementsMember_ifrs-full_BottomOfRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_ifrs-full_LeaseholdImprovementsMember_ifrs-full_TopOfRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_LeasedPlantandEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:LeasedPlantandEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EasyDNABrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">GENE:EasyDNABrandedTestsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_EasyDNABrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">GENE:EasyDNABrandedTestsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_EasyDNABrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">GENE:EasyDNABrandedTestsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AffinityDNABrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">GENE:AffinityDNABrandedTestsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_AffinityDNABrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">GENE:AffinityDNABrandedTestsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_AffinityDNABrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">GENE:AffinityDNABrandedTestsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_GeneTypeBrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">GENE:GeneTypeBrandedTestsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_GeneTypeBrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">GENE:GeneTypeBrandedTestsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_GeneTypeBrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">GENE:GeneTypeBrandedTestsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_LicenseFeesMember_ifrs-full_GoodsOrServicesTransferredOverTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">GENE:LicenseFeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_LicenseFeesMember_ifrs-full_GoodsOrServicesTransferredOverTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">GENE:LicenseFeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_LicenseFeesMember_ifrs-full_GoodsOrServicesTransferredOverTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">GENE:LicenseFeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AmericaAndCanadaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AmericaAndCanadaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_AmericaAndCanadaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AmericaAndCanadaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_AmericaAndCanadaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AmericaAndCanadaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EuropeMiddleEastAndAfricaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:EuropeMiddleEastAndAfricaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_EuropeMiddleEastAndAfricaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:EuropeMiddleEastAndAfricaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_EuropeMiddleEastAndAfricaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:EuropeMiddleEastAndAfricaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_LatinAmericasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:LatinAmericasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_LatinAmericasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:LatinAmericasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_LatinAmericasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:LatinAmericasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AsiaPacificsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AsiaPacificsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_AsiaPacificsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AsiaPacificsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_AsiaPacificsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AsiaPacificsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-042019-12-05_custom_AustralianGovernmentTaxIncentiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">GENE:AustralianGovernmentTaxIncentiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-04</xbrli:startDate>
        <xbrli:endDate>2019-12-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_AustralianGovernmentTaxIncentiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">GENE:AustralianGovernmentTaxIncentiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_BrandNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:BrandNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_ifrs-full_BrandNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:BrandNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_ifrs-full_BrandNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:BrandNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_PropertyPlantAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_ifrs-full_PropertyPlantAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_ifrs-full_PropertyPlantAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_TradeDebtorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">GENE:TradeDebtorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_TradeDebtorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">GENE:TradeDebtorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_TradeDebtorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">GENE:TradeDebtorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_CapitalRaisingCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">GENE:CapitalRaisingCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_CapitalRaisingCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">GENE:CapitalRaisingCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_CapitalRaisingCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">GENE:CapitalRaisingCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_IntangibleAssetsAndGoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_ifrs-full_IntangibleAssetsAndGoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_ifrs-full_IntangibleAssetsAndGoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_ProvisionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">GENE:ProvisionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_ProvisionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">GENE:ProvisionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_ProvisionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">GENE:ProvisionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_RightofuseAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_ifrs-full_RightofuseAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_ifrs-full_RightofuseAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_AUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_AUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_AUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_MTMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:MTMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_MTMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:MTMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_MTMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:MTMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_MTMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:MTMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_MTMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:MTMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_UKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:UKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_UKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:UKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_UKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:UKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_UKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:UKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_UKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:UKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_AUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_AUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_MTMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:MTMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_UKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:UKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_SubsidiariesUnitedStatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:SubsidiariesUnitedStatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_SubsidiariesUnitedStatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:SubsidiariesUnitedStatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_SubsidiariesUnitedStatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:SubsidiariesUnitedStatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_SubsidiariesAustraliaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:SubsidiariesAustraliaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_SubsidiariesAustraliaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:SubsidiariesAustraliaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_SubsidiariesAustraliaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:SubsidiariesAustraliaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_SubsidiariesMaltaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:SubsidiariesMaltaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_SubsidiariesMaltaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:SubsidiariesMaltaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_ifrs-full_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_ifrs-full_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_ifrs-full_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_ifrs-full_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_ifrs-full_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_ifrs-full_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_ifrs-full_GrossCarryingAmountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_ifrs-full_GrossCarryingAmountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_ifrs-full_GrossCarryingAmountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_ifrs-full_GrossCarryingAmountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_LaboratoryEquipmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:LaboratoryEquipmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_LaboratoryEquipmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:LaboratoryEquipmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_LaboratoryEquipmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:LaboratoryEquipmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_ComputerEquipmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:ComputerEquipmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_ComputerEquipmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:ComputerEquipmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_ComputerEquipmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:ComputerEquipmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_LaboratoryEquipmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:LaboratoryEquipmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_LaboratoryEquipmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:LaboratoryEquipmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_ComputerEquipmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:ComputerEquipmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_ComputerEquipmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">GENE:ComputerEquipmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_ifrs-full_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_ifrs-full_AccumulatedImpairmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_ifrs-full_AccumulatedImpairmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_ifrs-full_AccumulatedImpairmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_ifrs-full_AccumulatedImpairmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_AccumulatedImpairmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AffinityDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EasyDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_EasyDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_EasyDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_EasyDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_AffinityDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_AffinityDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EasyDNAMember_custom_RevenueGrowthMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">GENE:RevenueGrowthMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_RevenueGrowthMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">GENE:RevenueGrowthMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EasyDNAMember_custom_GrossMarginMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">GENE:GrossMarginMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_GrossMarginMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">GENE:GrossMarginMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EasyDNAMember_custom_PreTaxDiscountRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">GENE:PreTaxDiscountRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_PreTaxDiscountRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">GENE:PreTaxDiscountRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EasyDNAMember_custom_PostTaxDiscountRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">GENE:PostTaxDiscountRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_PostTaxDiscountRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">GENE:PostTaxDiscountRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EasyDNAMember_custom_BeyondFiscalYearTwoThousandTwentySevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">GENE:BeyondFiscalYearTwoThousandTwentySevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_BeyondFiscalYearTwoThousandTwentySevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">GENE:BeyondFiscalYearTwoThousandTwentySevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_BrandNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:BrandNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_BrandNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:BrandNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_ifrs-full_GrossCarryingAmountMember_custom_DomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">GENE:DomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_ifrs-full_GrossCarryingAmountMember_custom_DomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">GENE:DomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-14_custom_AffinityDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-142022-07-14_custom_AffinityDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-14</xbrli:startDate>
        <xbrli:endDate>2022-07-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-142023-06-30_custom_AffinityDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-14</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-13_custom_EasyDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-132021-08-13_custom_EasyDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-13</xbrli:startDate>
        <xbrli:endDate>2021-08-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-132022-06-30_custom_EasyDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-13</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_AnnualLeaveProvisionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">GENE:AnnualLeaveProvisionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_AnnualLeaveProvisionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">GENE:AnnualLeaveProvisionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_LongServiceLeaveProvisionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">GENE:LongServiceLeaveProvisionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_LongServiceLeaveProvisionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">GENE:LongServiceLeaveProvisionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_MakeGoodProvisionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">GENE:MakeGoodProvisionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_MakeGoodProvisionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">GENE:MakeGoodProvisionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_AnnualLeaveProvisionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">GENE:AnnualLeaveProvisionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AnnualLeaveProvisionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">GENE:AnnualLeaveProvisionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_AnnualLeaveProvisionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">GENE:AnnualLeaveProvisionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_LongServiceLeaveProvisionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">GENE:LongServiceLeaveProvisionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_LongServiceLeaveProvisionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">GENE:LongServiceLeaveProvisionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_LongServiceLeaveProvisionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">GENE:LongServiceLeaveProvisionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-19_custom_EasyDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-03_custom_EmployeeShareOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">GENE:EmployeeShareOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-07_custom_AmericanDepositarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">GENE:AmericanDepositarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-072023-02-07_custom_AmericanDepositarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">GENE:AmericanDepositarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-07</xbrli:startDate>
        <xbrli:endDate>2023-02-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-07_ifrs-full_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-072023-02-07_ifrs-full_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-07</xbrli:startDate>
        <xbrli:endDate>2023-02-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_WarrantsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:WarrantsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_WarrantsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:WarrantsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_WarrantsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:WarrantsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_WarrantsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:WarrantsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_WarrantsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:WarrantsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_WarrantsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:WarrantsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_EmployeeOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:EmployeeOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AdamKramerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:AdamKramerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_MikeTonroeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MikeTonroeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_CarlStubbingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:CarlStubbingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_KevinCamilleriMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:KevinCamilleriMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EmployeeOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:EmployeeOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_EmployeeOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:EmployeeOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_EmployeeOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:EmployeeOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_EmployeeOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:EmployeeOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_EmployeeOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:EmployeeOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_EmployeeSharePlansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:EmployeeSharePlansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_EmployeeSharePlansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:EmployeeSharePlansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EmployeeSharePlansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:EmployeeSharePlansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_EmployeeSharePlansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:EmployeeSharePlansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_EmployeeSharePlansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:EmployeeSharePlansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_UnlistedOptionsToVariousUnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:UnlistedOptionsToVariousUnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_UnlistedOptionsToVariousUnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:UnlistedOptionsToVariousUnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_UnlistedOptionsToDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:UnlistedOptionsToDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_UnlistedOptionsToDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:UnlistedOptionsToDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_UnlistedOptionsOptionsIssuedLodgeCorporatePtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:UnlistedOptionsOptionsIssuedLodgeCorporatePtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_UnlistedOptionsOptionsIssuedLodgeCorporatePtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:UnlistedOptionsOptionsIssuedLodgeCorporatePtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_UnlistedOptionsESOPOptionsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:UnlistedOptionsESOPOptionsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_UnlistedOptionsESOPOptionsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:UnlistedOptionsESOPOptionsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AffinityDNAMember90603109">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EasyDNAMember90603109">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_GeneTypeCorporateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_AffinityDNAMember90603250">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_EasyDNAMember90603265">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_GeneTypeCorporateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_AffinityDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_EasyDNAMember90603328">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_GeneTypeCorporateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_AffinityDNAMember90603468">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_EasyDNAMember90603484">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_GeneTypeCorporateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_AffinityDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_EasyDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_GeneTypeCorporateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_AffinityDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_EasyDNAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_GeneTypeCorporateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_AmericaAndCanadaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AmericaAndCanadaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EasyDNAMember_custom_AmericaAndCanadaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AmericaAndCanadaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_GeneTypeCorporateMember_custom_AmericaAndCanadaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AmericaAndCanadaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_EuropeMiddleEastAndAfricaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:EuropeMiddleEastAndAfricaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EasyDNAMember_custom_EuropeMiddleEastAndAfricaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:EuropeMiddleEastAndAfricaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_GeneTypeCorporateMember_custom_EuropeMiddleEastAndAfricaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:EuropeMiddleEastAndAfricaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_LatinAmericaContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:LatinAmericaContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EasyDNAMember_custom_LatinAmericaContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:LatinAmericaContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_GeneTypeCorporateMember_custom_LatinAmericaContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:LatinAmericaContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_LatinAmericaContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:LatinAmericaContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_AsiaPacificContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AsiaPacificContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EasyDNAMember_custom_AsiaPacificContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AsiaPacificContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_GeneTypeCorporateMember_custom_AsiaPacificContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AsiaPacificContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_AsiaPacificContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AsiaPacificContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_AffinityDNAMember_custom_AmericaAndCanadaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AmericaAndCanadaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_EasyDNAMember_custom_AmericaAndCanadaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AmericaAndCanadaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_GeneTypeCorporateMember_custom_AmericaAndCanadaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AmericaAndCanadaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_AffinityDNAMember_custom_EuropeMiddleEastAndAfricaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:EuropeMiddleEastAndAfricaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_EasyDNAMember_custom_EuropeMiddleEastAndAfricaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:EuropeMiddleEastAndAfricaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_GeneTypeCorporateMember_custom_EuropeMiddleEastAndAfricaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:EuropeMiddleEastAndAfricaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_AffinityDNAMember_custom_LatinAmericaContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:LatinAmericaContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_EasyDNAMember_custom_LatinAmericaContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:LatinAmericaContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_GeneTypeCorporateMember_custom_LatinAmericaContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:LatinAmericaContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_LatinAmericaContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:LatinAmericaContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_AffinityDNAMember_custom_AsiaPacificContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AsiaPacificContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_EasyDNAMember_custom_AsiaPacificContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AsiaPacificContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_GeneTypeCorporateMember_custom_AsiaPacificContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AsiaPacificContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_AsiaPacificContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AsiaPacificContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_AffinityDNAMember_custom_AmericaAndCanadaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AmericaAndCanadaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_EasyDNAMember_custom_AmericaAndCanadaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AmericaAndCanadaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_GeneTypeCorporateMember_custom_AmericaAndCanadaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AmericaAndCanadaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_AffinityDNAMember_custom_EuropeMiddleEastAndAfricaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:EuropeMiddleEastAndAfricaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_EasyDNAMember_custom_EuropeMiddleEastAndAfricaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:EuropeMiddleEastAndAfricaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_GeneTypeCorporateMember_custom_EuropeMiddleEastAndAfricaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:EuropeMiddleEastAndAfricaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_AffinityDNAMember_custom_LatinAmericaContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:LatinAmericaContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_EasyDNAMember_custom_LatinAmericaContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:LatinAmericaContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_GeneTypeCorporateMember_custom_LatinAmericaContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:LatinAmericaContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_LatinAmericaContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:LatinAmericaContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_AffinityDNAMember_custom_AsiaPacificContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:AffinityDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AsiaPacificContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_EasyDNAMember_custom_AsiaPacificContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:EasyDNAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AsiaPacificContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_GeneTypeCorporateMember_custom_AsiaPacificContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">GENE:GeneTypeCorporateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AsiaPacificContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_AsiaPacificContinentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">GENE:AsiaPacificContinentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-152020-12-21_custom_EmployeeStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:EmployeeStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-15</xbrli:startDate>
        <xbrli:endDate>2020-12-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-21_custom_EmployeeStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:EmployeeStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-092020-12-10_custom_ClassaPerformanceRightsMember_custom_DrLindsayWakefieldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:DrLindsayWakefieldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-09</xbrli:startDate>
        <xbrli:endDate>2020-12-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-092020-12-10_custom_ClassaPerformanceRightsMember_custom_DrJerzyMuchnickiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:DrJerzyMuchnickiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-09</xbrli:startDate>
        <xbrli:endDate>2020-12-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-092020-12-10_custom_ClassBPerformanceRightsMember_custom_DrJerzyMuchnickiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassBPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:DrJerzyMuchnickiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-09</xbrli:startDate>
        <xbrli:endDate>2020-12-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-092020-12-10_custom_ClassCPerformanceRightsMember_custom_DrJerzyMuchnickiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassCPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:DrJerzyMuchnickiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-09</xbrli:startDate>
        <xbrli:endDate>2020-12-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-092020-12-10_custom_ClassaPerformanceRightsMember_custom_MrPeterRubinsteinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrPeterRubinsteinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-09</xbrli:startDate>
        <xbrli:endDate>2020-12-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-092020-12-10_custom_ClassBPerformanceRightsMember_custom_MrPeterRubinsteinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassBPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrPeterRubinsteinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-09</xbrli:startDate>
        <xbrli:endDate>2020-12-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-092020-12-10_custom_ClassCPerformanceRightsMember_custom_MrPeterRubinsteinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassCPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrPeterRubinsteinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-09</xbrli:startDate>
        <xbrli:endDate>2020-12-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-092020-12-10_custom_ClassaPerformanceRightsMember_custom_MrNicholasBurrowsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrNicholasBurrowsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-09</xbrli:startDate>
        <xbrli:endDate>2020-12-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_ClassDPerformanceRightsMember_custom_MrSimonMorriesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassDPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrSimonMorriesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_ClassEPerformanceRightsMember_custom_MrStanleySackMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassEPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrStanleySackMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_PerformanceRightsMember_custom_MrMichaelTonroeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:PerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrMichaelTonroeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_PerformanceRightsMember_custom_MrCarlStubbingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:PerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrCarlStubbingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_PerformanceRightsMember_custom_MrKevinCamilleriMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:PerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrKevinCamilleriMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_PerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:PerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_PerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:PerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_PerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:PerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_PerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:PerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_ClassAAndBPerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassAAndBPerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_ClassBPerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassBPerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_ClassDPerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassDPerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_ClassEPerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassEPerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_PerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:PerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_OtherPerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:OtherPerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_PerformanceRightsMember_ifrs-full_BottomOfRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:PerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_PerformanceRightsMember_ifrs-full_TopOfRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:PerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_ClassaPerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_ClassCPerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassCPerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_ClassaPerformanceRightsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_MrCarlStubbingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrCarlStubbingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_MrCarlStubbingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrCarlStubbingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_MrCarlStubbingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrCarlStubbingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_MrKevinCamilleriMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrKevinCamilleriMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_MrKevinCamilleriMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrKevinCamilleriMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_MrKevinCamilleriMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrKevinCamilleriMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_ClassaPerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_ClassaPerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_MrMichaelTonroeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrMichaelTonroeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_MrMichaelTonroeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrMichaelTonroeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_MrMichaelTonroeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrMichaelTonroeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_ClassaPerformanceRightsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_ClassaPerformanceRightsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_ClassaPerformanceRightsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_ClassDPerformanceRightsMember_custom_MrSimonMorrissMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassDPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrSimonMorrissMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_ClassDPerformanceRightsMember_custom_MrSimonMorrissMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassDPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrSimonMorrissMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_ClassDPerformanceRightsMember_custom_MrSimonMorrissMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassDPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrSimonMorrissMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_ClassEPerformanceRightsMember_custom_MrStanleySackMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassEPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrStanleySackMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_ClassEPerformanceRightsMember_custom_MrStanleySackMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassEPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrStanleySackMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_ClassEPerformanceRightsMember_custom_MrStanleySackMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassEPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrStanleySackMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_DrLindsayWakefieldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:DrLindsayWakefieldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_ClassaPerformanceRightsMember_custom_DrLindsayWakefieldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:DrLindsayWakefieldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_ClassaPerformanceRightsMember_custom_DrLindsayWakefieldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:DrLindsayWakefieldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_DrJerzyMuchnickiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:DrJerzyMuchnickiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_ClassaPerformanceRightsMember_custom_DrJerzyMuchnickiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:DrJerzyMuchnickiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_ClassaPerformanceRightsMember_custom_DrJerzyMuchnickiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:DrJerzyMuchnickiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_MrPeterRubinsteinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrPeterRubinsteinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_ClassaPerformanceRightsMember_custom_MrPeterRubinsteinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrPeterRubinsteinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_ClassaPerformanceRightsMember_custom_MrPeterRubinsteinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrPeterRubinsteinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_ClassaPerformanceRightsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_ClassaPerformanceRightsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_ClassaPerformanceRightsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_KentgroveCapitalPtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">GENE:KentgroveCapitalPtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_KentgroveCapitalPtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">GENE:KentgroveCapitalPtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_KentgroveCapitalPtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">GENE:KentgroveCapitalPtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_WarrantstobeIssuedHCWainwrightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:WarrantstobeIssuedHCWainwrightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_WarrantstobeIssuedHCWainwrightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:WarrantstobeIssuedHCWainwrightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_WarrantstobeIssuedHCWainwrightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:WarrantstobeIssuedHCWainwrightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_ReversalOfForfeitedPerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">GENE:ReversalOfForfeitedPerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_ReversalOfForfeitedPerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">GENE:ReversalOfForfeitedPerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_ReversalOfForfeitedPerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">GENE:ReversalOfForfeitedPerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_EmployeeStocksOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:EmployeeStocksOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_EmployeeStocksOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:EmployeeStocksOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_EmployeeStocksOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:EmployeeStocksOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_PriceWaterHouseCoopersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">GENE:PriceWaterHouseCoopersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_PriceWaterHouseCoopersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">GENE:PriceWaterHouseCoopersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_PriceWaterHouseCoopersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">GENE:PriceWaterHouseCoopersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_GrantThorntonAuditPtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">GENE:GrantThorntonAuditPtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_GrantThorntonAuditPtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">GENE:GrantThorntonAuditPtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_GrantThorntonAuditPtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">GENE:GrantThorntonAuditPtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-092020-12-10_custom_PerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:PerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-09</xbrli:startDate>
        <xbrli:endDate>2020-12-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_MrSimonMorrisMember_custom_ClassDPerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrSimonMorrisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassDPerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_MrMichaelTonroeMember_custom_ClassaPerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrMichaelTonroeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_ClassaPerformanceRightsMember_custom_MrCarlStubbingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrCarlStubbingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_MrKevinCamilleriMember_custom_ClassaPerformanceRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrKevinCamilleriMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">GENE:ClassaPerformanceRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_Mr.PhilipsHainsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:Mr.PhilipsHainsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_Mr.PhilipsHainsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:Mr.PhilipsHainsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_MrStanleySackMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrStanleySackMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_MrStanleySackMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrStanleySackMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_MrPeterRubinsteinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrPeterRubinsteinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_MrPeterRubinsteinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrPeterRubinsteinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_MrPeterRubinsteinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:MrPeterRubinsteinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_DrJerzyMuchnickisMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:DrJerzyMuchnickisMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012021-06-30_custom_DrJerzyMuchnickisMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">GENE:DrJerzyMuchnickisMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_GeneTypePtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneTypePtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_GeneTypePtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneTypePtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_GeneTypePtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneTypePtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_GeneTypePtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneTypePtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_GeneticTechnologiesCorporationPtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneticTechnologiesCorporationPtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_GeneticTechnologiesCorporationPtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneticTechnologiesCorporationPtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_GeneticTechnologiesCorporationPtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneticTechnologiesCorporationPtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_GeneticTechnologiesCorporationPtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneticTechnologiesCorporationPtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_GeneVenturesPtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneVenturesPtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_GeneVenturesPtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneVenturesPtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_GeneVenturesPtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneVenturesPtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_GeneVenturesPtyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneVenturesPtyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_GeneTypeCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneTypeCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_GeneTypeCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneTypeCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_GeneTypeCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneTypeCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_GeneTypeCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneTypeCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_PhenogenSciencesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:PhenogenSciencesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_PhenogenSciencesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:PhenogenSciencesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_PhenogenSciencesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:PhenogenSciencesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_PhenogenSciencesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:PhenogenSciencesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_HainanAochengGeneticTechnologiesCoLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:HainanAochengGeneticTechnologiesCoLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_HainanAochengGeneticTechnologiesCoLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:HainanAochengGeneticTechnologiesCoLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_HainanAochengGeneticTechnologiesCoLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:HainanAochengGeneticTechnologiesCoLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_HainanAochengGeneticTechnologiesCoLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:HainanAochengGeneticTechnologiesCoLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_GeneticTechnologiesHKLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneticTechnologiesHKLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_GeneticTechnologiesHKLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneticTechnologiesHKLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_GeneticTechnologiesHKLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneticTechnologiesHKLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_GeneticTechnologiesHKLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GeneticTechnologiesHKLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_HelixGeneticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:HelixGeneticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_HelixGeneticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:HelixGeneticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_HelixGeneticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:HelixGeneticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_HelixGeneticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:HelixGeneticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_GenetypeUKLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GenetypeUKLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_GenetypeUKLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GenetypeUKLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_GenetypeUKLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GenetypeUKLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_GenetypeUKLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">GENE:GenetypeUKLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_CashAtBankOnHandMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:CashAtBankOnHandMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_CashAtBankOnHandMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:CashAtBankOnHandMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_TradeAndOtherReceivablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_TradeAndOtherReceivablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_TradeAndOtherPayablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:TradeAndOtherPayablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_TradeAndOtherPayablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:TradeAndOtherPayablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_ifrs-full_CurrencyRiskMember_country_AU">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_ifrs-full_CurrencyRiskMember_country_AU">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_ifrs-full_InterestRateRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_ifrs-full_InterestRateRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_LessThanSixMonthsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">GENE:LessThanSixMonthsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_SixAndTwelveMonthsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">GENE:SixAndTwelveMonthsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_BetweenOneAndTwoYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">GENE:BetweenOneAndTwoYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_BetweenTwoAndFiveYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">GENE:BetweenTwoAndFiveYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_OverFiveYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">GENE:OverFiveYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_TotalContractualCashFlowsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:TotalContractualCashFlowsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_CarryingAmountAssetsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:CarryingAmountAssetsLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_LessThanSixMonthsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">GENE:LessThanSixMonthsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_SixAndTwelveMonthsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">GENE:SixAndTwelveMonthsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_BetweenOneAndTwoYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">GENE:BetweenOneAndTwoYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_BetweenTwoAndFiveYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">GENE:BetweenTwoAndFiveYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_OverFiveYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">GENE:OverFiveYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_TotalContractualCashFlowsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:TotalContractualCashFlowsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_CarryingAmountAssetsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:CarryingAmountAssetsLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_CashAtBankOnHandMember_ifrs-full_FloatingInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:CashAtBankOnHandMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_CashAtBankOnHandMember_ifrs-full_FixedInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:CashAtBankOnHandMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_CashAtBankOnHandMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:CashAtBankOnHandMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_CashAtBankOnHandMember_ifrs-full_FloatingInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:CashAtBankOnHandMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_CashAtBankOnHandMember_ifrs-full_FixedInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:CashAtBankOnHandMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_CashAtBankOnHandMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:CashAtBankOnHandMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_PerformanceBondAndDepositsMember_ifrs-full_FloatingInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:PerformanceBondAndDepositsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_PerformanceBondAndDepositsMember_ifrs-full_FixedInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:PerformanceBondAndDepositsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_PerformanceBondAndDepositsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:PerformanceBondAndDepositsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_PerformanceBondAndDepositsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:PerformanceBondAndDepositsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_PerformanceBondAndDepositsMember_ifrs-full_FloatingInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:PerformanceBondAndDepositsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_PerformanceBondAndDepositsMember_ifrs-full_FixedInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:PerformanceBondAndDepositsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_PerformanceBondAndDepositsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:PerformanceBondAndDepositsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_PerformanceBondAndDepositsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">GENE:PerformanceBondAndDepositsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_FloatingInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_FixedInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_ifrs-full_FloatingInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_ifrs-full_FixedInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_BorrowingMember_ifrs-full_FloatingInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:BorrowingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_BorrowingMember_ifrs-full_FixedInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:BorrowingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_BorrowingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:BorrowingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_BorrowingMember_ifrs-full_FloatingInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:BorrowingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_BorrowingMember_ifrs-full_FixedInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:BorrowingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_BorrowingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:BorrowingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_LeasesMember_ifrs-full_FloatingInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:LeasesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_LeasesMember_ifrs-full_FixedInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:LeasesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_LeasesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:LeasesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_LeasesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:LeasesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_LeasesMember_ifrs-full_FloatingInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:LeasesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_LeasesMember_ifrs-full_FixedInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:LeasesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_LeasesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:LeasesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012022-06-30_custom_LeasesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">GENE:LeasesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_ifrs-full_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_ifrs-full_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_ifrs-full_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001166272</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="AUD">
      <xbrli:measure>iso4217:AUD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="AUDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:AUD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>GENE:Integer</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="CAD">
      <xbrli:measure>iso4217:CAD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="EUR">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="GBP">
      <xbrli:measure>iso4217:GBP</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000678" toRefs="Footnote000705"></ix:relationship>
  <ix:relationship fromRefs="Fact000679" toRefs="Footnote000705"></ix:relationship>
  <ix:relationship fromRefs="Fact000680" toRefs="Footnote000705"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0690" toRefs="Footnote000720"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0691" toRefs="Footnote000720"></ix:relationship>
  <ix:relationship fromRefs="Fact000692" toRefs="Footnote000720"></ix:relationship>
  <ix:relationship fromRefs="Fact001180" toRefs="Footnote001191"></ix:relationship>
  <ix:relationship fromRefs="Fact001181" toRefs="Footnote001191"></ix:relationship>
  <ix:relationship fromRefs="Fact001186" toRefs="Footnote001192"></ix:relationship>
  <ix:relationship fromRefs="Fact001187" toRefs="Footnote001192"></ix:relationship>
  <ix:relationship fromRefs="Fact001558" toRefs="Footnote001565"></ix:relationship>
  <ix:relationship fromRefs="Fact001591" toRefs="Footnote001604"></ix:relationship>
  <ix:relationship fromRefs="Fact001642" toRefs="Footnote001656"></ix:relationship>
  <ix:relationship fromRefs="Fact001643" toRefs="Footnote001656"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl1747" toRefs="Footnote001774"></ix:relationship>
  <ix:relationship fromRefs="Fact001749" toRefs="Footnote001774"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl1767" toRefs="Footnote001774"></ix:relationship>
  <ix:relationship fromRefs="Fact001769" toRefs="Footnote001774"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl2801" toRefs="Footnote002832"></ix:relationship>
  <ix:relationship fromRefs="Fact002802" toRefs="Footnote002832"></ix:relationship>
  <ix:relationship fromRefs="Fact002803" toRefs="Footnote002832"></ix:relationship>
  <ix:relationship fromRefs="Fact002813" toRefs="Footnote002832"></ix:relationship>
  <ix:relationship fromRefs="Fact002814" toRefs="Footnote002832"></ix:relationship>
  <ix:relationship fromRefs="Fact002815" toRefs="Footnote002832"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl2805" toRefs="Footnote002833"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl2806" toRefs="Footnote002833"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl2807" toRefs="Footnote002833"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl2817" toRefs="Footnote002833"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl2818" toRefs="Footnote002833"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl2819" toRefs="Footnote002833"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl2809" toRefs="Footnote002834"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl2810" toRefs="Footnote002834"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl2811" toRefs="Footnote002834"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl2821" toRefs="Footnote002834"></ix:relationship>
  <ix:relationship fromRefs="Fact002822" toRefs="Footnote002834"></ix:relationship>
  <ix:relationship fromRefs="Fact002823" toRefs="Footnote002834"></ix:relationship>
  <ix:relationship fromRefs="Fact002946" toRefs="Footnote003033"></ix:relationship>
  <ix:relationship fromRefs="Fact002948" toRefs="Footnote003033"></ix:relationship>
  <ix:relationship fromRefs="Fact002950" toRefs="Footnote003033"></ix:relationship>
  <ix:relationship fromRefs="Fact002952" toRefs="Footnote003033"></ix:relationship>
  <ix:relationship fromRefs="Fact002970" toRefs="Footnote003034"></ix:relationship>
  <ix:relationship fromRefs="Fact002972" toRefs="Footnote003034"></ix:relationship>
  <ix:relationship fromRefs="Fact002974" toRefs="Footnote003034"></ix:relationship>
  <ix:relationship fromRefs="Fact002976" toRefs="Footnote003034"></ix:relationship>
  <ix:relationship fromRefs="Fact002978" toRefs="Footnote003034"></ix:relationship>
  <ix:relationship fromRefs="Fact002980" toRefs="Footnote003034"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right">Commission file number <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntityFileNumber_c20220701__20230630_zeJ5ojwY88tj"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:EntityFileNumber">000-51504</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington D.C. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20549</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_902_edei--DocumentType_c20220701__20230630_zQuctXZ6anLb"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:DocumentType">20-F</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span id="xdx_900_edei--DocumentRegistrationStatement_c20220701__20230630_zRwHfdi2pYJ2"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" format="ixt:booleanfalse" name="dei:DocumentRegistrationStatement">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EX- CHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.6pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.6pt; text-align: center"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--DocumentAnnualReport_c20220701__20230630_zYoX7JhDynr1"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the fiscal year ended <span id="xdx_907_edei--DocumentPeriodEndDate_c20220701__20230630_zLMe1JFBffQl"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_901_edei--CurrentFiscalYearEndDate_c20220701__20230630_znGaTuH7lA94"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">June 30</ix:nonNumeric></span>, <span id="xdx_905_edei--DocumentFiscalYearFocus_c20220701__20230630_zp2zL9wXmdZ8"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></span></ix:nonNumeric></span></b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.6pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.6pt; text-align: center"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--DocumentTransitionReport_c20220701__20230630_zeTffBBo8YHg"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRANSITION REPORT PURSUANT TO SECTION 13 OR
    15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the transition period <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to</span></b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.6pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.6pt; text-align: center"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--DocumentShellCompanyReport_c20220701__20230630_zevMhPxRjPi7"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" format="ixt:booleanfalse" name="dei:DocumentShellCompanyReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EX- CHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Date of event requiring this shell company report
.. . . . . . . . . . . . . . . . . . <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90A_edei--EntityRegistrantName_c20220701__20230630_zINUpxx1VRca"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:EntityRegistrantName">GENETIC
TECHNOLOGIES LIMITED</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Exact name of Registrant
as specified in its charter and translation of Registrant&#8217;s name into English)</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20220701__20230630_ziqadAQ6xH19"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode">Australia</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Jurisdiction of incorporation
or <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">organization)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span id="xdx_906_edei--EntityAddressAddressLine1_c20220701__20230630_z2mlV3VKZull"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:EntityAddressAddressLine1">60-66 Hanover Street</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressCityOrTown_c20220701__20230630_z66N1hVkzSTd"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:EntityAddressCityOrTown">Fitzroy</ix:nonNumeric></span>,
Victoria, <span id="xdx_90E_edei--EntityAddressPostalZipCode_c20220701__20230630_zYJpeX0plgR5"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:EntityAddressPostalZipCode">3065</ix:nonNumeric></span>, <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--EntityAddressCountry_c20220701__20230630_zAEuaJW2h70c"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Australia</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Address of principal executive
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span id="xdx_901_edei--ContactPersonnelName_c20220701__20230630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zmUNc67TDq25"><ix:nonNumeric contextRef="From2022-07-012023-06-30_dei_BusinessContactMember" name="dei:ContactPersonnelName">Simon Morriss</ix:nonNumeric></span>,
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityAddressAddressLine1_c20220701__20230630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zjdQFNVijsDk"><ix:nonNumeric contextRef="From2022-07-012023-06-30_dei_BusinessContactMember" name="dei:EntityAddressAddressLine1">60-66 Hanover Street</ix:nonNumeric></span>,
<span id="xdx_905_edei--EntityAddressCityOrTown_c20220701__20230630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zLsqo36v3qYb"><ix:nonNumeric contextRef="From2022-07-012023-06-30_dei_BusinessContactMember" name="dei:EntityAddressCityOrTown">Fitzroy</ix:nonNumeric></span>, Victoria, <span id="xdx_90B_edei--EntityAddressPostalZipCode_c20220701__20230630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zrJPfpcWTs86"><ix:nonNumeric contextRef="From2022-07-012023-06-30_dei_BusinessContactMember" name="dei:EntityAddressPostalZipCode">3065</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressCountry_c20220701__20230630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zHy6k3IHgvL6"><ix:nonNumeric contextRef="From2022-07-012023-06-30_dei_BusinessContactMember" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Australia</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone: <span id="xdx_900_edei--CityAreaCode_c20220701__20230630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z7VDAAs5otC"><ix:nonNumeric contextRef="From2022-07-012023-06-30_dei_BusinessContactMember" name="dei:CityAreaCode">+61</ix:nonNumeric></span> <span id="xdx_903_edei--LocalPhoneNumber_c20220701__20230630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zwk0TNCWXqxf"><ix:nonNumeric contextRef="From2022-07-012023-06-30_dei_BusinessContactMember" name="dei:LocalPhoneNumber">3 8412 7000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Name, telephone, e-mail
and/or facsimile number and address of company contact <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">person)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Securities registered or to be registered pursuant
to Section 12(b) of the <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 36%">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">class</span></b></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which regis<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tered</span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Securities registered or to be registered pursuant
to Section 12(g) of the Act: American Depositary Shares, each representing 600 Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act: <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Number of outstanding shares of each of the issuer&#8217;s
classes of capital or common stock as of the close of the period covered by the annual report. There were <span id="xdx_907_edei--EntityCommonStockSharesOutstanding_iI_pid_c20230630_zInwVgqaqHrk"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,541,658,143</ix:nonFraction></span> Ordinary Shares
outstanding as of June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0">&#9744; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9746; <span id="xdx_907_edei--EntityWellKnownSeasonedIssuer_c20220701__20230630_zoH3XLoty0x2"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">If this report is an annual or transition report,
indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"> &#9744; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes &#9746;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityVoluntaryFilers_c20220701__20230630_zyjm2yYbHGEh"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Note &#8212; Checking the box above will not relieve
any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations
under those Sections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">Indicate by check mark whether
the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;
<span id="xdx_90C_edei--EntityCurrentReportingStatus_c20220701__20230630_ztaRVxv7Wqwc"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9744;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;
<span id="xdx_90F_edei--EntityInteractiveDataCurrent_c20220701__20230630_zTQyKz8Buscj"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9744;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth company. See definition
of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of
the Exchange Act. (Check one):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 33%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntityFilerCategory_c20220701__20230630_zHEmjqieWEG1"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20220701__20230630_zPH2JKJeMjHb"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">If an emerging growth company
that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a)
of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">&#8224; The term &#8220;new
or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting
Standards Codification after April 5, 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">Indicate by check mark whether
the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that
prepared or issued its audit report.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0">&#9744; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9746; <span id="xdx_905_edei--IcfrAuditorAttestationFlag_c20220701__20230630_z8TTWliN5k4d"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag">No</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"> &#9744; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes &#9746;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--DocumentFinStmtErrorCorrectionFlag_c20220701__20230630_zvEkf4eT395a" title="Document Financial Statement Error Correction [Flag]"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" format="ixt:booleanfalse" name="dei:DocumentFinStmtErrorCorrectionFlag">No</ix:nonNumeric></span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"> &#9744; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes &#9746;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Indicate by check mark which basis of accounting
the registrant has used to prepare the financial statements included in this <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">filing:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. GAAP <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 56%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10.5pt; text-align: center"><span id="xdx_90B_edei--DocumentAccountingStandard_c20220701__20230630_zsP6fCWk2Gf8"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:DocumentAccountingStandard">International Financial Reporting Standards</ix:nonNumeric></span> as issued y <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10.45pt; text-align: center">International Accounting
    Standards Board <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 6pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">If &#8220;Other&#8221; has been checked in response
to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0">&#9744; Item 17 &#9744;
Item <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">If this is an annual report, indicate by check
mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"> &#9744; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes &#9746;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityShellCompany_c20220701__20230630_zzOLWEOu3Hge"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PAST FIVE <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">YEARS)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Indicate by check mark whether the registrant has
filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to
the distribution of securities under a plan confirmed by a court. &#9744; Yes &#9744; No</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">TABLE OF <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTENTS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identity of Directors, Senior Management and Advisers</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer Statistics And Expected Timetable</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserved</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalisation and Indebtedness</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasons for the Offer and Use of Proceeds</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information on the Company</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">History and Development of the Company</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Overview</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organizational Structure</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, Plant and Equipment</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating and Financial Review and Prospects</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Results</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity and Capital Resources</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and Development, Patents and Licenses, etc.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trend Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.E</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical Accounting Estimates</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Senior Management and Employees</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors and Senior Management</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board Practices</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.E</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Ownership</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major Shareholders and Related Party Transactions</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major Shareholders</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Party Transactions</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interests of Experts and Counsel</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements and Other Financial Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_033"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant Changes</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_034"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Offer and Listing</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_035"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer and Listing Details</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_036"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_037"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Markets</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_038"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Shareholders</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.E</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_039"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.F</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_040"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses of the Issue</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_041"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_042"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Capital</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_043"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Constitution</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_044"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Contracts</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_045"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange Controls</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.E</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_046"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.F</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_047"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends and Paying Agents</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.G</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_048"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement by Experts</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.H</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_049"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documents on Display</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.I</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_050"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiary Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.J</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_051"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual Report to Security Holders</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_052"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative And Qualitative Disclosures About Market Risk</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_053"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description Of Securities Other Than Equity Securities</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_054"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt Securities</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_055"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants and Rights</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_056"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Securities</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_057"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">American Depositary Shares</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_059"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults, Dividend Arrearages and Delinquencies</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_060"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Modifications to The Rights Of Security Holders and Use Of Proceeds</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_061"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_062"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure controls and procedures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_063"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s annual report on internal control over financial reporting</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_064"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attestation report of the registered public accounting firm</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_065"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in internal control over financial reporting</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_066"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserved</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_067"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Committee Financial Expert</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_068"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code Of Ethics</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_069"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_070"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemptions From The Listing Standards For Audit Committees</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.E</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_071"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchases Of Equity Securities By The Issuer And Affiliated Purchasers</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.F</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_072"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in Registrant&#8217;s Certifying Accountant</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.G</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_073"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Governance</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.H</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_074"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosure</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.I</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_075"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.J</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_076"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider Trading Policies</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    17.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_078"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    18.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_079"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    19.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#F_080"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTRODUCTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In this
Annual Report, the &#8220;Company,&#8221; &#8220;Genetic Technologies&#8221;, &#8220;GTG&#8221;, &#8220;the Group&#8221;, &#8220;we,&#8221;
&#8220;us&#8221; and &#8220;our&#8221; refer to Genetic Technologies Limited and its consolidated subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our consolidated
financial statements are set out beginning on page F-1 of this Annual Report (refer to Item 18 &#8220;Financial <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">References
to the &#8220;ADSs&#8221; are to our ADSs described in Item 12.D &#8220;American Depositary Shares&#8221; and references to the &#8220;Ordinary
Shares&#8221; are to our Ordinary Shares described in Item 10.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our fiscal
year ends on June 30 and references in this Annual Report to any specific fiscal year are to the twelve-month period ended on June 30
of such year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORWARD-LOOKING
STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report contains forward-looking statements that involve risks and uncertainties. We use words such as &#8220;anticipates&#8221;,
</span>&#8220;believes&#8221;, &#8220;plans&#8221;, &#8220;expects&#8221;, &#8220;future&#8221;, &#8220;intends&#8221; and similar expressions
to identify such forward-looking statements. This Annual Report also contains forward-looking statements attributed to certain third parties
relating to their estimates regarding the growth of Genetic Technologies and related markets and spending. You should not place undue
reliance on these forward-looking statements, which apply only as of the date of this Annual Report. Our actual results could differ materially
from those anticipated in these forward- looking statements for many reasons, including the risks faced by us described below under the
caption &#8220;Risk Factors&#8221; and elsewhere in this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although
we believe that the expectations reflected in such forward-looking statements are reasonable at this time, we can give no assurance that
such expectations will prove to be correct. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking
statements. Important factors that could cause actual results to differ materially from our expectations are contained in cautionary statements
in this Annual Report including, without limitation, in conjunction with the forward-looking statements included in this Annual Report
and specifically under Item 3.D &#8220;Risk Factors&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All
subsequent written and oral forward-looking statements attributable to us are expressly qualified in their entirety by reference to these
cautionary statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">AUSTRALIAN DISCLOSURE <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">REQUIREMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our ordinary
shares are primarily quoted on the Australian Securities Exchange (&#8220;ASX&#8221;) in addition to our listing of our ADSs on the NASDAQ
Global Select Market. As part of our ASX listing, we are required to comply with various disclosure requirements as set out under the
Australian Corporations Act 2001 and the ASX Listing Rules. Information furnished under the sub-heading &#8220;Australian <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
Requirements&#8221; is intended to comply with ASX listing and Corporations Act 2001 disclosure requirements and is not intended </span>to
fulfill information required by this Annual report on Form 20-F.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">ENFORCEMENT OF LIABILITIES AND SERVICE OF
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROCESS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are
incorporated under the laws of Western Australia in the Commonwealth of Australia. All of our directors and executive officers, and any
experts named in this Annual Report, reside outside the U.S. Substantially all of our assets, our directors&#8217; and executive officers&#8217;
assets and such experts&#8217; assets are located outside the U.S. As a result, it may not be possible for investors to affect service
of process within the U.S. upon us or our directors, executive officers or such experts, or to enforce against them or us in U.S. courts,
judgments obtained in U.S. courts based upon the civil liability provisions of the federal securities laws of the U.S. In addition, we
have been advised by our Australian solicitors that there is doubt that the courts of Australia will enforce against us, our directors,
executive officers and experts named herein, judgments obtained in the U.S. based upon the civil liability provisions of the federal securities
laws of the U.S. or will enter judgments in original actions brought in Australian courts based upon the federal securities laws of the
U.S.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_001"></span>PART</span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span id="F_002"></span>Item 1. Identity of Directors, Senior Management and
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advisers</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Not <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applicable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span id="F_003"></span>Item 2. Offer Statistics and Expected <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timetable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_004"></span>Item 3. Key Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="F_005"></span>Item
3.A Reserved</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-indent: 0.5in"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span id="F_006"></span>Item 3.B Capitalisation and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indebtedness</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Not <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span id="F_007"></span>Item 3.C Reasons for the Offer and Use of
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Not <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span id="F_008"></span>Item 3.D Risk <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Factors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Before
you purchase our ADSs, you should be aware that there are risks, including those described below. You should consider carefully these
risk factors together with all of the other information contained elsewhere in this Annual Report before you decide to purchase our ADSs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Risk Factor <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Related to our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    variety of risks associated with commercializing our products and product candidates internationally could materially adversely
    affect our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Company has a history of incurring <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">losses.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be successful in transitioning from our existing product portfolio to our next generation of risk assessment tests, and our newly developed approach to marketing and distribution of such products may not generate revenues.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our products may never achieve significant market <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face additional risks as a result of the EasyDNA and AffinityDNA acquisitions and may be unable to integrate our businesses </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully and realize the anticipated synergies and related benefits of these acquisitions or do so within the anticipated time <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">frame.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure to demonstrate the clinical utility of our products could have a material adverse effect on our financial condition and results of operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If our competitors develop superior products, our operations and financial condition could be <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">affected.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have important relationships with external parties over whom we have limited <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">control.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be subject to liability and our insurance may not be sufficient to cover <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">damages.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security breaches, privacy issues, loss of data and other incidents could compromise sensitive or personal information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We use potentially hazardous materials, chemicals and patient samples in our business and any disputes relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our industry is subject to rapidly changing technology and new and increasing amounts of scientific data related to genes and genetic variants and their role in disease.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We depend on the collaborative efforts of our academic and corporate partners for research, development and commercialization of our products. A breach by our partners of their obligations, or the termination of the relationship, could deprive us of valuable resources and require additional investment of time and money.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If our sole laboratory facility becomes inoperable, we may be unable to perform our tests and our business will be <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">harmed.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The loss of key members of our senior management team or our inability to attract and retain highly skilled scientists, clinicians and salespeople could adversely affect our business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 5; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in the way that the Food &amp; Drug Administration (FDA) regulates our tests could result in the delay or additional expense in offering our tests and tests that we may develop in the future.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business could be harmed from the loss or suspension of a license or imposition of a fine or penalties under, or future changes in, or changing interpretations of, Clinical Laboratory Improvements Amendments (CLIA) or state laboratory licensing laws to which we are subject.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure to establish and comply with appropriate quality standards to assure that the highest level of quality is observed in the performance of our testing services and in the design, manufacture and marketing of our products could adversely affect the results of our operations and adversely impact our reputation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We could be adversely affected by violations of the Foreign Corrupt Practices Act (FCPA) and other worldwide anti-bribery <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">laws.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure to comply with health information privacy laws, including Health Insurance Portability and Accountability Act of 1996 (HIPAA) or other U.S. federal or state health information privacy and security laws, as applicable, may negatively impact our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we or our partners fail to comply with the complex federal, state, local and foreign laws and regulations to the extent that apply to our business, we could suffer severe consequences that could materially and adversely affect our operating results and financial condition.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A failure to comply with any of federal or state laws to the extent such are applicable to our business, particularly laws related to the elimination of healthcare fraud, may adversely impact our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face risks associated with currency exchange rate fluctuations, which could adversely affect our operating <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government regulation of genetic research or testing may adversely affect the demand for our services and impair our business and operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure in our information technology systems could significantly increase testing turn-around times or impact on the billing processes or otherwise disrupt our operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any significant disruption in service on our website or in our computer or logistics systems, whether due to a failure with our information technology systems or that of a third-party vendor, could harm our reputation and may result in a loss of <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">customers.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breaches of network or information technology, natural disasters or terrorist attacks could have an adverse impact on our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ethical and other concerns surrounding the use of genetic information may reduce the demand for our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">services.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks associated with our intellectual <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">property.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely heavily upon patents and proprietary technology that may fail to protect our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may face difficulties in certain jurisdictions in protecting our intellectual property rights, which may diminish the value of our intellectual property rights in those jurisdictions.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our operations may be adversely affected by the effects of extreme weather conditions or other interruptions in the timely transportation of specimens.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Consumer Initiated Testing (CIT) Platform will expose us to various <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discontinuation or recalls of existing testing products or our customers using new technologies to perform their own tests could adversely affect our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Polygenic Risk Score (PRS) test may not be able to obtain necessary regulatory clearance, and therefore we may not generate any revenue.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the PRS test is required to obtain and maintain FDA approvals, it will be subject to continuing governmental regulations and additional foreign regulations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Declining general economic or business conditions may have a negative impact on our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Related to our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ADSs may be delisted from the NASDAQ Capital <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our stock price is volatile and can fluctuate significantly based on events not in our control and general industry conditions. As a result, the value of your investment may decline significantly.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fact that we do not expect to pay cash dividends may lead to decreased prices for our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You may have difficulty in effecting service of legal process and enforcing judgments against us and our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">management.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because we are not required to provide you with the same information as an issuer of securities based in the United States, you may not be afforded the same protection or information you would have if you had invested in a public corporation based in the United States.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from Nasdaq corporate governance listing standards and these practices may afford less protection to shareholders than they would enjoy if we complied fully with Nasdaq corporate governance listing standards.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of being a U.S. public company, we are subject to additional regulatory compliance requirements, including Section 404, and if we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will incur significant costs as a result of operating as a company with ADSs that are publicly traded in the United States, and our management will be required to devote substantial time to new compliance initiatives.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The dual listing of our ordinary shares and the ADSs may negatively impact the liquidity and value of the <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADSs.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australian takeover laws may discourage takeover offers being made for us or may discourage the acquisition of a significant position in our ordinary shares or ADSs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Constitution and Australian laws and regulations applicable to us may adversely affect our ability to take actions that could be beneficial to our shareholders.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A lack of significant liquidity for our ADSs may negatively affect your ability to resell our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">securities.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In certain circumstances, holders of ADSs may have limited rights relative to holders of Ordinary <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Related to <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be classified as a passive foreign investment company, which could result in adverse U.S. federal income tax consequences for U.S. holders.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a United States person is treated as owning at least 10% of our ordinary shares, such holder may be subject to adverse U.S. federal income tax consequences.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes to tax laws could materially adversely affect our company and reduce net returns to our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shareholders.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or non-realization of expected benefits.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Risks Related to our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">A variety of risks
associated with commercializing our products and product candidates internationally could <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">materially
</span>adversely affect our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">We, or
our licensing partners, may seek regulatory approval for our products or product candidates in multiple jurisdictions, accordingly, we
expect that we will be subject to additional risks for our products and product candidates related to operating in foreign countries if
we obtain the necessary approvals, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing regulatory requirements in foreign <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">countries;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential for so-called parallel importing, when a local seller, faced with high or higher local prices, opts to import goods from a foreign market (with low or lower prices) rather than buying them locally;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">abroad;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign taxes, including withholding of payroll <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">taxes;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties staffing and managing foreign <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operations;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce uncertainty in countries where labor unrest is more common than in Australia or the <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as in Australia or the U.S.;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business interruptions resulting from geo-political actions, including war and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">terrorism.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
and other risks associated with our or our licensing partners&#8217; international operations may materially adversely affect our ability
to attain or maintain profitable operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">Our Company has a history of incurring
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have
incurred operating losses in every year since the year ended June 30, 2011. As at June 30, 2023, the Company had accumulated losses of
A$156,715,687 and the extent of any future losses and whether or not the Company can generate profits in future years remains uncertain.
The Company currently does not generate sufficient revenue to cover its operating expenses. We expect our capital outlays and operating
expenditures to remain constant for the foreseeable future as we continue to focus on R&amp;D and new product development, IP creation
and the introduction of predictive genetic testing products. If we fail to generate sufficient revenue and eventually become profitable,
or if we are unable to fund our continuing losses by raising additional financing when required, our shareholders could lose all or part
of their investments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">We
may not be successful in expanding our revenues, and therefore improving operational profitability, of the recently acquired EasyDNA and
AffinityDNA businesses or achieve significant commercial sales of the portfolio to our next generation of geneType risk assessment tests.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although
GTG have recently achieved a significant increase in product revenues, which are largely attributable to the recently acquired EasyDNA
and AffinityDNA businesses and the Company has recently developed, launched and marketed our geneType Multi- risk test, we believe that
our future success is dependent upon our ability to grow revenues from our existing product offerings and to successfully introduce and
sell our newly developed products including our innovative hereditary breast and ovarian cancer test, due for launch in financial year
2024. Although we believe that we now have world class products that are poised to be an important part of making predictive genetic testing
a mainstream healthcare activity, we may not be successful in transitioning from our existing products to these products, and there can
be no assurance that the demand for these new products will develop. Furthermore, we plan to introduce our new products to healthcare
providers through a global network of distribution partners instead of through our own sales force. Although we believe that we are building
worthwhile sales and distribution relationships with experienced distribution firms, there can be no assurance that we will be able to
enter into distribution arrangements on terms satisfactory to us, and that our marketing strategy will be successful and result in significant
revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">Our products may never achieve
significant market <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">We may
expend substantial funds and management effort on the development and marketing of our predictive genetic testing <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">products
with no assurance that we will be successful in selling our products or services. Our ability to enter into distribution arrangements
</span>to successfully sell our molecular risk assessment and predictive genetic testing products and services will depend significantly
on the perception that our products and services can reduce patient risk and improve medical outcomes, and that our products and services
are superior to existing tests. Our business could also be adversely affected if we expend money without any return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">We
face additional risks as a result of the EasyDNA and AffinityDNA acquisitions. We may be unable to integrate our businesses successfully
and realize the anticipated synergies and related benefits of these acquisitions or do so within our anticipated timeframes. Including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in integrating and managing the combined operations of EasyDNA and AffinityDNA, and realizing the anticipated economic, operational, and other benefits in a timely manner, which could result in substantial costs and delays or other operational, technical, or financial problems;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions to the EasyDNA and AffinityDNA businesses and their operations and relationships with service providers and other third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss of key employees of EasyDNA and AffinityDNA and other challenges associated with integrating new employees into our culture, as well as reputational harm if integration is not successful;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion of management time and focus from operating our business to addressing the EasyDNA and AffnityDNA operations integration challenges;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion of significant resources from the ongoing development of our existing products, services, and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operations;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to successfully realize our intended business <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strategy;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase in the operating losses that we expect to incur in future <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">periods;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory complexities of integrating or managing the combined operations or expanding into other industries or parts of the healthcare industry;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory developments or enforcement trends focusing on corporate practice of <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">medicine;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater than anticipated costs related to the integration of the EasyDNA and AffinityDNA businesses and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operations;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase in compliance and related costs associated with the addition of a regulated <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business;</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">responsibility for the liabilities of EasyDNA and AffinityDNA, including those that were not disclosed to us or exceed our estimates, as well as, without limitation, liabilities arising out of their failure to maintain effective data protection and privacy practices controls and comply with applicable regulations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential accounting charges to the extent intangibles recorded in connection with the EasyDNA and AffinityDNA acquisitions, such as goodwill, trademarks, client relationships, or intellectual property, are later determined to be impaired and written down in value.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to demonstrate the clinical utility of our geneType products could have a material adverse effect on our financial condition and results
of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company
believes that its current GeneType risk assessment tests, along with the pipeline of new tests for additional disease indications under
development have the capacity to transform health outcomes for entire populations. However, it is critical for the Company to demonstrate
the clinical utility of its new products at scale. Clinical utility is the usefulness of a test for clinical practice. If the Company
is unable to demonstrate clinical utility, or if the data is deemed insufficient to validate utility, there may be insufficient demand
for the Company&#8217;s products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If our competitors develop superior
products, our operations and financial condition could be <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are
currently subject to increased competition from biotechnology and diagnostic companies, academic and research institutions and government
or other publicly-funded agencies that are pursuing products and services which are substantially similar to our molecular risk assessment
testing products, or which otherwise address the needs of our customers and potential customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our competitors
in the predictive genetic testing and assessment market include private and public sector enterprises located in Australia, the U.S. and
elsewhere. Many of the organizations competing with us are much larger and have more ready access to needed <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">resources.
In particular, they would have greater experience in the areas of finance, research and development, manufacturing, marketing, </span>sales,
distribution, technical and regulatory matters than we do. In addition, many of the larger current and potential competitors have already
established name / brand recognition and more extensive collaborative relationships.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our competitive
position in the molecular risk assessment and predictive testing area is based upon, amongst other things, our ability to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to strengthen and maintain scientific credibility through the process of obtaining scientific validation through clinical trials supported by peer-reviewed publication in medical journals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">create and maintain scientifically advanced technology and offer proprietary products and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">services;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to strengthen and improve the messaging regarding the importance and value that our cancer risk assessment tests provide to patients and physicians;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversify our product offerings in disease <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">types;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain and maintain patent or other protection for our products and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">services;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain and maintain required government approvals and other accreditations on a timely basis; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully market our products and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">services.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we
are not successful in meeting these goals, our business could be adversely affected. Similarly, our competitors may succeed in developing
technologies, products or services that are more effective than any that we are developing or that would render our technology, products
and services obsolete, noncompetitive or uneconomical.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">We have important relationships
with external parties over whom we have limited <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have
relationships with academic consultants, research collaborators at other institutions and other advisers who are not employed by us. Accordingly,
we have limited control over their activities and can expect only limited amounts of their time to be dedicated to our activities. These
persons may have consulting, employment or advisory arrangements with other entities that may conflict with or compete with their obligations
to us. Our consultants typically sign agreements that provide for confidentiality of our proprietary information and results of studies.
However, we may not be able to maintain the confidentiality of our technology, the dissemination of which could hurt our competitive position
and results of operations. To the extent that our scientific consultants, collaborators or advisors develop inventions or processes that
may be applicable to our proposed products, disputes may arise as to the ownership of the proprietary rights to such information, and
we may not be successful with any dispute outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">We may be subject to liability
and our insurance may not be sufficient to cover <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">damages.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business
exposes us to potential liability risks that are inherent in the testing, manufacturing, marketing and sale of molecular risk assessment
and predictive tests. The use of our products and product candidates, whether for clinical trials or commercial sale, may expose us to
professional and product liability claims and possible adverse publicity. We may be subject to claims resulting from incorrect results
of analysis of genetic variations or other screening tests performed using our products. Litigation of such claims could be costly. Further,
if a court were to require us to pay damages to a plaintiff, the amount of such damages could be significant and severely damage our financial
condition. Although we have public and product liability insurance coverage under broad form liability and professional indemnity policies,
the level or breadth of our coverage may not be adequate to fully cover any potential liability claims. In addition, we may not be able
to obtain additional liability coverage in the future at an acceptable cost. A successful claim or series of claims brought against us
in excess of our insurance coverage and the effect of professional and/or product liability litigation upon the reputation and marketability
of our technology and products, together with the diversion of the attention of key personnel, could negatively affect our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Security
breaches, privacy issues, loss of data and other incidents could compromise sensitive or personal information related to our business
or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the
ordinary course of our business, we collect and store sensitive data, including Protected Health Information, (PHI), personally identifiable
information, genetic information, credit card information, intellectual property and proprietary business information owned or controlled
by ourselves or our customers, payers and other parties. We manage and maintain our applications and data utilizing a combination of on-site
systems, managed data center systems and cloud-based systems. We also communicate PHI and other sensitive patient data through our various
customer tools and platforms. In addition to storing and transmitting sensitive data that is subject to multiple legal protections, these
applications and data encompass a wide variety of business-critical information including research and development information, commercial
information, and business and financial information. We face a number of risks relative to protecting this critical information, including
loss of access risk, inappropriate disclosure, inappropriate modification, and the risk of our being unable to adequately monitor and
modify our controls over our critical information. Any technical problems that may arise in connection with our data and systems, including
those that are hosted by third-party providers, could result in interruptions to our business and operations or exposure to security vulnerabilities.
These types of problems may be caused by a variety of factors, including infrastructure changes, intentional or accidental human actions
or omissions, software errors, malware, viruses, security attacks, fraud, spikes in customer usage and denial of service issues. In addition,
there has recently been a significant increase in ransomware and cyber security attacks related to the ongoing conflict between Russia
and Ukraine, which could result in substantial harm to internal systems necessary for running our critical operations and revenue generating
services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The secure
processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy, and
we devote significant resources to protecting such information. Although we take what we believe to be reasonable and appropriate measures,
including a formal, dedicated enterprise security program, to protect sensitive information from various compromises (including unauthorized
access, disclosure, or modification or lack of availability), our information technology and infrastructure may be vulnerable to attacks
by hackers or viruses or breached due to employee error, malfeasance or other disruptions. For example, we have been subject to phishing
incidents in the past, and we may experience additional incidents in the future. Any such breach or interruption could compromise our
networks, and the information stored therein could be accessed by unauthorized parties, altered, publicly disclosed, lost or stolen.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Unauthorized
access, loss or dissemination could also disrupt our operations (including our ability to conduct our analyses, provide test results,
bill payers or patients, process claims and appeals, provide customer assistance, conduct research and development <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">activities,
collect, process and prepare company financial information, provide information about our tests and other patient and physician </span>education
and outreach efforts through our website, and manage the administrative aspects of our business) and damage our reputation, any of which
could adversely affect our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition
to data security risks, we also face privacy risks. Should we actually violate, or be perceived to have violated, any privacy commitments
we make to patients or consumers, we could be subject to a complaint from an affected individual or interested privacy regulator, such
as the FTC, a state Attorney General, an EU Member State Data Protection Authority, or a data protection authority in another international
jurisdiction. This risk is heightened given the sensitivity of the data we collect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any security
compromise that causes an apparent privacy violation could also result in legal claims or proceedings; liability under federal, state,
foreign, or multinational laws that regulate the privacy, security, or breach of personal information, such as but not <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
to the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology </span>for
Economic and Clinical Health Act of 2009, or HITECH, state data security and data breach notification laws, the European Union&#8217;s
General Data Protection Regulation, or GDPR, and the UK Data Protection Act of 2018; and related regulatory penalties. Penalties for failure
to comply with a requirement of HIPAA or HITECH vary significantly, and, depending on the knowledge and culpability of the HIPAA-regulated
entity, may include civil monetary penalties of up to US$1.5 million per calendar year for each provision of <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA</span>
that is violated. A person who knowingly obtains or discloses individually identifiable health information in violation of HIPAA may face
a criminal penalty of up to US$50,000 and up to one-year imprisonment. The criminal penalties increase if the wrongful conduct involves
false pretenses or the intent to sell, transfer or use identifiable health information for commercial advantage, personal gain or malicious
harm. Penalties for unfair or deceptive acts or practices under the FTC Act or state Unfair and Deceptive Acts and Practices, or UDAP,
statutes may also vary significantly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There
has been unprecedented activity in the development of data protection regulation around the world. As a result, the interpretation and
application of consumer, health-related and data protection laws in the United States, Europe and elsewhere are often uncertain, contradictory
and in flux. The GDPR took effect on May 25, 2018. The GDPR applies to any entity established in the EU as well as extraterritorially
to any entity outside the EU that offers goods or services to, or monitors the behavior of, individuals who are located in the EU. The
GDPR imposes strict requirements on controllers and processors of personal data, including enhanced protections for &#8220;special categories&#8221;
of personal data, which includes sensitive information such as health and genetic information of data subjects. The GDPR also grants individuals
various rights in relation to their personal data, including the rights of access, rectification, objection to certain processing and
deletion. The GDPR provides an individual with an express right to seek legal remedies if the individual believes his or her rights have
been violated. Failure to comply with the requirements of the GDPR or the related national data protection laws of the member states of
the EU, which may deviate from or be more restrictive than the GDPR, may result in significant administrative fines issued by EU regulators.
Maximum penalties for violations of the GDPR are capped at 20M euros or 4% of an organization&#8217;s annual global revenue, whichever
is greater.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally,
the implementation of GDPR has led other jurisdictions to either amend or propose legislation to amend their existing data privacy and
cybersecurity laws to resemble the requirements of GDPR. For example, on June 28, 2018, California adopted the California Consumer Privacy
Act of 2018, or the CCPA. The CCPA regulates how certain for-profit businesses that meet one or more CCPA applicability thresholds collect,
use, and disclose the personal information of consumers who reside in California. Among other things, the CCPA confers to California consumers
the right to receive notice of the categories of personal information that will be collected by a business, how the business will use
and share the personal information, and the third parties who will receive the personal information. The CCPA also confers rights to access,
delete, or transfer personal information; and the right to receive equal service and pricing from a business after exercising a consumer
right granted by the CCPA. In addition, the CCPA allows California consumers the right to opt out of the &#8220;sale&#8221; of their personal
information, which the CCPA defines broadly as any disclosure of personal information to a third party in exchange for monetary or other
valuable consideration. The CCPA also requires a business to implement reasonable security procedures to safeguard personal information
against unauthorized access, use, or disclosure. The CCPA does not apply to PHI collected by certain parties subject to HIPAA, or to de-identified
data as defined under HIPAA. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data
breaches resulting from a business&#8217;s failure to implement and maintain reasonable data security procedures that is expected to increase
data breach litigation. On January 1, 2023, the California Privacy Rights Act, or CPRA, is scheduled to go into effect and will substantially
amend the CCPA. The CPRA would, among other things, amend the CCPA to give California residents the ability to limit the use of their
sensitive information, provide for penalties for CPRA violations concerning California residents under the age of 16, and establish a
new California Privacy Protection Agency to implement and enforce the law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Virginia,
Colorado, and Utah have recently enacted similar privacy acts, and dozens of other states in the United States are currently considering
similar consumer data privacy laws, which could impact our operations if enacted. Some observers have noted that the CCPA could mark the
beginning of a trend toward more stringent privacy legislation in the United States, which could increase our potential liability and
adversely affect our business, results of operations, and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">It is
possible the GDPR, CCPA and other emerging United States and international data protection laws may be interpreted and applied in a manner
that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices,
which could adversely affect our business. In addition, these privacy laws and regulations may differ from country to country and state
to state, and our obligations under these laws and regulations vary based on the nature of our activities in the particular jurisdiction,
such as whether we collect samples from individuals in the local jurisdiction, perform testing in the local jurisdiction, or process personal
information regarding employees or other individuals in the local jurisdiction. Complying with these various laws and regulations could
cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our
business. We can provide no assurance that we are or will remain in compliance with diverse privacy and data security requirements in
all of the jurisdictions in which we do business. Failure to comply with privacy and data security requirements could result in a variety
of consequences, including civil or criminal penalties, litigation, or damage to our reputation, any of which could have a material adverse
effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We
use potentially hazardous materials, chemicals and patient samples in our business and any disputes relating to improper handling, storage
or disposal of these materials could be time consuming and costly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our research
and development, production and service activities involve the controlled use of hazardous laboratory materials and chemicals, including
small quantities of acid and alcohol, and fluid (i.e. saliva, blood) as well as tissue samples from customers. We do not knowingly deal
with infectious samples. We, our collaborators and service providers are subject to stringent Australian <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal,</span>
state and local laws and regulations governing occupational health and safety standards, including those governing the use, storage, handling
and disposal of these materials and certain waste products. However, we could be liable for accidental contamination or discharge or any
resultant injury from hazardous materials, and conveyance, processing, and storage of and data on patient samples. If we, our collaborators
or service providers fail to comply with applicable laws or regulations, we could be required to pay penalties or be held liable for any
damages that result and this liability could exceed our financial resources. Further, future changes to environmental health and safety
laws could cause us to incur additional expense or restrict our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition,
our collaborators and service providers may be working with these same types of hazardous materials, including hazardous chemicals, in
connection with our collaborations. In the event of a lawsuit or investigation, we could be held responsible for any injury caused to
persons or property by exposure to, or release of, these hazardous materials or customer samples that may contain infectious materials.
The cost of this liability could exceed our resources. While we maintain broad form liability insurance coverage for these risks, the
level or breadth of our coverage may not be adequate to fully cover potential liability claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our
industry is subject to rapidly changing technology and new and increasing amounts of scientific data related to genes and genetic variants
and their role in disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our failure
to develop tests to keep pace with these changes could make us obsolete. In recent years, there have been numerous advances in methods
used to analyze very large amounts of genomic information and the role of genetics and gene variants in disease and treatment therapies.
Our industry has and will continue to be characterized by rapid technological change, increasingly larger amounts of data, frequent new
testing service introductions and evolving industry standards, all of which could make our tests obsolete. Our future success will also
depend on our ability to keep pace with the evolving needs of our customers on a timely and cost-effective basis and to pursue new market
opportunities that develop as a result of technological and scientific advances. Our tests could become obsolete and our business adversely
affected unless we continually update our offerings to reflect new scientific knowledge about genes and genetic variations and their role
in diseases and treatment therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We
depend on the collaborative efforts of our academic and corporate partners for research, development and commercialization of our products.
A breach by our partners of their obligations, or the termination of the relationship, could deprive us of valuable resources and require
additional investment of time and money.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our strategy
for research, development and commercialization of our products has historically involved entering into various arrangements with academic,
corporate partners and others. As a result, the success of our strategy depends, in part, upon the strength of those relationships and
these outside parties undertaking their responsibilities and performing their tasks to the best of their ability and responding in a timely
manner. Our collaborators may also be our competitors. We cannot necessarily control the amount and timing of resources that our collaborators
devote to performing their contractual obligations and we have no certainty that these parties will perform their obligations as expected
or that any revenue will be derived from these arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If our
collaborators breach or terminate their agreement with us or otherwise fail to conduct their collaborative activities in a timely manner,
the development or commercialization of the product candidate or research program under such collaborative arrangement may be delayed.
If that is the case, we may be required to undertake unforeseen additional responsibilities or to devote unforeseen additional funds or
other resources to such development or commercialization, or such development or commercialization could be terminated. The termination
or cancellation of collaborative arrangements could adversely affect our financial condition, intellectual property position and general
operations. In addition, disagreements between collaborators and us could lead to delays in the collaborative research, development, or
commercialization of certain products or could require or result in formal legal process or arbitration for resolution. These consequences
could be time-consuming and expensive and could have material adverse effects on the <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We rely
upon scientific, technical and clinical data supplied by academic and corporate collaborators, licensors, licensees, independent contractors
and others in the evaluation and development of potential therapeutic methods. There may be errors or omissions in this data that would
materially adversely affect the development of these methods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">If our sole
laboratory facility becomes inoperable, we may be unable to perform our tests and our business will be <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We rely
heavily upon our sole laboratory facilities in Melbourne, Australia, which has been certified under the U.S. CLIA. Our current lease of
laboratory premises expires February 28, 2025. The facility and the equipment we use to perform our tests would be costly to replace and
could require substantial lead time to repair or replace. If we were to lose our CLIA certification or other required certifications or
licenses, or if the facility is harmed or rendered inoperable by natural or man-made disasters, including flooding and power outages,
it will be difficult or impossible for us to perform our tests for some period of time. The inability to perform our tests or the backlog
of tests that could develop if our facility is inoperable for even a short period of time may result in the loss of customers or harm
our reputation, and we may be unable to regain those customers in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we
no longer had our own facility and needed to rely on a third party to perform our tests, we could only use another facility with established
state licensure and CLIA accreditation. We cannot assure you that we would be able to find another CLIA <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certified</span>
facility willing to comply with the required procedures, that this laboratory would be willing to perform the tests on commercially reasonable
terms, or that it would be able to meet our quality standards. In order to establish a redundant clinical reference laboratory facility,
we would have to spend considerable time and money securing adequate space, constructing the facility, recruiting and training employees,
and establishing the additional operational and administrative infrastructure necessary to support a second facility. We may not be able,
or it may take considerable time, to replicate our testing processes or results in a new facility. Additionally, any new clinical reference
laboratory facility would be subject to certification under CLIA and licensing by several states, including California and New York, which
could take a significant amount of time and result in delays in our ability to begin operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The
loss of key members of our senior management team or our inability to attract and retain highly skilled scientists, clinicians and salespeople
could adversely affect our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our success
depends largely on the skills, experience and performance of key members of our executive management team and others in key management
positions. The efforts of each of these persons together will be critical as we continue to develop our technologies and testing processes,
continue our international expansion and transition to a company with multiple commercialized products. If we were to lose one or more
of these key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business
strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our research
and development programs and commercial laboratory operations depend on our ability to attract and retain highly skilled scientists and
technicians, including licensed laboratory technicians, chemists, biostatisticians and engineers. We may not be able to attract or retain
qualified scientists and technicians in the future due to the competition for qualified personnel among life science businesses. In addition,
if there were to be a shortage of clinical laboratory scientists in coming years, this would make it more difficult to hire sufficient
numbers of qualified personnel. We also face competition from universities and public and private research institutions in recruiting
and retaining highly qualified scientific personnel. Our success also depends on our ability to attract and retain salespeople with extensive
experience in oncology and have close relationships with medical oncologists, pathologists and other hospital personnel. We may have difficulties
sourcing, recruiting or retaining qualified salespeople, which could cause delays or a decline in the rate of adoption of our tests. If
we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that
could adversely affect our ability to support our research and development and sales programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Changes in
the way that the FDA regulates our tests could result in the delay or additional expense in offering our tests and tests that we may develop
in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Historically,
the U.S. Food and Drug Administration (&#8220;FDA&#8221;) has exercised enforcement discretion with respect to most Laboratory Developed
Tests (&#8220;LDTs&#8221;) and has not required laboratories that furnish LDTs to comply with the agency&#8217;s requirements for medical
devices (e.g., establishment registration, device listing, quality systems regulations, premarket clearance or premarket approval, and
post-market controls). In recent years, however, the FDA publicly announced its intention to regulate certain LDTs and issued two draft
guidance documents that set forth a proposed phased-in risk-based regulatory framework that would apply varying levels of FDA oversight
to LDTs. However, these guidance documents were withdrawn at the end of the Obama administration and replaced by an informal discussion
paper reflecting some of the feedback that FDA had received on LDT regulation. The FDA acknowledged that the discussion paper in January
2017 does not represent the formal position of the FDA and is not enforceable. Nevertheless, the FDA wanted to share its synthesis of
the feedback that it had received in the hope that it might advance public discussion on future LDT oversight. Notwithstanding the discussion
paper, the FDA continues to exercise enforcement discretion and may decide to regulate certain LDTs on a case-by-case basis at any time,
which could result in delay or additional expense in offering our tests and tests that we may develop in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a
matter of policy, the FDA generally does not review Direct-to-Consumer LDTs that are created and performed in a single laboratory, if
they are offered to patients only when prescribed by a health care provider.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Legislative
proposals addressing the FDA&#8217;s oversight of LDTs have been introduced in the current and previous Congresses, and we expect that
new legislative proposals will be introduced from time-to-time. On May 17, 2022, the Senate Health, Education, Labor and Pensions (HELP)
Committee released an FDA user fees reauthorization legislative package, which incorporates contents from the Verifying Accurate Leading-edge
IVCT Development (VALID) Act that would establish a new category of in vitro clinical tests (IVCTs) comprised of traditional in vitro
diagnostics and LDTs, and grant the FDA authority to review and approve them pre-market. Such arrangement increased the likelihood for
Congress to pass a legislation that will give the FDA clear authority to regulate LDTs, but the eventual result is difficult to predict
at this time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA ultimately regulates certain LDTs, whether via final guidance, final regulation, or as instructed by Congress, our tests may be
subject to certain additional regulatory requirements. Complying with the FDA&#8217;s requirements can be expensive, time-consuming, </span>and
subject us to significant or unanticipated delays. Insofar as we may be required to obtain premarket clearance or approval to perform
or continue performing an LDT, we cannot assure you that we will be able to obtain such authorization. Even if we obtain regulatory clearance
or approval where required, such authorization may not be for the intended uses that we believe are commercially attractive or are critical
to the commercial success of our tests. As a result, the application of the FDA&#8217;s requirements to our tests could materially and
adversely affect our business, financial condition, and results of <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our
business could be harmed from the loss or suspension of a license or imposition of a fine or penalties under, or future changes in, or
changing interpretations of, CLIA or state laboratory licensing laws to which we are subject.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The clinical
laboratory testing industry is subject to extensive federal and state regulation. The regulations implementing CLIA set out federal regulatory
standards that apply to virtually all clinical laboratories operating in the U.S. (regardless of the location, size or type of laboratory),
including those operated by physicians in their offices, by requiring that they be certified by the federal government or by a federally
approved accreditation agency. CLIA is a U.S. federal law regulating clinical laboratories that perform testing on specimens derived from
humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA is intended to ensure the
quality and reliability of clinical laboratories in the U.S. by mandating specific standards in the areas of personnel qualifications,
administration, and participation in proficiency testing, patient test management, quality control, quality assurance and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspections.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Certain
US States also require state laboratory licenses in order to test specimens received from patients residing in those states or requests
received from ordering physicians in those states. We currently hold out-of-state laboratory licenses in California, New York, Maryland,
Rhode Island, and Pennsylvania.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further,
CLIA does not pre-empt state law, which in some cases may be more stringent than federal law and require additional personnel qualifications,
quality control, record maintenance and proficiency testing. The sanction for failure to comply with CLIA and state requirements may be
suspension, revocation or limitation of a laboratory&#8217;s CLIA certificate, which is necessary to conduct business, as well as significant
fines, civil and criminal penalties, the imposition of directed plan of correction, and on-site monitoring. If we were to be found out
of compliance with CLIA program requirements and subjected to sanctions, our business and reputation could be harmed. Several states have
similar laws, and we may be subject to similar penalties. If the CLIA certification of one laboratory owned by the Company is suspended
or revoked that may preclude the Company from owning or operating any other CLIA regulated laboratory for two years. Further, even if
it were possible for us to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue
in doing so.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We cannot
assure you that applicable statutes and regulations will not be interpreted or applied by a prosecutorial, regulatory or judicial authority
in a manner that would adversely affect our business. Potential sanctions for violation of these statutes and regulations include significant
fines and the suspension or loss of various licenses, certificates and authorizations, which could have a material adverse effect on our
business. In addition, compliance with future legislation could impose additional requirements on us, which may be costly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Failure
to establish and comply with appropriate quality standards to assure that the highest level of quality is observed in the performance
of our testing services and in the design, manufacture and marketing of our products could adversely affect the results of our operations
and adversely impact our reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The
provision of clinical testing services, and the design, manufacture and marketing of diagnostic products involve certain inherent risks.
The services that we provide and the products that we design, manufacture and market are intended to provide information for healthcare
providers in providing patient care. Therefore, users of our services and products may have a greater sensitivity to errors than the users
of services or products that are intended for other purposes. Similarly, negligence in performing our services can lead to injury or other
adverse events. We may be sued under common law, physician liability or other liability law for acts or omissions by our laboratory personnel.
We are subject to the attendant risk of substantial damages awards and risk to our reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We could be adversely affected
by violations of the FCPA and other worldwide anti-bribery <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are
subject to the FCPA, which prohibits companies and their intermediaries from making payments in violation of law to non-U.S. government
officials for the purpose of obtaining or retaining business or securing any other improper advantage. We are increasing our direct sales
and operations personnel outside the United States, in which we have limited experience. We use a limited number of independent distributors
to sell our tests internationally, which requires a high degree of vigilance in maintaining our policy against participation in corrupt
activity, because these distributors could be deemed to be our agents, and we could be held responsible for their actions. Other U.S.
companies in the medical device and pharmaceutical fields have faced criminal penalties under the FCPA for allowing their agents to deviate
from appropriate practices in doing business with these individuals. We are also subject to similar anti- bribery laws in the jurisdictions
in which we operate, including anti-bribery laws in Australia which also prohibits commercial bribery and makes it a crime for companies
to fail to prevent bribery. These laws are complex and far-reaching in nature, and, as a result, we cannot assure you that we would not
be required in the future to alter one or more of our practices to be in compliance with these laws or any changes in these laws or the
interpretation thereof. Any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant
management distraction, involve significant costs and expenses, including legal fees, and could result in a material adverse effect on
our business, prospects, financial condition or results of operations. We could also incur severe penalties, including criminal and civil
penalties, disgorgement and other remedial measures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If
we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial
results or prevent fraud.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective
internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure
controls and procedures, are designed to prevent fraud. Any failure to design and implement an effective system of internal control may
reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses. Ineffective internal
controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the
trading price of the ADSs and our Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of
June 30, 2020, we had identified a material weakness in our internal control over financial reporting in relation to segregation of duties.
Such material weakness was remedied as of June 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of
June 30, 2023, our Chief Executive Officer and Chief Financial Officer assessed the effectiveness of our internal control over financial
reporting. We did not identify any material weakness in our internal control over financial reporting during the year. However, we cannot
assure you that the measures we have taken to date, and actions we may take in the future, will be sufficient to prevent potential future
material weaknesses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Failure
to comply with health information privacy laws, including HIPAA or other U.S. federal or state health information privacy and security
laws, as applicable, may negatively impact our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant
to the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technology
for Economic and Clinical Health Act of 2009, or HITECH, covered entities (including health plans, healthcare clearinghouses, </span>and
certain healthcare providers), as well as their respective &#8220;business associates&#8221; that create, receive, maintain or transmit
individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security
and transmission of individually identifiable health information. Individuals and entities who are subject to HIPAA must comply with comprehensive
privacy and security standards with respect to the use and disclosure of protected health information, as well as standards for electronic
transactions, including specified transaction and code set rules. Under HITECH, HIPAA was expanded, including requirements to provide
notification of certain identified data breaches, direct patient access to laboratory records, the extension of certain HIPAA privacy
and security standards directly to business associates, and heightened penalties for noncompliance, and enforcement efforts. Failure to
comply with HIPAA or other U.S. federal and state health information privacy and security laws, as applicable, could result in significant
penalties</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If
we or our partners fail to comply with the complex federal, state, local and foreign laws and regulations to the extent that apply to
our business, we could suffer severe consequences that could materially and adversely affect our operating results and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our operations are subject
to extensive federal, state, local and foreign laws and regulations, all of which are subject to <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">change. </span>The
U.S. laws and regulations that may apply to our business include, among other <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLIA, which requires that laboratories obtain certification from the federal government, and state licensure <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">laws;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA laws and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulations;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, which imposes comprehensive federal standards with respect to the privacy and security of protected health information and requirements for the use of certain standardized electronic transactions; amendments to HIPAA under HITECH, which strengthen and expand HIPAA privacy and security compliance requirements, increase penalties for violators, extend enforcement authority to state attorneys general and impose requirements for breach notification;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state laws regulating genetic testing and protecting the privacy of genetic test results, as well as state laws protecting the privacy and security of health information and personal data and mandating reporting of breaches to affected individuals and state regulators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal and state fraud and abuse laws, such as false claims and anti-kickback laws, and prohibitions on self-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">referral;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 216 of the federal Protecting Access to Medicare Act of 2014 (&#8220;PAMA&#8221;), which requires applicable laboratories to report private payer data in a timely and accurate manner;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state laws that impose reporting and other compliance-related requirements; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">similar foreign laws and regulations that apply to us in the countries in which we <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operate.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These
laws and regulations are complex and are subject to interpretation by the courts and by government agencies. Our failure to comply could
lead to significant administrative civil or criminal penalties, exclusion from participation in state and federal health care programs,
imprisonment, disgorgement, and prohibitions or restrictions on our laboratory&#8217;s ability to provide or receive payment for our services.
We believe that we are in material compliance with all statutory and regulatory requirements that apply to us, but there is a risk that
one or more government agencies could take a contrary position, or that a private, party could file suit under the qui tam <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provisions</span>
of the federal False Claims Act or a similar state law. Such occurrences, regardless of their outcome, could damage our reputation and
adversely affect important business relationships with third parties, including managed care organizations, and other private third-party
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A
failure to comply with any of federal or state laws to the extent such are applicable to our business, particularly laws related to the
elimination of healthcare fraud, may adversely impact our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The
healthcare industry is subject to changing political, economic, and regulatory influences that may affect our business. During the past
several years, the healthcare industry has been subject to an increase in governmental regulation and subject to potential disruption
due to legislative initiatives and government regulation, as well as judicial interpretations thereof. While these regulations may not
directly impact us or our offerings in every instance, they will affect the healthcare industry as a whole and may impact patient use
of our services. We currently accept payments only from our customers not any third-party payers, such as government healthcare programs
or health insurers. Because of this approach, we are not subject to many of the laws and regulations that impact many other participants
in the healthcare industry.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the
government asserts broader regulatory control over companies like ours or if we determine that we will change our business model and accept
payment from and/or participate in third-party payer programs, the complexity of our operations and our compliance obligations will materially
increase. Failure to comply with any applicable federal, state, and local laws and regulations could have a material adverse effect on
our business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">While
we seek to conduct our business in compliance with all applicable healthcare laws and regulations, regulatory or law enforcement authorities
may not agree with our interpretation of these laws and regulations and may seek to enforce legal remedies or penalties against us for
violations. Any action brought against us for violation of these or other laws or regulations, even if we <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation </span>of
our business. If our operations are found to be in violation of any of the federal, state, fraud and abuse or other healthcare laws and
regulations that apply to us, we may be subject to penalties, including significant criminal, civil, and administrative penalties, damages
and fines, disgorgement, additional reporting requirements and oversight, and imprisonment for individuals, as well as contractual damages
and reputational harm. We could also be required to curtail or cease our operations. Any of the foregoing consequences could seriously
harm our business and our financial results. From time to time we may need to change our operations, particularly pricing or billing practices,
in response to changing interpretations of these laws and regulations or regulatory or judicial determinations with respect to these laws
and regulations. These occurrences, regardless of their outcome, could damage our reputation and harm important business relationships
that we have with healthcare providers, payers and others.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">We face risks associated with currency
exchange rate fluctuations, which could adversely affect our operating <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We receive a portion of our revenues
and pay a portion of our expenses in currencies other than the Australian dollar, such as the U.S. dollar, the Euro and the British pound.
As a result, we are at risk for exchange rate fluctuations between such foreign currencies and the Australian dollar, which could affect
the results of our operations. If the Australian dollar strengthens against foreign currencies, the translation of these foreign currency
denominated transactions will result in decreased revenues and operating expenses. We may not be able to offset adverse foreign currency
impact with increased revenues. Other than holding foreign currency bank accounts in which revenues from foreign currency denominated
sales are held, offering a natural hedge against some foreign currency expenditures, we do not currently utilize other hedging
strategies to mitigate foreign currency risk. Even if we were to implement hedging strategies to mitigate foreign currency risk, these
strategies might not eliminate our total exposure to foreign exchange rate fluctuations and would involve costs and risks of their own,
such as ongoing management time and expertise, external costs to implement the strategies and potential accounting implications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Government
regulation of genetic research or testing may adversely affect the demand for our services and impair our business and operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition
to the regulatory framework governing healthcare, genetic research and testing has been the focus of public attention and regulatory scrutiny.
From time to time, federal, state and/or local governments adopt regulations relating to the conduct of genetic research and genetic testing.
In the future, these regulations could limit or restrict genetic research activities as well as genetic testing for research or clinical
purposes. In addition, if such regulations are adopted, these regulations may be inconsistent with, or in conflict with, regulations adopted
by other government bodies. Regulations relating to genetic research activities could adversely affect our ability to conduct our research
and development activities. Regulations restricting genetic testing could adversely affect our ability to market and sell our products
and services. Accordingly, any regulations of this nature could increase the costs of our operations or restrict our ability to conduct
our testing business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Failure
in our information technology systems could significantly increase testing turn-around times or impact on the billing processes or otherwise
disrupt our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
laboratory operations depend, in part, on the continued performance of our information technology systems. Our information</span> technology
systems are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptions. Sustained system failures
or interruption of our systems in our laboratory operations could disrupt our ability to process laboratory requisitions, perform testing,
and provide test results in a timely manner and/or billing process. Failure of our information technology systems could adversely affect
our business and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any
significant disruption in service on our website or in our computer or logistics systems, whether due to a failure with our information
technology systems or that of a third-party vendor, could harm our reputation and may result in a loss of customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Customers
purchase and access our services through our websites. Our reputation and ability to attract, retain and serve our customers, patients,
and members is dependent upon the reliable performance of our website, network infrastructure and content delivery processes. Interruptions
in any of these systems, whether due to system failures, computer viruses or physical or electronic break-ins, could affect the security
or availability of our website, including our databases, and prevent our customers, patients, and members from accessing and using our
services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our
systems and operations are also vulnerable to damage or interruption from fire, flood, power loss, telecommunications failure, terrorist
attacks, acts of war, electronic and physical break-ins, earthquake and similar events. For example, our headquarters are located in Melbourne,
Australia where increased bush fire and flood activity has recently been experienced. In the event of any catastrophic failure involving
our website, we may be unable to serve our web traffic. In addition, our sole laboratory in Melbourne, Australia is responsible for a
significant portion of our operations of our geneType risk assessment tests, these operations would be materially disrupted in the event
any of these events were to occur. The occurrence of any of the foregoing risks could result in damage to our systems or could cause them
to fail completely, and our insurance may not cover such risks or may be insufficient to compensate us for losses that may occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally,
our business model is dependent on our ability to deliver kits to customers and have kits processed and returned to us. This requires
coordination between our logistics providers and third-party shipping services. Operational disruptions may be caused by factors outside
of our control such as hostilities, political unrest, terrorist attacks, natural disasters, pandemics (such as COVID-19) and public health
emergencies, affecting the geographies where our operations and customers are located. We may not be effective at preventing or mitigating
the effects of such disruptions, particularly in the case of a catastrophic event. In addition, operational disruptions may occur during
the holiday season, causing delays or failures in deliveries of our kits. Any such disruption may result in lost revenues, a loss of customers
and reputational damage, which would have an adverse effect on our business, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Breaches
of network or information technology, natural disasters or terrorist attacks could have an adverse impact on our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cyber-attacks
or other breaches of information technology security, natural disasters, or acts of terrorism or war may result in hardware failure or
disrupt our product testing or research and development activities. There has been a substantial increase in frequency of successful and
unsuccessful cyber-attacks on companies in recent years. Such an event may result in our inability, or the inability of our collaborative
partners, to operate the facilities to conduct and complete the necessary activities, which even if the event is for a limited period
of time, may result in significant expenses and/ or significant damage or delay to our commercial or research activities. While we maintain
insurance cover for some of these events, the potential liabilities associated with these events could exceeded the cover we maintain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Ethical and other concerns surrounding
the use of genetic information may reduce the demand for our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Public
opinion regarding ethical issues related to the confidentiality and appropriate use of genetic testing may influence government authorities
to call for limits on, or regulation of the use of, genetic testing. In addition, such authorities could prohibit testing for genetic
predisposition to certain conditions, particularly for those that have no known cure. Furthermore, adverse publicity or public opinion
relating to genetic research and testing, even in the absence of any governmental regulation, could reduce the potential markets for our
products and services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Risks associated with our intellectual
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The
patenting of genes and issues surrounding access to genetic knowledge are the subjects of extensive and ongoing public debate in many
countries. By way of example, the Australian Law Reform Commission has previously conducted two inquiries into the social uses of genetic
information. The patents we hold in respect of &#8220;non-coding&#8221; DNA have broad scope and have also been the subject of debate
and some criticism in the media. Individuals or organizations, in any one of the countries in which these patents have issued, could take
legal action to seek their amendment, revocation or invalidation, something which has happened previously, on several occasions in various
jurisdictions, though we have prevailed in all such cases. Furthermore, any time that we initiate legal action against parties that infringe
our patents we face a risk that the infringer will defend itself through a counterclaim of patent invalidity or other such claims. Subsequent
legal action could potentially overturn, invalidate or limit the scope of our patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">We rely heavily upon patents and proprietary
technology that may fail to protect our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We rely
upon our portfolio of patent rights, patent applications and exclusive licenses to patents and patent applications relating to genetic
technologies. We expect to aggressively patent and protect our proprietary technologies. However, we cannot be certain that any additional
patents will be issued to us because of our domestic or foreign patent applications or that any of our patents will withstand challenges
by others. Patents issued to, or licensed by us may be infringed or third parties may independently develop the same or similar technologies.
Similarly, our patents may not provide us with meaningful protection from competitors, including those who may pursue patents which may
prevent, limit or interfere with our products or which may require licensing and the payment of significant fees or royalties by us to
such third parties in order to enable us to conduct our business. We may sue or be sued by third parties regarding our patents and other
intellectual property rights. These suits are often costly and would divert valuable funds, time and technical resources from our operations
and cause a distraction to management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also
rely upon unpatented proprietary technologies and databases. Although we require employees, consultants and collaborators to sign confidentiality
agreements, we may not be able to adequately protect our rights in such unpatented proprietary technologies and databases, which could
have a material adverse effect on our business. For example, others may independently develop substantially equivalent proprietary information
or techniques or otherwise gain access to our proprietary technologies or disclose our technologies to our competitors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We
may face difficulties in certain jurisdictions in protecting our intellectual property rights, which may diminish the value of our intellectual
property rights in those jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The
laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia
and many companies have encountered significant difficulties in protecting and defending such rights in such other jurisdictions. </span>If
we or our collaboration partners encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual
property rights for our business in such jurisdictions, the value of those rights may be diminished and we may face additional competition
from others in those jurisdictions. In addition, many countries limit the enforceability of patents against governments agencies or government
contractors. In those countries, the patent owner may have limited remedies, which could materially diminish the value of such patent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our
operations may be adversely affected by the effects of extreme weather conditions or other interruptions in the timely transportation
of specimens.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may
be required to transport specimens from the U.S. or other distant locations to our laboratory located in Melbourne, Australia. Our operations
may be adversely impacted by extreme weather conditions or other interruptions such as was the case with the COVID pandemic in the timely
transportation of such specimens or otherwise to provide our services, from time to time. The occurrence of any such event and/or a disruption
to our operations as a result may harm our reputation and adversely impact our results of <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our CIT Platform will expose us to
various <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our
Consumer Initiated Testing platform (CIT), allows consumers to directly request any of our tests online with a practitioner involved in
the process, will be subject to various risks, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk of failure to protect personal medical <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">information;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk of breach of cyber security for the platform; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk that the platform will fail to perform as <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expected.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify">Our ability to conduct our
services in a particular U.S. state or non-U.S. jurisdiction is dependent upon the applicable laws governing remote healthcare, the
practice of medicine and healthcare delivery in general in such location which are subject to changing political, regulatory and
other influences, and corporate practice of medicine limitations. Some state medical boards have established new rules or
interpreted existing rules in a manner that limits or restricts the practice of telemedicine. The extent to which a U.S. state or <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">non-</span>U.S.
jurisdiction considers particular actions or relationships to constitute practicing medicine is subject to change and to evolving
interpretations by (in the case of U.S. states) medical boards and state attorneys general, among others, and (in the case of
non-U.S. jurisdictions) the relevant regulatory and legal authorities, each with broad discretion. Accordingly, we must monitor our
compliance with law in every jurisdiction in which we operate, on an ongoing basis, and we cannot provide assurance that our
activities and arrangements, if challenged, will be found to be in compliance with the law. If a successful legal challenge or an
adverse change in the relevant laws were to occur, we could be subject to significant penalties. Further, if we were unable to adapt
our business model to comply with such laws, our operations in the affected jurisdictions would be disrupted, which could have a
material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><b><i>Discontinuation or recalls
of existing testing products or our customers using new technologies to perform their own <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tests
could adversely affect our business.</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Discontinuation
or recalls of existing testing products or our customers using new technologies to perform their own tests could adversely affect the
Company&#8217;s business. Manufacturers may discontinue or recall reagents, test kits or instruments used by us to perform laboratory
testing. Such discontinuations or recalls could adversely affect our costs, testing volume and revenue. In addition, advances in technology
may lead to the development of more cost-effective technologies such as point-of-care testing equipment that can be operated by physicians
or other healthcare providers in their offices or by patients themselves without requiring the services of freestanding clinical laboratories.
Development of such technology and its use by our customers could reduce the demand for our laboratory testing services and the utilization
of certain tests offered by us and negatively impact our revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">The PRS test may not be able to obtain
necessary regulatory clearance, we may not generate any <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">All of
our existing products are subject to regulation in Australia by the Therapeutic Goods Association (TGA), the U.S. by the FDA and/or other
domestic and international governmental, public health agencies, regulatory bodies or non-governmental organizations. The process of obtaining
required approvals or clearances for a potential new product varies according to the nature of and uses for a specific product. These
processes can involve lengthy and detailed laboratory testing, human clinical trials, sampling activities, and other costly, time-consuming
procedures. The submission of an application to a regulatory authority does not guarantee that the authority will grant an approval or
clearance for the product. Each authority may impose its own requirements and can delay or refuse to grant approval or clearance, even
though a product has been approved in another country. The time taken to obtain approval or clearance varies depending on the nature of
the application and may result in the passage of a significant period of time from the date of submission of the application. Delays in
the approval or clearance processes increase the risk that we will not succeed in introducing or selling the subject products, and we
may be required to abandon the PRS after devoting substantial time and resources to its development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">If
our PRS test is required to obtain and maintain FDA approvals, it will be subject to continuing governmental regulations and additional
foreign regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">If the
FDA determines that enforcement discretion is not appropriate or that LDTs are generally subject to FDA regulation and that premarket
review, including clearance or approval, is required for our PRS tests or any of our future tests, diagnostic test kits that we may develop,
or other products that would be classified as medical devices, the process of obtaining regulatory clearances or approvals to market a
medical device can be costly and time consuming, and we may not be able to obtain these clearances or approvals on a timely <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">basis,
if at all. In particular, the FDA permits commercial distribution of a new medical device only after the device has received clearance
</span>under Section 510(k) of the Federal Food, Drug and Cosmetic Act, or is the subject of an approved premarket approval application,
or PMA or reclassification of the device through the De Novo classification process, unless the device is specifically exempt from those
requirements. The FDA will clear marketing of a lower risk medical device through the 510(k) process if the manufacturer demonstrates
that the new product is substantially equivalent to other 510(k)-cleared products. High risk devices deemed to pose the greatest risk,
such as life-sustaining, life-supporting, or implantable devices, or devices not deemed substantially equivalent to a previously cleared
device, require the approval of a PMA. The PMA process is more costly, lengthy and uncertain than the 510(k)-clearance process. A PMA
application must be supported by extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing
and labeling data, to demonstrate to the FDA&#8217;s satisfaction the safety and efficacy of the device for its intended use. The De Novo
classification process is an alternate pathway to classify medical devices that are automatically classified into Class III but which
are low to moderate risk. A manufacturer can submit a petition for direct De Novo review if the manufacturer is unable to identify an
appropriate predicate device and the new device or new use of the device presents moderate or low risk. De Novo classification may also
be available after receipt of a &#8220;not substantially equivalent&#8221; letter following submission of a 510(k) to FDA. Our currently
commercialized products have not received FDA clearance or approval, as they are marketed under the FDA&#8217;s enforcement discretion
for LDTs. Even if regulatory clearance or approval of a product is required and granted, such clearance or approval may be subject to
limitations on the intended uses for which the product may be marketed and reduce our potential to successfully commercialize the product
and generate revenue from the product. If the FDA determines that our promotional materials, labeling, training or other marketing or
educational activities constitute promotion of an unapproved use, it could request that we cease or modify our training or promotional
materials or subject us to regulatory enforcement actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are
also subject to other federal, state, and foreign regulation concerning the manufacture and sale of our products. Our failure to comply
with U.S. federal, state and foreign governmental regulations could lead to the issuance of warning letters or untitled letters, government
investigation, the imposition of injunctions, suspensions or loss of regulatory clearance or approvals, product recalls, termination of
distribution, product seizures or civil penalties. In the most extreme cases, criminal sanctions or closure of our manufacturing facility
are possible, any of which could adversely affect our business, operating results and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The FDA
and similar foreign governmental authorities have the authority to require the recall of regulated products in the event of material deficiencies
or defects in design or manufacture. In the case of the FDA, the authority to require a recall must be based on an FDA finding that there
is a reasonable probability that the device would cause serious injury or death. In addition, foreign governmental bodies have the authority
to require the recall of our products in the event of material deficiencies or defects in design or manufacture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Manufacturers may, under their
own initiative, recall a product if any material deficiency in a device is found. A government-mandated or voluntary recall by us could
occur as a result of component failures, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of
any of our products would divert managerial and financial resources and have an adverse effect on our financial condition and results
of operations. The FDA requires that certain classifications of recalls be reported to FDA within 10 working days after the recall is
initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate
voluntary recalls involving our products in the future that we determine do not require notification of the FDA. If the FDA disagrees
with our determinations, they could require us to report those actions as recalls. A future recall announcement could harm our reputation
with customers and negatively affect our sales. In addition, the FDA could take enforcement action for failing to report the recalls when
they were conducted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Declining general economic
or business conditions may have a negative impact on our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the
current economic climate deteriorates, our business, including our access to patient samples and the addressable market for diagnostic
tests that we may successfully develop, as well as the financial condition of our suppliers and our third-party payers, could be adversely
affected, resulting in a negative impact on our business, financial condition, results of operations and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">RISKS RELATED TO OUR
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0">Our ADSs may be delisted from the
NASDAQ Capital <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March
13, 2020, the Company received a determination letter (the &#8220;Letter&#8221;) from NASDAQ indicating that we did not comply with the
stockholders&#8217; equity rule. The Letter indicated that Listing Rule 5815(d)(4)(B) does not permit an issuer that is deficient in stockholders&#8217;
equity to present a plan of compliance to the NASDAQ Staff if such issuer has failed to comply with that provision within one year of
a Hearing Panel (the &#8220;Panel&#8221;) determination of compliance. The Letter stated that since the Company was not compliant with
the equity rule within one year of the Compliance Letter, the Staff cannot allow us to submit a plan of compliance. We requested an appeal
hearing with the Panel to review the delisting determination. Upon NASDAQ&#8217;s receipt of the hearing request by the Company, NASDAQ
stayed the suspension of our securities and the filing of the Form 25-NSE pending the Panel&#8217;s decision. An oral hearing took place
on April 30, 2020 and in a letter dated May 12, 2020, the Panel granted the Company the full 180-day extension until September 9, 2020,
to publicly disclose full compliance with the minimum shareholder equity requirement under NASDAQ rules. The Company subsequently regained
compliance with NASDAQ Listing Rule 5550(b)(1) as of August 25, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 21, 2020, we closed a
registered direct offering of 1,025,000 ADSs, each representing six hundred (600) of the Company&#8217;s ordinary shares, at a purchase
price of United States Dollars (US$) US$5.00 per ADS - or in Australian dollars A$0.012 per ordinary share. The gross proceeds for this
offering were approximately US$5.1 million. Against the offering, the Company agreed to issue 39,975,000 warrants exercisable
at US$0.0104 each, expiring in 5 years from issue date, to H.C. Wainwright &amp; Co which would form part of cost of raising capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 25, 2021, we closed
a registered direct offering of 1,250,000 ADSs, each representing six hundred (600) of the Company&#8217;s ordinary shares, at a purchase
price of United States Dollars (US$) US$5.25 per ADS - or in Australian dollars A$0.01125 per ordinary share. The gross proceeds for
this offering were approximately US$6.56 million. Against the offering, the Company agreed to issue 48,750,000 warrants exercisable
at US$0.010938 each, expiring in 5 years from issue date, to H.C. Wainwright &amp; Co which would form part of cost of raising capital.
The said warrants were subject to shareholder approval, which was granted by shareholders at the Company&#8217;s Annual General Meeting
(AGM) held 24 November 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 8, 2023, we closed
a registered direct offering of 3,846,155 ADSs, each representing six hundred (600) of the Company&#8217;s ordinary shares, at a purchase
price of United States Dollars (US$) US$1.30 per ADS. The gross proceeds for this offering were approximately US$5 million. Against
the offering, the Company agreed to issue 250,000 warrants exercisable at US$1.625 each, expiring in 5 years from issue date, to H.C.
Wainwright &amp; Co which would form part of cost of raising capital. The said warrants are subject to shareholder approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July
17, 2023, the Company received notification from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement
of Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market, since the closing bid price for the Company&#8217;s
American Depositary Shares (ADS) on the Nasdaq Capital Market was below US$1.00 for 34 consecutive trading days. Nasdaq Listing Rule 5550(a)(2)
requires the ADS to maintain a minimum bid price of US$1.00 per share (the &#8220;Minimum Bid Requirement&#8221;), and Nasdaq Listing
Rule 5810(c)(3)(A) provides that failure to meet such requirement exists if the deficiency continues for a period of 30 consecutive business
days. The Notification has no immediate effect on the listing of the Company&#8217;s ADS on the Nasdaq Capital Market. Under Nasdaq Listing
Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of Notification, which was July 17, 2023, to regain compliance
with the minimum bid requirement, during which time the ADS will continue to trade on the Nasdaq Capital Market. If at any time before
January 15, 2024, the bid price of the ADS closes at or above US$1.00 per ADS for a minimum of 10 consecutive business days, the Company
will regain compliance with the Minimum Bid Requirement. In the event the Company does not regain compliance with the Minimum Bid Requirement
by January 15, 2024, <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the</span> Company may be eligible for an additional period of 180 calendar
days to regain compliance or may be subject to delisting of the ADS from the Nasdaq Capital Market. The Company will continuously monitor
the closing bid price of its ADS between now and January 15, 2024, and will evaluate its options to regain compliance with Nasdaq Listing
Rule 5550(a)(2) before such date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">However,
there can be no assurance that the Company will continue to be successful in maintaining net assets and minimum bid compliance and that
our securities will remain listed on the NASDAQ Capital Market. The delisting of our ADSs by NASDAQ would have material negative impacts
on the liquidity of our securities and our ability to raise future capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Our stock price
is volatile and can fluctuate significantly based on events not in our control and general industry <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions. </span>As
a result, the value of your investment may decline <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The biotechnology
sector can be particularly vulnerable to abrupt changes in investor sentiment. Stock prices of companies in the biotechnology industry,
including ours, can swing dramatically, with little relationship to operating performance. Our stock price may be affected by a number
of factors including, but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">global economic uncertainty and financial market volatility caused by political instability, changes in international trade relationships and international conflicts, such as the conflict between Russia and Ukraine;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product development <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">events;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the outcome of <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decisions relating to intellectual property <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">rights;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the entrance of competitive products or technologies into our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">markets;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new medical <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discoveries;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the establishment of strategic partnerships and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">alliances;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in pricing policies or other practices related to the healthcare industry; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other industry and market changes or <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trends.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since our listing on the Australian
Securities Exchange in August 2000, the price of our Ordinary Shares has ranged from a low of A$0.002 to a high of A$0.88 per share. Further
fluctuations are likely to occur due to events which are not within our control and general market conditions affecting the biotechnology
sector or the stock market generally.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition,
low trading volume may increase the volatility of the price of our ADSs. A thin trading market could cause the price of our ADSs to fluctuate
significantly more than the stock market as a whole. For example, trades involving a relatively small number of our ADSs may have a greater
impact on the trading price for our ADSs than would be the case if the trading volume were higher.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">The fact that we do not expect to
pay cash dividends may lead to decreased prices for our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have
never declared or paid a cash dividend on our Ordinary Shares and we do not anticipate doing so in the foreseeable future. We intend to
retain future cash earnings, if any, for reinvestment in the development and expansion of our business. Whether we pay cash dividends
in the future will be at the discretion of our Board of Directors and may be dependent on our financial condition, results of operations,
capital requirements and any other factors our Board of Directors decides is relevant. As a result, an investor may only recognize an
economic gain on an investment in our stock from an appreciation in the price of our stock, which is uncertain and unpredictable. There
is no guarantee that our Ordinary Shares will appreciate in value or even maintain the price at which an investor purchased the Ordinary
Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">You may have difficulty in effecting
service of legal process and enforcing judgments against us and our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify">We are a public company limited
by shares, registered and operating under the Australian <i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporations Act 2001</i>. All of our directors and officers named in this
Annual Report reside outside the U.S. Substantially all, or a substantial portion of, the assets of those persons are also located outside
the U.S. As a result, it may not be possible to affect service on such persons in the U.S. or to enforce, in foreign courts, judgments
against such persons obtained in U.S. courts and predicated on the civil liability provisions of the federal securities laws of the U.S.
Furthermore, substantially all of our directly owned assets are located outside the U.S., and, as such, any judgment obtained in the U.S.
against us may not be collectible within the U.S. There is doubt as to the enforceability in the Commonwealth of Australia, in original
actions or in actions for enforcement of judgments of U.S. courts, of civil liabilities predicated solely upon federal or state securities
laws of the U.S., especially in the case of enforcement of judgments of U.S. courts where the defendant has not been properly served in
Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Because
we are not required to provide you with the same information as an issuer of securities based in the United States, you may not be afforded
the same protection or information you would have if you had invested in a public corporation based in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are
exempt from certain provisions of the Securities Exchange Act of 1934, as amended, commonly referred to as the Exchange Act, that are
applicable to U.S. public companies, including (i) the rules under the Exchange Act requiring the filing with the SEC of quarterly reports
on Form 10-Q and current reports on Form 8-K; (ii) the sections of the Exchange Act regulating the solicitation of proxies, consents or
authorizations in respect of a security registered under the Exchange Act; and (iii) the sections of the Exchange Act requiring insiders
to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short
period of time. The exempt provisions would be available to you if you had invested in a U.S. corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
in line with the Australian Securities Exchange regulations, we disclose our reviewed financial results on a semi-annual </span>basis
(under International Standard on Review Engagements) and our audited financial results on an annual basis (under International Standards
on Auditing). The information, which may have an effect on our stock price on the Australian Securities Exchange, will be disclosed to
the Australian Securities Exchange and also the Securities Exchange Commission. Other relevant information pertaining to our Company will
also be disclosed in line with the Australian Securities Exchange regulations and information dissemination requirements for listed companies.
We provide our semi-annual results and other material information that we make public in Australia in the U.S. under the cover of an SEC
Form 6-K. Nevertheless, you may not be afforded the same protection or information, which would be made available to you, were you investing
in a United States public corporation because the requirements of a Form 10-Q and Form 8-K are not applicable to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As
a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ
significantly from Nasdaq corporate governance listing standards and these practices may afford less protection to shareholders than they
would enjoy if we complied fully with Nasdaq corporate governance listing standards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a foreign
private issuer listed on Nasdaq, we will be subject to their corporate governance listing standards. However, Nasdaq rules permit foreign
private issuers to follow the corporate governance practices of its home country. Some corporate governance practices in Australia may
differ from Nasdaq corporate governance listing standards. For example, we could include non-independent directors as members of our Remuneration
committee, and our independent directors may not necessarily hold regularly scheduled meetings at which only independent members of the
board of directors are present. Currently, we follow home country practice to the maximum extent possible. Therefore, our shareholders
may be afforded less protection than they otherwise would have under corporate governance listing standards applicable to U.S. domestic
issuers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may
lose our foreign private issuer status in the future, which could result in significant additional cost and expense. While we currently
qualify as a foreign private issuer, the determination of foreign private issuer status is made annually on the last business day of an
issuer&#8217;s most recently completed second fiscal quarter and, accordingly, our next determination will be made on December 31, 2023.
In the future, we would lose our foreign private issuer status if we to fail to meet the requirements necessary to maintain our foreign
private issuer status as of the relevant determination date. For example, if 50% or more of our securities are held by U.S. residents
and more than 50% of our senior management or directors are residents or citizens of the United States, we could lose our foreign private
issuer status. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly more
than costs we incur as a foreign private issuer. If we are not a foreign private issuer, we will be required to file periodic reports
and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive in certain respects than
the forms available to a foreign private issuer. We would be required under current SEC rules to prepare our financial statements in accordance
with U.S. GAAP rather than IFRS, and modify certain of our policies to comply with corporate governance practices required of U.S. domestic
issuers. Such conversion of our financial statements to U.S. GAAP would involve significant time and cost. In addition, we may lose our
ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private
issuers such as the ones described above and exemptions from procedural requirements related to the solicitation of proxies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As
a result of being a U.S. public company, we are subject to additional regulatory compliance requirements, including Section 404, and if
we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent
fraud.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant
to Section 404, our management will be required to assess and attest to the effectiveness of our internal control over financial reporting
in connection with issuing our consolidated financial statements as of and for the fiscal year ending June 30, 2023. Section 404 also
requires an attestation report on the effectiveness of internal control over financial reporting be provided by our independent registered
public accounting firm beginning with our annual report following the date on which we are no longer a non-accelerated filer. The cost
of complying with Section 404 will significantly increase and management&#8217;s attention may be diverted from other business concerns,
which could adversely affect our results. We may need to hire more employees in the future or engage outside consultants to comply with
these requirements, which will further increase expenses. If we fail to comply with the requirements of Section 404 in the required timeframe,
we may be subject to sanctions or investigations by regulatory authorities, including the <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC</span>
and Nasdaq. Furthermore, if we are unable to attest to the effectiveness of our internal control over financial reporting, we could lose
investor confidence in the accuracy and completeness of our financial reports, and the market price of our ordinary shares and ADSs could
decline. Failure to implement or maintain effective internal control over financial reporting could also restrict our future access to
the capital markets and subject each of us, our directors and our officers to both significant monetary and criminal liability. In addition,
changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies,
increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards
are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice
may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding
compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources
to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expense
and a diversion of management&#8217;s time and attention from revenue generating activities to compliance activities. If our efforts to
comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities
related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business, financial
position, results and prospects may be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We
will incur significant costs as a result of operating as a company with ADSs that are publicly traded in the United States, and our management
will be required to devote substantial time to new compliance initiatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a company
whose ADSs are publicly traded in the United States, we have incurred and will continue to incur significant legal, accounting, insurance
and other expenses. In addition, the Sarbanes-Oxley Act, Dodd-Frank Wall Street Reform and Consumer Protection Act and related rules implemented
by the United States Securities and Exchange Commission, or SEC, and Nasdaq have imposed various requirements on public companies listed
in the United States including requiring establishment and maintenance of effective disclosure and financial controls. Our management
and other personnel will need to devote a substantial amount of time to these compliance initiatives, and we will need to add additional
personnel and build our internal compliance infrastructure. Moreover, these rules and regulations will increase our legal and financial
compliance costs and will make some activities more time-consuming and costly. These laws and regulations could also make it more difficult
and expensive for us to attract and retain qualified persons to serve on our board of directors, our board committees or as our senior
management. Furthermore, if we are unable to satisfy our obligations as a public company listed in the United States, we could be subject
to delisting of the ADSs, fines, sanctions and other regulatory action and potentially civil litigation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">The dual listing of our ordinary shares
and the ADSs may negatively impact the liquidity and value of the <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADSs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our ADSs
are listed on Nasdaq and our ordinary shares are listed on the ASX. We cannot predict the effect of this dual listing on the value of
our ordinary shares and ADSs. However, the dual listing of our ordinary shares and ADSs may dilute the liquidity of these securities in
one or both markets and may negatively impact the development of an active trading market for the ADSs in the United States. The price
of the ADSs could also be negatively impacted by trading in our ordinary shares on the ASX.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australian
takeover laws may discourage takeover offers being made for us or may discourage the acquisition of a significant </span>position in our
ordinary shares or ADSs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are
incorporated in Australia and are subject to the takeover laws of Australia. Among other things, we are subject to the Corporations Act
2001. Subject to a range of exceptions, the Corporations Act 2001 prohibits the acquisition of a direct or indirect interest in our issued
voting shares if the acquisition of that interest will lead to a person&#8217;s voting power in us increasing to more than 20%, or increasing
from a starting point that is above 20% and below 90%. Australian takeover laws may discourage takeover offers being made for us or may
discourage the acquisition of a significant position in our ordinary shares. This may have the ancillary effect of entrenching our board
of directors and may deprive or limit our shareholders&#8217; opportunity to sell their ordinary shares and may further restrict the ability
of our shareholders to obtain a premium from such transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our
Constitution and Australian laws and regulations applicable to us may adversely affect our ability to take actions that could be beneficial
to our shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As an
Australian company we are subject to different corporate requirements than a corporation organized under the laws of the United States.
Our Constitution, as well as the Corporations Act 2001, sets forth various rights and obligations that apply to us as an Australian company
and which may not apply to a U.S. corporation. These requirements may operate differently than those of many U.S. companies. You should
carefully review the summary of these matters set forth under our Constitution, which is included as an exhibit to this annual report,
prior to investing in our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">A lack of significant liquidity for
our ADSs may negatively affect your ability to resell our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our ADSs
have traded on the NASDAQ Capital Market since June 30, 2010. An active trading market for the ADSs, however, may not be maintained in
the future. If an active trading market is not maintained, the liquidity and trading prices of the ADSs could be negatively affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">In certain circumstances, holders
of ADSs may have limited rights relative to holders of Ordinary <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The rights
of holders of ADSs with respect to the voting of Ordinary Shares and the right to receive certain distributions may be limited in certain
respects by the deposit agreement entered into by us and The Bank of New York Mellon. For example, although ADS holders are entitled under
the deposit agreement, subject to any applicable provisions of Australian law and of our Constitution, to instruct the depositary as to
the exercise of the voting rights pertaining to the Ordinary Shares represented by the American Depositary Shares, and the depositary
has agreed that it will try, as far as practical, to vote the Ordinary Shares so represented in accordance with such instructions, ADS
holders may not receive notices sent by the depositary in time to ensure that the depositary will vote the Ordinary Shares. This means
that, from a practical point of view, the holders of ADSs may not be able to exercise their right to vote. In addition, under the deposit
agreement, the depositary has the right to restrict distributions to holders of the ADSs in the event that it is unlawful or impractical
to make such distributions. We have no obligation to take any action to permit distributions to holders of our American Depositary Receipts,
or ADSs. As a result, holders of ADSs may not receive distributions made by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">RISKS RELATED TO <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAXATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We
may be classified as a passive foreign investment company, which could result in adverse U.S. federal income tax consequences for U.S.
holders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In general,
a non-U.S. company will be considered a passive foreign investment company, or PFIC, for U.S. federal income tax purposes for any taxable
year in which (1) 75% or more of its gross income consists of passive income (the &#8220;income test&#8221;) or (2) 50% or more of the
average quarterly value of its assets is attributable to assets that produce, or are held for the production of, passive income (the &#8220;asset
test&#8221;). For purposes of these tests, passive income generally includes dividends, interest, gains from the sale or exchange of investment
property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or
indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets
and received directly its proportionate share of the income of such other corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based
on the nature and composition of our income, assets, activities and market capitalization, we believe that we were classified as a PFIC
for our taxable year ended June 30, 2023. However, our PFIC status is based on an annual determination that is subject to a number of
uncertainties and may change from year to year. Our PFIC status will depend on the composition of our income (including with respect to
the R&amp;D Tax Credit) and the composition and value of our assets, which may be determined in large part by reference to the market
value of the ADSs and our Ordinary Shares, which may be volatile, from time to time. Our status may also depend, in part, on how quickly
we utilize the cash we raise in any offering of our securities. There can be no assurance that we will not be considered a PFIC in any
past, current or future taxable year, and our U.S. counsel expresses no opinion regarding our conclusions or our expectations regarding
our PFIC status.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we
are a PFIC for any taxable year during which a U.S. holder (as defined in the section titled &#8220;Item 10.E. Additional Information&#8212;Taxation,
United States Federal Income Taxation&#8221;) holds the ADSs or Ordinary Shares, the U.S. holder may be subject to adverse tax consequences
regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual
or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements. We will continue to
be treated as a PFIC with respect to such U.S. holder in all succeeding years during which the U.S. holder owns the ADSs or Ordinary Shares,
regardless of whether we continue to meet the income or asset tests described above, unless the U.S. holder makes a valid and timely qualified
electing fund (QEF) or mark-to-market election, or makes a deemed sale election once we cease to be a PFIC; however, we do not currently
intend to provide the information necessary for a U.S. holder to make a QEF election. For further discussion of the PFIC rules and the
adverse U.S. federal income tax consequences to U.S. holders in the event we are classified as a PFIC, see &#8220;Item 10.E. Additional
Information&#8212;Taxation, United States Federal Income Taxation&#8212;Passive Foreign Investment Company Rules.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">If a United
States person is treated as owning at least 10% of our ordinary shares, such holder may be subject to <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse </span>U.S.
federal income tax <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consequences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If a U.S.
holder (as defined in the section titled &#8220;Item 10.E. Additional Information&#8212;Taxation, United States Federal Income Taxation&#8221;)
is treated as owning (directly, indirectly or constructively) at least 10% of the value or voting power of our Ordinary Shares or ADSs,
such U.S. holder may be treated, for U.S. federal income tax purposes, as a &#8220;United States shareholder&#8221; with respect to each
&#8220;controlled foreign corporation&#8221; in our group, if any. Because our group includes a U.S. subsidiary (geneType Inc., previously
the named Phenogen Sciences Inc.), certain of our current and future non-U.S. subsidiaries will be treated as controlled foreign corporations,
regardless of whether we are treated as a controlled foreign corporation. A United States shareholder of a controlled foreign corporation
may be required to annually report and include in its U.S. taxable income its pro rata share of &#8220;Subpart F income,&#8221; &#8220;global
intangible low- taxed income&#8221; and investments in U.S. property by controlled foreign corporations, regardless of whether we make
any distributions. An individual that is a United States shareholder with respect to a controlled foreign corporation generally would
not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation.
We cannot provide any assurances that we will furnish to any United States shareholder information that may be necessary to comply with
the reporting <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</span> payment obligations described above. Failure to comply with such obligations
may subject a United States shareholder to significant monetary penalties and stall the beginning of the statute of limitations period
for relevant U.S. federal income tax returns. U.S. holders should consult their tax advisors regarding the potential application of these
rules to their investment in the Ordinary Shares or ADSs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Changes to tax laws could materially
adversely affect our company and reduce net returns to our <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our tax
treatment is subject to the enactment of, or changes in, tax laws, regulations and treaties, or the interpretation thereof, tax policy
initiatives and reforms under consideration and the practices of tax authorities in jurisdictions in which we operate, including those
related to the Organization for Economic Co-Operation and Development&#8217;s Base Erosion and Profit Shifting Project, the European Commission&#8217;s
state aid investigations and other initiatives. Such changes may include (but are not limited to) the taxation of operating income, investment
income, dividends received or (in the specific context of withholding tax) dividends paid. We are unable to predict what tax reform may
be proposed or enacted in the future or what effect such changes would have on our business, but such changes, to the extent they are
brought into tax legislation, regulations, policies or practices, could affect our financial position and overall or effective tax rates
in the future in countries where we have operations, reduce post-tax returns to our shareholders, and increase the complexity, burden
and cost of tax compliance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Tax
authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or
non-realization of expected benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify">A tax authority may disagree
with tax positions that we have taken, which could result in increased tax liabilities. For example, <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the </span>U.S.
Internal Revenue Service or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid
between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid
with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a
jurisdiction where we believe we have not established a taxable connection, often referred to as a &#8220;permanent
establishment&#8221; under international tax treaties, and such an assertion, if successful, could increase our expected tax
liability in one or more jurisdictions. A tax authority may take the position that material income tax liabilities, interest and
penalties are payable by us, in which case, we expect that we might contest such assessment. Contesting such an assessment may be
lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated
effective tax rate, where applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span id="F_009"></span>Item 4. Information on
the <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_010"></span>Item 4.A History and Development
of the <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Originally
incorporated under the laws of Western Australia on January 5, 1987, as Concord Mining N.L. the Company operated </span>as a mining company.
On August 13, 1991, the Company changed its name to Consolidated Victorian Gold Mines N.L. On December 2, 1991, the Company changed its
name to Consolidated Victorian Mines N.L. On March 15, 1995, the Company changed its name to Duketon Goldfields N.L.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October
15, 1999, the Company&#8217;s corporate status was changed from a No Liability Company to a company limited by shares. On August 29, 2000,
following the acquisition of Swiss company GeneType AG, the Company changed its name to Genetic <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technologies
Limited, which is its current name. At that time, the mining activities were phased out to focus on becoming a biotechnology </span>company,
following which its stock exchange listing was duly transferred from the mining board of the ASX to the industrial board and its shares
were thereafter classified under the industry Company &#8220;Health and Biotechnology&#8221;, completing its transformation from a mining
company into a biotechnology company. The Company&#8217;s current activities in biotechnology primarily concentrate on one clearly defined
area of activity which is covered under Item 4.B &#8220;Business Overview&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In October
2009, a new strategic direction was established to focus efforts in creating a portfolio of tests that would be aimed at assisting medical
clinicians with cancer management. This would comprise tests that were created by the Company and in-licensed from third parties which
would then be marketed by us in the Asia-Pacific region.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April
14, 2010, the Company announced that it had acquired certain assets from Perlegen Sciences, Inc. in California, with the main asset being
the BREVAGen&#8482; breast cancer risk assessment test (&#8220;BREVAGen&#8482;&#8221;). On June 28, 2010, the Company incorporated a wholly
owned subsidiary named Phenogen Sciences Inc, whose name changed to geneType Inc. on 4 April 2022, in the State of Delaware which commenced
selling the BREVAGen&#8482; test in the U.S. marketplace in June 2011. In October 2014, the Company released its next generation breast
cancer risk assessment test BREVAGen<i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November
19, 2014, the Company completed the sale of its Heritage Australian Genetics business to Specialist Diagnostic Services Ltd (SDS), the
wholly owned pathology subsidiary of Primary Health Care Ltd.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November
2016, the Company executed an exclusive worldwide license agreement with The University of Melbourne, for the development and commercialization
of a novel colorectal cancer (CRC) risk assessment test, providing the Company with an opportunity to enhance its pipeline of risk assessment
products. Additionally, in June 2017, the Company executed an investigator- initiated Research Agreement with The Ohio State University,
reflecting the growing awareness of the Company&#8217;s expertise in SNP- based risk assessment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During
2018, the Company executed a further collaborative research and services agreement with The University of Melbourne, with the research
designed to broaden the applicability of BREVAGen<i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus,</i> enabling its use by women with extended family history of breast cancer
as well as increase the range of factors analyzed in assessing breast cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May
2019, the Company announced the development of two new cancer risk assessment tests branded as &#8220;GeneType for Colorectal Cancer&#8221;
and &#8220;GeneType for Breast Cancer.&#8221; The new breast cancer test provides substantial improvement over its legacy breast cancer
test BREVAGen<i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus</i>, by incorporating multiple additional clinical risk factors. This test will provide healthcare providers and
their patients with a 5-year and lifetime risk assessment of the patient developing breast cancer. The colorectal cancer test will provide
healthcare providers and their patients a 5-year, 10-year, and lifetime risk assessment of the patient developing colorectal <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June 2020, the Company received
US Patent No: US10,683,549, Methods for assessing risk of developing breast cancer. The Company is the first company in the world to
successfully commercialize a polygenic risk test for breast cancer. The granted patent covers the Company&#8217;s proprietary
panels of single nucleotide polymorphisms (SNPs) and the combination of clinical and phenotypic risk models to create the most comprehensive
risk assessment tool on the market: GeneType for Breast Cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company
hired and trained a new internal sales employee to educate doctors on the Company&#8217;s polygenic risk score (PRS) tests and introduce
them to preventative health strategies. The Company received a positive response from doctors. Initial test results showed 10 per cent
of subjects were high risk and 41 per cent were moderate risk. The Company believes that these results will help create personalized strategies
specifically designed for the patient risk profile. We think early indications show the tests lead to better screening compliance and
to the development of personalized screening solutions. This confirms the Company&#8217;s objective of focusing on preventative health
rather than &#8216;after the fact&#8217; medicine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At the
same time, the Company continued to refine existing, and to develop other, risk assessment tests across a range of diseases including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breast <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancer</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Colorectal <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancer</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ovarian <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancer</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prostate <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancer</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coronary artery <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disease</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type 2 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diabetes</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreatic <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancer</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melanoma</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Atrial <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fibrillation</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company
has developed a polygenic risk score (PRS) test for COVID-19 in 2022, which may enable an assessment of the risk of people developing
a serious disease should they contract the virus. The test aims to predict disease severity using a combination of genetic and clinical
information. The Company has built strong relationships with international biobanks and health studies, including UK Biobank. They allow
us to secure additional, current COVID-19 patient data to continuously develop, refine, and validate the COVID-19 risk test.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s
single nucleotide polymorphism (SNP) array panels are supplied by US-based Thermo Fisher Scientific Inc., a world leader in genetic testing
and the Company&#8217;s manufacturing partner for geneType products. The SNP array panel is a key reagent the Company needs to process
the polygenic risk test portion of the COVID-19 risk test. The test aims to categorize subjects as being at high, average, or low risk
of developing life-threatening conditions due to COVID-19.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company
filed a provisional patent application for its COVID-19 risk test with IP Australia, an agency of Department of Industry, Innovation and
Science (Intellectual Property Australia) (2020901739 - Methods of assessing risk of developing a severe response to Coronavirus infection).
The provisional patent covers the specific single nucleotide polymorphism (SNP) algorithm the Company designed to calculate a PRS and
the testing model that combines PRS and the clinical risk factors that together constitute the COVID-19 risk test. Subsequently this patent
has been granted in the United States and pending grant in several other key markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company
executed an acquisition agreement (&#8220;Acquisition Agreement&#8221;) on July 19<sup style="font-family: Times New Roman, Times, Serif; font-size: 10pt">th</sup>, 2021 to acquire the direct-to- consumer
eCommerce business and distribution rights associated with General Genetics Corporation and its associated brands trading as EasyDNA,
from BelHealth Investment Fund LP. The Acquisition Agreement provides for the acquisition of all brands, websites and agency reseller
agreements associated with EasyDNA. This includes over 70 websites in 40 countries and six brand identities. Under the terms of the Acquisition
Agreement, the Company acquired 100% of EasyDNA&#8217;s brands and assets within the General Genetics Corporation business for a purchase
price of US$4 million, comprising cash consideration of US$2.5 million and US$1.5 million of <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADSs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company
executed an asset purchase agreement (&#8220;APA&#8221;) on July 14th, 2022 to acquire the direct-to-consumer eCommerce <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business,
laboratory testing and distribution agreements associated with AffinityDNA. The APA provides for the acquisition of all brands </span>and
websites associated with AffinityDNA. This includes the AffinityDNA Amazon sales channel rights. Under the terms of the APA, the Company
acquired 100% of AffinityDNA&#8217;s brands and assets for a purchase price of GBP555,000, comprising cash consideration of GBP227,500
on completion and GBP227,500 payable in July 2023 subject to the AffinityDNA business attaining certain financial performance parameters.
The second payment was payable on the achievement of a gross profit target for the 12-month period from the <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquisition
date. This target was not achieved and therefore no further payment is to be made in respect of the acquisition of AffinityDNA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On 3 February
2023, GTG announced the launch of the first Comprehensive Risk Test for Breast &amp; Ovarian Cancer. The test evaluates a woman&#8217;s
risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic
cancer. In combination with other clinical risk factors, the test provides a comprehensive risk assessment in a simple saliva test.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">SEC maintains
an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically
with the SEC and state the address of that site (http:// www.sec.gov). The Company&#8217;s website address is https:// genetype.com. The
information contained on our website is not incorporated by reference into this annual report on Form 20-F.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Corporate <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s
registered office, headquarters and laboratory is located at 60-66 Hanover Street, Fitzroy, Victoria, 3065, Australia and its telephone
number is +61 3 8412 7000. The office of its U.S. subsidiary, geneType Inc. (formerly Phenogen Sciences Inc.), is located at 1300 Baxter
Street, Suite 255, Charlotte, North Carolina, 28204 U.S.A. The telephone number for the geneType Inc. office is (704) 926 5700. The Company&#8217;s
website address is www.genetype.com. The information in its website is not incorporated by reference into this Annual Report and should
not be considered as part of this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s
Australian Company Number (ACN) is 009 212 328. The Company&#8217;s Australian Business Number (ABN) is 17 009 212 328. The Company operates
pursuant to its constitution, the Australian <i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporations Act 2001</i>, the Listing Rules of the Australian Securities Exchange, the
Marketplace Rules of The NASDAQ Stock Market, and where applicable, local, state and federal legislation in the countries in which the
Company operates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span id="F_011"></span>Item 4.B Business Overview Description of
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Founded
in 1989, Genetic Technologies listed its Ordinary Shares on the ASX (GTG) in 2000 and its ADSs on NASDAQ&#8217;s Capital Market (GENE)
in 2005. Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians
proactively manage people&#8217;s health. The Company&#8217;s legacy product, BREVAGen<i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus</i>, was a clinically validated risk assessment
test for non-hereditary breast cancer and was first in its class. BREVAGen<i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus</i> improved upon the predictive power of the first
generation BREVAGen&#8482; test and was designed to facilitate better informed decisions about breast cancer screening and preventive
treatment plans. BREVAGen<i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus </i>expanded the application of BREVAGen&#8482; from Caucasian women to include African Americans and
Hispanics and was directed towards women aged 35 years or above who have not had breast cancer and have one or more risk factors for developing
breast cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The
Company successfully launched the first generation BREVAGen&#8482; test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc.
(now geneType Inc.), and BREVAGen<i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus </i>was launched in October 2014. The Company marketed BREVAGen<i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus </i>to healthcare professionals
in comprehensive breast health care and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment
specialists (such as breast surgeons).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May
2019, the Company announced that it had developed two new cancer risk assessment tests branded as &#8216;geneType for Colorectal Cancer&#8217;
and &#8216;geneType for Breast Cancer&#8217;. The new breast cancer test provides substantial improvement over the Company&#8217;s legacy
breast cancer test BREVAGen<i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus</i>, by incorporating multiple additional clinical risk factors. This test will provide healthcare
providers and their patients with a 5-year and lifetime risk assessment of the patient developing breast cancer. The colorectal cancer
test will provide healthcare providers and their patients a 5-year, 10-year, and lifetime risk assessment of the patient developing colorectal
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June 2020, the Company received
US Patent No: US 10,683,549, Methods for assessing risk of developing breast cancer. The Company is the first company in the world to
successfully commercialize a polygenic risk test for breast cancer. The granted patent covers the Company&#8217;s proprietary
panels of single nucleotide polymorphisms (SNPs) and the combination of clinical and phenotypic risk models to create the most comprehensive
risk assessment tool on the market: geneType for Breast Cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In February
2022 the Company received US Patent No: US 11,257,569, Methods of assessing risk of developing a severe response to Coronavirus infection.
The granted US patent covers the proprietary technology incorporated into GTG&#8217;s geneType COVID- 19 Risk Test, which provides a probability
that a person will develop severe symptoms requiring hospitalization should they become <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">infected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During
the 2023 financial year the Company continued to refine existing, and develop other, risk assessment tests across a range of diseases,
including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breast <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancer</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Colorectal <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancer</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ovarian <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancer</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prostate <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancer</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coronary artery <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disease</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type 2 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diabetes</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreatic <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancer</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melanoma</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Atrial <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fibrillation</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">The Company&#8217;s Genetic
Testing <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following the acquisition
of Genetype AG in 1999 and the subsequent renaming to Genetic Technologies Limited, the Company focused on establishing a genetic testing
business, which over the following decade saw it become the largest provider of paternity and related testing services in Australia. The
Company&#8217;s service testing laboratory in Melbourne became the leading non-Government genetic testing service provider in Australia.
The genetic testing services of the Company expanded to include at certain times:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">testing</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Animal <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Testing</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forensic <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Testing</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plant <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Testing</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
acquisition of GeneType AG also provided the Company with ownership rights to a potentially significant portfolio of issued patents. </span>During
the intervening years, this portfolio has since been expanded by both organic growth and the acquisition of intellectual property assets
from third parties. The patent portfolio is constantly reviewed to ensure that the Company maintains potentially important patents but
at the same time keep costs to a minimum by no longer pursuing less commercially attractive and relevant intellectual property.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A strategic
alliance with Myriad Genetics Inc. delivered to the Company exclusive rights in Australia and New Zealand to perform DNA testing for susceptibility
to a range of cancers. In April 2003, the Company established its cancer susceptibility testing facility within its Australian laboratory.
In June 2003, this facility was granted provisional accreditation by the National Association of Testing Authorities, Australia (&#8220;NATA&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November
2003, the Company joined the world-wide genetic testing network GENDIA as the sole reference laboratory for the network in Australia and
New Zealand. GENDIA consists of more than 50 laboratories from around the world, each contributing expertise in their respective disciplines
to create a network capable of providing more than 2,000 different genetic tests. This provided the Company with the ability to offer
comprehensive testing services to its customer base in the Asia-Pacific region as well as increasing its exposure to other markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In April
2010 the Company purchased various assets from Perlegen Sciences, Inc. of Mountain View, California, which included a breast cancer non-familial
risk assessment test, BREVAGen&#8482;. The Company then began validating the test in our Australian laboratory and initiated the process
for obtaining CLIA certification which would enable the Company to undertake the testing of samples received from the U.S. market. By
July 2010, a new U.S. subsidiary named Phenogen Sciences Inc, now named geneType Inc., had been incorporated by the Company in Delaware
to market and distribute the BREVAGen&#8482; test across the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In October
2014, the Company announced the U.S. release of BREVAGen<i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus</i>, an easy-to-use predictive risk test for the millions of women at
risk of developing sporadic, or non-hereditary, breast cancer, representing a marked enhancement in accuracy <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</span>
broader patient applicability, over its first generation BREVAGen&#8482; product. The Company also made a pivotal change of sales and
marketing emphasis toward large comprehensive breast treatment and imaging centers, which are more complex entities with a longer sales
cycle, but higher potential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">GeneType for Breast Cancer<i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">;
a State-of-the-Art </i>Breast Cancer Risk Assessment Test designed to enable a more personalized breast cancer risk assessment in a greater
number of women</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The identification,
in 2007, of a number of single nucleotide polymorphisms (SNPs), each with an associated small relative risk of breast cancer, led to the
development of the first commercially available genetic risk test for sporadic breast cancer, BREVAGen&#8482;. The Company launched the
product in the U.S. in June 2011. In October 2014, the Company released its next generation breast cancer risk assessment test, BREVAGen<i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus</i>.
This new version of the test incorporated a 10-fold expanded panel of genetic markers (SNPs), known to be associated with the development
of sporadic breast cancer, providing an increase in predictive power relative to its first- generation predecessor test. In addition,
the new test was clinically validated in a broader population of women including, African American and Hispanic women. This increased
the applicable market beyond the Caucasian only indication of the first-generation test, and simplified the marketing process in medical
clinics and breast health centers in the U.S.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The
expanded panel of SNPs incorporated into our breast cancer tests were identified from multiple large-scale genome-wide association studies
and subsequently tested in case-control studies utilizing specific Caucasian, African American and Hispanic patient <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">samples.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">BREVAGen<i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus
</i>was a first-in-class, clinically validated, predictive risk test for sporadic breast cancer which examined a woman&#8217;s clinical
risk factors, combined with seventy-seven scientifically validated genetic biomarkers (SNPs), to allow for more personalized breast cancer
risk assessment and risk management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May
2019, the Company announced the development of its next generation breast cancer risk assessment test, &#8216;GeneType for Breast Cancer&#8217;.
The new breast cancer test provides substantial improvement over its legacy breast cancer test BREVAGen<i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus </i>by incorporating multiple
additional clinical risk factors. This test will provide healthcare providers and their patients with a 5-year and lifetime risk assessment
of the patient developing breast cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germline
genetic testing for mutations in BRCA1 and BRCA2 allows for the identification of individuals at significantly increased </span>risk for
breast and other cancers. However, such mutations are relatively rare in the general population and account for less than 10% of all breast
cancer cases. The remaining 90% of non-familial or sporadic breast cancer have to be defined by other genetic/clinical markers common
to the population at large and this is where the Company has focused its attention.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The newly
developed &#8216;geneType for Breast Cancer&#8217; test is aimed at risk detection of non-BRCA related sporadic breast cancer (that is,
for those women who do not have an identified family history of breast cancer). Importantly, this means that the Company&#8217;s new test
covers 95% of women.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June
2020, the Company received the approval for its U.S. patent number US 10,683,549, &#8220;Methods for Assessing Risk of Developing Breast
Cancer.&#8221; The granted patent covers the Company&#8217;s proprietary panels of single nucleotide polymorphisms (SNPs) and the combination
of clinical and phenotypic risk models to create the most comprehensive risk assessment tool on the market: geneType for Breast Cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GeneType for Colorectal<i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">; a State-of-the-Art</i>
Risk Assessment Test for Colorectal <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancer</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Next generation
risk assessments combine multiple clinical and genetic risk factors to better stratify individuals at increased risk of developing disease.
&#8216;geneType for Colorectal Cancer&#8217; incorporates the most impactful risk factors in order to define an individual&#8217;s risk
of developing colorectal cancer, so the healthcare provider can make screening and preventative care recommendations that are tailored
to their patient&#8217;s personalized risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Colorectal
cancer is the third most commonly diagnosed cancer in the U.S., yet 1 in 3 adults are not receiving the appropriate colorectal cancer
screening for their age. In addition, rates of colorectal cancer among 20-49 year old is steadily increasing. Identifying patients who
are most at risk for colorectal cancer can lead to enhanced screening protocols and better outcomes. Most individuals diagnosed with colorectal
cancer do not have a significant family history of the disease. &#8216;geneType for Colorectal Cancer&#8217; evaluates the genometric
risk of developing colorectal cancer for men and women over age 30 who do not have a known pathogenic gene variant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In sporadic
colorectal cancer, no single gene mutation is causal of disease. Rather, common DNA variations or SNPs, each contribute a small but measurable
risk of developing disease. &#8216;geneType for Colorectal Cancer&#8217; analyses a patient&#8217;s DNA for more than 40 SNPs that have
been clinically validated in their association with colorectal cancer. By combining the effects of all of these SNPs into a single polygenic
risk score (PRS), &#8216;geneType for Colorectal Cancer&#8217; will provide a superior risk stratification over standard risk assessments
that incorporate only clinical factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify; text-indent: 35.95pt">&#160;</p>


<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#8216;geneType
for Colorectal Cancer&#8217; is clinically validated for men and women of 30 years of age or older and for individuals of Caucasian descent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Commercial launch of geneType Multi-Risk
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Test</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The geneType
brand was re-launched globally in October 2021 following redevelopment of the Company&#8217;s websites, marketing and advertising, media
releases and announcements to the ASX and NASDAQ. The commercial launch of the geneType Multi-Risk Test in February 2022 included the
first phase launch to cover risk assessment for six serious diseases including breast, colorectal, prostate, and ovarian cancers, coronary
artery disease and Type-2 diabetes covering more than 50% of all serious diseases, all in one test sample. The geneType Multi-Test received
simultaneous NATA accreditation and CMS certification in Australia and USA respectively. The first phase of the geneType Multi-Test became
available to Health Care Professionals (HCPs) in February 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">World&#8217;s First Comprehensive Risk Test
for Breast &amp; Ovarian <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancer</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In February
2023 the Company announced the development of a &#8216;World First&#8217; Comprehensive Risk Assessment Test which evaluates a women&#8217;s
risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic
cancer. Combined with other clinical risk factors the test provides a comprehensive risk assessment in a simple saliva test.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company
intend to provide updates as it continuously improves its tests and add fully validated models for additional <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ethnicities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Direct-to-consumer channel of lifestyle genetic
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tests</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s
acquisition of EasyDNA in August 2021, gave us our direct-to-consumer channel for the sale and distribution of lifestyle genetic tests.
The EasyDNA brand of tests can be completed by the customer without the need to consult a healthcare professional. The laboratory testing
of the EasyDNA genetic tests is performed by contracted laboratories in the US, Europe and Australia. EasyDNA customers order their tests
online using our network of websites covering 40 countries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May
2022, the Company announced the acquisition of AffinityDNA and the business began integration when the first payment due under the acquisition
agreement was settled on 14 July 2022. AffinityDNA joins EasyDNA as the Company&#8217;s Direct to Consumer (DTC) avenues to the market
for DNA testing. During the first part of the financial year, we have focused on the integration of our people, products and AffinityDNA
platform to deliver a &#8220;One Company-Multi-brand and Mult-channel&#8221; approach for GTG &#8211; EasyDNA, AffinityDNA and geneType.
The acquisition expands GTG&#8217;s portfolio of tests to 51 in 14 categories available in more than 40 countries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Further integration will
continue as the Company leverages its well-established worldwide marketplace (including <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amazon). </span>This
marketplace will also be used to provide an avenue to promote the Company&#8217;s geneType <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company
has a strong &#8216;whole of life&#8217; portfolio of high-quality products both in the market and under development and a substantial
international platform for the distribution of the direct-to-consumer products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Government <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">CLIA AND FDA <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2011, the Company obtained certification of its Australian laboratory under the U.S. Clinical Laboratories Improvements </span>Amendments
of 1988 (&#8220;CLIA&#8221;), as regulated by the Centers for Medicare and Medicaid. This certification enables the Company to accept
and test samples from U.S. residents, and was the culmination of preparations required for the U.S. launch of the Company&#8217;s BREVAGen&#8482;
test which occurred in June 2011.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July
2013, the Company was inspected by a representative of the New York State Department of Health, Clinical Laboratory Evaluation Program
(&#8220;CLEP&#8221;). The Company&#8217;s laboratory received an inspection result with no deficiencies reported and, on August 30, 2013,
the Company announced that it had received its Clinical Laboratory Permit from the New York State Department of Health. This permit, which
allows the Company to offer its risk assessment tests to residents of New York State, allows the Company to provide testing services to
all 50 U.S. states.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">From its headquarters in Melbourne, Victoria, the
Company&#8217;s laboratory holds a number of accreditations <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The CLIA license required for all laboratories offering testing the <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The CLEP license, an additional certification required to offer tests in New York State; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Medical Device Establishment License (MDEL) required for <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Physicians
who order clinical tests for their patients have historically represented the primary source of its testing volume. Fees invoiced to patients
and third parties are based on its fee schedule, which may be subject to limitations imposed by third-party payers. The clinical laboratory
industry is highly regulated and subject to significant and changing Federal and state laws and regulations. These laws and regulations
affect key aspects of the Company&#8217;s business, including licensure and operations, billing and payment for laboratory services, sales
and marketing interactions with ordering physicians, security and confidentiality of health information, and environmental and occupational
safety. Oversight by government officials includes regular inspections and audits. The Company seek to and believe that it conducts business
in compliance with all applicable laws and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">CLIA,
extends Federal licensing requirements to all clinical laboratories (regardless of the location, size or type of laboratory), including
those operated by physicians in their offices, based on the complexity of the tests they perform. CLIA also establishes a stringent proficiency
testing program for laboratories and includes substantial sanctions, such as suspension, revocation or limitation of a laboratory&#8217;s
CLIA certificate (which is necessary to conduct business), and significant fines and/or criminal penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The geneType
tests on samples provided are processed at its laboratory in Melbourne, Australia. The Company&#8217;s laboratory completed its first
CLIA inspection under CLIA guidelines and received its certificate of compliance effective November 17, 2011. A re- certification from
CMS i.e., paper survey, was performed in November 2013 and another on-site re-certification followed up in February 2016. Paper surveys
were also conducted in November 2017 and December 2019. Furthermore, the Company&#8217;s laboratory completed its first CLEP inspection
under the NYS DOH CLEP guidelines and received its certificate of compliance effective August 30, 2013. Since the initial survey, the
laboratory has been successful in submitting documents via the NYS eCLEP Health Commerce System for each subsequent year to date. Although
no firm date has been provided, the laboratory is expecting an on-site visit in the coming 12 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The
Company believes that it is in compliance with all applicable federal and state laboratory requirements. Under CLIA, the Company remains
subject to state and local laboratory regulations. CLIA provides that a state may adopt laboratory regulations that are more stringent
than those under federal law, and some states require additional personnel qualifications, quality control, record maintenance and other
requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following
a successful CLIA audit during the year, the Company renewed its status as a fully NATA and CLIA &#8211; accredited laboratory. The Company
in a unique position to service both the Australian and US markets subject to regulatory approvals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although
the U.S. Food and Drug Administration (&#8220;FDA&#8221;) has consistently claimed that it has the authority to regulate laboratory-developed
tests (&#8220;LDTs&#8221;) that are developed, validated and performed only by a CLIA certified laboratory, it has historically exercised
enforcement discretion in not otherwise regulating most LDTs and has not required laboratories that furnish LDTs to comply with the agency&#8217;s
requirements for medical devices (e.g., establishment registration, device listing, quality systems regulations, premarket clearance or
premarket approval, and post-market controls). As a matter of policy, the FDA generally does not review Direct- to-Consumer LDTs that
are created and performed in a single laboratory, if they are offered to patients only when prescribed by a healthcare provider. More
recently, the FDA has indicated that it will apply a risk-based approach to determine the regulatory pathway for all in-vitro diagnostics,
which includes LDTs, as it does with all medical devices. Accordingly, the regulatory pathway for the Company&#8217;s LDTs will depend
on the level of risk to patients, based on the intended use of the LDT and the controls necessary to provide a reasonable assurance of
the LDTs safety and effectiveness. The two primary types of marketing pathways for medical devices are clearance of a premarket notification
under Section 510(k) of the Federal Food, Drug, and Cosmetic Act, or 510(k), and approval of a premarket approval application, or PMA.
Legislative proposals addressing the FDA&#8217;s oversight of LDTs have been introduced in the current and previous Congresses, and we
expect that new legislative proposals will be introduced from time-to-time. The likelihood that Congress will pass such legislation and
the extent to which such legislation may affect the FDA&#8217;s plans to regulate certain LDTs as medical devices is difficult to predict
at this time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">HIPAA and other privacy <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">laws</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Health
Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), established comprehensive federal standards for the privacy
and security of health information. The HIPAA standards apply to three types of organizations: health plans, healthcare clearing houses,
and healthcare providers that conduct certain healthcare transactions electronically (&#8220;Covered Entities&#8221;). Title II of HIPAA,
the Administrative Simplification Act, contains provisions that address the privacy of health data, the security of health data, the standardization
of identifying numbers used in the healthcare system and the standardization of certain healthcare transactions. The privacy regulations
protect medical records and other protected health information by limiting their use and release, giving patients the right to access
their medical records and limiting most disclosures of health information to the minimum amount necessary to accomplish an intended purpose.
The HIPAA security standards require the adoption of administrative, physical, and technical safeguards and the adoption of written security
policies and procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February
17, 2009, Congress enacted Subtitle D of the Health Information Technology for Economic and Clinical Health Act, or HITECH, provisions
of the American Recovery and Reinvestment Act of 2009. HITECH expanded and strengthened HIPAA, created new targets for enforcement, imposed
new penalties for noncompliance and established new breach notification requirements for Covered Entities. Regulations implementing major
provisions of HITECH were finalized on January 25, 2013, through <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication</span> of the HIPAA
Omnibus Rule (the &#8220;Omnibus <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under
HITECH&#8217;s breach notification requirements, Covered Entities must report breaches of protected health information that has not been
encrypted or otherwise secured in accordance with guidance from the Secretary of the U.S. Department of Health and Human Services (the
&#8220;Secretary&#8221;). Required breach notices must be made as soon as is reasonably practicable, but no later than 60 days following
discovery of the breach. Reports must be made to affected individuals and to the Secretary and, in some cases depending on the size of
the breach; they must be reported through local and national media. Breach reports can lead to investigation, enforcement and civil litigation,
including class action lawsuits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition
to the federal privacy and security regulations, there are a number of state laws regarding the privacy and security of health information
and personal data that are applicable to clinical laboratories. Many states have also implemented genetic testing and privacy laws imposing
specific patient consent requirements and protecting test results by strictly limiting the disclosure of those results. State requirements
are particularly stringent regarding predictive genetic tests, due to the risk of genetic discrimination against healthy patients identified
through testing as being at a high risk for disease. The Company believes that it has taken the steps required to comply with health information
privacy and security statutes and regulations, including genetic testing and genetic information privacy laws in all jurisdictions, both
state and federal. However, these laws constantly change, and the Company may not be able to maintain compliance in all jurisdictions
where it does business. Failure to maintain compliance, or changes in state or federal laws regarding privacy or security could result
in civil and/or criminal penalties, significant reputational damage and could have a material adverse effect on the Company&#8217;s business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Transparency Laws and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the
U.S., the Physician Payments Sunshine Act (the &#8220;Sunshine Act&#8221;) requires medical device manufacturers to track and report to
the federal government certain payments and other transfers of value made to physicians, other healthcare providers (such as physicians
assistants and nurse practitioners), and teaching hospitals and ownership or investment interests held by physicians and their immediate
family members. There are also state &#8220;sunshine&#8221; laws that require manufacturers to provide reports to state governments on
pricing and marketing information. Several states have enacted legislation requiring medical device manufacturers to, among other things,
establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales and marketing
activities, and such laws may also prohibit or limit certain other sales and marketing practices. These laws may adversely affect our
sales, marketing, and other activities by imposing administrative and compliance burdens on us. If the Company fail to track and report
as required by these laws or to otherwise comply with these laws, it could be subject to the penalty provisions of the pertinent state
and federal authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Other Healthcare Compliance <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our operations
in the U.S. may subject us to healthcare regulation and enforcement by the U.S. federal government and the states in which we conduct
our business, including federal fraud and abuse laws (such as anti-kickback and false claims laws and transparency laws). Failure to comply
with such laws may result in significant penalties, including civil, administrative, and criminal penalties, fines, imprisonment, disgorgement,
exclusion from participation in federal health care programs, and other penalties</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Environmental and Safety Laws and
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company
is subject to laws and regulations related to the protection of the environment, the health and safety of employees and the handling,
transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials. For <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">example,
the U.S. Occupational Safety and Health Administration (&#8220;OSHA&#8221;) has established extensive requirements relating specifically
</span>to workplace safety for healthcare employers in the U.S. This includes requirements to develop and implement multi-faceted programs
to protect workers from exposure to blood-borne pathogens, including preventing or minimizing any exposure through needle stick injuries.
For purposes of transportation, some biological materials and laboratory supplies are classified as hazardous materials and are subject
to regulation by one or more of the following agencies: the U.S. Department of Transportation, the U.S. Public Health Service, the U.S.
Postal Service and the International Air Transport Association. The Company generally use third- party vendors to dispose of regulated
medical waste, hazardous waste and radioactive materials and contractually require them to comply with applicable laws and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s
operations are also subject to environmental regulations under Australian State legislation. In particular, the Company is subject to
the requirements of the <i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environment Protection Act 1993</i>. A license has been obtained under this Act to produce listed waste.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Product <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Despite
significant resource allocation and efforts by a dedicated sales team, sales of BREVAGen<i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus </i>were insufficient to defray the costs
of the sales team. By late 2017, management decided that its sales strategy was not working and disbanded much of the sales infrastructure
in the U.S. and transitioned to an ecommerce-based solution that allowed consumers to initiate testing <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">online.</span>
Management then designed a &#8220;pivot plan&#8221; in an effort to reposition the Company, refine and improve products and reload with
a newly developed approach to market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
COVID-19 social distancing impacting on the Company&#8217;s ability to fully engage with physicians, the Company introduced </span>a consumer-initiated
testing (CIT) platform. This sales pipeline deviates from a traditional sales approach that targets clinicians. Instead, it allows patients
to request a test directly, with clinician oversight of the testing process through an independent provider network and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">telemedicine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The COVID-19
Risk Test was launched in the US market in June 2021. The Company entered into a license agreement with Infinity BiologiX LLC in May 2021
for the online sale and distribution of the COVID-19 Risk Test to customers in the USA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acquired the EasyDNA business acquired in August 2021 and the AffinityDNA business in July 2022, distributing </span>its consumer
and lifestyle DNA tests direct to customers through its website portals and network of laboratory partners in North America, Europe and
Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company launched the geneType Multi-Test for breast and colon cancer in February 2022 for the Australian and US markets </span>to be distributed
to Health Care Professionals through the Company&#8217;s website portals. The Company is finalizing the development and verification in
its Australian laboratory of the phase two elements of the geneType Multi-Test product to include tests for prostate and ovarian cancers,
coronary heart disease and Type-2 Diabetes. The Company expects to launch the complete suite of tests in the Multi- Test in 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In March 2023, the Company announced
the commercial release of a Melanoma, Atrial Fibrillation, and Pancreatic geneType risk assessment tests.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In April 2023, the Melbourne facility successfully
completed a NATA audit with no findings from the <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Reimbursement and Clinical <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Studies</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Beginning
in April 1, 2017, the Company converted to a direct pay relationship with patients in an effort to foster economic and process certainty
to the transaction for the healthcare provider and the patient. The change addressed reimbursement issues from third-party payers, including
low levels of reimbursement, prolonged payment time, patient confusion around eligibility and financial responsibility and poor coverage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This shift
also has reduced the Company&#8217;s reliance on clinical utility studies that had been designed as a means to achieve reimbursement coverage
through the private insurers. The Company recognized however that scientific and clinical data are key drivers to help strengthen our
commercial position. The Company intends to explore opportunities to engage in further research collaborations to support clinical utility.
Physicians and the major breast health centers seek multiple points of confirmation that the medical device works as intended and leads
to a meaningful improvement in women&#8217;s health. Therefore, the more papers that are published regarding the Company&#8217;s genetic
tests, profiling product performance characteristics including clinical validity and utility, the more likely physicians will be to use
the tests.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June
2022 the Company completed an independently developed and validated customizable Budget Impact Model (&#8220;BIM&#8221;), which demonstrates
significant health and economic benefits directly attributed to the implementation of geneType Breast Cancer Risk Assessment Test for
US customers. The BIM was independently developed and validated by ALVA10, whose mission is to create an economic ecosystem that pulls
technology into healthcare, aligning effective healthcare solutions to payer economics. The BIM illustrates the clinical pathways patients
would experience and the economic implications of commercialization and utilization of a test or device. The main finding of the BIM is
the potential for US payers to reduce the annual costs of breast cancer treatment by US$1.4 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">billion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">US payers,
including commercial insurers, large employers, and benefit groups such as Medicare, are typically reluctant to cover new diagnostic tools,
with reimbursement often taking years to receive. Critically, GTG&#8217;s customizable BIM enables US payers to accelerate their understanding
of the economic impact of implementing GTG&#8217;s geneType Breast Cancer Risk Assessment Test prior to commercialization. This could
provide a faster and more certain outcome and minimizing their technology adoption risk. GTG&#8217;s BIM is a comprehensive and dynamic
tool and can be customized for any US payer. Importantly it will also enable GTG to identify those US Payers who are most likely to be
fast adopters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Research &amp; Development <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Projects</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During
the year ended June 30, 2023, the Company supported the following research and development programs, details of which are provided below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breast Cancer Risk Assessment Test (geneType for Breast <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancer)</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Colorectal Cancer Risk Assessment Test (geneType for Colorectal <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancer)</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research Agreement executed with Memorial Sloan Kettering New <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">York</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research collaboration with The University of <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melbourne</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research collaboration with Ohio State <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">University</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research collaboration with Washington State <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">University</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expanded range of other cancer and disease target predictive risk assessment <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tests</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In previous
years, other projects, which have since been terminated or otherwise commercialized, have also been supported by the Company. The Company
is constantly seeking new opportunities and plans to focus more on research and development activities in the future. In addition, the
Company plans on having its science and management team engage with the world&#8217;s leading scientific experts working on predictive
genetic testing and its role within world health systems. Historically, some projects have arisen from new inventions made by the Company
while some have been made by others who have approached the Company seeking collaboration and support for their activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Collaboration with The University
of <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melbourne</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November
29, 2016, the Company announced the signing of an exclusive worldwide license agreement with The University of Melbourne for the development
and commercialization of a novel colorectal cancer (CRC) risk assessment test. The core technology behind this test was developed by a
research team at the University&#8217;s Centre for Epidemiology and Biostatistics, with results from preliminary modelling studies first
published online in Future Oncology on 1 February 2016, in a Paper entitled &#8220;Quantifying the utility of single nucleotide polymorphisms
to guide colorectal cancer screening,&#8221; 2016 Feb: 12(4), 503-13. This simulated case-control study of 1 million patients indicated
that a panel of 45 known susceptibility SNPs can stratify the population into clinically useful CRC risk categories. In practice, the
technology could be used to identify people at high risk for CRC who should be subjected to intensive screening, ultimately reducing the
risk of occurrence and death from the disease. Those identified as low risk of CRC can be spared expensive and invasive screening, thereby
preventing adverse events and unjustified expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A scientific
validation study supporting this work has been completed, and a report of the research program progress has been delivered to the Company.
Whilst the terms of the agreement are confidential, these events represent an important first milestone in the development of a new test
as the Company seeks to diversify its product pipeline and become a key player in the SNP-based cancer risk assessment landscape. We continue
to identify new and exciting ways to collaborate with the University of Melbourne to improve the standard of care for practitioners and
their patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Research Collaboration Memorial Sloan
Kettering New <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">York</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In early
2019, the Company&#8217;s U.S. subsidiary entered into a Research Agreement with Memorial Sloan Kettering Cancer Center of New York and
the University of Cambridge. This collaborative research study is to be led by Mark Robson, MD, Chief of the Breast Medicine Service at
Sloan Kettering. The study is intended to assess whether the provision of individual risk information informed by a polygenic risk score
reduces decisional conflict among BRCA mutation carriers considering preventive surgery.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company
believes this collaboration will benefit its engagement and collaboration with high profile cancer genetics researchers who are at the
forefront of risk assessment research, and by providing us with data that may potentially be beneficial in developing additional risk
assessment products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
medical diagnostics and biotechnology industries are subject to intense competition. As more information regarding cancer genomics and
personalized medicine becomes available to the public, the Company anticipates that more products aimed at identifying cancer risk will
be developed and that these may compete with its products. The use of Single Nucleotide Polymorphisms (SNPs), for disease risk prediction
is still a relatively new field of medicine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organizations
such as Ancestry.com, 23andMe and Color Genomics in the U.S. have developed SNP based risk tests<i>, </i>are attracting significant consumer
interest in genetic tests that predict clinical risk of contracting serious diseases. A number of other organizations, including deCODE
(Iceland), Intergenetics, and ThermoFisher have attempted to commercialize SNP-based genetic tests, to both physicians and consumers,
to assess sporadic cancer risk in relevant patient populations. New entrants that the Company are aware of that are in the product development
stage include Counsyl Inc. and Invitae Corporation in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our major direct-to-consumer EasyDNA and AffinityDNA product competitors are AncestryDNA, 23andMe, MyHeritage, Gene by Gene and
Color Genomics.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt">Australian Disclosure <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Requirements</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Business Strategies and Prospects for Future
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The Company&#8217;s competitive position in the
genetic testing market is based upon, amongst other things, its ability <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to strengthen and maintain scientific credibility through the process of obtaining scientific validation through clinical trials supported by peer-reviewed publication in medical journals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">create and maintain scientifically advanced technology and offer proprietary products and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">services;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to strengthen and improve the messaging regarding the importance and value that the Company&#8217;s cancer risk assessment tests provide to patients and physicians;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversify the Company&#8217;s product offerings into other serious disease <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">types;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain and maintain patent or other protection for the Company&#8217;s products and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">services;</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain and maintain required government approvals and other accreditations on a timely basis; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully market the Company&#8217;s products and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">services.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">If the Company is not successful
in meeting these goals, its business could be adversely affected. Similarly, the Company&#8217;s competitors may succeed in developing
technologies, products or services that are more effective than any that it is developing or that would render the Company&#8217;s technology
and services obsolete, noncompetitive or uneconomical.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">No dividends were paid during
the course of the fiscal year ended June 30, 2023. There are no dividends or distributions recommended or declared for payment to members,
but not yet paid, during the year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span id="F_012"></span>Item 4.C
Organizational <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Structure</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The diagram
below shows the Company&#8217;s organizational structure as of the date of this Annual Report. All of the Company&#8217;s subsidiaries
in the chart below are wholly owned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><img src="form20-f_001.jpg" alt="" />&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span id="F_013"></span>Item 4.D Property, Plant and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As at date of this Report, the Company has executed
four leases in respect of premises occupied by the <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fitzroy,
Victoria</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company
rents offices and a laboratory premises at 60-66 Hanover Street, Fitzroy, Victoria, Australia (an inner suburb of Melbourne) from Crude
Pty. Ltd. The current lease will expire on February 28, 2025. The total rental charge in respect of the year ended June 30, 2023 was A$233,634
(2022: A$230,940).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt">Charlotte, North <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carolina</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">GeneType
Inc. (formerly named Phenogen Sciences Inc.), the Company&#8217;s U.S. subsidiary, rents office premises located at 1300 Baxter Street,
Suite 255, Charlotte, North Carolina, U.S. from Midtown Area Partners LLC. The current lease will expire on July 31, 2023. A lease agreement
was signed on March 27, 2023 for a three-year term, commencing on August 1, 2023 and expiring July 31, 2026. The total rental expense
towards the premise for the year ended June 30, 2023 was A$19,724 (2022: A$23,300).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt">Slacks Creek, <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Queensland</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company
rents office premises located at Suite 1B/1 Sesame Court, Slacks Creek, Queensland, Australia from Kennedy Family Slacks Creek Pty. Ltd.
The Company relocated its office premise from 1 July 2022 through a new two-year lease, expiring on June 30, 2024, with Growth Steel Australia
Pty. Ltd. The property was subsequently sold to Kennedy Family Slacks Creek Pty. Ltd. in December 2022. The total rental charge in respect
of the year ended June 30, 2023 was A$31,335 (2022: A$12,871).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt">Hove, East <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sussex</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company
rents office premises located at 60 Lansdowne Place, Hove, East Sussex, United Kingdom from Andrew, Chris &amp; Stephen Tugwell. The current
lease will expire on May 30, 2025. The total rental charge in respect of the year ended June 30, 2023 was A$25,206 (2022: Nil).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span id="F_014"></span>Item 4A. Unresolved Staff <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0">Not <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applicable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span id="F_015"></span>Item 5. Operating and Financial Review and
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospects</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">The following
discussion and analysis should be read in conjunction with the Company&#8217;s financial statements, the notes to the financial statements
and other financial information appearing elsewhere in this Annual Report. In addition to historical information, the following discussion
and other parts of this Annual Report contain forward-looking statements that reflect the Company&#8217;s plans, estimates, intentions,
expectations and beliefs. The Company&#8217;s actual results could differ materially from those discussed in the forward- looking statements.
See the &#8220;Risk Factors&#8221; section of Item 3 and other forward-looking statements in this Annual Report for a discussion of some,
but not all, factors that could cause or contribute to such differences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span id="F_016"></span>Item 5.A Operating Results
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overview</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founded
in 1989, Genetic Technologies is an established Australian-based molecular diagnostics company that offers predictive </span>genetic testing
and risk assessment tools. During the year ended June 30, 2015, the Company divested its interest in other genetic testing services, which
up until then, together with licensing of non-coding technology, had provided the main source of income to fund operations, to concentrate
on the principal activity of the provision of molecular risk assessment tests for cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s
revenues during its years ended June 30, 2021 and 2020 were generated principally by sales of its &#8216;geneType for Colorectal Cancer&#8217;
and &#8216;geneType for Breast Cancer&#8217; genetic tests to healthcare providers through a global network of distribution partners and
the Company&#8217;s website portals. The Company&#8217;s revenues during its years ended June 30, 2022 and 2023 were generated principally
by sales of its EasyDNA and AffinityDNA branded genetic test products through its international network of proprietary EasyDNA and AffinityDNA
branded websites as well as Amazon (AffinityDNA). The company acquired the business and assets of EasyDNA and AffinityDNA in August 2021
and July 2022, respectively. The acquisition of AffinityDNA has resulted in a new business segment within the Company&#8217;s segment
information as compared to the prior year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since
inception up to June 30, 2023, the Company has incurred A$156,715,687 in accumulated losses. The Company&#8217;s losses have resulted
principally from costs incurred in research and development, general and administrative and sales and marketing costs associated with
its operations. Further losses are anticipated as the Company continues to invest in new genetic testing product research and development,
and explore optimal distribution methodologies to commercialize its product offering. Refer to the Financial Statements section in Item
18.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Fiscal <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As an
Australian company, the Company&#8217;s fiscal, or financial, year ends on June 30 each year. The Company produces audited consolidated
accounts at the end of June each year and furnish half-yearly accounts for the periods ending on December 31 each year, both of which
are prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) as issued by the International Accounting
Standards Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Comparison of the year ended June 30, 2023
to the year ended June 30, <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
presentation of the Statement of Profit or Loss and Other Comprehensive Income is in line with the Company management&#8217;s </span>monthly
reporting of the Group&#8217;s results and performance presented to the Board of Directors. For the financial year ended June 30, 2023,
the Company reports a total comprehensive loss of A$11,650,334 (2022: A$7,103,134), the result includes a non-cash impairment expense
of A$2,125,725 (2022: A$564,161).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Revenues from <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During
the 2023 financial year, the Company&#8217;s consolidated gross revenues from continuing operations, excluding other revenue, increased
by A$1,891,302 (28%) from A$6,794,816 to A$8,686,118 from the previous year. The increase in revenue is mainly due to increase in sales
of EasyDNA (A$1,708,823) direct-to-consumer genetic tests as well as sales of AffinityDNA (A$944,508), following the acquisition of the
AffinityDNA business on 14 July 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Finance <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">income</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Finance
income increased by A$183,905 (507%) from A$36,256 to A$220,161 when compared to the previous year. The increase is due to the combination
of higher interest rates and additional interest income gained from fixed deposits placed during the year following the receipt of funds
from the capital raised in February 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Other <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">income</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other
income decreased by A$946,569 (34%) from A$2,783,391 to A$1,836,822 when compared to the previous year. The majority of the Other income
recorded for the financial year is largely the research and development tax incentive refund received from the Australian Taxation Office.
Research and development tax incentive income (or &#8220;R&amp;D tax credit&#8221;) recorded for the financial year was A$1,616,064 (2022:
A$2,397,552). The R&amp;D tax incentive is recognized on an accruals basis when realizable. The lower R&amp;D tax credit is due to the
decreasing external R&amp; D expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Raw materials and changes in <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inventory</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s
raw materials and changes in inventory costs increased by A$1,321,731 (44%) from A$3,013,534 to A$4,335,265 from the prior financial year.
The increase in raw materials is in line with the increase in product revenues from EasyDNA and AffinityNDA experienced during the financial
year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commissions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Commissions
increased to A$236,019 (2022: A$156,625), the increase being attributable to commissions paid/payable in respect to agency sales for EasyDNA
and AffinityDNA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Employee benefits <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Employee
benefits expense increased by A$339,411 (6%) to A$6,208,066 during the financial year (2022: A$5,868,655). The increase is largely the
result of an increase in number of employees from 52 to 60 following the acquisition of the AffinityDNA business and an expansion of commercialization
staff for the geneType test.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Advertising and promotional <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
and promotional expenses increased to A$2,712,353, a 44% increase from comparative period (2022: A$1,885,402) </span>(44%). The majority
of this increase is attributable to pay-per-click advertising costs, A$1,556,627 (2022: A$987,460) for the EasyDNA <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
AffinityDNA businesses. Additionally, other marketing costs increased to A$861,639 in the current financial year against A$675,493 </span>in
the prior year as the Company expanded the geneType branded genetic tests in the Australian and U.S. markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Professional <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fees</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Professional
fees decreased by A$474,804 (26%) from A$1,835,444 to A$1,360,640 when compared to the previous year. The decrease is mainly related to
the decrease in consulting fees, A$558,987 (2022: A$994,275).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Research and development <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Laboratory,
research and development costs increased by A$575,650 (82%) from A$705,507 to A$1,281,157 when compared to the previous year. This category
of expenditure includes patent application and annual renewal fees. Laboratory, research and development costs increased as the Company
continued development, and accelerated commercialization of its pipeline of the new PRS tests for a range of human disease types. Also
under development are a suite of gene-panel tests for a range of hereditary cancers. The research and development activities cover the
following diseases: breast cancer, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, melanoma, Type-2-diabetes, cardiovascular
disease, and atrial fibrillation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Depreciation and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amortization</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Depreciation
and amortization expense attributable to the laboratory testing equipment, computer equipment, office equipment, leases amortization and
other intangible assets was A$676,583 (2022: A$578,668), with the increase related to an increase in laboratory testing equipment depreciation
as a result of prior period purchase and first-time recognition of lease amortization for the AffinityDNA office lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Impairment <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Impairment
expenses increased to A$2,125,725 for the 2023 financial year (2022: A$564,161). Impairment expense is mainly the result of an impairment
expense recognized against the goodwill associated with the acquisition of EasyDNA, A$1,845,000, as initial product revenues has not met
expectations. The balance of the expense recorded for the financial year is the result of additional allowance for un-collectability of
certain debtor balances outstanding as at June 30, 2023.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt">&#160;</p>


<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
expenses increased to A$3,687,030 (2022: A$2,154,375) during the financial year. The increase is mainly related to increase in IT and
communication expenses (A$585,875), travel and entertainment expenses (A$299,622) and administrative expenses (A$249,387).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
costs</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
costs increased to A$29,515 (2022: A$15,215). Finance costs relate to non-cash lease interest charges required to be recognized under
accounting standard AASB16.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax credit</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax credit recognized for the financial year was A$158,329 (2022: A$32,125) which mainly relates to the recognition of deferred tax assets
to offset against the remaining deferred tax liabilities arising from the acquisition of EasyDNA and AffinityDNA&#8217;s brands and other
identifiable intangible assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comparison
of the year ended June 30, 2022 to the year ended June 30, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current presentation is in line with the Company management&#8217;s monthly reporting of the Group&#8217;s results and performance presented
to the Board of Directors. For the financial year ended June 30, 2022, the Company reports a total comprehensive loss of A$7,103,134
(2021: A$7,115,087).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from operations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the 2022 financial year, the Company&#8217;s consolidated gross revenues from continuing operations, excluding other revenue, increased
by A$6,674,262 (5,536%) from A$120,554 to A$6,794,816 when compared to previous year. The increase in revenue is mainly due to sales
of EasyDNA direct-to-consumer genetic tests following the acquisition of the EasyDNA business on August 13th, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
income</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
income decreased by A$26,138 (42%) from A$62,394 to A$36,256 when compared to the previous year. The decrease was due to the reduction
in cash balances as at year-end of A$11,731,325 as compared to A$20,902,282 in the prior year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income mainly consists of research and development tax incentive refund received from the Australian Taxation Office. The Research and
development tax incentive refund (or &#8220;R&amp;D tax credit&#8221;) increased by 140% from A$997,908 to A$2,397,552 when compared
to the previous year. The R&amp;D tax credit is recognized on an accruals basis when realizable. The higher R&amp;D tax credit was due
to increased expenditure on the R&amp;D activities. The increase was offset by reduction in Government grants income for COVID-19 relief
received in prior year amounting to A$287,883. The increase was also attributable to foreign currency gains amounting to A$359,884 as
compared to A$57,899 in the prior year, as a result of a weakening of the Australian dollar against the United States Dollar during the
financial year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw
materials and changes in inventory</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s raw materials and changes in inventory costs increased by A$2,843,077 (1,668%) from A$170,457 in the previous financial
year to A$3,013,534 in the current financial year. Direct materials utilized for geneType for breast and colorectal cancer as well as
EasyDNA direct-to-consumer genetic testing products, increased by A$2,867,386 (2,473%) from A$115,934 to A$2,983,320 due to an increased
number of tests conducted during the year. There was a decrease in inventories written-off by A$24,309 to A$30,214 in the current financial
year when compared to A$54,523 in the previous financial year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EasyDNA and geneType/Corporate segments contributed A$2,951,815 and A$61,719, respectively of the total cost of sales in the 2022 financial
year. The EasyDNA business incurred the majority of the costs in line with the sale of genetic tests since its acquisition in August
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commissions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commissions
were A$156,625 for the 2022 financial year, no commissions expenditure was recorded for the comparative period. Commissions paid were
in respect to agency sales for EasyDNA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Options: NewSection; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
benefits expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
benefits expense increased by A$2,000,324 (52%) to A$5,868,655 during the 2022 financial year when compared to A$3,868,331 in the previous
financial year. The increase is mainly related to the increase in number of employees from 18 to 52 as a result of the acquisition of
the EasyDNA business during the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
and promotional expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
and promotional expenses increased by A$1,449,128 (332%) from A$436,274 to A$1,885,402 when compared to the previous year. The major
movement during the year related to pay-per-click advertising costs incurred of A$987,460 (2021: Nil) for the EasyDNA business. Additionally,
other marketing costs increased to A$675,493 for the 2022 financial year against A$310,960 in the prior year as the Company launched
the geneType branded genetic tests for breast and colorectal cancer in the Australian and US markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
fees</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
fees increased by A$374,043 (26%) from A$1,461,401 to A$1,835,444 when compared to the previous year. The increase was mainly related
to the increase in consulting fees by A$410,549 to A$994,275 during the 2022 financial year when compared to A$583,726 in the previous
financial year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratory,
research and development costs decreased by A$460,024 (39%) from A$1,165,531 to A$705,507 when compared to the previous year. Laboratory,
research and development costs increased as the Company continued development, and accelerated commercialization of its pipeline of the
new PRS tests for a range of human disease types. Also under development are a suite of gene-panel tests for a range of hereditary cancers.
The research and development activities cover the following diseases: breast cancer, colorectal cancer, prostate cancer, ovarian cancer,
melanoma, Type-2-diabetes, coronary artery disease, atrial fibrillation, and COVID severity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization expense attributable to the laboratory testing equipment and other intangible assets increased by A$192,391 (50%) from
A$386,277 to A$578,668 in 2022 financial year due to the purchase of laboratory equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
expenses increased by A$532,113 (1660%) to A$564,161 during the financial year when compared to A$32,048 in the previous financial year.
Impairment expense was a result of management&#8217;s judgement on the collectability of debtor balances outstanding as at June 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
expenses increased by A$870,504 (68%) to A$2,154,375 during the financial year when compared to A$1,283,871 in the previous financial
year. The increase mainly related to an increase in buildings and facilities expenses such as country office charges (A$226,827), service
charges (A$116,752) and credit card merchant charges (A$253,098) attributable to EasyDNA sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
costs</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
costs decreased by A$1,123 (7%) from A$16,338 to A$15,215 when compared to the previous year. Finance costs incurred in 2022 and 2021
were primarily lease interest charges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax credit/(expense)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax credit recognized during the 2022 financial year related to reversal of deferred tax liabilities arising from the acquisition of
EasyDNA&#8217;s brands and other intangible assets. No tax impact was recorded in the 2021 financial year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Australian
Disclosure Requirements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
Changes in the State of Affairs</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no significant changes within the state of affairs during the year ended June 30, 2023 except as noted in the &#8220;Important
Corporate Developments&#8221; section included in Item 4.A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Likely
Developments and Expected Results of Operations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the date of the Directors&#8217; Report there no other matters not already disclosed within the Company&#8217;s Directors&#8217; Report
and financial statements, and related notes, for the 2023 financial year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental
Regulations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are not subject to any significant environmental regulations under either Commonwealth of Australia or State/ Territory legislation.
We consider that adequate systems are in place to manage our obligations and are not aware of any breach of environmental requirements
pertaining to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_017"></span>Item
5.B Liquidity and Capital Resources</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -2.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, the Company&#8217;s operations have been financed primarily from capital contributions by our stockholders, proceeds from
our licensing activities and revenues from operations, grants, and interest earned on the Company&#8217;s cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently
the Company&#8217;s overall cash position depends on completion of its research and development activities, overall market acceptance
of, and revenue generated by, its new genetic testing products. The Company&#8217;s cash and cash equivalents were A$7,851,197 as of
June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended June 30, 2023, 2022 and 2021 the Company incurred total comprehensive losses of A$11,650,334, A$7,103,134 and A$7,115,087,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended June 30, 2023, 2022 and 2021 the Company&#8217;s net cash flows used in continuing operations were A$9,723,095, A$5,659,456
and A$6,295,929, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will continue to bring its comprehensive suite of risk assessment tests and direct to consumer portfolio to major global markets
across global markets. The Company can also expand and upgrade the laboratory to incorporate next generation sequencing and high-density
SNP arrays. These will allow-for the first time-risk assessments for 100 per cent of a person&#8217;s genomic risk, including monogenic,
polygenic, clinical risk factors, and family history.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b>. For the year ended June 30, 2023, the Company incurred a total comprehensive loss of A$11,650,334 (2022: A$7,103,134)
and net cash outflow from operations of A$9,723,095 (2022: A$5,659,456). As at June 30, 2023, the Company held total cash and cash equivalents
of A$7,851,197 and total net current assets of A$7,185,750.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company expects to continue to incur losses and cash outflows for the foreseeable future as it continues to invest resources in research
and development activities for geneType risk assessment tests and to invest in the commercialization activities for geneType,
EasyDNA and AffinityDNA, via marketing, sales and distribution channels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continuing viability of the company and its ability to continue as a going concern, and meet its debts and commitments as they fall due,
is dependent on the satisfactory completion of an equity raising forecast for the early part of the 2024 calendar year. The Company does
not currently have binding commitments from any party to subscribe for shares and any raise will be subject to maintaining active listing
on the NASDAQ exchange as well as compliance with the Group&#8217;s obligations under ASX Listing Rule 7.1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 17, 2023, the company received notification from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price
requirement of Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market, since the closing bid price for the
company&#8217;s American Depositary Shares (ADS) on the Nasdaq Capital Market was below US$1.00 for 34 consecutive trading days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notification has no immediate effect on the listing of the Company&#8217;s ADS on the Nasdaq Capital Market. Under Nasdaq Listing
Rule 5810(c)(3)(A), the company has a period of 180 calendar days from the date of Notification to regain compliance with the
minimum bid requirement, during which time the ADS will continue to trade on the Nasdaq Capital Market. If at any time before
January 15, 2024, the bid price of the ADS closes at or above US$1.00 per ADS for a minimum of 10 consecutive business days, the
Company will regain compliance with the Minimum Bid Requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 41; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-compliance
with the NASDAQ&#8217;s minimum bid price requirement can be cured with positive business developments (announced to the market), leading
to an increase in the ADS price to above US$1 or a stock split. The company also has the option of applying for an extension of time,
a further 180 days, to regain compliance. This development isn&#8217;t expected to impede the company&#8217;s ability to raise additional
equity capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the uncertainty surrounding the timing, quantum or the ability to raise additional equity, there is a material uncertainty that may
cast significant doubt on the Group&#8217;s ability to continue as a going concern and therefore, that it may be unable to realize
its assets and discharge its liabilities in the normal course of business. However, the Directors believe that the Company will be
successful in its equity raising endeavours, and has a strong track record in this regard, and accordingly, have prepared the financial
report on a going concern basis. As such no adjustments have been made to the financial statements relating to the recoverability and
classification of the asset carrying amounts or classification of liabilities that might be necessary should the Group not be able to
continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Activities. </i></b>The Company&#8217;s net cash used in operating activities was A$9,723,095, A$5,659,456 and A$6,295,929 for the years
ended June 30, 2023, 2022 and 2021, respectively. Cash used in operating activities for each period consisted primarily of losses incurred
in operations reduced by non-cash items such as impairment expenses, depreciation and amortization expenses, share based payments expenses,
foreign exchange movements and unrealized profits and losses relating to investments. In approximate order of magnitude, cash outflows
typically consist of staff-related costs, marketing expenses, service testing expenses, general and administrative expenses, legal/patent
fees and research and development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investing
Activities</i></b>. The Company&#8217;s net cash used in investing activities was A$311,937, A$3,461,163 and A$748,706 for the years
ended June 30, 2023, 2022 and 2021, respectively. During the year ended June 30, 2023 the Company paid A$486,188 for the acquisition
of the AffinityDNA business, representing the first tranche payment due under the acquisition agreement. During the 2022 financial year
the Company made a cash payment contribution of A$3,400,625 towards the acquisition of EasyDNA from General Genetics Corporation. The
purchase of plant and equipment was A$17,552, A$63,926 and A$748,706 in the past 3 financial years, respectively. There were no further
significant capital expenditures for the years ended June 30, 2023, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financing
Activities</i></b>. The Company&#8217;s net cash (used in)/from financing activities was A$5,919,943, A$(279,064), and A$13,689,996 for
the years ended June 30, 2023, 2022 and 2021, respectively. During the year ended June 30, 2023, the Company generated cash flows of
A$7,172,399 from the issue of Ordinary Shares less costs associated with the transactions of A$851,624. There were no capital raising
during the year ended June 30, 2022. During the 2021 financial year the Company raised equity capital which contributed A$13,940,938
net of costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases.
</i></b>The Company has four property leases in place at June 30, 2023. These leases relate to the premises occupied by the Company in
Fitzroy, Victoria, Australia and Slacks Creek, Queensland, Australia, by its U.S. subsidiary, geneType Inc. (formerly Phenogen Sciences
Inc.), in Charlotte, North Carolina, U.S. and by its U.K. subsidiary, GeneType UK Limited in Hove, East Sussex, United Kingdom. The total
rental charge in respect of the year ended June 30, 2023 was A$233,634, A$31,335, A$19,724 and A$25,206, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
future minimum lease payments in respect of the four leases that were in place and had remaining non-cancellable lease terms as of June
30, 2023 were A$551,879.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_018"></span>Item
5.C Research and Development, Patents and Licenses, etc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal business industry is biotechnology, with a historical emphasis on genomics and genetics, the licensing of our non- coding patents,
reduction to practice of our fetal cell patents and expansion of the related service testing business. Research and development expenditure
as below is reflective of the intense focus by the scientific and laboratory team to develop and market a suite of world-leading predictive
genetic tests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table details historic R&amp;D expenditure by project.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">2022</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">A$</p></td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">2021</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">A$</p></td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Polygenic Risk Testing</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">3,679,139</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4,204,919</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">986,622</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total R&amp;D expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,679,139</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,204,919</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">986,622</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other expenditure</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,973,214</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,572,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,833,906</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total expenditure</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">22,652,353</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">16,777,586</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,820,528</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">R&amp;D as a % of total expenditure</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.19</td><td style="text-align: left">%</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 42; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="F_019"></span>Item
5.D Trend Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Item 5.A. &#8220;Operating Results&#8221; and Item 5.B. &#8220;Liquidity and Capital Resources&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="F_020"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
5.E Critical Accounting Estimates</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_021"></span>Item
6. Directors, Senior Management and Employees</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Start
of the Remuneration Report (Audited) for <b><span style="text-decoration: underline">Australian Disclosure Requirements</span></b>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Genetic Technologies Limited Board of Directors (&#8220;the Board&#8221;) presents the 2022/2023 Remuneration Report, which has been
prepared in accordance with the relevant Corporations Act 2001 and accounting standards requirements. The remuneration report sets out
remuneration information for our company&#8217;s key management personnel (&#8220;KMP&#8221;) as defined in the International Accounting
Standards 24 &#8216;Related Party Disclosures&#8217; and the Australian Corporations Act 2001 for the financial year ended June 30, 2023.
The remuneration report which complies with s300A of the Corporations Act 2001 has been audited as required by s308 (3C) of the Corporations
Act 2001.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_022"></span>Item
6.A Directors and Senior Management</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors of the Company as of the date of this Annual Report are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mr.
Peter Rubinstein</b>, BEc. LLB <i>(Independent Non-Executive and Chairman)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Rubinstein was appointed to the Board on January 31, 2018 and appointed as Chairman in April 2020. He has over 20 years&#8217; experience
in early-stage technology commercialization through to public listings on the ASX. He is a lawyer, having worked at a large national
firm prior to moving in-house at Montech, the commercial arm of Monash University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Rubinstein has had significant exposure to the creation, launch and management of a diverse range of technology companies in biotech,
digital payments and renewable energy. Mr. Rubinstein is also a Non-Executive Director of DigitalX Limited (ASX: DCC).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
Jerzy (George) Muchnicki</b>, MBBS <i>(Non-Independent Non-Executive)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Muchnicki was appointed to the Board on January 31, 2018 and acted as Interim Chief Executive Officer from September 2019 till the appointment
of Mr. Simon Morriss to the role. Dr. Muchnicki graduated from Monash University and has held positions in private practice for over
25 years and was Head of Student Health at The University of Melbourne. For the past 14 years, he has been involved in commercialization
and funding R&amp;D in the biotechnology sector from gene silencing to regenerative medicine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Muchnicki brings with him strong commercial and medical skills, including broad interests in software development, blockchain and sustainable
building materials. He is a co-founder and Non-Executive Director of Speed Panel Holdings a world leader in fire rated and acoustic wall
solutions. He is also the co-founder of Candlebets, a software development company that is creating blockchain enabled platforms for
the gaming industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
Lindsay Wakefield</b>, MBBS <i>(Independent Non-Executive)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Wakefield was appointed to the Board on September 24, 2014. He started Safetech Pty Ltd in 1985 and over the next 25 years, Safetech
became a force in the Australian material handling and lifting equipment market, designing and manufacturing a wide range of industrial
products. In 1993, he left medicine to become the full-time CEO of Safetech. In 2006, Safetech was awarded the Telstra Australian National
Business of the Year. In 2013, Safetech merged and ultimately acquired Tiemen Materials Handling.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr
Wakefield continues as the CEO of Safetech. It is Australia&#8217;s largest manufacturer and supplier of dock equipment, freight hoists
and custom lifting solutions. Safetech employs approximately 100 people. Dr Wakefield has been a biotech investor for more than 20 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mr.
Nick Burrows</b>, B.Com. FAICD, FCA, FGIA, FTIA, F Fin <i>(Independent Non-Executive)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Burrows has over 30 years&#8217; commercial experience and was appointed to the Board on September 1, 2019. He is a contemporary independent
Non-Executive Director across the Listed, government and private sectors with significant expertise in corporate governance, and strategic,
commercial, financial and risk management oversight, underpinned by his background as a chartered accountant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Burrows was Chief Financial Officer and Company Secretary of Tassal Group Limited for 21 years from 1988 to 2009, and accordingly brings
to the Board strong independent C-suite commercial experience and the benefits of an extensive and contemporary senior executive ASX200
listed entity background. Mr. Burrows current and past Board and advisory portfolio encompasses listed and regulated entities, government
business enterprises, state-owned and local government entities and authorities, large private/ family companies community organizations,
membership-based bodies and Not-for-Profits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 28.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr
Burrows&#8217; expertise spans a raft of industry sectors encompassing water and sewerage, infrastructure, renewable energy, forestry,
agribusiness, public transport, tourism and hospitality, education and the vocational education sector, aquaculture, civil engineering,
construction, and finance and valuations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 28.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr
Burrows is a Fellow of the Australian Institute of Company Directors, Institute of Chartered Accountants Australia, Governance Institute
of Australia Ltd, Taxation Institute of Australia and the Financial Services Institute of Australasia and is also a Chartered Accountant.
Mr Burrows also served as National President of the Governance Institute of Australia in 2002 and served on their National Board for
6 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior
Management</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a professional team of qualified and experienced personnel, including a number of research and development scientists and
technicians. The Company currently has 60 full-time-equivalent employees in addition to the four Non-Executive Directors listed above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mr.
Simon Morriss,</b> GAICD <i>(Chief Executive Officer)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Morriss was appointed as Chief Executive Officer on February 1, 2021 and brings over 20 years&#8217; experience within the Pharmaceutical,
Healthcare and FMCG industries having held senior executive positions at Sanofi and Blackmores. He brings a wealth of experience in managing
teams and successfully executing across sales, marketing and brand building.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
Mr. Morriss has been critical in leading commercialization across these industries and understands the unique pressures and opportunities.
He has led companies through strategic adaptation to execution and will be driving Genetic Technologies commercialization strategy and
continue to drive innovation across the business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mr.
Tony Di Pietro,</b> BComm, CA, AGIA, MAICD <i>(Company Secretary/Chief Financial Officer)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr
Tony Di Pietro was appointed Company Secretary &amp; Chief Financial Officer November 28, 2022. Mr Di Pietro is a Chartered Accountant
with significant corporate accounting experience, gained both in Australia and the UK. He holds a Graduate Diploma of Applied Corporate
Governance from the Governance Institute of Australia and is a member of the Australian Institute of Company Directors. Tony is a finance
executive with extensive technical accounting, corporate tax, and company secretarial experience. Mr Di Pietro has held senior roles
within the Biotechnology/MedTech industry for the past 20 years including INOVIQ Ltd (ASX:IIQ), BARD1 Life Sciences Ltd (ASX:BD1), Sienna
Cancer Diagnostics Ltd (SDX), and Acrux Ltd (ASX:ACR). Tony played a significant role in the ASX listing of both Sienna and Acrux and
the merger between Sienna and BARD1. He has also gained valuable experience in other industry sectors, employed by companies such as
BHP Ltd, ExxonMobil Ltd, HSBC Ltd and Wilson Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
Richard Allman</b>, PhD <i>(Scientific Advisor, former Chief Scientific Officer)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Allman joined the Company in December 2004 and was appointed as Scientific Director in December 2012 and Chief Scientific Officer in
2016. He has over 20 years of scientific and research experience in both the academic arena in the UK and the commercial sector in Australia.
He has wide experience in research leadership, innovation management, and intellectual property strategy, covering oncology, diagnostics,
and product development. Prior to entering the biotech sector, Dr. Allman&#8217;s academic career encompassed oncology research, drug
development, and assay design. Dr. Allman ceased full-time employment with the Company on October 6, 2022. Dr. Allman has continued his
association with the Company as a consulting Scientific Advisor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mr.
Carl Stubbings</b> <i>(Chief Commercial Officer)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr
Stubbings joined the Company in 2021 and was appointed as Chief Commercial Officer on September 1, 2021. Mr Stubbings is an experienced
senior leader in the biotechnology and diagnostics industry with a focus on commercialization, sales, marketing and business development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">He
has considerable experience commercializing diagnostic products, both locally and globally. Based in the USA for 13 years, he served
as Senior Vice President for Panbio USA Ltd and Vice-President of Sales and Marketing for Focus Diagnostics, a subsidiary of Quest Diagnostics
(NASDAQ:DGX), one of the world&#8217;s largest pathology laboratories.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2012, Mr Stubbings moved back to Australia where he was appointed Chief Business Officer at Benitec Biopharma Limited (ASX: BLT,
NASDAQ: BNTC). More recently he has assisted several Australian biotech companies with their commercialization strategies. These companies
include BCAL Diagnostics, a start-up company developing a blood test for breast cancer, Minomic, an Immuno Oncology company with a test
for prostate cancer, and Biotron (ASX: BIT), a listed company that is developing and commercializing anti-viral small molecule therapies.
In 2019 Mr Stubbings was appointed CEO and Managing Director of Sienna Cancer Diagnostics Ltd (ASX: SDX). In that role, he helped lead
the successful merger between Sienna and BARD1 Life Sciences (ASX:BD1). Following the merger, Mr Stubbings was appointed Chief Operating
Officer of the merged entity BARD1 Life Sciences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr
Stubbings has a Bachelor of Applied Science (Medical Technology) from the Queensland University of Technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mr.
Kevin Camilleri</b> <i>(Chief Executive Officer of EasyDNA)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr
Camilleri joined the Company in 2021 and was appointed as Chief Executive Officer of EasyDNA on August 16, 2021. He was founder member
of the EasyDNA brand in 2001 and grew the business over time into a leading international online provider of genetic testing services.
A business graduate from the University of Bath in the UK, Mr. Camilleri has over the years accumulated a broad range of skills covering
most aspects of business management including strategic, financial, organizational, operational and commercial skills. He brings to the
company the ability to manage a cross-border organization in line with Genetic Technologies strategy for international expansion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mr.
Mike Tonroe, BSc, FCA, MAICD</b> <i>(former Company Secretary/Chief Financial Officer)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Tonroe joined the company on June 15, 2021, resigning November 28, 2022. Mike has over 25 years of experience with private and listed
companies in Australia, UK, US and Canada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mike
held the role of Chief Financial Officer and Company Secretary at dual-listed Opthea and was Chief Financial Officer and Company Secretary
at the Australian Synchrotron in Melbourne and he also has extensive accounting expertise having worked for both Deloitte and KPMG in
the UK and Hong Kong.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Tonroe is a fellow of the Institute of Chartered Accountants in England and Wales, a member of the Australian Institute of Company Directors
and holds a graduate degree in Business Studies from Buckingham University, UK.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_023"></span>Item
6.B Compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Elements
of compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
external advice is sought from remuneration consultants when required, however no advice has been sought during the period ended June
30, 2023, or comparative period. The board aims to ensure that remuneration practices are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt; color: #231F20">&#9679;</span></td>
    <td><span style="font-size: 10pt; color: #231F20">competitive and reasonable, enabling the Company to attract and retain key <span style="letter-spacing: -0.1pt">talent</span></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt; color: #231F20">&#9679;</span></td>
    <td><span style="font-size: 10pt; color: #231F20">aligned to the Company&#8217;s strategic and business objectives and the creation of shareholder <span style="letter-spacing: -0.1pt">value</span></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt; color: #231F20">&#9679;</span></td>
    <td><span style="font-size: 10pt; color: #231F20">transparent and easily understood, <span style="letter-spacing: -0.25pt">and</span></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt; color: #231F20">&#9679;</span></td>
    <td><span style="font-size: 10pt; color: #231F20">acceptable to <span style="letter-spacing: -0.1pt">shareholders.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Element</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purpose</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Performance
    metrics</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed
    annual remuneration (FR)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    competitive market salary including superannuation and non-monetary benefits</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-Term
    Incentive (STI)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reward
    for in-year performance and retention</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    and individual performance goals</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-Term
    Incentive (LTI)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alignment
    to long-term shareholder value</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    price, capital raised, company and individual performance goals</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(i)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed
    annual remuneration (FR)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Objective</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Remuneration Committee oversees the setting of fixed remuneration on an annual basis. The process consists of a review of Company, divisional
and individual performance, relevant comparative remuneration in the market and internally and, where appropriate, external advice on
policies and practices. The members of the Committee have access to external advice independent of Management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Structure</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed
remuneration consists of some or all of the following components:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">base
    salary;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">non-monetary
    benefits, for example health insurance; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">superannuation
    benefits, which includes employer contributions,</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the exception of the employer contributions to superannuation, Executives are given some flexibility to decide the composition of their
total fixed remuneration and the allocation between cash and other benefits. It is intended that the manner of payment chosen will be
optimal for the recipient without creating any additional cost for the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed
remuneration is reviewed annually with reference to individual performance, market benchmarks for individual roles and the overall financial
performance of the Company. Any changes to the fixed remuneration of Executives are first approved by the Remuneration Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
employee remuneration is evaluated on a regular basis using a set of variables and taking into account the addition of the statutory
superannuation contribution. An assessment of existing base salaries is made annually using comparisons against independent market data
which provides information on salaries and other benefits paid for comparable roles within the biotech and pharmaceutical industries,
using third party salary survey data. Annual performance reviews with each employee are based on a rating system which is used to assess
his or her eligibility for salary increases. Other qualitative factors, including the specialized knowledge and experience of
the individual and the difficulty of replacing that person, are also taken into account when considering salary adjustments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remuneration
Committee membership</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at the date of this Report, the composition of the committee is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Lindsay Wakefield &#8211; Chairman of the Committee</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Nicholas Burrows (Member)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Peter Rubinstein (Member)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(ii)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Short-Term
    Incentives (STI)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short
Term Incentive (STI) is an annual plan that applies to Executives and other senior employees that is based on the performance of both
the Company and the individual during a given financial year. STI ranges vary depending on the role, responsibilities and deliverables
achieved by each individual. Actual STI payments granted to the relevant employee will depend on the extent to which the pre-agreed specific
targets are met within a financial year. Specific targets are quantifiable with the agreed method of measurement defined at the beginning
of the financial year. The ongoing performance of the Executive or senior employee is evaluated regularly during the performance cycle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
objectives, and their relative weighting, vary depending on the position and responsibility of the respective individual, but in respect
of the year ended June 30, 2023 include, amongst other things, the achievement of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    targets for cost reduction or efficiency gains;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">contributing
    to business growth and expansion; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    or the delivery of results which exceed agreed targets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
measures are chosen as they represent the key drivers for the short-term success of the business and provide a framework for delivering
long term value. Personal and operating objectives vary according to the role and responsibility of the Executive and include objectives
such as service delivery to customers, project delivery, compliance outcomes, intellectual property management and various staff management
and leadership objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Achievement
of an individual&#8217;s targets or objectives is documented and assessed by both the individual and his or her direct manager. The individual
will participate in an annual performance review and must provide evidence of the objectives that he or she has delivered during the
period under review. Each objective is then rated on an achievement scale. Depending on the aggregate of the ratings, the individual
may be eligible to receive an STI payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">STI
payments, if any, are generally paid in August or September of each year subject to the completion of the performance review process
and the receipt of a satisfactory rating. The Remuneration Committee conducts this process in the case of the CEO. During the financial
year ended June 30, 2023, no Short-Term Incentive payments were made to Executives and other senior employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(iii)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Long-Term
    Incentives (LTI)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
objective of the Company&#8217;s LTI arrangements is to reward Executives and senior employees in a manner that aligns their remuneration
with the creation of shareholder wealth. As such, significant LTI grants are generally only made to Executives who are able to influence
the generation of shareholder wealth and have an impact on the Company&#8217;s long-term profitability. There are share price targets
to be met before performance rights vest in respect of the LTI grants made to Executives. Options with a vesting period also serve as
a retention tool and may reduce the likelihood of high performing Executives and senior employees being targeted by other companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long
Term Incentive (LTI) grants to Executives and senior employees are delivered in the form of options over unissued ordinary shares in
the Company which are granted under the terms and conditions of the Company&#8217;s Employee Option Plan. Selected Executives who contribute
significantly to the long-term profitability of the Company are invited to participate in the Employee Option Plan. The remuneration
value of these grants varies and is determined with reference to the nature of the individual&#8217;s role, as well as his or her individual
potential and specific performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
cases where an Executive ceases employment prior to the vesting of his or her options, the options are forfeited after a prescribed period
if they have not been exercised. The prescribed period ranges from two to six months, depending on the circumstances under which they
left the Company, e.g. resignation, retirement, termination or death. In the event of a change of control of the Company, the performance
period end date will be brought forward to the date of the change of control and awards will vest over this shortened period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Link
between remuneration and performance</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statutory performance indicators</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company aims to align executive remuneration to the Company&#8217;s strategic and business objectives and the creation of shareholder
wealth. The table below shows measures of the Company&#8217;s financial performance over the last five years as required by the Corporations
Act 2001. However, these are not necessarily consistent with the measures used in determining the variable amounts of remuneration to
be awarded to KMPs. As a consequence, there may not always be a direct correlation between the statutory key performance measures and
the variable remuneration awarded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2019</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Loss for the year attributable to owners (A$)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,750,923</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,130,998</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,077,619</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,294,775</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,425,604</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Basic earnings per share (cents)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.2</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share price at year end (A$)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.003</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.003</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.009</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.005</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.006</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s earnings have remained negative since inception due to the nature of the business. Shareholder wealth reflects this speculative
and volatile market sector. No dividends have ever been declared by the Company. The Company will continue its research and development
activities, leading to an expansion of its intellectual property portfolio, as well as continued growth of product revenues from its
three key brands; geneType, EasyDNA and AffinityDNA. The overall objective is to achieve key development and commercial milestones in
order to add further shareholder value.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remuneration
expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
of the nature and amount of each major element of the compensation of each director of the Company and each of the named officers of
the Company and its subsidiaries, for services in all capacities during the financial year ended June 30, 2023 are listed below. All
figures are stated in Australian dollars (A$).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Short-term benefits</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.1pt"><b>Post-<br />
employment </b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Superannuation </span></b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Other long-term benefits</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Share- based payments Equity</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Percentage (%)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">Name and title</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Salary/fees</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.2pt"><b>STI<sup>#</sup></b></span></td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Other**</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">***</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">****</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">*****</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Totals</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Fixed</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Variable</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify; font-weight: bold">Non-Executive Directors</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Rem.</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Rem.</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Dr. Lindsay Wakefield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: center">2023</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">67,462</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">7,084</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">74,546</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mr. Peter Rubinstein</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,951</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mr. Nicholas Burrows</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,462</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,084</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-Independent Non-Executive Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Jerzy Muchnicki</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,125</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-weight: bold">Management</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Richard Allman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,162</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,707</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,336</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,071</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87,283</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Mike Tonroe <span style="letter-spacing: -0.25pt"><sup>(3)</sup></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,584</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,031</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,192</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,444</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,251</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Simon Morriss <span style="letter-spacing: -0.25pt"><sup>(2)</sup></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330,565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,188</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,985</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,285</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191,346</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">587,744</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Tony Di Pietro <span style="letter-spacing: -0.25pt"><sup>(6)</sup></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,958</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,028</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184,430</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Carl Stubbings <span style="letter-spacing: -0.25pt"><sup>(4)</sup></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">223,444</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,205</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,335</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,953</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,309</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,368</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">296,944</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Kevin Camilleri <span style="letter-spacing: -0.25pt"><sup>(5)</sup></span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">233,276</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,725</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,276</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,131</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,739</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">281,147</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">85</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold">Totals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,406,012</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">91,856</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,256</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">113,511</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,978</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">253,453</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,907,066</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">82</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Referencing
the table above:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>#
</sup>Represents the payment of short-term incentives for the 2022 financial year, no short-term incentive was payable for the 2023 financial
year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Other includes movement in Annual Leave component</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***
Post-employment benefits as per Corporations Regulation 2M.3.03 (1) Item 7</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">****
Other long-term benefits as per Corporations Regulation 2M.3.03 (1) Item 8</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*****
Equity settled share-based payments as per Corporations Regulation 2M.3.03 (1) Item 11</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
of the nature and amount of each major element of the compensation of each director of the Company and each of the named officers of
the Company and its subsidiaries, for services in all capacities during the financial year ended June 30, 2022 are listed below. All
figures are stated in Australian dollars (A$).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Short-term benefits</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.1pt"><b>Post-<br />
employment </b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Superannuation </span></b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Other long-term benefits</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Share- based payments Equity</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Percentage (%)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">Name and title</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Salary/fees</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.2pt"><b>STI<sup>*</sup></b></span></td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Other**</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">***</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">****</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">*****</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Totals</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Fixed</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Variable</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify; font-weight: bold">Non-Executive Directors</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Rem.</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Rem.</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Dr. Lindsay Wakefield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: center">2022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">67,462</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">6,746</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">4,010</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">78,218</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">95</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mr. Peter Rubinstein</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,477</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,347</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,593</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mr. Nicholas Burrows</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,462</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,746</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74,208</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-Independent Non-Executive Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Jerzy Muchnicki</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145,117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,194</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,684</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,995</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-weight: bold">Management</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Richard Allman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">195,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,683</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,366</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,231</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224,645</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Mike Tonroe <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">289,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">472</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,043</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">428,946</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Simon Morriss <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">346,688</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,606</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">780</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191,346</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">628,670</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Stanley Sack <sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107,188</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,438</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,626</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Carl Stubbings <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">201,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,205</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,765</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,459</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,593</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Kevin Camilleri <sup>(5)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">211,982</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,355</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,528</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,719</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">254,584</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">93</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Totals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,787,414</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,750</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">63,249</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">125,822</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,797</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">387,046</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,412,078</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Referencing
the table above:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Represents the payment of short-term incentives for the 2021 financial year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Other includes movement in Annual Leave component</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***
Post-employment benefits as per Corporations Regulation 2M.3.03 (1) Item 7</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">****
Other long-term benefits as per Corporations Regulation 2M.3.03 (1) Item 8</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*****
Equity settled share-based payments as per Corporations Regulation 2M.3.03 (1) Item 11 Notes pertaining to changes during the year:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the financial year ended June 30, 2020, the Board approved to obtain consulting services in relation to capital raises, compliance, NASDAQ
hearings and investor relations from its Non-Executive director and current Chairman, Mr. Peter Rubinstein. The services procured were
through Mr. Peter Rubinstein&#8217;s associate entity, ValueAdmin.com Pty Ltd, and amounted to A$60,000 for the year ended June 30, 2023
(2022: A$60,000).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)
</sup>Mr. Sack was appointed as Chief Operating Officer (COO) on May 18, 2020. He resigned on April 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)
</sup>Mr. Morriss was appointed as Chief Executive Officer (CEO) on February 1, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)
</sup>Mr. Tonroe was appointed as Chief Financial Officer (CFO) on June 15, 2021. He resigned on November 28, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)
</sup>Mr Stubbings was appointed as Chief Commercial Officer (CCO) on September 1, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)
</sup>Mr Camilleri was appointed as Chief Executive Officer of EasyDNA on August 16, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)
</sup>Mr Di Pietro was appointed as Company Secretary &amp; Chief Financial Officer on November 28, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual
agreements with the directors and other key management personnel</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name:</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Jerzy Muchnicki</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Independent
    Non-Executive Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed
    remuneration:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$64,455
    (inclusive of superannuation)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Peter Rubinstein</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive
    Director and Chairman</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed
    remuneration:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$104,720
    (inclusive of superannuation)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consulting
    fee:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$60,000
    (excluding GST)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Lindsay Wakefield</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive
    Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed
    remuneration:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$74,546
    (inclusive of superannuation)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Nicholas Burrows</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive
    Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed
    remuneration:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$74,546
    (inclusive of superannuation)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Simon Morriss</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed
    remuneration:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$365,274
    (inclusive of superannuation)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Mike Tonroe</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">former
    Chief Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed
    remuneration:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$300,000
    (inclusive of superannuation)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Tony Di Pietro</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Secretary &amp; Chief Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed
    remuneration:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$300,000
    (inclusive of superannuation)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Richard Allman</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer until October 6,2022/Scientific Advisor (Consultant)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed
    remuneration:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$200,530
    (inclusive of superannuation) when employed as Chief Scientific Officer/Remains on call and invoices the company for his time on
    a project by project basis.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Carl Stubbings</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Commercial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed
    remuneration:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$257,415
    (inclusive of superannuation)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Kevin Camilleri</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, EasyDNA</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed
    remuneration:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$233,276</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 50; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
Terms and Conditions:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key provisions contained in the agreements of the directors of the Company include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company does not have a set tenure for directors, and under the Corporations Act 2001 and the Constitution, the directorship can
    cease under prescribed circumstances (example, bankruptcy, conviction of an offence). In addition, the director may resign by providing
    notice in writing at any time.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    form of remuneration linked to short term incentives has been issued to any of the directors.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following are the key provisions contained in the agreements of the other Key Management Personnel:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mr.
Simon Morriss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genetic
    Technologies or Mr. Morriss may terminate the employment agreement by providing two weeks written notice within the first six months
    of employment. Thereafter the notice period is 4 months written notice. Genetic Technologies may, at its own election, make payment
    in lieu of notice.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Morriss shall be subject to restrictions on competing with Genetic Technologies Limited and its related bodies corporate during the
    employment and for a period of up to 24 months after the employment ends. Mr. Morriss is also prevented from soliciting Genetic Technologies
    employees&#8217; customers or suppliers to cease employment or conducting business with the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Morriss&#8217; CEO employment agreement otherwise contains standard terms and conditions for agreements of its nature, including
    confidentiality, retention of intellectual property and leave.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mr.
Mike Tonroe (resigned on November 28, 2022)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genetic
    Technologies or Mr. Tonroe may terminate the employment agreement by providing two weeks written notice within the first six months
    of employment. Thereafter the notice period is 4 months written notice. Genetic Technologies may, at its own election, make payment
    in lieu of notice.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Tonroe shall be subject to restrictions on competing with Genetic Technologies Limited and its related bodies corporate during the
    employment and for a period of up to 24 months after the employment ends. Mr. Tonroe is also prevented from soliciting Genetic Technologies
    employees&#8217; customers or suppliers to cease employment or conducting business with the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Tonroe&#8217;s CFO employment agreement otherwise contains standard terms and conditions for agreements of its nature, including
    confidentiality, retention of intellectual property and leave.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mr.
Tony Di Pietro (appointed November 28, 2022)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genetic
    Technologies or Mr. Di Pietro may terminate the employment agreement by providing two weeks written notice within the first six months
    of employment. Thereafter the notice period is 4 months written notice. Genetic Technologies may, at its own election, make payment
    in lieu of notice.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Di Pietro shall be subject to restrictions on competing with Genetic Technologies Limited and its related bodies corporate during
    the employment and for a period of up to 24 months after the employment ends. Mr. Di Pietro is also prevented from soliciting Genetic
    Technologies employees&#8217; customers or suppliers to cease employment or conducting business with the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Di Pietro&#8217;s CFO employment agreement otherwise contains standard terms and conditions for agreements of its nature, including
    confidentiality, retention of intellectual property and leave.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
Richard Allman</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Towards
    termination, the agreement states that the Company or the employee may terminate at any time by providing a 30-day notice to the
    other party or the agreement will be terminated on the expiration of that notice.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    termination of this agreement the Company will pay the employee the salary package due up to and including the date of termination.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mr.
Carl Stubbings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genetic
    Technologies or Mr. Stubbings may terminate the employment agreement by providing two weeks written notice within the first six months
    of employment. Thereafter the notice period is 4 months written notice. Genetic Technologies may, at its own election, make payment
    in lieu of notice.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Stubbings shall be subject to restrictions on competing with Genetic Technologies Limited and its related bodies corporate during
    the employment and for a period of up to 24 months after the employment ends. Mr. Stubbings is also prevented from soliciting Genetic
    Technologies employees&#8217; customers or suppliers to cease employment or conducting business with the Company.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                                         Stubbings&#8217;s CCO employment agreement otherwise contains standard terms and conditions for agreements of its nature, including
                                                         confidentiality, retention of intellectual property and leave.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 51; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mr.
Kevin Camilleri</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genetic
    Technologies or Mr. Camilleri may terminate the employment agreement by providing two weeks written notice within the first six months
    of employment. Thereafter the notice period is 4 months written notice. Genetic Technologies may, at its own election, make payment
    in lieu of notice.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Camilleri shall be subject to restrictions on competing with Genetic Technologies Limited and its related bodies corporate during
    the employment and for a period of up to 12 months after the employment ends. Mr. Camilleri is also prevented from soliciting Genetic
    Technologies employees&#8217; customers or suppliers to cease employment or conducting business with the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Camilleri&#8217;s EasyDNA CEO employment agreement otherwise contains standard terms and conditions for agreements of its nature,
    including confidentiality, retention of intellectual property and leave.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of those Executives nominated as Key Management Personnel under section 300A of the <i>Corporations Act 2001 </i>have been disclosed
in this Report. No other employees of the Company meet the definition of &#8220;Key Management Personnel&#8221; as defined in <i>IAS
24 Related Party Disclosures</i>, or &#8220;senior manager&#8221; as defined in the <i>Corporations Act 2001.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
officers are those officers who were involved during the year in the strategic direction, general management or control of the business
at a company or operating division level. The remuneration paid to Executives is set with reference to prevailing market levels and comprises
a fixed salary, short-term incentives (which are linked to agreed key performance indicators), and an option or performance share component
(long term incentive). Options/Performance shares are granted to Executives in line with their respective levels of experience and responsibility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
Based Payments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
holdings and details of options exercised, granted, and forfeited, as part of remuneration</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
options were issued under employee incentive scheme during the financial year ended June 30, 2023 and June 30, 2022. On December 21,
2020, the Company issued 5,000,000 options to Executives and 7,850,000 to other employees, under an employee incentive scheme. The
options have an exercise price of A$0.008 (0.8 cents) per option and expire on December 1, 2023. During the financial year ending
June 30, 2023 250,000,000 options lapsed due to expiry (2022: 10,000,000, 2021: 5,000,000). No options were exercised during the
financial years ending June 30, 2023, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
of the options held by the Executives and Directors nominated as Key Management Personnel at the year ended June 30, 2023 are set out
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
holdings of Key Management Personnel June 30, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance at start of the year</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Granted as remuneration</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Granted as part of cost of capital</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercised</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lapsed</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance at end of the year</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vested
and exercisable</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Lindsay Wakefield</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 37%; text-align: left">Mr. Peter Rubinstein</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">125,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">(125,000,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Jerzy Muchnicki</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(125,000,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Richard Allman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mr. Stanley Sack</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mr. Mike Tonroe</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mr. Carl Stubbings</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mr. Kevin Camilleri</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">255,000,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(250,000,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,000,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,000,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 52; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company introduced a Staff Share Plan on November 30, 2001. On November 19, 2008, the shareholders of the Company approved the introduction
of a new Employee Option Plan. Collectively, these Plans establish the eligibility of our employees and those of any subsidiaries, and
of consultants and independent contractors to a participating company who are declared by the Board to be eligible, to participate. Broadly
speaking, the respective Plans permits us, at the discretion of the Board, to issue traditional options (with an exercise price). The
Plans conform to the IFSA Executive Share and Option Scheme Guidelines and, where participation is to be made available to staff who
reside outside Australia, there may have to be modifications to the terms of grant to meet or better comply with local laws or practice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, there was one executive and 7 employees who held options that had been granted under the Company&#8217;s respective
option plans. Options issued under the Plan carry no rights to dividends and no voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, there was a total of 8,000,000 unlisted employee options outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted under the Employee Option Plan carry no rights to dividends and no voting rights and generally have an expiry date of five years
from the date of the offer to grant options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended June 30, 2023, the Company did not record a share-based payments expense in respect of the options granted (2022: Nil).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is additional information relating to the options granted under the Employee Share Option Plan as of June 30,
2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="12" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Options outstanding</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Options exercisable</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of exercise prices</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Remaining weight- ed average contrac- tual life (years)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">A$0.008</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,400,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.008</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.42</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,400,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.008</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlisted
performance rights holdings and details of performance rights exercised, granted, and forfeited, as part of remuneration</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
Rights are not currently quoted on the ASX and as such have no ready market value. The Performance Rights each grant the holder a right
of grant of one ordinary Share in the Company upon vesting of the Performance Rights for nil consideration. Accordingly, the Performance
Rights may have a present value at the date of their grant. Various factors impact upon the value of Performance Rights including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    period outstanding before the expiry date of the Performance Rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    underlying price or value of the securities into which they may be converted;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    proportion of the issued capital as expanded consequent upon conversion of the Performance Rights into Shares (i.e. whether or not
    the shares that might be acquired upon exercise of the options represent a controlling or other significant interest); and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    value of the shares into which the Performance Rights may be converted.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
management personnel, being the recipients of the performance rights, must remain employed by the Company for the relevant performance
right to vest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
new performance rights were issued during the financial year. (2022: 80,000,000). The performance rights issued to Mr Michael Tonroe,
40,000,000, in the prior financial year lapsed upon his resignation in November 2022 (2022: 15,000,000). No performance rights were exercised
during the financial year (2022: 3,937,500).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
of performance rights granted in the year ended June 30, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended June 30, 2022, the Board has approved for the following Performance Rights to be issued to the Key Management Personnel
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000,000
    Performance Rights to Mr. Michael Tonroe</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,000,000
    Performance Rights to Mr. Carl Stubbings</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,000,000
    Performance Rights to Mr. Kevin Camilleri</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 53; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
hurdles</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
management personnel, being the recipients of the performance rights, must remain engaged by the Company at the time of satisfaction
of the performance hurdle in order for the relevant Performance Right to vest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
performance rights for key management personnel vest and are exercisable upon the Share price reaching A$0.016 while or greater for more
than 15-day consecutive ASX trading days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are various formulae which can be applied to determining the theoretical value of performance rights (including the formula known as
the Black-Scholes Model valuation formula and the Binomial model).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company commissioned an independent valuation of these performance rights. The independent valuer has applied the Binomial model in providing
the valuation of the performance rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inherent
in the application of the Binomial model are a number of inputs, some of which must be assumed. The data relied upon in applying the
Binomial model was:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise
    price being 0.0 cents per Performance Right for all classes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VWAP
    hurdle for key management personnel (15 days consecutive share price hurdle) equaling A$0.016 for Performance Rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    and market cap hurdles as listed above for Performance Rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    continuously compounded risk-free rate is as per table below (calculated based on yield of Australian government bonds, as at the
    grant dates for a 2 or 3 year period matching the expected life of Performance Rights);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    expected option life of 3 years for key management personnel and 2 years for others; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    volatility measure between 149% to 161%.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the independent valuation of the performance rights, the Company agrees that the total value of these performance rights to be issued
to each member of key management personnel (depending on the share price at issue) is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
rights issued during prior year, vested during the year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Performance Rights issued</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation (cents)</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total fair value of Performance Rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense accounted for in 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense accounted for during the year</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Mr. Carl Stubbings</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.52</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">103,104</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">26,459</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">34,368</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mr. Kevin Camilleri</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.42</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">83,216</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,719</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,739</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">40,000,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">186,320</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">43,178</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">62,107</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Performance
rights issued during prior year, lapsed during the financial year ending June30, 2023</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Performance Rights issued</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation<br />
(cents)</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total fair value of Performance Rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense accounted for in 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense accounted for during the year</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left; padding-bottom: 1.5pt">Mr. Michael Tonroe</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">40,000,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">0.73</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">291,428</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">101,043</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">40,000,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">291,428</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">101,043</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 54; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
of performance rights granted in prior years</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the independent valuation of the performance rights, the Company agrees that the total value of the outstanding performance rights
issued to key management personnel (depending on the share price at issue) is as follows:</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
of Class A Performance Rights granted prior to the year ended June 30, 2022</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
hurdles</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Class A Performance Rights vest and are exercisable upon the Share price reaching A$0.012 or greater for more than 10- day consecutive
ASX trading days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Class B Performance Rights vest and are exercisable upon the Share price reaching A$0.014 or greater for more than 10-day consecutive
ASX trading days and sales commence on the Consumer Initiated Testing (CIT) platform in either Australia or the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Class C Performance Rights vest and are exercisable upon a minimum of 4,000 tests being processed in any 12-month period or the market
cap of GTG reaching A$100 million or above and being sustained for more than 10 consecutive ASX trading days, whichever happens sooner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Class D Performance Rights vest and are exercisable upon the Share price reaching A$0.016 or greater for more than 15- day consecutive
ASX trading days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Class E Performance Rights vest and are exercisable upon the first commercial sale of the Company&#8217;s COVID-19 risk test with IBX
(Infinity BioLogix).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company commissioned an independent valuation of these performance rights. The independent valuer has applied the Binomial model in providing
the valuation of these performance rights. Inherent in the application of the Binomial model are a number of inputs, some of which must
be assumed. The data relied upon in applying the Binomial model was:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise
    price being 0.0 cents per Performance Right for all classes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VWAP
    hurdle (10 days consecutive share price hurdle) equaling A$0.012 for Class A and A$0.014 for Class B, and (15 days consecutive share
    price hurdle) equaling A$0.016 for Class D Performance Rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    and market cap hurdles as listed above for Class C and Class E Performance Rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    continuously compounded risk-free rate being 0.111% for all classes of Performance Rights (based on a 3 year Australian Government
    yield as at December 21, 2020);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    expected option life of 2 years for Class E Performance Rights and 3 years for all other classes of Performance Rights; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    volatility measure of 158.23%.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
values calculated are set out below and are recognized as a share-based payment expense is included within general and administrative
costs in the statement of profit or loss and other comprehensive income. Performance rights issued during prior years, lapse during the
year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation
of class A performance rights granted in prior years, and held by key management personnel at June 30, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Performance Rights issued</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Valuation per Class A (cents)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total fair value of Class A Performance Rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.25pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.1pt"><b>Expense </b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accounted in <span style="letter-spacing: -0.2pt">2021</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.25pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.1pt"><b>Expense </b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accounted for during the <span style="letter-spacing: -0.2pt">year</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.25pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Dr. Lindsay Wakefield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.6702</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33,512</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33,512</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mr. Nicholas Burrows</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.6702</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,512</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,512</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Jerzy Muchnicki</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.6702</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,268</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,268</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mr. Peter Rubinstein</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.6702</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,268</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,268</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">25,000,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">167,560</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">167,560</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 55; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation
of class B performance rights granted in prior years, and held by key management personnel at June 30, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Performance Rights issued</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation
per Class B (cents)</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total fair value of Class B</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Performance</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rights A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense accounted in 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense accounted for during the year</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Dr. Jerzy Muchnicki</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.6646</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">166,158</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">166,158</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mr. Peter Rubinstein</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.6646</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">166,158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">166,158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">50,000,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">332,316</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">332,316</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation
of class C performance rights granted in prior years, and held by key management personnel at June 30, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Performance Rights issued</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation per Class C (cents)</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
fair value of Class C Performance Rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense
accounted in 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense accounted for during the year</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Dr. Jerzy Muchnicki</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.6702</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">167,541</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mr. Peter Rubinstein</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.6702</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">167,541</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">50,000,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">335,082</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation
of class D performance rights granted in prior years, and held by key management personnel at June 30, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
of Performance Rights issued</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation
per Class D (cents)</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total fair value of Class D Performance Rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense
accounted in 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense
accounted for during the year</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Mr Simon Morriss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">60,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.96</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">574,037</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">191,346</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">191,346</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation
of class E performance rights granted in prior years and exercised in the financial year ending June 30, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
of Performance Rights issued</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation
per Class E (cents)</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total fair value of Class E Performance Rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense
accounted in 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense
accounted for during the year</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Mr Stanley Sack</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,937,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">35,438</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,622</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class
A performance rights issued in prior years, that lapsed during the financial year ending June 30, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b></b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Number
of <span style="letter-spacing: -0.1pt">Performance<br />
</span>Rights issued</b></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Valuation
per Class A (cents)</b></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; color: #231F20">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; color: #231F20"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0; color: #231F20"><b>Total fair value of Class A <span style="letter-spacing: -0.1pt">Performance Rights</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0; color: #231F20"><span style="letter-spacing: -0.25pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center; color: #231F20">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="letter-spacing: -0.1pt"><b>Expense
</b></span><b>accounted in <span style="letter-spacing: -0.2pt">2022</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0; color: #231F20"><span style="letter-spacing: -0.25pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="letter-spacing: -0.1pt"><b>Expense
</b></span><b>accounted for during the <span style="letter-spacing: -0.2pt">year</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0; color: #231F20"><span style="letter-spacing: -0.25pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; color: #231F20; text-align: left">Dr. Lindsay Wakefield</td><td style="width: 2%; color: #231F20">&#160;</td>
    <td style="width: 1%; color: #231F20; text-align: left">&#160;</td><td style="width: 9%; color: #231F20; text-align: right">3,750,000</td><td style="width: 1%; color: #231F20; text-align: left">&#160;</td><td style="width: 2%; color: #231F20">&#160;</td>
    <td style="width: 1%; color: #231F20; text-align: left">&#160;</td><td style="width: 9%; color: #231F20; text-align: right">0.77</td><td style="width: 1%; color: #231F20; text-align: left">&#160;</td><td style="width: 2%; color: #231F20">&#160;</td>
    <td style="width: 1%; color: #231F20; text-align: left">&#160;</td><td style="width: 9%; color: #231F20; text-align: right">28,875</td><td style="width: 1%; color: #231F20; text-align: left">&#160;</td><td style="width: 2%; color: #231F20">&#160;</td>
    <td style="width: 1%; color: #231F20; text-align: left">&#160;</td><td style="width: 9%; color: #231F20; text-align: right">4,010</td><td style="width: 1%; color: #231F20; text-align: left">&#160;</td><td style="width: 2%; color: #231F20">&#160;</td>
    <td style="width: 1%; color: #231F20; text-align: left">&#160;</td><td style="width: 9%; color: #231F20; text-align: right">-</td><td style="width: 1%; color: #231F20; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: #231F20; text-align: left">Dr. Jerzy Muchnicki</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">6,250,000</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">0.77</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">48,125</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">6,684</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">-</td><td style="color: #231F20; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: #231F20; text-align: left">Mr. Peter Rubinstein</td><td style="padding-bottom: 1.5pt; color: #231F20">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: right">5,000,000</td><td style="padding-bottom: 1.5pt; color: #231F20; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: #231F20">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: #231F20; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: #231F20; text-align: right">0.77</td><td style="padding-bottom: 1.5pt; color: #231F20; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: #231F20">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: right">38,500</td><td style="padding-bottom: 1.5pt; color: #231F20; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: #231F20">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: right">5,347</td><td style="padding-bottom: 1.5pt; color: #231F20; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: #231F20">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: right">-</td><td style="padding-bottom: 1.5pt; color: #231F20; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: #231F20; font-weight: bold">Total</td><td style="padding-bottom: 1.5pt; color: #231F20; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: #231F20; font-weight: bold; text-align: right">15,000,000</td><td style="padding-bottom: 1.5pt; color: #231F20; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: #231F20; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: #231F20; font-weight: bold; text-align: right">115,500</td><td style="padding-bottom: 1.5pt; color: #231F20; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: #231F20; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: #231F20; font-weight: bold; text-align: right">16,041</td><td style="padding-bottom: 1.5pt; color: #231F20; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: #231F20; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: right">-</td><td style="padding-bottom: 1.5pt; color: #231F20; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>


<!-- Field: Page; Sequence: 56; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
values calculated as set out above are recognized as a share-based payment expense is included within general and administrative costs
in the statement of profit or loss and other comprehensive income for the relevant period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is the reconciliation of Performance Rights for the year ended June 30, 2023 held by Key Management Personnel:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">Performance Rights</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Balance at start of the year</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Granted as remuneration</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercised</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Lapsed/ Forfeited</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Balance at the end of year</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Dr. Lindsay Wakefield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mr. Peter Rubinstein</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mr. Nicholas Burrows</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Jerzy Muchnicki</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Richard Allman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mr. Tony Di Pietro</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mr. Mike Tonroe</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40,000,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mr. Simon Morriss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mr. Carl Stubbings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mr. Kevin Camilleri</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">265,000,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(40,000,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">225,000,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
rights included in the balance at start of the financial year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unlisted performance rights granted and outstanding as of June 30, 2023 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"><span style="letter-spacing: -0.2pt"><b>2023</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; color: #231F20">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: center"><b>Fair
                                                                                                 Value</b>
                                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"><b><span style="letter-spacing: -0.1pt"></span><span style="letter-spacing: -0.25pt">A$</span></b></p></td><td style="text-align: center; padding-bottom: 1.5pt; color: #231F20">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; color: #231F20; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; color: #231F20; font-weight: bold">Expiration Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: #231F20; font-weight: bold">Director</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; color: #231F20; text-align: left">Mr. Peter Rubinstein (Class A)</td><td style="width: 2%; color: #231F20">&#160;</td>
    <td style="width: 1%; color: #231F20; text-align: left">&#160;</td><td style="width: 14%; color: #231F20; text-align: right">7,500,000</td><td style="width: 1%; color: #231F20; text-align: left">&#160;</td><td style="width: 2%; color: #231F20">&#160;</td>
    <td style="width: 1%; color: #231F20; text-align: left">&#160;</td><td style="width: 16%; color: #231F20; text-align: right">50,268</td><td style="width: 1%; color: #231F20; text-align: left">&#160;</td><td style="width: 2%; color: #231F20">&#160;</td>
    <td style="width: 14%; color: #231F20; text-align: right">21-Dec-2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: #231F20; text-align: left">Mr Nick Burrows (Class A)</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">5,000,000</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">33,512</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: right">21-Dec-2023</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: #231F20; text-align: left">Dr. Jerzy Muchnicki (Class A)</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">7,500,000</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">50,268</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: right">21-Dec-2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: #231F20; text-align: left">Mr. Lindsay Wakefield (Class A)</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">5,000,000</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">33,512</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: right">21-Dec-2023</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: #231F20; text-align: left">Mr. Peter Rubinstein (Class B)</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">25,000,000</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">166,158</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: right">21-Dec-2023</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: #231F20; text-align: left">Dr. Jerzy Muchnicki (Class B)</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">25,000,000</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">166,158</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: right">21-Dec-2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: #231F20; text-align: left">Mr. Peter Rubinstein (Class C)</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">25,000,000</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">167,541</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: right">21-Dec-2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: #231F20; text-align: left">Dr. Jerzy Muchnicki (Class C)</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">25,000,000</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">167,541</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: right">21-Dec-2023</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: #231F20; text-align: left">Mr. Simon Morriss (Class D)</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">60,000,000</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">574,037</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: right">4-Feb-2024</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: #231F20; text-align: left">Mr. Carl Stubbings</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">20,000,000</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; text-align: right">103,104</td><td style="color: #231F20; text-align: left">&#160;</td><td style="color: #231F20">&#160;</td>
    <td style="color: #231F20; text-align: right">22-Sep-2024</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: #231F20; text-align: left; padding-bottom: 1.5pt">Mr. Kevin Camilleri</td><td style="color: #231F20; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: right">20,000,000</td><td style="padding-bottom: 1.5pt; color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: #231F20; text-align: right">83,216</td><td style="padding-bottom: 1.5pt; color: #231F20; text-align: left">&#160;</td><td style="color: #231F20; padding-bottom: 1.5pt">&#160;</td>
    <td style="color: #231F20; text-align: right; padding-bottom: 1.5pt">22-Nov-2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: #231F20; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Balance at the end of the financial year</td><td style="color: #231F20; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: #231F20; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: #231F20; font-weight: bold; text-align: right">225,000,000</td><td style="padding-bottom: 1.5pt; color: #231F20; font-weight: bold; text-align: left">&#160;</td><td style="color: #231F20; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: #231F20; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: #231F20; font-weight: bold; text-align: right">1,595,315</td><td style="padding-bottom: 1.5pt; color: #231F20; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 11pt; padding-bottom: 1.5pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<!-- Field: Page; Sequence: 57; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is additional information relating to the performance rights granted, as of June 30, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="12" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Performance rights outstanding</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Performance rights exercisable</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of exercise prices</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Performance Rights</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Remaining Weighted average contractual life (years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Perf.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>rights</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 15%; text-align: justify">&#160;A$0.00 - A$0.00</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">225,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">0.000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">0.66</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: justify">&#160;225,000,000</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">0.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australian
disclosure requirements: ordinary shares of Genetic Technologies Limited held by key management personnel at the date of this Directors&#8217;
report are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares</span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at start of the year<sup>1</sup></span></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted as remuneration</span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Received on exercised options</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Changes<sup>2</sup></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at the end of year</span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: justify">Dr. Lindsay Wakefield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,418,104</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,418,104</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mr. Peter Rubinstein</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">308,132,009</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">308,132,009</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Mr. Nicholas Burrows</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,670,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,670,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Jerzy Muchnicki</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">263,085,885</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(38,400,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224,685,885</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Richard Allman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">553,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">553,338</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mr. Tony Di Pietro</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mr. Mike Tonroe</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mr. Simon Morriss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mr. Carl Stubbings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">750,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">750,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mr. Kevin Camilleri</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">582,859,336</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(37,150,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">545,709,336</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1.
</sup>Balance may include shares held prior to individuals becoming KMP. For individuals who became KMP during the period, the balance
is as at the date they became KMP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>2.
</sup>Other changes incorporate changes from acquisition and disposals of ordinary share transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification
and Insurance with respect to Directors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are obligated pursuant to an indemnity agreement, to indemnify the current Directors and executive officers and former Directors against
all liabilities to third parties that may arise from their position as Directors or officers of the Company and our controlled entities,
except where to do so would be prohibited by law. In addition, the Company does currently carry insurance in respect of Directors&#8217;
and officers&#8217; liabilities for current and former Directors, Company Secretary and executive officers or employees under certain
circumstances as specified in the insurance policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loans
to Key Management Personnel</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no loans to KMP&#8217;s during the financial year or prior financial year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting
and comments at the Company&#8217;s 2022 Annual General Meeting</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company received 84.49% of the vote in favor of its Remuneration Report for the 2022 financial year. The Company did not receive any
specific feedback at the AGM on its remuneration policies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(End
of the Remuneration Report (Audited) for <b><span style="text-decoration: underline">Australian Disclosure Requirements</span></b>)</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
Australian Disclosure Requirements</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditor&#8217;s
Independence Declaration</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no former partners or directors of Grant Thornton Audit Pty Ltd, the Company&#8217;s auditor, who were or were at any time during
the financial year, an officer of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the auditor&#8217;s independence declaration under Section 307C of the Corporations Act 2001 in relation to the audit for the
year ended June 30, 2023 is included in Exhibit 15.4 of this annual report on Form 20-F.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors&#8217;
resolution</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of our directors&#8217; report are incorporated in various places within this annual report on the Form 20-F. A table charting
these components is included within &#8216;Exhibit 15.3 Appendix 4E&#8217;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report is made in accordance with a resolution of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
Peter Rubinstein</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director Melbourne</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
30, 2023</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_024"></span>Item
6.C Board Practices</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Company&#8217;s Constitution, its Board of Directors is required to comprise at least three Directors. As of the date of this Annual
Report, our Board comprised four Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
role of the Board includes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reviewing
    and making recommendations in remuneration packages and policies applicable to directors, senior executives and consultants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nomination
    of external auditors and reviewing the adequacy of external audit arrangements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establishing
    the overall internal control framework over financial reporting, quality and integrity of personnel and investment appraisal. In
    establishing an appropriate framework, the board recognized that no cost-effective internal control systems will preclude all errors
    and irregularities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establishing
    and maintaining appropriate ethical standards in dealings with business associates, suppliers, advisers and regulators, competitors,
    the community and other employees.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
    areas of significant business risk and implementing corrective action as soon as practicable after a risk is identified.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominating
    audit and remuneration committee members.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board meets to discuss business regularly throughout the year, with additional meetings being held when circumstances warrant. Included
in the table below are details of the meetings of the Board and the sub-committees of the Board that were held during the 2023 financial
year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Directors&#8217; meetings</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Audit &amp; Risk Committee meetings</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Remuneration Committee meetings</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Attended</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Eligible</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Attended</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Eligible</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Attended</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Eligible</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Dr. Lindsay Wakefield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">6</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">6</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Jerzy Muchnicki</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mr. Peter Rubinstein</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mr. Nicholas Burrows</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Committees
of the Board</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board has established an Audit &amp; Risk Committee which operates under a specific Charter approved by the Board. It is the Board&#8217;s
responsibility to ensure that an effective internal control framework exists within the Company. This includes internal controls to deal
with both the effectiveness and efficiency of significant business processes, the safeguarding of assets, the maintenance of proper accounting
records, and the reliability of financial information as well as non-financial considerations such as the benchmarking of operational
key performance indicators.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board has delegated the responsibility for the establishment and maintenance of a framework of internal control and ethical standards
for the management of the Company to the Audit &amp; Risk Committee. The Audit &amp; Risk Committee also provides the Board with assurance
regarding the reliability of financial information for inclusion in the financial reports. As at date of this report, all of the members
of the Audit &amp; Risk Committee are independent Non-Executive Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Remuneration Committee is, amongst other things, responsible for determining and reviewing remuneration arrangements for the Directors,
the Chief Executive Officer and the Senior Leadership Team. The Chairman of the Committee is an independent non- executive director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Remuneration Committee assesses the appropriateness of the nature and amount of remuneration paid to Directors and Executives on a periodic
basis by reference to relevant employment market conditions, with the overall objective of ensuring maximum shareholder benefit from
the retention of a high-quality Board and senior leadership team.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Committee
membership</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at the date of this Report, the composition of these two Sub-Committees are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    &amp; Risk Committee:</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Nicholas Burrows &#8212; Chairman of the Committee</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Peter Rubinstein</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Lindsay Wakefield</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remuneration
    Committee:</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Lindsay Wakefield &#8212; Chairman of the Committee</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Peter Rubinstein</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Nicholas Burrows</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with NASDAQ Rules</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASDAQ
listing rules require that the Company disclose the home country practices that we will follow in lieu of compliance with NASDAQ corporate
governance rules. The following describes the home country practices and the related NASDAQ rule:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Majority
of Independent Directors</span>: The Company follows home country practice rather than NASDAQ&#8217;s requirement in Marketplace Rule 4350(c)
(1) that the majority of the Board of each issuer be comprised of independent directors as defined in Marketplace Rule 4200. As of the
date of this Annual Report, with there were three independent Directors namely Mr. Nick Burrows, Mr. Peter Rubinstein and Dr. Lindsay
Wakefield which led to our Board of Directors being comprised of a majority of independent directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Compensation
of Officers</span>: The Company follows home country practice rather than NASDAQ&#8217;s requirement in Marketplace Rule 4350(c) (3) that
chief executive compensation be determined or recommended to the Board by the majority of independent directors or a compensation committee
of independent directors. Similarly, compensation of other officers is not determined or recommended to the Board by a majority of the
independent directors or a compensation committee comprised solely of independent directors. These decisions are made by the Company&#8217;s
remuneration committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Nomination</span>:
The Company follow home country practice rather than NASDAQ&#8217;s requirement in Marketplace Rule 4350(c)(4) that director nominees
be selected or recommended by a majority of the independent directors or by a nominations committee comprised of independent directors.
These decisions are made by the Company&#8217;s full Board which is comprised of a majority of independent directors which constitute
Mr. Nick Burrows, Mr. Peter Rubinstein, Dr. Jerzy Muchnicki and Dr. Lindsay Wakefield.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ASX does not have a requirement that each listed issuer have a nominations committee or otherwise follow the procedures embodied in NASDAQ&#8217;s
Marketplace Rule. Furthermore, no law, rule or regulation of the ASIC has such a requirement nor does the applicable corporate law legislation.
Accordingly, selections or recommendations of director nominees by a committee that is not comprised of a majority of directors that
are not independent is not prohibited by the laws of Australia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Quorum</span>:
The Company follows home country practice rather than NASDAQ&#8217;s requirement in Marketplace Rule 4350(f) that each issuer provides
for a quorum of at least 33 1/3 percent of the outstanding shares of the issuer&#8217;s ordinary stock (voting stock). Pursuant to the
Company&#8217;s Constitution it is currently required to have a quorum for a general meeting of three persons. The practice followed
by the Company is not prohibited by Australian law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Shareholder
Approval for Capital Issuance</span>: The Company has elected to follow certain home country practices in lieu of NASDAQ Marketplace Rule
5635. For example, the Company is entitled to an annual 15% of capital placement capacity under ASX Listing Rule 7.1 without shareholder
approval. If this amount of annual entitlement is aggregated with an additional placement of Ordinary Shares, including through the grant
of options over Ordinary Shares, that exceeds 20% of the outstanding share capital, only the excess over the 15% annual allowance requires
shareholder approval under Australian law. Such home country practice is not prohibited by the laws of Australia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
diversity matrix</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
    Diversity Matrix (As of June 30, 2023)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Country
    of Principal Executive Offices</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    Private Issuer</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
    Prohibited under Home Country Law</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Number of Directors</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Female</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Male</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Binary</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Did
    Not Disclose Gender</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part
    I: Gender Identity</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part
    II: Demographic Background</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underrepresented
    Individual in Home Country Jurisdiction</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LGBTQ+</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Did
    Not Disclose Demographic Background</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at 7th August 2023 the Company has less than 5 Directors and at that date does not have a diverse director on the Board. Accordingly,
we are not in compliance with Nasdaq Rule 5605(f) as we did not meet the applicable board diversity objective by the end of the phase-
in period on that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Directors acknowledge the importance of board diversity and this is considered as part of the Company&#8217;s regular
director skills assessment process. In considering the output from this skills assessment process, the Board has formally identified
the need to address and prioritize Board diversity. Accordingly, one of the key People and Culture strategic pillar initiatives from
the Company&#8217;s current strategic plan, is to identify and appoint a suitable female director over the course of the financial year
ended June 30, 2024. The Company&#8217;s Remuneration Committee will oversee this process, consistent with its Charter, and will provide
a formal recommendation to the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_025"></span>Item
6.D Employees</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, the Company comprising the Company and its subsidiaries, employed 60 full-time equivalent employees.
The number of full-time equivalent employees as of the end of each respective financial year ended June 30 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">60</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_026"></span>Item
6.E Share Ownership</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
relevant interest of the directors in the share capital of the Company as notified by them to the Australian Securities Exchange in accordance
with section 205G(1) of the <i>Corporations Act 2001 </i>as of the date of this Annual Report is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Director</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage of Capital held</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Dr. Lindsay Wakefield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">9,418,104</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">0.10</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Jerzy Muchnicki</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224,685,885</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.85</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mr. Peter Rubinstein</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">308,132,009</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.34</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mr. Nicholas Burrows</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,670,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.02</td><td style="text-align: left">%</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 61; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_027"></span>Item
7. Major Shareholders and Related Party Transactions</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_028"></span>Item
7.A Major Shareholders</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at the date of this Annual Report, no shareholders hold a beneficial ownership of 5% or more of our voting securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of Ordinary Shares on issue in Genetic Technologies Limited as of the date of this Annual Report was 11,541,658,143. The number
of holders of Ordinary Shares in Genetic Technologies Limited as of the date of this Annual Report was approximately 4,846 (August 21,
2023).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is not aware of any direct or indirect ownership or control of it by another corporation(s), by any foreign government or by
any other natural or legal person(s) severally or jointly. Principal shareholders do not enjoy any special or different voting rights
from those to which other holders of Ordinary Shares are entitled. The Company does not know of any arrangements, the operation of which
may at a subsequent date result in a change in control of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Record
Holders</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 21, 2023, there were 4,846 holders of record of our ordinary shares, of which 33 record holders, holding approximately 0.02%
of our ordinary shares, had registered addresses in the United States. These numbers are not representative of the number of beneficial
holders of our shares nor are they representative of where such beneficial holders reside, since many of these ordinary shares were held
of record by brokers or other nominees. The majority of trading by our U.S. investors is done by means of ADSs that are held of record
by HSBC Custody Nominees (Australia) Ltd., which held 70.35% of our ordinary shares as of such date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_029"></span>Item
7.B Related Party Transactions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended June 30, 2023, 2022 and 2021, the only transactions between entities within the Company and other related parties occurred,
are as listed below. Except where noted, all amounts were charged on similar to market terms and at commercial rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
within the Company and with other related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended June 30, 2023, other than compensation paid to directors and other members of key management personnel, see &#8220;Item
6.B Compensation&#8221;, the only transactions between entities within the Company and other related parties are as listed below. Except
where noted, all amounts were charged on similar to market terms and at commercial rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Phillip Hains (Former Chief Financial Officer)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2019, the Company announced that it had appointed Mr. Phillip Hains (MBA, CA) as the Chief Financial Officer who has over 30
years of extensive experience in roles with a portfolio of ASX and NASDAQ listed companies and provides CFO services through his firm
The CFO Solution. Prior to this point the Company had a similar arrangement with The CFO Solution, where it would engage and provide
services of overall CFO, accounting and other finance related activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the prior reporting period, the Company paid A$91,615 to The CFO Solution towards provision of overall CFO, accounting and other finance
related activities. During the reporting period, the Company did not transact with The CFO Solution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Stanley Sack (former Chief Operating Officer)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 18, 2020, the Company appointed Mr. Stanley Sack who provides consulting in the capacity of Chief Operating Officer. Mr. Sack had
spent 15 years in large listed entities in executive positions managing large business divisions. He has worked with a high-net-worth
family managing all their operating businesses and private equity activities. Mr. Sack built an Allied Health Business in the aged care
and community care space which became the biggest Mobile Allied Health Business in Australia, and was recently sold to a large medical
insurance company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the reporting period, the Company had no transactions (2022: A$107,188) with Mr. Stanley Sack&#8217;s entity Cobben Investments Pty Ltd
towards provision of consulting services in relation to provision of duties related to Chief Operating Officer of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Peter Rubinstein (Non-Executive Director and Chairman)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the financial year ended June 30, 2020, the Board approved to obtain consulting services in relation to capital raises, compliance, NASDAQ
hearings and investor relations from its Non-Executive Director and current Chairman, Mr. Peter Rubinstein. The services procured were
through Mr. Peter Rubinstein&#8217;s associate entity ValueAdmin.com Pty Ltd and amounted to A$60,000 (2022: A$60,000), which is included
as part of the cash salary and fees in the remuneration report as at June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transactions with parties related to Key Management Personnel during the year other than that disclosed above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Jerzy Muchnicki (Non-Independent Non-Executive Director)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the financial year ended June 30, 2022, the Board approved to obtain consulting services in relation to PRS and Germline Integration;
Epigenetics; Somatic Testing; NIPT; Carrier testing and related marketing advice from its Non-Independent Non- Executive Director, Dr.
Jerzy Muchnicki. The services procured were through Dr. Jerzy Muchnicki&#8217;s private consultancy and amounted to A$50,000 (2021: Nil)
that is included as part of the cash salary and fees in the remuneration report as at June 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transactions with parties related to Key Management Personnel during the year other than that disclosed above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
Rights Issuance</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
receiving another requisite shareholder approval on December 10, 2020, the Company issued additional 125,000,000 Performance Rights to
Directors of the Company as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000
    Class A Performance Rights to Dr. Lindsay Wakefield</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,500,000
    Class A Performance Rights, 25,000,000 Class B Performance Rights and 25,000,000 Class C Performance Rights to Dr. Jerzy Muchnicki</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,500,00
    Class A Performance Rights, 25,000,000 Class B Performance Rights and 25,000,000 Class C Performance Rights to Mr. Peter Rubinstein</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000
    Class A Performance Rights to Mr. Nicholas Burrows</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended June 30, 2021, the Board has approved for the following Performance Rights to be issued to the Chief Executive Officer
and Chief Operating Officer:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60,000,000
    Class D Performance Rights to Mr. Simon Morriss</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,937,500
    Class E Performance Rights to Mr. Stanley Sack</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended June 30, 2022 the Board has approved for the following Performance Rights to be issued to the Key Management Personnel
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000,000
    Performance Rights to Mr. Michael Tonroe</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,000,000
    Performance Rights to Mr. Carl Stubbings</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,000,000
    Performance Rights to Mr. Kevin Camilleri</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has accounted for these Performance Rights in accordance with its accounting policy for share-based payment transactions, recording
A$125,500 (2022: A$437,508, 2021: A$622,725) of associated expense in the current reporting period. During the financial year ending
June 30, 2023 the Performances Rights issued to Mr. Michael Tonroe were forfeit as Mr. Tonroe resigned from his position as CFO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_030"></span>Item
7.C Interests of Experts and Counsel</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_031"></span>Item
8. Financial Information</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="F_032"></span>Item
8.A Consolidated Statements and Other Financial Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information included in Item 18 of this Annual Report is referred to and referenced into this Item 8.A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
Proceedings</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not currently a party to any legal proceedings. From time to time, we may be a party to litigation or subject to claims incident
to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe
that the final outcome of these ordinary course matters will not have a significant effect on our financial position or profitability.
Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management
resources and other factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
our businesses are profitable beyond our expected research and development needs, our Directors are unlikely to be able to recommend
that any dividend be paid to our shareholders. Our Directors will not resolve a formal dividend policy until we generate profits. Our
current intention is to reinvest our income in the continued development and expansion of our businesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_033"></span>Item
8.B Significant Changes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no significant changes in the operational or financial condition of the Company since June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_034"></span>Item
9. The Offer and Listing</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_035"></span>Item
9.A Offer and Listing Details</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Ordinary Shares have been listed on the Australian Securities Exchange (the &#8220;ASX&#8221;) since July 1987 and trade
there under the symbol GTG. The Company&#8217;s securities are also listed on NASDAQ&#8217;s Capital Market (under the ticker GENE) in
the form of American Depositary Shares, each of which represents 600 Ordinary Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_036"></span>Item
9.B Plan of Distribution</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_037"></span>Item
9.C Markets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 9.A Offer and Listing Details.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_038"></span>Item
9.D Selling Shareholders</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_039"></span>Item
9.E Dilution</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_040"></span>Item
9.F Expenses of the Issue</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_041"></span>Item
10. Additional Information</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_042"></span>Item
10.A Share Capital</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_043"></span>Item
10.B Our Constitution</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
registration number is 009 212 328. Our Constitution has been posted on the Company&#8217;s website and has been filed with the
SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purposes
and Objects</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Constitution does not specify any purposes or objects of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Powers of the Directors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the provisions of our Constitution our Directors may exercise all of the powers of our company, other than those that are required by
our Constitution or the Corporations Act 2001 of Australia to be exercised at a general meeting of shareholders. A director may participate
in a meeting and vote on a proposal, arrangement or contract in which he or she is materially interested, so long as the director&#8217;s
interest is declared in accordance with the Corporations Act 2001. The authority of our directors to enter into borrowing arrangements
on our behalf is not limited, except in the same manner as any other transaction by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights
Attached to Our Ordinary Shares</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
concept of authorized share capital no longer exists in Australia and as a result, our authorized share capital is unlimited.
All our outstanding Ordinary Shares are validly issued, fully paid and non-assessable. The rights attached to our Ordinary Shares are
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividend
rights. </i>If our board of directors recommends a dividend, registered holders of our Ordinary Shares may declare a dividend by ordinary
resolution in a general meeting. The dividend, however, cannot exceed the amount recommended by our board of directors. Our board of
directors may declare an interim dividend.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting
rights.</i> Holders of Ordinary Shares have one vote for each Ordinary Share held on all matters submitted to a vote of shareholders.
Such voting rights may be affected by the grant of any special voting rights to the holders of a class of shares with preferential rights
that may be authorized in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
quorum required for an ordinary meeting of shareholders consists of at least three shareholders represented in person or by proxy. A
meeting adjourned for lack of a quorum generally is adjourned to the same day in the following week at the same time and place or any
time and place as the directors designate in a notice to the shareholders. At the reconvened meeting, the required quorum consists of
any two members present in person or by proxy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
ordinary resolution, such as a resolution for the declaration of dividends, requires approval by the holders of a majority of the voting
rights represented at the meeting, in person, by proxy or by written ballot and voting thereon. Under our Constitution, a special resolution,
such as amending our Constitution, approving any change in capitalization, winding-up, authorization of a class of shares with special
rights, or other changes as specified in our Constitution, requires approval of a special majority, representing the holders of no less
than 75% of the voting rights represented at the meeting in person, by proxy or by written ballot, and voting thereon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our Constitution, our directors are elected at our annual general meeting of shareholders by a vote of the holders of a majority of
the voting power represented and voting at such meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Rights
in our profits. </i>Our shareholders have the right to share in our profits distributed as a dividend and any other permitted distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Rights
in the event of liquidation. </i>In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be
distributed to the holders of Ordinary Shares in proportion to the nominal value of their holdings. This right may be affected by the
grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changing
Rights Attached to Shares</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to our Constitution, in order to change the rights attached to any class of shares, unless otherwise provided by the terms of the class,
such change must be adopted by a general meeting of the shareholders and by a separate general meeting of the holders of the affected
class with a majority of 75% of the voting power participating in such meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
and Extraordinary Meetings</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors must convene an annual meeting of shareholders at least once every calendar year, within five months of our last fiscal
year-end. Notice of at least 28 days prior to the date of the meeting is required. An extraordinary meeting may be convened by the board
of directors, it decides or upon a demand of any directors, or of one or more shareholders holding in the aggregate at least five percent
of our issued capital. An extraordinary meeting must be called not more than 21 days after the request is made. The meeting must be held
not later than two months after the request is given.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitations
on the Rights to Own Securities in Our Company</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
our Constitution nor the laws of the Commonwealth of Australia restrict in any way the ownership or voting of our shares. However, acquisitions
and proposed acquisitions of securities in Australian companies may be subject to review and approval by the Australian Federal Treasurer
under the Takeovers Act as described under Item 10.D below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in Our Capital</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Listing Rules of the ASX, without shareholder approval, we may not issue more than 25% of our outstanding Ordinary Shares in any
twelve month period other than by a pro rata rights offering or a share purchase plan offer (of shares with a value at the issue price
of up to A$30,000 per shareholder to a maximum of 30% of our outstanding shares) in each case to the then existing shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Takeovers
Act</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no limitations, either under the laws of Australia or under the Company&#8217;s Constitution, to the right of non-residents to hold
or vote our Technologies Ordinary Shares other than the Commonwealth Foreign Acquisitions and Takeovers Act 1975 (the &#8220;Takeovers
Act&#8221;). The Takeovers Act may affect the right of non-Australian residents, including U.S. residents, to hold Ordinary Shares but
does not affect the right to vote, or any other rights associated with, any Ordinary Shares held in compliance with its provisions. Acquisitions
of shares in Australian companies by foreign interests are subject to review and approval by the Treasurer of the Commonwealth of Australia
under the Takeovers Act. The Takeovers Act applies to any acquisition of outstanding shares of an Australian company that exceeds, or
results in a foreign person or persons controlling the voting power of more than a certain percentage of those shares. The thresholds
are 15% where the shares are acquired by a foreign person, or Company of associated foreign persons, or 40% in aggregate in the case
of foreign persons who are not associated. Any proposed acquisition that would result in an individual foreign person (with associates)
holding more than 15% must be notified to the Treasurer in advance of the acquisition. There are statutory limitations in Australia on
foreign ownership of certain businesses, such as banks and airlines, not relevant to the Company. However, there are no other statutory
or regulatory provisions of Australian law or Australian Securities Exchange requirements that restrict foreign ownership or control
of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporations
Act 2001</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
applied to the Company, the <i>Corporations Act 2001 </i>prohibits any legal person (including a corporation) from acquiring a relevant
interest in Ordinary Shares if after the acquisition that person or any other person&#8217;s voting power in the Company increases from
20% or below to more than 20%, or from a starting point that is above 20% and below 90%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prohibition is subject to a number of specific exceptions set out in section 611 of the <i>Corporations Act 2001 </i>which must be strictly
complied with to be applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general terms, a person is considered to have a &#8220;relevant interest&#8221; in a share in the Company if that person is the holder
of that share, has the power to exercise, or control the exercise of, a right to vote attached to that share, or has the power to dispose
of, or to control the exercise of a power to dispose of that share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
does not matter how remote the relevant interest is or how it arises. The concepts of &#8220;power&#8221; and &#8220;control&#8221; are
given wide and extended meanings in this context in order to deem certain persons to hold a relevant interest. For example, each person
who has voting power above 20% in a company or a managed investment scheme which in turn holds shares in the Company is deemed to have
a relevant interest in those shares. Certain situations (set out in section 609 of the <i>Corporations Act 2001</i>) which would otherwise
constitute the holding of a relevant interest are excluded from the definition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
person&#8217;s voting power in the Company is that percentage of the total votes attached to Ordinary Shares in which that person and
its associates (as defined in the <i>Corporations Act 2001</i>) holds a relevant interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_044"></span>Item
10.C Material Contracts</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the financial years ending June 30, 2021, 2022, and 2023, the Company entered into agreements with H.C. Wainwright &amp; Co, to act as
placement agents to the share offerings made on multiple occasions the Company raised a total of A$22,881,958 before costs of the transactions.
Towards the cost of these transactions, the Company issued the following securities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">156,000,000
    warrants issued to H.C. Wainwright &amp; Co. LLC on December 21, 2020 exercisable at US$0.004166 expiring on December 21, 2025, amounting
    to A$1,462,442. The warrants are exercisable for fully paid ordinary shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,975,000
    warrants issued to H.C. Wainwright &amp; Co. LLC on December 21, 2020, exercisable at US$0.0104 expiring on December 21, 2025,
    amounting to A$360,017. The warrants are exercisable for fully paid ordinary shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,750,000
    warrants issued to H.C. Wainwright &amp; Co. LLC on November 24, 2021, exercisable at US$0.00109375 expiring 5 years after date of
    issue, amounting to A$476,297. The warrants are exercisable for fully paid ordinary shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000
    warrants to be issued to H.C. Wainwright &amp; Co. LLC, subject to shareholder approval scheduled for the 2023 Annual General Meeting
    (AGM), exercisable at US$1.625 expiring 5 years after date of issue, amounting to A$134,956. The warrants are exercisable for fully
    paid ordinary shares.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at June 30, 2023, the following warrants remain outstanding and exercisable and relate to capital raising activities prior to June 30,
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,114,200
                                            warrants issued to H.C. Wainwright &amp; Co. LLC on April 3, 2020, exercisable at US$0.00365
                                            each and expiring on</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    1, 2025, amounting to A$175,137. The warrants are exercisable for fully paid ordinary shares.</span></p></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,177,578
                                                                              warrants issued to H.C. Wainwright &amp; Co. LLC on April 22, 2020, exercisable at US$0.00417 each and expiring on April 19, 2025,
                                                                              amounting to A$149,693. The warrants are exercisable for fully paid ordinary shares.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company executed an acquisition agreement (&#8220;Acquisition Agreement&#8221;) on July 19, 2021 to acquire the direct-to- consumer eCommerce
business and distribution rights associated with General Genetics Corporation and its associated brands trading as EasyDNA, from BelHealth
Investment Fund LP. The Acquisition Agreement provides for the acquisition of all brands, websites and agency reseller agreements associated
with EasyDNA. This includes over 70 websites in 40 countries and six brand identities. Under the terms of the Acquisition Agreement,
the Company acquired 100% of EasyDNA&#8217;s brands and assets within the General Genetics Corporation business for a purchase price
of US$4 million, comprising cash consideration of US$2.5 million and US$1.5 million of ADSs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company executed an asset purchase agreement (&#8220;APA&#8221;) on July 14, 2022 to acquire the direct-to-consumer eCommerce
business, laboratory testing and distribution agreements associated with AffinityDNA. The APA provides for the acquisition of all
brands and websites associated with AffinityDNA. This includes the AffinityDNA Amazon sales channel rights. Under the terms of the
APA, the Company acquired 100% of AffinityDNA&#8217;s brands and assets for a purchase price of GBP555,000, comprising cash
consideration of GBP227,500 on completion and GBP227,500 payable in July 2023 subject to the AffinityDNA business attaining certain
financial performance parameters. The second payment was payable on the achievement of a gross profit target for the 12-month period
from the acquisition date. This target was not achieved and therefore no further payment is to be made in respect of the acquisition
of AffinityDNA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no other material contracts entered into during the two years preceding the date of this Annual Report which were outside the ordinary
course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_045"></span>Item
10.D Exchange Controls</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
existing Australian legislation, the Reserve Bank of Australia does not inhibit the import and export of funds, and, generally, no permission
is required to be given to the Company for the movement of funds in and out of Australia. However, payments to or from (or relating to)
Iraq, its agencies or nationals, the government or a public authority of Libya, or certain Libyan undertakings, the authorities in the
Federal Republic of Yugoslavia (Serbia and Montenegro) or their agencies, the Taliban (also referred to as the Islamic Emirate of Afghanistan),
or the National Union for the Total Independence of Angola (also known as UNITA), its senior officials or the adult members of their
immediate families, may not be made without the specific approval of the Reserve Bank of Australia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
at the present time, remittances of any dividends, interest or other payment by the Company to non-resident holders of our securities
in the U.S. are not, subject to the above, restricted by exchange controls or other limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_046"></span>Item
10.E Taxation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary is based on the tax laws of the United States (including the Internal Revenue Code of 1986, as amended, or the Code,
its legislative history, existing and proposed regulations thereunder, published rulings and court decisions) and on the Australian tax
law and practice, in each case as in effect on the date hereof. In addition, this summary is based on the Convention between the Government
of the United States of America and the Government of Australia for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion
with Respect to Taxes on Income, signed on August 6, 1982, as amended and currently in force, or the. The foregoing laws and legal authorities
as well as the Treaty are subject to change (or changes in interpretation), possibly with retroactive effect. Finally, this summary is
based in part upon the representations of our ADS Depositary and the assumption that each obligation in the Deposit Agreement and any
related agreement will be performed in accordance with its terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discussion does not address any aspects of U.S. taxation other than federal income taxation or any aspects of Australian taxation other
than federal income taxation, stamp duty and goods and services tax. This discussion does not necessarily address all aspects of U.S.
or Australian federal tax considerations that may be important to particular investors in light of their individual investment circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospective
investors are urged to consult their tax advisers regarding the U.S. and Australian federal, state and local tax consequences and any
other tax consequences of owning and disposing of ADSs and Ordinary Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australian
Tax Consequences</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this section, we discuss Australian tax considerations that apply to non-Australian tax residents who are residents of the United States
with respect to the ownership and disposal by the absolute beneficial owners of ADSs. This summary does not discuss any foreign or state
tax considerations, other than stamp duty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nature
of ADSs for Australian Taxation Purposes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADSs
held by a U.S. holder will be treated for Australian taxation purposes as being held under a &#8220;bare trust&#8221; for that holder.
Consequently, the underlying Ordinary Shares will be regarded as owned by the ADS holder for Australian income tax and capital gains
tax purposes. Dividends paid on the underlying Ordinary Shares will also be treated as dividends paid to the ADS holder, as the person
beneficially entitled to those dividends. Therefore, in the following analysis, we discuss the tax consequences to non-Australian resident
holders of Ordinary Shares which, for Australian taxation purposes, will be the same as to U.S. holders of ADSs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation
of Dividends</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia
operates a dividend imputation system under which dividends may be declared to be &#8220;franked&#8221; to the extent of tax paid on
company profits. Fully franked dividends are not subject to dividend withholding tax. Dividends payable by our company to non-Australian
resident stockholders will be subject to dividend withholding tax, to the extent the dividends are unfranked. Dividend withholding tax
will be imposed at 30%, unless a stockholder is a resident of a country with which Australia has a double taxation agreement. Under the
provisions of the Treaty, the Australian tax withheld on unfranked dividends paid by us to which a resident of the United States is beneficially
entitled is generally limited to 15% if the U.S. resident holds less than 10% of the voting rights of our company, unless the shares
are effectively connected to a permanent establishment or fixed base in Australia through which the stockholder carries on business or
provides independent personal services, respectively. Where a U.S. corporate resident holds 10% or more of the voting rights of our company,
the withholding tax rate is reduced to 5%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
on Sales or other Dispositions of Shares - Capital Gains Tax</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Australian
resident stockholders who hold their shares in us on capital account will not be subject to Australian capital gains tax on any gain
made on a sale or other disposal of our shares, unless they hold 10% or more of our issued capital and the Company holds real property
situated in Australia, the market value of which is 50% or more of the market value of the Company. The Australian Taxation Office maintains
the view that the Treaty does not limit Australian capital gains tax. Australian capital gains tax applies to net capital gains charged
at a taxpayer&#8217;s marginal tax rate but, for certain stockholders, a discount of the capital gain may apply if the shares have been
held for 12 months or more. For individuals, this discount is 50%. For superannuation funds, the discount is 33%. There is no discount
for a company that derives a net capital gain. Net capital gains are calculated after deducting capital losses, which may only be offset
against such gains.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
on Sales or other Dispositions of Shares - Stockholders Holding Shares on Revenue Account</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
non-Australian resident stockholders may hold shares on revenue rather than on capital account, for example, share traders. These stockholders
may have the gains made on the sale or other disposal of the shares included in their assessable income under the ordinary income provisions
of the income tax law, if the gains are sourced in Australia. Non-Australian resident stockholders assessable under these ordinary income
provisions in respect of gains made on shares held on revenue account would be assessed for those gains at the Australian tax rates for
non-Australian residents, which start at a marginal rate of 32.5%. Some relief from the Australian income tax may be available to non-Australian
resident stockholders under the Treaty, for example, because the stockholder derives business profits not through a permanent establishment
in Australia. To the extent an amount would be included in a non- Australian resident stockholder&#8217;s assessable income under both
the capital gains tax provisions and the ordinary income provisions, the capital gain amount would generally be reduced, so that the
stockholder would not be subject to double tax on any part of the income gain or capital gain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dual
Residency</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a stockholder were a resident of both Australia and the United States under the respective domestic taxation laws of those countries,
that stockholder may be subject to tax as an Australian resident. If, however, the stockholder is determined to be a U.S. resident for
the purposes of the Treaty, the Australian tax would be subject to limitation by the Treaty. Stockholders should obtain specialist taxation
advice in these circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stamp
Duty</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
transfer of shares through trading on the Australian Securities Exchange, whether by Australian residents or foreign residents, is not
subject to stamp duty within Australia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australian
Death Duty</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia
does not have estate or death duties. Further, no capital gains tax liability is realized upon the inheritance of a deceased person&#8217;s
shares. However, the subsequent disposal of the shares by beneficiaries may give rise to a capital gains tax liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goods
and Services Tax</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issue or transfer of shares will not incur Australian goods and services tax and does not require a stockholder to register for Australian
goods and services tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
States Federal Income Taxation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion is a summary of U.S. federal income tax considerations generally applicable to the ownership and disposition of
the ADSs or Ordinary Shares by a U.S. holder (as defined below). This summary applies only to U.S. holders that hold such ADSs or Ordinary
Shares as capital assets (generally, property held for investment) for U.S. federal income tax purposes. This summary does not address
all U.S. federal income tax considerations that may be relevant to a particular U.S. holder and does not represent a detailed discussion
of all of the U.S. federal income tax considerations applicable to a holder of our ADSs or Ordinary Shares that may be subject to special
tax rules including, without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks, financial institutions or insurance companies;</span></td></tr>

<tr style="vertical-align: top">
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">brokers, dealers or traders in securities, currencies, commodities,
or notional principal contracts;</span></td></tr>

<tr style="vertical-align: top">
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt entities or organizations, including an &#8220;individual
retirement account&#8221; or &#8220;Roth IRA&#8221; as defined in Section 408 or 408A of the Code (as defined below), respectively;</span></td></tr>

<tr style="vertical-align: top">
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">real estate investment trusts, regulated investment companies
or grantor trusts;</span></td></tr>

<tr style="vertical-align: top">
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that hold ADSs or Ordinary Shares as part of a &#8220;hedging,&#8221;
&#8220;integrated,&#8221; &#8220;wash sale&#8221; or &#8220;conversion&#8221; transaction or as a position in a &#8220;straddle&#8221;
for U.S. federal income tax purposes;</span></td></tr>

<tr style="vertical-align: top">
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S corporations, partnerships, or other entities or arrangements
classified as passthrough entities for U.S. federal income tax purposes, or U.S. holders who hold the ADSs or Ordinary Shares through
such an entity;</span></td></tr>

<tr style="vertical-align: top">
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain former citizens or long-term residents of the United
States;</span></td></tr>

<tr style="vertical-align: top">
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that received ADSs or Ordinary Shares pursuant to the
exercise of any employee share option or otherwise as compensation for the performance of services;</span></td></tr>

<tr style="vertical-align: top">
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons who have elected mark-to-market accounting;</span></td></tr>

<tr style="vertical-align: top">
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">holders that own or have owned directly, indirectly, or through
attribution 10% or more of the voting power or value of ADSs or Ordinary Shares; and</span></td></tr>

<tr style="vertical-align: top">
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">holders that have a &#8220;functional currency&#8221; other
than the U.S. dollar.</span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
holder of the ADSs or Ordinary Shares who fall within one of the categories above is advised to consult their tax advisers regarding
the specific tax consequences which may apply to their particular situation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a partnership (or any other entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds the ADSs or Ordinary
Shares, the tax consequences relating to an investment in such ADSs or Ordinary Shares will depend in part upon the status of the partner
and the activities of the partnership. Such a partner or partnership should consult its tax advisers regarding the U.S. federal income
tax considerations of owning and disposing of the ADSs or Ordinary Shares in its particular circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discussion in this section is based on the Code, existing, proposed and temporary U.S. Treasury Regulations promulgated thereunder, administrative
and judicial interpretations thereof, and the Treaty, in each case as in effect and available on the date hereof. Such authorities are
subject to change, which change could apply retroactively, and to differing interpretations, all of which could affect the tax considerations
described below. There can be no assurance that the U.S. Internal Revenue Service, or the IRS, will not take a position concerning the
tax consequences of the ownership and disposition of ADSs or Ordinary Shares or that such a position would not be sustained by a court.
U.S. holders should consult their own tax advisers concerning the U.S. federal, state, local and non-U.S. tax consequences of owning
and disposing of ADSs or Ordinary Shares in their particular circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary does not address the estate or gift tax considerations, alternative minimum tax considerations, the potential application of
the Medicare contribution tax on net investment income, the special tax accounting rules under Section 451(b) of the Code, or any U.S.
state, local, or non-U.S. tax considerations applicable to the acquisition, ownership and disposition of ADSs or Ordinary Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used herein, a &#8220;U.S. holder&#8221; is a beneficial owner of an ADS that is, for U.S. federal income tax purposes, (i) an individual
who is a citizen or resident of the United States, (ii) a corporation (or an entity taxable as a corporation) created or organized in
or under the laws of the United States, any State thereof or the District of Columbia, (iii) an estate the income of which is subject
to U.S. federal income tax without regard to its source or (iv) a trust if (1) a court within the United States is able to exercise primary
supervision over the ad- ministration of the trust, and one or more United States persons have the authority to control all substantial
decisions of the trust, or (2) the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a
United States person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GIVEN
THE COMPLEXITY OF THE TAX LAWS AND BECAUSE THE TAX CONSEQUENCES TO ANY PARTICULAR INVESTOR MAY BE AFFECTED BY MATTERS NOT DISCUSSED HEREIN,
ALL CURRENT AND PROSPECTIVE HOLDERS OF ORDINARY SHARES AND THE ADSs ARE URGED TO CONSULT THEIR OWN TAX ADVISORS WITH RESPECT TO THE SPECIFIC
TAX CONSEQUENCES OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF ADSs, INCLUDING THE APPLICABILITY AND EFFECT OF U.S. FEDERAL, STATE
AND LOCAL TAX LAWS, AS WELL AS AUSTRALIAN AND OTHER NON-U.S. TAX LAWS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nature
of ADSs for U.S. Federal Income Tax Purposes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, for U.S. federal income tax purposes, a holder of an ADS will be treated as the owner of the underlying Ordinary Shares. Accordingly,
except as specifically noted below, the tax consequences discussed below with respect to ADSs will be the same as for Ordinary Shares.
Exchanges of Ordinary Shares for ADSs, and ADSs for Ordinary Shares, generally will not be subject to U.S. federal income tax.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distributions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, subject to the passive foreign investment company rules discussed below, a distribution on an ADS or Ordinary Share will constitute
a dividend for U.S. federal income tax purposes to the extent that it is made from our current or accumulated earnings and profits as
determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, it generally
will be treated as a non-taxable reduction of basis to the extent of the U.S. holder&#8217;s tax basis in the ADS or Ordinary Share on
which it is paid, and to the extent it exceeds that basis it generally will be treated as capital gain. The Company has not maintained
and does not plan to maintain calculations of earnings and profits under U.S. federal income tax principles. Accordingly, it is unlikely
that U.S. holders will be able to establish that a distribution by the Company is in excess of its current and accumulated earnings and
profits (as computed under U.S. federal income tax principles). Therefore, a U.S. holder should expect that a distribution by the Company
will generally be treated as taxable in its entirety as a dividend to U.S. holders for U.S. federal income tax purposes even though the
distribution may be treated in whole or in part as a non-taxable distribution for Australian tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross amount of any dividend on an ADS or Ordinary Share (which will include the amount of any Australian taxes withheld) generally will
be subject to U.S. federal income tax as foreign source dividend income, and will not be eligible for the corporate dividends received
deduction. In general, the amount of a dividend paid in Australian dollars will be its value in U.S. dollars based on the prevailing
spot market exchange rate in effect on the day the U.S. holder receives the dividend or, in the case of a dividend received in respect
of an ADS, on the date the Depositary receives it, whether or not the dividend is converted into U.S. dollars at that time. A U.S. holder
will have a tax basis in any distributed Australian dollars equal to its U.S. dollar amount on the date of receipt, and any gain or loss
realized on a subsequent conversion or other disposition of Australian dollars generally will be treated as U.S. source ordinary income
or loss. If dividends paid in Australian dollars are converted into U.S. dollars on the date they are received by a U.S. holder, the
U.S. holder generally should not be required to recognize foreign currency gain or loss in respect of the dividend.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain exceptions, a dividend that a non-corporate holder receives on an ADS or Ordinary Share may qualify for the preferential
rates of taxation with respect to dividends on the ADSs or Ordinary Shares applicable to long-term capital gains (i.e., gains from
the sale of capital assets held for more than one year) and &#8220;qualified dividend income&#8221; (as discussed below). A dividend
on an ADS or Ordinary Share will be a qualified dividend if (i) either (a) the ADSs or Ordinary Shares, as applicable, are readily
tradable on an established market in the United States or (b) we are eligible for the benefits of a comprehensive income tax treaty
with the United States that the Secretary of the Treasury determines is satisfactory for purposes of these rules and that includes
an exchange of information program, and (ii) we were not, in the year prior to the year the dividend was paid, and are not, in the
year the dividend is paid, a passive foreign investment company (&#8220;PFIC&#8221;). The ADSs are listed on the NASDAQ Capital
Market, which should qualify them as readily tradable on an established securities market in the United States. In any event, the
Treaty satisfies the requirements of clause (i)(b), and we believe we qualify as a resident of Australia entitled to the benefits of
the Treaty (though there can be no assurance in this regard). However, based on our audited financial statements and relevant market
and shareholder data, we believe we were a PFIC for U.S. federal income tax purposes for our taxable year ended June 30, 2023.
Therefore, in light of the discussion in the section entitled &#8220;Passive Foreign Investment Company Rules,&#8221; you should
assume that dividends generally will not constitute qualified dividend income eligible for reduced rates of taxation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
Australian withholding tax imposed on dividends received with respect to the ADSs or Ordinary Shares will be treated as a foreign income
tax eligible for credit against a U.S. holder&#8217;s U.S. federal income tax liability, subject to generally applicable limitations
under U.S. federal income tax law. Alternatively, any Australian withholding tax may be taken as a deduction against taxable income,
provided the U.S. holder takes a deduction and not a credit for all foreign income taxes paid or accrued in the same taxable year. The
rules relating to the determination of the foreign tax credit are complex and subject to numerous limitations that must be applied on
an individual basis. In addition, the creditability of foreign taxes could be affected by actions taken by intermediaries in the chain
of ownership between the holders of the ADSs and our company if, as a result of such actions, the holders of the ADSs are not properly
treated as beneficial owners of the underlying Ordinary Shares. U.S. holders are urged to consult with their own tax advisers to determine
whether and to what extent they will be entitled to foreign tax credits as well as with respect to the determination of the foreign tax
credit limitation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale,
Exchange or Other Taxable Disposition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 38.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the passive foreign investment company rules discussed below, on a sale, exchange or other taxable disposition of an Ordinary
Share or ADS, a U.S. holder generally will recognize capital gain or loss in an amount equal to the difference between the U.S.
holder&#8217;s adjusted tax basis in the Ordinary Share or ADS and the amount realized on the sale, exchange or other taxable
disposition, each determined in U.S. dollars. The adjusted tax basis in the ADSs or Ordinary Shares generally will be equal to the
cost of such ADSs or Ordinary Shares. Capital gain from the sale, exchange or other taxable disposition of the ADSs or Ordinary
Shares by a non-corporate U.S. holder is generally eligible for a preferential rate of taxation applicable to long-term taxable
capital gains if the non-corporate U.S. holder&#8217;s holding period determined at the time of such sale, exchange or other taxable
disposition for such securities exceeds one year. Capital gains recognized by corporate U.S. holders generally are subject to U.S.
federal income tax at the same rate as ordinary income. The deductibility of capital losses is subject to limitations. Any gain or
loss a U.S. holder recognizes generally will be U.S. source for U.S. foreign tax credit purposes. The rules relating to the
determination of the foreign tax credit are complex, and U.S. holders are urged to consult with their own tax advisers regarding the
application of such rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a cash basis taxpayer, units of foreign currency paid or received are translated into U.S. dollars at the spot rate on the settlement
date of the purchase or sale. In that case, no foreign currency exchange gain or loss will result from currency fluctuations between
the trade date and the settlement date of such a purchase or sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
accrual basis taxpayer may elect the same treatment required of cash basis taxpayers with respect to purchases and sales of our Ordinary
Shares or ADSs that are traded on an established securities market, provided the election is applied consistently from year to year.
Such election may not be changed without the consent of the IRS. For an accrual basis taxpayer who does not make such election, units
of foreign currency paid or received are translated into U.S. dollars at the spot rate on the trade date of the purchase or sale. Such
an accrual basis taxpayer may recognize exchange gain or loss based on currency fluctuations between the trade date and the settlement
date. Any foreign currency gain or loss a U.S. holder realizes will be U.S. source ordinary income or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Passive
Foreign Investment Company Rules</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
special set of U.S. federal income tax rules applies to a foreign corporation that is a PFIC for U.S. federal income tax purposes. As
noted above, based on our audited financial statements and relevant market and shareholder data, we believe that we were a PFIC for U.S.
federal income tax purposes for our taxable year ended June 30, 2023. There can be no assurance that we will not be considered a PFIC
in any past, current or future taxable year. However, our PFIC status is based on an annual determination and may change from year to
year. Our status as a PFIC will depend on the composition of our income (including with respect to the R&amp;D Tax Credit) and the composition
and value of our assets, which may be determined in large part by reference to the market value of the ADSs and Ordinary Shares, which
may be volatile, from time to time. Our status may also depend, in part, on how quickly we utilize the cash we raise in any offering
of our securities. Our U.S. counsel expresses no opinion regarding our conclusions or our expectations regarding our PFIC status.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, a non-U.S. corporation is a PFIC if at least 75% of its gross income for the taxable year is passive income (the &#8220;income
test&#8221;) or if at least 50% of the average quarterly value of its total gross assets for the taxable year (which would generally
be measured by fair market value of our assets, and for which purpose the total value of our assets may be determined in part by the
market value of the ADSs and Ordinary Shares, which are subject to change) produce passive income or are held for the production of passive
income (the &#8220;asset test&#8221;). Passive income for this purpose generally includes dividends, interest, royalties, rents, gains
from commodities and securities transactions, the excess of gains over losses from the disposition of assets which produce passive income,
and includes amounts derived by reason of the temporary investment of funds raised in offerings of our securities. If a non-U.S. corporation
owns directly or indirectly at least 25% by value of the stock of another corporation or the partnership interests in a partnership,
the non-U.S. corporation is treated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation
or partnership and as receiving directly its proportionate share of the other corporation&#8217;s or partnership&#8217;s income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are classified as a PFIC in any year with respect to which a U.S. holder owns ADSs or Ordinary Shares, we will continue to be treated
as a PFIC with respect to such U.S. holder in all succeeding years during which the U.S. holder owns the ADSs or Ordinary Shares, regardless
of whether we continue to meet the tests described above unless we cease to be a PFIC and the U.S. holder has made a &#8220;deemed sale&#8221;
election under the PFIC rules. If the &#8220;deemed sale&#8221; election is made, a U.S. holder will be deemed to have sold the securities
the U.S. holder holds at their fair market value as of the date of such deemed sale and any gain from such deemed sale would be subject
to the rules described below. After the deemed sale election, so long as we do not become a PFIC in a subsequent taxable year, the U.S.
holder&#8217;s securities with respect to which such election was made will not be treated as shares in a PFIC and the U.S. holder will
not be subject to the rules described below with respect to any &#8220;excess distribution&#8221; the U.S. holder receives from us or
any gain from an actual sale or other disposition of the securities. U.S. holders should consult their tax advisors as to the possibility
and consequences of making a deemed sale or other &#8220;purging&#8221; election if such election becomes available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC, and you are a U.S. holder that does not make one of the elections described herein, a special tax regime will apply to
both (a) any &#8220;excess distribution&#8221; by us to you (generally, your ratable portion of distributions in any year, other than
the taxable year in which your holding period in the Ordinary Shares or ADSs begins, which are greater than 125% of the average annual
distribution received by you in the shorter of the three preceding years or the portion of your holding period for the ADSs or Ordinary
Shares that preceded the year of the distribution) and (b) any gain realized on the sale or other disposition of the ADSs or Ordinary
Shares. Under this regime, any excess distribution and realized gain will be treated as ordinary income and will be subject to tax as
if (a) the excess distribution or gain had been realized ratably over your holding period, (b) the amount deemed realized in each year
had been subject to tax in each year of that holding period at the highest marginal rate for such year (other than income allocated to
the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. holder&#8217;s regular ordinary
income rate for the current year and would not be subject to the interest charge discussed below) and (c) the interest charge generally
applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those years. In addition, dividend distributions
made to you will not qualify for the lower rates of taxation applicable to qualified dividends discussed above under &#8220;Distributions.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
elections may alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment of our Ordinary
Shares or ADSs. If a U.S. holder makes a mark-to-market election with respect to their Ordinary Shares or ADSs, the U.S. holder
generally will recognize as ordinary income any excess of the fair market value of such Ordinary Shares or ADSs at the end of each
taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis
of such Ordinary Shares or ADSs over their fair market value at the end of the taxable year (but only to the extent of the net
amount of income previously included as a result of the mark-to-market election). If a U.S. holder makes the election, the U.S.
holder&#8217;s tax basis in their Ordinary Shares or ADSs will be adjusted to reflect these income or loss amounts. Any gain
recognized on the sale or other disposition of Ordinary Shares or ADSs in a year in which we are a PFIC will be treated as ordinary
income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a
result of the mark-to-market election). The mark-to-market election is available only if we are a PFIC and the Ordinary Shares or
ADSs are &#8220;regularly traded&#8221; on a &#8220;qualified exchange.&#8221; Our Ordinary Shares or ADSs will be treated as
&#8220;regularly traded&#8221; in any calendar year in which more than a de minimis quantity of our Ordinary Shares or ADSs are
traded on a qualified exchange on at least 15 days during each calendar quarter (subject to the rule that trades that have as one of
their principal purposes the meeting of the trading requirement are disregarded). The NASDAQ Capital Market is a qualified exchange
for this purpose and, consequently, if the ADSs are regularly traded, the mark-to-market election will be available to a U.S.
holder. It should be noted that it is intended that only the ADSs and not the Ordinary Shares will be listed on the NASDAQ Capital
Market. Consequently, the Ordinary Shares may not be marketable if the ASX (where the Ordinary Shares are currently listed) does not
meet the applicable requirements. U.S. holders should consult their tax advisors regarding the availability of the mark-to-market
election for Ordinary Shares that are not represented by ADSs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
a mark-to-market election generally cannot be made for equity interests in any lower-tier PFICs that we own, unless shares of such lower-tier
PFIC are themselves &#8220;marketable.&#8221; As a result, even if a U.S. holder validly makes a mark-to-market election with respect
to our Ordinary Shares or ADSs, the U.S. holder may continue to be subject to the PFIC rules (described above) with respect to its indirect
interest in any of our investments that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. U.S. holders
should consult their tax advisors as to the availability and desirability of a mark-to-market election, as well as the impact of such
election on interests in any lower-tier PFICs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently intend to provide the information necessary for U.S. holders to make qualified electing fund elections if we were treated
as a PFIC for any taxable year. U.S. holders should consult their tax advisors to determine whether any of the other elections described
above would be available and if so, what the consequences of the alternative treatments would be in their particular circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are determined to be a PFIC, the general tax treatment for U.S. holders described in this section would apply to indirect distributions
and gains deemed to be realized by U.S. holders in respect of any of our subsidiaries that also may be determined to be PFICs. U.S. holders
should consult their tax advisors regarding the application of the PFIC rules to our subsidiaries. If a U.S. holder owns Ordinary Shares
or ADSs during any taxable year in which we are a PFIC, the U.S. holder may be required to file an IRS Form 8621 (Information Return
by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund) with respect to the company, generally with the
U.S. holder&#8217;s federal income tax return for that year. You should consult your tax advisor concerning any filing requirements arising
from the PFIC rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. federal income tax rules relating to PFICs are complex. Prospective U.S. investors are urged to consult their own tax advisors with
respect to the acquisition, ownership and disposition of our Ordinary Shares or ADSs, the consequences to them of an investment in a
PFIC, any elections available with respect to Ordinary Shares and ADSs and the IRS information reporting obligations with respect to
the acquisition, ownership and disposition of Ordinary Shares and ADSs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
Reporting and Backup Withholding</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
holders generally will be subject to information reporting requirements with respect to dividends on the Ordinary Shares or ADSs and
on the proceeds from the sale, exchange or disposition of the Ordinary Shares or ADSs that are paid within the United States or through
U.S.-related financial intermediaries, unless the U.S. holder is an &#8220;exempt recipient.&#8221; In addition, U.S. holders may be
subject to backup withholding on such payments unless the U.S. holder provides a taxpayer identification number and a duly executed IRS
Form W-9 or otherwise establishes an exemption. Backup withholding is not an additional tax, and the amount of any backup withholding
will be allowed as a credit against a U.S. holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund,
provided that the required information is timely furnished to the IRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reporting
Obligations of Individual Owners of Foreign Financial Assets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain exceptions (including an exception for property held in accounts maintained by U.S. financial institutions), Section 6038D
of the Code generally requires certain individual U.S. holders (and certain entities that are closely held by U.S. individuals) to report
information relating to an interest in the Ordinary Shares or ADSs by filing IRS Form 8938 (Statement of Specified Foreign Financial
Assets) with their U.S. federal income tax return. Such U.S. holders (or entities) who fail to timely furnish the required information
may be subject to penalties. Additionally, if any such U.S. holder (or entity) does not report the required information, the statute
of limitations with respect to tax returns of the U.S. holder (or entity) to which the information relates may not close until three
years after such information is reported. U.S. holders are urged to consult their tax advisors regarding their information reporting
obligations, if any, with respect to their ownership and disposition of the Ordinary Shares or ADSs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
DISCUSSION ABOVE IS NOT INTENDED TO CONSTITUTE A COMPLETE ANALYSIS OF ALL TAX CONSIDERATIONS APPLICABLE TO AN INVESTMENT IN ORDINARY
SHARES OR ADSs. EACH CURRENT AND POTENTIAL HOLDER IS URGED TO CONSULT THEIR OWN TAX ADVISERS CONCERNING THE TAX CONSEQUENCES RELEVANT
TO THEM IN THEIR PARTICULAR SITUATION.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_047"></span>Item
10.F Dividends and Paying Agents</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
dividends were declared or paid to members for the year ended June 30, 2023 (2022: nil). The Company&#8217;s franking account balance
was nil at June 30, 2023 (2022: nil).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_048"></span>Item
10.G Statement by Experts</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_049"></span>Item
10.H Documents on Display</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
documents concerning the Company which are referred to in this Annual Report may be inspected at the offices of the Company at 60-66
Hanover Street, Fitzroy, Victoria 3065 Australia. As a &#8220;foreign private issuer&#8221; we are subject to the information requirements
of the U.S. Securities Exchange Act of 1934, as amended, and, in accordance therewith, we are required to file reports, including annual
reports on Form 20-F, and other information with the U.S. Securities and Exchange Commission in electronic form. Any filings we make
electronically are available to the public over the Internet at the Commission&#8217;s website at http://www.sec.gov. We also maintain
a website at www.genetype.com. Information on our website and websites linked to it do not constitute a part of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_050"></span>Item
10.I Subsidiary Information</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_051"></span>Item
10.J Annual Report to Security Holders</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_052"></span>Item
11. Quantitative and Qualitative Disclosures about Market Risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
market risk relates primarily to exposure to changes in foreign currency exchange rates and interest rates. Refer Note 31 of the attached
financial statements for further analysis surrounding market risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Rate Risk</i></b>. As of June 30, 2023, we had A$7,851,197 in cash and cash equivalents of which A$6,216,646 was subject to interest
rate risk. Interest income earned on the cash balances is affected by changes in the levels of market interest rates. We invest excess
cash in interest-bearing, investment-grade securities and time deposits in high-quality institutions. We do not utilize derivative financial
instruments, derivative commodity instruments, positions or transactions in any material matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
we believe that, while the investment-grade securities and time-deposits we hold are subject to changes in financial standing of the
issuer of such securities, the principal is not subject to any material risks arising from changes in interest rates, foreign currency
exchange rates, commodity prices, equity prices or other market changes that affect market risk sensitive instruments. Since we hold
cash and cash equivalents in Banks which are located outside Australia, we are subject to certain cross-border risks, though due to the
size of the holdings these risks are not generally significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Currency Exchange Rate Risk</i></b>. We operate in Australia with active operations in the U.S.A., United Kingdom and Europe, and are
accordingly subject to certain foreign currency exposure. This includes foreign-currency denominated receivables, payables, and other
balance sheet positions as well as future cash flows resulting from anticipated transactions including intra-company transactions. Historically,
currency translation gains and losses have been reflected as adjustments to stockholders&#8217; equity, while transaction gains and losses
have been reflected as components of income and loss. Transaction gains and losses could be material depending upon changes in the exchange
rates between the Australian dollar and the U.S. dollar. A significant amount of our current revenue is denominated in U.S. dollars which
provides us with a limited natural hedge against exchange rate movements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_053"></span>Item
12. Description of Securities Other Than Equity Securities</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_054"></span>Item
12.A Debt Securities</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_055"></span>Item
12.B Warrants and Rights</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_056"></span>Item
12.C Other Securities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_057"></span>Item
12.D American Depositary Shares Fees and Charges Payable by ADS Holders</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the fees and charges that a holder of our ADSs may have to pay, directly or indirectly, to our depositary, The
Bank of New York Mellon, or BNYM, pursuant to the Deposit Agreement, which was filed as Exhibit 2.1 to our Registration Statement on
Form F-6 filed with the SEC on January 14, 2002, and the types of services and the amount of the fees or charges paid for such services.
The disclosure under this heading &#8220;Fees and Charges Payable by ADS Holders&#8221; is subject to and qualified in its entirety by
reference to the full text of the Deposit Agreement. The holder of an ADS may have to pay the following fees and charges to BNYM in connection
with ownership of the ADS:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persons
Depositing or Withdrawing Shares Must</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pay:</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For:</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    US$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    US$0.02 (or less) per ADS</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Any cash distribution to you</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been
    deposited for issuance of ADSs</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Distribution of securities distributed to holders of deposited securities which are distributed by the depositary to ADS
    holders</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    US$1.50 (or less) per ADR</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Transfers, combination and split-up of ADRs</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Expenses of the depositary</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Converting foreign currency to U.S. dollars</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary collects its fees for issuance and cancellation of ADSs directly from investors depositing shares or surrendering ADSs
for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to
investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees.
The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing
investors or by charging the book-entry system accounts of participants acting for them. The depositary may generally refuse to
provide fee-attracting services until its fees for those services are paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_058"></span>PART
II</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_059"></span>Item
13. Defaults, Dividend Arrearages and Delinquencies</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_060"></span>Item
14. Material Modifications to the Rights of Security Holders and Use of Proceeds</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_061"></span>Item
15. Controls and Procedures</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="F_062"></span>Item
15.A Disclosure controls and procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain disclosure controls and procedures as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934 (the &#8220;Exchange Act&#8221;), as amended, that are designed to ensure that information required to be disclosed in the reports
that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods
specified in the rules and forms of the Securities and Exchange Commission. Disclosure controls and procedures include, without limitation,
controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities
Exchange Act of 1934 is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer,
as appropriate, to allow timely decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures or
our internal control over financial reporting are designed and operated to be effective at the reasonable assurance level. However, our
Management does not expect that our disclosure controls and procedures and our internal control over financial reporting will prevent
all error and fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the control system are met. Additionally, the design of a control system must reflect the fact that there are
resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in
all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any,
have been detected or that our control system will operate effectively under all circumstances. Moreover, the design of any system of
controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design
will succeed in achieving its stated goals under all potential future conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Management has carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial
Officer, of the effectiveness of our disclosure controls and procedures as of June 30, 2023. Based on that evaluation, the Chief Executive
Officer and the Chief Financial Officer concluded that the Company&#8217;s disclosure controls and procedures were effective as of June
30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_063"></span>Item
15.B Management&#8217;s annual report on internal control over financial reporting</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Management is responsible for establishing and maintaining adequate internal control over financial reporting. The Securities Exchange
Act of 1934 defines internal control over financial reporting in Rules 13a-15(f) and 15d-15(f) as a process designed by, or under the
supervision of, the Company&#8217;s Chief Executive Officer and Chief Financial Officer effected by the Company&#8217;s Board of Directors,
Management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies
and procedures that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pertain
    to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets
    of the Company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    reasonable assurance that transactions are recorded as necessary to permit the preparation of financial statements in accordance
    with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance
    with authorizations of Management and directors of the Company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s
    assets that could have a material effect on the consolidated financial statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Management, under the supervision and with participation of our Chief Executive Officer and Chief Financial Officer, has assessed the
effectiveness of the Company&#8217;s internal control over financial reporting as of June 30, 2023. Based on that evaluation, the Chief
Executive Officer and the Chief Financial Officer concluded that the Company&#8217;s internal control over financial reporting was effective
as of June 30, 2023. In making this assessment, Management used the criteria set forth by the Committee of Sponsoring Organizations of
the Treadway Commission, or COSO, in Internal Control-Integrated Framework (2013).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report does not include an attestation report of the Company&#8217;s registered public accounting firm regarding internal control
over financial reporting. Management&#8217;s report was not subject to attestation by the Company&#8217;s registered public accounting
firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only Management&#8217;s report in
this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_064"></span>Item
15.C Attestation report of the registered public accounting firm</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_065"></span>Item
15.D Changes in Internal Control over Financial Reporting</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in the internal control over financial reporting during the year ended June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_066"></span>Item
16. Reserved</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_067"></span>Item
16.A Audit Committee Financial Expert</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 2, 2019, the Company appointed Mr. Nick Burrows to the Board as an independent Non-Executive Director. Mr. Burrows is a financial
expert and hence the Company subsequently appointed Mr. Burrows as the Chairman of the Audit &amp; Risk Committee replacing Mr. Peter
Rubinstein, former Chairman of the Audit &amp; Risk Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_068"></span>Item
16.B Code of Ethics</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a Code of Ethics (styled &#8220;Code of Conduct&#8221;) that applies to all of our Directors and employees, including our
principal executive officer, principal financial officer and principal accounting officer or controller. The Code can be downloaded at
our website (www.genetype.com). Additionally, any person, upon request, can ask for a hard copy or electronic file of the Code. If we
make any substantive amendment to the Code or grant any waivers, including any implicit waiver, from a provision of the Code, we will
disclose the nature of such amendment or waiver on our website. During the year ended June 30, 2023, no such amendment was made, or waiver
granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_069"></span>Item
16.C Principal Accountant Fees and Services</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the fees billed to us by our Independent Registered Public Accounting Firms, Grant Thornton Audit Pty Ltd
and PricewaterhouseCoopers, during the financial years ended June 30, 2023 and 2022, respectively:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Services rendered</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="9">PricewaterhouseCoopers in respect of:</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees <sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">20,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related fees <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All other fees <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="9">Grant Thornton Audit Pty Ltd in respect of:</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees <sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">320,569</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241,882</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related fees <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All other fees <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 2.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><sup>(1)
</sup>Audit fees consist of services that would normally be provided in connection with statutory, half year review and regulatory filings
or engagements, including services that generally only the independent accountant can reasonably provide such as comfort letters.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><sup>(2) </sup>Audit-related
fees consist of fees billed for assurance and related services that generally only the statutory auditor could reasonably provide to
a client.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><sup>(3)
</sup>All other fees consist of fees billed for financial and information technology due diligence services in respect of the Company&#8217;s
acquisition of the business and assets associated with the EasyDNA brand that completed on August 13<sup>th</sup>, 2021</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 76; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Committee Pre-Approval Policies and Procedures</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has established pre-approval and procedures for the engagement of its Independent Registered Public Accounting Firm
for audit and non-audit services. The Board of Directors reviews the scope of the services to be provided, before their commencement,
in order to ensure that there are no independence issues and the services are not prohibited services, as defined by the Sarbanes-Oxley
Act of 2002. The Board of Directors has considered advice received from the Audit &amp; Risk Committee and is satisfied that the provision
of the non-audit services is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001.
The directors are satisfied that the provision of the non-audit services as set out above, did not compromise the auditor independence
requirements of the Corporations Act 2001 because the services are not deemed to undermine the general principles relating to auditor
independence as set out in APES 110 Code of Ethics for Professional Accountants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_070"></span>Item
16.D Exemptions from the Listing Standards for Audit Committees</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_071"></span>Item
16.E Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_072"></span>Item
16.F Change in Registrant&#8217;s Certifying Accountant</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_073"></span>Item
16.G Corporate Governance</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refer
to Item 6C regarding the Company&#8217;s Corporate Governance practices and the key differences between the Listing Rules of the Australian
Securities Exchange and NASDAQ&#8217;s Marketplace Rules as they apply to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_074"></span>Item
16.H Mine Safety Disclosure</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_075"></span>Item
16.I Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_076"></span>Item
16.J insider Trading Policies</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has adopted a Securities Trading Policy which covers insider trading. Refer to exhibit 4.13 for further details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_077"></span>PART
III</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_078"></span>Item
17. Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has responded to Item 18 in lieu of responding to this Item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_079"></span>Item
18. Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
full text of the Company&#8217;s audited financial statements for the fiscal years ended June 30, 2023 and 2022 begins on page F-1 of
this Annual Report on Form 20-F.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australian
Disclosure Requirements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors&#8217; Declaration</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the directors&#8217; opinion:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
the financial statements and Notes set out on pages F-4 to F-56 are in accordance with the Corporations Act 2001, including:</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Complying with Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements,
and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Giving a true and fair view of the consolidated entity&#8217;s financial position as at June 30, 2023 and of its performance for the
fiscal year ended on that date, and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
There are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and
payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
1 &#8216;Basis of preparation&#8217; confirms that the financial statements also comply with International Financial Reporting Standards
as issued by the International Accounting Standards Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
directors have been given the declarations by the chief executive officer and chief financial officer required by section 295A of the
Corporations Act 2001.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
declaration is made in accordance with a resolution of the directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 0.5in">&#160;</td>
  <td style="border-bottom: Black 1.5pt solid; width: 2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Peter Rubinstein</i></span></td>
  <td>&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melbourne,
August 30, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="F_080"></span>Item
19. Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following documents are filed as exhibits to this Annual Report on Form 20-F:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.8in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1166272/000110465910063649/a10-23877_1ex1d1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Constitution of the Registrant (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Registration Statement on Form 20-F filed with the Commission on December 21, 2010)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1166272/000101915512000567/geneticdepnrec.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposit Agreement, dated as of January 14, 2002, by and among Genetic Technologies Limited, The Bank of New York Mellon, as Depositary, and the Owners and Holders of American Depositary Receipts (such agreement is incorporated herein by reference to the Registration Statement on Form F-6 relating to the ADSs (File No. 333-14270) filed with the Commission on January 14, 2002).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1166272/000149315220019793/ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Annual Report on Form 20-F filed with the Commission on October 22, 2020)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1166272/000110465920042634/tm2014700d2_ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Compensation Warrant issued on April 3, 2020 (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Report on Form 6-K filed with the Commission on April 2, 2020)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1166272/000149315220008348/ex4-5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-funded Warrant (incorporated by reference to Exhibit 4.5 to the Company&#8217;s registration statement on Form F-1/A filed on May 12, 2020)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1166272/000149315220008348/ex4-6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.6 to the Company&#8217;s registration statement on Form F-1/A filed on May 12, 2020)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1166272/000104746905021767/a2162190zex-4_2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Staff Share Plan 2001 dated November 30, 2001 (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Registration Statement on Form 20-F filed with the Commission on August 19, 2005)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1166272/000110465920042634/tm2014700d2_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement Agent Agreement effective March 30, 2020 (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Report on Form 6-K filed with the Commission on April 2, 2020)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1166272/000149315220008348/ex10-9.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.9 to the Company&#8217;s registration statement on Form F-1/A filed on May 12, 2020)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1166272/000110465918064930/a18-24094_1ex4db1d2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renewal of Lease over premises in Fitzroy, Victoria, Australia with an effective date of September 1, 2018 (incorporated by reference to 20-F filed October 3, 2019)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1166272/000149315220013595/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement dated July 16, 2020 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Report on Form 6-K filed with the Commission on July 20, 2020)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1166272/000149315221001711/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement dated January 21, 2021 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Report on Form 6-K filed with the Commission on January 5, 2021)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1166272/000149315221021609/ex4-11.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Rights Agreement dated August 12, 2021 (incorporated by reference to Exhibit 4.11 of the Company&#8217;s Annual Report on Form 20-F filed with the Commission on August 31, 2021)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1166272/000149315221021609/ex4-12.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Solicitation Agreement dated July 18, 2021 (incorporated by reference to Exhibit 4.12 of the Company&#8217;s Annual Report on Form 20-F filed with the Commission on August 31, 2021)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1166272/000149315222024334/ex4-12.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale of Business Agreement dated July 14, 2022 (incorporated by reference to Exhibit 4.12 of the Company&#8217;s Annual Report on Form 20-F filed with the Commission on August 30, 2022)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex4-13.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Trading Policy</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1166272/000149315223003785/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Report on Form 6-K filed with the Commission on February 7, 2023)</span></a></td></tr>
  </table>

<p style="margin: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 78; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.8in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.01</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex12-01.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 302 Certification of the Chief Executive Officer</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.02</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex12-02.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 302 Certification of the Chief Financial Officer</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.01</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex13-01.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 906 Certification of the Chief Executive Officer</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.02</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex13-02.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 906 Certification of the Chief Financial Officer</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex15-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appendix 4E</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex15-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditor&#8217;s Independence Declaration</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex15-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Auditor&#8217;s Report</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.
                                                         INS</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.
    SCH</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.
                                                         CAL</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.
    DEF</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.
    LAB</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Labels Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.
    PRE</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*Certain
information which constitutes a clearly unwarranted invasion of personal privacy pursuant to Item 601(a)(6) of Regulation S-K has been
omitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized
the undersigned to sign this Annual Report on its behalf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GENETIC
    TECHNOLOGIES LIMITED</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    August 30, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Simon Morriss</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simon
    Morriss</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 80; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023
Financial Report</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENETIC
TECHNOLOGIES LIMITED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#SJ_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genetic Technologies Limited - Report of Independent Registered Public Accounting Firm (PCAOB ID 0<span id="xdx_90D_edei--AuditorFirmId_c20220701__20230630_zqgT1KqhyVhf"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:AuditorFirmId">2233</ix:nonNumeric></span>).</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#SJ_002">Genetic Technologies Limited - Consolidated Statements of Profit or Loss and Other Comprehensive Income/(Loss) for the years ended June 30, 2023, 2022 and 2021.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#SJ_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genetic Technologies Limited - Consolidated Statements of Financial Position as of June 30, 2023 and 2022.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#SJ_004">Genetic Technologies Limited - Consolidated Statements of Cash Flows for the years ended June 30, 2023, 2022 and 2021.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#SJ_005">Genetic Technologies Limited - Consolidated Statements of Changes in Equity for the years ended June 30, 2023, 2022 and 2021.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#SJ_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genetic Technologies Limited - Notes to Consolidated Financial Statements.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 81; Value: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="SJ_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
of Directors and Shareholders</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genetic
Technologies Limited</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the financial statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Genetic Technologies Limited and subsidiaries (the &#8220;Company&#8221;)
as of June 30, 2023 and 2022, the related consolidated statement of profit or loss and other comprehensive income, changes in shareholders&#8217;
equity, and cashflows for the three years ended June 30, 2023, and the related notes (collectively referred to as the &#8220;financial
statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the
Company as of June 30, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period
ended June 30, 2023, in conformity with International Financial Reporting Standards, as issued by the International Accounting Standards
Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
for opinion</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence supporting
the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe
that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going
concern</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
2(a)(iv) to the financial statements, the Company incurred a total comprehensive loss of A$11,650,334 (2022: A$7,103,134) and net cash
outflow from operations of A$9,723,095 (2022: A$5,659,456). As at June 30, 2023, the Company held total cash and cash equivalents of
A$7,851,197 and total net current assets of A$7,185,750. These conditions, along with other matters as set forth in Note 2(a)(iv), raise
substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters
are also described in Note 2(a)(iv). The financial statements do not include any adjustments that might result from the outcome of this
uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
audit matters</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated
or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated
financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit
matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical
audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and Development Tax Incentive</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described further in Note 5 and Note 12 of the financial report, Genetic Technologies Limited determines the eligibility of the research
and development (&#8220;R&amp;D&#8221;) activities under the Australian government tax incentive scheme. The R&amp;D receivable for the
period was A$1,616,064 and the income recognized in the consolidated statement of profit or loss and other comprehensive income
was A$1,616,064 for the year then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is inherent subjectivity involved in the Company&#8217;s judgements in relation to the calculation and recognition of the R&amp;D tax
incentive income and receivable, with several assumptions made in determining the eligibility of claimable expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
procedures included, amongst others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtained
                                            an understanding of the process undertaken to calculate the research and development tax
                                            incentive;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilized
                                            an internal research and development tax specialist to:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#9675;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Review
                                            the methodology used by the Company for consistency with the R&amp;D tax offset rules; and</td></tr>
                                                                                                                                      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td></tr>
                                                                                                                                      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consider
                                            the nature of the expenses against the eligibility criteria of the R&amp;D tax incentive
                                            scheme to assess whether the expenses included in the estimate were likely to meet the eligibility
                                            criteria;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inspected
                                            supporting documentation for a sample of expenses claimed to assess validity of the claimed
                                            amount and eligibility against the R&amp;D tax incentive scheme criteria;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Validated
                                            the approval process for a sample of expenses;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compared
                                            the nature of R&amp;D expenditure included in the current year estimate to the prior year
                                            claim;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Considered
                                            the Company&#8217;s history of successful claims;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inspected
                                            copies of relevant correspondence with Aus Industry and the Australian Taxation Office related
                                            to the claims; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assessed
                                            the adequacy of the Company&#8217;s disclosures in relation to the R&amp;D tax incentive.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
of goodwill and other long-lived assets impairment assessment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described further in Note 15 of the financial report, goodwill amounted to A$3,116,893 at June 30, 2023, as a result of the acquisitions
of EasyDNA and AffinityDNA and the impairment loss of A$1,845,000 for EasyDNA that was recognized in the period. At June 30, 2023,
Genetic Technologies Limited also has other intangibles assets of A$520,472 made up of brands, trademarks, trade names, and domain
names acquired via the EasyDNA and AffinityDNA acquisitions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with AASB 136 Impairment of Assets, goodwill and other intangible assets acquired in a business combination must be allocated
to the Group&#8217;s cash generating units (&#8220;CGUs&#8221;). For each CGU to which goodwill has been allocated, the Group is required
to assess if the carrying value of the CGU is in excess of the recoverable value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Goodwill and other long-lived assets impairment assessment has been assessed as a critical audit matter due to the judgement required
by management in preparing a value in use model to satisfy the impairment test as prescribed in IFRS 36 Impairment of Assets, including
significant estimation involved in forecasting of future cash flows and applying an appropriate discount rate which inherently involves
a high degree of estimation and judgement by management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
procedures included, amongst others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assessed
                                            management&#8217;s determination of the Company having two CGUs and their allocation of goodwill;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assessed
                                            whether management has the requisite expertise to prepare the impairment model;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reviewed
                                            the impairment model for compliance with IFRS 36 Impairment of Assets;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assessed
                                            the reasonableness and appropriateness of inputs and assumptions to the model, with involvement
                                            of our internal valuation specialist;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            management&#8217;s future cash flow forecasts and obtained an understanding of the process
                                            by which they were developed, including:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assessed
                                            management&#8217;s key assumptions for reasonableness and obtaining available evidence to
                                            support key assumptions;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Considered
                                            the reasonableness of the revenue and cost forecasts against current period actuals;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performed
                                            a sensitivity analysis on the key assumptions;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tested
                                            the underlying calculations for mathematical accuracy of the model; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the disclosures in the financial statements for appropriateness and consistency with accounting
                                            standards.</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
combination</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described further in Note 17 to the financial statements, on July 14, 2022, the Company completed the acquisition of AffinityDNA&#8217;s
direct-to-consumer eCommerce business and distribution rights. This transaction was accounted for as a business combination using the
acquisition method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
for these transactions is a complex and judgmental exercise requiring management to determine the fair value of acquired assets and liabilities
as well as the goodwill arising on acquisition and as a result has been assessed as a critical audit matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
procedures included, amongst others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Read
                                            the executed acquisition agreement and evaluated the Company&#8217;s acquisition accounting
                                            against the requirements of International Financial Reporting Standards;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tested
                                            the accuracy of the purchase consideration against the executed acquisition agreements;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assessed
                                            the fair values of the acquired assets and liabilities recognized, with involvement
                                            of our valuations specialist, including:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the competence, capabilities and objectivity of management&#8217;s expert who assisted the
                                            Company in estimating fair values;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assessed
                                            the valuation of identified intangible assets recognized as part of the purchase price
                                            allocation calculations;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assessed
                                            the completeness of identified intangible assets through discussions with management and
                                            with the internal valuation specialist;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the mathematical accuracy of the Company&#8217;s calculation of the resulting goodwill arising
                                            on the PPA calculations;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reviewed
                                            the work of the independent valuers engaged by the Group to assist with the PPA calculations;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilized
                                            an internal valuation specialist to review the work performed by management&#8217;s expert;
                                            and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assessed
                                            the adequacy of the Company&#8217;s disclosures in relation to business combination.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -17.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_907_edei--AuditorName_c20220701__20230630_zoP3wrMPpX1a"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:AuditorName">GRANT THORNTON AUDIT PTY LTD</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--AuditorLocation_c20220701__20230630_zuPUzPJegLnc"><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="dei:AuditorLocation">Melbourne,
Australia</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
30, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="SJ_002"></span>CONSOLIDATED
STATEMENT OF PROFIT OR LOSS AND COMPREHENSIVE INCOME</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended June 30, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
Australian dollars, except number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_113_zD4qHoPx4z65" summary="xdx: Statement - Consolidated Statement of Profit or Loss and Comprehensive Income" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_493_20220701__20230630_zGUiTbVTkUq8" style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2023</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_497_20210701__20220630_z7u0QV8CbKR6" style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2022</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20200701__20210630_zWe7V0QjDwLk" style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2021</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--Revenue_maPLBTzl5M_zUw1WPivWoOi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; width: 40%">Revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 11%; text-align: center">4A</td><td style="width: 1%; text-align: left"></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">8,686,118</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,794,816</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">120,554</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--FinanceIncome_maPLBTzl5M_zip7RicBrdhj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Finance income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">220,161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">36,256</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">62,394</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--OtherIncome_maPLBTzl5M_zmDeoJtbvw09" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,836,822</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,783,391</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,559,961</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ChangesInInventories_maPLBTzl5M_zTQfADTwiFUb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Changes in inventories</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:ChangesInInventories" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">72,257</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:ChangesInInventories" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">321,223</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:ChangesInInventories" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">14,463</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--RawMaterialsAndConsumablesUsed_iN_pp0p0_di_msPLBTzl5M_zfSrQdpKOh5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Raw materials</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:RawMaterialsAndConsumablesUsed" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">4,407,522</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:RawMaterialsAndConsumablesUsed" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,692,311</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:RawMaterialsAndConsumablesUsed" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">184,920</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eifrs-full--FeeAndCommissionIncomeExpense_maPLBTzl5M_zwZ0qF3MnUGg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">Commissions</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:FeeAndCommissionIncomeExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">236,019</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:FeeAndCommissionIncomeExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">156,625</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0078">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--EmployeeBenefitsExpense_iN_pp0p0_di_msPLBTzl5M_zmyLnOcaYER" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Employee benefits expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">6,208,066</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">5,868,655</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">3,868,331</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eifrs-full--AdvertisingExpense_iN_pp0p0_di_msPLBTzl5M_zqulJ1G4imnh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Advertising and promotional expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,712,353</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,885,402</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">436,274</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eifrs-full--ProfessionalFeesExpense_iN_pp0p0_di_msPLBTzl5M_zLmO8ys59Gw8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,360,640</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,835,444</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,461,401</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eifrs-full--ResearchAndDevelopmentExpense_iN_pp0p0_di_msPLBTzl5M_zgKIWH5Ev5F8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,281,157</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">705,507</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,165,531</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eifrs-full--DepreciationAndAmortisationExpense_iN_pp0p0_di_msPLBTzl5M_zt4F5WWe4YCb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">676,583</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">578,668</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">386,277</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--ImpairmentExpenses_iN_pp0p0_di_msPLBTzl5M_z1eSsMdzJWEi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Impairment expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:ImpairmentExpenses" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,125,725</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:ImpairmentExpenses" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">564,161</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:ImpairmentExpenses" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">32,048</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eifrs-full--OtherExpenseByNature_iN_pp0p0_di_msPLBTzl5M_zwwYqd3DVmxe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -10pt; text-align: left">Other expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:OtherExpenseByNature" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">3,687,030</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:OtherExpenseByNature" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,154,375</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:OtherExpenseByNature" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,283,871</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eifrs-full--FinanceCosts_iN_pp0p0_di_msPLBTzl5M_zuZyfIMZN4Sg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Finance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">29,515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">15,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">16,338</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eifrs-full--ProfitLossBeforeTax_iT_pp0p0_mtPLBTzl5M_maPLzp8S_znjo0XtKxAy9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Loss from operations before income tax</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">11,909,252</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">7,163,123</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">7,077,619</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_pp0p0_di_msPLzp8S_zNzU05cdjvD" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Income tax credit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">158,329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">32,125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0118">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--ProfitLoss_iT_pp0p0_mtPLzp8S_maCIzhVK_zo4XUrsmdUWg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss for the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">11,750,923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">7,130,998</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">7,077,619</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eifrs-full--OtherComprehensiveIncomeAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Other comprehensive income/(loss)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_i01_pp0p0_maOCIzV0L_zqlRuk7NlgBk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Exchange gains/(losses) on translation of con- trolled foreign operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">100,589</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">27,864</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">37,468</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eifrs-full--OtherComprehensiveIncome_i01T_pp0p0_mtOCIzV0L_maCIzhVK_zb5o6S75ulgh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Other comprehensive income/(loss) for the year, net of tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">100,589</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">27,864</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">37,468</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eifrs-full--ComprehensiveIncome_iT_pp0p0_mtCIzhVK_zbM1c2Q9jnQk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total comprehensive loss attributable to the members of Genetic Technologies Ltd</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">11,650,334</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">7,103,134</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">7,115,087</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--EarningsPerShareAbstract_iB_zhoVOeQyjDX5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold">Loss per share (cents per share)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--BasicEarningsLossPerShare_i01_pid_uAUDPShares_zJCzSwG0l4Fa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: -10pt; text-align: left">Basic and diluted net loss per ordinary share</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eifrs-full--DilutedEarningsLossPerShare_i01_uAUDPShares_c20220701__20230630_zDPNXFXYxje8" title="Diluted net loss per ordinary share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBvZiBQcm9maXQgb3IgTG9zcyBhbmQgQ29tcHJlaGVuc2l2ZSBJbmNvbWUA">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="AUDPShares"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="AUDPShares">0.012</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eifrs-full--DilutedEarningsLossPerShare_i01_uAUDPShares_c20210701__20220630_zD2fWZJxGYVj" title="Diluted net loss per ordinary share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBvZiBQcm9maXQgb3IgTG9zcyBhbmQgQ29tcHJlaGVuc2l2ZSBJbmNvbWUA">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="AUDPShares"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="AUDPShares">0.08</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eifrs-full--DilutedEarningsLossPerShare_i01_uAUDPShares_c20200701__20210630_z4mwYWQCyk79" title="Diluted net loss per ordinary share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBvZiBQcm9maXQgb3IgTG9zcyBhbmQgQ29tcHJlaGVuc2l2ZSBJbmNvbWUA">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="AUDPShares"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="AUDPShares">0.08</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eifrs-full--BasicEarningsLossPerShare_i01_pid_uAUDPShares_zOUglQ91ImPd" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: -10pt; text-align: left">Basic  net loss per ordinary share</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="AUDPShares">0.012</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="AUDPShares">0.08</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="AUDPShares">0.08</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40F_eifrs-full--WeightedAverageShares_i01_pid_zFK7NoHDdlh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 20pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average shares outstanding</span></p></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,138,075,003</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,220,348,281</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,544,157,979</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above consolidated statement of profit or loss and comprehensive income should be read in conjunction with the accompanying notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="SJ_003"></span>CONSOLIDATED
STATEMENT OF FINANCIAL POSITION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at June 30, 2023</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
Australian dollars)</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_111_zCtOT7hY46Z4" summary="xdx: Statement - Consolidated Statement of Financial Position" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230630_zoTUDtrjbRDi" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p>
                                                             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220630_zsIn2rmGbmQ6" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022
                                            </b></span><b></b></p>
                                                             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--CurrentAssetsAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--CashAndCashEquivalents_i02I_pp0p0_maCAzjVG_zx42BLnHHtY" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; width: 46%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 14%; text-align: center">11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">7,851,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,731,325</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--TradeAndOtherCurrentReceivables_i02I_pp0p0_maCAzjVG_z5YRVpwrdj07" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Trade and other receivables</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,921,657</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,421,238</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--Inventories_i02I_pp0p0_maCAzjVG_zUnpBe6A5PNk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Inventories</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Inventories" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">325,893</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Inventories" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">398,150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--OtherCurrentAssets_i02I_pp0p0_maCAzjVG_z6WBe8xjuru3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentAssets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">399,048</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentAssets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">166,087</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CurrentAssets_i02TI_pp0p0_mtCAzjVG_maAz8LS_zfxijnZ7S2Ff" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">10,497,795</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">14,716,800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--NoncurrentAssetsAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Non-current assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--RightofuseAssets_i02I_pp0p0_maNAzHFX_zZ0101FzTu9a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">509,553</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">647,150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--PropertyPlantAndEquipment_i02I_pp0p0_maNAzHFX_zPVXXhaIuIxc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">89,623</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">306,175</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--Goodwill_i02I_pp0p0_maNAzHFX_zJs2phvlnzr2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">3,116,893</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">4,506,653</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--OtherIntangibleAssets_i02I_pp0p0_maNAzHFX_z15WGa8xXr9d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Other intangible assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherIntangibleAssets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">520,472</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherIntangibleAssets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">624,920</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--OtherNoncurrentAssets_i02I_pp0p0_maNAzHFX_zjRl8Qk75P6c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Other non-current assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0198">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0199">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--DeferredTaxAssets_i02I_pp0p0_maNAzHFX_zP0CKl00qrCj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Deferred tax asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">121,901</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0202">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--NoncurrentAssets_i02TI_pp0p0_mtNAzHFX_maAz8LS_zU2VbSMUggf9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: -10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">4,358,442</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">6,084,898</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--Assets_i01TI_pp0p0_mtAz8LS_maNALzf7b_z3Fn94RNCjN3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">14,856,237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">20,801,698</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--LiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold">LIABILITIES</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--CurrentLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--TradeAndOtherCurrentPayables_i02I_pp0p0_maCLzP3q_zWVnJ0ZMx4Ti" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,617,333</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,122,379</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--CurrentContractLiabilities_i02I_pp0p0_maCLzP3q_ztRbb39h8iEa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Contract liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">4C</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentContractLiabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">849,212</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentContractLiabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">814,150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--CurrentProvisions_i02I_pp0p0_maCLzP3q_zF1FkUKsbgfi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">Provisions</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentProvisions" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">541,930</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentProvisions" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">611,060</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--CurrentLeaseLiabilities_i02I_pp0p0_maCLzP3q_z6hChcEOHqUi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">303,570</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">264,130</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--CurrentLiabilities_i02TI_pp0p0_mtCLzP3q_maLzZqH_zoCrLgE282kd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">3,312,045</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">3,811,719</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--NoncurrentLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Non-current liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--NoncurrentProvisions_i02I_pp0p0_maNLzBnR_zDoq7fbgUR78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Provisions</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentProvisions" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">30,439</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentProvisions" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">22,499</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--NoncurrentLeaseLiabilities_i02I_pp0p0_maNLzBnR_zifjHftoipK" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">229,276</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">388,396</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--DeferredTaxLiabilities_i02I_pp0p0_maNLzBnR_zkma7r8H8gU6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Deferred tax liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">121,901</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">148,013</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--NoncurrentLiabilities_i02TI_pp0p0_mtNLzBnR_maLzZqH_z32o0nbMUUx2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: -10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">381,616</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">558,908</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--Liabilities_i01TI_pp0p0_mtLzZqH_msNALzf7b_z2oCTDdjUTj6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">3,693,661</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">4,370,627</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--NetAssetsLiabilities_i01TI_pp0p0_mtNALzf7b_zqcM5GWiaYzc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NetAssetsLiabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,162,576</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NetAssetsLiabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">16,431,071</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--EquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold">EQUITY</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--IssuedCapital_i01I_pp0p0_maEzqOy_zHDhqgrqRiIi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Contributed equity</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">161,342,707</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">155,138,636</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--OtherReserves_i01I_pp0p0_maEzqOy_zkZD89Bshg4a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">Reserves</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">6,535,556</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,498,651</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--RetainedEarnings_i01I_pp0p0_maEzqOy_zYPocWvD4iAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Accumulated losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">23</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">156,715,687</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">150,206,216</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eifrs-full--Equity_i01TI_pp0p0_mtEzqOy_zKb6K494qAn5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,162,576</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">16,431,071</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above consolidated statement of financial position should be read in conjunction with the accompanying notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="SJ_004"></span>CONSOLIDATED
STATEMENT OF CASH FLOWS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the year ended June 30, 2023 </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
Australian dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_112_zLvhmfNTtnEf" summary="xdx: Statement - Consolidated Statement of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20220701__20230630_zlKrug2K9M0a" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
                                            </b></span><b></b></p>
                                                             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210701__20220630_zGmwgssD91v2" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p>
                                                             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span><b>A$</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20200701__20210630_zmtgouhGoZLl" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p>
                                                             <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CashFlowsFromUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Cash flows from/(used in) operating activities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--ReceiptsFromSalesOfGoodsAndRenderingOfServices_i01_pp0p0_maRDTIAz5fU_znoHpYZnXkX1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; width: 40%; text-align: left">Receipts from customers</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 11%; text-align: center">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">8,771,325</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">5,745,162</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">121,190</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--PaymentsToSuppliersForGoodsAndServices_i01N_pp0p0_di_msRDTIAz5fU_zU9MsXI30C1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Payments to suppliers and employees</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsToSuppliersForGoodsAndServices" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">20,453,567</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsToSuppliersForGoodsAndServices" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">13,802,170</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsToSuppliersForGoodsAndServices" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">7,747,186</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--RDTaxIncentiveAndOtherGrantsReceived_i01_pp0p0_maRDTIAz5fU_z6lcWE2PGA7e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">R&amp;D tax incentive and other grants received</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:RDTaxIncentiveAndOtherGrantsReceived" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,959,147</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:RDTaxIncentiveAndOtherGrantsReceived" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,397,552</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:RDTaxIncentiveAndOtherGrantsReceived" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,330,067</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--CashFlowsFromUsedInOperatingActivities_i01T_pp0p0_mtRDTIAz5fU_maIDICAz6zM_zXQheqx9jgld" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash flows (used in) operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">9,723,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">5,659,456</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">6,295,929</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CashFlowsFromUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Cash flows from/(used in) investing activities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_i01N_pp0p0_di_msCFFUIzdjU_zyMabSsbz8V9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Purchases of plant and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">17,552</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">63,926</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">748,706</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eifrs-full--PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_i01N_pp0p0_di_msCFFUIzdjU_zEKZZ1cHg2Rb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Purchases of intangible assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">32,868</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--InterestReceivedClassifiedAsInvestingActivities_i01_pp0p0_maCFFUIzdjU_z44PSLEtWxYd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Interest received</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">191,803</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">36,256</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PaymentForPurchaseOfBusinessNetOfCashAcquired_i01N_pp0p0_di_msCFFUIzdjU_zTRGZI5HseD5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Payment for purchase of business, net of cash acquired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:PaymentForPurchaseOfBusinessNetOfCashAcquired" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">486,188</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:PaymentForPurchaseOfBusinessNetOfCashAcquired" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">3,400,625</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CashFlowsFromUsedInInvestingActivities_i01T_pp0p0_mtCFFUIzdjU_maIDICAz6zM_zUvM43xVemqj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash flows (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">311,937</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">3,461,163</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">748,706</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--CashFlowsFromUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Cash flows from/(used in) financing activities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--ProceedsFromIssuingShares_i01_pp0p0_maCFFUIzbb2_zMCQquDSN25i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Proceeds from the issue of shares</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">7,172,399</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">15,897,629</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--PaymentsForShareIssueCosts_i01N_pp0p0_di_msCFFUIzbb2_zZpVkavwDAVg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Equity transaction costs</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">916,060</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">10,474</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,956,691</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eifrs-full--PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_i01N_pp0p0_di_msCFFUIzbb2_zYSMmhmB1ZYh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Principal elements of lease payments</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">336,396</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">268,590</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">236,893</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eifrs-full--InterestPaidClassifiedAsFinancingActivities_i01N_pp0p0_di_msCFFUIzbb2_zEKAhokqqQ4k" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Interest paid</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">14,049</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eifrs-full--CashFlowsFromUsedInFinancingActivities_i01T_pp0p0_mtCFFUIzbb2_maIDICAz6zM_zjqU6gDF5Ac7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash flows from/(used in) financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">5,919,943</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">279,064</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">13,689,996</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_iT_pp0p0_mtIDICAz6zM_z3u3TEuSKfQd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -10pt; font-weight: bold; text-align: left">Net (decrease)/ increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">4,115,089</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">9,399,683</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">6,645,361</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--CashAndCashEquivalents_iS_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Cash and cash equivalents at beginning of year</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,731,325</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">20,902,282</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">14,214,160</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--EffectOfExchangeRateChangesOnCashAndCashEquivalents_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Net foreign exchange difference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">234,961</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">228,726</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">42,761</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CashAndCashEquivalents_iE_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at end of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">7,851,197</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,731,325</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">20,902,282</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above consolidated statements of cash flows should be read in conjunction with the accompanying notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="SJ_005"></span>CONSOLIDATED
STATEMENT OF CHANGES IN EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the year ended June 30, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
Australian dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_114_zTuB820fDhV6" summary="xdx: Statement - Consolidated Statement of Changes in Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BB_ifrs-full--ComponentsOfEquityAxis_ifrs-full--IssuedCapitalMember_zUhANwqVtzY8" style="text-align: center; font-weight: bold">Contributed equity</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BF_ifrs-full--ComponentsOfEquityAxis_ifrs-full--OtherReservesMember_z0pc24RwFDLc" style="font-weight: bold; text-align: center">Reserves</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BD_ifrs-full--ComponentsOfEquityAxis_ifrs-full--RetainedEarningsMember_zpCvQtl3HSOh" style="text-align: center; font-weight: bold">Accumulat- ed losses</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BE_zClBAx2SsBbe" style="font-weight: bold; text-align: center">Total equity</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_432_c20200701__20210630_eifrs-full--Equity_iS_zLzqg9EHxFoh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; width: 44%; font-weight: bold; padding-bottom: 1.5pt">Balance at June 30, 2020</td><td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">140,111,073</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">9,928,571</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">136,047,037</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">13,992,607</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--ProfitLoss_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-07-012021-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">7,077,619</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">7,077,619</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eifrs-full--OtherComprehensiveIncome_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2020-07-012021-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">37,468</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">37,468</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eifrs-full--ComprehensiveIncome_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total comprehensive loss</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2020-07-012021-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">37,468</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2020-07-012021-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">7,077,619</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">7,115,087</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_iB_zqrUjxoaZm37" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Transactions with owners in their capacity as owners</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--IssueOfEquity_i01_zDfhknvblm5j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Contributions of equity, net of transaction costs and tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2020-07-012021-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">11,764,379</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">11,764,379</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ExerciseOfOptionsWarrants_i01_z5hNOmSaOCe4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercise of options/warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:ExerciseOfOptionsWarrants" contextRef="From2020-07-012021-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,699,522</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:ExerciseOfOptionsWarrants" contextRef="From2020-07-012021-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">973,467</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:ExerciseOfOptionsWarrants" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">726,055</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--IssueOfPerformanceRights_i01_zgLgpulNGJp2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issue of performance rights</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:IssueOfPerformanceRights" contextRef="From2020-07-012021-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">622,725</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:IssueOfPerformanceRights" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">622,725</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--OptionsWarrantsExpired_i01_zspThPOhxfsi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Options expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:OptionsWarrantsExpired" contextRef="From2020-07-012021-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">49,438</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:OptionsWarrantsExpired" contextRef="From2020-07-012021-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">49,438</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ValuationOfWarrants_i01_zzbIRlvt3G85" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Valuation of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ExerciseOfPerformanceRights_i01_zBF4xD9Q7gze" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Exercise of performance rights</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--IssueOfOptionsWarrants_i01_zjBuWz4Wse23" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Issue of options/warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:IssueOfOptionsWarrants" contextRef="From2020-07-012021-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,542,356</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:IssueOfOptionsWarrants" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,542,356</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--IncreaseDecreaseThroughTransactionsWithOwners_i01_zcmSVIjTgwna" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with owners in their capacity as owners</span> </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="From2020-07-012021-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">13,463,901</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="From2020-07-012021-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,142,176</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="From2020-07-012021-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">49,438</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">14,655,515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20210701__20220630_eifrs-full--Equity_iS_zK5uHczkE4Va" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; padding-bottom: 1.5pt">Balance at June 30, 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">153,574,974</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">11,033,279</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">143,075,218</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">21,533,035</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--ProfitLoss_zyxypsXa6Wbf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-07-012022-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">7,130,998</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">7,130,998</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eifrs-full--OtherComprehensiveIncome_zOalpqk3vhwh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0426">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2021-07-012022-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">27,864</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">27,864</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--ComprehensiveIncome_zUFqsuycJFB9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total comprehensive loss</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-07-012022-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">27,864</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-07-012022-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">7,130,998</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">7,103,134</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_iB_zUcG37nWjCz9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Transactions with owners in their capacity as owners</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--IssueOfEquity_i01_z1CmwEcVSSrj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Contributions of equity, net of transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2021-07-012022-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,563,662</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0442">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,563,662</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--IssueOfPerformanceRights_i01_zK7Wdgw8r5Pc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Issue of performance rights</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:IssueOfPerformanceRights" contextRef="From2021-07-012022-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">437,508</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:IssueOfPerformanceRights" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">437,508</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--IncreaseDecreaseThroughTransactionsWithOwners_i01_zKUgZhLqz7Ee" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with owners in their capacity as owners</span> </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="From2021-07-012022-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,563,662</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="From2021-07-012022-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">437,508</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,001,170</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20220701__20230630_eifrs-full--Equity_iS_zBrxWrJfs9t6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; padding-bottom: 1.5pt">Balance at June 30, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">155,138,636</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">11,498,651</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">150,206,216</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">16,431,071</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20220701__20230630_eifrs-full--Equity_iS_z0QiDkLmqpo5" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; padding-bottom: 1.5pt">Balance</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">155,138,636</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">11,498,651</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">150,206,216</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">16,431,071</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--ProfitLoss_zdPPlgMweX49" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2022-07-012023-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">11,750,923</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">11,750,923</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eifrs-full--OtherComprehensiveIncome_zwtz6teXDdJ6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2022-07-012023-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">100,589</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0473">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">100,589</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--ComprehensiveIncome_zk5uXSOicqQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total comprehensive loss</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0476">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2022-07-012023-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">100,589</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2022-07-012023-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">11,750,923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">11,650,334</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--TransactionsWithOwnersInTheirCapacityAsOwnersAbstract_iB_zwiWCqqguN5d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Transactions with owners in their capacity as owners</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--IssueOfEquity_i01_zTeS06O7hVuh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Contributions of equity, net of transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2022-07-012023-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,256,339</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0487">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0488">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,256,339</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ValuationOfWarrants_i01_z4OzCtKnCGRe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Valuation of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:ValuationOfWarrants" contextRef="From2022-07-012023-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">134,956</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:ValuationOfWarrants" contextRef="From2022-07-012023-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">134,956</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0494">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ExerciseOfPerformanceRights_i01_zW9JR4DBO0we" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercise of performance rights</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:ExerciseOfPerformanceRights" contextRef="From2022-07-012023-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">82,688</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:ExerciseOfPerformanceRights" contextRef="From2022-07-012023-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">82,688</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0498">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0499">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--OptionsWarrantsExpired_i01_z1UcfYHDfNbc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Options/warrants expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0501">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:OptionsWarrantsExpired" contextRef="From2022-07-012023-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">5,241,452</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:OptionsWarrantsExpired" contextRef="From2022-07-012023-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">5,241,452</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0504">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--IssueOfPerformanceRights_i01_z2gASmlo84el" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Issue of performance rights</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0506">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:IssueOfPerformanceRights" contextRef="From2022-07-012023-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">125,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0508">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:IssueOfPerformanceRights" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">125,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--IncreaseDecreaseThroughTransactionsWithOwners_i01_zFjUgdofc6Ak" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with owners in their capacity as owners</span> </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="From2022-07-012023-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,204,071</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="From2022-07-012023-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">5,063,684</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="From2022-07-012023-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">5,241,452</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,381,839</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_431_c20220701__20230630_eifrs-full--Equity_iE_z5bbXDxpa3uk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; padding-bottom: 1.5pt">Balance at June 30, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">161,342,707</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,535,556</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">156,715,687</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">11,162,576</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20220701__20230630_eifrs-full--Equity_iE_z1FeAGrn82K2" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; padding-bottom: 1.5pt">Balance</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">161,342,707</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,535,556</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">156,715,687</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">11,162,576</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above consolidated statements of changes in equity should be read in conjunction with the accompanying notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="SJ_006"></span>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the year ended June 30, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfCorporateInformationTextBlock"><p id="xdx_809_ecustom--DisclosureOfCorporateInformationTextBlock_zBNKT7m1FGwf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_828_zSA3dBV1cV2b">CORPORATE INFORMATION</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genetic
Technologies Limited (the &#8220;Company&#8221;) is a molecular diagnostics company that offers predictive genetic testing and risk assessment
tools. These consolidated financial statements comprise the Company and its subsidiaries (together referred to as the &#8220;Group&#8221;).
The Financial Report of the Company for the year ended June 30, 2023 was authorized for issue in accordance with a resolution
of the Directors dated on August 30, 2023. Genetic Technologies Limited is incorporated in Australia and is a company limited by shares.
The Directors have the power to amend and reissue the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Ordinary Shares are publicly traded on the Australian Securities Exchange under the symbol GTG and, via Level II American
Depositary Receipts, on the NASDAQ Capital Market under the ticker GENE.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"><p id="xdx_80B_ecustom--DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_zLS9Ck13ZDVa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_829_zXS8OJfn2k02">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DescriptionOfAccountingPolicyForBasisOfPreparationPolicyTextBlock"><p id="xdx_84C_ecustom--DescriptionOfAccountingPolicyForBasisOfPreparationPolicyTextBlock_z9MWQXZ9TFxe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
<span id="xdx_862_zagh21G6a4Th">Basis of preparation</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)
Compliance with International Financial Reporting Standards as issued by the International Accounting Standards Board</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
general purpose financial statements of Genetic Technologies Limited and its subsidiaries have been prepared in accordance with International
Financial Reporting Standards (&#8220;IFRS&#8221;), as issued by the International Accounting Standards Board and Australian equivalent
International Financial Reporting Standards, as issued by the Australian Accounting Standards Board. Genetic Technologies Limited is
a for-profit entity for the purpose of preparing the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Historical cost convention</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements have been prepared under the historical cost convention except for financial assets and liabilities (including derivative
instruments) which are measured at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Critical accounting estimates</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements requires the use of certain critical accounting estimates. It also requires Management to exercise
its judgement in the process of applying the Company&#8217;s accounting policies. The areas involving a higher degree of judgement or
complexity, or areas where assumptions and estimates are critical to the financial statements, are disclosed in Note 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iv)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Going concern</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended June 30, 2023, the Company incurred a total comprehensive loss of A$<span id="xdx_902_eifrs-full--ComprehensiveIncome_iN_pp0p0_di_c20220701__20230630_zdYe4vZiiyQg"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">11,650,334</ix:nonFraction></span> (2022: A$<span id="xdx_905_eifrs-full--ComprehensiveIncome_iN_pp0p0_di_c20210701__20220630_zUT8C88DhN3j"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">7,103,134</ix:nonFraction></span>) and net cash outflow
from operations of A$<span id="xdx_902_eifrs-full--CashFlowsFromUsedInOperatingActivities_iN_pp0p0_di_c20220701__20230630_z8ZtZBj84Fz9"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">9,723,095</ix:nonFraction></span> (2022: A$<span id="xdx_90B_eifrs-full--CashFlowsFromUsedInOperatingActivities_iN_pp0p0_di_c20210701__20220630_znBxlfwLymMk"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">5,659,456</ix:nonFraction></span>). As at June 30, 2023, the Company held total cash and cash equivalents of A$<span id="xdx_90F_eifrs-full--CashAndCashEquivalents_iI_pp0p0_c20230630_zX3oDsp23vN9"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">7,851,197</ix:nonFraction></span>
and total net current assets of A$<span id="xdx_909_ecustom--CurrentAssetsNet_iI_pp0p0_c20230630_znNvH2qNXNv1"><ix:nonFraction name="GENE:CurrentAssetsNet" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">7,185,750</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company expects to continue to incur losses and cash outflows for the foreseeable future as it continues to invest resources in research
and development activities for geneType risk assessment tests and to invest in the commercialization activities for geneType,
EasyDNA and AffinityDNA, via marketing, sales and distribution channels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continuing viability of the company and its ability to continue as a going concern, and meet its debts and commitments as they fall due,
is dependent on the satisfactory completion of an equity raising forecast for the early part of the 2024 calendar year. The Company does
not currently have binding commitments from any party to subscribe for shares and any raise will be subject to maintaining active listing
on the NASDAQ exchange as well as compliance with the Group&#8217;s obligations under ASX Listing Rule 7.1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 17, 2023, the company received notification from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price
requirement of Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market, since the closing bid price for the
company&#8217;s American Depositary Shares (ADS) on the Nasdaq Capital Market was below US$1.00 for 34 consecutive trading days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Nasdaq Listing Rule 5810(c)(3)(A), the company has a period of 180 calendar days from the date of Notification to regain compliance with
the minimum bid requirement, during which time the ADS will continue to trade on the Nasdaq Capital Market. If at any time before January
15, 2024, the bid price of the ADS closes at or above US$1.00 per ADS for a minimum of 10 consecutive business days, the Company will
regain compliance with the Minimum Bid Requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
Basis of preparation (cont.)</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iv)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Going concern (cont.)</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the uncertainty surrounding the timing, quantum or the ability to raise additional equity, there is a material uncertainty that may
cast significant doubt on the Group&#8217;s ability to continue as a going concern and therefore, that it may be unable to realize
its assets and discharge its liabilities in the normal course of business. However, the Directors believe that the Company will be
successful in its equity raising endeavours, and has a strong track record in this regard, and accordingly, have prepared the financial
report on a going concern basis. As such no adjustments have been made to the financial statements relating to the recoverability and
classification of the asset carrying amounts or classification of liabilities that might be necessary should the Group not be able to
continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(v)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>New standards and interpretations</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has applied the following standards and amendments for the first time for its annual reporting period commencing 1 July 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -17.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Onerous
                                            Contracts &#8211; Cost of Fulfilling a Contract &#8211;</i>Amendments to IAS 37</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
                                            Improvements to IFRS Standards 2018&#8211;2020</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Property,
                                            Plant and Equipment: Proceeds before Intended Use &#8211;</i> Amendments to IAS 16</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reference
                                            to the Conceptual Framework &#8211;</i> Amendments to IFRS 3</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amendments listed above did not have any impact on the amounts recognized in prior periods and are not expected to significantly affect
the current or future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(vi)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>New standards and interpretations not yet adopted.</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no standards that are not yet effective and that would be expected to have a material impact on the Company in the current or future
reporting years and on foreseeable future transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DescriptionOfAccountingPolicyForPrinciplesOfConsolidationPolicyTextBlock"><p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForPrinciplesOfConsolidationPolicyTextBlock_zseMpHABZ8Nk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
<span id="xdx_862_z28qcuay89R">Principles of consolidation</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subsidiaries</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries
are all entities (including structured entities) over which the Company has control. The Company controls an entity when the Company
is exposed to, or has rights to, variable returns from its involvement with the Company and has the ability to affect those returns through
its power to direct the activities of the Company. Subsidiaries are fully consolidated from the date on which control is transferred
to the Company. They are deconsolidated from the date that control ceases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
acquisition method of accounting is used to account for business combinations by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intercompany
transactions, balances and unrealized gains on transactions between Group companies are eliminated. Unrealized losses are also eliminated
unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed
where necessary to ensure consistency with the policies adopted by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loss of control</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Group loses control over a subsidiary, it derecognizes the assets and liabilities of the subsidiary, and any related NCI and other
components of equity. Any resulting gain or loss is recognized in profit or loss. Any interest retained in the former subsidiary is measured
at fair value when control is lost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.) </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>2.</b> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" name="ifrs-full:DescriptionOfPrimaryReasonsForBusinessCombination"><p id="xdx_84E_eifrs-full--DescriptionOfPrimaryReasonsForBusinessCombination_zRm4wD77B5Ja" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)
<span id="xdx_86A_zFrKWo6YHtJ7">Business combination</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group accounts for business combinations using the acquisition method when the acquired set of activities and assets meets the
definition of a business and control is transferred to the Group (Note 2(b)(i)). In determining whether a particular set of
activities and assets is a business, the Group assesses whether the set of assets and activities acquired includes, at a minimum, an
input and substantive process and whether the acquired set has the ability to produce outputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has an option to apply a &#8216;concentration test&#8217; that permits a simplified assessment of whether an acquired set of activities
and assets is not a business. The optional concentration test is met if substantially all of the fair value of the gross assets acquired
is concentrated in a single identifiable asset or group of similar identifiable assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Any goodwill
that arises is tested annually for impairment (Note 2(k)). Any gain on a bargain purchase is recognized in profit or loss immediately.
Transaction costs are expensed as incurred, except if related to the issue of debt or equity securities (Note 2(u)).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consideration transferred does not include amounts related to the settlement of pre-existing relationships. Such amounts are generally
recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
contingent consideration is measured at fair value at the date of acquisition. If an obligation to pay contingent consideration that
meets the definition of a financial instrument is classified as equity, then it is not remeasured and settlement is accounted for within
equity. Otherwise, other contingent consideration is remeasured at fair value at each reporting date and subsequent changes in the fair
value of the contingent consideration are recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
share-based payment awards (replacement awards) are required to be exchanged for awards held by the acquiree&#8217;s employees (acquiree&#8217;s
awards), then all or a portion of the amount of the acquirer&#8217;s replacement awards is included in measuring the consideration transferred
in the business combination. This determination is based on the market-based measure of the replacement awards compared with the market-based
measure of the acquiree&#8217;s awards and the extent to which the replacement awards relate to pre-combination service.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -14.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory"><p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForSegmentReportingExplanatory_zKSHoDCFQsEj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)
<span id="xdx_86C_zWg0b5t0u8c3">Segment reporting</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The acquisition
of EasyDNA in the 2022 financial year changed how the Company reports segment information as compared to the prior year. Therefore, the
2021 financial year period presentation of segment information was recast to conform with the current segment reporting structure.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -13.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"><p id="xdx_84A_eifrs-full--DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_zJsfBymbcv7k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(e)
<span id="xdx_861_zvOkXMUXuEWf">Foreign currency translation</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Functional and presentation currency</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
included in the financial statements of each of the Company&#8217;s entities are measured using the currency of the primary economic
environment in which the company operates (&#8216;the functional currency&#8217;). The consolidated financial statements are presented
in Australian dollar ($), which is Genetic Technologies Limited&#8217;s functional and presentation currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transactions and balances</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign
exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities
denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
foreign exchange gains and losses are presented in the consolidated statement of profit or loss on a net basis, within other expenses
or other income, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-monetary
items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was
determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss.
For example, translation differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss
are recognized in profit or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities
classified as at fair value through other comprehensive income are recognized in other comprehensive income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)  </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>2.</b> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(e)
Foreign currency translation (cont.)</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Group companies</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results and financial position of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional
currency different from the presentation currency are translated into the presentation currency as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assets
    and liabilities for each consolidated statement of financial position presented are translated at the closing rate at the date of
    that consolidated statement of financial position;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">income
    and expenses for each consolidated statement of profit or loss and other comprehensive income are translated at average exchange
    rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in
    which case income and expenses are translated at the dates of the transactions); and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    resulting exchange differences are recognized in other comprehensive income.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
consolidation, exchange differences arising from the translation of any net investment in foreign entities, and of borrowings and other
financial instruments designated as hedges of such investments, are recognized in other comprehensive income. When a foreign operation
is sold or any borrowings forming part of the net investment are repaid, the associated exchange differences are reclassified to profit
or loss, as part of the gain or loss on sale.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue"><p id="xdx_844_eifrs-full--DescriptionOfAccountingPolicyForRecognitionOfRevenue_z3JTds9Yr2f7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(f)
<span id="xdx_86A_zuzTCyHtBYz2">Revenue recognition</span></b></span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
IFRS 15, revenue is recognized based on contract with customers when performance obligations were satisfied. The following recognition
criteria must also be met before revenue is recognized:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue from sale of goods - Genetic testing revenues</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Genetype</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from the provision of genetic and clinical risk testing for cancer and other serious diseases under the geneType brand are recognized
at a point time when the Company has provided the customer with their test results, the single performance obligation. Invoices are usually
payable within 30 days. Where consideration is received in advance of performance, it is initially recorded as contract liabilities and
then revenue is recognized as the performance obligations are satisfied. Revenue is recognized where consideration for collection
is probable and is above 50%. The geneType brand have more than 75% probability of being collected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>EasyDNA
and AffinityDNA</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from provision of genetic test direct to consumer under the EasyDNA and AffinityDNA brand is recognized at a point in time when the Company
has provided the customer with their test results, the single performance obligation. Where consideration is received in advance of performance,
it is initially recorded as contract liabilities and then revenue is recognized as the performance obligations are satisfied. Revenue
recognized under the EasyDNA and AffinityDNA brands are mainly upfront, hence, no issue in collectability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue from services - license fees</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from contracts with service providers is recognized when the contracted sales parameters are met, the single performance obligation.
Revenue is recognized over time based on the higher of actual sales incurred or minimum fees requirement on a quarterly basis. The Company
did not recognize or receive any license fee revenue in the current financial year. Fixed license fee revenue recognized in the prior
period have been fully impaired as it is unlikely that these amounts will be recovered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract liabilities</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these
amounts as deferred income in its consolidated statement of financial position. Similarly, if the Group satisfies a performance obligation
before it receives the consideration, the Group recognizes either a contract asset or a receivable in its consolidated statement
of financial position, depending on whether something other than the passage of time is required before the consideration is due.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DescriptionOfAccountingPolicyForOtherIncomeExplanatory"><p id="xdx_84A_ecustom--DescriptionOfAccountingPolicyForOtherIncomeExplanatory_zEpCphVovHya" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(g)
<span id="xdx_863_zV0dc5WtoM46">Other income</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research and development tax incentive income</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Australian government replaced the research and development tax concession with research and development (R&amp;D) tax incentive from
July 1, 2011. The R&amp;D tax incentive applies to expenditure incurred and the use of depreciating assets in an income year commencing
on or after July 1, 2011. A refundable tax offset is available to eligible companies with an annual aggregate turnover of less than A$<span id="xdx_901_ecustom--MaximumAnnualAggregateTurnoverToAvailRefundableTaxOffset_pn6n6_c20220701__20230630__ifrs-full--TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis__custom--AustralianGovernmentTaxIncentiveMember_za5ESMY68iZ4" title="Maximum annual aggregate turnover to avail refundable tax offset"><ix:nonFraction name="GENE:MaximumAnnualAggregateTurnoverToAvailRefundableTaxOffset" contextRef="From2022-07-012023-06-30_custom_AustralianGovernmentTaxIncentiveMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="AUD">20</ix:nonFraction></span>
million. A new legislation subsequently came into place, where for the first income year commencing on or after 1 July 2021, for companies
with an aggregated turnover below A$<span id="xdx_906_ecustom--MaximumAnnualAggregateTurnoverToAvailRefundableTaxOffset_pn6n6_c20220701__20230630__ifrs-full--TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis__custom--AustralianGovernmentTaxIncentiveMember_z8l1zrLraANh" title="Maximum annual aggregate turnover to avail refundable tax offset"><ix:nonFraction name="GENE:MaximumAnnualAggregateTurnoverToAvailRefundableTaxOffset" contextRef="From2022-07-012023-06-30_custom_AustralianGovernmentTaxIncentiveMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="AUD">20</ix:nonFraction></span> million, the refundable R&amp;D tax offset will be a premium of <span id="xdx_900_ecustom--MaximumAnnualAggregateTurnoverToAvailRefundableTaxOffsetPercentage_pid_dp_uPure_c20220701__20230630__ifrs-full--TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis__custom--AustralianGovernmentTaxIncentiveMember_zAYRZC0CKi7i" title="Maximum annual aggregate turnover to avail refundable tax offset percentage"><ix:nonFraction name="GENE:MaximumAnnualAggregateTurnoverToAvailRefundableTaxOffsetPercentage" contextRef="From2022-07-012023-06-30_custom_AustralianGovernmentTaxIncentiveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18.5</ix:nonFraction></span> percentage points above the
claimant&#8217;s company tax rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has assessed the Company&#8217;s activities and expenditure to determine which are likely to be eligible under the incentive scheme.
The Company accounts for the R&amp;D tax incentive as a government grant. The grant is recognized as other income over the period in
which the R&amp;D expense is recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Government Grants</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
from government grants is recognized in the consolidated statement of profit or loss and comprehensive income on a systematic basis
over the periods in which the Company recognizes as expense the related costs for which the grants are intended to compensate in accordance
with IAS 20 Accounting for Government Grants and Disclosure of Government Assistance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
receivable for reimbursable amounts that have not been collected is reflected in trade and other receivables on our consolidated statement
of financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"><p id="xdx_84E_eifrs-full--DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_zh0RQnUxUJs1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(h)
<span id="xdx_867_zIuDjtTet4R9">Finance income and finance costs</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s finance income and finance costs include interest income and interest expenses. Interest income or expense is recognized
using the effective interest method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory"><p id="xdx_84F_eifrs-full--DescriptionOfAccountingPolicyForIncomeTaxExplanatory_zR7dq99X9LCh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(i)
<span id="xdx_867_zo4MJO8ye9m2">Income tax</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax expense or credit for the period is the tax payable on the current period&#8217;s taxable income based on the applicable income
tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to
unused tax losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period
in the countries where the Company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates
positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes
provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities
and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise
from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset
or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable
profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period
and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets are recognized only if it is probable that future taxable amounts will be available to utilize those temporary differences
and losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.) </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -12.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory"><p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForLeasesExplanatory_zRDFsfgDSFjc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(j)
<span id="xdx_862_zQdA7RubHRBj">Leases</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
any new contracts entered into on or after July 1, 2019, the Group considers whether a contract is, or contains a lease. A lease is defined
as &#8216;a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange
for consideration&#8217;. To apply this definition the Company assesses whether the contract meets three key evaluations which are whether:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    contract contains an identified asset, which is either explicitly identified in the contract or implicitly specified by being identified
    at the time the asset is made available to the Group,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company has the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period
    of use, considering its rights within the defined scope of the contract,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company has the right to direct the use of the identified asset throughout the period of use. The Company assess whether it has the
    right to direct &#8216;how and for what purpose&#8217; the asset is used throughout the period of use.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
are recognized as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the
Group. Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the
lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The right-of-use
asset is depreciated over the shorter of the asset&#8217;s useful life and the lease term on a straight-line basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value
of the following lease payments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fixed
    payments (including in-substance fixed payments), less any lease incentives receivable,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amounts
    expected to be payable by the lessee under residual value guarantees,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments
    of penalties for terminating the lease, if the lease term reflects the lessee exercising that option.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lease payments are discounted using the interest rate implicit in the lease, if that rate can be determined, or the Group&#8217;s incremental
borrowing rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
assets are measured at cost comprising the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount of the initial measurement of lease liability,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    lease payments made at or before the commencement date, less any lease incentives received,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    initial direct costs, and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restoration
    costs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
associated with short-term leases and leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss.
Short-term leases are leases with a lease term of 12 months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Short-term
leases and leases of low-value assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has elected not to recognize right-of-use assets and lease liabilities for leases of low-value assets and short-term leases, including
IT equipment. The Group recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease
term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"><p id="xdx_844_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_zT8NEKqNtwi5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(k)
<span id="xdx_862_z2Z7KZouvhUl">Impairment of assets</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Non-financial
asset</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group assesses at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists, the
Group makes an estimate of the asset&#8217;s recoverable amount. An asset&#8217;s recoverable amount is the higher of its fair value
less costs of disposal or its value in use and is determined for an individual asset, unless the asset does not generate cash inflows
that are largely independent of those from other assets or group of assets and the asset&#8217;s value-in-use cannot be estimated to
be close to its fair value. In such cases, the asset is tested for impairment as part of the cash-generating unit to which it belongs.
Cash generating unit is the smallest group of assets that generates cash inflows from continuing use that are largely independent of
the cash inflows of other assets or CGUs. When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount,
the asset or cash-generating unit is considered impaired and is written down to its recoverable amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects
current market assessments of the time value of money and the risks specific to the asset. Impairment losses relating to operations are
recognized as a separate line in the statement of profit or loss unless the asset is carried at its revalued amount, in which case the
impairment loss is treated as a revaluation decrease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
assessment is made at each reporting date as to whether there is any indication that previously recognized impairment losses may no longer
exist or may have decreased. If such indication exists, the recoverable amount is estimated. A previously recognized impairment loss
is reversed only if there has been a change in the estimates used to determine the asset&#8217;s recoverable amount since the last impairment
loss was recognized. If so, the carrying amount of the asset is increased to its recoverable amount. The increased amount cannot exceed
the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior
years. Such reversal is recognized in profit or loss unless it reverses a decrement previously charged to equity, in which case the reversal
is treated as a revaluation increase. After such a reversal, the depreciation charge is adjusted in future periods to allocate the asset&#8217;s
revised carrying amount, less any residual value, on a systematic basis over its remaining useful life. An impairment loss in respect
of goodwill is not reversed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financial
asset</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group records the impairment losses for financial assets as lifetime expected credit losses. These are the expected shortfalls in contractual
cash flows, considering the potential for default at any point during the life of the financial instrument. In calculating, the Group
uses its historical experience, external indicators and forward-looking information to calculate the expected credit losses using a provision
matrix.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"><p id="xdx_84E_eifrs-full--DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_zIJsVX8fVYc3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(l)
<span id="xdx_864_zy8ILOzkBaze">Cash and cash equivalents</span></b></span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held
at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that
are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts.
Bank overdrafts are shown within borrowings in current liabilities in the consolidated statement of financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory"><p id="xdx_84C_eifrs-full--DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_z69Bg0olOdOh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(m)
<span id="xdx_86E_zVdcc5YChXbb">Trade and other receivables</span></b></span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
receivables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method, less
loss allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refer
Note 31 for details of management of interest rate, foreign exchange and liquidity risks applicable to trade and other payables for which,
due to their short-term nature, their carrying value approximates their fair value.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories"><p id="xdx_84C_eifrs-full--DescriptionOfAccountingPolicyForMeasuringInventories_zWO2nVa9X9li" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(n)
<span id="xdx_868_zUhta9pzEPyj">Inventories</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Raw materials and stores, work in progress and finished goods</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw
materials and stores, work in progress and finished goods are stated at the lower of cost and net realizable value. Cost comprises direct
materials, direct labor and an appropriate proportion of variable and fixed overhead expenditure, the latter being allocated on the basis
of normal operating capacity. Costs are assigned to individual items of inventory on the basis of weighted average costs. Costs of purchased
inventory are determined after deducting rebates and discounts. Net realizable value is the estimated selling price in the ordinary course
of business less the estimated costs of completion and the estimated costs necessary to make the sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.) </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"><p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_zni7cMBvHtrk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(o)
<span id="xdx_868_zCoOaHyvD4d1">Property, plant and equipment</span></b></span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment is stated at historical cost less accumulated depreciation. Historical cost includes expenditure that is directly
attributable to the acquisition of the items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
costs are included in the asset&#8217;s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that
future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying
amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged
to profit or loss during the reporting period in which they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is calculated using the straight-line method to allocate their cost or revalued amounts, net of their residual values, over their estimated
useful lives or, in the case of leasehold improvements and certain leased plant and equipment, the shorter lease term as follows:</span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationOfEstimatedUsefulLifeExplanatory"><p id="xdx_89D_ecustom--DisclosureOfDetailedInformationOfEstimatedUsefulLifeExplanatory_zrZR8nn53S94" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zh6LkgaEbli" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIFE</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plant
    and equipment</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--PropertyPlantAndEquipmentsMember__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zueIKqNkcMH3" title="Estimated useful life"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_PropertyPlantAndEquipmentsMember_ifrs-full_BottomOfRangeMember" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">3</ix:nonNumeric></span>
    - <span id="xdx_90A_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--PropertyPlantAndEquipmentsMember__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zZ9cphmM7Aal" title="Estimated useful life"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_PropertyPlantAndEquipmentsMember_ifrs-full_TopOfRangeMember" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">5</ix:nonNumeric></span> years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture,
    fittings and equipment</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--FixturesAndFittingsMember__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_z86P9eRfE3zd" title="Estimated useful life"><ix:nonNumeric contextRef="From2022-07-012023-06-30_ifrs-full_FixturesAndFittingsMember_ifrs-full_BottomOfRangeMember" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">3</ix:nonNumeric></span>
    - <span id="xdx_907_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--FixturesAndFittingsMember__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_z2xCwYjbVQIb" title="Estimated useful life"><ix:nonNumeric contextRef="From2022-07-012023-06-30_ifrs-full_FixturesAndFittingsMember_ifrs-full_TopOfRangeMember" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">5</ix:nonNumeric></span> years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--LeaseholdImprovementsMember__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zbGYIgXF3Hed" title="Estimated useful life"><ix:nonNumeric contextRef="From2022-07-012023-06-30_ifrs-full_LeaseholdImprovementsMember_ifrs-full_BottomOfRangeMember" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">1</ix:nonNumeric></span>
    - <span id="xdx_908_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--LeaseholdImprovementsMember__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zZauyZDcFyQ1" title="Estimated useful life"><ix:nonNumeric contextRef="From2022-07-012023-06-30_ifrs-full_LeaseholdImprovementsMember_ifrs-full_TopOfRangeMember" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">3</ix:nonNumeric></span> years (lease term)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leased
    plant and equipment</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LeasedPlantandEquipmentMember_zdTXPiIR2sm3" title="Estimated useful life"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_LeasedPlantandEquipmentMember" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">3</ix:nonNumeric></span>
    years (lease term)</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_zQhGdkVDn007" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assets&#8217; residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
asset&#8217;s carrying amount is written down immediately to its recoverable amount if the asset&#8217;s carrying amount is greater than
its estimated recoverable amount (Note 2(k)).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on disposals are determined by comparing proceeds with carrying amount. These are included in profit or loss. When revalued
assets are sold, it is Company policy to transfer any amounts included in other reserves in respect of those assets to retained earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"><p id="xdx_842_eifrs-full--DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_z8e1bTZbAiXh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(p)
<span id="xdx_86A_zPWaoSwUECRa">Intangible assets and goodwill</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Goodwill</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
arises on the acquisition of a business combination. Goodwill is calculated as the excess sum of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            consideration transferred;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            non-controlling interest; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            acquisition date fair value of any previously held equity interest; over the acquisition
                                            date fair value of net identifiable assets acquired.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is not amortized. Instead, goodwill is tested annually for impairment, or more frequently if events or changes in circumstances indicate
that it might be impaired, and is carried at cost less accumulated impairment losses. Impairment losses on goodwill are taken to profit
or loss and are not subsequently reversed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is allocated to the Group&#8217;s cash-generating units representing the lowest level at which goodwill is monitored.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Brand name and customer contracts</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brand,
trademark, trade names and domain names acquired in a business combination that qualify for separate recognition are recognized as intangible
assets at their fair values.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brand,
trademark, trade names and domain names are amortized on a straight-lined basis over their estimated useful lives of <span id="xdx_90F_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--BrandTradeMarkTradeNamesMember_znUBd8aOQnl8"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_BrandTradeMarkTradeNamesMember" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">5</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory"><p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_zrjMWlt08T7d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(q)
<span id="xdx_865_zPOTdjvkeYN1">Trade and other payables</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
payables and other payables are carried at amortized cost and represent liabilities for goods and services provided to the Company prior
to the end of the financial year that are unpaid and arise when the Company becomes obliged to make future payments in respect of the
purchase of these goods and services. Trade payables and other payables generally have terms of between 30 and 60 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.) </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>2.</b> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory"><p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForProvisionsExplanatory_zcedEFxWGS25" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(r)
<span id="xdx_868_zeZ5KGTCLT69">Provisions</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
for legal claims, service warranties and make good obligations are recognized when the Company has a present legal or constructive obligation
as a result of past events, it is probable that an outflow of resources will be required to settle the obligation and the amount can
be reliably estimated. Provisions are not recognized for future operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering
the class of obligations as a whole. A provision is recognized even if the likelihood of an outflow with respect to any one item included
in the same class of obligations may be small.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
are measured at the present value of management&#8217;s best estimate of the expenditure required to settle the present obligation at
the end of the reporting period. The discount rate used to determine the present value is a pre-tax rate that reflects current market
assessments of the time value of money and the risks specific to the liability. The increase in the provision due to the passage of time
is recognized as interest expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"><p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_zhPLfDbxtOQk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(s)
<span id="xdx_863_z706Vd6pbGla">Employee benefits</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Short-term obligations</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
for wages and salaries, including non-monetary benefits, annual leave and accumulating sick leave that are expected to be settled wholly
within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees&#8217;
services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled.
The liabilities are presented as current employee benefit obligations in the consolidated statement of financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other long-term employee benefit obligations</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some countries, the Company also has liabilities for long service leave and annual leave that are not expected to be settled wholly within
12 months after the end of the period in which the employees render the related service. These obligations are therefore measured as
the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting
period using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee
departures and periods of service. Expected future payments are discounted using market yields at the end of the reporting period of
high-quality corporate bonds with terms and currencies that match, as closely as possible, the estimated future cash outflows. Remeasurements
as a result of experience adjustments and changes in actuarial assumptions are recognized in general and administrative expenses in profit
or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
obligations are presented as current liabilities in the consolidated statement of financial position if the Company does not have an
unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement
is expected to occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"><p id="xdx_847_eifrs-full--DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_z3DGha4ZE3qc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(t)
<span id="xdx_865_zNsZbZVi7g4f">Fair value measurement</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is
based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal
market, in the most advantageous market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in
their economic best interests. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximizing the
use of relevant observable inputs and minimizing the use of unobservable inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities measured at fair value are classified into three levels, using a fair value hierarchy that reflects the significance
of the inputs used in making the measurements. Classifications are reviewed at each reporting date and transfers between levels are determined
based on a reassessment of the lowest level of input that is significant to the fair value measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.) </span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">2. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(t)
Fair value measurement</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value hierarchy levels 1 to 3 are based on the degree to which the fair value is observable:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for
    the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not
    based on observable market data (unobservable inputs).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
recurring and non-recurring fair value measurements, external valuers may be used when internal expertise is either not available or
when the valuation is deemed to be significant. External valuers are selected based on market knowledge and reputation. Where there is
a significant change in fair value of an asset or liability from one period to another, an analysis is undertaken, which includes a verification
of the major inputs applied in the latest valuation and a comparison, where applicable, with external sources of data.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DescriptionOfAccountingPolicyForContributedEquityPolicyTextBlock"><p id="xdx_84E_ecustom--DescriptionOfAccountingPolicyForContributedEquityPolicyTextBlock_zHazCyrxK76h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(u)
<span id="xdx_860_zVe9y9q77D3g">Contributed equity</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
and paid-up capital is recognized at the fair value of the consideration received by the Company. Transaction costs arising on the issue
of Ordinary Shares are recognized directly in equity as a deduction, net of tax, of the proceeds received. The Company has a share-based
payment option plan under which options to subscribe for the Company&#8217;s shares have been granted to certain executives and other
employees.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"><p id="xdx_844_eifrs-full--DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_zsNjHvp1QKf8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(v)
<span id="xdx_86F_znd94wnmpMU1">Loss per share</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basic loss per share</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is calculated by dividing:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    loss attributable to owners of the Company, excluding any costs of servicing equity other than ordinary shares,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares
    issued during the year and excluding treasury shares.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Diluted loss per share</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
loss per share adjusts the figures used in the determination of basic loss per share to take into account:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after
    income tax effect of interest and other financing costs associated with dilutive potential ordinary shares, and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential
    ordinary shares.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the basis of the Company&#8217;s losses, the outstanding options and performance rights as at June 30, 2023 are considered to be anti-
dilutive and therefore were excluded from the diluted weighted average number of ordinary shares calculation.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"><p id="xdx_844_eifrs-full--DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_z5ymdOKTMog" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(w)
<span id="xdx_865_z5GKlZOXLoxg">Goods and services tax (GST) and other sales taxes</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivables
and payables are stated inclusive of the amount of GST and other sales taxes receivable or payable. The net amount of GST and other taxes
recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated statement
of financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
flows are presented on a gross basis. The GST and other sales taxes components of cash flows arising from investing or financing activities
which are recoverable from, or payable to the taxation authority, are presented as operating cash flows.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -14.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DescriptionOfAccountingPolicyForParentEntityFinancialInformationPolicyTextBlock"><p id="xdx_843_ecustom--DescriptionOfAccountingPolicyForParentEntityFinancialInformationPolicyTextBlock_znt9Z5ZSwkli" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(x)
<span id="xdx_86B_z4MB4pSJDWak">Parent entity financial information</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial information for the parent entity, Genetic Technologies Limited, disclosed in Note 33 has been prepared on the same basis as
the consolidated financial statements. Loans to subsidiaries are written down to their recoverable value as at balance date.</span></p>

</ix:nonNumeric><p id="xdx_852_z6AeZSP07lT7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory"><p id="xdx_80F_eifrs-full--DisclosureOfAccountingJudgementsAndEstimatesExplanatory_z1wHNhujXg0g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_826_zZIZ8LXpLkX3">CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates
and judgements are evaluated and based on historical experience and other factors, including expectations of future events that may have
a financial impact on the Company and that are believed to be reasonable under the circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Share-based
payments transactions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has determined that the fair value of the equity instruments is a critical judgement. The Company measures the cost of equity-settled
transactions with employees and service providers by reference to the value of the equity instruments at the date on which they are granted.
Management has determined the fair value by engaging an independent valuer for more complex equity instruments, such as warrants and
performance rights, by using a Black-Scholes or Binomial model, and utilized internal resources to perform fair value by straight forward
equity instruments by using Black-Scholes model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Goodwill</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group tests annually, or more frequently if events or changes in circumstances indicate impairment, whether goodwill and other indefinite
life intangible assets have suffered any impairment, in accordance with the accounting policy stated in Note 2(k). The value-in-use calculation
used in assessing potential impairment of goodwill incorporates a number of key estimates and assumptions which is a critical judgement.
CGUs are identified by determining the smallest identifiable group of assets that generate largely independent cash inflows from other
assets or groups of assets. Identifying those largely independent cash inflows requires significant judgement in assessing the Group&#8217;s
sources of revenue and how assets are utilized in generating those revenues. Goodwill is required to be allocated to the CGUs or groups
of CGUs that are expected to benefit from the synergies of the combination acquired where goodwill cannot be allocated to individual
CGUs on a reasonable and consistent basis. Significant judgement is required to assess which CGUs or groups of CGUs benefit from the
synergies and thus determine how the goodwill is allocated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
of non-financial assets other than goodwill and other indefinite life intangible assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group assesses impairment of non-financial assets other than goodwill and other indefinite life intangible assets at each reporting date
by evaluation conditions specific to the Group and to the particular asset that may lead to impairment. If an impairment trigger exists,
the recoverable amount of the asset is determined. This involves fair value less costs of disposal or value-in-use calculation which
incorporate a number of key estimates and assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
combination and the contingent consideration</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
combination are initially accounted for on a provisional basis. The fair value of assets acquired and liabilities assumed are initially
estimated by the Group taking into consideration all available information at the reporting date. Fair value adjustments on the finalization
of the business combination accounting is retrospective, where applicable, to the period the combination occurred and may have an
impact on the assets and liabilities, depreciation and amortization reported.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the AffinityDNA acquisition, a second payment of A$<span id="xdx_900_ecustom--PaymentForPurchaseOfBusinessNetOfCashAcquired_c20220701__20230630_ze8oQAxOHxPk" title="Payment for purchase of cash acquired"><ix:nonFraction name="GENE:PaymentForPurchaseOfBusinessNetOfCashAcquired" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">486,188</ix:nonFraction></span> (&#163;<span id="xdx_903_ecustom--PaymentForPurchaseOfBusinessNetOfCashAcquired_uEUR_c20220701__20230630_zjsPYabQu3H" title="Payment for purchase of cash acquired"><ix:nonFraction name="GENE:PaymentForPurchaseOfBusinessNetOfCashAcquired" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">277,500</ix:nonFraction></span>) would be due to the prior owners of the business if a pre-determined
gross profit target for the 12-month period from the acquisition date is achieved. Management used judgement by not including the second
payment in the calculation of fair value of consideration transferred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfRevenueExplanatory"><p id="xdx_800_eifrs-full--DisclosureOfRevenueExplanatory_zzabUGwAHdch" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_827_zirPfGqA71e3">REVENUE AND DEFERRED INCOME</span></span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4A.
REVENUE </b></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory"><p id="xdx_899_eifrs-full--DisclosureOfRevenueFromContractsWithCustomersExplanatory_zFM6xd5Lqxn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zm0FCetoreMb" style="display: none">SUMMARY
OF REVENUE</span></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; padding-left: 10pt">Sales of EasyDNA branded test - point in time</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--Revenue_pp0p0_c20220701__20230630__ifrs-full--ProductsAndServicesAxis__custom--EasyDNABrandedTestsMember__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_zcJYvcPbOvc6" title="Revenue" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_EasyDNABrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">7,698,605</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--Revenue_pp0p0_c20210701__20220630__ifrs-full--ProductsAndServicesAxis__custom--EasyDNABrandedTestsMember__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_zqQ7icseKJg5" title="Revenue" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_EasyDNABrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">5,989,782</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--Revenue_pp0p0_c20200701__20210630__ifrs-full--ProductsAndServicesAxis__custom--EasyDNABrandedTestsMember__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_za2NdwpjMsb5" title="Revenue" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0621">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Sales of AffinityDNA branded test - point in time</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--Revenue_pp0p0_c20220701__20230630__ifrs-full--ProductsAndServicesAxis__custom--AffinityDNABrandedTestsMember__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_zEfmjpsDtuVi" title="Revenue" style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_AffinityDNABrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">944,058</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--Revenue_pp0p0_c20210701__20220630__ifrs-full--ProductsAndServicesAxis__custom--AffinityDNABrandedTestsMember__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_zPGB06yfLoyk" title="Revenue" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--Revenue_pp0p0_c20200701__20210630__ifrs-full--ProductsAndServicesAxis__custom--AffinityDNABrandedTestsMember__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_z3rC9dBXgzDb" title="Revenue" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0627">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Sales of geneType branded test - point in time</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--Revenue_pp0p0_c20220701__20230630__ifrs-full--ProductsAndServicesAxis__custom--GeneTypeBrandedTestsMember__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_zaoLKHjW3B51" title="Revenue" style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_GeneTypeBrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">43,455</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--Revenue_pp0p0_c20210701__20220630__ifrs-full--ProductsAndServicesAxis__custom--GeneTypeBrandedTestsMember__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_zawVcQR3y7Ak" title="Revenue" style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_GeneTypeBrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">7,551</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--Revenue_pp0p0_c20200701__20210630__ifrs-full--ProductsAndServicesAxis__custom--GeneTypeBrandedTestsMember__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_zzfu8198MCrb" title="Revenue" style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_GeneTypeBrandedTestsMember_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">25,347</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">License fees - over time</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--Revenue_pp0p0_c20220701__20230630__ifrs-full--ProductsAndServicesAxis__custom--LicenseFeesMember__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredOverTimeMember_zIjA9MCQM4ae" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0634">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--Revenue_pp0p0_c20210701__20220630__ifrs-full--ProductsAndServicesAxis__custom--LicenseFeesMember__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredOverTimeMember_zEeoM1xt2Ajh" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_LicenseFeesMember_ifrs-full_GoodsOrServicesTransferredOverTimeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">797,483</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--Revenue_pp0p0_c20200701__20210630__ifrs-full--ProductsAndServicesAxis__custom--LicenseFeesMember__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredOverTimeMember_zfgY6cwRwCV8" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_LicenseFeesMember_ifrs-full_GoodsOrServicesTransferredOverTimeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">95,207</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total revenue from contract with customers</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--Revenue_pp0p0_c20220701__20230630_zCDemza7vb2a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">8,686,118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--Revenue_pp0p0_c20210701__20220630_zWZw5RU6Pvo8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">6,794,816</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--Revenue_pp0p0_c20200701__20210630_zQ6edCJ3BxJ9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">120,554</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AA_zYIx3C2gnhu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4B.
DISAGGREGATION OF REVENUE FROM CONTRACTS WITH CUSTOMERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfGeographicalAreasExplanatory"><p id="xdx_89B_eifrs-full--DisclosureOfGeographicalAreasExplanatory_zb5ujNhVhMn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s revenue disaggregated by primary geographical markets is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zEdAhD2BFu5e" style="display: none">SCHEDULE
OF DISAGGREGATED BY GEOGRAPHICAL MARKETS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 46%; text-align: left">America and Canada</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--Revenue_c20220701__20230630__ifrs-full--GeographicalAreasAxis__custom--AmericaAndCanadaMember_zTnf4JYbCBq8" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_AmericaAndCanadaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,242,169</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--Revenue_c20210701__20220630__ifrs-full--GeographicalAreasAxis__custom--AmericaAndCanadaMember_zDfLa6cuO1r7" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_AmericaAndCanadaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,274,551</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--Revenue_c20200701__20210630__ifrs-full--GeographicalAreasAxis__custom--AmericaAndCanadaMember_z1IwVtfAKdX4" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_AmericaAndCanadaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">120,554</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Europe Middle East and Africa</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--Revenue_c20220701__20230630__ifrs-full--GeographicalAreasAxis__custom--EuropeMiddleEastAndAfricaMember_zgOL4jfr3ODi" style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_EuropeMiddleEastAndAfricaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,494,626</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--Revenue_c20210701__20220630__ifrs-full--GeographicalAreasAxis__custom--EuropeMiddleEastAndAfricaMember_z2C1KHsuDPg7" style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_EuropeMiddleEastAndAfricaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,501,302</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--Revenue_c20200701__20210630__ifrs-full--GeographicalAreasAxis__custom--EuropeMiddleEastAndAfricaMember_zJIKXOc5OOw9" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Latin America</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--Revenue_c20220701__20230630__ifrs-full--GeographicalAreasAxis__custom--LatinAmericasMember_zhCmM21jG1d2" style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_LatinAmericasMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">322,033</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--Revenue_c20210701__20220630__ifrs-full--GeographicalAreasAxis__custom--LatinAmericasMember_zaHislF3iDhe" style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_LatinAmericasMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">128,840</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--Revenue_c20200701__20210630__ifrs-full--GeographicalAreasAxis__custom--LatinAmericasMember_zF80azJbrgQ5" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Asia Pacific</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--Revenue_c20220701__20230630__ifrs-full--GeographicalAreasAxis__custom--AsiaPacificsMember_zOY2feJMqwCa" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_AsiaPacificsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,627,290</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--Revenue_c20210701__20220630__ifrs-full--GeographicalAreasAxis__custom--AsiaPacificsMember_z3VZqXBYpx07" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_AsiaPacificsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,890,123</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--Revenue_c20200701__20210630__ifrs-full--GeographicalAreasAxis__custom--AsiaPacificsMember_zhv1gsAbPV6b" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0653">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total revenue</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--Revenue_c20220701__20230630_zMIBHKHguSDg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">8,686,118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--Revenue_c20210701__20220630_zmjRT1mzq1p6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,794,816</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--Revenue_c20200701__20210630_zbPpVk7RWhb2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">120,554</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zQLQoIXRwwRd" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4C.
CONTRACT BALANCES</span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfContractBalancesExplanatory"><p id="xdx_893_ecustom--DisclosureOfContractBalancesExplanatory_zWJuFFl1ot6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B3_zcA33PNfhDHe" style="display: none">SCHEDULE
OF CONTRACT BALANCES</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230630_zT0ZqdTvAzE8" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220630_zsa1AyN3BeH3" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--TradeReceivables_iI_zEVDqnosjpM3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Receivables, which are included in &#8216;net trade receivables&#8217;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: center">12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,049,393</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">390,587</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CurrentContractLiabilities_iI_zPVeQllyFLwi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Contract liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CurrentContractLiabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">849,212</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CurrentContractLiabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">814,150</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 470.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8AC_zXoeCyZjPoZh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
liabilities arises from revenue for all business units, which is the consideration received in respect of unsatisfied performance obligation.
There are <span id="xdx_90A_eifrs-full--ContractAssets_iI_do_c20230630_zLw40sObGxd4"><ix:nonFraction name="ifrs-full:ContractAssets" contextRef="AsOf2023-06-30" format="ixt-sec:numwordsen" decimals="0" unitRef="AUD">no</ix:nonFraction></span> contract assets as at 30 June 2023 (2022:<span id="xdx_908_eifrs-full--ContractAssets_iI_dxL_c20220630_zxImpR6oAOy9" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0666"> Nil</span></span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of A$<span id="xdx_90B_eifrs-full--CurrentContractLiabilities_iI_c20220630_zNws20ga8U99"><ix:nonFraction name="ifrs-full:CurrentContractLiabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">814,150</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">included
in deferred income (contract liabilities) at 30 June 2022 has been recognized as revenue in 2023 (2022: <span id="xdx_90F_eifrs-full--RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_dxL_c20210701__20220630_zW2oKFWpmXI2" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0668">Nil</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
revenue was recognized in 2023 from performance obligations satisfied (or partially satisfied) in previous periods (2022: <span id="xdx_90B_ecustom--PerformanceObligations_iI_dxL_c20220630_z1GAYpYU1Dh7" title="Performance obligations::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0670">Nil</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
2021: <span id="xdx_90D_ecustom--PerformanceObligations_iI_dxL_c20210630_zmen6TwKurD2" title="Performance obligations::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0672">Nil</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory"><p id="xdx_807_eifrs-full--DisclosureOfOtherOperatingIncomeExplanatory_zZBNq3NyKqha" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_827_zsjKP8vz9MU">OTHER INCOME</span></b></span></p>



<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfOtherIncomeExplanatory"><p id="xdx_890_ecustom--DisclosureOfOtherIncomeExplanatory_z2gm26vePDBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zOfuCOEOarl" style="display: none">SCHEDULE
OF OTHER INCOME</span></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220701__20230630_zrfVIDNhs8Wk" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210701__20220630_zZM9vpBLS273" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20200701__20210630_zbwMucmY14r" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--TaxIncentiveIncomeOnResearchAndDevelopment_maOIzhsm_z4bXfHvCofld" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development tax incentive income <i id="xdx_F4C_z37hHF6BYlTb">(1)</i></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="GENE:TaxIncentiveIncomeOnResearchAndDevelopment" contextRef="From2022-07-01to2023-06-30" id="Fact000678" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,616,064</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="GENE:TaxIncentiveIncomeOnResearchAndDevelopment" contextRef="From2021-07-012022-06-30" id="Fact000679" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,397,552</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="GENE:TaxIncentiveIncomeOnResearchAndDevelopment" contextRef="From2020-07-012021-06-30" id="Fact000680" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">997,908</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ExportMarketingAndDevelopmentGrant_maOIzhsm_zTSk1QM2dOVg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Export Marketing &amp; Development Grant</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0682">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0683">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:ExportMarketingAndDevelopmentGrant" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OtherNonOperatingIncomeAndExpenditure_maOIzhsm_zkozH57cog3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:OtherNonOperatingIncomeAndExpenditure" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">45,724</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:OtherNonOperatingIncomeAndExpenditure" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">25,955</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:OtherNonOperatingIncomeAndExpenditure" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">116,271</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--RevenueFromGovernmentGrants_maOIzhsm_zHioQhaoPi67" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government grant income &#8211; COVID-19 relief <i id="xdx_F4E_zIM95Ffn9857">(2)</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0691">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:RevenueFromGovernmentGrants" contextRef="From2020-07-012021-06-30" id="Fact000692" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">287,883</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--NetUnrealisedForeignExchangeGain_maOIzhsm_zFCliNTFvZr7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net unrealized foreign exchange gain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:NetUnrealisedForeignExchangeGain" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">152,963</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:NetUnrealisedForeignExchangeGain" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">244,762</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--NetRealisedForeignExchangeGain_maOIzhsm_zUTmGnYX6Au5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net realized foreign exchange gain</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:NetRealisedForeignExchangeGain" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">22,071</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:NetRealisedForeignExchangeGain" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">115,122</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:NetRealisedForeignExchangeGain" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">57,899</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--OtherIncome_iT_pp0p0_mtOIzhsm_zPvYYSQzKQ17" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other income</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,836,822</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,783,391</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,559,961</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zApuYhQPJ1Jk" style="margin-top: 0; margin-bottom: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER INCOME</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F07_zDmLhIjqgJvi">(1)</i></span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F16_zWLRtdWV95we"><ix:footnote id="Footnote000705" xml:lang="en-US">R&amp;D tax incentive</ix:footnote></i></span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s research and development activities are eligible under an Australian government tax incentive for eligible expenditure.
Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts
are recognized when it has been established that the conditions of the tax incentive have been met and that the expected amount can be
reliably measured. For the year ended June 30, 2023, the Company has included an item in other income of A$<span id="xdx_90A_ecustom--TaxIncentiveIncomeOnResearchAndDevelopment_c20220701__20230630_znDUnjd2Mvx6" title="Research and development tax incentive income" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9USEVSIElOQ09NRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="GENE:TaxIncentiveIncomeOnResearchAndDevelopment" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,616,064</ix:nonFraction></span>, (2022: A$<span id="xdx_905_ecustom--TaxIncentiveIncomeOnResearchAndDevelopment_c20210701__20220630_zDWm7DSxNnH" title="Research and development tax incentive income" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9USEVSIElOQ09NRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="GENE:TaxIncentiveIncomeOnResearchAndDevelopment" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,397,552</ix:nonFraction></span>,
2021: A$<span id="xdx_901_ecustom--TaxIncentiveIncomeOnResearchAndDevelopment_c20200701__20210630_zYEm9RhBM84f" title="Research and development tax incentive income" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9USEVSIElOQ09NRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="GENE:TaxIncentiveIncomeOnResearchAndDevelopment" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">997,908</ix:nonFraction></span>) to recognize income over the period necessary to match the grant on a systematic basis with the costs that they are
intended to compensate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 5, 2019, the Treasury Laws Amendment (R&amp;D Tax Incentive Bill 2019) was introduced into Parliament. The draft bill contains
proposed amendments to the R&amp;D tax incentive regulations. Under the proposed amendments, the refundable tax offset rate for companies
with an aggregated turnover of less than A$<span id="xdx_905_ecustom--MaximumAnnualAggregateTurnoverToAvailRefundableTaxOffset_pn6n6_c20191204__20191205__ifrs-full--TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis__custom--AustralianGovernmentTaxIncentiveMember_z4MIHfMUzMQh" title="Maximum annual aggregate turnover to avail refundable tax offset" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9USEVSIElOQ09NRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="GENE:MaximumAnnualAggregateTurnoverToAvailRefundableTaxOffset" contextRef="From2019-12-042019-12-05_custom_AustralianGovernmentTaxIncentiveMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="AUD">20</ix:nonFraction></span> million would become <span id="xdx_908_ecustom--MaximumAnnualAggregateTurnoverToAvailRefundableTaxOffsetPercentage_pid_dp_uPure_c20191204__20191205__ifrs-full--TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis__custom--AustralianGovernmentTaxIncentiveMember_zLTUjkTnllRd" title="Maximum annual aggregate turnover to avail refundable tax offset percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9USEVSIElOQ09NRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="GENE:MaximumAnnualAggregateTurnoverToAvailRefundableTaxOffsetPercentage" contextRef="From2019-12-042019-12-05_custom_AustralianGovernmentTaxIncentiveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">41</ix:nonFraction></span>%. In lieu of that bill, the below legislation came into place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the 2022 financial year new legislation came into place, where for the first income year commencing on or after 1 July 2021, for companies
with an aggregated turnover below A$<span id="xdx_90C_ecustom--MaximumAnnualAggregateTurnoverToAvailRefundableTaxOffset_pn6n6_c20210701__20220630__ifrs-full--TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis__custom--AustralianGovernmentTaxIncentiveMember_zNx3C20QDaNf" title="Maximum annual aggregate turnover to avail refundable tax offset" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9USEVSIElOQ09NRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="GENE:MaximumAnnualAggregateTurnoverToAvailRefundableTaxOffset" contextRef="From2021-07-012022-06-30_custom_AustralianGovernmentTaxIncentiveMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="AUD">20</ix:nonFraction></span> million, the refundable R&amp;D tax offset will be a premium of <span id="xdx_902_ecustom--MaximumAnnualAggregateTurnoverToAvailRefundableTaxOffsetPercentage_pid_dp_uPure_c20210701__20220630__ifrs-full--TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis__custom--AustralianGovernmentTaxIncentiveMember_zvBCcYdxLq3g" title="Maximum annual aggregate turnover to avail refundable tax offset percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9USEVSIElOQ09NRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="GENE:MaximumAnnualAggregateTurnoverToAvailRefundableTaxOffsetPercentage" contextRef="From2021-07-012022-06-30_custom_AustralianGovernmentTaxIncentiveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18.5</ix:nonFraction></span> percentage points above the
claimant&#8217;s company tax rate. The Company has therefore calculated the R&amp;D tax incentive for 2022 and 2023 by applying the legislation
brought into effect during the 2022 financial year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F01_zmR5foOw1WSi">(2)</i></span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F15_zqY9ToW98K6l"><ix:footnote id="Footnote000720" xml:lang="en-US">Government Grant income &#8211; COVID-19 Relief</ix:footnote></i></span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 relief relates to government assistance received during the year, from the Australian Government (at both federal and state
level) and the U.S. Small Business Administration, in response to the economic and financial challenges in the current economy.</span></p>

<p id="xdx_8A5_zFg5QOeQUQE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfEmployeeBenefitsExplanatory"><p id="xdx_808_eifrs-full--DisclosureOfEmployeeBenefitsExplanatory_zWWqYHOboSVf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_820_zbE5Z8eXLsFc">EMPLOYEE BENEFITS EXPENSE</span></b></span></p>



<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfEmployeeBenefitsExpenseExplanatory"><p id="xdx_899_ecustom--DisclosureOfEmployeeBenefitsExpenseExplanatory_zVxiDLGwzen4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zMgkkoTdDjSh" style="display: none">SCHEDULE
OF EMPLOYEE BENEFITS EXPENSE</span></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220701__20230630_zsaINePS9ik3" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210701__20220630_z28u6WwSh9d8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20200701__20210630_zsVGcQmuIPog" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--WagesAndSalaries_maEBEz0VP_z6dyiDNSiBaa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; padding-left: 10pt">Salaries and wages</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,938,516</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,490,186</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,480,336</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DirectorFees_maEBEz0VP_zmfsB8nePDPe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Director fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:DirectorFees" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">288,024</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:DirectorFees" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">288,024</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:DirectorFees" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">288,024</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SuperannuationContribution_maEBEz0VP_zFRAxwuqDGt6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Superannuation contribution</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:SuperannuationContribution" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">415,128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:SuperannuationContribution" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">347,018</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:SuperannuationContribution" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">203,242</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_maEBEz0VP_zdv92nYlG7W4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Share-based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">125,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">437,508</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">714,577</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--OtherEmployeeExpense_maEBEz0VP_ztd3Vm5XcUcg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other employee costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherEmployeeExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">440,898</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherEmployeeExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">305,919</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherEmployeeExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">182,152</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--EmployeeBenefitsExpense_iT_mtEBEz0VP_zbcOmQVwHu7d" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Total employee benefits expenses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,208,066</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">5,868,655</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">3,868,331</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 473.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8A7_zUev3X2HUh2j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> &#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory"><p id="xdx_80D_eifrs-full--DisclosureOfOtherOperatingExpenseExplanatory_zgBudfkz2Hy2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>7.</b> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_829_zcuytdrIHFxd">OTHER EXPENSES</span></b></span></p>



<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfOtherExpensesExplanatory"><p id="xdx_897_ecustom--DisclosureOfOtherExpensesExplanatory_zIYXAMlma2Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8BC_zBJgY0zwJga5" style="display: none">SCHEDULE OF OTHER EXPENSES</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 10pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220701__20230630_zLj13NP3QMLa" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20210701__20220630_zBIXnfHQGox6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20200701__20210630_zHqHCUGFnCwa" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_407_ecustom--BuildingsAndFacilitiesCosts_maOEBNzCkH_z6IGIQiIIir5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 46%; text-align: left">Buildings and facilities costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="GENE:BuildingsAndFacilitiesCosts" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">695,844</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="GENE:BuildingsAndFacilitiesCosts" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">748,580</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="GENE:BuildingsAndFacilitiesCosts" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">345,624</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--InsuranceExpense_maOEBNzCkH_zxzebpbFdc3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:InsuranceExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">403,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:InsuranceExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">345,450</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:InsuranceExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">302,722</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--InvestorRelationsAndShareholderMaintenance_maOEBNzCkH_zEhZLCjzQ24b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Investor relations and shareholder maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:InvestorRelationsAndShareholderMaintenance" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">469,151</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:InvestorRelationsAndShareholderMaintenance" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">344,355</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:InvestorRelationsAndShareholderMaintenance" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">273,187</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--NetUnrealisedForeignExchangeLoss_maOEBNzCkH_zlLDUoPM6wh1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net unrealized foreign exchange loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:NetUnrealisedForeignExchangeLoss" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">13,521</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0767">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:NetUnrealisedForeignExchangeLoss" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">47,896</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--NetForeignExchangeLoss_maOEBNzCkH_zAG1spLGV4M9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net realized foreign exchange loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0770">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0771">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--BankAndSimilarCharges_maOEBNzCkH_zhozHqiONDWl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Bank and credit card merchant charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:BankAndSimilarCharges" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">426,589</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:BankAndSimilarCharges" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">296,883</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:BankAndSimilarCharges" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">14,582</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--CommunicationExpense_maOEBNzCkH_zfH0F1jqUQ4l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">IT and communication</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CommunicationExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">670,008</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CommunicationExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">84,133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CommunicationExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">75,311</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--TravelExpense_maOEBNzCkH_zT7xBi3cZly5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Travel and entertainment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TravelExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">366,920</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TravelExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">67,298</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TravelExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">12,318</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--AdministrativeExpense_maOEBNzCkH_ziXHqTWH3pHd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdministrativeExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">370,571</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdministrativeExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">121,184</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdministrativeExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">82,264</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OtherExpense_maOEBNzCkH_zNZBNgyWZJ41" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:OtherExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">271,259</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:OtherExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">146,492</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:OtherExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">129,967</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--OtherExpenseByNature_iT_mtOEBNzCkH_zLSKowH35nQb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other expenses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherExpenseByNature" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">3,687,030</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherExpenseByNature" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,154,375</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherExpenseByNature" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,283,871</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zCF0mG1aBiC8" style="margin-top: 0; margin-bottom: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory"><p id="xdx_809_eifrs-full--DisclosureOfFinanceIncomeExpenseExplanatory_ziFnYxxtMQfl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_829_z0z4ofkYOqpk">FINANCE INCOME / (FINANCE COSTS)</span></b></span></p>



<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfFinanceIncomeCostsExplanatory"><p id="xdx_899_ecustom--DisclosureOfFinanceIncomeCostsExplanatory_z6G4DqJou9zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8BE_z1Vb1w8QzgOl" style="display: none">SCHEDULE OF FINANCE INCOME / (FINANCE COSTS)</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220701__20230630_zUZzoBoHh6o4" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210701__20220630_zi0ZFHEoH8fa" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20200701__20210630_z9IGG0tplQ7h" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--InterestIncome_z6572MoX80Ok" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 46%; text-align: left; padding-bottom: 1.5pt">Interest income</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="GENE:InterestIncome" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">220,161</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="GENE:InterestIncome" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">36,256</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="GENE:InterestIncome" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">62,394</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--FinanceIncome_zjEVv4RtS3Qj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total finance income</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">220,161</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">36,256</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">62,394</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--InterestExpenseOnLeaseLiabilities_iN_di_zocIpDOFGm6d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Lease interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">29,515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">15,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">16,338</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eifrs-full--FinanceCosts_iN_di_zWU0roBLkSo4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total finance costs</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">29,515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">15,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">16,338</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><p id="xdx_8AF_zrDFCT9R1mO7" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify; text-indent: -10pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfIncomeTaxExplanatory"><p id="xdx_805_eifrs-full--DisclosureOfIncomeTaxExplanatory_z6VgePqgVQKl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82D_z43vKBF0vEa1">INCOME TAX CREDIT/(EXPENSE)</span></b></span></p>



<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:ScheduleOfIncomeTaxExpenseExplanatory"><p id="xdx_897_ecustom--ScheduleOfIncomeTaxExpenseExplanatory_z9N5mZy16GJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_8B7_zR1WAkFPOhCd" style="display: none">SCHEDULE
OF INCOME TAX EXPENSE</span></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220701__20230630_zeEgVELBto35" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20210701__20220630_zEEQ8CFVXQ7k" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20200701__20210630_zpHHQZhz4LP3" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Reconciliation of income tax expense to prima facie tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--AccountingProfit_iN_pp0p0_di_z5gEta8I1Nac" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 46%; text-align: left">Loss before income tax credit</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="ifrs-full:AccountingProfit" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,909,252</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="ifrs-full:AccountingProfit" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">7,163,123</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="ifrs-full:AccountingProfit" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">7,077,619</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40E_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_zsxQ4ds6IV7d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 20pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax at the Australian tax rate of <span id="xdx_903_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20220701__20230630_zRPqu7nNtg82" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIElOQ09NRSBUQVggRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% (2022: <span id="xdx_902_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20210701__20220630_zjfII7gkROrc" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIElOQ09NRSBUQVggRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% and 2021: <span id="xdx_902_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20200701__20210630_zhZguIX3sgH1" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIElOQ09NRSBUQVggRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">26</ix:nonFraction></span>%)</span></p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,977,313</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,790,781</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,840,181</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--TaxEffectAmountsWhichAreNotDeductibletaxableInCalculatingTaxableIncome_zv2tinQLHrh7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Tax effect amounts which are not deductible/(taxable) in calculating taxable income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--TaxEffectOfShareBasedPaymentsExpense_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Share-based payments expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:TaxEffectOfShareBasedPaymentsExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">31,375</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:TaxEffectOfShareBasedPaymentsExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">109,377</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:TaxEffectOfShareBasedPaymentsExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">185,790</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--TaxEffectOfResearchAndDevelopmentTaxIncentive_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development tax incentive</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:TaxEffectOfResearchAndDevelopmentTaxIncentive" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">919,785</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:TaxEffectOfResearchAndDevelopmentTaxIncentive" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,116,714</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:TaxEffectOfResearchAndDevelopmentTaxIncentive" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">588,659</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TaxEffectOfImpairmentOfGoodwill_z1slKKvs3Lfc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Impairment of goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TaxEffectOfImpairmentOfGoodwill" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">461,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0847">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--TaxEffectFromOtherAssessableItems_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other assessable items</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0849">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0851">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--IncomeTaxExpensesBeforeUnrecognizedTaxLosses_pp0p0_ze11T1Jsz6B8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Income tax expenses before unrecognized tax losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:IncomeTaxExpensesBeforeUnrecognizedTaxLosses" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">1,564,903</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:IncomeTaxExpensesBeforeUnrecognizedTaxLosses" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">564,690</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:IncomeTaxExpensesBeforeUnrecognizedTaxLosses" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">1,065,732</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--TaxEffectOfForeignTaxRates_zFwbIVlANxQb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Difference in overseas tax rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TaxEffectOfForeignTaxRates" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">53,673</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:TaxEffectOfForeignTaxRates" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">79,604</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TaxEffectOfForeignTaxRates" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">16,688</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--TaxEffectOfUnderOverProvision_zHveVvbo2m81" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Over provision in prior years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:TaxEffectOfUnderOverProvision" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">454,928</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:TaxEffectOfUnderOverProvision" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">348,607</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:TaxEffectOfUnderOverProvision" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">235,653</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--TemporaryDifferencesNotRecognized_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Temporary differences not recognized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:TemporaryDifferencesNotRecognized" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">29,979</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:TemporaryDifferencesNotRecognized" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">301,694</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:TemporaryDifferencesNotRecognized" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">419,965</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--TaxEffectOfResearchAndDevelopmentTaxCredit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:TaxEffectOfResearchAndDevelopmentTaxCredit" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">404,016</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:TaxEffectOfResearchAndDevelopmentTaxCredit" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">599,388</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:TaxEffectOfResearchAndDevelopmentTaxCredit" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">275,631</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--UnrecognizedTaxLosses_iN_pp0p0_di_ziNuHh0dVJN3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Tax losses not recognized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:UnrecognizedTaxLosses" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">2,543,441</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:UnrecognizedTaxLosses" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">1,861,858</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:UnrecognizedTaxLosses" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">1,980,293</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--UtilizationOfTaxLossesNotPreviouslyRecognized_pp0p0_z5injeKpbZBi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Utilization of tax losses not previously recognized</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:UtilizationOfTaxLossesNotPreviouslyRecognized" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">361,575</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0879">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--IncomeTaxExpenseContinuingOperations_pp0p0_zseXxlk6Ptf7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income tax credit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">158,329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">32,125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0883">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zPATegLXN23l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.) </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
INCOME TAX CREDIT/(EXPENSE) (cont.)</b></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfDeferredTaxesExplanatory"><p id="xdx_89B_eifrs-full--DisclosureOfDeferredTaxesExplanatory_zzjwRNxADPwb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_8B4_zDwI3K5UNoIg" style="display: none">SCHEDULE
OF NET DEFERRED TAX ASSETS</span></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230630_zPc0pJW5T9b4" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220630_z5oiUUepzgci" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20210630_zS6JELtY6p33" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Net deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Deferred tax liabilities recognized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--DeferredTaxLiabilities_iNI_pp0p0_di_hifrs-full--TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis__ifrs-full--BrandNamesMember_z9nM37zaflx1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 46%; text-align: left; padding-bottom: 1.5pt">Brands and trademarks</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="AsOf2023-06-30_ifrs-full_BrandNamesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">121,901</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="AsOf2022-06-30_ifrs-full_BrandNamesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">148,013</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0889">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--DeferredTaxLiabilities_iNI_pp0p0_di_zL5gzNfS1R22" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">121,901</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">148,013</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0893">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Deferred tax assets recognized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--TaxEffectOfTaxLoss_iI_zDxgZ3ljnwr9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Tax losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:TaxEffectOfTaxLoss" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">121,901</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0896">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--DeferredTaxAssets_iI_zCtY7iKqOiFg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">121,901</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0900">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Deferred tax assets not recognized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--DeferredTaxAssets_iI_pp0p0_hifrs-full--TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis__ifrs-full--PropertyPlantAndEquipmentMember_zuoaAGR827Ya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0904">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2021-06-30_ifrs-full_PropertyPlantAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">8,004</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--DeferredTaxAssets_iI_pp0p0_hifrs-full--TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis__custom--TradeDebtorMember_zW5Jb4gcZHA9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Trade debtor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2023-06-30_custom_TradeDebtorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">222,144</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2022-06-30_custom_TradeDebtorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">58,041</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0909">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--DeferredTaxAssets_iI_pp0p0_hifrs-full--TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis__custom--CapitalRaisingCostsMember_zGeMVoVcPy6j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Capital raising costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2023-06-30_custom_CapitalRaisingCostsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">582,168</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2022-06-30_custom_CapitalRaisingCostsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">661,863</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2021-06-30_custom_CapitalRaisingCostsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">975,270</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--DeferredTaxAssets_iI_pp0p0_hifrs-full--TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis__ifrs-full--IntangibleAssetsAndGoodwillMember_zSTj7r1YqEp7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2023-06-30_ifrs-full_IntangibleAssetsAndGoodwillMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,407,570</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2022-06-30_ifrs-full_IntangibleAssetsAndGoodwillMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,456,225</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2021-06-30_ifrs-full_IntangibleAssetsAndGoodwillMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,701,477</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--DeferredTaxAssets_iI_pp0p0_hifrs-full--TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis__custom--ProvisionsMember_zUgOVS01Klfd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Provisions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2023-06-30_custom_ProvisionsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">342,252</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2022-06-30_custom_ProvisionsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">442,383</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2021-06-30_custom_ProvisionsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">297,907</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxAsset_iI_pp0p0_zAF6gUISLxO2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:DeferredTaxAsset" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,554,134</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:DeferredTaxAsset" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,618,512</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:DeferredTaxAsset" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,982,658</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Deferred tax liabilities not recognized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxLiabilitiesNotRecognized_iNI_pp0p0_di_hifrs-full--TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis__ifrs-full--RightofuseAssetsMember_zIn6Y0th2GFa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:DeferredTaxLiabilitiesNotRecognized" contextRef="AsOf2023-06-30_ifrs-full_RightofuseAssetsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">127,388</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:DeferredTaxLiabilitiesNotRecognized" contextRef="AsOf2022-06-30_ifrs-full_RightofuseAssetsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">161,787</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:DeferredTaxLiabilitiesNotRecognized" contextRef="AsOf2021-06-30_ifrs-full_RightofuseAssetsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">34,735</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesNotRecognized_iNI_pp0p0_di_zSAYmHsHNelg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:DeferredTaxLiabilitiesNotRecognized" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">127,388</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:DeferredTaxLiabilitiesNotRecognized" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">161,787</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:DeferredTaxLiabilitiesNotRecognized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">34,735</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eifrs-full--DeferredTaxLiabilityAsset_iI_pp0p0_z4QUwTj6oOy8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net deferred tax assets on temporary differences not brought to account</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">2,426,746</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">2,456,725</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilityAsset" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,947,923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--NetDeferredTaxAssets_iI_pp0p0_zfYOxFe2OtMl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total net deferred tax assets/(liabilities)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0939">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:NetDeferredTaxAssets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">148,013</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zOdgUs65f4Fb" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"><p id="xdx_894_eifrs-full--DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_zOJWdTpQAcai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_8B0_zU0M6k2vQvB3" style="display: none">SCHEDULE
OF TAX LOSSES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 46%; text-align: left; padding-bottom: 1.5pt">Unused tax losses for which no deferred tax asset has been recognized</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_iI_pp0p0_c20230630_z0cZD14pUa1" title="Unused tax losses for which no deferred tax asset has been recognised" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">119,096,654</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_iI_pp0p0_c20220630_zHhDhOsTd3Ja" title="Unused tax losses for which no deferred tax asset has been recognised" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">105,287,311</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_iI_pp0p0_c20210630_zHBiMvehFB0k" title="Unused tax losses for which no deferred tax asset has been recognised" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">100,694,696</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Potential tax benefit @ <span id="xdx_90A_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20220701__20230630__ifrs-full--GeographicalAreasAxis__custom--AUMember_z6LtY1XmwAZ8" title="Applicable tax rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBMT1NTRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span id="xdx_906_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20210701__20220630__ifrs-full--GeographicalAreasAxis__custom--AUMember_zOzNIC5mzrRj" title="Applicable tax rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBMT1NTRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span id="xdx_906_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20200701__20210630__ifrs-full--GeographicalAreasAxis__custom--AUMember_zwZlKBtQGeM4" title="Applicable tax rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBMT1NTRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2022-07-012023-06-30_custom_AUMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2021-07-012022-06-30_custom_AUMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2020-07-012021-06-30_custom_AUMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">26</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>% (Australia)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--UnusedTaxLossesAvailable_iI_pp0p0_c20230630__ifrs-full--GeographicalAreasAxis__custom--AUMember_znVh05a1QXwa" title="Potential tax benefit" style="text-align: right"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2023-06-30_custom_AUMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">21,897,732</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--UnusedTaxLossesAvailable_iI_pp0p0_c20220630__ifrs-full--GeographicalAreasAxis__custom--AUMember_zl3y2uiVxPLh" title="Potential tax benefit" style="text-align: right"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2022-06-30_custom_AUMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">19,020,914</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--UnusedTaxLossesAvailable_iI_pp0p0_c20210630__ifrs-full--GeographicalAreasAxis__custom--AUMember_zPZeyQqe7mHc" title="Potential tax benefit" style="text-align: right"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2021-06-30_custom_AUMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">19,025,063</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Potential tax benefit @ <span id="xdx_908_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20220701__20230630__ifrs-full--GeographicalAreasAxis__country--US_zKHhHMRLaSR7" title="Applicable tax rate"><span id="xdx_901_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20210701__20220630__ifrs-full--GeographicalAreasAxis__country--US_zVIXBQDHwX97" title="Applicable tax rate"><span id="xdx_909_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20200701__20210630__ifrs-full--GeographicalAreasAxis__country--US_zfmYwsebvNo4" title="Applicable tax rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBMT1NTRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2022-07-012023-06-30_country_US" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2021-07-012022-06-30_country_US" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2020-07-012021-06-30_country_US" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>% (USA)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--UnusedTaxLossesAvailable_iI_c20230630__ifrs-full--GeographicalAreasAxis__country--US_zSF3NmQhg6eh" title="Potential tax benefit" style="text-align: right"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2023-06-30_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,568,458</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--UnusedTaxLossesAvailable_iI_c20220630__ifrs-full--GeographicalAreasAxis__country--US_zA00FmLI3gL9" title="Potential tax benefit" style="text-align: right"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2022-06-30_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">5,950,299</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--UnusedTaxLossesAvailable_iI_c20210630__ifrs-full--GeographicalAreasAxis__country--US_zgLkftYnKooh" title="Potential tax benefit" style="text-align: right"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2021-06-30_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">5,665,976</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Potential tax benefit @ <span id="xdx_90B_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20220701__20230630__ifrs-full--GeographicalAreasAxis__custom--MTMember_zsfB6W1dKgr3" title="Applicable tax rate"><span id="xdx_903_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20210701__20220630__ifrs-full--GeographicalAreasAxis__custom--MTMember_z3LDiYnUE1Jh" title="Applicable tax rate"><span id="xdx_903_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20200701__20210630__ifrs-full--GeographicalAreasAxis__custom--MTMember_zSBysUecoEKd" title="Applicable tax rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBMT1NTRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2022-07-012023-06-30_custom_MTMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2021-07-012022-06-30_custom_MTMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2020-07-012021-06-30_custom_MTMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>% (Malta)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--UnusedTaxLossesAvailable_iI_c20230630__ifrs-full--GeographicalAreasAxis__custom--MTMember_ztODc206olrc" title="Potential tax benefit" style="text-align: right"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2023-06-30_custom_MTMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">65,895</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--UnusedTaxLossesAvailable_iI_c20220630__ifrs-full--GeographicalAreasAxis__custom--MTMember_zHOgaGW4xmzk" title="Potential tax benefit" style="text-align: right"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2022-06-30_custom_MTMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">304,115</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--UnusedTaxLossesAvailable_iI_c20210630__ifrs-full--GeographicalAreasAxis__custom--MTMember_zTP8XVTEFZBf" title="Potential tax benefit" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0985">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Potential tax benefit @ <span id="xdx_904_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20220701__20230630__ifrs-full--GeographicalAreasAxis__custom--UKMember_zIwyUYiHeVH5" title="Applicable tax rate"><span id="xdx_90A_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20210701__20220630__ifrs-full--GeographicalAreasAxis__custom--UKMember_zi2yVFssZxjh" title="Applicable tax rate"><span id="xdx_905_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20200701__20210630__ifrs-full--GeographicalAreasAxis__custom--UKMember_zoaCNXSUJ8gk" title="Applicable tax rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBMT1NTRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2022-07-012023-06-30_custom_UKMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2021-07-012022-06-30_custom_UKMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2020-07-012021-06-30_custom_UKMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>% (UK)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--UnusedTaxLossesAvailable_iI_c20230630__ifrs-full--GeographicalAreasAxis__custom--UKMember_zIDD5Sos9clk" title="Potential tax benefit" style="text-align: right"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2023-06-30_custom_UKMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">7,427</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--UnusedTaxLossesAvailable_iI_c20220630__ifrs-full--GeographicalAreasAxis__custom--UKMember_zyeOgwbBXOOa" title="Potential tax benefit" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0995">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--UnusedTaxLossesAvailable_iI_c20210630__ifrs-full--GeographicalAreasAxis__custom--UKMember_z9Ev3RvAkoje" title="Potential tax benefit" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0997">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zwVxprCPRcN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Company continuing to meet the relevant statutory tests, the tax losses are available for offset against future taxable income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.) </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
INCOME TAX CREDIT/(EXPENSE) (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2023, the Company had a potential tax benefit related to tax losses carried forward of A$<span id="xdx_907_ecustom--UnusedTaxLossesAvailable_iI_pp0p0_c20230630_zUEjwbQJdWH" title="Potential tax benefit"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">28,539,512</ix:nonFraction></span> (2022: A$<span id="xdx_905_ecustom--UnusedTaxLossesAvailable_iI_pp0p0_c20220630_zLIFoKINGVej" title="Potential tax benefit"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">25,275,328</ix:nonFraction></span>, 2021:
A$<span id="xdx_90B_ecustom--UnusedTaxLossesAvailable_iI_pp0p0_c20210630_z0CKjCIP4HZ6" title="Potential tax benefit"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">24,691,039</ix:nonFraction></span>). Such amount includes net losses of A$<span id="xdx_90B_ecustom--UnusedTaxLossesAvailable_iI_pp0p0_c20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--SubsidiariesUnitedStatesMember_zdvMySQbDTa5" title="Potential tax benefit"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2023-06-30_custom_SubsidiariesUnitedStatesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">6,568,458</ix:nonFraction></span> (2022: A$<span id="xdx_90C_ecustom--UnusedTaxLossesAvailable_iI_pp0p0_c20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--SubsidiariesUnitedStatesMember_zgrJVn626Y0d" title="Potential tax benefit"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2022-06-30_custom_SubsidiariesUnitedStatesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">5,950,299</ix:nonFraction></span>, 2021: A$<span id="xdx_905_ecustom--UnusedTaxLossesAvailable_iI_pp0p0_c20210630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--SubsidiariesUnitedStatesMember_zVZQeF565uU1" title="Potential tax benefit"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2021-06-30_custom_SubsidiariesUnitedStatesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">5,665,976</ix:nonFraction></span>) related to subsidiaries in the United
States (U.S.). The Tax Cuts and Jobs Act (TCJA) enacted by Congress in the U.S. on December 22, 2017 cut the top corporate income tax
rate from 35% to 21%. For tax years beginning after December 31, 2017, the graduated corporate tax rate structure is eliminated and corporate
taxable income will be taxed at 21% flat rate. Additionally, the previous <span id="xdx_90A_ecustom--ExpirationPeriodOfUnusedTaxLosses_dtY_c20220701__20230630__ifrs-full--GeographicalAreasAxis__country--US_zGBNirlafqRc" title="Expiration period limitation on carry forward net operating losses"><ix:nonNumeric contextRef="From2022-07-012023-06-30_country_US" format="ixt-sec:duryear" name="GENE:ExpirationPeriodOfUnusedTaxLosses">20</ix:nonNumeric></span>-year limitation on carry forward net operating losses (NOL&#8217;s)
has been removed, allowing the NOL&#8217;s to be carried forward indefinitely. The remaining tax losses carried forward of A$<span id="xdx_908_ecustom--UnusedTaxLossesAvailable_iI_pp0p0_c20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--SubsidiariesAustraliaMember_z2wXtzMlvIh" title="Remaining tax losses carried forward"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2023-06-30_custom_SubsidiariesAustraliaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">21,897,732</ix:nonFraction></span>
(2022: A$<span id="xdx_908_ecustom--UnusedTaxLossesAvailable_iI_pp0p0_c20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--SubsidiariesAustraliaMember_zR6S7m4j7GKb" title="Remaining tax losses carried forward"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2022-06-30_custom_SubsidiariesAustraliaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">19,020,914</ix:nonFraction></span>, 2021: A$<span id="xdx_907_ecustom--UnusedTaxLossesAvailable_iI_pp0p0_c20210630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--SubsidiariesAustraliaMember_zEBIJoVuStvd" title="Remaining tax losses carried forward"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2021-06-30_custom_SubsidiariesAustraliaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">19,025,063</ix:nonFraction></span>) are indefinite and are attributable to the Company&#8217;s operations in Australia, as well
as A$<span id="xdx_908_ecustom--UnusedTaxLossesAvailable_iI_pp0p0_c20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--SubsidiariesMaltaMember_zpqUj3uRutEd" title="Remaining tax losses carried forward"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2023-06-30_custom_SubsidiariesMaltaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">65,895</ix:nonFraction></span> (2022: A$<span id="xdx_907_ecustom--UnusedTaxLossesAvailable_iI_pp0p0_c20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--SubsidiariesMaltaMember_zMR1SzPiUbo1" title="Remaining tax losses carried forward"><ix:nonFraction name="GENE:UnusedTaxLossesAvailable" contextRef="AsOf2022-06-30_custom_SubsidiariesMaltaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">304,115</ix:nonFraction></span>, 2021:<span id="xdx_903_ecustom--UnusedTaxLossesAvailable_iI_pp0p0_c20210630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--SubsidiariesMaltaMember_zkqKsAVFkvKc" title="Remaining tax losses carried forward"> Nil</span>) and A$<span id="xdx_905_eifrs-full--TaxEffectOfTaxLosses_c20220701__20230630_zxi7v1bKb7i9"><ix:nonFraction name="ifrs-full:TaxEffectOfTaxLosses" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">7,427</ix:nonFraction></span> (2022: <span id="xdx_909_eifrs-full--TaxEffectOfTaxLosses_dxL_c20210701__20220630_zZhWpxlrsJEf" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1025">Nil</span></span>) tax losses attributable to Company&#8217;s operations in Malta and UK,
respectively. As such the total unused tax losses available to the Company, equal A$<span id="xdx_908_ecustom--TotalUnusedTaxLosses_iI_pp0p0_c20230630_z7AJg2l3kpOe" title="Total unused tax losses"><ix:nonFraction name="GENE:TotalUnusedTaxLosses" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">28,539,511</ix:nonFraction></span> (2022: A$<span id="xdx_904_ecustom--TotalUnusedTaxLosses_iI_pp0p0_c20220630_zGNDVN7R1WHl" title="Total unused tax losses"><ix:nonFraction name="GENE:TotalUnusedTaxLosses" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">25,275,328</ix:nonFraction></span>, 2021: A$<span id="xdx_901_ecustom--TotalUnusedTaxLosses_iI_pp0p0_c20210630_zSTUAzQqWYZ1" title="Total unused tax losses"><ix:nonFraction name="GENE:TotalUnusedTaxLosses" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">24,691,039</ix:nonFraction></span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at balance date, there are unrecognized tax losses with a benefit of approximately A$<span id="xdx_90F_ecustom--UnrecognizedTaxLossesWithBenefit_iI_pp0p0_c20230630_zwsykcgmlsp3" title="Unrecognized tax losses with benefits"><ix:nonFraction name="GENE:UnrecognizedTaxLossesWithBenefit" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">28,539,511</ix:nonFraction></span> (2022: A$<span id="xdx_901_ecustom--UnrecognizedTaxLossesWithBenefit_iI_pp0p0_c20220630_zaHW1NYERAN9" title="Unrecognized tax losses with benefits"><ix:nonFraction name="GENE:UnrecognizedTaxLossesWithBenefit" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">25,275,328</ix:nonFraction></span>, 2021: A$<span id="xdx_906_ecustom--UnrecognizedTaxLossesWithBenefit_iI_pp0p0_c20210630_zLJJiKOQy773" title="Unrecognized tax losses with benefits"><ix:nonFraction name="GENE:UnrecognizedTaxLossesWithBenefit" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">24,691,039</ix:nonFraction></span>)
that have not been recognized as a deferred tax asset to the Company. These unrecognized deferred tax assets will only be obtained if:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company derives future assessable income of a nature and amount sufficient to enable the benefits to be realized;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company continues to comply with the conditions for deductibility imposed by the law; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    changes in tax legislation adversely affect the Company from realizing the benefit.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has assessed the tax position of the Company and concluded that any potential uncertainty does not have a material impact on the financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
consolidation legislation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genetic
Technologies Limited and its wholly owned Australian subsidiaries implemented the tax consolidation legislation as from July 1, 2003.
The accounting policy in relation to this legislation is set out in Note 2(i).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
entities in the tax consolidated Company have entered into a Tax Sharing Agreement which, in the opinion of the Directors, limits the
joint and several liabilities of the wholly owned entities in the case of a default by the head entity, Genetic Technologies Limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
entities have also entered into a Tax Funding Agreement under which the wholly owned entities fully compensate Genetic Technologies Limited
for any current tax payable assumed and are compensated by Genetic Technologies Limited for any current tax receivable and deferred tax
assets relating to unused tax losses or unused tax credits that are transferred to Genetic Technologies Limited under the tax consolidation
legislation. The funding amounts are determined by reference to the amounts recognized in the respective subsidiaries&#8217; financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amounts receivable or payable under the Tax Funding Agreement are due upon receipt of the funding advice from the head entity, which
is issued as soon as practicable after the end of each financial year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at June 30, 2023, there are <span id="xdx_904_eifrs-full--TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_iI_dxL_c20230630_zCZkeC4adEu1" title="Unrecognized temporary differences associated with the Group&apos;s investments in subsidiaries::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1039">no</span></span> unrecognized temporary differences associated with the Company&#8217;s investments in subsidiaries, as
the Company has no liability for additional taxation should unremitted earnings be remitted (2022: Nil, 2021: Nil).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory"><p id="xdx_80A_eifrs-full--DisclosureOfEarningsPerShareExplanatory_zdEV9xZvyrA1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_821_zm95cO0IEPja">LOSS PER SHARE</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" continuedAt="Con001043-01" escape="true" name="ifrs-full:EarningsPerShareExplanatory"><p id="xdx_89D_eifrs-full--EarningsPerShareExplanatory_zsCFCFIn0mPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following reflects the income and share data used in the calculations of basic and diluted loss per share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zmwYasWIANIc" style="display: none">SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES USED AS DENOMINATOR</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220701__20230630_zuwOqmUXFaO6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20210701__20220630_zNUmS2JZv53a" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20200701__20210630_zAD84OAIpOec" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--ProfitLoss_zjVlJqawwzF9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Loss for the year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">11,750,923</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">7,130,998</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">7,077,619</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_407_eifrs-full--WeightedAverageShares_i_pdd" style="vertical-align: bottom; background-color: White">
    <td>Weighted average number of Ordinary Shares used in calculating loss per share (number of shares)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,138,075,003</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,220,348,281</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,544,157,979</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
</ix:nonNumeric><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%"><ix:continuation continuedAt="Con001043-02" id="Con001043-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note:</span></ix:continuation></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 94%"><ix:continuation id="Con001043-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
                                                                     of the <span id="xdx_90D_ecustom--IfrsAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630_zHgOv9wXvMb3" title="Number of options outstanding excluded from calculation diluted earnings per share"><ix:nonFraction name="GENE:IfrsAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">233,400,000</ix:nonFraction></span> (2022: <span id="xdx_90B_ecustom--IfrsAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630_z9LR7mehxX5a" title="Number of options outstanding excluded from calculation diluted earnings per share"><ix:nonFraction name="GENE:IfrsAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">757,400,000</ix:nonFraction></span> and 2021: <span id="xdx_904_ecustom--IfrsAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630_zYtxOWgd3xK3" title="Number of options outstanding excluded from calculation diluted earnings per share"><ix:nonFraction name="GENE:IfrsAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">725,787,500</ix:nonFraction></span>) options/performance rights over the Company&#8217;s Ordinary Shares
                                                                     that were outstanding as at the reporting date are considered to be dilutive for the purposes of calculating diluted earnings per
                                                                     share.</span></p>
    </ix:continuation><p id="xdx_8A2_zZRglJKaKOZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr>
  </table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.) </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory"><p id="xdx_800_eifrs-full--DisclosureOfCashAndCashEquivalentsExplanatory_zg5uWmeoMOy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span id="xdx_822_zTds2y9Ejlk8">CASH AND CASH EQUIVALENTS</span> </b></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfCashFlowStatementExplanatory"><p id="xdx_89A_eifrs-full--DisclosureOfCashFlowStatementExplanatory_z4JFmpYNmgpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_ziYNICGTmr3d" style="display: none">SCHEDULE OF
CASH AND CASH EQUIVALENTS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20220701__20230630_zLPsYNOzkCxl" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210701__20220630_zuqJu5T2qXN3" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20200701__20210630_zh9DANzKbuK" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Reconciliation of cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 46%; text-align: left; padding-bottom: 1.5pt">Cash at bank and on hand</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--Cash_iI_pp0p0_c20230630_zKNuvxDIFnNk" title="Cash at bank and on hand" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:Cash" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">7,851,197</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--Cash_c20220630_pp0p0" title="Cash at bank and on hand" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:Cash" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,731,325</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--Cash_c20210630_pp0p0" title="Cash at bank and on hand" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:Cash" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">20,902,282</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total cash and cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--CashAndCashEquivalents_iI_pp0p0_c20230630_zOphFxMuYDT5" title="Total cash and cash equivalents" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">7,851,197</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--CashAndCashEquivalents_c20220630_pp0p0" title="Total cash and cash equivalents" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,731,325</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--CashAndCashEquivalents_c20210630_pp0p0" title="Total cash and cash equivalents" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">20,902,282</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Reconciliation of loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Reconciliation of loss for the year after income tax to net cash flows used in operating activities is as follows:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--ProfitLoss_pp0p0_zJo95BxVzmA5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Loss for the year after income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">11,750,923</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">7,130,998</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">7,077,619</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_di_zItXEYCaFWV8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Tax credit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">158,329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">32,125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1081">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--ProfitLossBeforeTax_za8Ud4T2QUc4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Loss for the year before income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">11,909,252</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">7,163,123</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">7,077,619</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-style: italic; text-align: left">Adjust for non-cash items and non-operational items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--AdjustmentsForDepreciationAndAmortisationExpense_zgb7FCCE45Sh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Amortization and depreciation expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">380,409</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">343,427</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">265,748</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AdjustmentsForDepreciationOfRightofuseOfAssets_zLbWkX9xjRl9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Depreciation of right-of-use of assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:AdjustmentsForDepreciationOfRightofuseOfAssets" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">296,174</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:AdjustmentsForDepreciationOfRightofuseOfAssets" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">235,241</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:AdjustmentsForDepreciationOfRightofuseOfAssets" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">212,474</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--ImpairmentLossRecognisedInProfitOrLossTradeReceivables_zzKNj4JLuMHk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Impairment of receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossTradeReceivables" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">280,725</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossTradeReceivables" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">564,161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1097">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--ImpairmentLossRecognisedInProfitOrLossGoodwill_zYYoKz4KhQwi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Impairment of goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,845,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1100">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--AdjustmentsForSharebasedPayments_zowpYYghNPV8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Share-based payments expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">125,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">437,508</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">714,577</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AdjustmentsForInventoryWrittenoff_zPpau2YDjPnc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Inventory written-off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1107">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:AdjustmentsForInventoryWrittenoff" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">30,214</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:AdjustmentsForInventoryWrittenoff" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">54,523</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--AdjustmentsForFinanceCosts_zuJr2ZTUDOi3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Finance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForFinanceCosts" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">29,515</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForFinanceCosts" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">15,215</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForFinanceCosts" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">16,338</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--AdjustmentsForFinanceIncome_iN_di_z4xtCmjOjn9k" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Finance income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForFinanceIncome" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">220,161</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForFinanceIncome" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">36,256</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForFinanceIncome" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">62,394</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--AdjustmentsForUnrealisedForeignExchangeLossesGains_zVZMvrhhXt57" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net foreign exchange (gains) / losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">152,963</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">244,762</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">9,755</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--AdjustmentsForReconcileProfitLoss_maAFPzWCm_zDuh3XDNUqa2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-size: 10pt">Adjust
    for non-cash items</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForReconcileProfitLoss" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">9,325,053</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForReconcileProfitLoss" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">5,818,375</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForReconcileProfitLoss" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">5,866,598</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.) </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
CASH AND CASH EQUIVALENTS (cont.) </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Reconciliation of cash and cash equivalents (cont.)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-style: italic; text-align: left">Adjust for changes in assets and liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_maAFPzWCm_zs01aHJWIkej" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 46%; text-align: left">Decrease / (Increase) in trade and other receivables</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">256,213</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">1,889,124</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">284,971</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40C_eifrs-full--AdjustmentsForDecreaseIncreaseInOtherAssets_maAFPzWCm_zMrNvEShnXbe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">(Increase) / Decrease in other operating assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">232,961</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">16,493</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">182,602</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eifrs-full--AdjustmentsForDecreaseIncreaseInInventories_maAFPzWCm_zJxNdIMDIHmc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Decrease / (Increase) in inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">72,257</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">351,437</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">14,463</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AdjustmentsForDecreaseIncreaseInNonCurrentAssets_maAFPzWCm_z94DiTJxzAE5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Decrease / (Increase) in other non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1139">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:AdjustmentsForDecreaseIncreaseInNonCurrentAssets" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">97,868</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1141">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_maAFPzWCm_zoeqvYLQjYK7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">(Decrease) / Increase in trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">432,361</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,178,301</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">14,991</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eifrs-full--AdjustmentsForProvisions_maAFPzWCm_zdrcNtevqvJe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">(Decrease) / Increase in provisions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForProvisions" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">61,190</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForProvisions" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">106,818</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForProvisions" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">38,770</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--CashFlowsFromUsedInOperations_mtAFPzWCm_zNv7gNej2vTh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash flows used in operating activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperations" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">9,723,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperations" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">5,659,456</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperations" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">6,295,928</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Financing facilities available</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">As at June 30, 2023, the following financing facilities had been nego- tiated and were available:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-style: italic; text-align: left">Total facilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Credit cards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--TotalFinancingFacilityAvailableUnderCreditCards_iI_pp0p0_c20230630_zyz0hmBbr578" title="Total facilities - Credit cards" style="text-align: right"><ix:nonFraction name="GENE:TotalFinancingFacilityAvailableUnderCreditCards" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">188,630</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--TotalFinancingFacilityAvailableUnderCreditCards_c20220630_pp0p0" title="Total facilities - Credit cards" style="text-align: right"><ix:nonFraction name="GENE:TotalFinancingFacilityAvailableUnderCreditCards" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">190,020</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--TotalFinancingFacilityAvailableUnderCreditCards_c20210630_pp0p0" title="Total facilities - Credit cards" style="text-align: right"><ix:nonFraction name="GENE:TotalFinancingFacilityAvailableUnderCreditCards" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">190,020</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-style: italic; text-align: left">Facilities used as at reporting date</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Credit cards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--FinancingFacilityUsedUnderCreditCards_iI_pp0p0_c20230630_zh8hZtqIWcG2" title="Facilities used as at reporting date - Credit cards" style="text-align: right">(<ix:nonFraction name="GENE:FinancingFacilityUsedUnderCreditCards" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">16,029</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--FinancingFacilityUsedUnderCreditCards_c20220630_pp0p0" title="Facilities used as at reporting date - Credit cards" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--FinancingFacilityUsedUnderCreditCards_c20210630_pp0p0" title="Facilities used as at reporting date - Credit cards" style="text-align: right">(<ix:nonFraction name="GENE:FinancingFacilityUsedUnderCreditCards" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">9,511</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-style: italic; text-align: left">Facilities unused as at reporting date</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Credit cards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--UnusedFinancingFacilityUnderCreditCards_iI_pp0p0_c20230630_zS87jZVrFiL6" title="Facilities unused as at reporting date - Credit cards" style="text-align: right"><ix:nonFraction name="GENE:UnusedFinancingFacilityUnderCreditCards" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">172,601</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--UnusedFinancingFacilityUnderCreditCards_c20220630_pp0p0" title="Facilities unused as at reporting date - Credit cards" style="text-align: right"><ix:nonFraction name="GENE:UnusedFinancingFacilityUnderCreditCards" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">190,020</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--UnusedFinancingFacilityUnderCreditCards_c20210630_pp0p0" title="Facilities unused as at reporting date - Credit cards" style="text-align: right"><ix:nonFraction name="GENE:UnusedFinancingFacilityUnderCreditCards" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">180,509</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zTzm5Xv6e2nl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s main interest rate risk arises in relation to its short-term deposits with various financial institutions. If rates were
to decrease, the Company may generate less interest revenue from such deposits. However, given the relatively short duration of such
deposits, the associate risk is relatively minimal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a Short-Term Investment Policy which was developed to manage the Company&#8217;s surplus cash and cash equivalents. In this
context, the Company adopts a prudent approach that is tailored to cash forecasts rather than seeking high returns that may compromise
access to funds as and when they are required. Under the policy, the Company deposits its surplus cash in a range of deposits over different
time frames and with different institutions in order to diversify its portfolio and minimize risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory"><p id="xdx_808_eifrs-full--DisclosureOfTradeAndOtherReceivablesExplanatory_zQjR1Vt8At9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
<span id="xdx_82E_zeUt97enj8K7">TRADE AND OTHER RECEIVABLES (CURRENT)</span></b></span></p>



<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfTradeAndOtherCurrentReceivablesExplanatory"><p id="xdx_895_ecustom--DisclosureOfTradeAndOtherCurrentReceivablesExplanatory_zNn2Ejc1g2Y6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8BE_zky3GrPaebI8" style="display: none">SCHEDULE OF TRADE AND OTHER RECEIVABLES (CURRENT)</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230630_zIj0Owy9fFq3" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220630_zzuShmmDkbgc" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CurrentTradeReceivablesGross_iI_pp0p0_maCTRzoPp_zNuKsGFqBrE8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Trade receivables</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="GENE:CurrentTradeReceivablesGross" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,080,479</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="GENE:CurrentTradeReceivablesGross" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,036,998</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--CurrentsImpairmentLoss_iN_pp0p0_di_msCTRzoPp_z74x1EWOBgFf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: impairment loss <sup id="xdx_F4D_zI7a7SWOpXth">(1)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:CurrentsImpairmentLoss" contextRef="AsOf2023-06-30" id="Fact001180" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">888,576</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:CurrentsImpairmentLoss" contextRef="AsOf2022-06-30" id="Fact001181" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">594,798</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eifrs-full--CurrentTradeReceivables_iTI_pp0p0_mtCTRzoPp_maTAOCRztCH_zrj761IVwm3e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net trade receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentTradeReceivables" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">191,903</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentTradeReceivables" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">442,200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--OtherCurrentReceivables_iI_pp0p0_maTAOCRztCH_zu6xMdk7dge3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other receivables <sup id="xdx_F4E_zxJ8H4YL5rZi">(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2023-06-30" id="Fact001186" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,729,754</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2022-06-30" id="Fact001187" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,979,038</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--TradeAndOtherCurrentReceivables_iTI_pp0p0_mtTAOCRztCH_z3END16DVm6l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total net current trade and other receivables</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,921,657</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,421,238</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td>&#160;</td>
  <td style="text-align: center; width: 0.25in"><span id="xdx_F03_z3NdHiGQKPci" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
  <td style="text-align: justify"><span id="xdx_F10_zcoVXhaniXHl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001191" xml:lang="en-US"><i>Provision
  of impairment losses against trade receivables relate to license fees from IBX contract in the prior year. The Company did not
  recognize or receive any license fee revenue in the current financial year.</i></ix:footnote></span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
  <td id="xdx_F07_zjCaC5psU1n4" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
  <td style="text-align: justify"><span id="xdx_F17_zikbL1yusfT9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001192" xml:lang="en-US"><i>Other
  receivables includes the R&amp;D tax incentive refund accrued for the 2023 financial year A$</i></ix:footnote></span><i><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eifrs-full--AccruedIncomeOtherThanContractAssets_iI_c20230630_zxMVWVuwfsUh" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRSQURFIEFORCBPVEhFUiBSRUNFSVZBQkxFUyAoQ1VSUkVOVCkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="ifrs-full:AccruedIncomeOtherThanContractAssets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,616,064</ix:nonFraction></span>
  </span></i><i><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2022: A$</span></i><i><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eifrs-full--AccruedIncomeOtherThanContractAssets_iI_c20220630_zGEjAjBD4Ing" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRSQURFIEFORCBPVEhFUiBSRUNFSVZBQkxFUyAoQ1VSUkVOVCkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="ifrs-full:AccruedIncomeOtherThanContractAssets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,943,083</ix:nonFraction></span></span></i><i><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">).</span></i></td></tr>
</table>




</ix:nonNumeric><p id="xdx_8AB_zFjFtFUyXypd" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory"><p id="xdx_80C_eifrs-full--DisclosureOfOtherCurrentAssetsExplanatory_ziAovNLoozjc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_zCmdzcVO7fS4">OTHER CURRENT ASSETS</span></b></span></p>



<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory"><p id="xdx_894_ecustom--DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatory_z9jHbje26Fnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B4_z7yZdDY8It53" style="display: none">SCHEDULE
OF OTHER CURRENT ASSETS</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230630_zaFemekfd1H8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220630_zGW7hJ5jWL2c" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_400_ecustom--PrepaymentsOtherCurrentAssets_iI_pp0p0_maOCAzczU_zduGhc6CKGTh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-left: 10pt">Prepayments</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="GENE:PrepaymentsOtherCurrentAssets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">381,608</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="GENE:PrepaymentsOtherCurrentAssets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">147,854</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--ShorttermDepositsNotClassifiedAsCashEquivalents_iI_pp0p0_maOCAzczU_zXIKsW2KsN84" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Bonds and deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">17,440</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">13,257</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CurrentPrepaymentsAndOtherCurrentAssets_iI_pp0p0_maOCAzczU_zAdkj8BUsyT4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1206">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">4,976</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--OtherCurrentAssets_iTI_pp0p0_mtOCAzczU_zJQNHKpUMbn5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current prepayments and other assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentAssets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">399,048</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentAssets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">166,087</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 452.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<!-- Field: Split-Segment; Name: 001 -->
</ix:nonNumeric><p id="xdx_8AC_zlSh1OU9CGcf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory"><p id="xdx_802_eifrs-full--DisclosureOfPropertyPlantAndEquipmentExplanatory_zoDj3idIgzei" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
<span id="xdx_824_z6499KRnnibi">PROPERTY, PLANT AND EQUIPMENT</span></b></span></p>



<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"><p id="xdx_899_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_zpMAvnHvf5J9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8B7_zemAKBQPb3ce" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCHEDULE
OF PROPERTY, PLANT AND EQUIPMENT</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Laboratory equipment, at cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--PropertyPlantAndEquipment1_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentMember_zHCtXN6PoStg" title="Opening net carrying amount" style="width: 14%; text-align: right"><ix:nonFraction name="GENE:PropertyPlantAndEquipment1" contextRef="From2022-07-012023-06-30_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">975,619</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--PropertyPlantAndEquipment1_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentMember_zfWjqqhiY5Ff" title="Opening net carrying amount" style="width: 14%; text-align: right"><ix:nonFraction name="GENE:PropertyPlantAndEquipment1" contextRef="From2021-07-012022-06-30_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">960,872</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less: cost written-off during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--LessCostWrittenoffDuringYear_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentMember_zd8NGd6vgYr6" title="Less: cost written-off during the year" style="text-align: right">(<ix:nonFraction name="GENE:LessCostWrittenoffDuringYear" contextRef="From2022-07-012023-06-30_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">8,243</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--LessCostWrittenoffDuringYear_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentMember_zxEyyxfF8y91" title="Less: cost written-off during the year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1222">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Add: additions during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentMember_zI2TfHBZq9T3" title="Add: additions during the year" style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2022-07-012023-06-30_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,402</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentMember_zMktQ48iZcr6" title="Add: additions during the year" style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2021-07-012022-06-30_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">14,747</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less: accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--PropertyEquipmentAccumulatedDepreciation_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentMember_z1ZTVpfmAbRl" title="Less: accumulated depreciation" style="text-align: right">(<ix:nonFraction name="GENE:PropertyEquipmentAccumulatedDepreciation" contextRef="From2022-07-012023-06-30_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">941,545</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--PropertyEquipmentAccumulatedDepreciation_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentMember_zBEEOomk61rj" title="Less: accumulated depreciation" style="text-align: right">(<ix:nonFraction name="GENE:PropertyEquipmentAccumulatedDepreciation" contextRef="From2021-07-012022-06-30_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">744,615</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Add: accumulated depreciation written-off during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--AccumulatedDepreciationWrittenoff_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentMember_zAVcxgwOeLs" title="Add: accumulated depreciation written-off during the year" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:AccumulatedDepreciationWrittenoff" contextRef="From2022-07-012023-06-30_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">8,243</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--AccumulatedDepreciationWrittenoff_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentMember_z1ha6JFDfTu2" title="Add: accumulated depreciation written-off during the year" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1234">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net laboratory equipment</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--PropertyPlantAndEquipment_iE_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentMember_zJmlsTk46uo8" title="Net laboratory equipment" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">40,476</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--PropertyPlantAndEquipment_iE_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentMember_z6fR5FLezmQl" title="Net laboratory equipment" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-06-30_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">231,004</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Computer equipment, at cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--PropertyPlantAndEquipment1_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zcVqAy5dhDCi" title="Opening net carrying amount" style="text-align: right"><ix:nonFraction name="GENE:PropertyPlantAndEquipment1" contextRef="From2022-07-012023-06-30_ifrs-full_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">292,817</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--PropertyPlantAndEquipment1_pp0p0_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_z3EWIVMpV1M8" title="Opening net carrying amount" style="text-align: right"><ix:nonFraction name="GENE:PropertyPlantAndEquipment1" contextRef="From2021-07-012022-06-30_ifrs-full_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">251,852</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less: cost written-off during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--LessCostWrittenoffDuringYear_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zijDNEpxgbae" title="Less: cost written-off during the year" style="text-align: right">(<ix:nonFraction name="GENE:LessCostWrittenoffDuringYear" contextRef="From2022-07-012023-06-30_ifrs-full_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">3,099</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--LessCostWrittenoffDuringYear_pp0p0_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zc6oft3F4R1f" title="Less: cost written-off during the year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1246">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Less: cost transferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--LessCostTransferred_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zPXbiMZmbFtk" title="Less: cost transferred" style="text-align: right">(<ix:nonFraction name="GENE:LessCostTransferred" contextRef="From2022-07-012023-06-30_ifrs-full_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">11,603</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--LessCostTransferred_pp0p0_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zFVWLDK75gCd" title="Less: cost transferred" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1250">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Add: additions during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zlMj2oriLkK4" title="Add: additions during the year" style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2022-07-012023-06-30_ifrs-full_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_pp0p0" title="Add: additions during the year" style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2021-07-012022-06-30_ifrs-full_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">40,965</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Less: accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--PropertyEquipmentAccumulatedDepreciation_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zJLVXrWT9iTc" title="Less: accumulated depreciation" style="text-align: right">(<ix:nonFraction name="GENE:PropertyEquipmentAccumulatedDepreciation" contextRef="From2022-07-012023-06-30_ifrs-full_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">261,580</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--PropertyEquipmentAccumulatedDepreciation_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_pp0p0" title="Less: accumulated depreciation" style="text-align: right">(<ix:nonFraction name="GENE:PropertyEquipmentAccumulatedDepreciation" contextRef="From2021-07-012022-06-30_ifrs-full_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">230,186</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Add: accumulated depreciation transferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--PropertyEquipmentAccumulatedDepreciationTransferred_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_z6QLGWnvvauk" title="Less: accumulated depreciation transferred" style="text-align: right"><ix:nonFraction name="GENE:PropertyEquipmentAccumulatedDepreciationTransferred" contextRef="From2022-07-012023-06-30_ifrs-full_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,897</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--PropertyEquipmentAccumulatedDepreciationTransferred_pp0p0_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zdEFgWTgDPh9" title="Less: accumulated depreciation transferred" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1262">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Add: accumulated depreciation written-off during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--AccumulatedDepreciationWrittenoff_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zsI3MpsNzgta" title="Add: accumulated depreciation written-off during the year" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:AccumulatedDepreciationWrittenoff" contextRef="From2022-07-012023-06-30_ifrs-full_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">3,099</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--AccumulatedDepreciationWrittenoff_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_pp0p0" title="Add: accumulated depreciation written-off during the year" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1266">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net computer equipment</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zq3xXGCBxBFb" title="Net computer equipment" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30_ifrs-full_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">42,681</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_z1XVjk2WtWMl" title="Net computer equipment" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-06-30_ifrs-full_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">62,631</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Office equipment, at cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--PropertyPlantAndEquipment1_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_zfGit7ic9LF7" title="Opening net carrying amount" style="text-align: right"><ix:nonFraction name="GENE:PropertyPlantAndEquipment1" contextRef="From2022-07-012023-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">18,709</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--PropertyPlantAndEquipment1_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_pp0p0" title="Opening net carrying amount" style="text-align: right"><ix:nonFraction name="GENE:PropertyPlantAndEquipment1" contextRef="From2021-07-012022-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">10,495</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less: cost written-off during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--LessCostWrittenoffDuringYear_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_zPl6NFMEtrVh" title="Less: cost written-off during the year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1276">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--LessCostWrittenoffDuringYear_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_pp0p0" title="Less: cost written-off during the year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Add: cost transferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--AddCostTransferred_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_z5jaGeXGCfB" title="Add: cost transferred" style="text-align: right"><ix:nonFraction name="GENE:AddCostTransferred" contextRef="From2022-07-012023-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,603</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--AddCostTransferred_pp0p0_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_z3wxEN7AWoQ8" title="Add: cost transferred" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1282">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Add: additions during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_zaFobJDyvA9k" title="Add: additions during the year" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1284">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_pp0p0" title="Add: additions during the year" style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2021-07-012022-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">8,214</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Less: accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--PropertyEquipmentAccumulatedDepreciation_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_z7v88ICGAos8" title="Less: accumulated depreciation" style="text-align: right">(<ix:nonFraction name="GENE:PropertyEquipmentAccumulatedDepreciation" contextRef="From2022-07-012023-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">11,949</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--PropertyEquipmentAccumulatedDepreciation_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_pp0p0" title="Less: accumulated depreciation" style="text-align: right">(<ix:nonFraction name="GENE:PropertyEquipmentAccumulatedDepreciation" contextRef="From2021-07-012022-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">6,169</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less: accumulated depreciation transferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--PropertyEquipmentAccumulatedDepreciationTransferred_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_zxFnPfGVg1G4" title="Less: accumulated depreciation transferred" style="text-align: right">(<ix:nonFraction name="GENE:PropertyEquipmentAccumulatedDepreciationTransferred" contextRef="From2022-07-012023-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">11,897</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--PropertyEquipmentAccumulatedDepreciationTransferred_pp0p0_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_zF5Sp4o31Zo6" title="Less: accumulated depreciation transferred" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1294">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Add: accumulated depreciation written-off during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--AccumulatedDepreciationWrittenoff_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_zPPNodBwMTB1" title="Add: accumulated depreciation written-off during the year" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1296">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--AccumulatedDepreciationWrittenoff_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_pp0p0" title="Add: accumulated depreciation written-off during the year" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1298">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net office equipment</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_zFvJNYjbLeV1" title="Net office equipment" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">6,466</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_zRheXY6B909a" title="Net office equipment" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">12,540</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total net property, plant and equipment</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20220701__20230630_zq6lrBJRKUd8" title="Total net property, plant and equipment" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">89,623</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20210701__20220630_zQCePAkbqgse" title="Total net property, plant and equipment" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">306,175</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Reconciliation of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Opening gross carrying amount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--PropertyPlantAndEquipment_iS_pp0p0_c20220701__20230630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zPKATVXJhvE1" title="Opening gross carrying amount" style="text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-06-30_ifrs-full_GrossCarryingAmountMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,284,395</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--PropertyPlantAndEquipment_iS_pp0p0_c20210701__20220630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zpZAGsCDjPfl" title="Opening gross carrying amount" style="text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2021-06-30_ifrs-full_GrossCarryingAmountMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,220,469</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Add: additions purchased during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20220701__20230630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zyjvnZJZImX" title="Add: additions purchased during the year" style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2022-07-012023-06-30_ifrs-full_GrossCarryingAmountMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">17,552</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20210701__20220630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zbSGF39Poxpf" title="Add: additions purchased during the year" style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2021-07-012022-06-30_ifrs-full_GrossCarryingAmountMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">63,926</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: cost written-off during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--LessCostWrittenoffDuringYear_pp0p0_c20220701__20230630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zig1efFFIbac" title="Less: cost written-off during the year" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:LessCostWrittenoffDuringYear" contextRef="From2022-07-012023-06-30_ifrs-full_GrossCarryingAmountMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">11,342</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--LessCostWrittenoffDuringYear_pp0p0_c20210701__20220630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z9tDJBHAkaa" title="Less: cost written-off during the year" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1318">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Closing gross carrying amount</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20220701__20230630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zPnKQngpPtwa" title="Closing gross carrying amount" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,290,605</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20210701__20220630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zrnyL5frdyN4" title="Closing gross carrying amount" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-06-30_ifrs-full_GrossCarryingAmountMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,284,395</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Opening accumulated depreciation and impairment losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--OpeningAccumulatedDepreciationAndImpairmentLosses_iS_pp0p0_c20220701__20230630_z7qaYwt1emO5" title="Opening accumulated depreciation and impairment losses" style="text-align: right">(<ix:nonFraction name="GENE:OpeningAccumulatedDepreciationAndImpairmentLosses" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">978,220</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--OpeningAccumulatedDepreciationAndImpairmentLosses_iS_pp0p0_c20210701__20220630_z3sVcrbVccYb" title="Opening accumulated depreciation and impairment losses" style="text-align: right">(<ix:nonFraction name="GENE:OpeningAccumulatedDepreciationAndImpairmentLosses" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">763,291</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Add: accumulated depreciation written-off during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--AccumulatedDepreciationWrittenoff_pp0p0_c20220701__20230630_zeUNxTnE1l22" title="Add: accumulated depreciation written-off during the year" style="text-align: right"><ix:nonFraction name="GENE:AccumulatedDepreciationWrittenoff" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,342</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--AccumulatedDepreciationWrittenoff_c20210701__20220630_pp0p0" title="Add: accumulated depreciation written-off during the year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1330">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less: cost written-off during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--LessCostWrittenoffDuringYear_pp0p0_c20220701__20230630_z5jk69ZMFGze" title="Less: cost written-off during the year" style="text-align: right">(<ix:nonFraction name="GENE:LessCostWrittenoffDuringYear" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">234,697</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--LessCostWrittenoffDuringYear_pp0p0_c20210701__20220630_zCmbFIZ3bXBf" title="Less: cost written-off during the year" style="text-align: right">(<ix:nonFraction name="GENE:LessCostWrittenoffDuringYear" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">214,929</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Add: foreign currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--AddForeignCurrencyTranslation_pp0p0_c20220701__20230630_zn46uQ2Ud2X7" title="Add: foreign currency translation" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:AddForeignCurrencyTranslation" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">593</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--AddForeignCurrencyTranslation_pp0p0_c20210701__20220630_z3WTSD5FoSP3" title="Add: foreign currency translation" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1338">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Closing accumulated depreciation and impairment losses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ClosingAccumulatedDepreciationAndImpairmentLosses_iE_pp0p0_c20220701__20230630_zdq2KEUtmfvl" title="Closing accumulated depreciation and impairment losses" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="GENE:ClosingAccumulatedDepreciationAndImpairmentLosses" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">1,200,982</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--ClosingAccumulatedDepreciationAndImpairmentLosses_iE_pp0p0_c20210701__20220630_z18o5DOpIy2l" title="Closing accumulated depreciation and impairment losses" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="GENE:ClosingAccumulatedDepreciationAndImpairmentLosses" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">978,220</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total net property, plant and equipment</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20220701__20230630_zF98tIoy31oj" title="Total net property, plant and equipment" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">89,623</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20210701__20220630_zYS7jNaKZr7b" title="Total net property, plant and equipment" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">306,175</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zgXPDuom7asi" style="margin-top: 0; margin-bottom: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPERTY, PLANT AND EQUIPMENT (cont.)</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:ScheduleOfReconciliationOfMovementsInPropertyPlantAndEquipmentByAssetCategoryExplanatory"><p id="xdx_89C_ecustom--ScheduleOfReconciliationOfMovementsInPropertyPlantAndEquipmentByAssetCategoryExplanatory_zggjCkkihyVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reconciliation
of movements in property, plant and equipment by asset category for the year ended June 30, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_8B4_zZjVmlSkJPZb" style="display: none">SCHEDULE
OF RECONCILIATION OF MOVEMENTS IN PROPERTY, PLANT AND EQUIPMENT BY ASSET CATEGORY</span></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Asset category</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opening net carrying Amount</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: -0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additions during year</b></span></p>
                                                                                                                                                                                                                                                     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: -0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transfer during year</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Depreciation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>expense<br />
 A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 6.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign currency translation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Closing net carrying amount</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 40%; text-align: left">Laboratory equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--PropertyPlantAndEquipment_iS_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentsMember_z692kZr10F3f" title="Opening net carrying amount" style="width: 6%; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-06-30_custom_LaboratoryEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">231,004</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentsMember_zgLK9xLJa6Pd" title="Additions during year" style="width: 6%; text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2022-07-012023-06-30_custom_LaboratoryEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">6,402</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentsMember_zBdEXWZLMS99" title="Transfer during year" style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1354">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_pp0p0_di_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentsMember_zyNidt2Y1vwa" title="Depreciation expense" style="width: 6%; text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2022-07-012023-06-30_custom_LaboratoryEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">196,928</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecustom--ForeignCurrencyTranslation_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentsMember_zLDKDC75xL65" title="Foreign currency translation" style="width: 6%; text-align: right">(<ix:nonFraction name="GENE:ForeignCurrencyTranslation" contextRef="From2022-07-012023-06-30_custom_LaboratoryEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">2</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentsMember_zvPhdRhFW9y7" title="Closing net carrying amount" style="width: 6%; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30_custom_LaboratoryEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">40,476</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Computer equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eifrs-full--PropertyPlantAndEquipment_iS_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ComputerEquipmentsMember_z0k5wCKjJOnk" title="Opening net carrying amount" style="text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-06-30_custom_ComputerEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">62,631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ComputerEquipmentsMember_zCenYeY1uZR1" title="Additions during year" style="text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2022-07-012023-06-30_custom_ComputerEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ComputerEquipmentsMember_zND3bPZGHJ6j" title="Transfer during year" style="text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" contextRef="From2022-07-012023-06-30_custom_ComputerEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">294</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_pp0p0_di_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ComputerEquipmentsMember_z2SbpaSKYbWb" title="Depreciation expense" style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2022-07-012023-06-30_custom_ComputerEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">31,394</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ForeignCurrencyTranslation_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ComputerEquipmentsMember_zIm0f0uq7bI1" title="Foreign currency translation" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1370">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ComputerEquipmentsMember_zkk9qnNVl0k3" title="Closing net carrying amount" style="text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30_custom_ComputerEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">42,681</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--PropertyPlantAndEquipment_iS_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_z6rsYMRg2je8" title="Opening net carrying amount" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">12,540</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_zbS7uEUalN9b" title="Additions during year" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1376">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_zJmdVQThERQd" title="Transfer during year" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" contextRef="From2022-07-012023-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">294</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_pp0p0_di_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_zXH5282uWTU7" title="Depreciation expense" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2022-07-012023-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">6,375</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ForeignCurrencyTranslation_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_zh8Iov3rxVsg" title="Foreign currency translation" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:ForeignCurrencyTranslation" contextRef="From2022-07-012023-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">595</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20220701__20230630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_z0Wt8V8DFXh7" title="Closing net carrying amount" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">6,466</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Totals</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--PropertyPlantAndEquipment_iS_pp0p0_c20220701__20230630_zaGgaFpZjeZb" title="Opening net carrying amount" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">306,175</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20220701__20230630_z3qESAQR01k3" title="Additions during year" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">17,552</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_pp0p0_c20220701__20230630_zuqDPuw7DT84" title="Transfer during year" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1390">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_pp0p0_di_c20220701__20230630_zvMqWQurPsR7" title="Depreciation expense" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">234,697</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ForeignCurrencyTranslation_pp0p0_c20220701__20230630_zKsJdSGh1dD5" title="Foreign currency translation" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="GENE:ForeignCurrencyTranslation" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">593</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20220701__20230630_zWCvJ7SFcWK5" title="Closing net carrying amount" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">89,623</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reconciliation
of movements in property, plant and equipment by asset category for the year ended June 30, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Asset category</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opening net carrying Amount</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additions during year</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: -0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disposals during year A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Depre- ciation expense</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Closing net carrying amount</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 35%; text-align: left">Laboratory equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--PropertyPlantAndEquipment_iS_pp0p0_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentsMember_z4B9w3iFsbZ9" title="Opening net carrying amount" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2021-06-30_custom_LaboratoryEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">412,889</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentsMember_pp0p0" title="Additions during year" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2021-07-012022-06-30_custom_LaboratoryEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">14,747</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--DisposalsPropertyPlantAndEquipment_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentsMember_pp0p0" title="Disposals during year" style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1402">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_pp0p0_di_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentsMember_zPoUvxn9igYk" title="Depreciation expense" style="width: 9%; text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2021-07-012022-06-30_custom_LaboratoryEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">196,632</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--LaboratoryEquipmentsMember_z21TZxCuqtA2" title="Closing net carrying amount" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-06-30_custom_LaboratoryEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">231,004</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Computer equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--PropertyPlantAndEquipment_iS_pp0p0_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ComputerEquipmentsMember_zpXiEBTfQkX1" title="Opening net carrying amount" style="text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2021-06-30_custom_ComputerEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">34,917</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ComputerEquipmentsMember_pp0p0" title="Additions during year" style="text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2021-07-012022-06-30_custom_ComputerEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">40,965</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--DisposalsPropertyPlantAndEquipment_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ComputerEquipmentsMember_pp0p0" title="Disposals during year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1412">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_pp0p0_di_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ComputerEquipmentsMember_zSVmS2CR9VA5" title="Depreciation expense" style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2021-07-012022-06-30_custom_ComputerEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">13,251</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ComputerEquipmentsMember_z2ZBx51OZnna" title="Closing net carrying amount" style="text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-06-30_custom_ComputerEquipmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">62,631</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--PropertyPlantAndEquipment_iS_pp0p0_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_z3alop4Qkhnk" title="Opening net carrying amount" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2021-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">9,372</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_pp0p0" title="Additions during year" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2021-07-012022-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">8,214</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--DisposalsPropertyPlantAndEquipment_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_pp0p0" title="Disposals during year" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1422">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_pp0p0_di_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_zNOrzl0TPEEa" title="Depreciation expense" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2021-07-012022-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">5,046</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20210701__20220630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OfficeEquipmentMember_zn5B1MfGd0Fe" title="Closing net carrying amount" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-06-30_ifrs-full_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">12,540</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Totals</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--PropertyPlantAndEquipment_iS_pp0p0_c20210701__20220630_zpAXlf42ZJef" title="Opening net carrying amount" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">457,178</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_c20210701__20220630_pp0p0" title="Additions during year" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">63,926</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--DisposalsPropertyPlantAndEquipment_c20210701__20220630_pp0p0" title="Disposals during year" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1432">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--DepreciationPropertyPlantAndEquipment_iN_pp0p0_di_c20210701__20220630_zLj7VW32bplf" title="Depreciation expense" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">214,929</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--PropertyPlantAndEquipment_iE_pp0p0_c20210701__20220630_ziRAFuOQrpPc" title="Closing net carrying amount" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">306,175</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A3_zRLbpRBv7WB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfGoodwillExplanatory"><p id="xdx_80B_eifrs-full--DisclosureOfGoodwillExplanatory_z7V2YV4imzdf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.
<span id="xdx_824_znrkTTgp9uHf">GOODWILL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>



<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory"><p id="xdx_890_eifrs-full--DisclosureOfReconciliationOfChangesInGoodwillExplanatory_z9uLERfMQzU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the movements in goodwill:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zJeZMHaA17u7" style="display: none">SUMMARY
OF CHANGES IN GOODWILL</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20220701__20230630_zEcWmYx08qq3" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20210701__20220630_zQIwP2jr5IY6" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross carrying amount:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--Goodwill_iS_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z6Cah9sukCt6" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%">Balance at beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2022-06-30_ifrs-full_GrossCarryingAmountMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,506,653</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1443">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zKtuy4a2je42" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Acquired through business combination - AffinityDNA (Note 17)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" contextRef="From2022-07-012023-06-30_ifrs-full_GrossCarryingAmountMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">455,240</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" contextRef="From2021-07-012022-06-30_ifrs-full_GrossCarryingAmountMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,506,653</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--Goodwill_iE_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zcr5BhU0xRac" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Balance at end of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,961,893</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2022-06-30_ifrs-full_GrossCarryingAmountMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,506,653</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accumulated impairment:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--Goodwill_iS_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedImpairmentMember_z4ZKD8sdhLL5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at beginning of period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1451">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1452">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--ImpairmentLossRecognisedInProfitOrLossGoodwill_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedImpairmentMember_zsNdZSeRjtW4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Impairment loss recognized</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill" contextRef="From2022-07-012023-06-30_ifrs-full_AccumulatedImpairmentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">1,845,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1455">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--Goodwill_iE_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedImpairmentMember_zzwpv2yUsOy2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance at end of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2023-06-30_ifrs-full_AccumulatedImpairmentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">1,845,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1458">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--Goodwill_iE_ztyrCLbw3Lvb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Carrying amount at the end of the period</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">3,116,893</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,506,653</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 461.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8AF_ztPvNGMrsXre" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has determined that the acquisition of AffinityDNA in the current year is a single cash generating unit. The total goodwill acquired
though business combination for AffinityDNA amounted to $<span id="xdx_902_eifrs-full--AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_c20220701__20230630__ifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_zSAEQTNTAjw9" title="Goodwill acquired through business combination"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">455,240</ix:nonFraction></span>. Further details of net assets acquired and of goodwill is disclosed
in Note 17.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.
GOODWILL (cont.)</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment testing for CGUs containing goodwill</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationAboutImpairmentOfGoodwill"><p id="xdx_89E_ecustom--DisclosureOfDetailedInformationAboutImpairmentOfGoodwill_zumaQTsBBp49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of impairment testing, goodwill has been allocated to the Group&#8217;s CGUs as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BA_zBnBJ7TdLZdc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF IMPAIRMENT TESTING GOODWILL</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20230630_zuGlpxdqCfSk" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20220630_zDN2Dv6zm0El" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net carrying amount at the end of the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--Goodwill_iI_hifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_zesjkbW2GeL6" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%">EasyDNA</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2023-06-30_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,661,653</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2022-06-30_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,506,653</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--Goodwill_iI_hifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_zFcPlxcCNgIh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">AffinityDNA</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2023-06-30_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">455,240</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1471">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--Goodwill_iI_zSICVXQl08R4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Goodwill allocation at 30 June</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">3,116,893</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,506,653</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8A9_z9VivAuhqIve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Key assumptions used for value-in-use calculations</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationAboutEstimatesUsedInGoodwillImpairmentAssessment"><p id="xdx_89F_ecustom--DisclosureOfDetailedInformationAboutEstimatesUsedInGoodwillImpairmentAssessment_zr9sUJSaf0bi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimates below were used in the goodwill impairment assessment for the acquired EasyDNA and AffinityDNA businesses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BF_zGYAfWNtoOjb" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SUMMARY
OF ESTIMATES USED IN GOODWILL IMPAIRMENT ASSESSMENT</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20220701__20230630__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_z2CW8LCNLMT2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">EasyDNA</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20220701__20230630__ifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_z8PENyrAtZyf" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">AffinityDNA</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_ecustom--GoodwillImpairmentAssessmentAssumptions_pid_dp_hifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--RevenueGrowthMember_zfDWaPIHjIYk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Revenue growth (FY2025 to FY2028)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="GENE:GoodwillImpairmentAssessmentAssumptions" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember_custom_RevenueGrowthMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.3</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="GENE:GoodwillImpairmentAssessmentAssumptions" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_RevenueGrowthMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.5</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_409_ecustom--GoodwillImpairmentAssessmentAssumptions_pid_dp_hifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--GrossMarginMember_zuWGsUMAJJTe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:GoodwillImpairmentAssessmentAssumptions" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember_custom_GrossMarginMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">47.5</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:GoodwillImpairmentAssessmentAssumptions" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_GrossMarginMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">45.0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_401_ecustom--GoodwillImpairmentAssessmentAssumptions_pid_dp_hifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--PreTaxDiscountRateMember_zsvHU17dOkbh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Pre-tax discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:GoodwillImpairmentAssessmentAssumptions" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember_custom_PreTaxDiscountRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">22.7</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:GoodwillImpairmentAssessmentAssumptions" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_PreTaxDiscountRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">22.7</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40E_ecustom--GoodwillImpairmentAssessmentAssumptions_pid_dp_hifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--PostTaxDiscountRateMember_zQDapE82HuRk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Post-tax discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:GoodwillImpairmentAssessmentAssumptions" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember_custom_PostTaxDiscountRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:GoodwillImpairmentAssessmentAssumptions" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_PostTaxDiscountRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40E_ecustom--GoodwillImpairmentAssessmentAssumptions_pid_dp_hifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--BeyondFiscalYearTwoThousandTwentySevenMember_zqSgJmezOvw7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Growth rate beyond FY2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:GoodwillImpairmentAssessmentAssumptions" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember_custom_BeyondFiscalYearTwoThousandTwentySevenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.3</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:GoodwillImpairmentAssessmentAssumptions" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_BeyondFiscalYearTwoThousandTwentySevenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.5</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_406_ecustom--GoodwillImpairmentAssessmentAssumptions_pid_dp_hifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--BeyondFiscalYearTwoThousandTwentySevenMember_zQazE6p3fUrb" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Assumptions for goodwill impairment assessment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:GoodwillImpairmentAssessmentAssumptions" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember_custom_BeyondFiscalYearTwoThousandTwentySevenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.3</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:GoodwillImpairmentAssessmentAssumptions" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_BeyondFiscalYearTwoThousandTwentySevenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.5</ix:nonFraction></td><td style="text-align: left">%</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AE_z3xtzCxgaoN" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key assumptions in the value-in-use impairment tests are estimated post-tax cash flows, revenue growth rates, gross margins and the discount
rate. Management is aware that reasonably possible negative changes in the estimated post-tax cash flows or the discount rate could cause
the recoverable amount to fall below the carrying amounts of the acquired EasyDNA and AffinityDNA businesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii) </i>I<i>mpairment
charge for goodwill</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>EasyDNA</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the impairment testing undertaken by management for the financial year ending June 30, 2023 an impairment loss of A$<span id="xdx_90B_eifrs-full--ImpairmentLossRecognisedInProfitOrLossGoodwill_c20220701__20230630__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_zzJk6HwxFCE5" title="Impairment loss recognised"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,845,000</ix:nonFraction></span> (2022:
<span id="xdx_90F_eifrs-full--ImpairmentLossRecognisedInProfitOrLossGoodwill_dxL_c20210701__20220630__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_znhxNyxFKTe2" title="Impairment loss recognised::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1498">Nil</span></span>) was recorded for the goodwill asset recorded as part of the EasyDNA business acquisition indicating that the carrying value exceeded
the recoverable amount of the CGU as at 30 June 2023. Although significant revenue was recorded in the financial year for EasyDNA, revenue
did not meet forecast expectations. Management believes there were a number of contributing factors, including increased competition
for the genetic tests offered by EasyDNA and slowing economic activity in key markets following the actions of central banks to bring
down inflation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the impairment loss recognized in the Group&#8217;s EasyDNA CGU, the recoverable amount was equal to the carrying amount. Therefore,
any adverse movement in a key assumption would lead to further impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>AffinityDNA</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s
assessment of impairment for AffinityDNA did not result in an impairment for AffinityDNA as the recoverable amounts exceeds it&#8217;s
carrying value by A$<span id="xdx_900_eifrs-full--IncreaseDecreaseThroughTransfersAndOtherChangesGoodwill_c20220701__20230630__ifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_zg7wi5TGdW6h" title="Carrying value"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesGoodwill" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">78,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eifrs-full--DescriptionOfReasonForChangeInMethodsAndAssumptionsUsedInPreparingSensitivityAnalysis_c20220701__20230630__ifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_zgLIV3gb6n3" title="Key impairment assumptions"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember" name="ifrs-full:DescriptionOfReasonForChangeInMethodsAndAssumptionsUsedInPreparingSensitivityAnalysis">Sensitivity
analysis undertaken on the key impairment model assumptions indicates that in order for the recoverable amount to be equal to their carrying
value for AffinityDNA, the discount rate would need to increase to 17.5% and revenue growth rate would need to decrease by 0.5%. Management
is not aware of any events that are expected to have an adverse effect on revenue growth</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory"><p id="xdx_807_eifrs-full--DisclosureOfIntangibleAssetsExplanatory_zSV6qQSTFWPb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.
<span id="xdx_825_zfuBOx6O22jh">OTHER INTANGIBLE ASSETS</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"><p id="xdx_89C_eifrs-full--DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_zOtaaVFiRzT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the movements in other intangible assets:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zusOYfGYuENc" style="display: none">SUMMARY
OF OTHER INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20220701__20230630_z3S2tIuJJZzd" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20210701__20220630_z5SbNJTjVALl" style="text-align: center; font-weight: bold">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross carrying amount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--OtherIntangibleAssets_iS_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z2o0X5No9gOd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Balance at beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:OtherIntangibleAssets" contextRef="AsOf2022-06-30_ifrs-full_GrossCarryingAmountMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">753,418</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1509">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__ifrs-full--BrandNamesMember_zSD6Rl3xBCKj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Brands, trademark and trade names, acquired through business combination</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="From2022-07-012023-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_BrandNamesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">41,264</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="From2021-07-012022-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_BrandNamesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">720,550</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--DomainNamesMember_zs9chRrbrDXh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Domain names</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1514">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" contextRef="From2021-07-012022-06-30_ifrs-full_GrossCarryingAmountMember_custom_DomainNamesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">32,868</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--OtherIntangibleAssets_iE_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zihwkveg3Hdf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Balance at end of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherIntangibleAssets" contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">794,682</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherIntangibleAssets" contextRef="AsOf2022-06-30_ifrs-full_GrossCarryingAmountMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">753,418</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accumulated amortization:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--OtherIntangibleAssets_iS_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedImpairmentMember_zCGGqM0LieD6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at beginning of period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:OtherIntangibleAssets" contextRef="AsOf2022-06-30_ifrs-full_AccumulatedImpairmentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">128,498</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1521">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--AmortizationOfOtherIntangibleAssets_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedImpairmentMember_zJs3apnu8JR" style="vertical-align: bottom; background-color: White">
    <td>Amortization for the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:AmortizationOfOtherIntangibleAssets" contextRef="From2022-07-012023-06-30_ifrs-full_AccumulatedImpairmentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">145,712</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:AmortizationOfOtherIntangibleAssets" contextRef="From2021-07-012022-06-30_ifrs-full_AccumulatedImpairmentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">128,498</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--OtherIntangibleAssets_iE_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedImpairmentMember_zyzNk07oBux5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance at end of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:OtherIntangibleAssets" contextRef="AsOf2023-06-30_ifrs-full_AccumulatedImpairmentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">274,210</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:OtherIntangibleAssets" contextRef="AsOf2022-06-30_ifrs-full_AccumulatedImpairmentMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">128,498</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eifrs-full--OtherIntangibleAssets_iE_zcuhzUqm0Nu5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Carrying amount at the end of the period</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherIntangibleAssets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">520,472</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherIntangibleAssets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">624,920</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8AD_zJ6vL5AHMiZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brand,
trademark, trade names and domain names acquired in a business combination that qualify for separate recognition are recognized as intangible
assets at their fair values. Brands, trademarks and trade names acquired through business combination for EasyDNA and AffinityDNA have
been recognized a one category of intangible asset for each segment as they are interconnected elements that collectively
contribute to a company&#8217;s image, recognition, and legal protection. They are essential components for establishing a strong market
presence, building consumer trust, and safeguarding a company&#8217;s intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Brand, trademark, trade names and domain names acquired in respect of the purchase of the EasyDNA business and its assets have been valued
using the &#8216;relief from royalty method&#8217;. The projected royalty cashflows were discounted to their present value assuming a
weighted average cost of capital of <span id="xdx_900_ecustom--WeightedAverageCostOfCapitalPercentage_pid_dp_c20220701__20230630__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_zPiS5GfkxKtk" title="Weighted average cost of capital"><ix:nonFraction name="GENE:WeightedAverageCostOfCapitalPercentage" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span>%. A net royalty rate of <span id="xdx_90A_ecustom--RoyaltyRatePercentage_pid_dp_c20220701__20230630__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_z6H9aOhSQVF2" title="Royalty rate"><ix:nonFraction name="GENE:RoyaltyRatePercentage" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.5</ix:nonFraction></span>% of projected EasyDNA revenues has been assumed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Brand, trademark, trade names and domain names acquired in respect of the purchase of AffinityDNA&#8217;s business and its assets have
been valued using the &#8216;relief from royalty method&#8217;. The projected royalty cashflows have been discounted to their present
value assuming a weighted average cost of capital of <span id="xdx_908_ecustom--WeightedAverageCostOfCapitalPercentage_pid_dp_c20220701__20230630__ifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_zlnqOET1cUwc" title="Weighted average cost of capital"><ix:nonFraction name="GENE:WeightedAverageCostOfCapitalPercentage" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">48</ix:nonFraction></span>%. A net royalty rate of <span id="xdx_904_ecustom--RoyaltyRatePercentage_pid_dp_c20220701__20230630__ifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_ziYHjpimbUX2" title="Royalty rate"><ix:nonFraction name="GENE:RoyaltyRatePercentage" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.5</ix:nonFraction></span>% of projected AffinityDNA revenues has been assumed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brand,
trademark, trade names and domain names are amortized on a straight-line basis over their estimated useful lives of five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfBusinessCombinationsExplanatory"><p id="xdx_801_eifrs-full--DisclosureOfBusinessCombinationsExplanatory_zDi9kde5BL7k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
<span><span id="xdx_82D_zEG4divz9562">BUSINESS ACQUISITION</span></span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
14 July 2022, the Company completed the acquisition of AffinityDNA&#8217;s direct-to-consumer eCommerce business and distribution rights.
The purchase consideration has two parts, A$<span id="xdx_905_eifrs-full--CashTransferred_iI_c20220714__ifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_zRDAHCsVzdoi" title="Amount settled in cash"><ix:nonFraction name="ifrs-full:CashTransferred" contextRef="AsOf2022-07-14_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">486,188</ix:nonFraction></span> (&#163;<span id="xdx_90E_eifrs-full--CashTransferred_iI_uEUR_c20220714__ifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_zWhxswkypgb7" title="Amount settled in cash"><ix:nonFraction name="ifrs-full:CashTransferred" contextRef="AsOf2022-07-14_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">277,500</ix:nonFraction></span>) on the acquisition date (which has been paid) and a further A$<span id="xdx_906_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_c20220714__ifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_zSKszcHZO7F" title="Total consideration"><ix:nonFraction name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" contextRef="AsOf2022-07-14_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">486,188</ix:nonFraction></span>
(&#163;<span id="xdx_900_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_uEUR_c20220714__ifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_zDTpwgYETQng" title="Total consideration"><ix:nonFraction name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" contextRef="AsOf2022-07-14_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">277,500</ix:nonFraction></span>) as contingent consideration. The second payment is payable on the achievement of certain financial targets and remained
unpaid at June 30, 2023. The second payment was payable on the achievement of a gross profit target for the 12-month period from the
acquisition date. This target was not achieved and therefore no further payment is to be made in respect of the acquisition of AffinityDNA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred in respect of acquisition were A$<span id="xdx_908_eifrs-full--AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_c20220714__20220714__ifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_zJhLKuZdEqGj" title="Acquistion cost"><ix:nonFraction name="ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" contextRef="From2022-07-142022-07-14_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">40,625</ix:nonFraction></span>, these have been recognized through profit or loss for the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
acquisition of AffinityDNA provides the Group with an additional and complimentary platform to further build its existing direct-to-consumer
offerings and lifestyle division. The acquisition also expands the Group&#8217;s portfolio of tests, geographic (including the UK and
US markets) and demographic access. The acquisition provides the group with operational, supply chain, distribution and commercial
synergies with its existing EasyDNA direct-to-consumer business that represents goodwill, which cannot be separately measured and identified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember" escape="true" name="ifrs-full:DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationExplanatory"><p id="xdx_898_eifrs-full--DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationExplanatory_hifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_zV8XUuU5vsTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets arising on acquisition were valued by an independent valuer. Details of net assets acquired and of goodwill are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zmn60ISfNylh" style="display: none">SUMMARY
OF BUSINESS ACQUISITION ASSETS AND GOODWILL ACQUIRED</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220714__ifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_z39icp7dBLZg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value of consideration transferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--CashTransferred_iI_zUVCa7PWTqnd" style="vertical-align: bottom; background-color: White">
    <td style="width: 82%; text-align: left; padding-bottom: 1.5pt">Amount settled in cash</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:CashTransferred" contextRef="AsOf2022-07-14_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">486,188</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_zgJ2DNEemYmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total consideration</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" contextRef="AsOf2022-07-14_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">486,188</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Recognized amounts of identifiable net assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_iI_maIAALAzH0S_zmj9jDiE0d3l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets <sup id="xdx_F48_zW7NF409Eff2">(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" contextRef="AsOf2022-07-14_custom_AffinityDNAMember" id="Fact001558" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">41,264</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_iNI_di_msIAALAzH0S_zvJonMUZW1Al" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="AsOf2022-07-14_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">10,316</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eifrs-full--IdentifiableAssetsAcquiredLiabilitiesAssumed_iTI_mtIAALAzH0S_zQIQpq2scOac" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Identifiable net assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" contextRef="AsOf2022-07-14_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">30,948</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--GoodwillRecognisedAsOfAcquisitionDate_iI_zpm2MmiLe9Kg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Goodwill on acquisition (Note 15)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" contextRef="AsOf2022-07-14_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">455,240</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zT1gKQC1yRKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total fair value of the contingent consideration transferred was on the basis that the probability of achieving the earn-out payment
at acquisition date was 0%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
arises on the acquisition of a business combination. Goodwill is calculated as the excess sum of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            consideration transferred;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            non-controlling interest; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            acquisition date fair value of any previously held equity interest; over the acquisition
                                            date fair value of net identifiable assets acquired.</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is not amortized. Instead, goodwill is tested annually for impairment, or more frequently if events or changes in circumstances indicate
that it might be impaired, and is carried at cost less accumulated impairment losses. Impairment losses on goodwill are taken to profit
or loss and are not subsequently reversed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F02_zlWYTX9fMyq2" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td><td style="text-align: justify"><span id="xdx_F18_zjEBBpooveJ3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001565" xml:lang="en-US">Intangible assets
relate to brand, trademark, trade names and domain names acquired as part of the business acquisition amounted to A$<span id="xdx_901_eifrs-full--IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_iI_c20220714__ifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_zUDMxybeZ1uj" title="Intangible assets" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQlVTSU5FU1MgQUNRVUlTSVRJT04gQVNTRVRTIEFORCBHT09EV0lMTCBBQ1FVSVJFRCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" contextRef="AsOf2022-07-14_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">41,264</ix:nonFraction></span> (refer to
Note 16 for further details). The useful life of these intangibles are amortized on a straight-line basis over their estimated useful
lives of <span id="xdx_906_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_dxL_c20220714__20220714__ifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_zsqYU9zIsf8b" title="Estimated useful lives::XDX::P5Y" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQlVTSU5FU1MgQUNRVUlTSVRJT04gQVNTRVRTIEFORCBHT09EV0lMTCBBQ1FVSVJFRCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><span style="-sec-ix-hidden: xdx2ixbrl1569">five years</span></span>.</ix:footnote></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AffinityDNA
reported revenue of A$<span id="xdx_907_eifrs-full--Revenue_c20220714__20230630__ifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_z6p4dWdNdfx"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-142023-06-30_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">944,058</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and incurred an operating loss of A$<span id="xdx_909_eifrs-full--ProfitLossBeforeTax_iN_di_c20220714__20230630__ifrs-full--BusinessCombinationsAxis__custom--AffinityDNAMember_zDtAThmadkh5"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2022-07-142023-06-30_custom_AffinityDNAMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">89,618</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from July 14, 2022 to the June 30, 2023. Given
that the acquisition date was fairly close to the start of the year, the impact to consolidated revenue and loss for the year would be
immaterial, even if the acquisition had occurred on 1 July 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
BUSINESS ACQUISITION (cont.)</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prior
year&#8217;s business acquisition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
13 August 2021, the Company completed the acquisition of EasyDNA&#8217;s assets and business. The purchase was settled by A$<span id="xdx_90E_eifrs-full--CashTransferred_iI_c20210813__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_z3aYHUK367X8" title="Amount settled in cash"><ix:nonFraction name="ifrs-full:CashTransferred" contextRef="AsOf2021-08-13_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">3,400,625</ix:nonFraction></span>
in cash and A$<span id="xdx_908_eifrs-full--EquityInterestsOfAcquirer_iI_c20210813__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_ztAKKcNUKxNl" title="Amount settled in shares, value"><ix:nonFraction name="ifrs-full:EquityInterestsOfAcquirer" contextRef="AsOf2021-08-13_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,574,136</ix:nonFraction></span> in GTG shares. Costs incurred in respect of acquisition were A$<span id="xdx_90C_eifrs-full--AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_c20210813__20210813__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_zUFGsMqzesj9" title="Acquistion cost"><ix:nonFraction name="ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" contextRef="From2021-08-132021-08-13_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">116,682</ix:nonFraction></span>, these have been recognized through profit
or loss for the period. The acquisition provides the foundation for the Company to grow its portfolio of serious disease test through
direct-to-consumer market and additional platform for growth and expansion into lifestyle testing. The acquisition will provide the Group
with operational and sales channel synergies that represents goodwill, which cannot be separately measured and identified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_EasyDNAMember" escape="true" name="ifrs-full:DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationExplanatory"><p id="xdx_89D_eifrs-full--DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationExplanatory_hifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_z8oswSRzdUE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets arising on acquisition were valued by an independent valuer. Details of net assets acquired and of goodwill are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BC_zpOGZCc25KV4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SUMMARY
OF BUSINESS ACQUISITION ASSETS AND GOODWILL ACQUIRED</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20210813__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_zZcFNKxWLqLc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value of consideration transferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Amount settled in cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--CashTransferred_iI_c20210813__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_zt6ZZAGvpmWe" title="Amount settled in cash" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:CashTransferred" contextRef="AsOf2021-08-13_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">3,400,625</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Amount settled in shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfInstrumentsOrInterestsIssuedOrIssuable_iI_c20210813__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_zc7M70bIIxVg" title="Amount settled in shares, shares" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" contextRef="AsOf2021-08-13_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">209,363,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--EquityInterestsOfAcquirer_iI_c20210813__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_zpGJHvqxPbrh" title="Amount settled in shares, value" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:EquityInterestsOfAcquirer" contextRef="AsOf2021-08-13_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,574,136</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total consideration</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_c20210813__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_zq5Pwcy20O2c" title="Total consideration" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" contextRef="AsOf2021-08-13_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,974,761</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Recognized amounts of identifiable net assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--FinancialAssetsRecognisedAsOfAcquisitionDate_iI_maIAALAzH0S_zO1up8vF4enk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssetsRecognisedAsOfAcquisitionDate" contextRef="AsOf2021-08-13_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">42,289</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_iI_maIAALAzH0S_zhLRCllS5SJf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets <sup id="xdx_F46_zX4p1rqggtK3">(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" contextRef="AsOf2021-08-13_custom_EasyDNAMember" id="Fact001591" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">720,550</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_iNI_di_msIAALAzH0S_zpO5F4md1VAf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" contextRef="AsOf2021-08-13_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">19,193</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--LeaseLiabilitiesRecognisedAsOfAcquisitionDate_iNI_di_msIAALAzH0S_z1vhvbnTFy3e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:LeaseLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="AsOf2021-08-13_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">42,289</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--EmployeeBenefitProvisionsRecognisedAsOfAcquisitionDate_iNI_di_msIAALAzH0S_zc3LMTDeHN3l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Employee benefit provisions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:EmployeeBenefitProvisionsRecognisedAsOfAcquisitionDate" contextRef="AsOf2021-08-13_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">53,111</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eifrs-full--DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_iNI_di_msIAALAzH0S_z4rEME7lRF54" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred tax liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="AsOf2021-08-13_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">180,138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eifrs-full--IdentifiableAssetsAcquiredLiabilitiesAssumed_iTI_mtIAALAzH0S_z4nMVQZQUjTg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Identifiable net assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" contextRef="AsOf2021-08-13_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">468,108</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--GoodwillRecognisedAsOfAcquisitionDate_iI_z2Z3ZhTyDXR3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Goodwill on acquisition (Note 15)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" contextRef="AsOf2021-08-13_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,506,653</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zaP0LEsj4XSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
arises on the acquisition of a business combination. Goodwill is calculated as the excess sum of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -34.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            consideration transferred;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            non-controlling interest; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            acquisition date fair value of any previously held equity interest; over the acquisition
                                            date fair value of net identifiable assets acquired.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is not amortized. Instead, goodwill is tested annually for impairment, or more frequently if events or changes in circumstances indicate
that it might be impaired, and is carried at cost less accumulated impairment losses. Impairment losses on goodwill are taken to profit
or loss and are not subsequently reversed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0E_zr2kuXH2hR0k">(1)</sup></span></td><td style="text-align: justify"><span id="xdx_F1B_zy3XlLMVskKa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001604" xml:lang="en-US">Intangible assets
relate to brand, trademark, trade names and domain names acquired as part of the business acquisition amounted to A$<span id="xdx_908_eifrs-full--IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_iI_c20210813__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_z1Ib7vpiMVu3" title="Intangible assets" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQlVTSU5FU1MgQUNRVUlTSVRJT04gQVNTRVRTIEFORCBHT09EV0lMTCBBQ1FVSVJFRCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" contextRef="AsOf2021-08-13_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">720,550</ix:nonFraction></span> (refer to
Note 16 for further details).</ix:footnote></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EasyDNA
reported revenue of A$<span id="xdx_909_eifrs-full--Revenue_c20210813__20220630__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_zPYSrqYahyZd" title="Revenue"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-08-132022-06-30_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">5,989,782</ix:nonFraction></span> and incurred an operating loss of A$<span id="xdx_901_eifrs-full--ProfitLossBeforeTax_iN_di_c20210813__20220630__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_zYWo2y5brBi3" title="Operating loss"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2021-08-132022-06-30_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">165,000</ix:nonFraction></span> from August 13, 2021 to the June 30, 2022. The revenue and
operating loss as at June 30, 2023 for EasyDNA CGU are A$<span id="xdx_90A_eifrs-full--Revenue_c20220701__20230630__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_zk8T5w5teJ5c" title="Revenue"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">7,698,605</ix:nonFraction></span> and A$<span id="xdx_904_eifrs-full--ProfitLossBeforeTax_iN_di_c20220701__20230630__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_zfiqv43Ckvul" title="Operating loss"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">2,871,259</ix:nonFraction></span>, respectively (see Note 25).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no contingent consideration arrangements related to the acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory"><p id="xdx_808_eifrs-full--DisclosureOfTradeAndOtherPayablesExplanatory_zVcCtEbay0qj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_826_z8hTgKvWnhs7">TRADE AND OTHER PAYABLES (CURRENT)</span></b></span></p>



<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationAboutTradeAndOtherPayables"><p id="xdx_897_ecustom--DisclosureOfDetailedInformationAboutTradeAndOtherPayables_zf0yiv6vgNkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B0_zsmnZUwuu1W4" style="display: none">SCHEDULE
OF TRADE AND OTHER PAYABLES</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230630_zCaE0i2pq0p6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220630_zxNuvaIJroD7" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--TradeAndOtherCurrentPayablesToTradeSuppliers_iI_pp0p0_maTAOCPz0vW_zd2l5uGatz86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Trade payables</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">837,952</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,153,856</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--AccrualsClassifiedAsCurrent_iI_pp0p0_maTAOCPz0vW_zPCaTmPJWct6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AccrualsClassifiedAsCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">618,163</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AccrualsClassifiedAsCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">953,439</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--OtherCurrentPayables_iI_pp0p0_maTAOCPz0vW_zKEC44qjcH5b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentPayables" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">161,218</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentPayables" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">15,084</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--TradeAndOtherCurrentPayables_iTI_pp0p0_mtTAOCPz0vW_zlnWunALzQR1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current trade and other payables</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,617,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,122,379</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AF_zPVW1rIyBy26" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfProvisionsExplanatory"><p id="xdx_800_eifrs-full--DisclosureOfProvisionsExplanatory_zppc4hM2jRXg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_za9j9PpRw6U8">PROVISIONS (CURRENT AND NON-CURRENT)</span></b></span></p>



<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationAboutProvisions"><p id="xdx_896_ecustom--DisclosureOfDetailedInformationAboutProvisions_zv5XHlBRGyug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B3_zeE8dm3jFjAa" style="display: none">SCHEDULE
OF CURRENT AND NON-CURRENT PROVISIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="display: none">&#160;</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230630_zDYj2NqgLzX8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20220630_zi6DZqEko4e2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Current provisions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CurrentProvisions_iI_pp0p0_hifrs-full--ClassesOfProvisionsAxis__custom--AnnualLeaveProvisionMember_zaWHgxkAuoWg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Annual leave</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:CurrentProvisions" contextRef="AsOf2023-06-30_custom_AnnualLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">328,924</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:CurrentProvisions" contextRef="AsOf2022-06-30_custom_AnnualLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">312,665</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--CurrentProvisions_iI_pp0p0_hifrs-full--ClassesOfProvisionsAxis__custom--LongServiceLeaveProvisionMember_zY2uX9uBDVi5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Long service leave</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentProvisions" contextRef="AsOf2023-06-30_custom_LongServiceLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">121,416</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentProvisions" contextRef="AsOf2022-06-30_custom_LongServiceLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">206,805</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--CurrentProvisions_iI_pp0p0_hifrs-full--ClassesOfProvisionsAxis__custom--MakeGoodProvisionMember_z2ovskuS4ULc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Make good <sup id="xdx_F4A_zT3M5fT2M2Bl">(1)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CurrentProvisions" contextRef="AsOf2023-06-30_custom_MakeGoodProvisionMember" id="Fact001642" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">91,590</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CurrentProvisions" contextRef="AsOf2022-06-30_custom_MakeGoodProvisionMember" id="Fact001643" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">91,590</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--CurrentProvisions_iI_pp0p0_maPzghi_za5x6wOIPI95" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current provisions</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentProvisions" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">541,930</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentProvisions" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">611,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Non-current provisions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--NoncurrentProvisions_iI_pp0p0_hifrs-full--ClassesOfProvisionsAxis__custom--LongServiceLeaveProvisionMember_zXEmYjyprAV1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Long service leave</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentProvisions" contextRef="AsOf2023-06-30_custom_LongServiceLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">30,439</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentProvisions" contextRef="AsOf2022-06-30_custom_LongServiceLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">22,499</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--NoncurrentProvisions_iI_pp0p0_maPzghi_zRJ1N35sju8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total non-current provisions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentProvisions" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">30,439</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentProvisions" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">22,499</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--Provisions_iTI_pp0p0_mtPzghi_zzLDdlhC2Dvg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total provisions</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Provisions" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">572,369</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Provisions" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">633,559</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F05_zd3njWpOCO74">(1)</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F16_zBTsGJ4Lt2Cj"><ix:footnote id="Footnote001656" xml:lang="en-US">Make good provision
in respect of the lease of the Melbourne office and laboratory</ix:footnote></i></span></td>
</tr></table>



</ix:nonNumeric><p id="xdx_8A4_zYfZIUMxKdU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfOtherProvisionsExplanatory"><p id="xdx_89C_eifrs-full--DisclosureOfOtherProvisionsExplanatory_zYYy6mPcZhKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8BC_zaD1cuH2KvCj">SCHEDULE
OF RECONCILIATION OF PROVISION</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220701__20230630_z2vRjeYJEsN5" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20210701__20220630_ziGjffiFB7Nl" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Reconciliation of annual leave provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--OtherProvisions_iS_pp0p0_hifrs-full--ClassesOfProvisionsAxis__custom--AnnualLeaveProvisionMember_zAjwh4iBi8Z3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Balance at the beginning of the financial year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="AsOf2022-06-30_custom_AnnualLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">312,665</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="AsOf2021-06-30_custom_AnnualLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">171,398</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--NewProvisionsOtherProvisions_hifrs-full--ClassesOfProvisionsAxis__custom--AnnualLeaveProvisionMember_zzCF2IPmPdi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Add: obligation accrued during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:NewProvisionsOtherProvisions" contextRef="From2022-07-012023-06-30_custom_AnnualLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">400,780</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:NewProvisionsOtherProvisions" contextRef="From2021-07-012022-06-30_custom_AnnualLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">366,816</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--ProvisionUsedOtherProvisions_iN_pp0p0_di_hifrs-full--ClassesOfProvisionsAxis__custom--AnnualLeaveProvisionMember_zc79hC06O5R" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less: utilized during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProvisionUsedOtherProvisions" contextRef="From2022-07-012023-06-30_custom_AnnualLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">388,457</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProvisionUsedOtherProvisions" contextRef="From2021-07-012022-06-30_custom_AnnualLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">225,549</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_pp0p0_hifrs-full--ClassesOfProvisionsAxis__custom--AnnualLeaveProvisionMember_zqEpQTAletbd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: FX on translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" contextRef="From2022-07-012023-06-30_custom_AnnualLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">3,936</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1670">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--OtherProvisions_iE_pp0p0_hifrs-full--ClassesOfProvisionsAxis__custom--AnnualLeaveProvisionMember_zy113b8iVuU9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Balance at the end of the financial year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="AsOf2023-06-30_custom_AnnualLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">328,924</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="AsOf2022-06-30_custom_AnnualLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">312,665</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Reconciliation of long service leave provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--OtherProvisions_iS_pp0p0_hifrs-full--ClassesOfProvisionsAxis__custom--LongServiceLeaveProvisionMember_zvuPGhenj5r8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Balance at the beginning of the financial year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="AsOf2022-06-30_custom_LongServiceLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">229,304</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="AsOf2021-06-30_custom_LongServiceLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">210,642</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ObligationAccrued_pp0p0_hifrs-full--ClassesOfProvisionsAxis__custom--LongServiceLeaveProvisionMember_znC6BmDb1hUi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Add: obligation accrued during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:ObligationAccrued" contextRef="From2022-07-012023-06-30_custom_LongServiceLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">21,723</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:ObligationAccrued" contextRef="From2021-07-012022-06-30_custom_LongServiceLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">18,662</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--UnusedProvisionReversedOtherProvisions_iN_pp0p0_di_hifrs-full--ClassesOfProvisionsAxis__custom--LongServiceLeaveProvisionMember_zhkkrl8h8Bd7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less: reversal during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:UnusedProvisionReversedOtherProvisions" contextRef="From2022-07-012023-06-30_custom_LongServiceLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">472</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1682">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ProvisionsPaidoffOtherProvisions_pp0p0_hifrs-full--ClassesOfProvisionsAxis__custom--LongServiceLeaveProvisionMember_zhNHS0PLsb69" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: paid off during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:ProvisionsPaidoffOtherProvisions" contextRef="From2022-07-012023-06-30_custom_LongServiceLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">98,700</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1685">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--OtherProvisions_iE_pp0p0_hifrs-full--ClassesOfProvisionsAxis__custom--LongServiceLeaveProvisionMember_zR4b4kEwFRa3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Balance at the end of the financial year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="AsOf2023-06-30_custom_LongServiceLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">151,855</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherProvisions" contextRef="AsOf2022-06-30_custom_LongServiceLeaveProvisionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">229,304</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zGf7XrNM1ua7" style="margin-top: 0; margin-bottom: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfLeasesExplanatory"><p id="xdx_80A_eifrs-full--DisclosureOfLeasesExplanatory_z7R5s85Bjsi8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>20.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zi8QI5YJTf9a">RIGHT-OF-USE ASSET / (LEASE LIABILITIES)</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amounts recognized in the statement of financial position</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationAboutRightofuseAssetsAndLeaseLiabilities"><p id="xdx_896_ecustom--DisclosureOfDetailedInformationAboutRightofuseAssetsAndLeaseLiabilities_zs3ZtihLwCob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
statement of financial position shows the following amounts relating to leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zdmpQhsv0ipl" style="display: none">SCHEDULE
OF RIGHT-OF-USE ASSETS AND LEASE LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20230630_z2XKAKlAcdI4" style="font-weight: bold; text-align: center">2023</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20220630_zBbl2BRuT9T2" style="text-align: center; font-weight: bold">2022</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; font-style: italic; text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--RightofuseAssets_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Right-of-use assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">509,553</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">647,150</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; font-style: italic; text-align: left">Lease Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--CurrentLeaseLiabilities_iNI_pp0p0_di_maLLz8uw_zmRIzfQ9D6Y2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Lease liabilities - Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">303,570</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">264,130</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eifrs-full--NoncurrentLeaseLiabilities_iNI_pp0p0_di_maLLz8uw_z6x7msQ84KP" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Lease liabilities - Non-Current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">229,276</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">388,396</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eifrs-full--LeaseLiabilities_iNTI_pp0p0_di_mtLLz8uw_zf52NGKCpOCd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">532,846</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">652,526</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zC5WyUGXDhD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)</i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <b><i>Amounts
recognized in the statement of profit or loss</i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationAboutExpensesRelatingToLeases"><p id="xdx_899_ecustom--DisclosureOfDetailedInformationAboutExpensesRelatingToLeases_zexvQsAnzX9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
statement of profit or loss under general and administrative expenses includes the following amounts relating to leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zibmafEEtMI9" style="display: none">SCHEDULE
OF EXPENSES RELATING TO LEASES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20220701__20230630_zAC3IaUfChA4" style="font-weight: bold; text-align: center">2023</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20210701__20220630_zLhizBn9akR8" style="text-align: center; font-weight: bold">2022</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Depreciation charge of right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AdjustmentsForDepreciationOfRightofuseOfAssets_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Depreciation Expense (for Leased Assets)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="GENE:AdjustmentsForDepreciationOfRightofuseOfAssets" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">296,174</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="GENE:AdjustmentsForDepreciationOfRightofuseOfAssets" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">235,241</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--InterestExpense_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense (included in finance costs)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:InterestExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">29,515</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:InterestExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">15,215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_zDTD48Cc23Xe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Low value leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">32,094</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">26,408</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8AB_zmV7okWy0zw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the financial year ended June 30, 2023, the total cash outflow was A$<span id="xdx_900_eifrs-full--CashOutflowForLeases_pp0p0_c20220701__20230630_zc6DoqpTc9W4" title="Cash outflow"><ix:nonFraction name="ifrs-full:CashOutflowForLeases" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">336,396</ix:nonFraction></span> (2022: A$<span id="xdx_900_eifrs-full--CashOutflowForLeases_c20210701__20220630_pp0p0" title="Cash outflow"><ix:nonFraction name="ifrs-full:CashOutflowForLeases" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">268,590</ix:nonFraction></span>).</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory"><p id="xdx_800_eifrs-full--DisclosureOfClassesOfShareCapitalExplanatory_zoG21cw6zhe9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>21.
<span id="xdx_82C_z20Zdf3KpC08">CONTRIBUTED EQUITY</span></b></span></p>



<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfIssuedCapitalExplanatory"><p id="xdx_896_eifrs-full--DisclosureOfIssuedCapitalExplanatory_zRqRc7aK74Qf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span style="display: none"><span id="xdx_8BA_zQvNoOlRivj6">SCHEDULE OF ISSUED AND PAID-UP CAPITAL</span></span></b></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Issued and paid-up capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left; padding-bottom: 1.5pt">Fully paid Ordinary Shares</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--OrdinarySharesIssuedAndFullyPaid_pp0p0_c20220701__20230630_zLMeCtaASkhj" title="Fully paid Ordinary Shares" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="GENE:OrdinarySharesIssuedAndFullyPaid" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">161,342,707</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecustom--OrdinarySharesIssuedAndFullyPaid_pp0p0_c20210701__20220630_zhayb7iswqYi" title="Fully paid Ordinary Shares" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="GENE:OrdinarySharesIssuedAndFullyPaid" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">155,138,636</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total contributed equity</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--IssuedCapital_iI_pp0p0_c20230630_zdBvoMxgJqa4" title="Total contributed equity" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">161,342,707</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--IssuedCapital_c20220630_pp0p0" title="Total contributed equity" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">155,138,636</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_z0mwMS2wa2xj" style="margin-top: 0; margin-bottom: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>21.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTRIBUTED EQUITY (cont.)</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationAboutReconciliationOfShareCapital"><p id="xdx_89F_ecustom--DisclosureOfDetailedInformationAboutReconciliationOfShareCapital_zTznESmNDz8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Movements
in shares on issue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B1_zDeo968zHk19" style="display: none">SCHEDULE OF MOVEMENTS IN SHARES ON ISSUE</span></b></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended June 30, 2023</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 10pt">Balance at the beginning of the financial year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfSharesOutstanding_iS_pid_c20220701__20230630_ztIRabo6rfX8" title="Number of shares at beginning" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,233,965,143</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--IssuedCapital_iS_pp0p0_c20220701__20230630_zCKOB5PjeVB7" title="Contributed equity, at the beginning" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">155,138,636</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Shares issued during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--IssueOfEquityShares_pid_c20220701__20230630_zVCkgto5g208" title="Shares issued during the year (in shares)" style="text-align: right"><ix:nonFraction name="GENE:IssueOfEquityShares" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,307,693,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--SharesIssuedDuringYear_pp0p0_c20220701__20230630_zWVqcbrENdcf" title="Shares issued during the year" style="text-align: right"><ix:nonFraction name="GENE:SharesIssuedDuringYear" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">7,172,399</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Add: Exercise of performance rights</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ExerciseOfPerformanceRightsShares_pid_c20220701__20230630_zQ86rLIsOech" title="Shares issued during the year (in shares)" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1743">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ExerciseOfPerformanceRightsContributedEquity_pp0p0_c20220701__20230630_zkQdt3PKE9j8" title="Exercise of performance rights" style="text-align: right"><ix:nonFraction name="GENE:ExerciseOfPerformanceRightsContributedEquity" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">82,688</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: transaction costs arising on share issue <sup>(i)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareIssueRelatedCostShares_pid_c20220701__20230630_fKGkp_zGGrH0rygGrf" title="Transaction costs arising on share issue (in shares)" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1747">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eifrs-full--ShareIssueRelatedCost_iN_pp0p0_di_c20220701__20230630_fKGkp_zewH1gHJT3mi" title="Less: transaction costs arising on share issue" style="text-align: right">(<ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="From2022-07-01to2023-06-30" id="Fact001749" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">916,060</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Less: valuation of warrants to be issued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ValuationOfWarrantsToBeIssuedShares_pid_c20220701__20230630_zwYZmFOZlURb" title="Valuation of warrants to be issued (in shares)" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1751">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--ValuationOfWarrantsToBeIssued_pp0p0_c20220701__20230630_zG1DIDg7n3Rk" title="Valuation of warrants to be issued" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:ValuationOfWarrantsToBeIssued" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">134,956</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Balance at the end of the financial year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfSharesOutstanding_iE_pid_c20220701__20230630_z1nlyQaat6x5" title="Number of shares at end" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,541,658,143</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--IssuedCapital_iE_pp0p0_c20220701__20230630_zi8AtY1WJopk" title="Contributed equity, at the end" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">161,342,707</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended June 30, 2022</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 10pt">Balance at the beginning of the financial year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfSharesOutstanding_iS_pid_c20210701__20220630_ztDtD3BwDD1g" title="Number of shares at beginning" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,016,726,743</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--IssuedCapital_iS_pp0p0_c20210701__20220630_zfwcnTUJu5Sa" title="Contributed equity, at the beginning" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">153,574,974</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Shares issued during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--IssueOfEquityShares_pid_c20210701__20220630_z0JJkQbggrSi" title="Shares issued during the year (in shares)" style="text-align: right"><ix:nonFraction name="GENE:IssueOfEquityShares" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">217,238,400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--SharesIssuedDuringYear_pp0p0_c20210701__20220630_znH9Ge1s9NE4" title="Shares issued during the year" style="text-align: right"><ix:nonFraction name="GENE:SharesIssuedDuringYear" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,574,136</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: transaction costs arising on share issue <sup>(i)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareIssueRelatedCostShares_pid_c20210701__20220630_fKGkp_z1UmUCQ2OYe8" title="Transaction costs arising on share issue (in shares)" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1767">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--ShareIssueRelatedCost_iN_pp0p0_di_c20210701__20220630_fKGkp_zW6AwD07Abag" title="Less: transaction costs arising on share issue" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="From2021-07-012022-06-30" id="Fact001769" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">10,474</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Balance at the end of the financial year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--NumberOfSharesOutstanding_iE_pid_c20210701__20220630_zSMzZcwQHxRf" title="Number of shares at end" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#8239;<ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,233,965,143</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--IssuedCapital_iE_pp0p0_c20210701__20220630_zJ1GZRVVFt18" title="Contributed equity, at the end" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">155,138,636</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span id="xdx_F0F_zR2oVrhNOzN3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F17_z1hhSgvnQhNa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001774" xml:lang="en-US">The
    details of securities arising on shares issued for the year ended June 30, 2023 and June 30 2022 are as below:</ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    July 19, 2021, the Company issued <span id="xdx_903_eifrs-full--NumberOfSharesIssued_iI_pid_uShares_c20210719__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_zDk5ET2kqSqf" title="Number of shares issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PVkVNRU5UUyBJTiBTSEFSRVMgT04gSVNTVUUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2021-07-19_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">209,363,400</ix:nonFraction></span> new ordinary shares, at fair value of A$<span id="xdx_909_ecustom--NumberOfSharesIssuedIssuedForAcquisition_iI_c20210719__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_zWcZyHgIsIz4" title="Shares issued for acquisition, value" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PVkVNRU5UUyBJTiBTSEFSRVMgT04gSVNTVUUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="GENE:NumberOfSharesIssuedIssuedForAcquisition" contextRef="AsOf2021-07-19_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,574,136</ix:nonFraction></span> in part consideration for the acquisition
    of <span id="xdx_902_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pid_dp_c20210719__ifrs-full--BusinessCombinationsAxis__custom--EasyDNAMember_zvh9vJrgzbM3" title="Percentage of ownership interests acquired" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PVkVNRU5UUyBJTiBTSEFSRVMgT04gSVNTVUUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" contextRef="AsOf2021-07-19_custom_EasyDNAMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of EasyDNA.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    November 3, 2021, the Company issued <span id="xdx_907_eifrs-full--NumberOfSharesIssued_iI_pid_c20211103__ifrs-full--TypesOfContractsAxis__custom--EmployeeShareOptionPlanMember_zkG7wH430uBl" title="Number of shares issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PVkVNRU5UUyBJTiBTSEFSRVMgT04gSVNTVUUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2021-11-03_custom_EmployeeShareOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,875,000</ix:nonFraction></span> new ordinary shares pursuant to the Company&#8217;s Employee Performance Rights Plan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 7, 2023, the Company issued <span id="xdx_907_eifrs-full--NumberOfSharesIssued_iI_pid_c20230207__ifrs-full--TypesOfContractsAxis__custom--AmericanDepositarySharesMember_zWUWI42nAnz2" title="Number of shares issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PVkVNRU5UUyBJTiBTSEFSRVMgT04gSVNTVUUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2023-02-07_custom_AmericanDepositarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,846,155</ix:nonFraction></span> ADSs, each representing six hundred (<span id="xdx_909_eifrs-full--NumberOfSharesIssued_iI_pid_c20230207_zV949avqkyk5" title="Ordinary shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PVkVNRU5UUyBJTiBTSEFSRVMgT04gSVNTVUUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2023-02-07" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600</ix:nonFraction></span>) of the Company&#8217;s ordinary shares,
    totaling <span id="xdx_907_ecustom--NumberOfSharesIssuedTotal_iI_pid_c20230207_ztQeqxBugnGd" title="Ordinary shares, totaling" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PVkVNRU5UUyBJTiBTSEFSRVMgT04gSVNTVUUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="GENE:NumberOfSharesIssuedTotal" contextRef="AsOf2023-02-07" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,307,693,000</ix:nonFraction></span> ordinary shares, at a purchase price of United States Dollars (US$) US$<span id="xdx_906_eifrs-full--ParValuePerShare_iI_pid_uUSDPShares_c20230207_zg1xmOabwp67" title="Ordinary shares per share" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PVkVNRU5UUyBJTiBTSEFSRVMgT04gSVNTVUUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="AsOf2023-02-07" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.30</ix:nonFraction></span> per ADS. The gross proceeds for
    this offering were approximately US$<span id="xdx_90C_eifrs-full--ProceedsFromIssuingShares_pn6n6_uUSD_c20230207__20230207__ifrs-full--TypesOfContractsAxis__custom--AmericanDepositarySharesMember_zEeJ2VHHivWi" title="Ordinary shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PVkVNRU5UUyBJTiBTSEFSRVMgT04gSVNTVUUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="From2023-02-072023-02-07_custom_AmericanDepositarySharesMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million. Against the offering, the Company agreed to issue <span id="xdx_90D_eifrs-full--NumberOfSharesIssued_iI_pid_uShares_c20230207__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zdoYGRENcYr3" title="Number of shares issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PVkVNRU5UUyBJTiBTSEFSRVMgT04gSVNTVUUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2023-02-07_ifrs-full_WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> warrants exercisable at
    US$<span id="xdx_90E_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_iI_pid_uUSDPShares_c20230207__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_zNK1IwMbBRj7" title="Warrant exercisable price , per share" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PVkVNRU5UUyBJTiBTSEFSRVMgT04gSVNTVUUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" contextRef="AsOf2023-02-07_ifrs-full_WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.625</ix:nonFraction></span> each, <span id="xdx_909_ecustom--DescriptionOfMaximumTermOfExpiringIssuedDate_c20230207__20230207__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--WarrantsMember_z24Ze89XLZsd" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PVkVNRU5UUyBJTiBTSEFSRVMgT04gSVNTVUUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" title="Description of term of expiring year"><ix:nonNumeric contextRef="From2023-02-072023-02-07_ifrs-full_WarrantsMember" name="GENE:DescriptionOfMaximumTermOfExpiringIssuedDate">expiring in 5 years from issue date</ix:nonNumeric></span>, to H.C. Wainwright &amp; Co which would form part of cost of raising capital.
    The said warrants are subject to shareholder approval at the Company&#8217;s 2023 annual general meeting.</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AF_z82wKtFAxjT9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terms
and conditions of contributed equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
shares have the right to receive dividends as declared and, in the event of winding up the Company, to participate in the proceeds from
the sale of all surplus assets in proportion to the number of and amounts paid up on shares held. Ordinary shares, which have no par
value, entitle their holder to one vote, either in person or by proxy, at a meeting of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"><p id="xdx_809_eifrs-full--DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_zUhqCZRr7cP2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>22.
<span id="xdx_820_zpKQ4P7w6pO4">RESERVES</span></b></span></p>



<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory"><p id="xdx_899_eifrs-full--DisclosureOfReservesAndOtherEquityInterestExplanatory_zQSxpxrVKn2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span style="display: none"><span id="xdx_8B6_zSihcpoepKN1">SCHEDULE OF RESERVES</span></span></b></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220701__20230630_zjahb4bGvnM4" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210701__20220630_zU4JdJZ5OHkj" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Foreign currency translation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--ReserveOfExchangeDifferencesOnTranslation_iI_pp0p0_c20230630_zZb2uE7Wcs62" title="Foreign currency translation" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">847,408</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--ReserveOfExchangeDifferencesOnTranslation_iI_pp0p0_c20220630_zTrdS80h8G3i" title="Foreign currency translation" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">746,819</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Share-based payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--ReserveOfSharebasedPayments_iI_pp0p0_c20230630_zIwtCdva4hg7" title="Share-based payments" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ReserveOfSharebasedPayments" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">5,688,148</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ReserveOfSharebasedPayments_iI_pp0p0_c20220630_zJsTG0PXBZb9" title="Share-based payments" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ReserveOfSharebasedPayments" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">10,751,832</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total reserves</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--OtherReserves_iI_pp0p0_c20230630_zO5jCYvQ1gw2" title="Total reserves" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">6,535,556</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--OtherReserves_iI_pp0p0_c20220630_zS9sg0bQ0V4c" title="Total reserves" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,498,651</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Reconciliation of foreign currency translation reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--ReserveOfExchangeDifferencesOnTranslation_iS_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Balance at the beginning of the financial year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">746,819</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">718,955</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Add: net currency translation gain / (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">100,589</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">27,864</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--ReserveOfExchangeDifferencesOnTranslation_iE_pp0p0_zxOZ4ow8LpMg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Balance at the end of the financial year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">847,408</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">746,819</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Reconciliation of share-based payments reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--ReserveOfSharebasedPayments_iS_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Balance at the beginning of the financial year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ReserveOfSharebasedPayments" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">10,751,832</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ReserveOfSharebasedPayments" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">10,314,324</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--IncreaseDecreaseThroughSharebasedPaymentExpense_z8nNaDuZAaSf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Add: share-based payments expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1828">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1829">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--IssuanceOfPerformanceRights_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Add: Issue of performance rights</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:IssuanceOfPerformanceRights" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">125,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:IssuanceOfPerformanceRights" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">437,508</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AddValuationOfWarrants_zcMytm2P7KB7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Add: Valuation of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:AddValuationOfWarrants" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">134,956</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1835">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ShareBasedPaymentReseveExerciseOfOptionswarrants_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Less: Options/warrants expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GENE:ShareBasedPaymentReseveExerciseOfOptionswarrants" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">5,241,452</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1838">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ShareBasedPaymentsReserveExerciseOfPerformanceRights_zCIoixyQdOyi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Less: Exercise of performance rights</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:ShareBasedPaymentsReserveExerciseOfPerformanceRights" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">82,688</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1841">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--ReserveOfSharebasedPayments_iE_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Balance at the end of the financial year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ReserveOfSharebasedPayments" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">5,688,148</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ReserveOfSharebasedPayments" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">10,751,832</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zAIqmjAAEdd7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
Based Payments Reserve</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nature
and Purpose</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
share-based payment reserve records items recognized as expenses on valuation of warrants, share options, and performance shares issued
to capital raising agents, key management personnel, other employees, and eligible contractors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationAboutWarrantsIssued"><p id="xdx_892_ecustom--DisclosureOfDetailedInformationAboutWarrantsIssued_zu9eCbIBKPMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the financial year ended June 30, 2023, the following warrants were issued to as a part of capital raising costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_ze8P9KIhlkWh" style="display: none">SCHEDULE OF WARRANT ISSUED</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Valuation date</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--WarrantsValuationDate_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zbBiH5hatF8c" title="Valuation date"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_WarrantsOneMember" format="ixt:datemonthdayyearen" name="GENE:WarrantsValuationDate">December 20, 2022</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 65%; text-align: left">Grant Date</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--WarrantsGrantDate_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zH6qx8Htvyv" title="Grant Date"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_WarrantsOneMember" format="ixt:datemonthdayyearen" name="GENE:WarrantsGrantDate">December 20, 2022</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants issued</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--WarrantsIssued_iI_uShares_c20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zLIAXAwH1QId" title="Warrants issued" style="text-align: right"><ix:nonFraction name="GENE:WarrantsIssued" contextRef="AsOf2023-06-30_custom_WarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Underlying asset price</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--WarrantUnderlyingAssetPrice_pid_uAUDPShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_z4CnXbTKq5xd" title="Underlying asset price" style="text-align: right"><ix:nonFraction name="GENE:WarrantUnderlyingAssetPrice" contextRef="From2022-07-012023-06-30_custom_WarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">1.525</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--WarrantsRiskFreeRate_pid_dp_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zYEMK9RXWqQc" title="Risk free rate" style="text-align: right"><ix:nonFraction name="GENE:WarrantsRiskFreeRate" contextRef="From2022-07-012023-06-30_custom_WarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.1</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--WarrantsVolatilityRate_pid_dp_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_z9wTKjlaIOGb" title="Volatility" style="text-align: right"><ix:nonFraction name="GENE:WarrantsVolatilityRate" contextRef="From2022-07-012023-06-30_custom_WarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">75</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercise price presented in United States Dollar</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--WarrantExercisePrice_uUSDPShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zQtKZ3AqFRV8" title="Exercise price presented in United States Dollar" style="text-align: right"><ix:nonFraction name="GENE:WarrantExercisePrice" contextRef="From2022-07-012023-06-30_custom_WarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.625</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exchange rate at valuation date</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ExchangeRateAtValuationDate_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zZ1EdvpzDYxf" title="Exchange rate at valuation date" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_WarrantsOneMember" name="GENE:ExchangeRateAtValuationDate">1 to USD$0.669</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercise price presented in Australian Dollar</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--WarrantsExercisePricePresentedInAustralianDollar_uAUDPShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zBx9cBTk0Xnb" title="Exercise price presented in Australian Dollar" style="text-align: right"><ix:nonFraction name="GENE:WarrantsExercisePricePresentedInAustralianDollar" contextRef="From2022-07-012023-06-30_custom_WarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">2.429</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Time to maturity of underlying warrants (years)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_ecustom--MaturityOfUnderlyingWarrantsYears_dtY_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zfQ0QEcUHCpd" title="Time to maturity of underlying warrants (years)"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_WarrantsOneMember" format="ixt-sec:duryear" name="GENE:MaturityOfUnderlyingWarrantsYears">5.12</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Value per warrant in Australian Dollar</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ValuePerWarrant_uAUDPShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_z2NF7ygA4p9f" title="Value per warrant in Australian Dollar" style="text-align: right"><ix:nonFraction name="GENE:ValuePerWarrant" contextRef="From2022-07-012023-06-30_custom_WarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.5398</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Model used</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--WarrantModelUsed_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zGeDYlFVzgX4" title="Model used"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_WarrantsOneMember" name="GENE:WarrantModelUsed">Black Scholes</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Valuation amount</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--WarrantValuationAmount_pp0p0_uAUD_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zvXnlgPEeTb7" title="Valuation amount" style="text-align: right"><ix:nonFraction name="GENE:WarrantValuationAmount" contextRef="From2022-07-012023-06-30_custom_WarrantsOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">134,956</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.) </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>22.
RESERVES (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
warrants were issued for the financial year ended June 30, 2022. During the financial year ended June 30, 2021, the following warrants
were issued to as a part of capital raising costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Valuation date</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--WarrantsValuationDate_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zHTW4xvhrvxc" title="Valuation date"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_WarrantsOneMember" format="ixt:datemonthdayyearen" name="GENE:WarrantsValuationDate">July 21, 2020</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 65%; text-align: left">Grant Date</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--WarrantsGrantDate_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zfoKMvcBHOd2" title="Grant Date"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_WarrantsOneMember" format="ixt:datemonthdayyearen" name="GENE:WarrantsGrantDate">June 1, 2020</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants issued</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--WarrantsIssued_iI_uShares_c20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zlTXiFMj5201" title="Warrants issued" style="text-align: right"><ix:nonFraction name="GENE:WarrantsIssued" contextRef="AsOf2021-06-30_custom_WarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,975,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Underlying asset price</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--WarrantUnderlyingAssetPrice_pid_uAUDPShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zTfWei6zOhba" title="Underlying asset price" style="text-align: right"><ix:nonFraction name="GENE:WarrantUnderlyingAssetPrice" contextRef="From2020-07-012021-06-30_custom_WarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.0070</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--WarrantsRiskFreeRate_pid_dp_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_ziUKuMFWJmDi" title="Risk free rate" style="text-align: right"><ix:nonFraction name="GENE:WarrantsRiskFreeRate" contextRef="From2020-07-012021-06-30_custom_WarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.42</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--WarrantsVolatilityRate_pid_dp_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zTmXyrYcwD7" title="Volatility" style="text-align: right"><ix:nonFraction name="GENE:WarrantsVolatilityRate" contextRef="From2020-07-012021-06-30_custom_WarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">148.66</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercise price presented in United States Dollar</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--WarrantExercisePrice_uUSDPShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_z6POZVrRrVyg" title="Exercise price presented in United States Dollar" style="text-align: right"><ix:nonFraction name="GENE:WarrantExercisePrice" contextRef="From2020-07-012021-06-30_custom_WarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00417</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exchange rate at valuation date</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ExchangeRateAtValuationDate_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zZUISPUr6MP7" title="Exchange rate at valuation date" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_WarrantsOneMember" name="GENE:ExchangeRateAtValuationDate">1 to US$0.7127</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercise price presented in Australian Dollar</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--WarrantsExercisePricePresentedInAustralianDollar_uAUDPShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zDBvtyuJaVNb" title="Exercise price presented in Australian Dollar" style="text-align: right"><ix:nonFraction name="GENE:WarrantsExercisePricePresentedInAustralianDollar" contextRef="From2020-07-012021-06-30_custom_WarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.0146</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Time to maturity of underlying warrants (years)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_ecustom--MaturityOfUnderlyingWarrantsYears_dtY_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_z1TYdPtHuDu9" title="Time to maturity of underlying warrants (years)"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_WarrantsOneMember" format="ixt-sec:duryear" name="GENE:MaturityOfUnderlyingWarrantsYears">5</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Value per warrant in Australian Dollar</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ValuePerWarrant_uAUDPShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_zMc92RXP3yVe" title="Value per warrant in Australian Dollar" style="text-align: right"><ix:nonFraction name="GENE:ValuePerWarrant" contextRef="From2020-07-012021-06-30_custom_WarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.009</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Model used</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--WarrantModelUsed_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_ziXHVvWzX2K7" title="Model used"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_WarrantsOneMember" name="GENE:WarrantModelUsed">Binomial</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Valuation amount</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--WarrantValuationAmount_pp0p0_uAUD_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsOneMember_z5PwyEecHaed" title="Valuation amount" style="text-align: right"><ix:nonFraction name="GENE:WarrantValuationAmount" contextRef="From2020-07-012021-06-30_custom_WarrantsOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">360,017</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Valuation date</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--WarrantsValuationDate_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsTwoMember_zhupoyeCpUXh" title="Valuation date"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_WarrantsTwoMember" format="ixt:datemonthdayyearen" name="GENE:WarrantsValuationDate">January 25, 2021</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 65%; text-align: left">Grant Date</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--WarrantsGrantDate_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsTwoMember_zrunj7iDmKl1" title="Grant Date"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_WarrantsTwoMember" format="ixt:datemonthdayyearen" name="GENE:WarrantsGrantDate">January 25, 2021</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants issued</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--WarrantsIssued_iI_uShares_c20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsTwoMember_zQefixCE8xK3" title="Warrants issued" style="text-align: right"><ix:nonFraction name="GENE:WarrantsIssued" contextRef="AsOf2021-06-30_custom_WarrantsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,750,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Underlying asset price</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--WarrantUnderlyingAssetPrice_pid_uAUDPShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsTwoMember_zKnYOn7LQmS" title="Underlying asset price" style="text-align: right"><ix:nonFraction name="GENE:WarrantUnderlyingAssetPrice" contextRef="From2020-07-012021-06-30_custom_WarrantsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.0110</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--WarrantsRiskFreeRate_pid_dp_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsTwoMember_zhqZl8LYMre5" title="Risk free rate" style="text-align: right"><ix:nonFraction name="GENE:WarrantsRiskFreeRate" contextRef="From2020-07-012021-06-30_custom_WarrantsTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.414</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--WarrantsVolatilityRate_pid_dp_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsTwoMember_z8CU9CJpVqah" title="Volatility" style="text-align: right"><ix:nonFraction name="GENE:WarrantsVolatilityRate" contextRef="From2020-07-012021-06-30_custom_WarrantsTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">147.29</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercise price presented in United States Dollar</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--WarrantExercisePrice_uUSDPShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsTwoMember_zg7VuWloYt1e" title="Exercise price presented in United States Dollar" style="text-align: right"><ix:nonFraction name="GENE:WarrantExercisePrice" contextRef="From2020-07-012021-06-30_custom_WarrantsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0109</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exchange rate at valuation date</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ExchangeRateAtValuationDate_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsTwoMember_zpygkN298kl3" title="Exchange rate at valuation date" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_WarrantsTwoMember" name="GENE:ExchangeRateAtValuationDate">1 to US$0.7708</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercise price presented in Australian Dollar</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--WarrantsExercisePricePresentedInAustralianDollar_uAUDPShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsTwoMember_zI7p13fAUh7c" title="Exercise price presented in Australian Dollar" style="text-align: right"><ix:nonFraction name="GENE:WarrantsExercisePricePresentedInAustralianDollar" contextRef="From2020-07-012021-06-30_custom_WarrantsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.0142</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Time to maturity of underlying warrants (years)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_ecustom--MaturityOfUnderlyingWarrantsYears_dtY_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsTwoMember_zsTFy4tI9Kpj" title="Time to maturity of underlying warrants (years)"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_WarrantsTwoMember" format="ixt-sec:duryear" name="GENE:MaturityOfUnderlyingWarrantsYears">5</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Value per warrant in Australian Dollar</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ValuePerWarrant_uAUDPShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsTwoMember_zN4P0j7mgQx1" title="Value per warrant in Australian Dollar" style="text-align: right"><ix:nonFraction name="GENE:ValuePerWarrant" contextRef="From2020-07-012021-06-30_custom_WarrantsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.0098</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Model used</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--WarrantModelUsed_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsTwoMember_zTJTzE0tFP58" title="Model used"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_WarrantsTwoMember" name="GENE:WarrantModelUsed">Binomial</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Valuation amount</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--WarrantValuationAmount_pp0p0_uAUD_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantsTwoMember_z1pSvecKY86j" title="Valuation amount" style="text-align: right"><ix:nonFraction name="GENE:WarrantValuationAmount" contextRef="From2020-07-012021-06-30_custom_WarrantsTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">476,297</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zPm8DMAM4JE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Share
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationAboutOptionIssuedAndGranted"><p id="xdx_891_ecustom--DisclosureOfDetailedInformationAboutOptionIssuedAndGranted_z0FH7zu9daa9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
share options were issued during the financial year ending June 30, 2023 or June 30, 2022. The following information relates to options
granted and issued against under the Employee Option Plan for the year ended June 30, 2021;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zmkpU9rV1qD5" style="display: none">SCHEDULE OF OPTION ISSUED AND GRANTED</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Options issued to</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant date for</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options issued</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>issued</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; text-align: left">Employee Option Plan</td><td style="width: 2%">&#160;</td>
    <td style="width: 18%"><span id="xdx_90B_ecustom--GrantDateForOptionsIssued_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zOFXzJ0nNpG1" title="Grant date for options issued"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_EmployeeOptionPlanMember" format="ixt:datemonthdayyearen" name="GENE:GrantDateForOptionsIssued">December 21, 2020</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_90C_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_ziC0MxulhWjc" title="Number of options issued"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2020-07-012021-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,850,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>22. RESERVES
(cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Grant Date</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--GrantDateForOptionsIssued_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zKvpMwjXRZt4" title="Grant date for options issued"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_EmployeeOptionPlanMember" format="ixt:datemonthdayyearen" name="GENE:GrantDateForOptionsIssued">December 21, 2020</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 65%; text-align: left">Options issued</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zAlPpesjqHeb" title="Number of options issued" style="width: 16%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2020-07-012021-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,850,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zJzJIzM1UVag" title="Dividend yield" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1936">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Historic volatility and expected volatility</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--HistoricVolatilityAndExpectedVolatilityShareOptionsGranted_dp_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zRsmQpodeLLg" title="Historic volatility and expected volatility" style="text-align: right"><ix:nonFraction name="GENE:HistoricVolatilityAndExpectedVolatilityShareOptionsGranted" contextRef="From2020-07-012021-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">155.34</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Option exercise price</td><td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_uAUDPShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zVbZT2T2T7z6" title="Option exercise price" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2020-07-012021-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Fair value of options at grant date</td><td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--FairValueOfOptionsAtGrantDate_pid_uAUDPShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zd6IH0aCChxi" title="Fair value of options at grant date" style="text-align: right"><ix:nonFraction name="GENE:FairValueOfOptionsAtGrantDate" contextRef="From2020-07-012021-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.007</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average exercise price</td><td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_pid_uAUDPShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zthiJSTfrTt7" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="From2020-07-012021-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zYsYOblD3pbd" title="Risk-free interest rate" style="text-align: right"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2020-07-012021-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.111</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life of an option</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ExpectedLifeShareOptionsGranted_dtY_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_z8n90ckVxmM3" title="Expected life of an option"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_EmployeeOptionPlanMember" format="ixt-sec:duryear" name="GENE:ExpectedLifeShareOptionsGranted">3</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Model used</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--OptionGrantedModelUsedDescription_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zeA5fx2FDd93" title="Model used"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_EmployeeOptionPlanMember" name="GENE:OptionGrantedModelUsedDescription">Binomial</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Valuation amount</td><td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ValuationAmount_pp0p0_uAUD_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_z9JJHddrMlAg" title="Valuation amount" style="text-align: right"><ix:nonFraction name="GENE:ValuationAmount" contextRef="From2020-07-012021-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">72,439</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zneKy2Jq5Lvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
Rights</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationAboutPerformanceRight"><p id="xdx_898_ecustom--DisclosureOfDetailedInformationAboutPerformanceRight_zCC2oT3aPmI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Performance Rights were issued for financial year ended June 30, 2023. The following information relates to issued Performance Rights
for the year ended June 30, 2022;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zFrnEoIAHVoc" style="display: none">SCHEDULE
OF INFORMATION ABOUT PERFORMANCE RIGHTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Performance rights issued to</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant date for</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>performance rights issued</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of performance rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><b>issued</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Adam Kramer</td><td style="width: 2%">&#160;</td>
    <td style="width: 18%; text-align: right"><span id="xdx_903_ecustom--GrantDateForOptionsIssued_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AdamKramerMember_zYGv8RddUhj4" title="Grant date for options issued"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_AdamKramerMember" format="ixt:datemonthdayyearen" name="GENE:GrantDateForOptionsIssued">March 3, 2021</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AdamKramerMember_zqV8BLZIlm2" title="Number of options issued" style="width: 16%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2022-07-012023-06-30_custom_AdamKramerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,937,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mike Tonroe</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_ecustom--GrantDateForOptionsIssued_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MikeTonroeMember_zU3xA4fprAP3" title="Grant date for options issued"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_MikeTonroeMember" format="ixt:datemonthdayyearen" name="GENE:GrantDateForOptionsIssued">June 15, 2021</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MikeTonroeMember_zSIpa04TTiIl" title="Number of options issued" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2022-07-012023-06-30_custom_MikeTonroeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Carl Stubbings</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_ecustom--GrantDateForOptionsIssued_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CarlStubbingsMember_zT6ksZqJpAF" title="Grant date for options issued"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_CarlStubbingsMember" format="ixt:datemonthdayyearen" name="GENE:GrantDateForOptionsIssued">September 22, 2021</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CarlStubbingsMember_zRaUW4alVr15" title="Number of options issued" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2022-07-012023-06-30_custom_CarlStubbingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Kevin Camilleri</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_ecustom--GrantDateForOptionsIssued_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--KevinCamilleriMember_znrUDV1ua0z3" title="Grant date for options issued"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_KevinCamilleriMember" format="ixt:datemonthdayyearen" name="GENE:GrantDateForOptionsIssued">November 22, 2021</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--KevinCamilleriMember_z164GWbhNqO" title="Number of options issued" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2022-07-012023-06-30_custom_KevinCamilleriMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">Grant Date</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin-top: 0; margin-bottom: 0">March 3,</p>
                                              <p style="margin-top: 0; margin-bottom: 0">2021</p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin-top: 0; margin-bottom: 0">June 15,</p>
                                              <p style="margin-top: 0; margin-bottom: 0">2021</p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin-top: 0; margin-bottom: 0">September 22,</p>
                                              <p style="margin-top: 0; margin-bottom: 0">2021</p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><p style="text-align: right; margin-top: 0; margin-bottom: 0">November 22,</p>
                    <p style="text-align: right; margin-top: 0; margin-bottom: 0">2021</p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Performance rights issued</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AdamKramerMember_zs2NVBywEB7b" title="Performance rights issued" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2022-07-012023-06-30_custom_AdamKramerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,937,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MikeTonroeMember_zswTdXHNVPfj" title="Number of options issued" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2022-07-012023-06-30_custom_MikeTonroeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CarlStubbingsMember_zehf2W5E54R9" title="Number of options issued" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2022-07-012023-06-30_custom_CarlStubbingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--KevinCamilleriMember_zRFKuv5cVXBb" title="Number of options issued" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2022-07-012023-06-30_custom_KevinCamilleriMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AdamKramerMember_zbHRLZbDlvrc" title="Dividend yield" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1980">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MikeTonroeMember_zLqousS4ZRid" title="Dividend yield" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1982">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CarlStubbingsMember_zw6UAS0jXn41" title="Dividend yield" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1984">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--KevinCamilleriMember_zW333vLMoaMb" title="Dividend yield" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1986">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Historic volatility and expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--HistoricVolatilityAndExpectedVolatilityShareOptionsGranted_dp_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AdamKramerMember_z5k3lVzrTUPc" title="Historic volatility and expected volatility" style="text-align: right"><ix:nonFraction name="GENE:HistoricVolatilityAndExpectedVolatilityShareOptionsGranted" contextRef="From2022-07-012023-06-30_custom_AdamKramerMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--HistoricVolatilityAndExpectedVolatilityShareOptionsGranted_dp_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MikeTonroeMember_zwa96YNX5U55" title="Historic volatility and expected volatility" style="text-align: right"><ix:nonFraction name="GENE:HistoricVolatilityAndExpectedVolatilityShareOptionsGranted" contextRef="From2022-07-012023-06-30_custom_MikeTonroeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">152</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--HistoricVolatilityAndExpectedVolatilityShareOptionsGranted_dp_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CarlStubbingsMember_znqizR4xJQSg" title="Historic volatility and expected volatility" style="text-align: right"><ix:nonFraction name="GENE:HistoricVolatilityAndExpectedVolatilityShareOptionsGranted" contextRef="From2022-07-012023-06-30_custom_CarlStubbingsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">149</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--HistoricVolatilityAndExpectedVolatilityShareOptionsGranted_dp_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--KevinCamilleriMember_z175vRbpQzOd" title="Historic volatility and expected volatility" style="text-align: right"><ix:nonFraction name="GENE:HistoricVolatilityAndExpectedVolatilityShareOptionsGranted" contextRef="From2022-07-012023-06-30_custom_KevinCamilleriMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">150</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Performance rights exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uAUDPShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AdamKramerMember_zoFKWWQStaC1" title="Option exercise price" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2022-07-012023-06-30_custom_AdamKramerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.009</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uAUDPShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MikeTonroeMember_zdOS5YwOE6Rl" title="Option exercise price" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2022-07-012023-06-30_custom_MikeTonroeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.0069</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uAUDPShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CarlStubbingsMember_zAsYyCUeArqb" title="Option exercise price" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2022-07-012023-06-30_custom_CarlStubbingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.0047</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uAUDPShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--KevinCamilleriMember_z9xoj3yiVPfk" title="Option exercise price" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2022-07-012023-06-30_custom_KevinCamilleriMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.0038</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair value of performance rights at grant date</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--FairValueOfOptionsAtGrantDate_uAUDPShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AdamKramerMember_zGCl8CUL8Yjk" title="Fair value of options at grant date" style="text-align: right"><ix:nonFraction name="GENE:FairValueOfOptionsAtGrantDate" contextRef="From2022-07-012023-06-30_custom_AdamKramerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.012</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--FairValueOfOptionsAtGrantDate_uAUDPShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MikeTonroeMember_zcQ1sG7u8hJc" title="Fair value of options at grant date" style="text-align: right"><ix:nonFraction name="GENE:FairValueOfOptionsAtGrantDate" contextRef="From2022-07-012023-06-30_custom_MikeTonroeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.0073</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--FairValueOfOptionsAtGrantDate_uAUDPShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CarlStubbingsMember_zOCl1UGfBUCf" title="Fair value of options at grant date" style="text-align: right"><ix:nonFraction name="GENE:FairValueOfOptionsAtGrantDate" contextRef="From2022-07-012023-06-30_custom_CarlStubbingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.0052</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--FairValueOfOptionsAtGrantDate_uAUDPShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--KevinCamilleriMember_z8fnTsOlBDGe" title="Fair value of options at grant date" style="text-align: right"><ix:nonFraction name="GENE:FairValueOfOptionsAtGrantDate" contextRef="From2022-07-012023-06-30_custom_KevinCamilleriMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.0042</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uAUDPShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AdamKramerMember_zHuUs4WHvqD4" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="From2022-07-012023-06-30_custom_AdamKramerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uAUDPShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MikeTonroeMember_z5jKUmUyy3X4" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="From2022-07-012023-06-30_custom_MikeTonroeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uAUDPShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CarlStubbingsMember_zbBo4KKolZUc" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="From2022-07-012023-06-30_custom_CarlStubbingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uAUDPShares_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--KevinCamilleriMember_zmwuFRwbEFq6" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="From2022-07-012023-06-30_custom_KevinCamilleriMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AdamKramerMember_zVtKJv3aPhkc" title="Risk-free interest rate" style="text-align: right"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2022-07-012023-06-30_custom_AdamKramerMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MikeTonroeMember_z1A5g1HcjnHc" title="Risk-free interest rate" style="text-align: right"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2022-07-012023-06-30_custom_MikeTonroeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.085</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CarlStubbingsMember_zlJtxJgIybY3" title="Risk-free interest rate" style="text-align: right"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2022-07-012023-06-30_custom_CarlStubbingsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--KevinCamilleriMember_z6xsCs3ZMEUa" title="Risk-free interest rate" style="text-align: right"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2022-07-012023-06-30_custom_KevinCamilleriMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.960</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life of the performance rights</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ExpectedLifeShareOptionsGranted_dtY_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AdamKramerMember_z8Ja4FQXPQGl" title="Expected life of an option"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_AdamKramerMember" format="ixt-sec:duryear" name="GENE:ExpectedLifeShareOptionsGranted">2.02</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ExpectedLifeShareOptionsGranted_dtY_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MikeTonroeMember_zm9iYy5Y022h" title="Expected life of an option"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_MikeTonroeMember" format="ixt-sec:duryear" name="GENE:ExpectedLifeShareOptionsGranted">3</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--ExpectedLifeShareOptionsGranted_dtY_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CarlStubbingsMember_zrO1HNHAcUR9" title="Expected life of an option"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_CarlStubbingsMember" format="ixt-sec:duryear" name="GENE:ExpectedLifeShareOptionsGranted">3</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--ExpectedLifeShareOptionsGranted_dtY_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--KevinCamilleriMember_zV8zB1ZBrfU3" title="Expected life of an option"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_KevinCamilleriMember" format="ixt-sec:duryear" name="GENE:ExpectedLifeShareOptionsGranted">3</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Model used</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--OptionGrantedModelUsedDescription_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AdamKramerMember_zxIj7megEeN5" title="Model used"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_AdamKramerMember" name="GENE:OptionGrantedModelUsedDescription">Binomial</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--OptionGrantedModelUsedDescription_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MikeTonroeMember_zEa23EDljBM" title="Model used"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_MikeTonroeMember" name="GENE:OptionGrantedModelUsedDescription">Binomial</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--OptionGrantedModelUsedDescription_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CarlStubbingsMember_zq0N8pfpilBh" title="Model used"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_CarlStubbingsMember" name="GENE:OptionGrantedModelUsedDescription">Binomial</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--OptionGrantedModelUsedDescription_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--KevinCamilleriMember_zLqGj6rpn6O5" title="Model used"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_KevinCamilleriMember" name="GENE:OptionGrantedModelUsedDescription">Binomial</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Valuation amount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ValuationAmount_pp0p0_uAUD_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--AdamKramerMember_z3TLrmYzeyJ" title="Valuation amount" style="text-align: right"><ix:nonFraction name="GENE:ValuationAmount" contextRef="From2022-07-012023-06-30_custom_AdamKramerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">47,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ValuationAmount_pp0p0_uAUD_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MikeTonroeMember_zwIvpN0BIawk" title="Valuation amount" style="text-align: right"><ix:nonFraction name="GENE:ValuationAmount" contextRef="From2022-07-012023-06-30_custom_MikeTonroeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">291,428</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ValuationAmount_pp0p0_uAUD_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CarlStubbingsMember_znV2uO3ZUdb1" title="Valuation amount" style="text-align: right"><ix:nonFraction name="GENE:ValuationAmount" contextRef="From2022-07-012023-06-30_custom_CarlStubbingsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">103,104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ValuationAmount_pp0p0_uAUD_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--KevinCamilleriMember_zSbdpZqVoHjc" title="Valuation amount" style="text-align: right"><ix:nonFraction name="GENE:ValuationAmount" contextRef="From2022-07-012023-06-30_custom_KevinCamilleriMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">83,216</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A3_z8Tu3rcF3YY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign
currency translation reserve</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nature
and Purpose</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
differences arising on translation of the foreign controlled entities are recognized in other comprehensive income as described in Note
2(e) and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the net investment
is disposed of.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 118; Options: NewSection; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfAccumulatedLossesTextBlock"><p id="xdx_804_ecustom--DisclosureOfAccumulatedLossesTextBlock_zNqns69qHVB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>23. <span id="xdx_829_z9wPTgoOhYDi">ACCUMULATED LOSSES</span></b></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationAboutAccumulatedLosses"><p id="xdx_893_ecustom--DisclosureOfDetailedInformationAboutAccumulatedLosses_z7ynMpVIk8Ij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span style="display: none"><span id="xdx_8B0_zZVe19BbibV1">SCHEDULE OF ACCUMULATED LOSSES</span></span></b></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220701__20230630_zrI5YBfhYJL1" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210701__20220630_zl8z96q3frvf" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--RetainedEarnings_iS_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; width: 64%; text-align: left">Balance at the beginning of the financial year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">150,206,216</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">143,075,218</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_409_eifrs-full--ProfitLossAttributableToOwnersOfParent_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Add: net loss attributable to owners of Genetic Technologies Limited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">11,750,923</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">7,130,998</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--OptionsExpiration_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Less: Options/warrants expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:OptionsExpiration" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">5,241,452</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2063">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--RetainedEarnings_iE_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Balance at the end of the financial year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">156,715,687</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">150,206,216</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zt5lu3yZKiPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfShareOptionsTextBlock"><p id="xdx_80B_ecustom--DisclosureOfShareOptionsTextBlock_zKRYGGJfIa84" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>24.
<span id="xdx_827_z0bRaGZzNnLh">SHARE OPTIONS</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employee
Option Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of options granted under an Employee Option Plan is recognized as an employee benefit expense with a corresponding increase
in equity. The fair value is measured at grant date and recognized over the vesting period over which the service vesting conditions
are to be satisfied. Employee Option Plan options have no other vesting conditions. The fair value at grant date is determined by management
with the assistance of an independent valuer, using a Black-Scholes option pricing model or a Binomial model simulation analysis. The
total amount to be expensed is determined by reference to the fair value of the options granted;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">including any market performance
    conditions (e.g. the entities share price)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">excluding the impact of any service and non-market
    performance vesting conditions (e.g. remaining an employee over a specified time period)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cumulative employee benefits expense recognized at each reporting date until vesting date reflects (i) the extent to which the vesting
period has expired; and (ii) the number of awards that, in the opinion of the Directors of the Company, will ultimately vest. This opinion
is formed based on the best information available at balance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
the terms of an equity-settled award are modified, as a minimum an expense is recognized as if the terms had not been modified. In addition,
an expense is recognized for any increase in the value of the transaction as a result of the modification, as at the date of modification.
Where appropriate, the dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted
earnings per share. The Company&#8217;s policy is to treat the options of terminated employees as forfeitures if termination occurs prior
to vesting conditions being reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 30, 2001, the Directors of the Company established a Staff Share Plan. On November 19, 2008, the shareholders of the Company
approved the introduction of a new Employee Option Plan. Under the terms of the respective Plans, the Directors may, at their discretion,
grant options over the ordinary shares in the Genetic Technologies Limited to executives, consultants, employees, and former Non-Executive
Directors, of the Company. The options, which are granted at nil cost, are not transferable and are not quoted on the ASX. As at June
30, 2023, there were 1 executive and 7 employees who held options that had been granted under the Plans. Options granted under the Plans
carry no rights to dividends and no voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 119; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>24. SHARE OPTIONS (cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)
Fair value of options granted</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended June 30, 2023, there were <span id="xdx_90B_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_do_uShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zRIXZdhZK2w" title="Number of options issued"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2022-07-012023-06-30_custom_EmployeeOptionPlanMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> options granted (2022: <span id="xdx_907_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_dxL_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zZ3tF32SQsJ5" title="Number of options issued::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl2072">Nil</span></span>). The Company, however issued various unlisted options to underwriters
and sub-underwriters as a part of capital raising costs in 2021. For valuations on the unlisted options issued please refer to Note 22.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"><p id="xdx_899_eifrs-full--DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_zvKbKWz2Gs13" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below are summaries of all and unlisted options, including ESOP which were issued in prior periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zz06cAVFAKn9" style="display: none">SCHEDULE OF NUMBER AND WEIGHTED AVERAGE EXERCISE PRICES OF SHARE UNLISTED OPTIONS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">exercise price</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">per share</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">option A$</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">exercise price</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">per share</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">option A$</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -10pt; width: 36%; text-align: left">Opening balance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uAUDPShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zO9NwVsaae9f" title="Average exercise price per share option, Opening balance" style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2022-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfOutstandingShareOptions_iS_pid_uShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zr5s2rb1EDxc" title="Number of options, Opening balance" style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">492,400,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uAUDPShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zyjf1xMzf0l9" title="Average exercise price per share option, Opening balance" style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2021-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfOutstandingShareOptions_iS_pid_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zuGUUREgsYF9" title="Number of options, Opening balance" style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2021-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">521,850,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lapsed during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_pid_uAUDPShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zdwAG6voLQxh" title="Average exercise price per share option, lapsed during the year" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" contextRef="From2022-07-012023-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_iN_pid_di_uShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zR6kPaUCbE6i" title="Number of options, lapsed during the year" style="text-align: right">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="From2022-07-012023-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">481,500,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_pid_uAUDPShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zTG9V2XWoK47" title="Average exercise price per share option, lapsed during the year" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" contextRef="From2021-07-012022-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.012</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_iN_pid_di_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zBhEl8InckZk" title="Number of options, lapsed during the year" style="text-align: right">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="From2021-07-012022-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,450,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Forfeited during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_pid_uAUDPShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zLjlQXYbnlGb" title="Average exercise price per share option, forfeited during the year" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="From2022-07-012023-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_pid_di_uShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zhd86OIljntj" title="Number of options, forfeited during the year" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="From2022-07-012023-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_pid_uAUDPShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zlxgqy96tLog" title="Average exercise price per share option, forfeited during the year" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2096">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_pid_di_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zovpOr2YgBQf" title="Number of options, forfeited during the year" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2098">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Closing balance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uAUDPShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zI5z5Oq9HMx3" title="Average exercise price per share option, Closing balance" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2023-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfOutstandingShareOptions_iE_pid_uShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_z32C3rukEl5h" title="Number of options, Closing balance" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2023-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,400,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uAUDPShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zYiSgWuKEVgg" title="Average exercise price per share option, Closing balance" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2022-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--NumberOfOutstandingShareOptions_iE_pid_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zfRV9nFspi2a" title="Number of options, Closing balance" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-06-30_custom_EmployeeOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">492,400,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zx4YJfKRbNke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationAboutShareBasedCompensationArrangementsByShareBasedPaymentAwardTableTextBlock"><p id="xdx_890_ecustom--DisclosureOfDetailedInformationAboutShareBasedCompensationArrangementsByShareBasedPaymentAwardTableTextBlock_zD0DcFpex1hi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
movements in the number of options granted under the Employee share plans are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zmmmbLKPw5V4" style="display: none">SCHEDULE OF NUMBER OF OPTIONS GRANTED UNDER THE PLANS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise price</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per share</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>option A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise price</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per share</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>option A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Balance at the beginning of the financial year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uAUDPShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_zlcYBQPL3IAg" title="Average exercise price per share option, Opening balance" style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2022-06-30_custom_EmployeeSharePlansMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfOutstandingShareOptions_iS_pid_uShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_z0f0LC5TNngh" title="Number of options, Opening balance" style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-06-30_custom_EmployeeSharePlansMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,900,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uAUDPShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_znH8Zhqbyphc" title="Average exercise price per share option, Opening balance" style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2021-06-30_custom_EmployeeSharePlansMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.011</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfOutstandingShareOptions_iS_pid_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_zF2EnGu796Bb" title="Number of options, Opening balance" style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2021-06-30_custom_EmployeeSharePlansMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,850,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Add: options granted during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_uAUDPShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_zFhWtVrfd533" title="Average exercise price per share option, Add: options granted during the year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2118">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_zlrf9TppsZ25" title="Number of options, Add: options granted during the year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2120">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_uAUDPShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_ztIy4602rst4" title="Average exercise price per share option, Add: options granted during the year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2122">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_zfWqYf1ImLyh" title="Number of options, Add: options granted during the year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2124">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: options lapsed during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_uAUDPShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_zImGrDBEjJi5" title="Average exercise price per share option, Less: options lapsed during the year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2126">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_iN_pid_di_uShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_zqoA9EjOjG49" title="Number of options, Less: options lapsed during the year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2128">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_uAUDPShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_zdcISRMKVuMh" title="Average exercise price per share option, Less: options lapsed during the year" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" contextRef="From2021-07-012022-06-30_custom_EmployeeSharePlansMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.010</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_iN_pid_di_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_z61LtIgv1cP6" title="Number of options, Less: options lapsed during the year" style="text-align: right">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" contextRef="From2021-07-012022-06-30_custom_EmployeeSharePlansMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,950,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: options forfeited during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_uAUDPShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_zPDYXUroA2il" title="Average exercise price per share option, Less: options forfeited during the year" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="From2022-07-012023-06-30_custom_EmployeeSharePlansMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_pid_di_uShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_zDoyKfnAuLu9" title="Number of options, Less: options forfeited during the year" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="From2022-07-012023-06-30_custom_EmployeeSharePlansMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_uAUDPShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_z2lxv2V0iH8c" title="Average exercise price per share option, Less: options forfeited during the year" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2138">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_pid_di_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_zJlc5vD3eSRc" title="Number of options, Less: options forfeited during the year" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2140">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Balance at the end of the financial year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uAUDPShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_zrjERP30NfL4" title="Average exercise price per share option, Closing balance" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2023-06-30_custom_EmployeeSharePlansMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--NumberOfOutstandingShareOptions_iE_pid_uShares_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_ziLKphDfSo76" title="Number of options, Closing balance" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2023-06-30_custom_EmployeeSharePlansMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,400,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uAUDPShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_zm5hkoYmlylk" title="Average exercise price per share option, Closing balance" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2022-06-30_custom_EmployeeSharePlansMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--NumberOfOutstandingShareOptions_iE_pid_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeSharePlansMember_zZQ4UY2DAEV1" title="Number of options, Closing balance" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-06-30_custom_EmployeeSharePlansMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,900,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A7_z40lbilBh1ei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<ix:exclude><!-- Field: Page; Sequence: 120; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>24. SHARE OPTIONS (cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationAboutMembersOfOptionsOutstandingByCode"><p id="xdx_89B_ecustom--DisclosureOfDetailedInformationAboutMembersOfOptionsOutstandingByCode_z0E19eJ0t08j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of options outstanding as at June 30, 2023 by ASX code, including the respective dates of expiry and exercise prices, are tabled
below. The options tabled below are not listed on ASX.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_z0OdU6h4vG6c" style="display: none">SCHEDULE OF MEMBERS OF OPTIONS OUTSTANDING BY ASX CODE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Unlisted options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise price</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per share</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>option
A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise price</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per share</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>option
                                                                                 A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Options to various underwriters (expiring October 30, 2022)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_uAUDPShares_c20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--UnlistedOptionsToVariousUnderwritersMember_zTX6ejgRJqu7" title="Average exercise price of options, balance at the end of the financial year" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2152">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--UnlistedOptionsToVariousUnderwritersMember_zRNPzFh4Kmf2" title="Number of options, Balance at the end of the financial year" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2154">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_uAUDPShares_c20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--UnlistedOptionsToVariousUnderwritersMember_zJzhG9E7yFj7" title="Average exercise price of options, balance at the end of the financial year" style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2022-06-30_custom_UnlistedOptionsToVariousUnderwritersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--UnlistedOptionsToVariousUnderwritersMember_zUiYt281zzBd" title="Number of options, Balance at the end of the financial year" style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-06-30_custom_UnlistedOptionsToVariousUnderwritersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">229,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options to directors (expiring December 20, 2022)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_uAUDPShares_c20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--UnlistedOptionsToDirectorsMember_zKbBvn2G9pR6" title="Average exercise price of options, balance at the end of the financial year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2160">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--UnlistedOptionsToDirectorsMember_z7Yk0fKWIp66" title="Number of options, Balance at the end of the financial year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2162">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_uAUDPShares_c20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--UnlistedOptionsToDirectorsMember_z0OH6Yu6mt06" title="Average exercise price of options, balance at the end of the financial year" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2022-06-30_custom_UnlistedOptionsToDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--UnlistedOptionsToDirectorsMember_z2Am7xE6xxae" title="Number of options, Balance at the end of the financial year" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-06-30_custom_UnlistedOptionsToDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options issued Lodge Corporate Pty Ltd (expiring March 6, 2023)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_uAUDPShares_c20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--UnlistedOptionsOptionsIssuedLodgeCorporatePtyLtdMember_zx0Bxvzu33i6" title="Average exercise price of options, balance at the end of the financial year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2168">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--UnlistedOptionsOptionsIssuedLodgeCorporatePtyLtdMember_zZ4T3aaXTM4i" title="Number of options, Balance at the end of the financial year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2170">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_uAUDPShares_c20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--UnlistedOptionsOptionsIssuedLodgeCorporatePtyLtdMember_zrrxp8yHzy2k" title="Average exercise price of options, balance at the end of the financial year" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2022-06-30_custom_UnlistedOptionsOptionsIssuedLodgeCorporatePtyLtdMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--UnlistedOptionsOptionsIssuedLodgeCorporatePtyLtdMember_ziXOwge9ZOUi" title="Number of options, Balance at the end of the financial year" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-06-30_custom_UnlistedOptionsOptionsIssuedLodgeCorporatePtyLtdMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">ESOP options (expiring December 1, 2023)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_uAUDPShares_c20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--UnlistedOptionsESOPOptionsTwoMember_z8hHRsh3CES7" title="Average exercise price of options, balance at the end of the financial year" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2023-06-30_custom_UnlistedOptionsESOPOptionsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--UnlistedOptionsESOPOptionsTwoMember_z9tXVoU76R15" title="Number of options, Balance at the end of the financial year" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2023-06-30_custom_UnlistedOptionsESOPOptionsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,400,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_uAUDPShares_c20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--UnlistedOptionsESOPOptionsTwoMember_zTOWshWehrt" title="Average exercise price of options, balance at the end of the financial year" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2022-06-30_custom_UnlistedOptionsESOPOptionsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--UnlistedOptionsESOPOptionsTwoMember_zT9QwKRxbm09" title="Number of options, Balance at the end of the financial year" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-06-30_custom_UnlistedOptionsESOPOptionsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,850,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_uAUDPShares_c20230630_z2pEbyxl3AUf" title="Average exercise price of options, balance at the end of the financial year" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20230630_zYX4rom8iqli" title="Number of options, Balance at the end of the financial year" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,400,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iI_uAUDPShares_c20220630_zrusnmZXvxv8" title="Average exercise price of options, balance at the end of the financial year" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20220630_zD8yI3blMml2" title="Number of options, Balance at the end of the financial year" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">494,350,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Exercisable at the end of the financial year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_iI_uAUDPShares_c20230630_zwfsBFlii5sg" title="Average exercise price of options, exercisable at the end of the financial year" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_iI_pid_uShares_c20230630_z1Qg4NIdsOz6" title="Exercisable at the end of the financial year" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,400,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_iI_uAUDPShares_c20220630_z6dRKVdDCbBk" title="Average exercise price of options, exercisable at the end of the financial year" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_iI_pid_uShares_c20220630_ziQbL7Gf9kOi" title="Exercisable at the end of the financial year" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">494,350,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zwPh606bqAYj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average remaining contractual life of options outstanding as at June 30, 2023 was <span id="xdx_90E_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zugyn2uGrBe5" title="Weighted average remaining contractual life of outstanding share options"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_EmployeeOptionPlanMember" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">0.42</ix:nonNumeric></span> years (2022: <span id="xdx_907_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeOptionPlanMember_zTw4SH4aHi7i" title="Weighted average remaining contractual life of outstanding share options"><ix:nonNumeric contextRef="From2021-07-012022-06-30_custom_EmployeeOptionPlanMember" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">0.43</ix:nonNumeric></span> years).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory"><p id="xdx_80B_eifrs-full--DisclosureOfEntitysReportableSegmentsExplanatory_z4dSR0Su3gLb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>25.
<span id="xdx_820_zH6zsFG9mfz3">SEGMENT INFORMATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
Identification of reportable segments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -14.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has identified three reportable segments as reported that is consistent with the internal reporting provided to the chief operating
decision maker, Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2022, the Company changed its reportable operating segments from two geographical segments, previously Australia and USA,
to two business unit segments, EasyDNA and geneType/Corporate as a result of integrating the EasyDNA acquisition in fiscal 2022. The
Company changed its reporting structure to better reflect what the chief operating decision maker is reviewing to make organizational
decisions and resource allocations. As a result, the 2021 presentation of segment information has been recast to conform with the current
segment reporting structure. In July 2022, a new business unit was created as a result of AffinityDNA acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
considers the business from a business unit perspective and has identified three reportable segments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EasyDNA:
</b>relates to EasyDNA branded test sales and expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AffinityDNA:
</b>relates to AffinityDNA branded test sales and expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GeneType
/ Corporate:</b> relates to geneType branded test sales and expense, includes corporate charges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 121; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>25. SEGMENT INFORMATION (cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
Business unit segments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory"><p id="xdx_890_eifrs-full--DisclosureOfOperatingSegmentsExplanatory_zNoyN88lNKfl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
segment information for the reportable segments is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zCbwqyNsBIk9" style="display: none">SUMMARY OF REPORTABLE SEGMENTS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">2023</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20220701__20230630__ifrs-full--SegmentsAxis__custom--AffinityDNAMember_zA6sNdo1yaMl" style="text-align: center; font-weight: bold">AffinityDNA</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20220701__20230630__ifrs-full--SegmentsAxis__custom--EasyDNAMember_zcX7mHaYnLAl" style="font-weight: bold; text-align: center">EasyDNA</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_492_20220701__20230630__ifrs-full--SegmentsAxis__custom--GeneTypeCorporateMember_zJ2NRzEhFnmd" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>geneType/</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate</b></span></p></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20220701__20230630_zfrLzCp3ww31" style="font-weight: bold; text-align: center">Total</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Segment revenue &amp; other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--Revenue_maRAOIzP1u_z54POWhemn7e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Revenue from contracts with customers</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">944,058</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">7,698,605</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">43,455</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">8,686,118</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--OtherIncome_maRAOIzP1u_z8UR6FcxlECj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2213">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,836,805</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,836,822</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--FinanceIncome_maRAOIzP1u_zWtE1BOIuz43" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Finance income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2218">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2219">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">220,161</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">220,161</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--RevenuesAndOtherIncome_iT_mtRAOIzP1u_zMZvfpLzmbW5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total segment revenue &amp; other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:RevenuesAndOtherIncome" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">944,058</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:RevenuesAndOtherIncome" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">7,698,622</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:RevenuesAndOtherIncome" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,100,421</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:RevenuesAndOtherIncome" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">10,743,101</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Segment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--DepreciationAndAmortisationExpense_iN_pp0p0_di_maSEzYWC_zNqqxGHxiZYf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">22,310</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">30,074</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">624,199</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">676,583</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eifrs-full--FinanceCosts_iN_pp0p0_di_maSEzYWC_z0Tzt1OObGr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Finance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,693</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,132</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">24,690</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">29,515</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eifrs-full--ChangesInInventoriesOfFinishedGoodsAndWorkInProgress_iN_pp0p0_di_maSEzYWC_z8rXpX36vko7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Raw materials and change in inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ChangesInInventoriesOfFinishedGoodsAndWorkInProgress" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">404,660</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ChangesInInventoriesOfFinishedGoodsAndWorkInProgress" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">3,896,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ChangesInInventoriesOfFinishedGoodsAndWorkInProgress" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">34,605</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ChangesInInventoriesOfFinishedGoodsAndWorkInProgress" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">4,335,265</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eifrs-full--FeeAndCommissionExpense_iN_pp0p0_di_maSEzYWC_zrqqjEbu3di6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Commissions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">42,727</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">193,292</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2245">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">236,019</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eifrs-full--EmployeeBenefitsExpense_iN_pp0p0_di_maSEzYWC_zRoKCYH47GTj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Employee benefits expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">209,219</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,593,699</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">4,405,148</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">6,208,066</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eifrs-full--AdvertisingExpense_iN_pp0p0_di_maSEzYWC_zKSgTI54j7bi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Advertising and promotional expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">35,926</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,681,875</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">994,552</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,712,353</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eifrs-full--ProfessionalFeesExpense_iN_pp0p0_di_maSEzYWC_zhOrGS2ILhh1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">62,522</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">18,414</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,279,704</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,360,640</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eifrs-full--ResearchAndDevelopmentExpense_iN_pp0p0_di_maSEzYWC_zbPbdBZ4VU66" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2263">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2264">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,281,157</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,281,157</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eifrs-full--DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_iN_pp0p0_di_maSEzYWC_zr4JdnyljLpg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Impairment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2268">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,125,725</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2270">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,125,725</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--OtherSegmentExpenses_iN_pp0p0_di_maSEzYWC_zlJ1bF5esIZh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:OtherSegmentExpenses" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">253,619</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:OtherSegmentExpenses" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,028,670</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:OtherSegmentExpenses" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,404,741</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:OtherSegmentExpenses" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">3,687,030</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--SegmentExpenses_iNT_di_mtSEzYWC_zpDkBKyoahUa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total segment expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:SegmentExpenses" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,033,676</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:SegmentExpenses" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">10,569,881</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:SegmentExpenses" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">12,513,521</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:SegmentExpenses" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">22,652,353</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_di_zQPTJZ14EEBc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Income tax credit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2283">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2284">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">158,329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">158,329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--ProfitLossAttributableToOwnersOfParent_zOMUltOw6u13" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss for the period</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">89,618</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">2,871,259</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">10,254,771</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">11,750,923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Segment Assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--Assets_iI_c20230630__ifrs-full--SegmentsAxis__custom--AffinityDNAMember_zF1hMlzR8de8" title="Total Segment Assets" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2023-06-30_custom_AffinityDNAMember90603250" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">625,421</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--Assets_iI_c20230630__ifrs-full--SegmentsAxis__custom--EasyDNAMember_zltXYq75U0Sg" title="Total Segment Assets" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2023-06-30_custom_EasyDNAMember90603265" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">3,320,967</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--Assets_iI_c20230630__ifrs-full--SegmentsAxis__custom--GeneTypeCorporateMember_z7oVp0uygIAc" title="Total Segment Assets" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">10,909,849</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--Assets_iI_c20230630_zTEAUgix4w38" title="Total Segment Assets" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">14,856,237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Segment Liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--Liabilities_iNI_di_c20230630__ifrs-full--SegmentsAxis__custom--AffinityDNAMember_zUZKdQcx9Xoa" title="Total Segment Liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2023-06-30_custom_AffinityDNAMember90603250" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">208,468</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--Liabilities_iNI_di_c20230630__ifrs-full--SegmentsAxis__custom--EasyDNAMember_ztkMvXeziOqa" title="Total Segment Liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2023-06-30_custom_EasyDNAMember90603265" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,308,206</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--Liabilities_iNI_di_c20230630__ifrs-full--SegmentsAxis__custom--GeneTypeCorporateMember_z6LOUeCUHO1l" title="Total Segment Liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,176,987</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--Liabilities_iNI_di_c20230630_zt6IpY51UE4e" title="Total Segment Liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">3,693,661</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 122; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>25. SEGMENT INFORMATION (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">2022</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20210701__20220630__ifrs-full--SegmentsAxis__custom--AffinityDNAMember_zf0VIsR9d4uk" style="text-align: center; font-weight: bold">AffinityDNA</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20210701__20220630__ifrs-full--SegmentsAxis__custom--EasyDNAMember_zR4QcFfSU0Kc" style="font-weight: bold; text-align: center">EasyDNA</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_495_20210701__20220630__ifrs-full--SegmentsAxis__custom--GeneTypeCorporateMember_zZm1t7leTb97" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>geneType/</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate</b></span></p></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20210701__20220630_z2EE1pFoSArb" style="font-weight: bold; text-align: center">Total</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Segment revenue &amp; other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--Revenue_maRAOIzP1u_zvtRdVd2Met5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Revenue from contracts with customers</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2309">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">5,989,782</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">805,034</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,794,816</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--OtherIncome_maRAOIzP1u_zNNjAPE86f3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl2314">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2315">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,783,391</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,783,391</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--FinanceIncome_pp0p0_maRAOIzP1u_z7msthMIvJs9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Finance income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2319">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2320">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">36,256</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">36,256</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--RevenuesAndOtherIncome_iT_mtRAOIzP1u_zsx6cTwZlTY3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total segment revenue &amp; other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2324">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:RevenuesAndOtherIncome" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">5,989,782</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:RevenuesAndOtherIncome" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">3,624,681</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:RevenuesAndOtherIncome" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">9,614,463</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Segment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--DepreciationAndAmortisationExpense_iN_pp0p0_di_maSEzYWC_zGSxkT9DGqwf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2329">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2330">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">578,668</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">578,668</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eifrs-full--FinanceCosts_iN_pp0p0_di_maSEzYWC_z11lkBPxUDnf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Finance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2334">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2335">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">15,215</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">15,215</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eifrs-full--ChangesInInventoriesOfFinishedGoodsAndWorkInProgress_iN_pp0p0_di_maSEzYWC_zEP8zzJOhjHc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Raw materials and change in inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2339">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ChangesInInventoriesOfFinishedGoodsAndWorkInProgress" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,951,815</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ChangesInInventoriesOfFinishedGoodsAndWorkInProgress" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">61,719</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ChangesInInventoriesOfFinishedGoodsAndWorkInProgress" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">3,013,534</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eifrs-full--FeeAndCommissionExpense_iN_pp0p0_di_maSEzYWC_zFVMUhfLivpj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Commissions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2344">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">156,625</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2346">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">156,625</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eifrs-full--EmployeeBenefitsExpense_iN_pp0p0_di_maSEzYWC_zFFfdNJJZdKf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Employee benefits expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2349">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,235,657</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">4,632,998</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">5,868,655</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eifrs-full--AdvertisingExpense_iN_pp0p0_di_maSEzYWC_zMyJZvBzDyMl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Advertising and promotional expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2354">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,079,291</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">806,111</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,885,402</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eifrs-full--ProfessionalFeesExpense_iN_pp0p0_di_maSEzYWC_zqOBPQCe9uKc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2359">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">21,685</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,813,759</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,835,444</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eifrs-full--ResearchAndDevelopmentExpense_iN_pp0p0_di_maSEzYWC_zRfmNV1F88Fc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2364">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2365">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">705,507</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">705,507</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eifrs-full--DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_iN_pp0p0_di_maSEzYWC_z2wkmyh8yet3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Impairment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2369">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2370">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">564,161</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">564,161</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--OtherSegmentExpenses_iN_pp0p0_di_maSEzYWC_zRd69M9itHAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2374">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:OtherSegmentExpenses" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">721,226</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:OtherSegmentExpenses" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,433,149</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:OtherSegmentExpenses" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,154,375</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--SegmentExpenses_iNT_di_mtSEzYWC_zY07gJ1P8Ajk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total segment expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2379">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:SegmentExpenses" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,166,299</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:SegmentExpenses" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">10,611,287</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:SegmentExpenses" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">16,777,586</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_di_zIhzLLVJrQ06" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Income tax credit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2384">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2385">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">32,125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">32,125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--ProfitLossAttributableToOwnersOfParent_zq4TQxfyTuLj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss for the period</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2389">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">176,517</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">6,954,481</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">7,130,998</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Segment Assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--Assets_iI_c20220630__ifrs-full--SegmentsAxis__custom--AffinityDNAMember_zV8Sy6znh50g" title="Total Segment Assets" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2394">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--Assets_iI_c20220630__ifrs-full--SegmentsAxis__custom--EasyDNAMember_zS95CqjJHsef" title="Total Segment Assets" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2022-06-30_custom_EasyDNAMember90603484" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,668,618</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--Assets_iI_c20220630__ifrs-full--SegmentsAxis__custom--GeneTypeCorporateMember_zPLfGNyyfGCd" title="Total Segment Assets" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">18,133,080</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--Assets_iI_c20220630_zuY2EcLe4Mv2" title="Total Segment Assets" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">20,801,698</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Segment Liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--Liabilities_iNI_di_c20220630__ifrs-full--SegmentsAxis__custom--AffinityDNAMember_zNh20YxtCbb5" title="Total Segment Liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2402">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--Liabilities_iNI_di_c20220630__ifrs-full--SegmentsAxis__custom--EasyDNAMember_zszW9b989sbe" title="Total Segment Liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2022-06-30_custom_EasyDNAMember90603484" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,969,878</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--Liabilities_iNI_di_c20220630__ifrs-full--SegmentsAxis__custom--GeneTypeCorporateMember_zseKdmCVfOo3" title="Total Segment Liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,400,749</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--Liabilities_iNI_di_c20220630_zTBbV7YsrkG1" title="Total Segment Liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,370,627</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 123; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>25. SEGMENT INFORMATION (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">2021</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20200701__20210630__ifrs-full--SegmentsAxis__custom--AffinityDNAMember_zHAP9bqBngl6" style="text-align: center; font-weight: bold">AffinityDNA</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20200701__20210630__ifrs-full--SegmentsAxis__custom--EasyDNAMember_zlT2J5qBfiy4" style="font-weight: bold; text-align: center">EasyDNA</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_496_20200701__20210630__ifrs-full--SegmentsAxis__custom--GeneTypeCorporateMember_zIlTfBIRfPz2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>geneType/</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate</b></span></p></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20200701__20210630_zf9Ev20iB5F7" style="font-weight: bold; text-align: center">Total</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Segment revenue &amp; other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--Revenue_maRAOIzP1u_zuiLK0GshLei" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Revenue from contracts with customers</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl2410">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl2411">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">120,554</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">120,554</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--OtherIncome_maRAOIzP1u_zDEJScoc2IKd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2415">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2416">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,559,961</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,559,961</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--FinanceIncome_pp0p0_maRAOIzP1u_zV126Te5UWMb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Finance income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2420">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2421">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">62,394</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">62,394</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--RevenuesAndOtherIncome_iT_mtRAOIzP1u_zm164vnFgKU5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total segment revenue &amp; other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2425">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2426">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:RevenuesAndOtherIncome" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,742,909</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:RevenuesAndOtherIncome" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,742,909</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Segment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--DepreciationAndAmortisationExpense_iN_pp0p0_di_maSEzYWC_z5nos5yRhBLg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2430">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2431">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">386,277</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">386,277</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eifrs-full--FinanceCosts_iN_pp0p0_di_maSEzYWC_z2xmQObayHCe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Finance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2435">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2436">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">16,338</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">16,338</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eifrs-full--ChangesInInventoriesOfFinishedGoodsAndWorkInProgress_iN_pp0p0_di_maSEzYWC_zMgnrna2z3pd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Raw materials and change in inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2440">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2441">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ChangesInInventoriesOfFinishedGoodsAndWorkInProgress" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">170,457</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ChangesInInventoriesOfFinishedGoodsAndWorkInProgress" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">170,457</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eifrs-full--FeeAndCommissionExpense_iN_pp0p0_di_maSEzYWC_zoLDYETTsaEi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Commissions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2445">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2446">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2447">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2448">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--EmployeeBenefitsExpense_iN_pp0p0_di_maSEzYWC_znUIN9baGkm6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Employee benefits expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2450">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2451">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">3,868,331</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">3,868,331</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eifrs-full--AdvertisingExpense_iN_pp0p0_di_maSEzYWC_zdFkkFkEoOqa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Advertising and promotional expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2455">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2456">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">436,274</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdvertisingExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">436,274</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eifrs-full--ProfessionalFeesExpense_iN_pp0p0_di_maSEzYWC_zrYRJIVMYzG1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2460">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2461">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,461,401</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,461,401</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eifrs-full--ResearchAndDevelopmentExpense_iN_pp0p0_di_maSEzYWC_z9kf9Hc0fGC" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2465">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2466">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,165,531</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,165,531</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eifrs-full--DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_iN_pp0p0_di_maSEzYWC_z4OadLhtm8Lb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Impairment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2470">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2471">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">32,048</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">32,048</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--OtherSegmentExpenses_iN_pp0p0_di_maSEzYWC_zdBuQ7A0caUd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2475">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2476">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:OtherSegmentExpenses" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,283,871</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:OtherSegmentExpenses" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,283,871</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--SegmentExpenses_iNT_di_mtSEzYWC_zT9c1hwRLTYg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total segment expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2480">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2481">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:SegmentExpenses" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">8,820,528</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="GENE:SegmentExpenses" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">8,820,528</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_di_zc4OJgXexEq6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Income tax credit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2485">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2486">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2487">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2488">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--ProfitLossAttributableToOwnersOfParent_zWwXBGvWNHAf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss for the period</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2490">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2491">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">7,077,619</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">7,077,619</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Segment Assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--Assets_iI_c20210630__ifrs-full--SegmentsAxis__custom--AffinityDNAMember_zpGU7tqVQjf9" title="Total Segment Assets" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2495">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--Assets_iI_c20210630__ifrs-full--SegmentsAxis__custom--EasyDNAMember_zV00YvhPNI71" title="Total Segment Assets" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2497">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--Assets_iI_c20210630__ifrs-full--SegmentsAxis__custom--GeneTypeCorporateMember_zaHyxEz4Tfud" title="Total Segment Assets" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">22,971,688</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--Assets_iI_c20210630_zQrI9myzuET" title="Total Segment Assets" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">22,971,688</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Segment Liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--Liabilities_iNI_di_c20210630__ifrs-full--SegmentsAxis__custom--AffinityDNAMember_zOx3iduBlIZ9" title="Total Segment Liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2503">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--Liabilities_iNI_di_c20210630__ifrs-full--SegmentsAxis__custom--EasyDNAMember_znvMwUpS971e" title="Total Segment Liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2505">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--Liabilities_iNI_di_c20210630__ifrs-full--SegmentsAxis__custom--GeneTypeCorporateMember_zCKGB28rSPub" title="Total Segment Liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,438,653</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--Liabilities_iNI_di_c20210630_zta2323Dw8Gl" title="Total Segment Liabilities" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,438,653</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zLIx9hHl2zH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)
Geographic information</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfGeographicInformationForReportableSegmentsExplanatory"><p id="xdx_899_ecustom--DisclosureOfGeographicInformationForReportableSegmentsExplanatory_z0B0x5Wkc6i5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
presenting the geographic information, segment revenue has been based on geographic location of customers. The geographic information
for the reportable segments is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zaq7wVV8ruG" style="display: none">SUMMARY
OF GEOGRAPHIC INFORMATION FOR THE REPORTABLE SEGMENTS REVENUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">2023</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20220701__20230630__ifrs-full--SegmentsAxis__custom--AffinityDNAMember_zQPC5ofFp7f6" style="text-align: center; font-weight: bold">AffinityDNA</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20220701__20230630__ifrs-full--SegmentsAxis__custom--EasyDNAMember_zQP8wH0Igf6j" style="font-weight: bold; text-align: center">EasyDNA</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49A_20220701__20230630__ifrs-full--SegmentsAxis__custom--GeneTypeCorporateMember_zGuehuNewKFl" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>geneType/</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate</b></span></p></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20220701__20230630_zHA4pV6Iv9bg" style="font-weight: bold; text-align: center">Total</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--Revenue_hifrs-full--GeographicalAreasAxis__custom--AmericaAndCanadaMember_zvEXRR9Jwjmc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; width: 36%; text-align: left">America and Canada</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_AmericaAndCanadaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">15,056</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember_custom_AmericaAndCanadaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,190,352</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember_custom_AmericaAndCanadaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">36,761</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_AmericaAndCanadaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,242,169</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--Revenue_hifrs-full--GeographicalAreasAxis__custom--EuropeMiddleEastAndAfricaMember_zS18rOkOZj89" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Europe Middle East and Africa</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_EuropeMiddleEastAndAfricaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">766,040</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember_custom_EuropeMiddleEastAndAfricaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">3,728,586</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2520">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_EuropeMiddleEastAndAfricaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,494,626</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--Revenue_hifrs-full--GeographicalAreasAxis__custom--LatinAmericaContinentMember_zk7sbxJS96O" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Latin America</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_LatinAmericaContinentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">144,727</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember_custom_LatinAmericaContinentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">177,306</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2525">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_LatinAmericaContinentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">322,033</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--Revenue_hifrs-full--GeographicalAreasAxis__custom--AsiaPacificContinentMember_z1FjNHeP2yZg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Asia Pacific</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember_custom_AsiaPacificContinentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">18,235</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember_custom_AsiaPacificContinentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,602,361</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember_custom_AsiaPacificContinentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,694</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_AsiaPacificContinentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,627,290</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--Revenue_zaLckhTTLgP5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_AffinityDNAMember90603109" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">944,058</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_EasyDNAMember90603109" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">7,698,605</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">43,455</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">8,686,118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 124; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>25. SEGMENT INFORMATION (cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)
Geographic information (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">2022</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20210701__20220630__ifrs-full--SegmentsAxis__custom--AffinityDNAMember_zrQOfcw0BIgb" style="text-align: center; font-weight: bold">AffinityDNA</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20210701__20220630__ifrs-full--SegmentsAxis__custom--EasyDNAMember_zb6NMnysiKQi" style="font-weight: bold; text-align: center">EasyDNA</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_491_20210701__20220630__ifrs-full--SegmentsAxis__custom--GeneTypeCorporateMember_zFdCfqmHZP24" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>geneType/</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate</b></span></p></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20210701__20220630_z2q7g7mCfGDl" style="font-weight: bold; text-align: center">Total&#8239;</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--Revenue_hifrs-full--GeographicalAreasAxis__custom--AmericaAndCanadaMember_zw1ksGO04Ew9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; width: 36%; text-align: left">America and Canada</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl2538">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember_custom_AmericaAndCanadaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,267,474</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember_custom_AmericaAndCanadaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">7,077</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_AmericaAndCanadaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,274,551</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--Revenue_hifrs-full--GeographicalAreasAxis__custom--EuropeMiddleEastAndAfricaMember_zmDEb5CTBda8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Europe Middle East and Africa</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2543">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember_custom_EuropeMiddleEastAndAfricaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,501,302</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2545">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_EuropeMiddleEastAndAfricaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">2,501,302</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--Revenue_hifrs-full--GeographicalAreasAxis__custom--LatinAmericaContinentMember_z23dr127dQN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Latin America</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2548">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember_custom_LatinAmericaContinentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">128,840</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2550">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_LatinAmericaContinentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">128,840</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--Revenue_hifrs-full--GeographicalAreasAxis__custom--AsiaPacificContinentMember_zX7P8E1bvPUe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Asia Pacific</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2553">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember_custom_AsiaPacificContinentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,092,166</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember_custom_AsiaPacificContinentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">797,957</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_AsiaPacificContinentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,890,123</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--Revenue_zoTkcBhD1P2c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2558">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_EasyDNAMember90603328" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">5,989,782</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">805,034</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,794,816</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">2021</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20200701__20210630__ifrs-full--SegmentsAxis__custom--AffinityDNAMember_zTCT2U8n2cbk" style="text-align: center; font-weight: bold">AffinityDNA</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20200701__20210630__ifrs-full--SegmentsAxis__custom--EasyDNAMember_zTL4gl9FcD31" style="font-weight: bold; text-align: center">EasyDNA</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_497_20200701__20210630__ifrs-full--SegmentsAxis__custom--GeneTypeCorporateMember_z6G0gkcjkCLi" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>geneType/</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate</b></span></p></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20200701__20210630_z8wjRmWeAKrb" style="font-weight: bold; text-align: center">Total</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--Revenue_hifrs-full--GeographicalAreasAxis__custom--AmericaAndCanadaMember_zf1kmjVjcfYg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">America and Canada</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl2563">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl2564">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember_custom_AmericaAndCanadaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">120,554</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_AmericaAndCanadaMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">120,554</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--Revenue_hifrs-full--GeographicalAreasAxis__custom--EuropeMiddleEastAndAfricaMember_zuEvS9WnAndg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Europe Middle East and Africa</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2568">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2569">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2570">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2571">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--Revenue_hifrs-full--GeographicalAreasAxis__custom--LatinAmericaContinentMember_zwelArEVlQ5d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Latin America</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2573">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2574">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2575">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2576">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--Revenue_hifrs-full--GeographicalAreasAxis__custom--AsiaPacificContinentMember_zWKlncBr0Vs1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Asia Pacific</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2578">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2579">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2580">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2581">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--Revenue_ztTzZsE8jVZ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2583">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2584">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30_custom_GeneTypeCorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">120,554</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">120,554</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory"><p id="xdx_80C_eifrs-full--DisclosureOfSharebasedPaymentArrangementsExplanatory_zi3jecx5TaPi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>26.
<span id="xdx_82C_zuUVn9qjWaZj">SHARE BASED PAYMENTS</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
Employee option plan</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2020, the Company issued <span id="xdx_908_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20201215__20201221__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeStockOptionsMember_zldRTvKojRMj" title="Number of options issued"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2020-12-152020-12-21_custom_EmployeeStockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,850,000</ix:nonFraction></span> options with an exercise price of A$<span id="xdx_908_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_c20201221__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeStockOptionsMember_zml3KhxeKSN9" title="Option exercise price"><ix:nonFraction name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" contextRef="AsOf2020-12-21_custom_EmployeeStockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.008</ix:nonFraction></span> (0.8cents) per option, expiring December 1,
2023 issued under an employee incentive scheme (2020: Nil). The Company, also issued various unlisted options to underwriters and sub-underwriters
as a part of capital raising costs in financial year ended June 30, 2021. Please refer to further details on options on Note 23.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no new options issued under the Employee Option Plan during the financial years ending June 30, 2022 and June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
Performance Rights Issuance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
receiving requisite shareholder approval on December 10, 2020, the Company issued performance rights to Directors of the Company as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_c20201209__20201210__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrLindsayWakefieldMember_zWq4lgZmPCma"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-12-092020-12-10_custom_ClassaPerformanceRightsMember_custom_DrLindsayWakefieldMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">5,000,000</ix:nonFraction></span> Class A Performance Rights
    to Dr. Lindsay Wakefield</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20201209__20201210__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickiMember_zuwHksrsVfm7"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-12-092020-12-10_custom_ClassaPerformanceRightsMember_custom_DrJerzyMuchnickiMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,500,000</ix:nonFraction></span> Class A Performance Rights, <span id="xdx_906_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20201209__20201210__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassBPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickiMember_z8TMdI6Svcld" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-12-092020-12-10_custom_ClassBPerformanceRightsMember_custom_DrJerzyMuchnickiMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000,000</ix:nonFraction></span> Class
    B Performance Rights and <span id="xdx_907_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20201209__20201210__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassCPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickiMember_zB3J50Sz0nki"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-12-092020-12-10_custom_ClassCPerformanceRightsMember_custom_DrJerzyMuchnickiMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000,000</ix:nonFraction></span> Class C Performance Rights to Dr. Jerzy Muchnicki</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20201209__20201210__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember_zrwubQ10n1fk" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-12-092020-12-10_custom_ClassaPerformanceRightsMember_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,500,000</ix:nonFraction></span> Class A Performance Rights, <span id="xdx_90F_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20201209__20201210__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassBPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember_zvSFlGwLwKc" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-12-092020-12-10_custom_ClassBPerformanceRightsMember_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000,000</ix:nonFraction></span> Class
    B Performance Rights and <span id="xdx_902_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20201209__20201210__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassCPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember_zmSe7TkwdzJj"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-12-092020-12-10_custom_ClassCPerformanceRightsMember_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000,000</ix:nonFraction></span> Class C Performance Rights to Mr. Peter Rubinstein</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_c20201209__20201210__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrNicholasBurrowsMember_zsBYZx559JM6" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-12-092020-12-10_custom_ClassaPerformanceRightsMember_custom_MrNicholasBurrowsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">5,000,000</ix:nonFraction></span> Class A Performance Rights to Mr. Nicholas
    Burrows</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
performance rights remain available to Directors to exercise at June 30, 2023, if vesting conditions are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the financial year ending June 30, 2021, the Board has approved the issue of the following performance rights to the Chief Executive
Officer and Chief Operating Officer:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassDPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrSimonMorriesMember_z4jFfwJIj3t8"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-07-012021-06-30_custom_ClassDPerformanceRightsMember_custom_MrSimonMorriesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000,000</ix:nonFraction></span> Class D Performance Rights
    to Mr. Simon Morris</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassEPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrStanleySackMember_zwK3uAYSNJ2l"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-07-012021-06-30_custom_ClassEPerformanceRightsMember_custom_MrStanleySackMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,937,500</ix:nonFraction></span> Class E Performance Rights to Mr. Stanley
    Sack</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 125; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>26.
SHARE BASED PAYMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
Performance Rights Issuance (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -14.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Stanley Sack exercised his performance rights during the financial year ending June 30, 2022. The performance rights issued to Mr. Simon
Morriss remain exercisable at June 30, 2023, if vesting conditions are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the financial year ending June 30, 2022, the Board has approved for the following performance rights to be issued to the Key Management
Personnel below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrMichaelTonroeMember_zOZN49TEAo5k"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2021-07-012022-06-30_custom_PerformanceRightsMember_custom_MrMichaelTonroeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000,000</ix:nonFraction></span> Performance
    Rights to Mr. Michael Tonroe</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrCarlStubbingsMember_zrUeerRMjA92"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2021-07-012022-06-30_custom_PerformanceRightsMember_custom_MrCarlStubbingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></span> Performance Rights
    to Mr. Carl Stubbings</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrKevinCamilleriMember_zhHKLaHJ4Ogg" title="Number of performance rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2021-07-012022-06-30_custom_PerformanceRightsMember_custom_MrKevinCamilleriMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></span> Performance Rights
    to Mr. Kevin Camilleri</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
performance rights issued to Mr. Michael Tonroe were forfeit during the 2023 financial year following his resignation. The performance
rights issued to Mr. Carl Stubbings and Mr. Kevin Camilleri remain exercisable at June 30, 2023, if vesting conditions are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has accounted for these performance rights in accordance with its accounting policy for share-based payment transactions and
has recorded a share-based payments expense of A$<span id="xdx_902_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember_zX9upmxL3kX9" title="Expenses arising from share-based payments"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2022-07-012023-06-30_custom_PerformanceRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">125,500</ix:nonFraction></span> in the Statement of Profit or Loss and Other Comprehensive Income for the current
reporting period (2022: A$<span id="xdx_90F_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember_zf1A0HqZy4x5" title="Expenses arising from share-based payments"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30_custom_PerformanceRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">437,508</ix:nonFraction></span> &amp; 2021: A$<span id="xdx_908_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember_zFvkaI41Kqvl" title="Expenses arising from share-based payments"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2020-07-012021-06-30_custom_PerformanceRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">622,725</ix:nonFraction></span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation
of Performance Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Performance Rights are not currently quoted on the ASX and as such have no ready market value. The performance rights each grant the
holder a right of grant of one ordinary Share in the Company upon vesting of the performance rights for nil consideration. Accordingly,
the performance rights may have a present value at the date of their grant. Various factors impact upon the value of performance rights
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the period outstanding before the
    expiry date of the performance rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the underlying price or value of the securities into
    which they may be converted;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proportion of the issued capital as expanded consequent
    upon conversion of the performance rights into Shares (i.e. whether or not the shares that might be acquired upon exercise of the
    options represent a controlling or other significant interest); and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the value of the shares into which the performance
    rights may be converted.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are various formulae which can be applied to determining the theoretical value of performance rights (including the formula known as
the Black-Scholes Model valuation formula and the Binomial model).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company commissioned an independent valuation of the performance rights. The independent valuer has applied the Binomial Model in providing
the valuation of the performance rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation
of Performance Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Performance Rights are not currently quoted on the ASX and as such have no ready market value. The performance rights each Inherent in
the application of the Binomial model are a number of inputs, some of which must be assumed. For the performance rights issued in the
year ended June 30, 2021, the data relied upon in applying the Binomial model was:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise price being <span id="xdx_902_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_pid_c20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember_z6o3aLPPmvne" title="Option exercise price"><ix:nonFraction name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" contextRef="AsOf2021-06-30_custom_PerformanceRightsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0</ix:nonFraction></span> cents per
    performance right for all classes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VWAP hurdle (<span id="xdx_908_ecustom--SharePriceHurdleNumberOfConsecutiveDays_dtD_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassAAndBPerformanceRightsMember_zLWVdPxulhhe" title="Consecutive share price hurdle"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_ClassAAndBPerformanceRightsMember" format="ixt-sec:durday" name="GENE:SharePriceHurdleNumberOfConsecutiveDays">10</ix:nonNumeric></span> days consecutive share price hurdle)
    equaling A$<span id="xdx_90D_ecustom--ConsecutiveSharePrice_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember_zB9wQmNkcp5g" title="Consecutive share price"><ix:nonFraction name="GENE:ConsecutiveSharePrice" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.012</ix:nonFraction></span> for Class A and A$<span id="xdx_90D_ecustom--ConsecutiveSharePrice_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassBPerformanceRightsMember_zMjn6XBNdOKa"><ix:nonFraction name="GENE:ConsecutiveSharePrice" contextRef="From2020-07-012021-06-30_custom_ClassBPerformanceRightsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.014</ix:nonFraction></span> for Class B, and (<span id="xdx_900_ecustom--SharePriceHurdleNumberOfConsecutiveDays_dtD_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassDPerformanceRightsMember_zmJuasHwV6l6"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_ClassDPerformanceRightsMember" format="ixt-sec:durday" name="GENE:SharePriceHurdleNumberOfConsecutiveDays">15</ix:nonNumeric></span> days consecutive share price hurdle) equaling $<span id="xdx_90A_ecustom--ConsecutiveSharePrice_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassDPerformanceRightsMember_zaU3FCytVaa9"><ix:nonFraction name="GENE:ConsecutiveSharePrice" contextRef="From2020-07-012021-06-30_custom_ClassDPerformanceRightsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.016</ix:nonFraction></span> for Class D performance
    rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales and market cap hurdles as listed above for Class
    C and Class E performance rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the continuously compounded risk-free rate being <span id="xdx_90D_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pid_dp_uPure_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember_zqZwbCRAKMuk" title="Risk-free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2020-07-012021-06-30_custom_PerformanceRightsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.111</ix:nonFraction></span>%
    for all classes of performance rights (calculated with reference to Refinitiv &#8211; closing share price as at December 21, 2020,
    and 3 year Australian Government yield as at December 21, 2020);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expected option life of <span id="xdx_900_ecustom--ExpectedLifeShareOptionsGranted_dtY_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassEPerformanceRightsMember_zL5mE8ddsSc4" title="Expected life of an option"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_ClassEPerformanceRightsMember" format="ixt-sec:duryear" name="GENE:ExpectedLifeShareOptionsGranted">2</ix:nonNumeric></span> years for Class E performance
    rights and <span id="xdx_902_ecustom--ExpectedLifeShareOptionsGranted_dtY_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember_zAdwmZwjJ938" title="Expected life of an option"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_PerformanceRightsMember" format="ixt-sec:duryear" name="GENE:ExpectedLifeShareOptionsGranted">3</ix:nonNumeric></span> years for all other classes of performance rights; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a volatility measure of <span id="xdx_906_ecustom--HistoricVolatilityAndExpectedVolatilityShareOptionsGranted_pid_dp_uPure_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember_z4mGcZagudN3" title="Expected volatility"><ix:nonFraction name="GENE:HistoricVolatilityAndExpectedVolatilityShareOptionsGranted" contextRef="From2020-07-012021-06-30_custom_PerformanceRightsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">158.23</ix:nonFraction></span>%.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 126; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>26. SHARE BASED PAYMENTS (cont.)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation
of Performance Rights (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the performance Rights issued during the financial year ending June 30, 2022, the data relied upon in applying the Binomial model was:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise price being <span id="xdx_90C_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_pid_c20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember_zv8UNf6oZPU4"><ix:nonFraction name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" contextRef="AsOf2022-06-30_custom_PerformanceRightsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0</ix:nonFraction></span> cents per
    performance right for all classes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VWAP hurdle for key management personnel (<span id="xdx_90E_ecustom--SharePriceHurdleNumberOfConsecutiveDays_dtD_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember_zb1vLpgiHOf5"><ix:nonNumeric contextRef="From2021-07-012022-06-30_custom_PerformanceRightsMember" format="ixt-sec:durday" name="GENE:SharePriceHurdleNumberOfConsecutiveDays">15</ix:nonNumeric></span> days consecutive
    share price hurdle) equaling A$<span id="xdx_905_ecustom--ConsecutiveSharePrice_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember_zDF2BAP7mAgl"><ix:nonFraction name="GENE:ConsecutiveSharePrice" contextRef="From2021-07-012022-06-30_custom_PerformanceRightsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.016</ix:nonFraction></span> for performance rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales and market cap hurdles as listed above for performance
    rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the continuously compounded risk-free rate is as per
    table below (calculated based on yield of Australian government bonds, as at the grant dates for a 2 or 3 year period matching the
    expected life of performance rights);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expected option life of <span id="xdx_901_ecustom--ExpectedLifeShareOptionsGranted_dtY_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember_zc78cGubHNE4"><ix:nonNumeric contextRef="From2021-07-012022-06-30_custom_PerformanceRightsMember" format="ixt-sec:duryear" name="GENE:ExpectedLifeShareOptionsGranted">3</ix:nonNumeric></span> years for key management
    personnel and <span id="xdx_901_ecustom--ExpectedLifeShareOptionsGranted_dtY_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--OtherPerformanceRightsMember_zkR4TVyDZ4fi"><ix:nonNumeric contextRef="From2021-07-012022-06-30_custom_OtherPerformanceRightsMember" format="ixt-sec:duryear" name="GENE:ExpectedLifeShareOptionsGranted">2</ix:nonNumeric></span> years for others; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a volatility measure between <span id="xdx_90C_ecustom--HistoricVolatilityAndExpectedVolatilityShareOptionsGranted_pid_dp_uPure_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zhwHf5SXlGSk" title="Expected volatility"><ix:nonFraction name="GENE:HistoricVolatilityAndExpectedVolatilityShareOptionsGranted" contextRef="From2021-07-012022-06-30_custom_PerformanceRightsMember_ifrs-full_BottomOfRangeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">149</ix:nonFraction></span>% to <span id="xdx_904_ecustom--HistoricVolatilityAndExpectedVolatilityShareOptionsGranted_pid_dp_uPure_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zS7CyXI1mAja" title="Expected volatility"><ix:nonFraction name="GENE:HistoricVolatilityAndExpectedVolatilityShareOptionsGranted" contextRef="From2021-07-012022-06-30_custom_PerformanceRightsMember_ifrs-full_TopOfRangeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">161</ix:nonFraction></span>%.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Performance
hurdles</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
management personnel, being the recipients of the performance rights, must remain engaged by the Company at the time of satisfaction
of the performance hurdle in order for the relevant performance right to vest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no performance rights issued for the year ended June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
rights issued during the year ended June 30, 2022</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--PerformanceHurdlesDescription_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember_zrsoWkcyHhia" title="Performance hurdles, description"><ix:nonNumeric contextRef="From2021-07-012022-06-30_custom_ClassaPerformanceRightsMember" name="GENE:PerformanceHurdlesDescription">The
performance rights for key management personnel vest and are exercisable upon the Share price reaching A$0.016 while or greater for more
than 15-day consecutive ASX trading days</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
rights issued during the year ended June 30, 2021</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--PerformanceHurdlesDescription_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember_zJJCGStjFyU3" title="Performance hurdles, description"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember" name="GENE:PerformanceHurdlesDescription">The
Class A Performance Rights vest and are exercisable upon the Share price reaching A$0.012 or greater for more than 10-day consecutive
ASX trading days.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--PerformanceHurdlesDescription_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassBPerformanceRightsMember_zSZjoOR94L08" title="Performance hurdles, description"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_ClassBPerformanceRightsMember" name="GENE:PerformanceHurdlesDescription">The
Class B Performance Rights vest and are exercisable upon the Share price reaching A$0.014 or greater for more than 10-day consecutive
ASX trading days and sales commence on the Consumer Initiated Testing (CIT) platform in either Australia or the United States of America.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--PerformanceHurdlesDescription_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassCPerformanceRightsMember_ziy3DDhWUBxj" title="Performance hurdles, description"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_ClassCPerformanceRightsMember" name="GENE:PerformanceHurdlesDescription">The
Class C Performance Rights vest and are exercisable upon a minimum of 4,000 tests being processed in any 12-month period or the market
cap of the Company reaching A$100 million or above and being sustained for more than 10 consecutive ASX trading days, whichever happens
sooner.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--PerformanceHurdlesDescription_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassDPerformanceRightsMember_z9bBMtMHs9M5" title="Performance hurdles, description"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_ClassDPerformanceRightsMember" name="GENE:PerformanceHurdlesDescription">The
Class D Performance Rights vest and are exercisable upon the Share price reaching A$0.016 or greater for more than 15-day consecutive
ASX trading days.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--PerformanceHurdlesDescription_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassEPerformanceRightsMember_zJk4JAhQmef1" title="Performance hurdles, description"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_ClassEPerformanceRightsMember" name="GENE:PerformanceHurdlesDescription">The
Class E Performance Rights vest and are exercisable upon the first commercial sale of the Company&#8217;s COVID-19 risk test with IBX
(Infinity BioLogix)</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
rights issued prior to the year ended June 30, 2021</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--PerformanceHurdlesDescription_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsOneMember_zxY5MEh96CVf" title="Performance hurdles, description"><ix:nonNumeric contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsOneMember" name="GENE:PerformanceHurdlesDescription">The
Class A Performance Rights vest and are exercisable upon the Share price reaching A$0.02 or greater for more than 10-day consecutive
ASX trading days.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 127; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>26. SHARE BASED PAYMENTS (cont.)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory"><p id="xdx_89C_eifrs-full--DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_zcd5jU5OGnOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Performance
rights issued during prior year</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zNVzRWMHeshj" style="display: none">SCHEDULE OF INDEPENDENT VALUATION OF PERFORMANCE RIGHTS GRANTED</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Performance</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Rights </p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">issued</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Valuation</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(cents)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total fair</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>value of</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Performance</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense</b></span></p>
                                                             <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>accounted</b></span></p>
                                                             <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for in 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>accounted</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for during</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>the year</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 35%; text-align: left">Mr. Carl Stubbings</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20210701__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrCarlStubbingsMember_z3PcYRvDdUy6" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2021-07-012022-06-30_custom_MrCarlStubbingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--WeightedAverageFairValueAtMeasurementDateGrantedPerShare_uAUDPShares_c20210701__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrCarlStubbingsMember_z1shb4uWUS89" style="width: 9%; text-align: right"><ix:nonFraction name="GENE:WeightedAverageFairValueAtMeasurementDateGrantedPerShare" contextRef="From2021-07-012022-06-30_custom_MrCarlStubbingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.52</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_iI_c20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrCarlStubbingsMember_zGFzrXIgo56i" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="AsOf2022-06-30_custom_MrCarlStubbingsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">103,104</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20210701__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrCarlStubbingsMember_zlEQRD8rZCd7" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30_custom_MrCarlStubbingsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">26,459</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrCarlStubbingsMember_zeI5GpSmXZp2" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2022-07-012023-06-30_custom_MrCarlStubbingsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">34,368</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Mr. Kevin Camilleri</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20210701__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrKevinCamilleriMember_zpWmlZbMvSni" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2021-07-012022-06-30_custom_MrKevinCamilleriMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--WeightedAverageFairValueAtMeasurementDateGrantedPerShare_uAUDPShares_c20210701__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrKevinCamilleriMember_zS78qoECpfDc" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="GENE:WeightedAverageFairValueAtMeasurementDateGrantedPerShare" contextRef="From2021-07-012022-06-30_custom_MrKevinCamilleriMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.42</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_iI_c20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrKevinCamilleriMember_z3fs4fsYrzh2" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="AsOf2022-06-30_custom_MrKevinCamilleriMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">83,216</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20210701__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrKevinCamilleriMember_zusD4uBiF0pa" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30_custom_MrKevinCamilleriMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">16,719</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrKevinCamilleriMember_znFqHbUUEJzg" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2022-07-012023-06-30_custom_MrKevinCamilleriMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">27,739</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember_zyH9WSXnRX6b" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2021-07-012022-06-30_custom_ClassaPerformanceRightsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_iI_c20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember_zJF6VYV9CQhc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="AsOf2022-06-30_custom_ClassaPerformanceRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">186,320</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember_zhaLk8zj86ye" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30_custom_ClassaPerformanceRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">43,178</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember_zrGY3CY7yS3b" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2022-07-012023-06-30_custom_ClassaPerformanceRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">62,107</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Performance
rights issued during prior year, that lapsed during the financial year ending June 30, 2023</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Performance</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Rights</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">issued</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Valuation</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(cents)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total fair</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>value of</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Performance</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>accounted</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for in 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>accounted</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for during</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>the year</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 35%; text-align: left; padding-bottom: 1.5pt">Mr. Michael Tonroe</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20210701__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrMichaelTonroeMember_zIyqKZP5zjWc" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2021-07-012022-06-30_custom_MrMichaelTonroeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td id="xdx_983_ecustom--WeightedAverageFairValueAtMeasurementDateGrantedPerShare_uAUDPShares_c20210701__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrMichaelTonroeMember_z4EfgAN2PGp" style="padding-bottom: 1.5pt; width: 9%; text-align: right"><ix:nonFraction name="GENE:WeightedAverageFairValueAtMeasurementDateGrantedPerShare" contextRef="From2021-07-012022-06-30_custom_MrMichaelTonroeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.73</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_iI_c20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrMichaelTonroeMember_zJh41IB1bKa9" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="AsOf2022-06-30_custom_MrMichaelTonroeMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">291,428</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20210701__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrMichaelTonroeMember_zU45TOO6Ck36" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30_custom_MrMichaelTonroeMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">101,043</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrMichaelTonroeMember_zS20VW4KN8Ik" style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2022-07-012023-06-30_custom_MrMichaelTonroeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">101,043</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsOneMember_zSyZjMfzF1zc" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2021-07-012022-06-30_custom_ClassaPerformanceRightsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_iI_c20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsOneMember_zaSgcTYJE1uj" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="AsOf2022-06-30_custom_ClassaPerformanceRightsOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">291,428</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsOneMember_zFGTgiy7LcDh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30_custom_ClassaPerformanceRightsOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">101,043</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsOneMember_z9KLGonYUGZb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2022-07-012023-06-30_custom_ClassaPerformanceRightsOneMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="AUD">101,043</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Performance</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Rights</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">issued</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation
per</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class D</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(cents)</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
fair</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>value of</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class D</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Performance</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>accounted</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for in 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>accounted</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for during</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>the year</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Mr Simon Morriss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassDPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrSimonMorrissMember_zNFjuonOcEqa" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2021-07-012022-06-30_custom_ClassDPerformanceRightsMember_custom_MrSimonMorrissMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_ecustom--WeightedAverageFairValueAtMeasurementDateGrantedPerShare_uAUDPShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassDPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrSimonMorrissMember_zssS0qubpa2d" style="width: 9%; text-align: right"><ix:nonFraction name="GENE:WeightedAverageFairValueAtMeasurementDateGrantedPerShare" contextRef="From2021-07-012022-06-30_custom_ClassDPerformanceRightsMember_custom_MrSimonMorrissMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_iI_c20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassDPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrSimonMorrissMember_zrgSvn25IaKa" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="AsOf2022-06-30_custom_ClassDPerformanceRightsMember_custom_MrSimonMorrissMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">574,037</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassDPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrSimonMorrissMember_zx2Brz7UtOIb" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30_custom_ClassDPerformanceRightsMember_custom_MrSimonMorrissMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">191,346</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassDPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrSimonMorrissMember_z00OstniM5C8" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2022-07-012023-06-30_custom_ClassDPerformanceRightsMember_custom_MrSimonMorrissMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">191,346</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Performance</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Rights</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">issued</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation
per</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class E</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(cents)</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total fair</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>value of</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class E</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Performance</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>accounted</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for in 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>accounted</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for during</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>the year</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Mr Stanley Sack</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassEPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrStanleySackMember_zNi7NPZNLb92" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2021-07-012022-06-30_custom_ClassEPerformanceRightsMember_custom_MrStanleySackMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,937,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_ecustom--WeightedAverageFairValueAtMeasurementDateGrantedPerShare_uAUDPShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassEPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrStanleySackMember_zo0EqQt8KE4g" style="width: 9%; text-align: right"><ix:nonFraction name="GENE:WeightedAverageFairValueAtMeasurementDateGrantedPerShare" contextRef="From2021-07-012022-06-30_custom_ClassEPerformanceRightsMember_custom_MrStanleySackMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.90</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_iI_c20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassEPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrStanleySackMember_zqvAPSnrZ512" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="AsOf2022-06-30_custom_ClassEPerformanceRightsMember_custom_MrStanleySackMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">35,438</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassEPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrStanleySackMember_zApdMZpDPXK9" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30_custom_ClassEPerformanceRightsMember_custom_MrStanleySackMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">35,438</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassEPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrStanleySackMember_zCXyDe1RuBac" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2691">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Performance
rights issued during prior years, that lapsed during the financial year ending June 30, 2022</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of <br />Performance</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">Rights</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">issued</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation per</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class A</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(cents)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total fair</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>value of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class A</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Performance</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>accounted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for in 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>accounted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for during</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for in 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Dr. Lindsay Wakefield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrLindsayWakefieldMember_z66i8RZuQB4b" title="Number of Performance Rights issued" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_DrLindsayWakefieldMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--WeightedAverageFairValueAtMeasurementDateGrantedPerShare_uAUDPShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrLindsayWakefieldMember_zvmHkz96Sdkb" title="Valuation per options (cents)" style="width: 9%; text-align: right"><ix:nonFraction name="GENE:WeightedAverageFairValueAtMeasurementDateGrantedPerShare" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_DrLindsayWakefieldMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.77</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_iI_c20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrLindsayWakefieldMember_z9lMylIZUUSc" title="Total fair value of performance rights" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="AsOf2021-06-30_custom_ClassaPerformanceRightsMember_custom_DrLindsayWakefieldMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">28,875</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrLindsayWakefieldMember_zwJCsaD5KH4e" title="Expenses arising from share-based payments" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_DrLindsayWakefieldMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">9,625</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrLindsayWakefieldMember_z5BZloQje232" title="Expenses arising from share-based payments" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30_custom_ClassaPerformanceRightsMember_custom_DrLindsayWakefieldMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,010</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Jerzy Muchnicki</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickiMember_z6LHUCMTz1D6" title="Number of Performance Rights issued" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_DrJerzyMuchnickiMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--WeightedAverageFairValueAtMeasurementDateGrantedPerShare_uAUDPShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickiMember_zRHfqaGwP0yb" title="Valuation per options (cents)" style="text-align: right"><ix:nonFraction name="GENE:WeightedAverageFairValueAtMeasurementDateGrantedPerShare" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_DrJerzyMuchnickiMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.77</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_iI_c20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickiMember_zIhslk9e0s1l" title="Total fair value of performance rights" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="AsOf2021-06-30_custom_ClassaPerformanceRightsMember_custom_DrJerzyMuchnickiMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">48,125</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickiMember_zndN9E8p5nL7" title="Expenses arising from share-based payments" style="text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_DrJerzyMuchnickiMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">16,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickiMember_zBAoZj7ZvALi" title="Expenses arising from share-based payments" style="text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30_custom_ClassaPerformanceRightsMember_custom_DrJerzyMuchnickiMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,684</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Mr. Peter Rubinstein</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember_zhH52vXByNh4" title="Number of Performance Rights issued" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98A_ecustom--WeightedAverageFairValueAtMeasurementDateGrantedPerShare_uAUDPShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember_zeWLmalhU5L2" title="Valuation per options (cents)" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="GENE:WeightedAverageFairValueAtMeasurementDateGrantedPerShare" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.77</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_iI_c20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember_zl2tx3HgesFd" title="Total fair value of performance rights" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="AsOf2021-06-30_custom_ClassaPerformanceRightsMember_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">38,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember_z9F7YzbNeNSk" title="Expenses arising from share-based payments" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">12,833</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember_z9zTK31cp2K2" title="Expenses arising from share-based payments" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30_custom_ClassaPerformanceRightsMember_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">5,347</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsTwoMember_zjk4EmhoOuJ7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_iI_c20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsTwoMember_zlb67lppiuui" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="AsOf2021-06-30_custom_ClassaPerformanceRightsTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">115,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsTwoMember_zxjs2kPe4r39" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">38,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsTwoMember_zPuuE99HDP0e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30_custom_ClassaPerformanceRightsTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">16,041</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 319.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eifrs-full--NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_pid_do_uShares_c20220701__20230630_zsbmOvgyaHNf" title="Number of performance rights cancelled / forfeited"><span id="xdx_90B_eifrs-full--NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_pid_do_uShares_c20210701__20220630_zxfmyMWjDej8" title="Number of performance rights cancelled / forfeited"><ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" contextRef="From2022-07-01to2023-06-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" contextRef="From2021-07-012022-06-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">No</ix:nonFraction></ix:nonFraction></span></span>
Performance Rights were cancelled/forfeited during the years ended June 30, 2023 and June 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 128; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>26. SHARE BASED PAYMENTS (cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Performance
rights issued during prior years, that lapsed during the financial year ending June 30, 2022</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Performance</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Rights</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">issued</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Valuation
per</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class A</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(cents)</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
fair</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>value of</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class A</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Performance</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>accounted</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for in 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>accounted</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for during</b></span></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for in 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Dr. Lindsay Wakefield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrLindsayWakefieldMember_ziA3lyvs9qMj" title="Number of Performance Rights issued" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_DrLindsayWakefieldMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--WeightedAverageFairValueAtMeasurementDateGrantedPerShare_uAUDPShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrLindsayWakefieldMember_zzD3xLgvnko4" title="Valuation per options (cents)" style="width: 9%; text-align: right"><ix:nonFraction name="GENE:WeightedAverageFairValueAtMeasurementDateGrantedPerShare" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_DrLindsayWakefieldMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.77</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_iI_c20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrLindsayWakefieldMember_zyiD24rjOjt2" title="Total fair value of performance rights" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="AsOf2021-06-30_custom_ClassaPerformanceRightsMember_custom_DrLindsayWakefieldMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">28,875</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrLindsayWakefieldMember_znGZtpmInUkd" title="Expenses arising from share-based payments" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_DrLindsayWakefieldMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">9,625</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrLindsayWakefieldMember_zUDcLQCpNRvb" title="Expenses arising from share-based payments" style="width: 9%; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30_custom_ClassaPerformanceRightsMember_custom_DrLindsayWakefieldMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,010</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Jerzy Muchnicki</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickiMember_zUjAUasNwTLj" title="Number of Performance Rights issued" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_DrJerzyMuchnickiMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--WeightedAverageFairValueAtMeasurementDateGrantedPerShare_uAUDPShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickiMember_z0OwUxEEC4yl" title="Valuation per options (cents)" style="text-align: right"><ix:nonFraction name="GENE:WeightedAverageFairValueAtMeasurementDateGrantedPerShare" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_DrJerzyMuchnickiMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.77</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_iI_c20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickiMember_zoB8qgb0v3lg" title="Total fair value of performance rights" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="AsOf2021-06-30_custom_ClassaPerformanceRightsMember_custom_DrJerzyMuchnickiMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">48,125</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickiMember_zm1ED5ONAr9h" title="Expenses arising from share-based payments" style="text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_DrJerzyMuchnickiMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">16,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickiMember_zF94FPBPVzDa" title="Expenses arising from share-based payments" style="text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30_custom_ClassaPerformanceRightsMember_custom_DrJerzyMuchnickiMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,684</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Mr. Peter Rubinstein</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember_zm3odWmMpV35" title="Number of Performance Rights issued" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_989_ecustom--WeightedAverageFairValueAtMeasurementDateGrantedPerShare_uAUDPShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember_zQpcsIBk7Cy5" title="Valuation per options (cents)" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="GENE:WeightedAverageFairValueAtMeasurementDateGrantedPerShare" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="INF" unitRef="AUDPShares">0.77</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_iI_c20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember_zPVlPSmTO0gk" title="Total fair value of performance rights" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="AsOf2021-06-30_custom_ClassaPerformanceRightsMember_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">38,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember_zIzx8Btp8Owc" title="Expenses arising from share-based payments" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsMember_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">12,833</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember_ztqAynSFSYx7" title="Expenses arising from share-based payments" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30_custom_ClassaPerformanceRightsMember_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">5,347</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsTwoMember_z5BgE2WLJS19" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_iI_c20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsTwoMember_zCwS5AHthTp9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" contextRef="AsOf2021-06-30_custom_ClassaPerformanceRightsTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">115,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsTwoMember_zbs99HIYa4Th" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2020-07-012021-06-30_custom_ClassaPerformanceRightsTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">38,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsTwoMember_zftnitq9qpY6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30_custom_ClassaPerformanceRightsTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">16,041</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zkdsEqyLfERg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 319.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eifrs-full--NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_pid_do_uShares_c20220701__20230630_zBhFKbagRmH3" title="Number of performance rights cancelled / forfeited"><span id="xdx_90C_eifrs-full--NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_pid_do_uShares_c20210701__20220630_zxSHAe4WBuZ1" title="Number of performance rights cancelled / forfeited"><ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" contextRef="From2022-07-01to2023-06-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" contextRef="From2021-07-012022-06-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">No</ix:nonFraction></ix:nonFraction></span></span>
Performance Rights were cancelled/forfeited during the years ended June 30, 2023 and June 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)
Expenses arising from share-based payment transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationAboutExpenseFromShareBasedPaymentTransactionsWithEmployeesTableTextBlock"><p id="xdx_891_ecustom--DisclosureOfDetailedInformationAboutExpenseFromShareBasedPaymentTransactionsWithEmployeesTableTextBlock_zKsxSf7mdE18" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
expenses arising from share-based payment transactions recognized during the period as part of employee benefit expense and equity raising
expenses were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_ziWK49pizhWi" style="display: none">SCHEDULE OF EXPENSES ARISING FROM SHARE-BASED PAYMENT TRANSACTIONS RECOGNIZED PART OF EMPLOYEE BENEFIT EXPENSE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20220701__20230630_ziGh3iYdIyoa" style="font-weight: bold; text-align: center">2023</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20210701__20220630_zuTAiBcJCyf4" style="text-align: center; font-weight: bold">2022</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20200701__20210630_zFuScuAToif2" style="text-align: center; font-weight: bold">2021</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ExpenseArisingFromSharebasedPaymentTransactions_hifrs-full--CounterpartiesAxis__custom--KentgroveCapitalPtyLtdMember_zmxb7IY0cXta" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 52%; text-align: left">Kentgrove options issued</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2771">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2772">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2020-07-012021-06-30_custom_KentgroveCapitalPtyLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">16,667</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ExpenseArisingFromSharebasedPaymentTransactions_hifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--WarrantstobeIssuedHCWainwrightMember_zJeweEGzHm9a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Warrants to be issued H.C. Wainwright, subject to shareholder approval</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2022-07-012023-06-30_custom_WarrantstobeIssuedHCWainwrightMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">134,956</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2776">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2777">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ExpenseArisingFromSharebasedPaymentTransactions_hifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember_zLGkaHvDEiU5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Performance rights issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2022-07-012023-06-30_custom_PerformanceRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">125,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2021-07-012022-06-30_custom_PerformanceRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">436,119</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2020-07-012021-06-30_custom_PerformanceRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">622,725</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ExpenseArisingFromSharebasedPaymentTransactions_hifrs-full--CounterpartiesAxis__custom--ReversalOfForfeitedPerformanceRightsMember_zUurTHez0wl1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Reversal of forfeited Performance Rights</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2783">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2784">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2785">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ExpenseArisingFromSharebasedPaymentTransactions_hifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--EmployeeStocksOptionsMember_zg3Rw8kYSZP" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Options issued under employee option plan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2787">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2021-07-012022-06-30_custom_EmployeeStocksOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,389</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2020-07-012021-06-30_custom_EmployeeStocksOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">75,186</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ExpenseArisingFromSharebasedPaymentTransactions_zTfriehRsNc4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Total expenses arising from share-based payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">260,456</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">437,508</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="GENE:ExpenseArisingFromSharebasedPaymentTransactions" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">714,578</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zjITmMkLXmrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 424.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"><p id="xdx_808_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_zVjuD7lHlqw7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>27.
<span id="xdx_82C_zW1MHcmbA2X8">CAPITAL COMMITMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no significant contracted capital expenditures at the end of the reporting periods ending June 30, 2021, 2022 &amp; 2023.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfAuditorsRemunerationExplanatory"><p id="xdx_80A_eifrs-full--DisclosureOfAuditorsRemunerationExplanatory_ztqMZ30Iqx5g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>28.
<span id="xdx_82C_zDDEiJrmwvi">AUDITORS&#8217; REMUNERATION</span></b></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationAboutAuditorsRemuneration"><p id="xdx_89A_ecustom--DisclosureOfDetailedInformationAboutAuditorsRemuneration_zCrgjCpJeWjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BC_zupxCYaip8Me" style="display: none">SCHEDULE OF AUDITOR&#8217;S REMUNERATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220701__20230630_zcn3LdZ8SnX5" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20210701__20220630_zSKUviubNnu6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20200701__20210630_zL4KQe5imwmk" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Audit and assurance services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">PricewaterhouseCoopers in respect of:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--AuditorsRemunerationForAuditServices_hifrs-full--CounterpartiesAxis__custom--PriceWaterHouseCoopersMember_zP1TfmtFidu" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit <sup id="xdx_F4A_zuoFdfYUeOGd">(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2801">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="From2021-07-012022-06-30_custom_PriceWaterHouseCoopersMember" id="Fact002802" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">20,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="From2020-07-012021-06-30_custom_PriceWaterHouseCoopersMember" id="Fact002803" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">72,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--AuditorsRemunerationForAuditRelatedServices_hifrs-full--CounterpartiesAxis__custom--PriceWaterHouseCoopersMember_zuA1HH4m2eW3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit related fees <sup id="xdx_F47_zWuYbp1jljf6">(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2805">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2806">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2807">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--AuditorsRemunerationForOtherServices_hifrs-full--CounterpartiesAxis__custom--PriceWaterHouseCoopersMember_zfHosbirzFI1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All other fees <sup id="xdx_F41_zLbQ8ZXRJdd5">(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2809">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2810">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2811">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Grant Thornton Audit Pty Ltd in respect of:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--AuditorsRemunerationForAuditServices_hifrs-full--CounterpartiesAxis__custom--GrantThorntonAuditPtyLtdMember_zJEYe5b0whVb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit <sup id="xdx_F43_zc8ux1Z2Vn0i">(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="From2022-07-012023-06-30_custom_GrantThorntonAuditPtyLtdMember" id="Fact002813" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">320,569</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="From2021-07-012022-06-30_custom_GrantThorntonAuditPtyLtdMember" id="Fact002814" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">241,882</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="From2020-07-012021-06-30_custom_GrantThorntonAuditPtyLtdMember" id="Fact002815" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">168,333</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AuditorsRemunerationForAuditRelatedServices_hifrs-full--CounterpartiesAxis__custom--GrantThorntonAuditPtyLtdMember_zOhc4G1Uxdvb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit related fees <sup id="xdx_F41_zt37xhlLDLV7">(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2817">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2818">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2819">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--AuditorsRemunerationForOtherServices_hifrs-full--CounterpartiesAxis__custom--GrantThorntonAuditPtyLtdMember_zg9ua1cg6LS6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All other fees <sup id="xdx_F45_zE5jjD2vjJnf">(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2821">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForOtherServices" contextRef="From2021-07-012022-06-30_custom_GrantThorntonAuditPtyLtdMember" id="Fact002822" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">30,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForOtherServices" contextRef="From2020-07-012021-06-30_custom_GrantThorntonAuditPtyLtdMember" id="Fact002823" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">65,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Other audit firms in respect of:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--AuditOfFinancialReportsOfSubsidiaries_hifrs-full--CounterpartiesAxis__custom--GrantThorntonAuditPtyLtdMember_zp97GdqU5HEf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Audit of the Financial Reports of subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2825">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2826">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2827">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--AuditorsRemuneration_zJ3Z5H6jmWU3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Total remuneration in respect of audit services</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction name="ifrs-full:AuditorsRemuneration" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">320,569</ix:nonFraction></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction name="ifrs-full:AuditorsRemuneration" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">291,882</ix:nonFraction></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction name="ifrs-full:AuditorsRemuneration" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">305,833</ix:nonFraction></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 129; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>28.
AUDITORS&#8217; REMUNERATION (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F07_zabMrgmir0S2">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_z8Ze9bISX6hg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote002832" xml:lang="en-US">Audit fees consist of services that
    would normally be provided in connection with statutory, half year review, and regulatory filings or engagements, including services
    that generally only the independent accountant can reasonably provide.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F03_zrV7BQ1PbiDb">(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_z3PFU8nozhUa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote002833" xml:lang="en-US">Audit related fees consist of fees billed for assurance
    and related services that generally only the statutory auditor could reason- ably provide to a client.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F02_zRVCVoIlZbGh">(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zhBo9q5oKnw8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote002834" xml:lang="en-US">All other fees consist of fees billed for financial
    and information technology due diligence services in respect of the Company&#8217;s acquisition of the business and assets associated
    with the EasyDNA brand that completed on August 13<sup>th</sup>, 2021.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A7_zpW7WgT3zUfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfRelatedPartyExplanatory"><p id="xdx_80A_eifrs-full--DisclosureOfRelatedPartyExplanatory_z54u9KsbX238" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>29.
<span id="xdx_828_zYf9cUBYLhk1">RELATED PARTY DISCLOSURES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Ultimate
parent</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genetic
Technologies Limited is the ultimate Australian parent company. As at the date of this Report, <span id="xdx_904_ecustom--NumberOfShareHoldersControllingMoreThanFiftyPercent_iI_do_uInteger_c20230630_zjwazOmkbjJe" title="Number of shareholders that control more than 50% of the issued capital"><ix:nonFraction name="GENE:NumberOfShareHoldersControllingMoreThanFiftyPercent" contextRef="AsOf2023-06-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Integer">no</ix:nonFraction></span> shareholder controls more than 50%
of the issued capital of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Transactions
within the Company and with other related parties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the financial years ended June 30, 2023, 2022 and 2021, other than compensation paid to directors and other members of key management
personnel, see &#8220;Item 6.B Compensation&#8221;, the only transactions between entities within the Company and other related parties
are as listed below. Except where noted, all amounts were charged on similar to market terms and at commercial rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Performance
Rights Issuance</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
receiving shareholder approval on December 10, 2020, the Company issued additional <span id="xdx_903_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20201209__20201210__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember_zr18Daeir6zh" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-12-092020-12-10_custom_PerformanceRightsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,000,000</ix:nonFraction></span> Performance Rights to Directors of the
Company as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20201209__20201210__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrLindsayWakefieldMember__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember_zHeThqo3d7vb" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-12-092020-12-10_custom_ClassaPerformanceRightsMember_custom_DrLindsayWakefieldMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> Class A Performance Rights
    to Dr. Lindsay Wakefield</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20201209__20201210__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickiMember__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember_zSNgbZwXc9bi" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-12-092020-12-10_custom_ClassaPerformanceRightsMember_custom_DrJerzyMuchnickiMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,500,000</ix:nonFraction></span> Class A Performance Rights, <span id="xdx_900_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20201209__20201210__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickiMember__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassBPerformanceRightsMember_z7pDHE6Kdaka" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-12-092020-12-10_custom_ClassBPerformanceRightsMember_custom_DrJerzyMuchnickiMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000,000</ix:nonFraction></span> Class
    B Performance Rights and <span id="xdx_909_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20201209__20201210__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickiMember__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassBPerformanceRightsMember_zLLo1ALWwhgl" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-12-092020-12-10_custom_ClassBPerformanceRightsMember_custom_DrJerzyMuchnickiMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000,000</ix:nonFraction></span> Class C Performance Rights to Dr. Jerzy Muchnicki</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20201209__20201210__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember_zfgM7qSRYb36" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-12-092020-12-10_custom_ClassaPerformanceRightsMember_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,500,000</ix:nonFraction></span> Class A Performance Rights, <span id="xdx_907_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20201209__20201210__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassBPerformanceRightsMember_zxZ4pdm7xA7i" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-12-092020-12-10_custom_ClassBPerformanceRightsMember_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000,000</ix:nonFraction></span> Class
    B Performance Rights and <span id="xdx_902_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20201209__20201210__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassBPerformanceRightsMember_zlZ6Vts6HCpj" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-12-092020-12-10_custom_ClassBPerformanceRightsMember_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000,000</ix:nonFraction></span> Class C Performance Rights to Mr. Peter Rubinstein</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20201209__20201210__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrNicholasBurrowsMember__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember_zcVSAgbCkpI8" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-12-092020-12-10_custom_ClassaPerformanceRightsMember_custom_MrNicholasBurrowsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> Class A Performance Rights to Mr. Nicholas
    Burrows</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the financial year ending June 30, 2021, the Board has approved for the following Performance Rights to be issued to the Chief Executive
Officer and Chief Operating Officer:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: left; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200701__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrSimonMorrisMember__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassDPerformanceRightsMember_zkpB3wRqDN4" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-07-012021-06-30_custom_MrSimonMorrisMember_custom_ClassDPerformanceRightsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000,000</ix:nonFraction></span> Class D Performance Rights
    to Mr. Simon Morris</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200701__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrStanleySackMember__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassEPerformanceRightsMember_zDd46W8kvqA8" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-07-012021-06-30_custom_ClassEPerformanceRightsMember_custom_MrStanleySackMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,937,500</ix:nonFraction></span> Class E Performance Rights to Mr. Stanley
    Sack</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Stanley Sack exercised his performance rights during the financial year ending June 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the financial year ending June 30, 2022, the Board has approved for the following Performance Rights to be issued to the Key Management
Personnel below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: left; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20210701__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrMichaelTonroeMember__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember_zPUX2fSDcXp7" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2021-07-012022-06-30_custom_MrMichaelTonroeMember_custom_ClassaPerformanceRightsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000,000</ix:nonFraction></span> Performance
    Rights to Mr. Michael Tonroe</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrCarlStubbingsMember_zHHsbMHqMj3i" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2021-07-012022-06-30_custom_ClassaPerformanceRightsMember_custom_MrCarlStubbingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></span> Performance Rights
    to Mr. Carl Stubbings</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20210701__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrKevinCamilleriMember__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--ClassaPerformanceRightsMember_z61K66eycy2d" title="Number of rights issued"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2021-07-012022-06-30_custom_MrKevinCamilleriMember_custom_ClassaPerformanceRightsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></span> Performance Rights
    to Mr. Kevin Camilleri</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
performance rights issued to Mr. Michael Tonroe were forfeit during the 2023 financial year following his resignation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has accounted for these Performance Rights in accordance with its accounting policy for share-based payment transactions and
has recorded A$<span id="xdx_90E_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_pp0p0_c20220701__20230630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember_zlXQADBiUgFk" title="Share-based payments expense"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2022-07-012023-06-30_custom_PerformanceRightsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">125,500</ix:nonFraction></span> (2022: A$<span id="xdx_907_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_pp0p0_c20210701__20220630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember_zuDBOjqeE0nf" title="Share-based payments expense"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2021-07-012022-06-30_custom_PerformanceRightsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">437,508</ix:nonFraction></span> &amp; 2021: A$<span id="xdx_90F_eifrs-full--ExpenseFromSharebasedPaymentTransactionsWithEmployees_pp0p0_c20200701__20210630__ifrs-full--TypesOfSharebasedPaymentArrangementsAxis__custom--PerformanceRightsMember_zuqn55ujpwF1" title="Share-based payments expense"><ix:nonFraction name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" contextRef="From2020-07-012021-06-30_custom_PerformanceRightsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">622,725</ix:nonFraction></span>) of associated expense in the reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 130; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>29. RELATED PARTY DISCLOSURES (cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Mr.
Phillip Hains (Former Chief Financial Officer)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2019, the Company announced that it had appointed Mr. Phillip Hains (MBA, CA) as the Chief Financial Officer who has over 30
years of extensive experience in roles with a portfolio of ASX and NASDAQ listed companies and provides CFO services through his firm
The CFO Solution. Prior to this point the Company had a similar arrangement with The CFO Solution, where it would engage and provide
services of overall CFO, accounting and other finance related activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the reporting period, the Company had not transacted with The CFO Solution towards provision of overall CFO, accounting and other finance
related activities (2022: A$<span id="xdx_90C_eifrs-full--ServicesReceivedRelatedPartyTransactions_pp0p0_c20210701__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--Mr.PhilipsHainsMember_z4Psvkt4W9Z8" title="Services received, related party transactions"><ix:nonFraction name="ifrs-full:ServicesReceivedRelatedPartyTransactions" contextRef="From2021-07-012022-06-30_custom_Mr.PhilipsHainsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">91,615</ix:nonFraction></span> &amp; 2021: A$<span id="xdx_90C_eifrs-full--ServicesReceivedRelatedPartyTransactions_pp0p0_c20200701__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--Mr.PhilipsHainsMember_zb8aEEx5Jcjl" title="Services received, related party transactions"><ix:nonFraction name="ifrs-full:ServicesReceivedRelatedPartyTransactions" contextRef="From2020-07-012021-06-30_custom_Mr.PhilipsHainsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">224,971</ix:nonFraction></span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Mr.
Stanley Sack (former Chief Operating Officer)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 18, 2020, the Company appointed Mr. Stanley Sack who provides consulting in the capacity of Chief Operating Officer. Mr. Sack has
spent 15 years in large listed entities in executive positions managing large business divisions. He has worked with a high-net- worth
family managing all their operating businesses and private equity activities. Mr. Sack built an Allied Health Business in the aged care
and community care space which became the biggest Mobile Allied Health Business in Australia, and was recently sold to a large medical
insurance company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the reporting period, the Company had not transacted with Mr. Stanley Sack&#8217;s entity Cobben Investments towards provision of consulting
services in relation to provision of duties related to Chief Operating Officer of the Company (2022: A$<span id="xdx_90C_eifrs-full--ServicesReceivedRelatedPartyTransactions_pp0p0_c20210701__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrStanleySackMember_zqzliA6hWx7b" title="Services received, related party transactions"><ix:nonFraction name="ifrs-full:ServicesReceivedRelatedPartyTransactions" contextRef="From2021-07-012022-06-30_custom_MrStanleySackMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">107,187</ix:nonFraction></span> &amp; 2021: A$<span id="xdx_90D_eifrs-full--ServicesReceivedRelatedPartyTransactions_pp0p0_c20200701__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrStanleySackMember_zDSTZzYXFSyd" title="Services received, related party transactions"><ix:nonFraction name="ifrs-full:ServicesReceivedRelatedPartyTransactions" contextRef="From2020-07-012021-06-30_custom_MrStanleySackMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">143,172</ix:nonFraction></span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Mr.
Peter Rubinstein (Non-Executive Director and Chairman)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the financial year ended June 30, 2020, the Board approved to obtain consulting services in relation to capital raises, compliance, NASDAQ
hearings and investor relations from its Non-Executive Director and current Chairman, Mr. Peter Rubinstein. The services procured were
through Mr. Peter Rubinstein&#8217;s associate entity ValueAdmin.com Pty Ltd and amounted to A$<span id="xdx_90B_eifrs-full--ServicesReceivedRelatedPartyTransactions_pp0p0_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember_zvZskmRWnhbk" title="Services received, related party transactions"><ix:nonFraction name="ifrs-full:ServicesReceivedRelatedPartyTransactions" contextRef="From2022-07-012023-06-30_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">60,000</ix:nonFraction></span> (2022: A$<span id="xdx_90B_eifrs-full--ServicesReceivedRelatedPartyTransactions_pp0p0_c20210701__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember_zffR41yoGSR1" title="Services received, related party transactions"><ix:nonFraction name="ifrs-full:ServicesReceivedRelatedPartyTransactions" contextRef="From2021-07-012022-06-30_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">60,000</ix:nonFraction></span> &amp; 2021: A$<span id="xdx_909_eifrs-full--ServicesReceivedRelatedPartyTransactions_pp0p0_c20200701__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrPeterRubinsteinMember_zqzfRawWia9g" title="Services received, related party transactions"><ix:nonFraction name="ifrs-full:ServicesReceivedRelatedPartyTransactions" contextRef="From2020-07-012021-06-30_custom_MrPeterRubinsteinMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">60,000</ix:nonFraction></span>)
that is included as part of the cash salary and fees in the remuneration report as at June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Dr.
Jerzy Muchnicki (Non-Independent Non-Executive Director)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the financial year ended June 30, 2022, the Board approved to obtain consulting services in relation to PRS and Germline Integration;
Epigenetics; Somatic Testing; NIPT; Carrier testing and related marketing advice from its Non-Independent Non-Executive Director, Dr.
Jerzy Muchnicki. The services procured were through Dr. Jerzy Muchnicki&#8217;s private consultancy and amounted to A$<span id="xdx_90E_eifrs-full--ServicesReceivedRelatedPartyTransactions_pp0p0_c20210701__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickisMember_z864EMBCtD5g" title="Services received, related party transactions"><ix:nonFraction name="ifrs-full:ServicesReceivedRelatedPartyTransactions" contextRef="From2021-07-012022-06-30_custom_DrJerzyMuchnickisMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">50,000</ix:nonFraction></span> (2021: <span id="xdx_909_eifrs-full--ServicesReceivedRelatedPartyTransactions_pp0p0_dxL_c20200701__20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrJerzyMuchnickisMember_zaMah8h342pb" title="Services received, related party transactions::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl2890">Nil</span></span>)
that is included as part of the cash salary and fees in the remuneration report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transactions with parties related to Key Management Personnel during the year other than that disclosed above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 131; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>29. RELATED PARTY DISCLOSURES (cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Details
of Directors and Key Management Personnel as at balance date</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: left; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Peter Rubinstein (Independent
    Non-Executive &amp; Chairman)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Jerzy Muchnicki (Non-Independent Non-Executive)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Lindsay Wakefield (Independent Non-Executive)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Nicholas Burrows (Independent Non-Executive)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
Management Personnel (KMPs)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Simon Morriss (Chief Executive
    Officer) (appointed 1 February 2021)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Richard Allman (Chief Scientific Officer) (ceased
    full-time employment 6 October 2022, then appointed consulting Scientific Advisor)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Tony Di Pietro (Chief Financial Officer) (appointed
    28 November 2022)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Mike Tonroe (Chief Financial Officer) (appointed
    15 June 2021, resigned on 28 November 2022)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Phillip Hains (Chief Financial Officer) (July 15,
    2019 to 15 June 2021)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Stanley Sack (former Chief Operating Officer) (May
    18, 2020 to April 30, 2022)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Kevin Camilleri (Chief Executive Officer of EasyDNA)
    (appointed August 16, 2021)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Carl Stubbings (Chief Commercial Officer) (appointed
    September 1, 2021)</span></td></tr>
  </table>
<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"><p id="xdx_890_eifrs-full--DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_zWg0KpiQjFS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BB_zG3tZT6Rggp7" style="display: none">SCHEDULE OF REMUNERATION OF KEY MANAGEMENT PERSONNEL</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220701__20230630_zAUPIbdLyhsj" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20210701__20220630_zy2UTdNf2HT3" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20200701__20210630_zJkqUsT06tTh" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Remuneration of Key Management Personnel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--KeyManagementPersonnelCompensationShorttermEmployeeBenefits_maKMPCz2ir_zhlGtCAwRCF5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 52%; text-align: left">Short-term employee benefits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,529,124</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,894,413</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,035,302</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--KeyManagementPersonnelCompensationPostemploymentBenefits_maKMPCz2ir_zgccf25O2itl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Post-employment benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">113,511</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">125,822</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">79,042</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_maKMPCz2ir_zc1WoVgnLa16" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Share-based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">253,453</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">387,046</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">650,911</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--KeyManagementPersonnelCompensationOtherLongtermBenefits_maKMPCz2ir_zbZ0pQEHkAl8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other long-term benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">10,978</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,797</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">4,589</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--KeyManagementPersonnelCompensationTerminationBenefits_maKMPCz2ir_ztndSGg4DHm7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Termination benefits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2910">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2911">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2912">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--KeyManagementPersonnelCompensation_iT_pp0p0_mtKMPCz2ir_zs4GEi6TmlJ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total remuneration of Key Management Personnel</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,907,066</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,412,078</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,769,844</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_z9dKuLryqgtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 132; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory"><p id="xdx_80D_eifrs-full--DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_z8GZOGE8bBX7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>30.
<span id="xdx_823_zcOMWHvVMN3i">SUBSIDIARIES</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory"><p id="xdx_896_eifrs-full--DisclosureOfInterestsInSubsidiariesExplanatory_zNIQNE5dqWnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following diagram is a depiction of the Company structure as at June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8B4_zimTGHIpBQV3" style="display: none">SCHEDULE OF SUBSIDIARY UNDERTAKINGS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Incorporation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Company interest (%)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net carrying value (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding-left: 0pt; font-weight: bold">Name of Company</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">details</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-style: italic; text-align: left">Entities held directly by parent</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 32%; text-align: left">GeneType Pty. Ltd. (Dormant)</td><td style="width: 2%">&#160;</td>
    <td style="width: 18%; text-align: center"><span id="xdx_90F_ecustom--IncorporationDetails_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneTypePtyLtdMember_zXDWgZqsbvY8" title="Incorporation details"><span id="xdx_909_ecustom--IncorporationDetails_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneTypePtyLtdMember_zSqwPN527jLe" title="Incorporation details"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_GeneTypePtyLtdMember" name="GENE:IncorporationDetails"><ix:nonNumeric contextRef="From2021-07-012022-06-30_custom_GeneTypePtyLtdMember" name="GENE:IncorporationDetails">September 5, 1990 Victoria, Australia</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneTypePtyLtdMember_zV2vRmfL3ONk" title="Company interest (%)" style="width: 8%; text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2022-07-012023-06-30_custom_GeneTypePtyLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneTypePtyLtdMember_zr9cKdHg9v2a" title="Company interest (%)" style="width: 8%; text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2021-07-012022-06-30_custom_GeneTypePtyLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneTypePtyLtdMember_zSXo4oiedn9d" title="Net carrying value" style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2930">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneTypePtyLtdMember_zN4DLayq4PDl" title="Net carrying value" style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2932">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Genetic Technologies Corporation Pty. Ltd. (Genetic testing)</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_ecustom--IncorporationDetails_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneticTechnologiesCorporationPtyLtdMember_zHGNPfAIPdl6" title="Incorporation details"><span id="xdx_903_ecustom--IncorporationDetails_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneticTechnologiesCorporationPtyLtdMember_z4IFFh259oPj" title="Incorporation details"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_GeneticTechnologiesCorporationPtyLtdMember" name="GENE:IncorporationDetails"><ix:nonNumeric contextRef="From2021-07-012022-06-30_custom_GeneticTechnologiesCorporationPtyLtdMember" name="GENE:IncorporationDetails">October 11, 1996 NSW, Australia</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneticTechnologiesCorporationPtyLtdMember_zjk3Xcu8KdUh" title="Company interest (%)" style="text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2022-07-012023-06-30_custom_GeneticTechnologiesCorporationPtyLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneticTechnologiesCorporationPtyLtdMember_zCmE5mtlXf45" title="Company interest (%)" style="text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2021-07-012022-06-30_custom_GeneticTechnologiesCorporationPtyLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneticTechnologiesCorporationPtyLtdMember_zAyrBOiu1dO3" title="Net carrying value" style="text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2023-06-30_custom_GeneticTechnologiesCorporationPtyLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneticTechnologiesCorporationPtyLtdMember_zLW0Dv7Bm9Gc" title="Net carrying value" style="text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2022-06-30_custom_GeneticTechnologiesCorporationPtyLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify"><span id="xdx_F47_zXhK1gjLWaf8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gene Ventures Pty. Ltd. <sup>(1) </sup>(Dormant)</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_904_ecustom--IncorporationDetails_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneVenturesPtyLtdMember_fKDEp_zDXUZLiP9da4" title="Incorporation details"><span id="xdx_901_ecustom--IncorporationDetails_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneVenturesPtyLtdMember_fKDEp_zzzwgVgo9uK1" title="Incorporation details"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_GeneVenturesPtyLtdMember" id="Fact002946" name="GENE:IncorporationDetails"><ix:nonNumeric contextRef="From2021-07-012022-06-30_custom_GeneVenturesPtyLtdMember" id="Fact002948" name="GENE:IncorporationDetails">March 7, 2001 NSW, Australia</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneVenturesPtyLtdMember_fKDEp_z2BflzCfgOC8" title="Company interest (%)" style="text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2022-07-012023-06-30_custom_GeneVenturesPtyLtdMember" id="Fact002950" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneVenturesPtyLtdMember_fKDEp_zDM2QBnHs9q1" title="Company interest (%)" style="text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2021-07-012022-06-30_custom_GeneVenturesPtyLtdMember" id="Fact002952" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneVenturesPtyLtdMember_fKg_____z7RBIrx0F5i6" title="Net carrying value" style="text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2023-06-30_custom_GeneVenturesPtyLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneVenturesPtyLtdMember_fKg_____zoAZodLft8Jg" title="Net carrying value" style="text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2022-06-30_custom_GeneVenturesPtyLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">GeneType Corporation (Dormant)</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_ecustom--IncorporationDetails_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneTypeCorporationMember_zCVVB7LeC84c" title="Incorporation details"><span id="xdx_900_ecustom--IncorporationDetails_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneTypeCorporationMember_z5c4YZldx2N2" title="Incorporation details"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporationMember" name="GENE:IncorporationDetails"><ix:nonNumeric contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporationMember" name="GENE:IncorporationDetails">December 18, 1989 California, U.S.A.</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneTypeCorporationMember_zFoOwrnbucf7" title="Company interest (%)" style="text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2022-07-012023-06-30_custom_GeneTypeCorporationMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneTypeCorporationMember_zT3wQEGX3xdh" title="Company interest (%)" style="text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2021-07-012022-06-30_custom_GeneTypeCorporationMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneTypeCorporationMember_zZMfkGQOvd1b" title="Net carrying value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2966">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneTypeCorporationMember_zbkppBnx3JJ5" title="Net carrying value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2968">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span id="xdx_F46_zJS1ZNDjRXMb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">geneType Inc. <sup>(2)</sup> (formerly Pheno- gen Sciences Inc.)</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_ecustom--IncorporationDetails_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--PhenogenSciencesIncMember_fKDIp_zjYML7bCPukb" title="Incorporation details"><span id="xdx_904_ecustom--IncorporationDetails_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--PhenogenSciencesIncMember_fKDIp_zgrkjddYK3Ml" title="Incorporation details"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_PhenogenSciencesIncMember" id="Fact002970" name="GENE:IncorporationDetails"><ix:nonNumeric contextRef="From2021-07-012022-06-30_custom_PhenogenSciencesIncMember" id="Fact002972" name="GENE:IncorporationDetails">June 28, 2010 Delaware, U.S.A.</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--PhenogenSciencesIncMember_fKDIp_zqDMILf4ohl2" title="Company interest (%)" style="text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2022-07-012023-06-30_custom_PhenogenSciencesIncMember" id="Fact002974" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--PhenogenSciencesIncMember_fKDIp_zd5oNc749aih" title="Company interest (%)" style="text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2021-07-012022-06-30_custom_PhenogenSciencesIncMember" id="Fact002976" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--PhenogenSciencesIncMember_fKDIp_z2P9izSwjAD1" title="Net carrying value" style="text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2023-06-30_custom_PhenogenSciencesIncMember" id="Fact002978" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,006</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--PhenogenSciencesIncMember_fKDIp_zc4bJbXA9Q4d" title="Net carrying value" style="text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2022-06-30_custom_PhenogenSciencesIncMember" id="Fact002980" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,006</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Hainan Aocheng Genetic Technolo- gies Co Ltd</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_ecustom--IncorporationDetails_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--HainanAochengGeneticTechnologiesCoLtdMember_zhdmsgOCCJ79" title="Incorporation details"><span id="xdx_90C_ecustom--IncorporationDetails_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--HainanAochengGeneticTechnologiesCoLtdMember_zrtKhh6ksxwe" title="Incorporation details"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_HainanAochengGeneticTechnologiesCoLtdMember" name="GENE:IncorporationDetails"><ix:nonNumeric contextRef="From2021-07-012022-06-30_custom_HainanAochengGeneticTechnologiesCoLtdMember" name="GENE:IncorporationDetails">March 18, 2019 Hong Kong, China</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--HainanAochengGeneticTechnologiesCoLtdMember_zlgEiZ0zBya9" title="Company interest (%)" style="text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2022-07-012023-06-30_custom_HainanAochengGeneticTechnologiesCoLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--HainanAochengGeneticTechnologiesCoLtdMember_zTb3jxYr53Ja" title="Company interest (%)" style="text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2021-07-012022-06-30_custom_HainanAochengGeneticTechnologiesCoLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--HainanAochengGeneticTechnologiesCoLtdMember_ze3AxlqFZHM5" title="Net carrying value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2990">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--HainanAochengGeneticTechnologiesCoLtdMember_z8D9lynLrv57" title="Net carrying value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2992">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Genetic Technologies HK Ltd</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_ecustom--IncorporationDetails_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneticTechnologiesHKLtdMember_z6pc4wazExz3" title="Incorporation details"><span id="xdx_905_ecustom--IncorporationDetails_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneticTechnologiesHKLtdMember_zoFZhHY93byc" title="Incorporation details"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_GeneticTechnologiesHKLtdMember" name="GENE:IncorporationDetails"><ix:nonNumeric contextRef="From2021-07-012022-06-30_custom_GeneticTechnologiesHKLtdMember" name="GENE:IncorporationDetails">March 18, 2019 Hong Kong, China</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneticTechnologiesHKLtdMember_z1fMVD0YmGv6" title="Company interest (%)" style="text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2022-07-012023-06-30_custom_GeneticTechnologiesHKLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneticTechnologiesHKLtdMember_zCV4XmoRP7gh" title="Company interest (%)" style="text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2021-07-012022-06-30_custom_GeneticTechnologiesHKLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneticTechnologiesHKLtdMember_z5pJ5TCtTc4e" title="Net carrying value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3002">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GeneticTechnologiesHKLtdMember_zKQTDcqTado1" title="Net carrying value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3004">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Helix Genetics Limited</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90B_ecustom--IncorporationDetails_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--HelixGeneticsMember_zppRZHYuTCg4" title="Incorporation details"><span id="xdx_90D_ecustom--IncorporationDetails_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--HelixGeneticsMember_z2qq24fuYbQ7" title="Incorporation details"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_HelixGeneticsMember" name="GENE:IncorporationDetails"><ix:nonNumeric contextRef="From2021-07-012022-06-30_custom_HelixGeneticsMember" name="GENE:IncorporationDetails">July 7, 2021 Malta</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--HelixGeneticsMember_zknhOrMykWB2" title="Company interest (%)" style="text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2022-07-012023-06-30_custom_HelixGeneticsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--HelixGeneticsMember_zBLmUy47HSyk" title="Company interest (%)" style="text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2021-07-012022-06-30_custom_HelixGeneticsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--HelixGeneticsMember_zCJIwE33gs46" title="Net carrying value" style="text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2023-06-30_custom_HelixGeneticsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,910</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--HelixGeneticsMember_zinFCxRpEJ9" title="Net carrying value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3016">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Genetype UK Limited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90C_ecustom--IncorporationDetails_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GenetypeUKLimitedMember_zag1VAbuYZpk" title="Incorporation details"><span id="xdx_90E_ecustom--IncorporationDetails_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GenetypeUKLimitedMember_zsTiwVHF7hQa" title="Incorporation details"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_GenetypeUKLimitedMember" name="GENE:IncorporationDetails"><ix:nonNumeric contextRef="From2021-07-012022-06-30_custom_GenetypeUKLimitedMember" name="GENE:IncorporationDetails">April 26, 2022 United Kingdom</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20220701__20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GenetypeUKLimitedMember_zRkBxFg4WP42" title="Company interest (%)" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2022-07-012023-06-30_custom_GenetypeUKLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_uPure_c20210701__20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GenetypeUKLimitedMember_zurP00EUXLaa" title="Company interest (%)" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2021-07-012022-06-30_custom_GenetypeUKLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20230630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GenetypeUKLimitedMember_zMAoAP5QAQHh" title="Net carrying value" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2023-06-30_custom_GenetypeUKLimitedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">176</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20220630__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--GenetypeUKLimitedMember_zC3UE8HOsrPf" title="Net carrying value" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3028">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; padding-bottom: 1.5pt">Total carrying value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20230630_zON7EtoaKR5h" title="Net carrying value" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">13,104</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--InvestmentsInSubsidiaries_iI_pp0p0_c20220630_zsqIFK8Top14" title="Net carrying value" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiaries" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,018</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: left; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F04_z0xvzpRrUjAl">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zLON03v7LR3f" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote003033" xml:lang="en-US">On 26 April 2018, the name of RareCellect
    Pty Ltd (ACN 096 135 9847) was changed to Gene Ventures Pty Ltd (ACN 096 135 947)</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0A_zx80U8905VF2">(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_z8zN4Hec9Acc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote003034" xml:lang="en-US">On 3 April 2023, the name of Phenogen Sciences Inc.
    was changed to geneType Inc.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zLAKxAQc3ro6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory"><p id="xdx_80F_eifrs-full--DisclosureOfFinancialInstrumentsExplanatory_z4VcSn1l0vI8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>31.
<span id="xdx_825_zmxAWGVlwpNl">FINANCIAL RISK MANAGEMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
note explains the Company&#8217;s exposure to financial risks and how these risks could affect the Company&#8217;s future financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s risk management is predominantly controlled by the board. The board monitors the Company&#8217;s financial risk management
policies and exposures and approves substantial financial transactions. It also reviews the effectiveness of internal controls relating
to market risk, credit risk and liquidity risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)
Market risk</i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)
Foreign exchange risk</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange
rate fluctuations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
exchange rate risk arises from financial assets and financial liabilities denominated in a currency that is not the Company&#8217;s functional
currency. Exposure to foreign currency risk may result in the fair value of future cash flows of a financial instrument fluctuating due
to the movement in foreign exchange rates of currencies in which the Company holds financial instruments which are other than the Australian
dollar (AUD) functional currency of the Company. This risk is measured using sensitivity analysis and cash flow forecasting. The cost
of hedging at this time outweighs any benefits that may be obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in Australian Dollar ($), which is Genetic Technologies Limited&#8217;s functional and
presentational currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 133; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>31. FINANCIAL RISK MANAGEMENT (cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exposure</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfMarketRiskExplanatory"><p id="xdx_893_eifrs-full--DisclosureOfMarketRiskExplanatory_zoZqtb1NEQJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s exposure to foreign currency risk at the end of the reporting period, expressed in Australian dollar, was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zlQZNjCLIhUf" style="display: none">SCHEDULE OF FINANCIAL ASSETS AND LIABILITIES IN FOREIGN CURRENCIES</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30, 2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">CAD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">EUR</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">GBP</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">CAD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">EUR</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left">Cash at Bank / on hand </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--FinancialAssets_iI_pp0p0_uUSD_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--CashAtBankOnHandMember_z0wjViESFcE8" title="Financial assets" style="width: 5%; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2023-06-30_custom_CashAtBankOnHandMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,296,082</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--FinancialAssets_iI_pp0p0_uCAD_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--CashAtBankOnHandMember_zTgN8Egmmbik" title="Financial assets" style="width: 5%; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2023-06-30_custom_CashAtBankOnHandMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="CAD">10,766</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--FinancialAssets_iI_pp0p0_uEUR_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--CashAtBankOnHandMember_z1FSMav54p1d" title="Financial assets" style="width: 5%; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2023-06-30_custom_CashAtBankOnHandMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="EUR">100,369</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--FinancialAssets_iI_pp0p0_uGBP_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--CashAtBankOnHandMember_zDpQNX3A9Svi" title="Financial assets" style="width: 5%; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2023-06-30_custom_CashAtBankOnHandMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="GBP">41,858</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--FinancialAssets_iI_pp0p0_uUSD_c20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--CashAtBankOnHandMember_zoeAavxTgE0g" title="Financial assets" style="width: 5%; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2022-06-30_custom_CashAtBankOnHandMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,299,787</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--FinancialAssets_iI_pp0p0_uCAD_c20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--CashAtBankOnHandMember_zX60b7AZpEGe" title="Financial assets" style="width: 5%; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2022-06-30_custom_CashAtBankOnHandMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="CAD">3,318</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--FinancialAssets_iI_pp0p0_uEUR_c20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--CashAtBankOnHandMember_z4WFGB9c3Ba" title="Financial assets" style="width: 5%; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2022-06-30_custom_CashAtBankOnHandMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="EUR">199,758</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Trade and other receivables </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--FinancialAssets_iI_pp0p0_uUSD_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--TradeAndOtherReceivablesMember_zhUl8No6P5Hh" title="Financial assets" style="text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2023-06-30_custom_TradeAndOtherReceivablesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">611,193</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--FinancialAssets_iI_pp0p0_uCAD_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--TradeAndOtherReceivablesMember_zOopMLoGGej2" title="Financial assets" style="text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2023-06-30_custom_TradeAndOtherReceivablesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="CAD">11,252</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--FinancialAssets_iI_pp0p0_uEUR_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--TradeAndOtherReceivablesMember_zqP16Z6udtKi" title="Financial assets" style="text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2023-06-30_custom_TradeAndOtherReceivablesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="EUR">17,690</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eifrs-full--FinancialAssets_iI_pp0p0_uGBP_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--TradeAndOtherReceivablesMember_zTnrzQKvMkQf" title="Financial assets" style="text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2023-06-30_custom_TradeAndOtherReceivablesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="GBP">26,376</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--FinancialAssets_iI_pp0p0_uUSD_c20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--TradeAndOtherReceivablesMember_zW5JwUsz83Rl" title="Financial assets" style="text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2022-06-30_custom_TradeAndOtherReceivablesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">606,075</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--FinancialAssets_iI_pp0p0_uCAD_c20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--TradeAndOtherReceivablesMember_zwTffbFnixZ" title="Financial assets" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3064">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--FinancialAssets_iI_pp0p0_uEUR_c20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--TradeAndOtherReceivablesMember_zMPemXfAxgLb" title="Financial assets" style="text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2022-06-30_custom_TradeAndOtherReceivablesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="EUR">16,033</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade and other payables </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eifrs-full--FinancialLiabilities_iI_pp0p0_uUSD_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--TradeAndOtherPayablesMember_zvRsyjIHWtNd" title="Financial liabilities" style="text-align: right">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_custom_TradeAndOtherPayablesMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">455,167</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--FinancialLiabilities_iI_pp0p0_uCAD_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--TradeAndOtherPayablesMember_zvtU1sVwnih2" title="Financial liabilities" style="text-align: right">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_custom_TradeAndOtherPayablesMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="CAD">3,795</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--FinancialLiabilities_iI_pp0p0_uEUR_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--TradeAndOtherPayablesMember_z487cXk7bzT8" title="Financial liabilities" style="text-align: right">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_custom_TradeAndOtherPayablesMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="EUR">151,327</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--FinancialLiabilities_iI_pp0p0_uGBP_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--TradeAndOtherPayablesMember_zXOmVh6m5IAg" title="Financial liabilities" style="text-align: right">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_custom_TradeAndOtherPayablesMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="GBP">31,441</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--FinancialLiabilities_iI_pp0p0_uUSD_c20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--TradeAndOtherPayablesMember_zmllyka7kBRd" title="Financial liabilities" style="text-align: right">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_custom_TradeAndOtherPayablesMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">412,511</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--FinancialLiabilities_iI_pp0p0_uCAD_c20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--TradeAndOtherPayablesMember_zyjAhEdMVp4g" title="Financial liabilities" style="text-align: right">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_custom_TradeAndOtherPayablesMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="CAD">1,652</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--FinancialLiabilities_iI_pp0p0_uEUR_c20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--TradeAndOtherPayablesMember_zNY9pNK9yuhl" title="Financial liabilities" style="text-align: right">(<ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_custom_TradeAndOtherPayablesMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="EUR">46,790</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_z5tds3upXEUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sensitivity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
shown in the table above, the Company is primarily exposed to changes in USD/AUD exchange rates. The sensitivity of profit or loss to
changes in the exchange rates arises mainly from USD denominated financial instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has conducted a sensitivity analysis of its exposure to foreign currency risk. Based on the financial instruments held as at
June 30, 2023, had the Australian dollar weakened/strengthened by <span id="xdx_90A_ecustom--ClosingForeignExchangeRateIncreaseDecrease_pid_dp_c20220701__20230630__ifrs-full--TypesOfRisksAxis__ifrs-full--CurrencyRiskMember__ifrs-full--GeographicalAreasAxis__country--AU_zUiN95JqrCAl" title="Foreign exchange rate increase decrease"><ix:nonFraction name="GENE:ClosingForeignExchangeRateIncreaseDecrease" contextRef="From2022-07-012023-06-30_ifrs-full_CurrencyRiskMember_country_AU" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.65</ix:nonFraction></span>% (2022: <span id="xdx_902_ecustom--ClosingForeignExchangeRateIncreaseDecrease_pid_dp_uPure_c20210701__20220630__ifrs-full--TypesOfRisksAxis__ifrs-full--CurrencyRiskMember__ifrs-full--GeographicalAreasAxis__country--AU_zNKkyOsXwj54" title="Foreign exchange rate increase decrease"><ix:nonFraction name="GENE:ClosingForeignExchangeRateIncreaseDecrease" contextRef="From2021-07-012022-06-30_ifrs-full_CurrencyRiskMember_country_AU" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.3</ix:nonFraction></span>%) against the USD with all other variables held constant,
the Company&#8217;s post-tax loss for the year would have been A$<span id="xdx_90D_ecustom--IncreaseDecreaseInPostTaxLoss_pp0p0_c20220701__20230630_z4mKzc7OlqV" title="Increase decrease in post tax loss"><ix:nonFraction name="GENE:IncreaseDecreaseInPostTaxLoss" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">52,988</ix:nonFraction></span> lower/higher (2022: A$<span id="xdx_90C_ecustom--IncreaseDecreaseInPostTaxLoss_pp0p0_c20210701__20220630_zapqaED29EN9" title="Increase decrease in post tax loss"><ix:nonFraction name="GENE:IncreaseDecreaseInPostTaxLoss" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">289,607</ix:nonFraction></span> lower/higher).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD: <span id="xdx_904_ecustom--ClosingForeignExchangeRateIncreaseDecrease_pid_dp_uPure_c20220701__20230630_zOvil58fLxfl" title="Percentage of foreign exchange rate decrease"><ix:nonFraction name="GENE:ClosingForeignExchangeRateIncreaseDecrease" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.65</ix:nonFraction></span>% (2022: <span id="xdx_908_ecustom--ClosingForeignExchangeRateIncreaseDecrease_pid_dp_uPure_c20210701__20220630_zFxhFVwFlFtk" title="Percentage of foreign exchange rate decrease"><ix:nonFraction name="GENE:ClosingForeignExchangeRateIncreaseDecrease" contextRef="From2021-07-012022-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.3</ix:nonFraction></span>%)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is less sensitive to movements in the AUD/USD exchange rates in 2023 than 2022 because of the reduced amount of USD denominated
cash and cash equivalents. The Company&#8217;s exposure to other foreign exchange movements is not material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)
Credit risk</i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exposure
to credit risk relating to financial assets arises from the potential non-performance by counterparties of contract obligations that
could lead to a financial loss to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)
Risk management</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
risk is managed through the maintenance of procedures (such as the utilization of systems for the approval, granting and renewal of credit
limits, regular monitoring of exposures against such limits and monitoring the financial stability of significant customers and counterparties),
ensuring to the extent possible that customers and counterparties to transactions are of sound credit worthiness. Such monitoring is
used in assessing receivables for impairment. Credit terms are normally 30 days from the invoice date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
is also minimized through investing surplus funds in financial institutions that maintain a high credit rating.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)
Security</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -14.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
some trade receivables the Company may obtain security in the form of guarantees, deeds of undertaking or letters of credit which can
be called upon if the counterparty is in default under the terms of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)
Impairment of financial assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -17.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has one type of financial asset subject to the expected credit loss model:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trade receivables for sales of inventory</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
cash and cash equivalents are also subject to the impairment requirements of IFRS 9, the identified impairment loss was immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 134; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>31. FINANCIAL RISK MANAGEMENT (cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)
Credit risk (Cont.)</i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)
Impairment of financial assets (Cont.)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trade
receivables</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for
all trade receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
measure the expected credit losses, trade receivables assets have been grouped based on shared credit risk characteristics and the days
past due.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)
Liquidity risk</i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
risk arises from the possibility that the Company might encounter difficulty in settling its debts or otherwise meeting its obligations
related to financial liabilities. The Company manages this risk through the following mechanisms:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing forward looking cash flow
    analyses in relation to its operating, investing and financing activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining funding from a variety of sources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining a reputable credit profile;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing credit risk related to financial assets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investing cash and cash equivalents and deposits at
    call with major financial institutions; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">comparing the maturity profile of financial liabilities
    with the realization profile of financial assets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)
Maturities of financial liabilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfLiquidityRiskExplanatory"><p id="xdx_899_eifrs-full--DisclosureOfLiquidityRiskExplanatory_zX08L00ZDlW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tables below analyze the Company&#8217;s financial liabilities into relevant maturity groupings based on their contractual maturities.
The amounts disclosed in the table are the contractual undiscounted cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zgxoUpuMJIr1" style="display: none">SCHEDULE OF MATURITIES OF FINANCIAL LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic; text-align: justify">Contractual maturities of</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20230630__ifrs-full--MaturityAxis__custom--LessThanSixMonthsMember_zbbpmnlYFCvk" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Less than</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">6 months</p></td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20230630__ifrs-full--MaturityAxis__custom--SixAndTwelveMonthsMember_zAvO2X2Fs2X9" style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6
&#8211; 12</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>months</b></span></p></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20230630__ifrs-full--MaturityAxis__custom--BetweenOneAndTwoYearsMember_zPbERRySg376" style="font-weight: bold; text-align: center">Between 1 and 2 years</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20230630__ifrs-full--MaturityAxis__custom--BetweenTwoAndFiveYearsMember_zKMZQD97sw3e" style="font-weight: bold; text-align: center">Between 2 and 5 years</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20230630__ifrs-full--MaturityAxis__custom--OverFiveYearsMember_zFxyiaqpvBGa" style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Over
5</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>years</b></span></p></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20230630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--TotalContractualCashFlowsMember_zq3CAncoc62e" style="font-weight: bold; text-align: center">Total contrac- tual cash flows</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20230630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--CarryingAmountAssetsLiabilitiesMember_zEWyHMVDxeN" style="font-weight: bold; text-align: center">Carrying amount (assets)/ liabilities</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; font-style: italic">financial liabilities</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold">At June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--TradeAndOtherCurrentPayables_iI_pp0p0_zrKNDdTpyfdc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 37%; text-align: left">Trade and other payables</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2023-06-30_custom_LessThanSixMonthsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,617,333</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3097">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3098">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3099">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3100">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2023-06-30_custom_TotalContractualCashFlowsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,617,333</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2023-06-30_custom_CarryingAmountAssetsLiabilitiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,617,333</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--LeaseLiabilities_iI_pp0p0_zOP3FMPDbms6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2023-06-30_custom_LessThanSixMonthsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">158,316</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2023-06-30_custom_SixAndTwelveMonthsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">161,154</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2023-06-30_custom_BetweenOneAndTwoYearsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">208,957</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2023-06-30_custom_BetweenTwoAndFiveYearsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">21,636</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2023-06-30_custom_OverFiveYearsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,817</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2023-06-30_custom_TotalContractualCashFlowsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">551,880</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2023-06-30_custom_CarryingAmountAssetsLiabilitiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">532,846</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--FinancialLiabilities_iI_pp0p0_zVhBsctnyh74" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_custom_LessThanSixMonthsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,775,649</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_custom_SixAndTwelveMonthsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">161,154</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_custom_BetweenOneAndTwoYearsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">208,957</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_custom_BetweenTwoAndFiveYearsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">21,636</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_custom_OverFiveYearsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,817</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_custom_TotalContractualCashFlowsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,169,213</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_custom_CarryingAmountAssetsLiabilitiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,150,179</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic; text-align: left"><b>Contractual maturities of</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" id="xdx_493_20220630__ifrs-full--MaturityAxis__custom--LessThanSixMonthsMember_z23PWVXa8kPk" style="font-weight: bold; text-align: center"><b>Less than 6 months</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" id="xdx_49C_20220630__ifrs-full--MaturityAxis__custom--SixAndTwelveMonthsMember_zf3eUZjNyRPe" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6
                                            &#8211; 12</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>months</b></span></p></td><td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" id="xdx_494_20220630__ifrs-full--MaturityAxis__custom--BetweenOneAndTwoYearsMember_zg2JWXTcW5va" style="font-weight: bold; text-align: center"><b>Between 1 and 2 years</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" id="xdx_49C_20220630__ifrs-full--MaturityAxis__custom--BetweenTwoAndFiveYearsMember_zyxU5OUqaJo7" style="font-weight: bold; text-align: center"><b>Between 2 and 5 years</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" id="xdx_498_20220630__ifrs-full--MaturityAxis__custom--OverFiveYearsMember_ziqZuJtQyyBi" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Over
                                            5</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>years</b></span></p></td><td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" id="xdx_49A_20220630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--TotalContractualCashFlowsMember_zFmrqvm1J0F2" style="font-weight: bold; text-align: center"><b>Total contrac- tual cash flows</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" id="xdx_49F_20220630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--CarryingAmountAssetsLiabilitiesMember_z3gQA76GkTEg" style="font-weight: bold; text-align: center"><b>Carrying amount (assets)/ liabilities</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">financial liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold">At June 30, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--TradeAndOtherCurrentPayables_iI_pp0p0_zx7a3ExC7Ux8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 37%; text-align: left">Trade and other payables</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2022-06-30_custom_LessThanSixMonthsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,122,379</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3121">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3122">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3123">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3124">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2022-06-30_custom_TotalContractualCashFlowsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,122,379</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2022-06-30_custom_CarryingAmountAssetsLiabilitiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,122,379</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--LeaseLiabilities_iI_pp0p0_zMojs6SUoK9a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2022-06-30_custom_LessThanSixMonthsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">133,507</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2022-06-30_custom_SixAndTwelveMonthsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">136,250</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2022-06-30_custom_BetweenOneAndTwoYearsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">255,601</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2022-06-30_custom_BetweenTwoAndFiveYearsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">163,896</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3132">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2022-06-30_custom_TotalContractualCashFlowsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">689,254</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2022-06-30_custom_CarryingAmountAssetsLiabilitiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">652,526</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--FinancialLiabilities_iI_pp0p0_zGuUo6MHCpsf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_custom_LessThanSixMonthsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,255,886</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_custom_SixAndTwelveMonthsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">136,250</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_custom_BetweenOneAndTwoYearsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">255,601</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_custom_BetweenTwoAndFiveYearsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">163,896</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3140">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_custom_TotalContractualCashFlowsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,811,633</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_custom_CarryingAmountAssetsLiabilitiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,774,905</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zkqI5VPNyLH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 135; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>31. FINANCIAL RISK MANAGEMENT (cont.)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(d)
Interest rate risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -14.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s main interest rate risk arises in relation to its short-term deposits with various financial institutions. If rates were
to decrease, the Company may generate less interest revenue from such deposits. However, given the relatively short duration of such
deposits, the associate risk is relatively minimal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a Short-Term Investment Policy which was developed to manage the Company&#8217;s surplus cash and cash equivalents. In this
context, the Company adopts a prudent approach that is tailored to cash forecasts rather than seeking high returns that may compromise
access to funds as and when they are required. Under the policy, the Company deposits its surplus cash in a range of deposits / securities
over different time frames and with different institutions in order to diversify its portfolio and minimize risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
a monthly basis, Management provides the Board with a detailed list of all cash and cash equivalents, showing the periods over which
the cash has been deposited, the name and credit rating of the institution holding the deposit and the interest rate at which the funds
have been deposited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2023, if interest rates had changed by +/- 50 basis points from the year-end rates, with all other variables held constant,
the Company&#8217;s loss for the year would have been A$<span id="xdx_907_ecustom--IncreaseDecreaseInProfitAndLossDueToReasonablyPossibleDecreaseInDesignatedRiskComponent_pp0p0_c20220701__20230630__ifrs-full--TypesOfRisksAxis__ifrs-full--InterestRateRiskMember_z1AZoT00ZsBi" title="Increase (decrease) in profit and loss due to reasonably possible decrease in designated risk component"><ix:nonFraction name="GENE:IncreaseDecreaseInProfitAndLossDueToReasonablyPossibleDecreaseInDesignatedRiskComponent" contextRef="From2022-07-012023-06-30_ifrs-full_InterestRateRiskMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">31,083</ix:nonFraction></span> lower / higher (2022: loss A$<span id="xdx_90B_ecustom--IncreaseDecreaseInProfitAndLossDueToReasonablyPossibleDecreaseInDesignatedRiskComponent_pp0p0_c20210701__20220630__ifrs-full--TypesOfRisksAxis__ifrs-full--InterestRateRiskMember_zJC4Nv1LRWrf" title="Increase (decrease) in profit and loss due to reasonably possible decrease in designated risk component"><ix:nonFraction name="GENE:IncreaseDecreaseInProfitAndLossDueToReasonablyPossibleDecreaseInDesignatedRiskComponent" contextRef="From2021-07-012022-06-30_ifrs-full_InterestRateRiskMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">40,369</ix:nonFraction></span> lower / higher), as a result of higher
/ lower interest income from cash and cash equivalents and deposits in place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory"><p id="xdx_896_eifrs-full--DisclosureOfFinancialInstrumentsByTypeOfInterestRateExplanatory_zaonFi404F0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exposure to interest rate risks and the effective interest rates of financial assets and liabilities, both recognized and unrealized,
for the Company is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zKpgzhp9iXQh" style="display: none">SCHEDULE OF EXPOSURE TO INTEREST RATE RISKS AND EFFECTIVE INTEREST RATES OF FINANCIAL ASSETS AND LIABILITIES</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Floating rate</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fixed rate</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Carrying amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted ave. effective rate</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Ave. maturity Period</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Days</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Financial assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Cash at bank / on hand</td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--FinancialAssets_iI_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--CashAtBankOnHandMember__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FloatingInterestRateMember_zK3NKWVVsL73" title="Financial assets" style="width: 6%; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2023-06-30_custom_CashAtBankOnHandMember_ifrs-full_FloatingInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,516,646</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--FinancialAssets_iI_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--CashAtBankOnHandMember__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FixedInterestRateMember_zfSVx6K3tOC8" style="width: 6%; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2023-06-30_custom_CashAtBankOnHandMember_ifrs-full_FixedInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,334,551</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--FinancialAssets_iI_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--CashAtBankOnHandMember_zlo3LfYwRtdg" style="width: 6%; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2023-06-30_custom_CashAtBankOnHandMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">7,851,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><span id="xdx_902_ecustom--InterestRateRiskWeightedAverageEffectiveRate_pid_dp_c20220701__20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--CashAtBankOnHandMember_zWC0sSpHUsFl" title="Weighted ave. effective rate %"><ix:nonFraction name="GENE:InterestRateRiskWeightedAverageEffectiveRate" contextRef="From2022-07-012023-06-30_custom_CashAtBankOnHandMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.46</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--AverageMaturityPeriodDays_c20220701__20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--CashAtBankOnHandMember_zHHEsCVWDOyl" title="Average maturity period days"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_CashAtBankOnHandMember" name="GENE:AverageMaturityPeriodDays">At call</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--FinancialAssets_iI_c20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--CashAtBankOnHandMember__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FloatingInterestRateMember_zbVD4lGwlSBc" title="Financial assets" style="text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2022-06-30_custom_CashAtBankOnHandMember_ifrs-full_FloatingInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,971,827</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--FinancialAssets_iI_c20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--CashAtBankOnHandMember__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FixedInterestRateMember_zwzPZBgDz1xd" style="text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2022-06-30_custom_CashAtBankOnHandMember_ifrs-full_FixedInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">9,759,498</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--FinancialAssets_iI_c20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--CashAtBankOnHandMember_zwxZnOzUexrc" style="text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2022-06-30_custom_CashAtBankOnHandMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">11,731,325</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_ecustom--InterestRateRiskWeightedAverageEffectiveRate_pid_dp_c20210701__20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--CashAtBankOnHandMember_zjFpUvYmHwLe" title="Weighted ave. effective rate %"><ix:nonFraction name="GENE:InterestRateRiskWeightedAverageEffectiveRate" contextRef="From2021-07-012022-06-30_custom_CashAtBankOnHandMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.31</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--AverageMaturityPeriodDays_c20210701__20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--CashAtBankOnHandMember_zE3cBh75jecc" title="Average maturity period days"><ix:nonNumeric contextRef="From2021-07-012022-06-30_custom_CashAtBankOnHandMember" name="GENE:AverageMaturityPeriodDays">At call</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bonds / deposits</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--FinancialAssets_iI_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--PerformanceBondAndDepositsMember__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FloatingInterestRateMember_zlCRUOufu8aa" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3165">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--FinancialAssets_iI_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--PerformanceBondAndDepositsMember__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FixedInterestRateMember_zkEI2puhwFK2" style="text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2023-06-30_custom_PerformanceBondAndDepositsMember_ifrs-full_FixedInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">17,440</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--FinancialAssets_iI_c20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--PerformanceBondAndDepositsMember_z7SIxx6loPM1" style="text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2023-06-30_custom_PerformanceBondAndDepositsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">17,440</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--AverageMaturityPeriodDays_c20220701__20230630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--PerformanceBondAndDepositsMember_znGzzCWjzZK2"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_PerformanceBondAndDepositsMember" name="GENE:AverageMaturityPeriodDays">At call</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--FinancialAssets_iI_c20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--PerformanceBondAndDepositsMember__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FloatingInterestRateMember_zFpaAcxPfTf9" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3169">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--FinancialAssets_iI_c20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--PerformanceBondAndDepositsMember__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FixedInterestRateMember_z3QusrVSh6Tf" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2022-06-30_custom_PerformanceBondAndDepositsMember_ifrs-full_FixedInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">13,257</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--FinancialAssets_iI_c20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--PerformanceBondAndDepositsMember_zQNPzRmcwGfg" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2022-06-30_custom_PerformanceBondAndDepositsMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">13,257</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--AverageMaturityPeriodDays_c20210701__20220630__ifrs-full--ClassesOfFinancialAssetsAxis__custom--PerformanceBondAndDepositsMember_zdoL4Nzzy2Zj"><ix:nonNumeric contextRef="From2021-07-012022-06-30_custom_PerformanceBondAndDepositsMember" name="GENE:AverageMaturityPeriodDays">At call</ix:nonNumeric></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Totals</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--FinancialAssets_iI_c20230630__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FloatingInterestRateMember_z6Mdth2cF6Zd" style="font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2023-06-30_ifrs-full_FloatingInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,516,646</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--FinancialAssets_iI_c20230630__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FixedInterestRateMember_zs4zjKiD5G4h" style="font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2023-06-30_ifrs-full_FixedInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">6,351,991</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--FinancialAssets_iI_c20230630_ztbA8ACAm6Sa" style="font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">7,868,637</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; padding-bottom: 1.5pt">2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--FinancialAssets_iI_c20220630__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FloatingInterestRateMember_zX33qIQ5qp59" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2022-06-30_ifrs-full_FloatingInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">1,971,827</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--FinancialAssets_iI_c20220630__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FixedInterestRateMember_zg3pxDuEuFW6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2022-06-30_ifrs-full_FixedInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">9,772,755</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--FinancialAssets_iI_c20220630_z9QoRJVXYO9h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialAssets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">11,744,582</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Financial liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Borrowings</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--FinancialLiabilities_iI_c20230630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--BorrowingMember__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FloatingInterestRateMember_zvryQNatP1gk" title="Financial liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3180">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--FinancialLiabilities_iI_c20230630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--BorrowingMember__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FixedInterestRateMember_ztYmJzkUFby1" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3181">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--FinancialLiabilities_iI_c20230630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--BorrowingMember_ziPraeT7ANGc" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3182">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--FinancialLiabilities_iI_c20220630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--BorrowingMember__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FloatingInterestRateMember_zkcBCLN9Jtf" title="Financial liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3184">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--FinancialLiabilities_iI_c20220630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--BorrowingMember__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FixedInterestRateMember_z2ydMNprh0r6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3185">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--FinancialLiabilities_iI_c20220630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--BorrowingMember_zVh2hwfwoAS7" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3186">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Leases</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--FinancialLiabilities_iI_c20230630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--LeasesMember__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FloatingInterestRateMember_zqNMysnntQoc" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3187">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--FinancialLiabilities_iI_c20230630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--LeasesMember__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FixedInterestRateMember_zoHKQCybtxFa" style="text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_custom_LeasesMember_ifrs-full_FixedInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">532,846</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--FinancialLiabilities_iI_c20230630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--LeasesMember_zTQhWEvpmpfg" style="text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2023-06-30_custom_LeasesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">532,846</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_ecustom--InterestRateRiskWeightedAverageEffectiveRate_pid_dp_c20220701__20230630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--LeasesMember_zjmHQsTkK4yi" title="Weighted ave. effective rate %"><ix:nonFraction name="GENE:InterestRateRiskWeightedAverageEffectiveRate" contextRef="From2022-07-012023-06-30_custom_LeasesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.77</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--FinancialLiabilities_iI_c20220630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--LeasesMember__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FloatingInterestRateMember_zjzre96a3luh" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3192">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--FinancialLiabilities_iI_c20220630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--LeasesMember__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FixedInterestRateMember_zOOm10XSZL5g" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_custom_LeasesMember_ifrs-full_FixedInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">652,526</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--FinancialLiabilities_iI_c20220630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--LeasesMember_z76WqzlxeI3b" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_custom_LeasesMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">652,526</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_905_ecustom--InterestRateRiskWeightedAverageEffectiveRate_pid_dp_c20210701__20220630__ifrs-full--ClassesOfFinancialLiabilitiesAxis__custom--LeasesMember_zHE3DPUZOOLg" title="Weighted ave. effective rate %"><ix:nonFraction name="GENE:InterestRateRiskWeightedAverageEffectiveRate" contextRef="From2021-07-012022-06-30_custom_LeasesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.55</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Totals</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; padding-bottom: 1.5pt">2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--FinancialLiabilities_iI_c20230630__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FloatingInterestRateMember_zdGNyOyoQtPd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3197">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--FinancialLiabilities_iI_c20230630__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FixedInterestRateMember_zaSGXH9Uhaxg" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3198">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--FinancialLiabilities_iI_c20230630_z8NJQYO1KQig" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl3199">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; padding-bottom: 1.5pt">2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--FinancialLiabilities_iI_c20220630__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FloatingInterestRateMember_zTVreQo0qT3i" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3200">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--FinancialLiabilities_iI_c20220630__ifrs-full--TypesOfInterestRatesAxis__ifrs-full--FixedInterestRateMember_zyLB36ewmaGg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30_ifrs-full_FixedInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">652,526</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--FinancialLiabilities_iI_c20220630_zLmihyimW3Ck" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">652,526</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A3_ziShiOfmA2jd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 136; Value: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfCapitalManagementExplanatory"><p id="xdx_800_ecustom--DisclosureOfCapitalManagementExplanatory_zb2x412eveM1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>32.
<span id="xdx_82D_z3S3FVAmXXU">CAPITAL MANAGEMENT</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)
Risk management</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s objectives when managing capital are to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safeguard their ability to continue
    as a going concern, so that they can continue to provide returns for shareholders and benefits for other stakeholders, and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain an optimal capital structure to reduce the
    cost of capital.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to maintain or adjust the capital structure, the Company may issue new shares or reduce its capital, subject to the provisions
of the Company&#8217;s constitution. The capital structure of the Company consists of equity attributed to equity holders of the Company,
comprising contributed equity, reserves and accumulated losses. By monitoring undiscounted cash flow forecasts and actual cash flows
provided to the board by the Company&#8217;s management, the board monitors the need to raise additional equity from the equity markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)
Dividends</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -14.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eifrs-full--DividendsPaid_pp0p0_do_c20220701__20230630_zBUehCYPZlod" title="Dividends"><ix:nonFraction name="ifrs-full:DividendsPaid" contextRef="From2022-07-01to2023-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="AUD">No</ix:nonFraction></span>
dividends were declared or paid to members for the year ended June 30, 2023 (2022: <span id="xdx_908_eifrs-full--DividendsPaid_pp0p0_dxL_c20210701__20220630_z9v8LjAvNuG1" title="Dividends::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl3208">nil</span></span>). The Company&#8217;s franking account balance
was <span id="xdx_90F_ecustom--FrankingAccountBalance_pp0p0_dxL_c20220701__20230630_zKaDEtE5wHo9" title="Franking account balance::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl3210">nil</span></span> at June 30, 2023 (2022: <span id="xdx_904_ecustom--FrankingAccountBalance_pp0p0_dxL_c20210701__20220630_zWC3KgHrWVpk" title="Franking account balance::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl3212">nil</span></span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfParentEntityFinancialInformationExplanatory"><p id="xdx_805_ecustom--DisclosureOfParentEntityFinancialInformationExplanatory_z4yhc26cw8Ak" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>33.
<span id="xdx_82B_zEN2jZTY4lB5">PARENT ENTITY FINANCIAL INFORMATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfDetailedInformationAboutIndividualFinancialInformationExplanatory"><p id="xdx_89C_ecustom--DisclosureOfDetailedInformationAboutIndividualFinancialInformationExplanatory_zd3ucLrCjMM6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
individual financial statements for the parent entity show the following aggregate amounts:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zQ28nl9iPVt9" style="display: none">SCHEDULE OF DISCLOSURE OF INDIVIDUAL FINANCIAL INFORMATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--ParentMember_zb3slAo5fhs7" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--ParentMember_zwLY2555aLl9" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20210630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--ParentMember_zx8RYqeEMIfa" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Statement of Financial Position</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CurrentAssets_iI_pp0p0_maAzcsc_z0lznlDHMDSb" style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; text-align: left">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2023-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">10,035,224</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2022-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">5,022,689</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2021-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">21,809,918</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--NoncurrentAssets_iI_pp0p0_maAzcsc_z9ArF5aGcEbb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="AsOf2023-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">4,237,344</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="AsOf2022-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">5,815,118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="AsOf2021-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,011,338</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--Assets_iTI_pp0p0_mtAzcsc_zyHmBo9wBrU5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2023-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">14,272,568</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2022-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">10,837,807</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2021-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">23,821,256</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CurrentLiabilities_iI_pp0p0_maLzQJD_zqZrxRfh0OJ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="AsOf2023-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,841,919</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="AsOf2022-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,270,626</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="AsOf2021-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">1,317,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--NoncurrentLiabilities_iI_pp0p0_maLzQJD_zh1YGas7J8K4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="AsOf2023-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">314,999</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="AsOf2022-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">589,745</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="AsOf2021-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">7,694,668</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--Liabilities_iTI_pp0p0_mtLzQJD_zTdrqM0oONDb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2023-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">3,156,918</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2022-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">2,860,371</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2021-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">9,012,046</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Shareholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--IssuedCapital_iI_pp0p0_maEzKHa_zXK0STtoj2y6" style="vertical-align: bottom; background-color: White">
    <td>Share Capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2023-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">161,342,707</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2022-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">155,138,636</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2021-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">153,574,974</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--OtherReserves_iI_pp0p0_maEzKHa_ztWmzXfMel9c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other reserves</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2023-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">117,131</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2022-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">117,131</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2021-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">117,131</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--SharebasedPayments_iI_pp0p0_maEzKHa_zecaF4MoxHjc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:SharebasedPayments" contextRef="AsOf2023-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">3,917,101</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:SharebasedPayments" contextRef="AsOf2022-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">8,937,157</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GENE:SharebasedPayments" contextRef="AsOf2021-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">8,499,649</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--RetainedEarnings_iI_pp0p0_maEzKHa_zw77fxFJi44g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2023-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">154,027,027</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2022-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">155,981,226</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2021-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">147,148,282</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--Equity_iTI_pp0p0_mtEzKHa_z8U1iSE0a2Za" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Equity</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">11,115,650</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">7,977,436</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">14,809,210</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ProfitorLoss_iI_pp0p0_zOnenCb1mhXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss for the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="GENE:ProfitorLoss" contextRef="AsOf2023-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">3,697,316</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="GENE:ProfitorLoss" contextRef="AsOf2022-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">8,833,064</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="GENE:ProfitorLoss" contextRef="AsOf2021-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="AUD">1,601,672</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zrFTg63QcVzj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended June 30, 2023, A$<span id="xdx_907_eifrs-full--ImpairmentLossRecognisedInProfitOrLoss_pp0p0_c20220701__20230630_zYMNQTdJ8xJe" title="Recognized impairment loss"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">30,956,037</ix:nonFraction></span> impairment loss previously recognized on intercompany loan balances between the parent and
its subsidiaries was reversed (2022: <span id="xdx_90A_eifrs-full--ImpairmentLossRecognisedInProfitOrLoss_pp0p0_dxL_c20210701__20220630_zp6ONyLeQqM5" title="Recognized impairment loss::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl3268">Nil</span></span>, 2021: A$<span id="xdx_905_eifrs-full--ImpairmentLossRecognisedInProfitOrLoss_pp0p0_c20200701__20210630_zNY81UzGgLj6" title="Recognized impairment loss"><ix:nonFraction name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" contextRef="From2020-07-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="AUD">4,482,965</ix:nonFraction></span> recognized as impairment loss reversal). The parent entity forgave loan balances
with subsidiaries representing A$<span id="xdx_901_eifrs-full--AdjustmentsForDecreaseIncreaseInLoansAndAdvancesToCustomers_c20220701__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--ParentMember_zQZGBeajY77d" title="Forgave loan balances"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInLoansAndAdvancesToCustomers" contextRef="From2022-07-012023-06-30_ifrs-full_ParentMember" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">26,072,596</ix:nonFraction></span> during the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="GENE:DisclosureOfContingentLiabilitiesAndContingentAssetsExplanatory"><p id="xdx_807_ecustom--DisclosureOfContingentLiabilitiesAndContingentAssetsExplanatory_zATmajZtgnoh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>34.
<span id="xdx_827_zqH3pRI38ABa">CONTINGENT LIABILITIES AND CONTINGENT ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -15.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is not aware of any contingent liabilities as at June 30, 2023 (2022: There were <span id="xdx_906_ecustom--ContingentLiabilities_iI_do_c20220630_zNyXEKH6DHFg" title="Contingent liabilities"><ix:nonFraction name="GENE:ContingentLiabilities" contextRef="AsOf2022-06-30" format="ixt-sec:numwordsen" decimals="0" unitRef="AUD">no</ix:nonFraction></span> contingent liabilities or assets).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-07-01to2023-06-30" escape="true" name="ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory"><p id="xdx_809_eifrs-full--DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_zVmZkGX2Ovz5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>35.
<span id="xdx_822_zm4SzblJna2">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the date of this report there have been no matters or circumstances that have arisen since the end of the period which significantly,
or may significantly affect:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s operations
    in future years;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The results of those operations
    in future years; or</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s state
    of affairs in future years.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -7.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Australian
Disclosure Requirements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
press releases, financial reports and other information are available using the stock code GTG on the Australian Securities Exchange
website: www2.asx.com.au</span></p>

</ix:nonNumeric><p id="xdx_81E_zpA8um3fMF8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 137; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>
</body>
</html>
[{"type": "20-F", "sequence": "1", "filename": "form20-f.htm", "secsgml_size_bytes": 3289316}]
{"company-data": {"conformed-name": "GENETIC TECHNOLOGIES LTD", "cik": "0001166272", "assigned-sic": "2836", "irs-number": "000000000"}, "filing-values": {"form-type": "20-F", "act": "34", "file-number": "000-51504", "film-number": "231223727"}, "business-address": {"street1": "60-66 HANOVER STREET", "city": "FITZROY, VICTORIA", "state": "C3", "zip": "3065", "phone": "011613-9415-1135"}, "mail-address": {"street1": "60-66 HANOVER STREET", "city": "FITZROY, VICTORIA", "state": "C3", "zip": "3065"}}
Commission file number
000-51504
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington D.C.
20549
FORM
20-F
☐
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EX- CHANGE ACT OF 1934
OR
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended
June 30
,
2023
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR
    15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period
from
to
OR
☐
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EX- CHANGE ACT OF 1934
Date of event requiring this shell company report
.. . . . . . . . . . . . . . . . . .
.
GENETIC
TECHNOLOGIES LIMITED
(Exact name of Registrant
as specified in its charter and translation of Registrant's name into English)
Australia
(Jurisdiction of incorporation
or
organization)
60-66 Hanover Street
,
Fitzroy
,
Victoria,
3065
,
Australia
(Address of principal executive
offices)
Simon Morriss
,
Chief Executive Officer
60-66 Hanover Street
,
Fitzroy
, Victoria,
3065
,
Australia
Telephone:
+61
3 8412 7000
(Name, telephone, e-mail
and/or facsimile number and address of company contact
person)
Securities registered or to be registered pursuant
to Section 12(b) of the
Act:
Title of each
class
Trading
    Symbol
Name of each exchange on which regis
tered
N/A
N/A
N/A
Securities registered or to be registered pursuant
to Section 12(g) of the Act: American Depositary Shares, each representing 600 Ordinary Shares.
Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act:
None
Number of outstanding shares of each of the issuer's
classes of capital or common stock as of the close of the period covered by the annual report. There were
11,541,658,143
Ordinary Shares
outstanding as of June 30, 2023.
Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities
Act.
☐
Yes
☒
No
If this report is an annual or transition report,
indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934.
☐
Yes ☒
No
Note — Checking the box above will not relieve
any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations
under those Sections.
Indicate by check mark whether
the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
☒
Yes
☐
No
Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files).
☒
Yes
☐
No
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth company. See definition
of "large accelerated filer," "accelerated filer," and "emerging growth company" in Rule 12b-2 of
the Exchange Act. (Check one):
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Emerging growth company
☐
If an emerging growth company
that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a)
of the Exchange Act. ☐
† The term "new
or revised financial accounting standard" refers to any update issued by the Financial Accounting Standards Board to its Accounting
Standards Codification after April 5, 2012.
Indicate by check mark whether
the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that
prepared or issued its audit report."
☐
Yes
☒
No
If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements.
☐
Yes ☒
No
Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's
executive officers during the relevant recovery period pursuant to §240.10D-1(b).
☐
Yes ☒
No
Indicate by check mark which basis of accounting
the registrant has used to prepare the financial statements included in this
filing:
U.S. GAAP
☐
International Financial Reporting Standards
as issued y
the
International Accounting
    Standards Board
☒
Other
☐
If "Other" has been checked in response
to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.
☐ Item 17 ☐
Item
18
If this is an annual report, indicate by check
mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).
☐
Yes ☒
No
(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PAST FIVE
YEARS)
Indicate by check mark whether the registrant has
filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to
the distribution of securities under a plan confirmed by a court. ☐ Yes ☐ No
TABLE OF
CONTENTS
Item
    1.
Identity of Directors, Senior Management and Advisers
1
Item
    2.
Offer Statistics And Expected Timetable
1
Item
    3.
Key Information
1
Item
    3.A
Reserved
1
Item
    3.B
Capitalisation and Indebtedness
1
Item
    3.C
Reasons for the Offer and Use of Proceeds
1
Item
    3.D
Risk Factors
1
Item
    4.
Information on the Company
21
Item
    4.A
History and Development of the Company
21
Item
    4.B
Business Overview
23
Item
    4.C
Organizational Structure
32
Item
    4.D
Property, Plant and Equipment
32
Item
    4A.
Unresolved Staff Comments
33
Item
    5.
Operating and Financial Review and Prospects
33
Item
    5.A
Operating Results
33
Item
    5.B
Liquidity and Capital Resources
37
Item
    5.C
Research and Development, Patents and Licenses, etc.
38
Item
    5.D
Trend Information
39
Item
    5.E
Critical Accounting Estimates
39
Item
    6.
Directors, Senior Management and Employees
39
Item
    6.A
Directors and Senior Management
39
Item
    6.B
Compensation
41
Item
    6.C
Board Practices
55
Item
    6.D
Employees
57
Item
    6.E
Share Ownership
57
Item
    7.
Major Shareholders and Related Party Transactions
58
Item
    7.A
Major Shareholders
58
Item
    7.B
Related Party Transactions
58
Item
    7.C
Interests of Experts and Counsel
59
Item
    8.
Financial Information
59
Item
    8.A
Consolidated Statements and Other Financial Information
59
Item
    8.B
Significant Changes
60
Item
    9.
The Offer and Listing
60
Item
    9.A
Offer and Listing Details
60
Item
    9.B
Plan of Distribution
60
Item
    9.C
Markets
60
Item
    9.D
Selling Shareholders
60
Item
    9.E
Dilution
60
Item
    9.F
Expenses of the Issue
60
Item
    10.
Additional Information
60
Item
    10.A
Share Capital
60
Item
    10.B
Our Constitution
60
Item
    10.C
Material Contracts
62
Item
    10.D
Exchange Controls
63
Item
    10.E
Taxation
63
Item
    10.F
Dividends and Paying Agents
69
i
Item
    10.G
Statement by Experts
69
Item
    10.H
Documents on Display
69
Item
    10.I
Subsidiary Information
69
Item
    10.J
Annual Report to Security Holders
69
Item
    11.
Quantitative And Qualitative Disclosures About Market Risk
69
Item
    12.
Description Of Securities Other Than Equity Securities
70
Item
    12.A
Debt Securities
70
Item
    12.B
Warrants and Rights
70
Item
    12.C
Other Securities
70
Item
    12.D
American Depositary Shares
70
Item
    13.
Defaults, Dividend Arrearages and Delinquencies
71
Item
    14.
Material Modifications to The Rights Of Security Holders and Use Of Proceeds
71
Item
    15.
Controls and Procedures
71
Item
    15.A
Disclosure controls and procedures
71
Item
    15.B
Management's annual report on internal control over financial reporting
71
Item
    15.C
Attestation report of the registered public accounting firm
72
Item
    15.D
Changes in internal control over financial reporting
72
Item
    16
Reserved
72
Item
    16.A
Audit Committee Financial Expert
72
Item
    16.B
Code Of Ethics
72
Item
    16.C
Principal Accountant Fees and Services
72
Item
    16.D
Exemptions From The Listing Standards For Audit Committees
73
Item
    16.E
Purchases Of Equity Securities By The Issuer And Affiliated Purchasers
73
Item
    16.F
Change in Registrant's Certifying Accountant
73
Item
    16.G
Corporate Governance
73
Item
    16.H
Mine Safety Disclosure
73
Item
    16.I
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
73
Item
    16.J
Insider Trading Policies
73
Item
    17.
Financial Statements
73
Item
    18.
Financial Statements
73
Item
    19.
Exhibits
74
ii
INTRODUCTION
In this
Annual Report, the "Company," "Genetic Technologies", "GTG", "the Group", "we,"
"us" and "our" refer to Genetic Technologies Limited and its consolidated subsidiaries.
Our consolidated
financial statements are set out beginning on page F-1 of this Annual Report (refer to Item 18 "Financial
Statements").
References
to the "ADSs" are to our ADSs described in Item 12.D "American Depositary Shares" and references to the "Ordinary
Shares" are to our Ordinary Shares described in Item 10.
Our fiscal
year ends on June 30 and references in this Annual Report to any specific fiscal year are to the twelve-month period ended on June 30
of such year.
FORWARD-LOOKING
STATEMENTS
This
Annual Report contains forward-looking statements that involve risks and uncertainties. We use words such as "anticipates",
"believes", "plans", "expects", "future", "intends" and similar expressions
to identify such forward-looking statements. This Annual Report also contains forward-looking statements attributed to certain third parties
relating to their estimates regarding the growth of Genetic Technologies and related markets and spending. You should not place undue
reliance on these forward-looking statements, which apply only as of the date of this Annual Report. Our actual results could differ materially
from those anticipated in these forward- looking statements for many reasons, including the risks faced by us described below under the
caption "Risk Factors" and elsewhere in this Annual Report.
Although
we believe that the expectations reflected in such forward-looking statements are reasonable at this time, we can give no assurance that
such expectations will prove to be correct. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking
statements. Important factors that could cause actual results to differ materially from our expectations are contained in cautionary statements
in this Annual Report including, without limitation, in conjunction with the forward-looking statements included in this Annual Report
and specifically under Item 3.D "Risk Factors".
All
subsequent written and oral forward-looking statements attributable to us are expressly qualified in their entirety by reference to these
cautionary statements.
AUSTRALIAN DISCLOSURE
REQUIREMENTS
Our ordinary
shares are primarily quoted on the Australian Securities Exchange ("ASX") in addition to our listing of our ADSs on the NASDAQ
Global Select Market. As part of our ASX listing, we are required to comply with various disclosure requirements as set out under the
Australian Corporations Act 2001 and the ASX Listing Rules. Information furnished under the sub-heading "Australian
Disclosure
Requirements" is intended to comply with ASX listing and Corporations Act 2001 disclosure requirements and is not intended
to
fulfill information required by this Annual report on Form 20-F.
ENFORCEMENT OF LIABILITIES AND SERVICE OF
PROCESS
We are
incorporated under the laws of Western Australia in the Commonwealth of Australia. All of our directors and executive officers, and any
experts named in this Annual Report, reside outside the U.S. Substantially all of our assets, our directors' and executive officers'
assets and such experts' assets are located outside the U.S. As a result, it may not be possible for investors to affect service
of process within the U.S. upon us or our directors, executive officers or such experts, or to enforce against them or us in U.S. courts,
judgments obtained in U.S. courts based upon the civil liability provisions of the federal securities laws of the U.S. In addition, we
have been advised by our Australian solicitors that there is doubt that the courts of Australia will enforce against us, our directors,
executive officers and experts named herein, judgments obtained in the U.S. based upon the civil liability provisions of the federal securities
laws of the U.S. or will enter judgments in original actions brought in Australian courts based upon the federal securities laws of the
U.S.
iii
PART
I
Item 1. Identity of Directors, Senior Management and
Advisers
Not
applicable
Item 2. Offer Statistics and Expected
Timetable
Not applicable.
Item 3. Key Information
Item
3.A Reserved
Item 3.B Capitalisation and
Indebtedness
Not
applicable.
Item 3.C Reasons for the Offer and Use of
Proceeds
Not
applicable.
Item 3.D Risk
Factors
Before
you purchase our ADSs, you should be aware that there are risks, including those described below. You should consider carefully these
risk factors together with all of the other information contained elsewhere in this Annual Report before you decide to purchase our ADSs.
Risk Factor
Summary
Risk Related to our
Business
●
A
    variety of risks associated with commercializing our products and product candidates internationally could materially adversely
    affect our business.
●
Our Company has a history of incurring
losses.
●
We may not be successful in transitioning from our existing product portfolio to our next generation of risk assessment tests, and our newly developed approach to marketing and distribution of such products may not generate revenues.
●
Our products may never achieve significant market
acceptance.
●
We face additional risks as a result of the EasyDNA and AffinityDNA acquisitions and may be unable to integrate our businesses
successfully and realize the anticipated synergies and related benefits of these acquisitions or do so within the anticipated time
frame.
●
Failure to demonstrate the clinical utility of our products could have a material adverse effect on our financial condition and results of operations.
●
If our competitors develop superior products, our operations and financial condition could be
affected.
●
We have important relationships with external parties over whom we have limited
control.
●
We may be subject to liability and our insurance may not be sufficient to cover
damages.
●
Security breaches, privacy issues, loss of data and other incidents could compromise sensitive or personal information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.
●
We use potentially hazardous materials, chemicals and patient samples in our business and any disputes relating to improper handling, storage or disposal of these materials could be time consuming and costly.
●
Our industry is subject to rapidly changing technology and new and increasing amounts of scientific data related to genes and genetic variants and their role in disease.
●
We depend on the collaborative efforts of our academic and corporate partners for research, development and commercialization of our products. A breach by our partners of their obligations, or the termination of the relationship, could deprive us of valuable resources and require additional investment of time and money.
●
If our sole laboratory facility becomes inoperable, we may be unable to perform our tests and our business will be
harmed.
●
The loss of key members of our senior management team or our inability to attract and retain highly skilled scientists, clinicians and salespeople could adversely affect our business.
1
●
Changes in the way that the Food & Drug Administration (FDA) regulates our tests could result in the delay or additional expense in offering our tests and tests that we may develop in the future.
●
Our business could be harmed from the loss or suspension of a license or imposition of a fine or penalties under, or future changes in, or changing interpretations of, Clinical Laboratory Improvements Amendments (CLIA) or state laboratory licensing laws to which we are subject.
●
Failure to establish and comply with appropriate quality standards to assure that the highest level of quality is observed in the performance of our testing services and in the design, manufacture and marketing of our products could adversely affect the results of our operations and adversely impact our reputation.
●
We could be adversely affected by violations of the Foreign Corrupt Practices Act (FCPA) and other worldwide anti-bribery
laws.
●
If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud.
●
Failure to comply with health information privacy laws, including Health Insurance Portability and Accountability Act of 1996 (HIPAA) or other U.S. federal or state health information privacy and security laws, as applicable, may negatively impact our
business.
●
If we or our partners fail to comply with the complex federal, state, local and foreign laws and regulations to the extent that apply to our business, we could suffer severe consequences that could materially and adversely affect our operating results and financial condition.
●
A failure to comply with any of federal or state laws to the extent such are applicable to our business, particularly laws related to the elimination of healthcare fraud, may adversely impact our business.
●
We face risks associated with currency exchange rate fluctuations, which could adversely affect our operating
results.
●
Government regulation of genetic research or testing may adversely affect the demand for our services and impair our business and operations.
●
Failure in our information technology systems could significantly increase testing turn-around times or impact on the billing processes or otherwise disrupt our operations.
●
Any significant disruption in service on our website or in our computer or logistics systems, whether due to a failure with our information technology systems or that of a third-party vendor, could harm our reputation and may result in a loss of
customers.
●
Breaches of network or information technology, natural disasters or terrorist attacks could have an adverse impact on our
business.
●
Ethical and other concerns surrounding the use of genetic information may reduce the demand for our
services.
●
Risks associated with our intellectual
property.
●
We rely heavily upon patents and proprietary technology that may fail to protect our
business.
●
We may face difficulties in certain jurisdictions in protecting our intellectual property rights, which may diminish the value of our intellectual property rights in those jurisdictions.
●
Our operations may be adversely affected by the effects of extreme weather conditions or other interruptions in the timely transportation of specimens.
●
Our Consumer Initiated Testing (CIT) Platform will expose us to various
risks.
●
Discontinuation or recalls of existing testing products or our customers using new technologies to perform their own tests could adversely affect our business.
●
The Polygenic Risk Score (PRS) test may not be able to obtain necessary regulatory clearance, and therefore we may not generate any revenue.
●
If the PRS test is required to obtain and maintain FDA approvals, it will be subject to continuing governmental regulations and additional foreign regulations.
●
Declining general economic or business conditions may have a negative impact on our
business.
Risk Related to our
Securities
●
Our ADSs may be delisted from the NASDAQ Capital
Market.
●
Our stock price is volatile and can fluctuate significantly based on events not in our control and general industry conditions. As a result, the value of your investment may decline significantly.
●
The fact that we do not expect to pay cash dividends may lead to decreased prices for our
stock.
●
You may have difficulty in effecting service of legal process and enforcing judgments against us and our
management.
2
●
Because we are not required to provide you with the same information as an issuer of securities based in the United States, you may not be afforded the same protection or information you would have if you had invested in a public corporation based in the United States.
●
As a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from Nasdaq corporate governance listing standards and these practices may afford less protection to shareholders than they would enjoy if we complied fully with Nasdaq corporate governance listing standards.
●
As a result of being a U.S. public company, we are subject to additional regulatory compliance requirements, including Section 404, and if we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud.
●
We will incur significant costs as a result of operating as a company with ADSs that are publicly traded in the United States, and our management will be required to devote substantial time to new compliance initiatives.
●
The dual listing of our ordinary shares and the ADSs may negatively impact the liquidity and value of the
ADSs.
●
Australian takeover laws may discourage takeover offers being made for us or may discourage the acquisition of a significant position in our ordinary shares or ADSs.
●
Our Constitution and Australian laws and regulations applicable to us may adversely affect our ability to take actions that could be beneficial to our shareholders.
●
A lack of significant liquidity for our ADSs may negatively affect your ability to resell our
securities.
●
In certain circumstances, holders of ADSs may have limited rights relative to holders of Ordinary
Shares.
Risk Related to
Taxation
●
We may be classified as a passive foreign investment company, which could result in adverse U.S. federal income tax consequences for U.S. holders.
●
If a United States person is treated as owning at least 10% of our ordinary shares, such holder may be subject to adverse U.S. federal income tax consequences.
●
Changes to tax laws could materially adversely affect our company and reduce net returns to our
shareholders.
●
Tax authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or non-realization of expected benefits.
Risks Related to our
Business
A variety of risks
associated with commercializing our products and product candidates internationally could
materially
adversely affect our
business.
We, or
our licensing partners, may seek regulatory approval for our products or product candidates in multiple jurisdictions, accordingly, we
expect that we will be subject to additional risks for our products and product candidates related to operating in foreign countries if
we obtain the necessary approvals, including:
●
differing regulatory requirements in foreign
countries;
●
the potential for so-called parallel importing, when a local seller, faced with high or higher local prices, opts to import goods from a foreign market (with low or lower prices) rather than buying them locally;
●
unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;
●
economic weakness, including inflation, or political instability in particular foreign economies and markets;
●
compliance with tax, employment, immigration and labor laws for employees living or traveling
abroad;
●
foreign taxes, including withholding of payroll
taxes;
●
foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;
●
difficulties staffing and managing foreign
operations;
●
workforce uncertainty in countries where labor unrest is more common than in Australia or the
U.S.;
●
challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as in Australia or the U.S.;
●
production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
●
business interruptions resulting from geo-political actions, including war and
terrorism.
These
and other risks associated with our or our licensing partners' international operations may materially adversely affect our ability
to attain or maintain profitable operations.
3
Our Company has a history of incurring
losses.
We have
incurred operating losses in every year since the year ended June 30, 2011. As at June 30, 2023, the Company had accumulated losses of
A$156,715,687 and the extent of any future losses and whether or not the Company can generate profits in future years remains uncertain.
The Company currently does not generate sufficient revenue to cover its operating expenses. We expect our capital outlays and operating
expenditures to remain constant for the foreseeable future as we continue to focus on R&D and new product development, IP creation
and the introduction of predictive genetic testing products. If we fail to generate sufficient revenue and eventually become profitable,
or if we are unable to fund our continuing losses by raising additional financing when required, our shareholders could lose all or part
of their investments.
We
may not be successful in expanding our revenues, and therefore improving operational profitability, of the recently acquired EasyDNA and
AffinityDNA businesses or achieve significant commercial sales of the portfolio to our next generation of geneType risk assessment tests.
Although
GTG have recently achieved a significant increase in product revenues, which are largely attributable to the recently acquired EasyDNA
and AffinityDNA businesses and the Company has recently developed, launched and marketed our geneType Multi- risk test, we believe that
our future success is dependent upon our ability to grow revenues from our existing product offerings and to successfully introduce and
sell our newly developed products including our innovative hereditary breast and ovarian cancer test, due for launch in financial year
2024. Although we believe that we now have world class products that are poised to be an important part of making predictive genetic testing
a mainstream healthcare activity, we may not be successful in transitioning from our existing products to these products, and there can
be no assurance that the demand for these new products will develop. Furthermore, we plan to introduce our new products to healthcare
providers through a global network of distribution partners instead of through our own sales force. Although we believe that we are building
worthwhile sales and distribution relationships with experienced distribution firms, there can be no assurance that we will be able to
enter into distribution arrangements on terms satisfactory to us, and that our marketing strategy will be successful and result in significant
revenues.
Our products may never achieve
significant market
acceptance.
We may
expend substantial funds and management effort on the development and marketing of our predictive genetic testing
products
with no assurance that we will be successful in selling our products or services. Our ability to enter into distribution arrangements
to successfully sell our molecular risk assessment and predictive genetic testing products and services will depend significantly
on the perception that our products and services can reduce patient risk and improve medical outcomes, and that our products and services
are superior to existing tests. Our business could also be adversely affected if we expend money without any return.
We
face additional risks as a result of the EasyDNA and AffinityDNA acquisitions. We may be unable to integrate our businesses successfully
and realize the anticipated synergies and related benefits of these acquisitions or do so within our anticipated timeframes. Including:
●
difficulties in integrating and managing the combined operations of EasyDNA and AffinityDNA, and realizing the anticipated economic, operational, and other benefits in a timely manner, which could result in substantial costs and delays or other operational, technical, or financial problems;
●
disruptions to the EasyDNA and AffinityDNA businesses and their operations and relationships with service providers and other third parties;
●
loss of key employees of EasyDNA and AffinityDNA and other challenges associated with integrating new employees into our culture, as well as reputational harm if integration is not successful;
●
diversion of management time and focus from operating our business to addressing the EasyDNA and AffnityDNA operations integration challenges;
●
diversion of significant resources from the ongoing development of our existing products, services, and
operations;
●
failure to successfully realize our intended business
strategy;
●
increase in the operating losses that we expect to incur in future
periods;
●
regulatory complexities of integrating or managing the combined operations or expanding into other industries or parts of the healthcare industry;
●
regulatory developments or enforcement trends focusing on corporate practice of
medicine;
●
greater than anticipated costs related to the integration of the EasyDNA and AffinityDNA businesses and
operations;
●
increase in compliance and related costs associated with the addition of a regulated
business;
4
●
responsibility for the liabilities of EasyDNA and AffinityDNA, including those that were not disclosed to us or exceed our estimates, as well as, without limitation, liabilities arising out of their failure to maintain effective data protection and privacy practices controls and comply with applicable regulations; and
●
potential accounting charges to the extent intangibles recorded in connection with the EasyDNA and AffinityDNA acquisitions, such as goodwill, trademarks, client relationships, or intellectual property, are later determined to be impaired and written down in value.
Failure
to demonstrate the clinical utility of our geneType products could have a material adverse effect on our financial condition and results
of operations.
The Company
believes that its current GeneType risk assessment tests, along with the pipeline of new tests for additional disease indications under
development have the capacity to transform health outcomes for entire populations. However, it is critical for the Company to demonstrate
the clinical utility of its new products at scale. Clinical utility is the usefulness of a test for clinical practice. If the Company
is unable to demonstrate clinical utility, or if the data is deemed insufficient to validate utility, there may be insufficient demand
for the Company's products.
If our competitors develop superior
products, our operations and financial condition could be
affected.
We are
currently subject to increased competition from biotechnology and diagnostic companies, academic and research institutions and government
or other publicly-funded agencies that are pursuing products and services which are substantially similar to our molecular risk assessment
testing products, or which otherwise address the needs of our customers and potential customers.
Our competitors
in the predictive genetic testing and assessment market include private and public sector enterprises located in Australia, the U.S. and
elsewhere. Many of the organizations competing with us are much larger and have more ready access to needed
resources.
In particular, they would have greater experience in the areas of finance, research and development, manufacturing, marketing,
sales,
distribution, technical and regulatory matters than we do. In addition, many of the larger current and potential competitors have already
established name / brand recognition and more extensive collaborative relationships.
Our competitive
position in the molecular risk assessment and predictive testing area is based upon, amongst other things, our ability to:
●
continue to strengthen and maintain scientific credibility through the process of obtaining scientific validation through clinical trials supported by peer-reviewed publication in medical journals;
●
create and maintain scientifically advanced technology and offer proprietary products and
services;
●
continue to strengthen and improve the messaging regarding the importance and value that our cancer risk assessment tests provide to patients and physicians;
●
diversify our product offerings in disease
types;
●
obtain and maintain patent or other protection for our products and
services;
●
obtain and maintain required government approvals and other accreditations on a timely basis;
and
●
successfully market our products and
services.
If we
are not successful in meeting these goals, our business could be adversely affected. Similarly, our competitors may succeed in developing
technologies, products or services that are more effective than any that we are developing or that would render our technology, products
and services obsolete, noncompetitive or uneconomical.
We have important relationships
with external parties over whom we have limited
control.
We have
relationships with academic consultants, research collaborators at other institutions and other advisers who are not employed by us. Accordingly,
we have limited control over their activities and can expect only limited amounts of their time to be dedicated to our activities. These
persons may have consulting, employment or advisory arrangements with other entities that may conflict with or compete with their obligations
to us. Our consultants typically sign agreements that provide for confidentiality of our proprietary information and results of studies.
However, we may not be able to maintain the confidentiality of our technology, the dissemination of which could hurt our competitive position
and results of operations. To the extent that our scientific consultants, collaborators or advisors develop inventions or processes that
may be applicable to our proposed products, disputes may arise as to the ownership of the proprietary rights to such information, and
we may not be successful with any dispute outcomes.
5
We may be subject to liability
and our insurance may not be sufficient to cover
damages.
Our business
exposes us to potential liability risks that are inherent in the testing, manufacturing, marketing and sale of molecular risk assessment
and predictive tests. The use of our products and product candidates, whether for clinical trials or commercial sale, may expose us to
professional and product liability claims and possible adverse publicity. We may be subject to claims resulting from incorrect results
of analysis of genetic variations or other screening tests performed using our products. Litigation of such claims could be costly. Further,
if a court were to require us to pay damages to a plaintiff, the amount of such damages could be significant and severely damage our financial
condition. Although we have public and product liability insurance coverage under broad form liability and professional indemnity policies,
the level or breadth of our coverage may not be adequate to fully cover any potential liability claims. In addition, we may not be able
to obtain additional liability coverage in the future at an acceptable cost. A successful claim or series of claims brought against us
in excess of our insurance coverage and the effect of professional and/or product liability litigation upon the reputation and marketability
of our technology and products, together with the diversion of the attention of key personnel, could negatively affect our business.
Security
breaches, privacy issues, loss of data and other incidents could compromise sensitive or personal information related to our business
or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.
In the
ordinary course of our business, we collect and store sensitive data, including Protected Health Information, (PHI), personally identifiable
information, genetic information, credit card information, intellectual property and proprietary business information owned or controlled
by ourselves or our customers, payers and other parties. We manage and maintain our applications and data utilizing a combination of on-site
systems, managed data center systems and cloud-based systems. We also communicate PHI and other sensitive patient data through our various
customer tools and platforms. In addition to storing and transmitting sensitive data that is subject to multiple legal protections, these
applications and data encompass a wide variety of business-critical information including research and development information, commercial
information, and business and financial information. We face a number of risks relative to protecting this critical information, including
loss of access risk, inappropriate disclosure, inappropriate modification, and the risk of our being unable to adequately monitor and
modify our controls over our critical information. Any technical problems that may arise in connection with our data and systems, including
those that are hosted by third-party providers, could result in interruptions to our business and operations or exposure to security vulnerabilities.
These types of problems may be caused by a variety of factors, including infrastructure changes, intentional or accidental human actions
or omissions, software errors, malware, viruses, security attacks, fraud, spikes in customer usage and denial of service issues. In addition,
there has recently been a significant increase in ransomware and cyber security attacks related to the ongoing conflict between Russia
and Ukraine, which could result in substantial harm to internal systems necessary for running our critical operations and revenue generating
services.
The secure
processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy, and
we devote significant resources to protecting such information. Although we take what we believe to be reasonable and appropriate measures,
including a formal, dedicated enterprise security program, to protect sensitive information from various compromises (including unauthorized
access, disclosure, or modification or lack of availability), our information technology and infrastructure may be vulnerable to attacks
by hackers or viruses or breached due to employee error, malfeasance or other disruptions. For example, we have been subject to phishing
incidents in the past, and we may experience additional incidents in the future. Any such breach or interruption could compromise our
networks, and the information stored therein could be accessed by unauthorized parties, altered, publicly disclosed, lost or stolen.
Unauthorized
access, loss or dissemination could also disrupt our operations (including our ability to conduct our analyses, provide test results,
bill payers or patients, process claims and appeals, provide customer assistance, conduct research and development
activities,
collect, process and prepare company financial information, provide information about our tests and other patient and physician
education
and outreach efforts through our website, and manage the administrative aspects of our business) and damage our reputation, any of which
could adversely affect our business.
In addition
to data security risks, we also face privacy risks. Should we actually violate, or be perceived to have violated, any privacy commitments
we make to patients or consumers, we could be subject to a complaint from an affected individual or interested privacy regulator, such
as the FTC, a state Attorney General, an EU Member State Data Protection Authority, or a data protection authority in another international
jurisdiction. This risk is heightened given the sensitivity of the data we collect.
Any security
compromise that causes an apparent privacy violation could also result in legal claims or proceedings; liability under federal, state,
foreign, or multinational laws that regulate the privacy, security, or breach of personal information, such as but not
limited
to the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology
for
Economic and Clinical Health Act of 2009, or HITECH, state data security and data breach notification laws, the European Union's
General Data Protection Regulation, or GDPR, and the UK Data Protection Act of 2018; and related regulatory penalties. Penalties for failure
to comply with a requirement of HIPAA or HITECH vary significantly, and, depending on the knowledge and culpability of the HIPAA-regulated
entity, may include civil monetary penalties of up to US$1.5 million per calendar year for each provision of
HIPAA
that is violated. A person who knowingly obtains or discloses individually identifiable health information in violation of HIPAA may face
a criminal penalty of up to US$50,000 and up to one-year imprisonment. The criminal penalties increase if the wrongful conduct involves
false pretenses or the intent to sell, transfer or use identifiable health information for commercial advantage, personal gain or malicious
harm. Penalties for unfair or deceptive acts or practices under the FTC Act or state Unfair and Deceptive Acts and Practices, or UDAP,
statutes may also vary significantly.
6
There
has been unprecedented activity in the development of data protection regulation around the world. As a result, the interpretation and
application of consumer, health-related and data protection laws in the United States, Europe and elsewhere are often uncertain, contradictory
and in flux. The GDPR took effect on May 25, 2018. The GDPR applies to any entity established in the EU as well as extraterritorially
to any entity outside the EU that offers goods or services to, or monitors the behavior of, individuals who are located in the EU. The
GDPR imposes strict requirements on controllers and processors of personal data, including enhanced protections for "special categories"
of personal data, which includes sensitive information such as health and genetic information of data subjects. The GDPR also grants individuals
various rights in relation to their personal data, including the rights of access, rectification, objection to certain processing and
deletion. The GDPR provides an individual with an express right to seek legal remedies if the individual believes his or her rights have
been violated. Failure to comply with the requirements of the GDPR or the related national data protection laws of the member states of
the EU, which may deviate from or be more restrictive than the GDPR, may result in significant administrative fines issued by EU regulators.
Maximum penalties for violations of the GDPR are capped at 20M euros or 4% of an organization's annual global revenue, whichever
is greater.
Additionally,
the implementation of GDPR has led other jurisdictions to either amend or propose legislation to amend their existing data privacy and
cybersecurity laws to resemble the requirements of GDPR. For example, on June 28, 2018, California adopted the California Consumer Privacy
Act of 2018, or the CCPA. The CCPA regulates how certain for-profit businesses that meet one or more CCPA applicability thresholds collect,
use, and disclose the personal information of consumers who reside in California. Among other things, the CCPA confers to California consumers
the right to receive notice of the categories of personal information that will be collected by a business, how the business will use
and share the personal information, and the third parties who will receive the personal information. The CCPA also confers rights to access,
delete, or transfer personal information; and the right to receive equal service and pricing from a business after exercising a consumer
right granted by the CCPA. In addition, the CCPA allows California consumers the right to opt out of the "sale" of their personal
information, which the CCPA defines broadly as any disclosure of personal information to a third party in exchange for monetary or other
valuable consideration. The CCPA also requires a business to implement reasonable security procedures to safeguard personal information
against unauthorized access, use, or disclosure. The CCPA does not apply to PHI collected by certain parties subject to HIPAA, or to de-identified
data as defined under HIPAA. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data
breaches resulting from a business's failure to implement and maintain reasonable data security procedures that is expected to increase
data breach litigation. On January 1, 2023, the California Privacy Rights Act, or CPRA, is scheduled to go into effect and will substantially
amend the CCPA. The CPRA would, among other things, amend the CCPA to give California residents the ability to limit the use of their
sensitive information, provide for penalties for CPRA violations concerning California residents under the age of 16, and establish a
new California Privacy Protection Agency to implement and enforce the law.
Virginia,
Colorado, and Utah have recently enacted similar privacy acts, and dozens of other states in the United States are currently considering
similar consumer data privacy laws, which could impact our operations if enacted. Some observers have noted that the CCPA could mark the
beginning of a trend toward more stringent privacy legislation in the United States, which could increase our potential liability and
adversely affect our business, results of operations, and financial condition.
It is
possible the GDPR, CCPA and other emerging United States and international data protection laws may be interpreted and applied in a manner
that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices,
which could adversely affect our business. In addition, these privacy laws and regulations may differ from country to country and state
to state, and our obligations under these laws and regulations vary based on the nature of our activities in the particular jurisdiction,
such as whether we collect samples from individuals in the local jurisdiction, perform testing in the local jurisdiction, or process personal
information regarding employees or other individuals in the local jurisdiction. Complying with these various laws and regulations could
cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our
business. We can provide no assurance that we are or will remain in compliance with diverse privacy and data security requirements in
all of the jurisdictions in which we do business. Failure to comply with privacy and data security requirements could result in a variety
of consequences, including civil or criminal penalties, litigation, or damage to our reputation, any of which could have a material adverse
effect on our business.
7
We
use potentially hazardous materials, chemicals and patient samples in our business and any disputes relating to improper handling, storage
or disposal of these materials could be time consuming and costly.
Our research
and development, production and service activities involve the controlled use of hazardous laboratory materials and chemicals, including
small quantities of acid and alcohol, and fluid (i.e. saliva, blood) as well as tissue samples from customers. We do not knowingly deal
with infectious samples. We, our collaborators and service providers are subject to stringent Australian
federal,
state and local laws and regulations governing occupational health and safety standards, including those governing the use, storage, handling
and disposal of these materials and certain waste products. However, we could be liable for accidental contamination or discharge or any
resultant injury from hazardous materials, and conveyance, processing, and storage of and data on patient samples. If we, our collaborators
or service providers fail to comply with applicable laws or regulations, we could be required to pay penalties or be held liable for any
damages that result and this liability could exceed our financial resources. Further, future changes to environmental health and safety
laws could cause us to incur additional expense or restrict our operations.
In addition,
our collaborators and service providers may be working with these same types of hazardous materials, including hazardous chemicals, in
connection with our collaborations. In the event of a lawsuit or investigation, we could be held responsible for any injury caused to
persons or property by exposure to, or release of, these hazardous materials or customer samples that may contain infectious materials.
The cost of this liability could exceed our resources. While we maintain broad form liability insurance coverage for these risks, the
level or breadth of our coverage may not be adequate to fully cover potential liability claims.
Our
industry is subject to rapidly changing technology and new and increasing amounts of scientific data related to genes and genetic variants
and their role in disease.
Our failure
to develop tests to keep pace with these changes could make us obsolete. In recent years, there have been numerous advances in methods
used to analyze very large amounts of genomic information and the role of genetics and gene variants in disease and treatment therapies.
Our industry has and will continue to be characterized by rapid technological change, increasingly larger amounts of data, frequent new
testing service introductions and evolving industry standards, all of which could make our tests obsolete. Our future success will also
depend on our ability to keep pace with the evolving needs of our customers on a timely and cost-effective basis and to pursue new market
opportunities that develop as a result of technological and scientific advances. Our tests could become obsolete and our business adversely
affected unless we continually update our offerings to reflect new scientific knowledge about genes and genetic variations and their role
in diseases and treatment therapies.
We
depend on the collaborative efforts of our academic and corporate partners for research, development and commercialization of our products.
A breach by our partners of their obligations, or the termination of the relationship, could deprive us of valuable resources and require
additional investment of time and money.
Our strategy
for research, development and commercialization of our products has historically involved entering into various arrangements with academic,
corporate partners and others. As a result, the success of our strategy depends, in part, upon the strength of those relationships and
these outside parties undertaking their responsibilities and performing their tasks to the best of their ability and responding in a timely
manner. Our collaborators may also be our competitors. We cannot necessarily control the amount and timing of resources that our collaborators
devote to performing their contractual obligations and we have no certainty that these parties will perform their obligations as expected
or that any revenue will be derived from these arrangements.
If our
collaborators breach or terminate their agreement with us or otherwise fail to conduct their collaborative activities in a timely manner,
the development or commercialization of the product candidate or research program under such collaborative arrangement may be delayed.
If that is the case, we may be required to undertake unforeseen additional responsibilities or to devote unforeseen additional funds or
other resources to such development or commercialization, or such development or commercialization could be terminated. The termination
or cancellation of collaborative arrangements could adversely affect our financial condition, intellectual property position and general
operations. In addition, disagreements between collaborators and us could lead to delays in the collaborative research, development, or
commercialization of certain products or could require or result in formal legal process or arbitration for resolution. These consequences
could be time-consuming and expensive and could have material adverse effects on the
Company.
We rely
upon scientific, technical and clinical data supplied by academic and corporate collaborators, licensors, licensees, independent contractors
and others in the evaluation and development of potential therapeutic methods. There may be errors or omissions in this data that would
materially adversely affect the development of these methods.
If our sole
laboratory facility becomes inoperable, we may be unable to perform our tests and our business will be
harmed.
We rely
heavily upon our sole laboratory facilities in Melbourne, Australia, which has been certified under the U.S. CLIA. Our current lease of
laboratory premises expires February 28, 2025. The facility and the equipment we use to perform our tests would be costly to replace and
could require substantial lead time to repair or replace. If we were to lose our CLIA certification or other required certifications or
licenses, or if the facility is harmed or rendered inoperable by natural or man-made disasters, including flooding and power outages,
it will be difficult or impossible for us to perform our tests for some period of time. The inability to perform our tests or the backlog
of tests that could develop if our facility is inoperable for even a short period of time may result in the loss of customers or harm
our reputation, and we may be unable to regain those customers in the future.
8
If we
no longer had our own facility and needed to rely on a third party to perform our tests, we could only use another facility with established
state licensure and CLIA accreditation. We cannot assure you that we would be able to find another CLIA
certified
facility willing to comply with the required procedures, that this laboratory would be willing to perform the tests on commercially reasonable
terms, or that it would be able to meet our quality standards. In order to establish a redundant clinical reference laboratory facility,
we would have to spend considerable time and money securing adequate space, constructing the facility, recruiting and training employees,
and establishing the additional operational and administrative infrastructure necessary to support a second facility. We may not be able,
or it may take considerable time, to replicate our testing processes or results in a new facility. Additionally, any new clinical reference
laboratory facility would be subject to certification under CLIA and licensing by several states, including California and New York, which
could take a significant amount of time and result in delays in our ability to begin operations.
The
loss of key members of our senior management team or our inability to attract and retain highly skilled scientists, clinicians and salespeople
could adversely affect our business.
Our success
depends largely on the skills, experience and performance of key members of our executive management team and others in key management
positions. The efforts of each of these persons together will be critical as we continue to develop our technologies and testing processes,
continue our international expansion and transition to a company with multiple commercialized products. If we were to lose one or more
of these key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business
strategies.
Our research
and development programs and commercial laboratory operations depend on our ability to attract and retain highly skilled scientists and
technicians, including licensed laboratory technicians, chemists, biostatisticians and engineers. We may not be able to attract or retain
qualified scientists and technicians in the future due to the competition for qualified personnel among life science businesses. In addition,
if there were to be a shortage of clinical laboratory scientists in coming years, this would make it more difficult to hire sufficient
numbers of qualified personnel. We also face competition from universities and public and private research institutions in recruiting
and retaining highly qualified scientific personnel. Our success also depends on our ability to attract and retain salespeople with extensive
experience in oncology and have close relationships with medical oncologists, pathologists and other hospital personnel. We may have difficulties
sourcing, recruiting or retaining qualified salespeople, which could cause delays or a decline in the rate of adoption of our tests. If
we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that
could adversely affect our ability to support our research and development and sales programs.
Changes in
the way that the FDA regulates our tests could result in the delay or additional expense in offering our tests and tests that we may develop
in the future.
Historically,
the U.S. Food and Drug Administration ("FDA") has exercised enforcement discretion with respect to most Laboratory Developed
Tests ("LDTs") and has not required laboratories that furnish LDTs to comply with the agency's requirements for medical
devices (e.g., establishment registration, device listing, quality systems regulations, premarket clearance or premarket approval, and
post-market controls). In recent years, however, the FDA publicly announced its intention to regulate certain LDTs and issued two draft
guidance documents that set forth a proposed phased-in risk-based regulatory framework that would apply varying levels of FDA oversight
to LDTs. However, these guidance documents were withdrawn at the end of the Obama administration and replaced by an informal discussion
paper reflecting some of the feedback that FDA had received on LDT regulation. The FDA acknowledged that the discussion paper in January
2017 does not represent the formal position of the FDA and is not enforceable. Nevertheless, the FDA wanted to share its synthesis of
the feedback that it had received in the hope that it might advance public discussion on future LDT oversight. Notwithstanding the discussion
paper, the FDA continues to exercise enforcement discretion and may decide to regulate certain LDTs on a case-by-case basis at any time,
which could result in delay or additional expense in offering our tests and tests that we may develop in the future.
As a
matter of policy, the FDA generally does not review Direct-to-Consumer LDTs that are created and performed in a single laboratory, if
they are offered to patients only when prescribed by a health care provider.
Legislative
proposals addressing the FDA's oversight of LDTs have been introduced in the current and previous Congresses, and we expect that
new legislative proposals will be introduced from time-to-time. On May 17, 2022, the Senate Health, Education, Labor and Pensions (HELP)
Committee released an FDA user fees reauthorization legislative package, which incorporates contents from the Verifying Accurate Leading-edge
IVCT Development (VALID) Act that would establish a new category of in vitro clinical tests (IVCTs) comprised of traditional in vitro
diagnostics and LDTs, and grant the FDA authority to review and approve them pre-market. Such arrangement increased the likelihood for
Congress to pass a legislation that will give the FDA clear authority to regulate LDTs, but the eventual result is difficult to predict
at this time.
If
the FDA ultimately regulates certain LDTs, whether via final guidance, final regulation, or as instructed by Congress, our tests may be
subject to certain additional regulatory requirements. Complying with the FDA's requirements can be expensive, time-consuming,
and
subject us to significant or unanticipated delays. Insofar as we may be required to obtain premarket clearance or approval to perform
or continue performing an LDT, we cannot assure you that we will be able to obtain such authorization. Even if we obtain regulatory clearance
or approval where required, such authorization may not be for the intended uses that we believe are commercially attractive or are critical
to the commercial success of our tests. As a result, the application of the FDA's requirements to our tests could materially and
adversely affect our business, financial condition, and results of
operations.
9
Our
business could be harmed from the loss or suspension of a license or imposition of a fine or penalties under, or future changes in, or
changing interpretations of, CLIA or state laboratory licensing laws to which we are subject.
The clinical
laboratory testing industry is subject to extensive federal and state regulation. The regulations implementing CLIA set out federal regulatory
standards that apply to virtually all clinical laboratories operating in the U.S. (regardless of the location, size or type of laboratory),
including those operated by physicians in their offices, by requiring that they be certified by the federal government or by a federally
approved accreditation agency. CLIA is a U.S. federal law regulating clinical laboratories that perform testing on specimens derived from
humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA is intended to ensure the
quality and reliability of clinical laboratories in the U.S. by mandating specific standards in the areas of personnel qualifications,
administration, and participation in proficiency testing, patient test management, quality control, quality assurance and
inspections.
Certain
US States also require state laboratory licenses in order to test specimens received from patients residing in those states or requests
received from ordering physicians in those states. We currently hold out-of-state laboratory licenses in California, New York, Maryland,
Rhode Island, and Pennsylvania.
Further,
CLIA does not pre-empt state law, which in some cases may be more stringent than federal law and require additional personnel qualifications,
quality control, record maintenance and proficiency testing. The sanction for failure to comply with CLIA and state requirements may be
suspension, revocation or limitation of a laboratory's CLIA certificate, which is necessary to conduct business, as well as significant
fines, civil and criminal penalties, the imposition of directed plan of correction, and on-site monitoring. If we were to be found out
of compliance with CLIA program requirements and subjected to sanctions, our business and reputation could be harmed. Several states have
similar laws, and we may be subject to similar penalties. If the CLIA certification of one laboratory owned by the Company is suspended
or revoked that may preclude the Company from owning or operating any other CLIA regulated laboratory for two years. Further, even if
it were possible for us to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue
in doing so.
We cannot
assure you that applicable statutes and regulations will not be interpreted or applied by a prosecutorial, regulatory or judicial authority
in a manner that would adversely affect our business. Potential sanctions for violation of these statutes and regulations include significant
fines and the suspension or loss of various licenses, certificates and authorizations, which could have a material adverse effect on our
business. In addition, compliance with future legislation could impose additional requirements on us, which may be costly.
Failure
to establish and comply with appropriate quality standards to assure that the highest level of quality is observed in the performance
of our testing services and in the design, manufacture and marketing of our products could adversely affect the results of our operations
and adversely impact our reputation.
The
provision of clinical testing services, and the design, manufacture and marketing of diagnostic products involve certain inherent risks.
The services that we provide and the products that we design, manufacture and market are intended to provide information for healthcare
providers in providing patient care. Therefore, users of our services and products may have a greater sensitivity to errors than the users
of services or products that are intended for other purposes. Similarly, negligence in performing our services can lead to injury or other
adverse events. We may be sued under common law, physician liability or other liability law for acts or omissions by our laboratory personnel.
We are subject to the attendant risk of substantial damages awards and risk to our reputation.
We could be adversely affected
by violations of the FCPA and other worldwide anti-bribery
laws.
We are
subject to the FCPA, which prohibits companies and their intermediaries from making payments in violation of law to non-U.S. government
officials for the purpose of obtaining or retaining business or securing any other improper advantage. We are increasing our direct sales
and operations personnel outside the United States, in which we have limited experience. We use a limited number of independent distributors
to sell our tests internationally, which requires a high degree of vigilance in maintaining our policy against participation in corrupt
activity, because these distributors could be deemed to be our agents, and we could be held responsible for their actions. Other U.S.
companies in the medical device and pharmaceutical fields have faced criminal penalties under the FCPA for allowing their agents to deviate
from appropriate practices in doing business with these individuals. We are also subject to similar anti- bribery laws in the jurisdictions
in which we operate, including anti-bribery laws in Australia which also prohibits commercial bribery and makes it a crime for companies
to fail to prevent bribery. These laws are complex and far-reaching in nature, and, as a result, we cannot assure you that we would not
be required in the future to alter one or more of our practices to be in compliance with these laws or any changes in these laws or the
interpretation thereof. Any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant
management distraction, involve significant costs and expenses, including legal fees, and could result in a material adverse effect on
our business, prospects, financial condition or results of operations. We could also incur severe penalties, including criminal and civil
penalties, disgorgement and other remedial measures.
10
If
we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial
results or prevent fraud.
Effective
internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure
controls and procedures, are designed to prevent fraud. Any failure to design and implement an effective system of internal control may
reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses. Ineffective internal
controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the
trading price of the ADSs and our Ordinary Shares.
As of
June 30, 2020, we had identified a material weakness in our internal control over financial reporting in relation to segregation of duties.
Such material weakness was remedied as of June 30, 2021.
As of
June 30, 2023, our Chief Executive Officer and Chief Financial Officer assessed the effectiveness of our internal control over financial
reporting. We did not identify any material weakness in our internal control over financial reporting during the year. However, we cannot
assure you that the measures we have taken to date, and actions we may take in the future, will be sufficient to prevent potential future
material weaknesses.
Failure
to comply with health information privacy laws, including HIPAA or other U.S. federal or state health information privacy and security
laws, as applicable, may negatively impact our business.
Pursuant
to the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information
Technology
for Economic and Clinical Health Act of 2009, or HITECH, covered entities (including health plans, healthcare clearinghouses,
and
certain healthcare providers), as well as their respective "business associates" that create, receive, maintain or transmit
individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security
and transmission of individually identifiable health information. Individuals and entities who are subject to HIPAA must comply with comprehensive
privacy and security standards with respect to the use and disclosure of protected health information, as well as standards for electronic
transactions, including specified transaction and code set rules. Under HITECH, HIPAA was expanded, including requirements to provide
notification of certain identified data breaches, direct patient access to laboratory records, the extension of certain HIPAA privacy
and security standards directly to business associates, and heightened penalties for noncompliance, and enforcement efforts. Failure to
comply with HIPAA or other U.S. federal and state health information privacy and security laws, as applicable, could result in significant
penalties
If
we or our partners fail to comply with the complex federal, state, local and foreign laws and regulations to the extent that apply to
our business, we could suffer severe consequences that could materially and adversely affect our operating results and financial condition.
Our operations are subject
to extensive federal, state, local and foreign laws and regulations, all of which are subject to
change.
The
U.S. laws and regulations that may apply to our business include, among other
things:
●
CLIA, which requires that laboratories obtain certification from the federal government, and state licensure
laws;
●
FDA laws and
regulations;
●
HIPAA, which imposes comprehensive federal standards with respect to the privacy and security of protected health information and requirements for the use of certain standardized electronic transactions; amendments to HIPAA under HITECH, which strengthen and expand HIPAA privacy and security compliance requirements, increase penalties for violators, extend enforcement authority to state attorneys general and impose requirements for breach notification;
●
state laws regulating genetic testing and protecting the privacy of genetic test results, as well as state laws protecting the privacy and security of health information and personal data and mandating reporting of breaches to affected individuals and state regulators;
●
federal and state fraud and abuse laws, such as false claims and anti-kickback laws, and prohibitions on self-
referral;
●
Section 216 of the federal Protecting Access to Medicare Act of 2014 ("PAMA"), which requires applicable laboratories to report private payer data in a timely and accurate manner;
●
state laws that impose reporting and other compliance-related requirements;
and
●
similar foreign laws and regulations that apply to us in the countries in which we
operate.
These
laws and regulations are complex and are subject to interpretation by the courts and by government agencies. Our failure to comply could
lead to significant administrative civil or criminal penalties, exclusion from participation in state and federal health care programs,
imprisonment, disgorgement, and prohibitions or restrictions on our laboratory's ability to provide or receive payment for our services.
We believe that we are in material compliance with all statutory and regulatory requirements that apply to us, but there is a risk that
one or more government agencies could take a contrary position, or that a private, party could file suit under the qui tam
provisions
of the federal False Claims Act or a similar state law. Such occurrences, regardless of their outcome, could damage our reputation and
adversely affect important business relationships with third parties, including managed care organizations, and other private third-party
payers.
11
A
failure to comply with any of federal or state laws to the extent such are applicable to our business, particularly laws related to the
elimination of healthcare fraud, may adversely impact our business.
The
healthcare industry is subject to changing political, economic, and regulatory influences that may affect our business. During the past
several years, the healthcare industry has been subject to an increase in governmental regulation and subject to potential disruption
due to legislative initiatives and government regulation, as well as judicial interpretations thereof. While these regulations may not
directly impact us or our offerings in every instance, they will affect the healthcare industry as a whole and may impact patient use
of our services. We currently accept payments only from our customers not any third-party payers, such as government healthcare programs
or health insurers. Because of this approach, we are not subject to many of the laws and regulations that impact many other participants
in the healthcare industry.
If the
government asserts broader regulatory control over companies like ours or if we determine that we will change our business model and accept
payment from and/or participate in third-party payer programs, the complexity of our operations and our compliance obligations will materially
increase. Failure to comply with any applicable federal, state, and local laws and regulations could have a material adverse effect on
our business, financial condition, and results of operations.
While
we seek to conduct our business in compliance with all applicable healthcare laws and regulations, regulatory or law enforcement authorities
may not agree with our interpretation of these laws and regulations and may seek to enforce legal remedies or penalties against us for
violations. Any action brought against us for violation of these or other laws or regulations, even if we
successfully
defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation
of
our business. If our operations are found to be in violation of any of the federal, state, fraud and abuse or other healthcare laws and
regulations that apply to us, we may be subject to penalties, including significant criminal, civil, and administrative penalties, damages
and fines, disgorgement, additional reporting requirements and oversight, and imprisonment for individuals, as well as contractual damages
and reputational harm. We could also be required to curtail or cease our operations. Any of the foregoing consequences could seriously
harm our business and our financial results. From time to time we may need to change our operations, particularly pricing or billing practices,
in response to changing interpretations of these laws and regulations or regulatory or judicial determinations with respect to these laws
and regulations. These occurrences, regardless of their outcome, could damage our reputation and harm important business relationships
that we have with healthcare providers, payers and others.
We face risks associated with currency
exchange rate fluctuations, which could adversely affect our operating
results.
We receive a portion of our revenues
and pay a portion of our expenses in currencies other than the Australian dollar, such as the U.S. dollar, the Euro and the British pound.
As a result, we are at risk for exchange rate fluctuations between such foreign currencies and the Australian dollar, which could affect
the results of our operations. If the Australian dollar strengthens against foreign currencies, the translation of these foreign currency
denominated transactions will result in decreased revenues and operating expenses. We may not be able to offset adverse foreign currency
impact with increased revenues. Other than holding foreign currency bank accounts in which revenues from foreign currency denominated
sales are held, offering a natural hedge against some foreign currency expenditures, we do not currently utilize other hedging
strategies to mitigate foreign currency risk. Even if we were to implement hedging strategies to mitigate foreign currency risk, these
strategies might not eliminate our total exposure to foreign exchange rate fluctuations and would involve costs and risks of their own,
such as ongoing management time and expertise, external costs to implement the strategies and potential accounting implications.
Government
regulation of genetic research or testing may adversely affect the demand for our services and impair our business and operations.
In addition
to the regulatory framework governing healthcare, genetic research and testing has been the focus of public attention and regulatory scrutiny.
From time to time, federal, state and/or local governments adopt regulations relating to the conduct of genetic research and genetic testing.
In the future, these regulations could limit or restrict genetic research activities as well as genetic testing for research or clinical
purposes. In addition, if such regulations are adopted, these regulations may be inconsistent with, or in conflict with, regulations adopted
by other government bodies. Regulations relating to genetic research activities could adversely affect our ability to conduct our research
and development activities. Regulations restricting genetic testing could adversely affect our ability to market and sell our products
and services. Accordingly, any regulations of this nature could increase the costs of our operations or restrict our ability to conduct
our testing business.
12
Failure
in our information technology systems could significantly increase testing turn-around times or impact on the billing processes or otherwise
disrupt our operations.
Our
laboratory operations depend, in part, on the continued performance of our information technology systems. Our information
technology
systems are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptions. Sustained system failures
or interruption of our systems in our laboratory operations could disrupt our ability to process laboratory requisitions, perform testing,
and provide test results in a timely manner and/or billing process. Failure of our information technology systems could adversely affect
our business and financial condition.
Any
significant disruption in service on our website or in our computer or logistics systems, whether due to a failure with our information
technology systems or that of a third-party vendor, could harm our reputation and may result in a loss of customers.
Customers
purchase and access our services through our websites. Our reputation and ability to attract, retain and serve our customers, patients,
and members is dependent upon the reliable performance of our website, network infrastructure and content delivery processes. Interruptions
in any of these systems, whether due to system failures, computer viruses or physical or electronic break-ins, could affect the security
or availability of our website, including our databases, and prevent our customers, patients, and members from accessing and using our
services.
Our
systems and operations are also vulnerable to damage or interruption from fire, flood, power loss, telecommunications failure, terrorist
attacks, acts of war, electronic and physical break-ins, earthquake and similar events. For example, our headquarters are located in Melbourne,
Australia where increased bush fire and flood activity has recently been experienced. In the event of any catastrophic failure involving
our website, we may be unable to serve our web traffic. In addition, our sole laboratory in Melbourne, Australia is responsible for a
significant portion of our operations of our geneType risk assessment tests, these operations would be materially disrupted in the event
any of these events were to occur. The occurrence of any of the foregoing risks could result in damage to our systems or could cause them
to fail completely, and our insurance may not cover such risks or may be insufficient to compensate us for losses that may occur.
Additionally,
our business model is dependent on our ability to deliver kits to customers and have kits processed and returned to us. This requires
coordination between our logistics providers and third-party shipping services. Operational disruptions may be caused by factors outside
of our control such as hostilities, political unrest, terrorist attacks, natural disasters, pandemics (such as COVID-19) and public health
emergencies, affecting the geographies where our operations and customers are located. We may not be effective at preventing or mitigating
the effects of such disruptions, particularly in the case of a catastrophic event. In addition, operational disruptions may occur during
the holiday season, causing delays or failures in deliveries of our kits. Any such disruption may result in lost revenues, a loss of customers
and reputational damage, which would have an adverse effect on our business, results of operations and financial condition.
Breaches
of network or information technology, natural disasters or terrorist attacks could have an adverse impact on our
business.
Cyber-attacks
or other breaches of information technology security, natural disasters, or acts of terrorism or war may result in hardware failure or
disrupt our product testing or research and development activities. There has been a substantial increase in frequency of successful and
unsuccessful cyber-attacks on companies in recent years. Such an event may result in our inability, or the inability of our collaborative
partners, to operate the facilities to conduct and complete the necessary activities, which even if the event is for a limited period
of time, may result in significant expenses and/ or significant damage or delay to our commercial or research activities. While we maintain
insurance cover for some of these events, the potential liabilities associated with these events could exceeded the cover we maintain.
Ethical and other concerns surrounding
the use of genetic information may reduce the demand for our
services.
Public
opinion regarding ethical issues related to the confidentiality and appropriate use of genetic testing may influence government authorities
to call for limits on, or regulation of the use of, genetic testing. In addition, such authorities could prohibit testing for genetic
predisposition to certain conditions, particularly for those that have no known cure. Furthermore, adverse publicity or public opinion
relating to genetic research and testing, even in the absence of any governmental regulation, could reduce the potential markets for our
products and services.
Risks associated with our intellectual
property.
The
patenting of genes and issues surrounding access to genetic knowledge are the subjects of extensive and ongoing public debate in many
countries. By way of example, the Australian Law Reform Commission has previously conducted two inquiries into the social uses of genetic
information. The patents we hold in respect of "non-coding" DNA have broad scope and have also been the subject of debate
and some criticism in the media. Individuals or organizations, in any one of the countries in which these patents have issued, could take
legal action to seek their amendment, revocation or invalidation, something which has happened previously, on several occasions in various
jurisdictions, though we have prevailed in all such cases. Furthermore, any time that we initiate legal action against parties that infringe
our patents we face a risk that the infringer will defend itself through a counterclaim of patent invalidity or other such claims. Subsequent
legal action could potentially overturn, invalidate or limit the scope of our patents.
13
We rely heavily upon patents and proprietary
technology that may fail to protect our
business.
We rely
upon our portfolio of patent rights, patent applications and exclusive licenses to patents and patent applications relating to genetic
technologies. We expect to aggressively patent and protect our proprietary technologies. However, we cannot be certain that any additional
patents will be issued to us because of our domestic or foreign patent applications or that any of our patents will withstand challenges
by others. Patents issued to, or licensed by us may be infringed or third parties may independently develop the same or similar technologies.
Similarly, our patents may not provide us with meaningful protection from competitors, including those who may pursue patents which may
prevent, limit or interfere with our products or which may require licensing and the payment of significant fees or royalties by us to
such third parties in order to enable us to conduct our business. We may sue or be sued by third parties regarding our patents and other
intellectual property rights. These suits are often costly and would divert valuable funds, time and technical resources from our operations
and cause a distraction to management.
We also
rely upon unpatented proprietary technologies and databases. Although we require employees, consultants and collaborators to sign confidentiality
agreements, we may not be able to adequately protect our rights in such unpatented proprietary technologies and databases, which could
have a material adverse effect on our business. For example, others may independently develop substantially equivalent proprietary information
or techniques or otherwise gain access to our proprietary technologies or disclose our technologies to our competitors.
We
may face difficulties in certain jurisdictions in protecting our intellectual property rights, which may diminish the value of our intellectual
property rights in those jurisdictions.
The
laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States and
Australia
and many companies have encountered significant difficulties in protecting and defending such rights in such other jurisdictions.
If
we or our collaboration partners encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual
property rights for our business in such jurisdictions, the value of those rights may be diminished and we may face additional competition
from others in those jurisdictions. In addition, many countries limit the enforceability of patents against governments agencies or government
contractors. In those countries, the patent owner may have limited remedies, which could materially diminish the value of such patent.
Our
operations may be adversely affected by the effects of extreme weather conditions or other interruptions in the timely transportation
of specimens.
We may
be required to transport specimens from the U.S. or other distant locations to our laboratory located in Melbourne, Australia. Our operations
may be adversely impacted by extreme weather conditions or other interruptions such as was the case with the COVID pandemic in the timely
transportation of such specimens or otherwise to provide our services, from time to time. The occurrence of any such event and/or a disruption
to our operations as a result may harm our reputation and adversely impact our results of
operations.
Our CIT Platform will expose us to
various
risks.
Our
Consumer Initiated Testing platform (CIT), allows consumers to directly request any of our tests online with a practitioner involved in
the process, will be subject to various risks, including:
●
The risk of failure to protect personal medical
information;
●
The risk of breach of cyber security for the platform;
and
●
The risk that the platform will fail to perform as
expected.
Our ability to conduct our
services in a particular U.S. state or non-U.S. jurisdiction is dependent upon the applicable laws governing remote healthcare, the
practice of medicine and healthcare delivery in general in such location which are subject to changing political, regulatory and
other influences, and corporate practice of medicine limitations. Some state medical boards have established new rules or
interpreted existing rules in a manner that limits or restricts the practice of telemedicine. The extent to which a U.S. state or
non-
U.S.
jurisdiction considers particular actions or relationships to constitute practicing medicine is subject to change and to evolving
interpretations by (in the case of U.S. states) medical boards and state attorneys general, among others, and (in the case of
non-U.S. jurisdictions) the relevant regulatory and legal authorities, each with broad discretion. Accordingly, we must monitor our
compliance with law in every jurisdiction in which we operate, on an ongoing basis, and we cannot provide assurance that our
activities and arrangements, if challenged, will be found to be in compliance with the law. If a successful legal challenge or an
adverse change in the relevant laws were to occur, we could be subject to significant penalties. Further, if we were unable to adapt
our business model to comply with such laws, our operations in the affected jurisdictions would be disrupted, which could have a
material adverse effect on our business, financial condition and results of operations.
14
Discontinuation or recalls
of existing testing products or our customers using new technologies to perform their own
tests
could adversely affect our business.
Discontinuation
or recalls of existing testing products or our customers using new technologies to perform their own tests could adversely affect the
Company's business. Manufacturers may discontinue or recall reagents, test kits or instruments used by us to perform laboratory
testing. Such discontinuations or recalls could adversely affect our costs, testing volume and revenue. In addition, advances in technology
may lead to the development of more cost-effective technologies such as point-of-care testing equipment that can be operated by physicians
or other healthcare providers in their offices or by patients themselves without requiring the services of freestanding clinical laboratories.
Development of such technology and its use by our customers could reduce the demand for our laboratory testing services and the utilization
of certain tests offered by us and negatively impact our revenues.
The PRS test may not be able to obtain
necessary regulatory clearance, we may not generate any
revenue.
All of
our existing products are subject to regulation in Australia by the Therapeutic Goods Association (TGA), the U.S. by the FDA and/or other
domestic and international governmental, public health agencies, regulatory bodies or non-governmental organizations. The process of obtaining
required approvals or clearances for a potential new product varies according to the nature of and uses for a specific product. These
processes can involve lengthy and detailed laboratory testing, human clinical trials, sampling activities, and other costly, time-consuming
procedures. The submission of an application to a regulatory authority does not guarantee that the authority will grant an approval or
clearance for the product. Each authority may impose its own requirements and can delay or refuse to grant approval or clearance, even
though a product has been approved in another country. The time taken to obtain approval or clearance varies depending on the nature of
the application and may result in the passage of a significant period of time from the date of submission of the application. Delays in
the approval or clearance processes increase the risk that we will not succeed in introducing or selling the subject products, and we
may be required to abandon the PRS after devoting substantial time and resources to its development.
If
our PRS test is required to obtain and maintain FDA approvals, it will be subject to continuing governmental regulations and additional
foreign regulations.
If the
FDA determines that enforcement discretion is not appropriate or that LDTs are generally subject to FDA regulation and that premarket
review, including clearance or approval, is required for our PRS tests or any of our future tests, diagnostic test kits that we may develop,
or other products that would be classified as medical devices, the process of obtaining regulatory clearances or approvals to market a
medical device can be costly and time consuming, and we may not be able to obtain these clearances or approvals on a timely
basis,
if at all. In particular, the FDA permits commercial distribution of a new medical device only after the device has received clearance
under Section 510(k) of the Federal Food, Drug and Cosmetic Act, or is the subject of an approved premarket approval application,
or PMA or reclassification of the device through the De Novo classification process, unless the device is specifically exempt from those
requirements. The FDA will clear marketing of a lower risk medical device through the 510(k) process if the manufacturer demonstrates
that the new product is substantially equivalent to other 510(k)-cleared products. High risk devices deemed to pose the greatest risk,
such as life-sustaining, life-supporting, or implantable devices, or devices not deemed substantially equivalent to a previously cleared
device, require the approval of a PMA. The PMA process is more costly, lengthy and uncertain than the 510(k)-clearance process. A PMA
application must be supported by extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing
and labeling data, to demonstrate to the FDA's satisfaction the safety and efficacy of the device for its intended use. The De Novo
classification process is an alternate pathway to classify medical devices that are automatically classified into Class III but which
are low to moderate risk. A manufacturer can submit a petition for direct De Novo review if the manufacturer is unable to identify an
appropriate predicate device and the new device or new use of the device presents moderate or low risk. De Novo classification may also
be available after receipt of a "not substantially equivalent" letter following submission of a 510(k) to FDA. Our currently
commercialized products have not received FDA clearance or approval, as they are marketed under the FDA's enforcement discretion
for LDTs. Even if regulatory clearance or approval of a product is required and granted, such clearance or approval may be subject to
limitations on the intended uses for which the product may be marketed and reduce our potential to successfully commercialize the product
and generate revenue from the product. If the FDA determines that our promotional materials, labeling, training or other marketing or
educational activities constitute promotion of an unapproved use, it could request that we cease or modify our training or promotional
materials or subject us to regulatory enforcement actions.
We are
also subject to other federal, state, and foreign regulation concerning the manufacture and sale of our products. Our failure to comply
with U.S. federal, state and foreign governmental regulations could lead to the issuance of warning letters or untitled letters, government
investigation, the imposition of injunctions, suspensions or loss of regulatory clearance or approvals, product recalls, termination of
distribution, product seizures or civil penalties. In the most extreme cases, criminal sanctions or closure of our manufacturing facility
are possible, any of which could adversely affect our business, operating results and prospects.
The FDA
and similar foreign governmental authorities have the authority to require the recall of regulated products in the event of material deficiencies
or defects in design or manufacture. In the case of the FDA, the authority to require a recall must be based on an FDA finding that there
is a reasonable probability that the device would cause serious injury or death. In addition, foreign governmental bodies have the authority
to require the recall of our products in the event of material deficiencies or defects in design or manufacture.
15
Manufacturers may, under their
own initiative, recall a product if any material deficiency in a device is found. A government-mandated or voluntary recall by us could
occur as a result of component failures, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of
any of our products would divert managerial and financial resources and have an adverse effect on our financial condition and results
of operations. The FDA requires that certain classifications of recalls be reported to FDA within 10 working days after the recall is
initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate
voluntary recalls involving our products in the future that we determine do not require notification of the FDA. If the FDA disagrees
with our determinations, they could require us to report those actions as recalls. A future recall announcement could harm our reputation
with customers and negatively affect our sales. In addition, the FDA could take enforcement action for failing to report the recalls when
they were conducted.
Declining general economic
or business conditions may have a negative impact on our
business.
If the
current economic climate deteriorates, our business, including our access to patient samples and the addressable market for diagnostic
tests that we may successfully develop, as well as the financial condition of our suppliers and our third-party payers, could be adversely
affected, resulting in a negative impact on our business, financial condition, results of operations and cash flows.
RISKS RELATED TO OUR
SECURITIES
Our ADSs may be delisted from the
NASDAQ Capital
Market.
On March
13, 2020, the Company received a determination letter (the "Letter") from NASDAQ indicating that we did not comply with the
stockholders' equity rule. The Letter indicated that Listing Rule 5815(d)(4)(B) does not permit an issuer that is deficient in stockholders'
equity to present a plan of compliance to the NASDAQ Staff if such issuer has failed to comply with that provision within one year of
a Hearing Panel (the "Panel") determination of compliance. The Letter stated that since the Company was not compliant with
the equity rule within one year of the Compliance Letter, the Staff cannot allow us to submit a plan of compliance. We requested an appeal
hearing with the Panel to review the delisting determination. Upon NASDAQ's receipt of the hearing request by the Company, NASDAQ
stayed the suspension of our securities and the filing of the Form 25-NSE pending the Panel's decision. An oral hearing took place
on April 30, 2020 and in a letter dated May 12, 2020, the Panel granted the Company the full 180-day extension until September 9, 2020,
to publicly disclose full compliance with the minimum shareholder equity requirement under NASDAQ rules. The Company subsequently regained
compliance with NASDAQ Listing Rule 5550(b)(1) as of August 25, 2020.
On July 21, 2020, we closed a
registered direct offering of 1,025,000 ADSs, each representing six hundred (600) of the Company's ordinary shares, at a purchase
price of United States Dollars (US$) US$5.00 per ADS - or in Australian dollars A$0.012 per ordinary share. The gross proceeds for this
offering were approximately US$5.1 million. Against the offering, the Company agreed to issue 39,975,000 warrants exercisable
at US$0.0104 each, expiring in 5 years from issue date, to H.C. Wainwright & Co which would form part of cost of raising capital.
On January 25, 2021, we closed
a registered direct offering of 1,250,000 ADSs, each representing six hundred (600) of the Company's ordinary shares, at a purchase
price of United States Dollars (US$) US$5.25 per ADS - or in Australian dollars A$0.01125 per ordinary share. The gross proceeds for
this offering were approximately US$6.56 million. Against the offering, the Company agreed to issue 48,750,000 warrants exercisable
at US$0.010938 each, expiring in 5 years from issue date, to H.C. Wainwright & Co which would form part of cost of raising capital.
The said warrants were subject to shareholder approval, which was granted by shareholders at the Company's Annual General Meeting
(AGM) held 24 November 2021.
On February 8, 2023, we closed
a registered direct offering of 3,846,155 ADSs, each representing six hundred (600) of the Company's ordinary shares, at a purchase
price of United States Dollars (US$) US$1.30 per ADS. The gross proceeds for this offering were approximately US$5 million. Against
the offering, the Company agreed to issue 250,000 warrants exercisable at US$1.625 each, expiring in 5 years from issue date, to H.C.
Wainwright & Co which would form part of cost of raising capital. The said warrants are subject to shareholder approval.
On July
17, 2023, the Company received notification from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement
of Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market, since the closing bid price for the Company's
American Depositary Shares (ADS) on the Nasdaq Capital Market was below US$1.00 for 34 consecutive trading days. Nasdaq Listing Rule 5550(a)(2)
requires the ADS to maintain a minimum bid price of US$1.00 per share (the "Minimum Bid Requirement"), and Nasdaq Listing
Rule 5810(c)(3)(A) provides that failure to meet such requirement exists if the deficiency continues for a period of 30 consecutive business
days. The Notification has no immediate effect on the listing of the Company's ADS on the Nasdaq Capital Market. Under Nasdaq Listing
Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of Notification, which was July 17, 2023, to regain compliance
with the minimum bid requirement, during which time the ADS will continue to trade on the Nasdaq Capital Market. If at any time before
January 15, 2024, the bid price of the ADS closes at or above US$1.00 per ADS for a minimum of 10 consecutive business days, the Company
will regain compliance with the Minimum Bid Requirement. In the event the Company does not regain compliance with the Minimum Bid Requirement
by January 15, 2024,
the
Company may be eligible for an additional period of 180 calendar
days to regain compliance or may be subject to delisting of the ADS from the Nasdaq Capital Market. The Company will continuously monitor
the closing bid price of its ADS between now and January 15, 2024, and will evaluate its options to regain compliance with Nasdaq Listing
Rule 5550(a)(2) before such date.
16
However,
there can be no assurance that the Company will continue to be successful in maintaining net assets and minimum bid compliance and that
our securities will remain listed on the NASDAQ Capital Market. The delisting of our ADSs by NASDAQ would have material negative impacts
on the liquidity of our securities and our ability to raise future capital.
Our stock price
is volatile and can fluctuate significantly based on events not in our control and general industry
conditions.
As
a result, the value of your investment may decline
significantly.
The biotechnology
sector can be particularly vulnerable to abrupt changes in investor sentiment. Stock prices of companies in the biotechnology industry,
including ours, can swing dramatically, with little relationship to operating performance. Our stock price may be affected by a number
of factors including, but not limited to:
●
global economic uncertainty and financial market volatility caused by political instability, changes in international trade relationships and international conflicts, such as the conflict between Russia and Ukraine;
●
product development
events;
●
the outcome of
litigation;
●
decisions relating to intellectual property
rights;
●
the entrance of competitive products or technologies into our
markets;
●
new medical
discoveries;
●
the establishment of strategic partnerships and
alliances;
●
changes in pricing policies or other practices related to the healthcare industry;
or
●
other industry and market changes or
trends.
Since our listing on the Australian
Securities Exchange in August 2000, the price of our Ordinary Shares has ranged from a low of A$0.002 to a high of A$0.88 per share. Further
fluctuations are likely to occur due to events which are not within our control and general market conditions affecting the biotechnology
sector or the stock market generally.
In addition,
low trading volume may increase the volatility of the price of our ADSs. A thin trading market could cause the price of our ADSs to fluctuate
significantly more than the stock market as a whole. For example, trades involving a relatively small number of our ADSs may have a greater
impact on the trading price for our ADSs than would be the case if the trading volume were higher.
The fact that we do not expect to
pay cash dividends may lead to decreased prices for our
stock.
We have
never declared or paid a cash dividend on our Ordinary Shares and we do not anticipate doing so in the foreseeable future. We intend to
retain future cash earnings, if any, for reinvestment in the development and expansion of our business. Whether we pay cash dividends
in the future will be at the discretion of our Board of Directors and may be dependent on our financial condition, results of operations,
capital requirements and any other factors our Board of Directors decides is relevant. As a result, an investor may only recognize an
economic gain on an investment in our stock from an appreciation in the price of our stock, which is uncertain and unpredictable. There
is no guarantee that our Ordinary Shares will appreciate in value or even maintain the price at which an investor purchased the Ordinary
Shares.
You may have difficulty in effecting
service of legal process and enforcing judgments against us and our
management.
We are a public company limited
by shares, registered and operating under the Australian
Corporations Act 2001
. All of our directors and officers named in this
Annual Report reside outside the U.S. Substantially all, or a substantial portion of, the assets of those persons are also located outside
the U.S. As a result, it may not be possible to affect service on such persons in the U.S. or to enforce, in foreign courts, judgments
against such persons obtained in U.S. courts and predicated on the civil liability provisions of the federal securities laws of the U.S.
Furthermore, substantially all of our directly owned assets are located outside the U.S., and, as such, any judgment obtained in the U.S.
against us may not be collectible within the U.S. There is doubt as to the enforceability in the Commonwealth of Australia, in original
actions or in actions for enforcement of judgments of U.S. courts, of civil liabilities predicated solely upon federal or state securities
laws of the U.S., especially in the case of enforcement of judgments of U.S. courts where the defendant has not been properly served in
Australia.
17
Because
we are not required to provide you with the same information as an issuer of securities based in the United States, you may not be afforded
the same protection or information you would have if you had invested in a public corporation based in the United States.
We are
exempt from certain provisions of the Securities Exchange Act of 1934, as amended, commonly referred to as the Exchange Act, that are
applicable to U.S. public companies, including (i) the rules under the Exchange Act requiring the filing with the SEC of quarterly reports
on Form 10-Q and current reports on Form 8-K; (ii) the sections of the Exchange Act regulating the solicitation of proxies, consents or
authorizations in respect of a security registered under the Exchange Act; and (iii) the sections of the Exchange Act requiring insiders
to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short
period of time. The exempt provisions would be available to you if you had invested in a U.S. corporation.
However,
in line with the Australian Securities Exchange regulations, we disclose our reviewed financial results on a semi-annual
basis
(under International Standard on Review Engagements) and our audited financial results on an annual basis (under International Standards
on Auditing). The information, which may have an effect on our stock price on the Australian Securities Exchange, will be disclosed to
the Australian Securities Exchange and also the Securities Exchange Commission. Other relevant information pertaining to our Company will
also be disclosed in line with the Australian Securities Exchange regulations and information dissemination requirements for listed companies.
We provide our semi-annual results and other material information that we make public in Australia in the U.S. under the cover of an SEC
Form 6-K. Nevertheless, you may not be afforded the same protection or information, which would be made available to you, were you investing
in a United States public corporation because the requirements of a Form 10-Q and Form 8-K are not applicable to us.
As
a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ
significantly from Nasdaq corporate governance listing standards and these practices may afford less protection to shareholders than they
would enjoy if we complied fully with Nasdaq corporate governance listing standards.
As a foreign
private issuer listed on Nasdaq, we will be subject to their corporate governance listing standards. However, Nasdaq rules permit foreign
private issuers to follow the corporate governance practices of its home country. Some corporate governance practices in Australia may
differ from Nasdaq corporate governance listing standards. For example, we could include non-independent directors as members of our Remuneration
committee, and our independent directors may not necessarily hold regularly scheduled meetings at which only independent members of the
board of directors are present. Currently, we follow home country practice to the maximum extent possible. Therefore, our shareholders
may be afforded less protection than they otherwise would have under corporate governance listing standards applicable to U.S. domestic
issuers.
We may
lose our foreign private issuer status in the future, which could result in significant additional cost and expense. While we currently
qualify as a foreign private issuer, the determination of foreign private issuer status is made annually on the last business day of an
issuer's most recently completed second fiscal quarter and, accordingly, our next determination will be made on December 31, 2023.
In the future, we would lose our foreign private issuer status if we to fail to meet the requirements necessary to maintain our foreign
private issuer status as of the relevant determination date. For example, if 50% or more of our securities are held by U.S. residents
and more than 50% of our senior management or directors are residents or citizens of the United States, we could lose our foreign private
issuer status. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly more
than costs we incur as a foreign private issuer. If we are not a foreign private issuer, we will be required to file periodic reports
and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive in certain respects than
the forms available to a foreign private issuer. We would be required under current SEC rules to prepare our financial statements in accordance
with U.S. GAAP rather than IFRS, and modify certain of our policies to comply with corporate governance practices required of U.S. domestic
issuers. Such conversion of our financial statements to U.S. GAAP would involve significant time and cost. In addition, we may lose our
ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private
issuers such as the ones described above and exemptions from procedural requirements related to the solicitation of proxies.
As
a result of being a U.S. public company, we are subject to additional regulatory compliance requirements, including Section 404, and if
we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent
fraud.
Pursuant
to Section 404, our management will be required to assess and attest to the effectiveness of our internal control over financial reporting
in connection with issuing our consolidated financial statements as of and for the fiscal year ending June 30, 2023. Section 404 also
requires an attestation report on the effectiveness of internal control over financial reporting be provided by our independent registered
public accounting firm beginning with our annual report following the date on which we are no longer a non-accelerated filer. The cost
of complying with Section 404 will significantly increase and management's attention may be diverted from other business concerns,
which could adversely affect our results. We may need to hire more employees in the future or engage outside consultants to comply with
these requirements, which will further increase expenses. If we fail to comply with the requirements of Section 404 in the required timeframe,
we may be subject to sanctions or investigations by regulatory authorities, including the
SEC
and Nasdaq. Furthermore, if we are unable to attest to the effectiveness of our internal control over financial reporting, we could lose
investor confidence in the accuracy and completeness of our financial reports, and the market price of our ordinary shares and ADSs could
decline. Failure to implement or maintain effective internal control over financial reporting could also restrict our future access to
the capital markets and subject each of us, our directors and our officers to both significant monetary and criminal liability. In addition,
changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies,
increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards
are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice
may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding
compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources
to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expense
and a diversion of management's time and attention from revenue generating activities to compliance activities. If our efforts to
comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities
related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business, financial
position, results and prospects may be adversely affected.
18
We
will incur significant costs as a result of operating as a company with ADSs that are publicly traded in the United States, and our management
will be required to devote substantial time to new compliance initiatives.
As a company
whose ADSs are publicly traded in the United States, we have incurred and will continue to incur significant legal, accounting, insurance
and other expenses. In addition, the Sarbanes-Oxley Act, Dodd-Frank Wall Street Reform and Consumer Protection Act and related rules implemented
by the United States Securities and Exchange Commission, or SEC, and Nasdaq have imposed various requirements on public companies listed
in the United States including requiring establishment and maintenance of effective disclosure and financial controls. Our management
and other personnel will need to devote a substantial amount of time to these compliance initiatives, and we will need to add additional
personnel and build our internal compliance infrastructure. Moreover, these rules and regulations will increase our legal and financial
compliance costs and will make some activities more time-consuming and costly. These laws and regulations could also make it more difficult
and expensive for us to attract and retain qualified persons to serve on our board of directors, our board committees or as our senior
management. Furthermore, if we are unable to satisfy our obligations as a public company listed in the United States, we could be subject
to delisting of the ADSs, fines, sanctions and other regulatory action and potentially civil litigation.
The dual listing of our ordinary shares
and the ADSs may negatively impact the liquidity and value of the
ADSs.
Our ADSs
are listed on Nasdaq and our ordinary shares are listed on the ASX. We cannot predict the effect of this dual listing on the value of
our ordinary shares and ADSs. However, the dual listing of our ordinary shares and ADSs may dilute the liquidity of these securities in
one or both markets and may negatively impact the development of an active trading market for the ADSs in the United States. The price
of the ADSs could also be negatively impacted by trading in our ordinary shares on the ASX.
Australian
takeover laws may discourage takeover offers being made for us or may discourage the acquisition of a significant
position in our
ordinary shares or ADSs.
We are
incorporated in Australia and are subject to the takeover laws of Australia. Among other things, we are subject to the Corporations Act
2001. Subject to a range of exceptions, the Corporations Act 2001 prohibits the acquisition of a direct or indirect interest in our issued
voting shares if the acquisition of that interest will lead to a person's voting power in us increasing to more than 20%, or increasing
from a starting point that is above 20% and below 90%. Australian takeover laws may discourage takeover offers being made for us or may
discourage the acquisition of a significant position in our ordinary shares. This may have the ancillary effect of entrenching our board
of directors and may deprive or limit our shareholders' opportunity to sell their ordinary shares and may further restrict the ability
of our shareholders to obtain a premium from such transactions.
Our
Constitution and Australian laws and regulations applicable to us may adversely affect our ability to take actions that could be beneficial
to our shareholders.
As an
Australian company we are subject to different corporate requirements than a corporation organized under the laws of the United States.
Our Constitution, as well as the Corporations Act 2001, sets forth various rights and obligations that apply to us as an Australian company
and which may not apply to a U.S. corporation. These requirements may operate differently than those of many U.S. companies. You should
carefully review the summary of these matters set forth under our Constitution, which is included as an exhibit to this annual report,
prior to investing in our securities.
A lack of significant liquidity for
our ADSs may negatively affect your ability to resell our
securities.
Our ADSs
have traded on the NASDAQ Capital Market since June 30, 2010. An active trading market for the ADSs, however, may not be maintained in
the future. If an active trading market is not maintained, the liquidity and trading prices of the ADSs could be negatively affected.
19
In certain circumstances, holders
of ADSs may have limited rights relative to holders of Ordinary
Shares.
The rights
of holders of ADSs with respect to the voting of Ordinary Shares and the right to receive certain distributions may be limited in certain
respects by the deposit agreement entered into by us and The Bank of New York Mellon. For example, although ADS holders are entitled under
the deposit agreement, subject to any applicable provisions of Australian law and of our Constitution, to instruct the depositary as to
the exercise of the voting rights pertaining to the Ordinary Shares represented by the American Depositary Shares, and the depositary
has agreed that it will try, as far as practical, to vote the Ordinary Shares so represented in accordance with such instructions, ADS
holders may not receive notices sent by the depositary in time to ensure that the depositary will vote the Ordinary Shares. This means
that, from a practical point of view, the holders of ADSs may not be able to exercise their right to vote. In addition, under the deposit
agreement, the depositary has the right to restrict distributions to holders of the ADSs in the event that it is unlawful or impractical
to make such distributions. We have no obligation to take any action to permit distributions to holders of our American Depositary Receipts,
or ADSs. As a result, holders of ADSs may not receive distributions made by us.
RISKS RELATED TO
TAXATION
We
may be classified as a passive foreign investment company, which could result in adverse U.S. federal income tax consequences for U.S.
holders.
In general,
a non-U.S. company will be considered a passive foreign investment company, or PFIC, for U.S. federal income tax purposes for any taxable
year in which (1) 75% or more of its gross income consists of passive income (the "income test") or (2) 50% or more of the
average quarterly value of its assets is attributable to assets that produce, or are held for the production of, passive income (the "asset
test"). For purposes of these tests, passive income generally includes dividends, interest, gains from the sale or exchange of investment
property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or
indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets
and received directly its proportionate share of the income of such other corporation.
Based
on the nature and composition of our income, assets, activities and market capitalization, we believe that we were classified as a PFIC
for our taxable year ended June 30, 2023. However, our PFIC status is based on an annual determination that is subject to a number of
uncertainties and may change from year to year. Our PFIC status will depend on the composition of our income (including with respect to
the R&D Tax Credit) and the composition and value of our assets, which may be determined in large part by reference to the market
value of the ADSs and our Ordinary Shares, which may be volatile, from time to time. Our status may also depend, in part, on how quickly
we utilize the cash we raise in any offering of our securities. There can be no assurance that we will not be considered a PFIC in any
past, current or future taxable year, and our U.S. counsel expresses no opinion regarding our conclusions or our expectations regarding
our PFIC status.
If we
are a PFIC for any taxable year during which a U.S. holder (as defined in the section titled "Item 10.E. Additional Information—Taxation,
United States Federal Income Taxation") holds the ADSs or Ordinary Shares, the U.S. holder may be subject to adverse tax consequences
regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual
or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements. We will continue to
be treated as a PFIC with respect to such U.S. holder in all succeeding years during which the U.S. holder owns the ADSs or Ordinary Shares,
regardless of whether we continue to meet the income or asset tests described above, unless the U.S. holder makes a valid and timely qualified
electing fund (QEF) or mark-to-market election, or makes a deemed sale election once we cease to be a PFIC; however, we do not currently
intend to provide the information necessary for a U.S. holder to make a QEF election. For further discussion of the PFIC rules and the
adverse U.S. federal income tax consequences to U.S. holders in the event we are classified as a PFIC, see "Item 10.E. Additional
Information—Taxation, United States Federal Income Taxation—Passive Foreign Investment Company Rules."
If a United
States person is treated as owning at least 10% of our ordinary shares, such holder may be subject to
adverse
U.S.
federal income tax
consequences.
If a U.S.
holder (as defined in the section titled "Item 10.E. Additional Information—Taxation, United States Federal Income Taxation")
is treated as owning (directly, indirectly or constructively) at least 10% of the value or voting power of our Ordinary Shares or ADSs,
such U.S. holder may be treated, for U.S. federal income tax purposes, as a "United States shareholder" with respect to each
"controlled foreign corporation" in our group, if any. Because our group includes a U.S. subsidiary (geneType Inc., previously
the named Phenogen Sciences Inc.), certain of our current and future non-U.S. subsidiaries will be treated as controlled foreign corporations,
regardless of whether we are treated as a controlled foreign corporation. A United States shareholder of a controlled foreign corporation
may be required to annually report and include in its U.S. taxable income its pro rata share of "Subpart F income," "global
intangible low- taxed income" and investments in U.S. property by controlled foreign corporations, regardless of whether we make
any distributions. An individual that is a United States shareholder with respect to a controlled foreign corporation generally would
not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation.
We cannot provide any assurances that we will furnish to any United States shareholder information that may be necessary to comply with
the reporting
and
payment obligations described above. Failure to comply with such obligations
may subject a United States shareholder to significant monetary penalties and stall the beginning of the statute of limitations period
for relevant U.S. federal income tax returns. U.S. holders should consult their tax advisors regarding the potential application of these
rules to their investment in the Ordinary Shares or ADSs.
20
Changes to tax laws could materially
adversely affect our company and reduce net returns to our
shareholders.
Our tax
treatment is subject to the enactment of, or changes in, tax laws, regulations and treaties, or the interpretation thereof, tax policy
initiatives and reforms under consideration and the practices of tax authorities in jurisdictions in which we operate, including those
related to the Organization for Economic Co-Operation and Development's Base Erosion and Profit Shifting Project, the European Commission's
state aid investigations and other initiatives. Such changes may include (but are not limited to) the taxation of operating income, investment
income, dividends received or (in the specific context of withholding tax) dividends paid. We are unable to predict what tax reform may
be proposed or enacted in the future or what effect such changes would have on our business, but such changes, to the extent they are
brought into tax legislation, regulations, policies or practices, could affect our financial position and overall or effective tax rates
in the future in countries where we have operations, reduce post-tax returns to our shareholders, and increase the complexity, burden
and cost of tax compliance.
Tax
authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or
non-realization of expected benefits.
A tax authority may disagree
with tax positions that we have taken, which could result in increased tax liabilities. For example,
the
U.S.
Internal Revenue Service or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid
between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid
with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a
jurisdiction where we believe we have not established a taxable connection, often referred to as a "permanent
establishment" under international tax treaties, and such an assertion, if successful, could increase our expected tax
liability in one or more jurisdictions. A tax authority may take the position that material income tax liabilities, interest and
penalties are payable by us, in which case, we expect that we might contest such assessment. Contesting such an assessment may be
lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated
effective tax rate, where applicable.
Item 4. Information on
the
Company
Item 4.A History and Development
of the
Company
Originally
incorporated under the laws of Western Australia on January 5, 1987, as Concord Mining N.L. the Company operated
as a mining company.
On August 13, 1991, the Company changed its name to Consolidated Victorian Gold Mines N.L. On December 2, 1991, the Company changed its
name to Consolidated Victorian Mines N.L. On March 15, 1995, the Company changed its name to Duketon Goldfields N.L.
On October
15, 1999, the Company's corporate status was changed from a No Liability Company to a company limited by shares. On August 29, 2000,
following the acquisition of Swiss company GeneType AG, the Company changed its name to Genetic
Technologies
Limited, which is its current name. At that time, the mining activities were phased out to focus on becoming a biotechnology
company,
following which its stock exchange listing was duly transferred from the mining board of the ASX to the industrial board and its shares
were thereafter classified under the industry Company "Health and Biotechnology", completing its transformation from a mining
company into a biotechnology company. The Company's current activities in biotechnology primarily concentrate on one clearly defined
area of activity which is covered under Item 4.B "Business Overview".
In October
2009, a new strategic direction was established to focus efforts in creating a portfolio of tests that would be aimed at assisting medical
clinicians with cancer management. This would comprise tests that were created by the Company and in-licensed from third parties which
would then be marketed by us in the Asia-Pacific region.
On April
14, 2010, the Company announced that it had acquired certain assets from Perlegen Sciences, Inc. in California, with the main asset being
the BREVAGen™ breast cancer risk assessment test ("BREVAGen™"). On June 28, 2010, the Company incorporated a wholly
owned subsidiary named Phenogen Sciences Inc, whose name changed to geneType Inc. on 4 April 2022, in the State of Delaware which commenced
selling the BREVAGen™ test in the U.S. marketplace in June 2011. In October 2014, the Company released its next generation breast
cancer risk assessment test BREVAGen
plus.
On November
19, 2014, the Company completed the sale of its Heritage Australian Genetics business to Specialist Diagnostic Services Ltd (SDS), the
wholly owned pathology subsidiary of Primary Health Care Ltd.
21
In November
2016, the Company executed an exclusive worldwide license agreement with The University of Melbourne, for the development and commercialization
of a novel colorectal cancer (CRC) risk assessment test, providing the Company with an opportunity to enhance its pipeline of risk assessment
products. Additionally, in June 2017, the Company executed an investigator- initiated Research Agreement with The Ohio State University,
reflecting the growing awareness of the Company's expertise in SNP- based risk assessment.
During
2018, the Company executed a further collaborative research and services agreement with The University of Melbourne, with the research
designed to broaden the applicability of BREVAGen
plus,
enabling its use by women with extended family history of breast cancer
as well as increase the range of factors analyzed in assessing breast cancer.
In May
2019, the Company announced the development of two new cancer risk assessment tests branded as "GeneType for Colorectal Cancer"
and "GeneType for Breast Cancer." The new breast cancer test provides substantial improvement over its legacy breast cancer
test BREVAGen
plus
, by incorporating multiple additional clinical risk factors. This test will provide healthcare providers and
their patients with a 5-year and lifetime risk assessment of the patient developing breast cancer. The colorectal cancer test will provide
healthcare providers and their patients a 5-year, 10-year, and lifetime risk assessment of the patient developing colorectal
cancer.
In June 2020, the Company received
US Patent No: US10,683,549, Methods for assessing risk of developing breast cancer. The Company is the first company in the world to
successfully commercialize a polygenic risk test for breast cancer. The granted patent covers the Company's proprietary
panels of single nucleotide polymorphisms (SNPs) and the combination of clinical and phenotypic risk models to create the most comprehensive
risk assessment tool on the market: GeneType for Breast Cancer.
The Company
hired and trained a new internal sales employee to educate doctors on the Company's polygenic risk score (PRS) tests and introduce
them to preventative health strategies. The Company received a positive response from doctors. Initial test results showed 10 per cent
of subjects were high risk and 41 per cent were moderate risk. The Company believes that these results will help create personalized strategies
specifically designed for the patient risk profile. We think early indications show the tests lead to better screening compliance and
to the development of personalized screening solutions. This confirms the Company's objective of focusing on preventative health
rather than 'after the fact' medicine.
At the
same time, the Company continued to refine existing, and to develop other, risk assessment tests across a range of diseases including:
●
Breast
cancer
●
Colorectal
cancer
●
Ovarian
cancer
●
Prostate
cancer
●
Coronary artery
disease
●
Type 2
diabetes
●
Pancreatic
cancer
●
Melanoma
●
Atrial
fibrillation
The Company
has developed a polygenic risk score (PRS) test for COVID-19 in 2022, which may enable an assessment of the risk of people developing
a serious disease should they contract the virus. The test aims to predict disease severity using a combination of genetic and clinical
information. The Company has built strong relationships with international biobanks and health studies, including UK Biobank. They allow
us to secure additional, current COVID-19 patient data to continuously develop, refine, and validate the COVID-19 risk test.
The Company's
single nucleotide polymorphism (SNP) array panels are supplied by US-based Thermo Fisher Scientific Inc., a world leader in genetic testing
and the Company's manufacturing partner for geneType products. The SNP array panel is a key reagent the Company needs to process
the polygenic risk test portion of the COVID-19 risk test. The test aims to categorize subjects as being at high, average, or low risk
of developing life-threatening conditions due to COVID-19.
The Company
filed a provisional patent application for its COVID-19 risk test with IP Australia, an agency of Department of Industry, Innovation and
Science (Intellectual Property Australia) (2020901739 - Methods of assessing risk of developing a severe response to Coronavirus infection).
The provisional patent covers the specific single nucleotide polymorphism (SNP) algorithm the Company designed to calculate a PRS and
the testing model that combines PRS and the clinical risk factors that together constitute the COVID-19 risk test. Subsequently this patent
has been granted in the United States and pending grant in several other key markets.
22
The Company
executed an acquisition agreement ("Acquisition Agreement") on July 19
th
, 2021 to acquire the direct-to- consumer
eCommerce business and distribution rights associated with General Genetics Corporation and its associated brands trading as EasyDNA,
from BelHealth Investment Fund LP. The Acquisition Agreement provides for the acquisition of all brands, websites and agency reseller
agreements associated with EasyDNA. This includes over 70 websites in 40 countries and six brand identities. Under the terms of the Acquisition
Agreement, the Company acquired 100% of EasyDNA's brands and assets within the General Genetics Corporation business for a purchase
price of US$4 million, comprising cash consideration of US$2.5 million and US$1.5 million of
ADSs.
The Company
executed an asset purchase agreement ("APA") on July 14th, 2022 to acquire the direct-to-consumer eCommerce
business,
laboratory testing and distribution agreements associated with AffinityDNA. The APA provides for the acquisition of all brands
and
websites associated with AffinityDNA. This includes the AffinityDNA Amazon sales channel rights. Under the terms of the APA, the Company
acquired 100% of AffinityDNA's brands and assets for a purchase price of GBP555,000, comprising cash consideration of GBP227,500
on completion and GBP227,500 payable in July 2023 subject to the AffinityDNA business attaining certain financial performance parameters.
The second payment was payable on the achievement of a gross profit target for the 12-month period from the
acquisition
date. This target was not achieved and therefore no further payment is to be made in respect of the acquisition of AffinityDNA.
On 3 February
2023, GTG announced the launch of the first Comprehensive Risk Test for Breast & Ovarian Cancer. The test evaluates a woman's
risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic
cancer. In combination with other clinical risk factors, the test provides a comprehensive risk assessment in a simple saliva test.
SEC maintains
an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically
with the SEC and state the address of that site (http:// www.sec.gov). The Company's website address is https:// genetype.com. The
information contained on our website is not incorporated by reference into this annual report on Form 20-F.
Corporate
Information
The Company's
registered office, headquarters and laboratory is located at 60-66 Hanover Street, Fitzroy, Victoria, 3065, Australia and its telephone
number is +61 3 8412 7000. The office of its U.S. subsidiary, geneType Inc. (formerly Phenogen Sciences Inc.), is located at 1300 Baxter
Street, Suite 255, Charlotte, North Carolina, 28204 U.S.A. The telephone number for the geneType Inc. office is (704) 926 5700. The Company's
website address is www.genetype.com. The information in its website is not incorporated by reference into this Annual Report and should
not be considered as part of this Annual Report.
The Company's
Australian Company Number (ACN) is 009 212 328. The Company's Australian Business Number (ABN) is 17 009 212 328. The Company operates
pursuant to its constitution, the Australian
Corporations Act 2001
, the Listing Rules of the Australian Securities Exchange, the
Marketplace Rules of The NASDAQ Stock Market, and where applicable, local, state and federal legislation in the countries in which the
Company operates.
Item 4.B Business Overview Description of
Business
Founded
in 1989, Genetic Technologies listed its Ordinary Shares on the ASX (GTG) in 2000 and its ADSs on NASDAQ's Capital Market (GENE)
in 2005. Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians
proactively manage people's health. The Company's legacy product, BREVAGen
plus
, was a clinically validated risk assessment
test for non-hereditary breast cancer and was first in its class. BREVAGen
plus
improved upon the predictive power of the first
generation BREVAGen™ test and was designed to facilitate better informed decisions about breast cancer screening and preventive
treatment plans. BREVAGen
plus
expanded the application of BREVAGen™ from Caucasian women to include African Americans and
Hispanics and was directed towards women aged 35 years or above who have not had breast cancer and have one or more risk factors for developing
breast cancer.
The
Company successfully launched the first generation BREVAGen™ test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc.
(now geneType Inc.), and BREVAGen
plus
was launched in October 2014. The Company marketed BREVAGen
plus
to healthcare professionals
in comprehensive breast health care and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment
specialists (such as breast surgeons).
In May
2019, the Company announced that it had developed two new cancer risk assessment tests branded as 'geneType for Colorectal Cancer'
and 'geneType for Breast Cancer'. The new breast cancer test provides substantial improvement over the Company's legacy
breast cancer test BREVAGen
plus
, by incorporating multiple additional clinical risk factors. This test will provide healthcare
providers and their patients with a 5-year and lifetime risk assessment of the patient developing breast cancer. The colorectal cancer
test will provide healthcare providers and their patients a 5-year, 10-year, and lifetime risk assessment of the patient developing colorectal
cancer.
23
In June 2020, the Company received
US Patent No: US 10,683,549, Methods for assessing risk of developing breast cancer. The Company is the first company in the world to
successfully commercialize a polygenic risk test for breast cancer. The granted patent covers the Company's proprietary
panels of single nucleotide polymorphisms (SNPs) and the combination of clinical and phenotypic risk models to create the most comprehensive
risk assessment tool on the market: geneType for Breast Cancer.
In February
2022 the Company received US Patent No: US 11,257,569, Methods of assessing risk of developing a severe response to Coronavirus infection.
The granted US patent covers the proprietary technology incorporated into GTG's geneType COVID- 19 Risk Test, which provides a probability
that a person will develop severe symptoms requiring hospitalization should they become
infected.
During
the 2023 financial year the Company continued to refine existing, and develop other, risk assessment tests across a range of diseases,
including:
●
Breast
cancer
●
Colorectal
cancer
●
Ovarian
cancer
●
Prostate
cancer
●
Coronary artery
disease
●
Type 2
diabetes
●
Pancreatic
cancer
●
Melanoma
●
Atrial
fibrillation
The Company's Genetic
Testing
Business
Following the acquisition
of Genetype AG in 1999 and the subsequent renaming to Genetic Technologies Limited, the Company focused on establishing a genetic testing
business, which over the following decade saw it become the largest provider of paternity and related testing services in Australia. The
Company's service testing laboratory in Melbourne became the leading non-Government genetic testing service provider in Australia.
The genetic testing services of the Company expanded to include at certain times:
●
Medical
testing
●
Animal
Testing
●
Forensic
Testing
●
Plant
Testing
The
acquisition of GeneType AG also provided the Company with ownership rights to a potentially significant portfolio of issued patents.
During
the intervening years, this portfolio has since been expanded by both organic growth and the acquisition of intellectual property assets
from third parties. The patent portfolio is constantly reviewed to ensure that the Company maintains potentially important patents but
at the same time keep costs to a minimum by no longer pursuing less commercially attractive and relevant intellectual property.
A strategic
alliance with Myriad Genetics Inc. delivered to the Company exclusive rights in Australia and New Zealand to perform DNA testing for susceptibility
to a range of cancers. In April 2003, the Company established its cancer susceptibility testing facility within its Australian laboratory.
In June 2003, this facility was granted provisional accreditation by the National Association of Testing Authorities, Australia ("NATA").
In November
2003, the Company joined the world-wide genetic testing network GENDIA as the sole reference laboratory for the network in Australia and
New Zealand. GENDIA consists of more than 50 laboratories from around the world, each contributing expertise in their respective disciplines
to create a network capable of providing more than 2,000 different genetic tests. This provided the Company with the ability to offer
comprehensive testing services to its customer base in the Asia-Pacific region as well as increasing its exposure to other markets.
In April
2010 the Company purchased various assets from Perlegen Sciences, Inc. of Mountain View, California, which included a breast cancer non-familial
risk assessment test, BREVAGen™. The Company then began validating the test in our Australian laboratory and initiated the process
for obtaining CLIA certification which would enable the Company to undertake the testing of samples received from the U.S. market. By
July 2010, a new U.S. subsidiary named Phenogen Sciences Inc, now named geneType Inc., had been incorporated by the Company in Delaware
to market and distribute the BREVAGen™ test across the United States.
24
In October
2014, the Company announced the U.S. release of BREVAGen
plus
, an easy-to-use predictive risk test for the millions of women at
risk of developing sporadic, or non-hereditary, breast cancer, representing a marked enhancement in accuracy
and
broader patient applicability, over its first generation BREVAGen™ product. The Company also made a pivotal change of sales and
marketing emphasis toward large comprehensive breast treatment and imaging centers, which are more complex entities with a longer sales
cycle, but higher potential.
GeneType for Breast Cancer
;
a State-of-the-Art
Breast Cancer Risk Assessment Test designed to enable a more personalized breast cancer risk assessment in a greater
number of women
The identification,
in 2007, of a number of single nucleotide polymorphisms (SNPs), each with an associated small relative risk of breast cancer, led to the
development of the first commercially available genetic risk test for sporadic breast cancer, BREVAGen™. The Company launched the
product in the U.S. in June 2011. In October 2014, the Company released its next generation breast cancer risk assessment test, BREVAGen
plus
.
This new version of the test incorporated a 10-fold expanded panel of genetic markers (SNPs), known to be associated with the development
of sporadic breast cancer, providing an increase in predictive power relative to its first- generation predecessor test. In addition,
the new test was clinically validated in a broader population of women including, African American and Hispanic women. This increased
the applicable market beyond the Caucasian only indication of the first-generation test, and simplified the marketing process in medical
clinics and breast health centers in the U.S.
The
expanded panel of SNPs incorporated into our breast cancer tests were identified from multiple large-scale genome-wide association studies
and subsequently tested in case-control studies utilizing specific Caucasian, African American and Hispanic patient
samples.
BREVAGen
plus
was a first-in-class, clinically validated, predictive risk test for sporadic breast cancer which examined a woman's clinical
risk factors, combined with seventy-seven scientifically validated genetic biomarkers (SNPs), to allow for more personalized breast cancer
risk assessment and risk management.
In May
2019, the Company announced the development of its next generation breast cancer risk assessment test, 'GeneType for Breast Cancer'.
The new breast cancer test provides substantial improvement over its legacy breast cancer test BREVAGen
plus
by incorporating multiple
additional clinical risk factors. This test will provide healthcare providers and their patients with a 5-year and lifetime risk assessment
of the patient developing breast cancer.
Germline
genetic testing for mutations in BRCA1 and BRCA2 allows for the identification of individuals at significantly increased
risk for
breast and other cancers. However, such mutations are relatively rare in the general population and account for less than 10% of all breast
cancer cases. The remaining 90% of non-familial or sporadic breast cancer have to be defined by other genetic/clinical markers common
to the population at large and this is where the Company has focused its attention.
The newly
developed 'geneType for Breast Cancer' test is aimed at risk detection of non-BRCA related sporadic breast cancer (that is,
for those women who do not have an identified family history of breast cancer). Importantly, this means that the Company's new test
covers 95% of women.
In June
2020, the Company received the approval for its U.S. patent number US 10,683,549, "Methods for Assessing Risk of Developing Breast
Cancer." The granted patent covers the Company's proprietary panels of single nucleotide polymorphisms (SNPs) and the combination
of clinical and phenotypic risk models to create the most comprehensive risk assessment tool on the market: geneType for Breast Cancer.
GeneType for Colorectal
; a State-of-the-Art
Risk Assessment Test for Colorectal
Cancer
Next generation
risk assessments combine multiple clinical and genetic risk factors to better stratify individuals at increased risk of developing disease.
'geneType for Colorectal Cancer' incorporates the most impactful risk factors in order to define an individual's risk
of developing colorectal cancer, so the healthcare provider can make screening and preventative care recommendations that are tailored
to their patient's personalized risk.
Colorectal
cancer is the third most commonly diagnosed cancer in the U.S., yet 1 in 3 adults are not receiving the appropriate colorectal cancer
screening for their age. In addition, rates of colorectal cancer among 20-49 year old is steadily increasing. Identifying patients who
are most at risk for colorectal cancer can lead to enhanced screening protocols and better outcomes. Most individuals diagnosed with colorectal
cancer do not have a significant family history of the disease. 'geneType for Colorectal Cancer' evaluates the genometric
risk of developing colorectal cancer for men and women over age 30 who do not have a known pathogenic gene variant.
In sporadic
colorectal cancer, no single gene mutation is causal of disease. Rather, common DNA variations or SNPs, each contribute a small but measurable
risk of developing disease. 'geneType for Colorectal Cancer' analyses a patient's DNA for more than 40 SNPs that have
been clinically validated in their association with colorectal cancer. By combining the effects of all of these SNPs into a single polygenic
risk score (PRS), 'geneType for Colorectal Cancer' will provide a superior risk stratification over standard risk assessments
that incorporate only clinical factors.
25
'geneType
for Colorectal Cancer' is clinically validated for men and women of 30 years of age or older and for individuals of Caucasian descent.
Commercial launch of geneType Multi-Risk
Test
The geneType
brand was re-launched globally in October 2021 following redevelopment of the Company's websites, marketing and advertising, media
releases and announcements to the ASX and NASDAQ. The commercial launch of the geneType Multi-Risk Test in February 2022 included the
first phase launch to cover risk assessment for six serious diseases including breast, colorectal, prostate, and ovarian cancers, coronary
artery disease and Type-2 diabetes covering more than 50% of all serious diseases, all in one test sample. The geneType Multi-Test received
simultaneous NATA accreditation and CMS certification in Australia and USA respectively. The first phase of the geneType Multi-Test became
available to Health Care Professionals (HCPs) in February 2022.
World's First Comprehensive Risk Test
for Breast & Ovarian
Cancer
In February
2023 the Company announced the development of a 'World First' Comprehensive Risk Assessment Test which evaluates a women's
risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic
cancer. Combined with other clinical risk factors the test provides a comprehensive risk assessment in a simple saliva test.
The Company
intend to provide updates as it continuously improves its tests and add fully validated models for additional
ethnicities.
Direct-to-consumer channel of lifestyle genetic
tests
The Company's
acquisition of EasyDNA in August 2021, gave us our direct-to-consumer channel for the sale and distribution of lifestyle genetic tests.
The EasyDNA brand of tests can be completed by the customer without the need to consult a healthcare professional. The laboratory testing
of the EasyDNA genetic tests is performed by contracted laboratories in the US, Europe and Australia. EasyDNA customers order their tests
online using our network of websites covering 40 countries.
In May
2022, the Company announced the acquisition of AffinityDNA and the business began integration when the first payment due under the acquisition
agreement was settled on 14 July 2022. AffinityDNA joins EasyDNA as the Company's Direct to Consumer (DTC) avenues to the market
for DNA testing. During the first part of the financial year, we have focused on the integration of our people, products and AffinityDNA
platform to deliver a "One Company-Multi-brand and Mult-channel" approach for GTG – EasyDNA, AffinityDNA and geneType.
The acquisition expands GTG's portfolio of tests to 51 in 14 categories available in more than 40 countries.
Further integration will
continue as the Company leverages its well-established worldwide marketplace (including
Amazon).
This
marketplace will also be used to provide an avenue to promote the Company's geneType
portfolio.
The Company
has a strong 'whole of life' portfolio of high-quality products both in the market and under development and a substantial
international platform for the distribution of the direct-to-consumer products.
Government
Regulations
CLIA AND FDA
Regulations
In
April 2011, the Company obtained certification of its Australian laboratory under the U.S. Clinical Laboratories Improvements
Amendments
of 1988 ("CLIA"), as regulated by the Centers for Medicare and Medicaid. This certification enables the Company to accept
and test samples from U.S. residents, and was the culmination of preparations required for the U.S. launch of the Company's BREVAGen™
test which occurred in June 2011.
In July
2013, the Company was inspected by a representative of the New York State Department of Health, Clinical Laboratory Evaluation Program
("CLEP"). The Company's laboratory received an inspection result with no deficiencies reported and, on August 30, 2013,
the Company announced that it had received its Clinical Laboratory Permit from the New York State Department of Health. This permit, which
allows the Company to offer its risk assessment tests to residents of New York State, allows the Company to provide testing services to
all 50 U.S. states.
From its headquarters in Melbourne, Victoria, the
Company's laboratory holds a number of accreditations
including:
●
The CLIA license required for all laboratories offering testing the
U.S.;
●
The CLEP license, an additional certification required to offer tests in New York State;
and
●
A Medical Device Establishment License (MDEL) required for
Canada.
26
Physicians
who order clinical tests for their patients have historically represented the primary source of its testing volume. Fees invoiced to patients
and third parties are based on its fee schedule, which may be subject to limitations imposed by third-party payers. The clinical laboratory
industry is highly regulated and subject to significant and changing Federal and state laws and regulations. These laws and regulations
affect key aspects of the Company's business, including licensure and operations, billing and payment for laboratory services, sales
and marketing interactions with ordering physicians, security and confidentiality of health information, and environmental and occupational
safety. Oversight by government officials includes regular inspections and audits. The Company seek to and believe that it conducts business
in compliance with all applicable laws and regulations.
CLIA,
extends Federal licensing requirements to all clinical laboratories (regardless of the location, size or type of laboratory), including
those operated by physicians in their offices, based on the complexity of the tests they perform. CLIA also establishes a stringent proficiency
testing program for laboratories and includes substantial sanctions, such as suspension, revocation or limitation of a laboratory's
CLIA certificate (which is necessary to conduct business), and significant fines and/or criminal penalties.
The geneType
tests on samples provided are processed at its laboratory in Melbourne, Australia. The Company's laboratory completed its first
CLIA inspection under CLIA guidelines and received its certificate of compliance effective November 17, 2011. A re- certification from
CMS i.e., paper survey, was performed in November 2013 and another on-site re-certification followed up in February 2016. Paper surveys
were also conducted in November 2017 and December 2019. Furthermore, the Company's laboratory completed its first CLEP inspection
under the NYS DOH CLEP guidelines and received its certificate of compliance effective August 30, 2013. Since the initial survey, the
laboratory has been successful in submitting documents via the NYS eCLEP Health Commerce System for each subsequent year to date. Although
no firm date has been provided, the laboratory is expecting an on-site visit in the coming 12
months.
The
Company believes that it is in compliance with all applicable federal and state laboratory requirements. Under CLIA, the Company remains
subject to state and local laboratory regulations. CLIA provides that a state may adopt laboratory regulations that are more stringent
than those under federal law, and some states require additional personnel qualifications, quality control, record maintenance and other
requirements.
Following
a successful CLIA audit during the year, the Company renewed its status as a fully NATA and CLIA – accredited laboratory. The Company
in a unique position to service both the Australian and US markets subject to regulatory approvals.
Although
the U.S. Food and Drug Administration ("FDA") has consistently claimed that it has the authority to regulate laboratory-developed
tests ("LDTs") that are developed, validated and performed only by a CLIA certified laboratory, it has historically exercised
enforcement discretion in not otherwise regulating most LDTs and has not required laboratories that furnish LDTs to comply with the agency's
requirements for medical devices (e.g., establishment registration, device listing, quality systems regulations, premarket clearance or
premarket approval, and post-market controls). As a matter of policy, the FDA generally does not review Direct- to-Consumer LDTs that
are created and performed in a single laboratory, if they are offered to patients only when prescribed by a healthcare provider. More
recently, the FDA has indicated that it will apply a risk-based approach to determine the regulatory pathway for all in-vitro diagnostics,
which includes LDTs, as it does with all medical devices. Accordingly, the regulatory pathway for the Company's LDTs will depend
on the level of risk to patients, based on the intended use of the LDT and the controls necessary to provide a reasonable assurance of
the LDTs safety and effectiveness. The two primary types of marketing pathways for medical devices are clearance of a premarket notification
under Section 510(k) of the Federal Food, Drug, and Cosmetic Act, or 510(k), and approval of a premarket approval application, or PMA.
Legislative proposals addressing the FDA's oversight of LDTs have been introduced in the current and previous Congresses, and we
expect that new legislative proposals will be introduced from time-to-time. The likelihood that Congress will pass such legislation and
the extent to which such legislation may affect the FDA's plans to regulate certain LDTs as medical devices is difficult to predict
at this time.
HIPAA and other privacy
laws
The Health
Insurance Portability and Accountability Act of 1996 ("HIPAA"), established comprehensive federal standards for the privacy
and security of health information. The HIPAA standards apply to three types of organizations: health plans, healthcare clearing houses,
and healthcare providers that conduct certain healthcare transactions electronically ("Covered Entities"). Title II of HIPAA,
the Administrative Simplification Act, contains provisions that address the privacy of health data, the security of health data, the standardization
of identifying numbers used in the healthcare system and the standardization of certain healthcare transactions. The privacy regulations
protect medical records and other protected health information by limiting their use and release, giving patients the right to access
their medical records and limiting most disclosures of health information to the minimum amount necessary to accomplish an intended purpose.
The HIPAA security standards require the adoption of administrative, physical, and technical safeguards and the adoption of written security
policies and procedures.
On February
17, 2009, Congress enacted Subtitle D of the Health Information Technology for Economic and Clinical Health Act, or HITECH, provisions
of the American Recovery and Reinvestment Act of 2009. HITECH expanded and strengthened HIPAA, created new targets for enforcement, imposed
new penalties for noncompliance and established new breach notification requirements for Covered Entities. Regulations implementing major
provisions of HITECH were finalized on January 25, 2013, through
publication
of the HIPAA
Omnibus Rule (the "Omnibus
Rule").
27
Under
HITECH's breach notification requirements, Covered Entities must report breaches of protected health information that has not been
encrypted or otherwise secured in accordance with guidance from the Secretary of the U.S. Department of Health and Human Services (the
"Secretary"). Required breach notices must be made as soon as is reasonably practicable, but no later than 60 days following
discovery of the breach. Reports must be made to affected individuals and to the Secretary and, in some cases depending on the size of
the breach; they must be reported through local and national media. Breach reports can lead to investigation, enforcement and civil litigation,
including class action lawsuits.
In addition
to the federal privacy and security regulations, there are a number of state laws regarding the privacy and security of health information
and personal data that are applicable to clinical laboratories. Many states have also implemented genetic testing and privacy laws imposing
specific patient consent requirements and protecting test results by strictly limiting the disclosure of those results. State requirements
are particularly stringent regarding predictive genetic tests, due to the risk of genetic discrimination against healthy patients identified
through testing as being at a high risk for disease. The Company believes that it has taken the steps required to comply with health information
privacy and security statutes and regulations, including genetic testing and genetic information privacy laws in all jurisdictions, both
state and federal. However, these laws constantly change, and the Company may not be able to maintain compliance in all jurisdictions
where it does business. Failure to maintain compliance, or changes in state or federal laws regarding privacy or security could result
in civil and/or criminal penalties, significant reputational damage and could have a material adverse effect on the Company's business.
Transparency Laws and
Regulations
In the
U.S., the Physician Payments Sunshine Act (the "Sunshine Act") requires medical device manufacturers to track and report to
the federal government certain payments and other transfers of value made to physicians, other healthcare providers (such as physicians
assistants and nurse practitioners), and teaching hospitals and ownership or investment interests held by physicians and their immediate
family members. There are also state "sunshine" laws that require manufacturers to provide reports to state governments on
pricing and marketing information. Several states have enacted legislation requiring medical device manufacturers to, among other things,
establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales and marketing
activities, and such laws may also prohibit or limit certain other sales and marketing practices. These laws may adversely affect our
sales, marketing, and other activities by imposing administrative and compliance burdens on us. If the Company fail to track and report
as required by these laws or to otherwise comply with these laws, it could be subject to the penalty provisions of the pertinent state
and federal authorities.
Other Healthcare Compliance
Requirements.
Our operations
in the U.S. may subject us to healthcare regulation and enforcement by the U.S. federal government and the states in which we conduct
our business, including federal fraud and abuse laws (such as anti-kickback and false claims laws and transparency laws). Failure to comply
with such laws may result in significant penalties, including civil, administrative, and criminal penalties, fines, imprisonment, disgorgement,
exclusion from participation in federal health care programs, and other penalties
Environmental and Safety Laws and
Regulations
The Company
is subject to laws and regulations related to the protection of the environment, the health and safety of employees and the handling,
transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials. For
example,
the U.S. Occupational Safety and Health Administration ("OSHA") has established extensive requirements relating specifically
to workplace safety for healthcare employers in the U.S. This includes requirements to develop and implement multi-faceted programs
to protect workers from exposure to blood-borne pathogens, including preventing or minimizing any exposure through needle stick injuries.
For purposes of transportation, some biological materials and laboratory supplies are classified as hazardous materials and are subject
to regulation by one or more of the following agencies: the U.S. Department of Transportation, the U.S. Public Health Service, the U.S.
Postal Service and the International Air Transport Association. The Company generally use third- party vendors to dispose of regulated
medical waste, hazardous waste and radioactive materials and contractually require them to comply with applicable laws and
regulations.
The Company's
operations are also subject to environmental regulations under Australian State legislation. In particular, the Company is subject to
the requirements of the
Environment Protection Act 1993
. A license has been obtained under this Act to produce listed waste.
Product
Distribution
Despite
significant resource allocation and efforts by a dedicated sales team, sales of BREVAGen
plus
were insufficient to defray the costs
of the sales team. By late 2017, management decided that its sales strategy was not working and disbanded much of the sales infrastructure
in the U.S. and transitioned to an ecommerce-based solution that allowed consumers to initiate testing
online.
Management then designed a "pivot plan" in an effort to reposition the Company, refine and improve products and reload with
a newly developed approach to market.
28
With
COVID-19 social distancing impacting on the Company's ability to fully engage with physicians, the Company introduced
a consumer-initiated
testing (CIT) platform. This sales pipeline deviates from a traditional sales approach that targets clinicians. Instead, it allows patients
to request a test directly, with clinician oversight of the testing process through an independent provider network and
telemedicine.
The COVID-19
Risk Test was launched in the US market in June 2021. The Company entered into a license agreement with Infinity BiologiX LLC in May 2021
for the online sale and distribution of the COVID-19 Risk Test to customers in the USA.
The
Company acquired the EasyDNA business acquired in August 2021 and the AffinityDNA business in July 2022, distributing
its consumer
and lifestyle DNA tests direct to customers through its website portals and network of laboratory partners in North America, Europe and
Australia.
The
Company launched the geneType Multi-Test for breast and colon cancer in February 2022 for the Australian and US markets
to be distributed
to Health Care Professionals through the Company's website portals. The Company is finalizing the development and verification in
its Australian laboratory of the phase two elements of the geneType Multi-Test product to include tests for prostate and ovarian cancers,
coronary heart disease and Type-2 Diabetes. The Company expects to launch the complete suite of tests in the Multi- Test in 2022.
In March 2023, the Company announced
the commercial release of a Melanoma, Atrial Fibrillation, and Pancreatic geneType risk assessment tests.
In April 2023, the Melbourne facility successfully
completed a NATA audit with no findings from the
assessors.
Reimbursement and Clinical
Studies
Beginning
in April 1, 2017, the Company converted to a direct pay relationship with patients in an effort to foster economic and process certainty
to the transaction for the healthcare provider and the patient. The change addressed reimbursement issues from third-party payers, including
low levels of reimbursement, prolonged payment time, patient confusion around eligibility and financial responsibility and poor coverage.
This shift
also has reduced the Company's reliance on clinical utility studies that had been designed as a means to achieve reimbursement coverage
through the private insurers. The Company recognized however that scientific and clinical data are key drivers to help strengthen our
commercial position. The Company intends to explore opportunities to engage in further research collaborations to support clinical utility.
Physicians and the major breast health centers seek multiple points of confirmation that the medical device works as intended and leads
to a meaningful improvement in women's health. Therefore, the more papers that are published regarding the Company's genetic
tests, profiling product performance characteristics including clinical validity and utility, the more likely physicians will be to use
the tests.
In June
2022 the Company completed an independently developed and validated customizable Budget Impact Model ("BIM"), which demonstrates
significant health and economic benefits directly attributed to the implementation of geneType Breast Cancer Risk Assessment Test for
US customers. The BIM was independently developed and validated by ALVA10, whose mission is to create an economic ecosystem that pulls
technology into healthcare, aligning effective healthcare solutions to payer economics. The BIM illustrates the clinical pathways patients
would experience and the economic implications of commercialization and utilization of a test or device. The main finding of the BIM is
the potential for US payers to reduce the annual costs of breast cancer treatment by US$1.4
billion.
US payers,
including commercial insurers, large employers, and benefit groups such as Medicare, are typically reluctant to cover new diagnostic tools,
with reimbursement often taking years to receive. Critically, GTG's customizable BIM enables US payers to accelerate their understanding
of the economic impact of implementing GTG's geneType Breast Cancer Risk Assessment Test prior to commercialization. This could
provide a faster and more certain outcome and minimizing their technology adoption risk. GTG's BIM is a comprehensive and dynamic
tool and can be customized for any US payer. Importantly it will also enable GTG to identify those US Payers who are most likely to be
fast adopters.
Research & Development
Projects
During
the year ended June 30, 2023, the Company supported the following research and development programs, details of which are provided below:
●
Breast Cancer Risk Assessment Test (geneType for Breast
Cancer)
29
●
Colorectal Cancer Risk Assessment Test (geneType for Colorectal
Cancer)
●
Research Agreement executed with Memorial Sloan Kettering New
York
●
Research collaboration with The University of
Melbourne
●
Research collaboration with Ohio State
University
●
Research collaboration with Washington State
University
●
Expanded range of other cancer and disease target predictive risk assessment
tests
In previous
years, other projects, which have since been terminated or otherwise commercialized, have also been supported by the Company. The Company
is constantly seeking new opportunities and plans to focus more on research and development activities in the future. In addition, the
Company plans on having its science and management team engage with the world's leading scientific experts working on predictive
genetic testing and its role within world health systems. Historically, some projects have arisen from new inventions made by the Company
while some have been made by others who have approached the Company seeking collaboration and support for their activities.
Collaboration with The University
of
Melbourne
On November
29, 2016, the Company announced the signing of an exclusive worldwide license agreement with The University of Melbourne for the development
and commercialization of a novel colorectal cancer (CRC) risk assessment test. The core technology behind this test was developed by a
research team at the University's Centre for Epidemiology and Biostatistics, with results from preliminary modelling studies first
published online in Future Oncology on 1 February 2016, in a Paper entitled "Quantifying the utility of single nucleotide polymorphisms
to guide colorectal cancer screening," 2016 Feb: 12(4), 503-13. This simulated case-control study of 1 million patients indicated
that a panel of 45 known susceptibility SNPs can stratify the population into clinically useful CRC risk categories. In practice, the
technology could be used to identify people at high risk for CRC who should be subjected to intensive screening, ultimately reducing the
risk of occurrence and death from the disease. Those identified as low risk of CRC can be spared expensive and invasive screening, thereby
preventing adverse events and unjustified expenses.
A scientific
validation study supporting this work has been completed, and a report of the research program progress has been delivered to the Company.
Whilst the terms of the agreement are confidential, these events represent an important first milestone in the development of a new test
as the Company seeks to diversify its product pipeline and become a key player in the SNP-based cancer risk assessment landscape. We continue
to identify new and exciting ways to collaborate with the University of Melbourne to improve the standard of care for practitioners and
their patients.
Research Collaboration Memorial Sloan
Kettering New
York
In early
2019, the Company's U.S. subsidiary entered into a Research Agreement with Memorial Sloan Kettering Cancer Center of New York and
the University of Cambridge. This collaborative research study is to be led by Mark Robson, MD, Chief of the Breast Medicine Service at
Sloan Kettering. The study is intended to assess whether the provision of individual risk information informed by a polygenic risk score
reduces decisional conflict among BRCA mutation carriers considering preventive surgery.
The Company
believes this collaboration will benefit its engagement and collaboration with high profile cancer genetics researchers who are at the
forefront of risk assessment research, and by providing us with data that may potentially be beneficial in developing additional risk
assessment products.
30
Competition
The
medical diagnostics and biotechnology industries are subject to intense competition. As more information regarding cancer genomics and
personalized medicine becomes available to the public, the Company anticipates that more products aimed at identifying cancer risk will
be developed and that these may compete with its products. The use of Single Nucleotide Polymorphisms (SNPs), for disease risk prediction
is still a relatively new field of medicine.
Organizations
such as Ancestry.com, 23andMe and Color Genomics in the U.S. have developed SNP based risk tests
,
are attracting significant consumer
interest in genetic tests that predict clinical risk of contracting serious diseases. A number of other organizations, including deCODE
(Iceland), Intergenetics, and ThermoFisher have attempted to commercialize SNP-based genetic tests, to both physicians and consumers,
to assess sporadic cancer risk in relevant patient populations. New entrants that the Company are aware of that are in the product development
stage include Counsyl Inc. and Invitae Corporation in the U.S.
We
believe our major direct-to-consumer EasyDNA and AffinityDNA product competitors are AncestryDNA, 23andMe, MyHeritage, Gene by Gene and
Color Genomics.
Australian Disclosure
Requirements
Business Strategies and Prospects for Future
Years
The Company's competitive position in the
genetic testing market is based upon, amongst other things, its ability
to:
●
continue to strengthen and maintain scientific credibility through the process of obtaining scientific validation through clinical trials supported by peer-reviewed publication in medical journals;
●
create and maintain scientifically advanced technology and offer proprietary products and
services;
●
continue to strengthen and improve the messaging regarding the importance and value that the Company's cancer risk assessment tests provide to patients and physicians;
●
diversify the Company's product offerings into other serious disease
types;
●
obtain and maintain patent or other protection for the Company's products and
services;
●
obtain and maintain required government approvals and other accreditations on a timely basis;
and
●
successfully market the Company's products and
services.
If the Company is not successful
in meeting these goals, its business could be adversely affected. Similarly, the Company's competitors may succeed in developing
technologies, products or services that are more effective than any that it is developing or that would render the Company's technology
and services obsolete, noncompetitive or uneconomical.
Dividends
No dividends were paid during
the course of the fiscal year ended June 30, 2023. There are no dividends or distributions recommended or declared for payment to members,
but not yet paid, during the year.
31
Item 4.C
Organizational
Structure
The diagram
below shows the Company's organizational structure as of the date of this Annual Report. All of the Company's subsidiaries
in the chart below are wholly owned.
Item 4.D Property, Plant and
Equipment
As at date of this Report, the Company has executed
four leases in respect of premises occupied by the
Company.
Fitzroy,
Victoria
The Company
rents offices and a laboratory premises at 60-66 Hanover Street, Fitzroy, Victoria, Australia (an inner suburb of Melbourne) from Crude
Pty. Ltd. The current lease will expire on February 28, 2025. The total rental charge in respect of the year ended June 30, 2023 was A$233,634
(2022: A$230,940).
Charlotte, North
Carolina
GeneType
Inc. (formerly named Phenogen Sciences Inc.), the Company's U.S. subsidiary, rents office premises located at 1300 Baxter Street,
Suite 255, Charlotte, North Carolina, U.S. from Midtown Area Partners LLC. The current lease will expire on July 31, 2023. A lease agreement
was signed on March 27, 2023 for a three-year term, commencing on August 1, 2023 and expiring July 31, 2026. The total rental expense
towards the premise for the year ended June 30, 2023 was A$19,724 (2022: A$23,300).
Slacks Creek,
Queensland
The Company
rents office premises located at Suite 1B/1 Sesame Court, Slacks Creek, Queensland, Australia from Kennedy Family Slacks Creek Pty. Ltd.
The Company relocated its office premise from 1 July 2022 through a new two-year lease, expiring on June 30, 2024, with Growth Steel Australia
Pty. Ltd. The property was subsequently sold to Kennedy Family Slacks Creek Pty. Ltd. in December 2022. The total rental charge in respect
of the year ended June 30, 2023 was A$31,335 (2022: A$12,871).
Hove, East
Sussex
The Company
rents office premises located at 60 Lansdowne Place, Hove, East Sussex, United Kingdom from Andrew, Chris & Stephen Tugwell. The current
lease will expire on May 30, 2025. The total rental charge in respect of the year ended June 30, 2023 was A$25,206 (2022: Nil).
32
Item 4A. Unresolved Staff
Comments
Not
applicable
Item 5. Operating and Financial Review and
Prospects
The following
discussion and analysis should be read in conjunction with the Company's financial statements, the notes to the financial statements
and other financial information appearing elsewhere in this Annual Report. In addition to historical information, the following discussion
and other parts of this Annual Report contain forward-looking statements that reflect the Company's plans, estimates, intentions,
expectations and beliefs. The Company's actual results could differ materially from those discussed in the forward- looking statements.
See the "Risk Factors" section of Item 3 and other forward-looking statements in this Annual Report for a discussion of some,
but not all, factors that could cause or contribute to such differences.
Item 5.A Operating Results
Overview
Founded
in 1989, Genetic Technologies is an established Australian-based molecular diagnostics company that offers predictive
genetic testing
and risk assessment tools. During the year ended June 30, 2015, the Company divested its interest in other genetic testing services, which
up until then, together with licensing of non-coding technology, had provided the main source of income to fund operations, to concentrate
on the principal activity of the provision of molecular risk assessment tests for cancer.
The Company's
revenues during its years ended June 30, 2021 and 2020 were generated principally by sales of its 'geneType for Colorectal Cancer'
and 'geneType for Breast Cancer' genetic tests to healthcare providers through a global network of distribution partners and
the Company's website portals. The Company's revenues during its years ended June 30, 2022 and 2023 were generated principally
by sales of its EasyDNA and AffinityDNA branded genetic test products through its international network of proprietary EasyDNA and AffinityDNA
branded websites as well as Amazon (AffinityDNA). The company acquired the business and assets of EasyDNA and AffinityDNA in August 2021
and July 2022, respectively. The acquisition of AffinityDNA has resulted in a new business segment within the Company's segment
information as compared to the prior year.
Since
inception up to June 30, 2023, the Company has incurred A$156,715,687 in accumulated losses. The Company's losses have resulted
principally from costs incurred in research and development, general and administrative and sales and marketing costs associated with
its operations. Further losses are anticipated as the Company continues to invest in new genetic testing product research and development,
and explore optimal distribution methodologies to commercialize its product offering. Refer to the Financial Statements section in Item
18.
Fiscal
year
As an
Australian company, the Company's fiscal, or financial, year ends on June 30 each year. The Company produces audited consolidated
accounts at the end of June each year and furnish half-yearly accounts for the periods ending on December 31 each year, both of which
are prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting
Standards Board.
Comparison of the year ended June 30, 2023
to the year ended June 30,
2022
The
presentation of the Statement of Profit or Loss and Other Comprehensive Income is in line with the Company management's
monthly
reporting of the Group's results and performance presented to the Board of Directors. For the financial year ended June 30, 2023,
the Company reports a total comprehensive loss of A$11,650,334 (2022: A$7,103,134), the result includes a non-cash impairment expense
of A$2,125,725 (2022: A$564,161).
Revenues from
operations
During
the 2023 financial year, the Company's consolidated gross revenues from continuing operations, excluding other revenue, increased
by A$1,891,302 (28%) from A$6,794,816 to A$8,686,118 from the previous year. The increase in revenue is mainly due to increase in sales
of EasyDNA (A$1,708,823) direct-to-consumer genetic tests as well as sales of AffinityDNA (A$944,508), following the acquisition of the
AffinityDNA business on 14 July 2022.
Finance
income
Finance
income increased by A$183,905 (507%) from A$36,256 to A$220,161 when compared to the previous year. The increase is due to the combination
of higher interest rates and additional interest income gained from fixed deposits placed during the year following the receipt of funds
from the capital raised in February 2023.
33
Other
income
Other
income decreased by A$946,569 (34%) from A$2,783,391 to A$1,836,822 when compared to the previous year. The majority of the Other income
recorded for the financial year is largely the research and development tax incentive refund received from the Australian Taxation Office.
Research and development tax incentive income (or "R&D tax credit") recorded for the financial year was A$1,616,064 (2022:
A$2,397,552). The R&D tax incentive is recognized on an accruals basis when realizable. The lower R&D tax credit is due to the
decreasing external R& D expenses.
Raw materials and changes in
inventory
The Company's
raw materials and changes in inventory costs increased by A$1,321,731 (44%) from A$3,013,534 to A$4,335,265 from the prior financial year.
The increase in raw materials is in line with the increase in product revenues from EasyDNA and AffinityNDA experienced during the financial
year.
Commissions
Commissions
increased to A$236,019 (2022: A$156,625), the increase being attributable to commissions paid/payable in respect to agency sales for EasyDNA
and AffinityDNA.
Employee benefits
expenses
Employee
benefits expense increased by A$339,411 (6%) to A$6,208,066 during the financial year (2022: A$5,868,655). The increase is largely the
result of an increase in number of employees from 52 to 60 following the acquisition of the AffinityDNA business and an expansion of commercialization
staff for the geneType test.
Advertising and promotional
expenses
Advertising
and promotional expenses increased to A$2,712,353, a 44% increase from comparative period (2022: A$1,885,402)
(44%). The majority
of this increase is attributable to pay-per-click advertising costs, A$1,556,627 (2022: A$987,460) for the EasyDNA
and
AffinityDNA businesses. Additionally, other marketing costs increased to A$861,639 in the current financial year against A$675,493
in
the prior year as the Company expanded the geneType branded genetic tests in the Australian and U.S. markets.
Professional
fees
Professional
fees decreased by A$474,804 (26%) from A$1,835,444 to A$1,360,640 when compared to the previous year. The decrease is mainly related to
the decrease in consulting fees, A$558,987 (2022: A$994,275).
Research and development
expenses
Laboratory,
research and development costs increased by A$575,650 (82%) from A$705,507 to A$1,281,157 when compared to the previous year. This category
of expenditure includes patent application and annual renewal fees. Laboratory, research and development costs increased as the Company
continued development, and accelerated commercialization of its pipeline of the new PRS tests for a range of human disease types. Also
under development are a suite of gene-panel tests for a range of hereditary cancers. The research and development activities cover the
following diseases: breast cancer, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, melanoma, Type-2-diabetes, cardiovascular
disease, and atrial fibrillation.
Depreciation and
amortization
Depreciation
and amortization expense attributable to the laboratory testing equipment, computer equipment, office equipment, leases amortization and
other intangible assets was A$676,583 (2022: A$578,668), with the increase related to an increase in laboratory testing equipment depreciation
as a result of prior period purchase and first-time recognition of lease amortization for the AffinityDNA office lease.
Impairment
expenses
Impairment
expenses increased to A$2,125,725 for the 2023 financial year (2022: A$564,161). Impairment expense is mainly the result of an impairment
expense recognized against the goodwill associated with the acquisition of EasyDNA, A$1,845,000, as initial product revenues has not met
expectations. The balance of the expense recorded for the financial year is the result of additional allowance for un-collectability of
certain debtor balances outstanding as at June 30, 2023.
34
Other
expenses
Other
expenses increased to A$3,687,030 (2022: A$2,154,375) during the financial year. The increase is mainly related to increase in IT and
communication expenses (A$585,875), travel and entertainment expenses (A$299,622) and administrative expenses (A$249,387).
Finance
costs
Finance
costs increased to A$29,515 (2022: A$15,215). Finance costs relate to non-cash lease interest charges required to be recognized under
accounting standard AASB16.
Income
tax credit
Income
tax credit recognized for the financial year was A$158,329 (2022: A$32,125) which mainly relates to the recognition of deferred tax assets
to offset against the remaining deferred tax liabilities arising from the acquisition of EasyDNA and AffinityDNA's brands and other
identifiable intangible assets.
Comparison
of the year ended June 30, 2022 to the year ended June 30, 2021
The
current presentation is in line with the Company management's monthly reporting of the Group's results and performance presented
to the Board of Directors. For the financial year ended June 30, 2022, the Company reports a total comprehensive loss of A$7,103,134
(2021: A$7,115,087).
Revenues
from operations
During
the 2022 financial year, the Company's consolidated gross revenues from continuing operations, excluding other revenue, increased
by A$6,674,262 (5,536%) from A$120,554 to A$6,794,816 when compared to previous year. The increase in revenue is mainly due to sales
of EasyDNA direct-to-consumer genetic tests following the acquisition of the EasyDNA business on August 13th, 2021.
Finance
income
Finance
income decreased by A$26,138 (42%) from A$62,394 to A$36,256 when compared to the previous year. The decrease was due to the reduction
in cash balances as at year-end of A$11,731,325 as compared to A$20,902,282 in the prior year.
Other
income
Other
income mainly consists of research and development tax incentive refund received from the Australian Taxation Office. The Research and
development tax incentive refund (or "R&D tax credit") increased by 140% from A$997,908 to A$2,397,552 when compared
to the previous year. The R&D tax credit is recognized on an accruals basis when realizable. The higher R&D tax credit was due
to increased expenditure on the R&D activities. The increase was offset by reduction in Government grants income for COVID-19 relief
received in prior year amounting to A$287,883. The increase was also attributable to foreign currency gains amounting to A$359,884 as
compared to A$57,899 in the prior year, as a result of a weakening of the Australian dollar against the United States Dollar during the
financial year.
Raw
materials and changes in inventory
The
Company's raw materials and changes in inventory costs increased by A$2,843,077 (1,668%) from A$170,457 in the previous financial
year to A$3,013,534 in the current financial year. Direct materials utilized for geneType for breast and colorectal cancer as well as
EasyDNA direct-to-consumer genetic testing products, increased by A$2,867,386 (2,473%) from A$115,934 to A$2,983,320 due to an increased
number of tests conducted during the year. There was a decrease in inventories written-off by A$24,309 to A$30,214 in the current financial
year when compared to A$54,523 in the previous financial year.
The
EasyDNA and geneType/Corporate segments contributed A$2,951,815 and A$61,719, respectively of the total cost of sales in the 2022 financial
year. The EasyDNA business incurred the majority of the costs in line with the sale of genetic tests since its acquisition in August
2021.
Commissions
Commissions
were A$156,625 for the 2022 financial year, no commissions expenditure was recorded for the comparative period. Commissions paid were
in respect to agency sales for EasyDNA.
35
Employee
benefits expenses
Employee
benefits expense increased by A$2,000,324 (52%) to A$5,868,655 during the 2022 financial year when compared to A$3,868,331 in the previous
financial year. The increase is mainly related to the increase in number of employees from 18 to 52 as a result of the acquisition of
the EasyDNA business during the year.
Advertising
and promotional expenses
Advertising
and promotional expenses increased by A$1,449,128 (332%) from A$436,274 to A$1,885,402 when compared to the previous year. The major
movement during the year related to pay-per-click advertising costs incurred of A$987,460 (2021: Nil) for the EasyDNA business. Additionally,
other marketing costs increased to A$675,493 for the 2022 financial year against A$310,960 in the prior year as the Company launched
the geneType branded genetic tests for breast and colorectal cancer in the Australian and US markets.
Professional
fees
Professional
fees increased by A$374,043 (26%) from A$1,461,401 to A$1,835,444 when compared to the previous year. The increase was mainly related
to the increase in consulting fees by A$410,549 to A$994,275 during the 2022 financial year when compared to A$583,726 in the previous
financial year.
Research
and development expenses
Laboratory,
research and development costs decreased by A$460,024 (39%) from A$1,165,531 to A$705,507 when compared to the previous year. Laboratory,
research and development costs increased as the Company continued development, and accelerated commercialization of its pipeline of the
new PRS tests for a range of human disease types. Also under development are a suite of gene-panel tests for a range of hereditary cancers.
The research and development activities cover the following diseases: breast cancer, colorectal cancer, prostate cancer, ovarian cancer,
melanoma, Type-2-diabetes, coronary artery disease, atrial fibrillation, and COVID severity.
Depreciation
and amortization
Depreciation
and amortization expense attributable to the laboratory testing equipment and other intangible assets increased by A$192,391 (50%) from
A$386,277 to A$578,668 in 2022 financial year due to the purchase of laboratory equipment.
Impairment
expenses
Impairment
expenses increased by A$532,113 (1660%) to A$564,161 during the financial year when compared to A$32,048 in the previous financial year.
Impairment expense was a result of management's judgement on the collectability of debtor balances outstanding as at June 30, 2022.
Other
expenses
Other
expenses increased by A$870,504 (68%) to A$2,154,375 during the financial year when compared to A$1,283,871 in the previous financial
year. The increase mainly related to an increase in buildings and facilities expenses such as country office charges (A$226,827), service
charges (A$116,752) and credit card merchant charges (A$253,098) attributable to EasyDNA sales.
Finance
costs
Finance
costs decreased by A$1,123 (7%) from A$16,338 to A$15,215 when compared to the previous year. Finance costs incurred in 2022 and 2021
were primarily lease interest charges.
Income
tax credit/(expense)
Income
tax credit recognized during the 2022 financial year related to reversal of deferred tax liabilities arising from the acquisition of
EasyDNA's brands and other intangible assets. No tax impact was recorded in the 2021 financial year.
36
Australian
Disclosure Requirements
Significant
Changes in the State of Affairs
There
have been no significant changes within the state of affairs during the year ended June 30, 2023 except as noted in the "Important
Corporate Developments" section included in Item 4.A.
Likely
Developments and Expected Results of Operations
At
the date of the Directors' Report there no other matters not already disclosed within the Company's Directors' Report
and financial statements, and related notes, for the 2023 financial year.
Environmental
Regulations
Our
operations are not subject to any significant environmental regulations under either Commonwealth of Australia or State/ Territory legislation.
We consider that adequate systems are in place to manage our obligations and are not aware of any breach of environmental requirements
pertaining to us.
Item
5.B Liquidity and Capital Resources
Summary
Since
inception, the Company's operations have been financed primarily from capital contributions by our stockholders, proceeds from
our licensing activities and revenues from operations, grants, and interest earned on the Company's cash and cash equivalents.
Currently
the Company's overall cash position depends on completion of its research and development activities, overall market acceptance
of, and revenue generated by, its new genetic testing products. The Company's cash and cash equivalents were A$7,851,197 as of
June 30, 2023.
During
the years ended June 30, 2023, 2022 and 2021 the Company incurred total comprehensive losses of A$11,650,334, A$7,103,134 and A$7,115,087,
respectively.
During
the years ended June 30, 2023, 2022 and 2021 the Company's net cash flows used in continuing operations were A$9,723,095, A$5,659,456
and A$6,295,929, respectively.
The
Company will continue to bring its comprehensive suite of risk assessment tests and direct to consumer portfolio to major global markets
across global markets. The Company can also expand and upgrade the laboratory to incorporate next generation sequencing and high-density
SNP arrays. These will allow-for the first time-risk assessments for 100 per cent of a person's genomic risk, including monogenic,
polygenic, clinical risk factors, and family history.
Going
Concern
. For the year ended June 30, 2023, the Company incurred a total comprehensive loss of A$11,650,334 (2022: A$7,103,134)
and net cash outflow from operations of A$9,723,095 (2022: A$5,659,456). As at June 30, 2023, the Company held total cash and cash equivalents
of A$7,851,197 and total net current assets of A$7,185,750.
The
company expects to continue to incur losses and cash outflows for the foreseeable future as it continues to invest resources in research
and development activities for geneType risk assessment tests and to invest in the commercialization activities for geneType,
EasyDNA and AffinityDNA, via marketing, sales and distribution channels.
The
continuing viability of the company and its ability to continue as a going concern, and meet its debts and commitments as they fall due,
is dependent on the satisfactory completion of an equity raising forecast for the early part of the 2024 calendar year. The Company does
not currently have binding commitments from any party to subscribe for shares and any raise will be subject to maintaining active listing
on the NASDAQ exchange as well as compliance with the Group's obligations under ASX Listing Rule 7.1.
On
July 17, 2023, the company received notification from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price
requirement of Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market, since the closing bid price for the
company's American Depositary Shares (ADS) on the Nasdaq Capital Market was below US$1.00 for 34 consecutive trading days.
The
Notification has no immediate effect on the listing of the Company's ADS on the Nasdaq Capital Market. Under Nasdaq Listing
Rule 5810(c)(3)(A), the company has a period of 180 calendar days from the date of Notification to regain compliance with the
minimum bid requirement, during which time the ADS will continue to trade on the Nasdaq Capital Market. If at any time before
January 15, 2024, the bid price of the ADS closes at or above US$1.00 per ADS for a minimum of 10 consecutive business days, the
Company will regain compliance with the Minimum Bid Requirement.
37
Re-compliance
with the NASDAQ's minimum bid price requirement can be cured with positive business developments (announced to the market), leading
to an increase in the ADS price to above US$1 or a stock split. The company also has the option of applying for an extension of time,
a further 180 days, to regain compliance. This development isn't expected to impede the company's ability to raise additional
equity capital.
Due
to the uncertainty surrounding the timing, quantum or the ability to raise additional equity, there is a material uncertainty that may
cast significant doubt on the Group's ability to continue as a going concern and therefore, that it may be unable to realize
its assets and discharge its liabilities in the normal course of business. However, the Directors believe that the Company will be
successful in its equity raising endeavours, and has a strong track record in this regard, and accordingly, have prepared the financial
report on a going concern basis. As such no adjustments have been made to the financial statements relating to the recoverability and
classification of the asset carrying amounts or classification of liabilities that might be necessary should the Group not be able to
continue as a going concern.
Operating
Activities.
The Company's net cash used in operating activities was A$9,723,095, A$5,659,456 and A$6,295,929 for the years
ended June 30, 2023, 2022 and 2021, respectively. Cash used in operating activities for each period consisted primarily of losses incurred
in operations reduced by non-cash items such as impairment expenses, depreciation and amortization expenses, share based payments expenses,
foreign exchange movements and unrealized profits and losses relating to investments. In approximate order of magnitude, cash outflows
typically consist of staff-related costs, marketing expenses, service testing expenses, general and administrative expenses, legal/patent
fees and research and development costs.
Investing
Activities
. The Company's net cash used in investing activities was A$311,937, A$3,461,163 and A$748,706 for the years
ended June 30, 2023, 2022 and 2021, respectively. During the year ended June 30, 2023 the Company paid A$486,188 for the acquisition
of the AffinityDNA business, representing the first tranche payment due under the acquisition agreement. During the 2022 financial year
the Company made a cash payment contribution of A$3,400,625 towards the acquisition of EasyDNA from General Genetics Corporation. The
purchase of plant and equipment was A$17,552, A$63,926 and A$748,706 in the past 3 financial years, respectively. There were no further
significant capital expenditures for the years ended June 30, 2023, 2022 and 2021.
Financing
Activities
. The Company's net cash (used in)/from financing activities was A$5,919,943, A$(279,064), and A$13,689,996 for
the years ended June 30, 2023, 2022 and 2021, respectively. During the year ended June 30, 2023, the Company generated cash flows of
A$7,172,399 from the issue of Ordinary Shares less costs associated with the transactions of A$851,624. There were no capital raising
during the year ended June 30, 2022. During the 2021 financial year the Company raised equity capital which contributed A$13,940,938
net of costs.
Leases.
The Company has four property leases in place at June 30, 2023. These leases relate to the premises occupied by the Company in
Fitzroy, Victoria, Australia and Slacks Creek, Queensland, Australia, by its U.S. subsidiary, geneType Inc. (formerly Phenogen Sciences
Inc.), in Charlotte, North Carolina, U.S. and by its U.K. subsidiary, GeneType UK Limited in Hove, East Sussex, United Kingdom. The total
rental charge in respect of the year ended June 30, 2023 was A$233,634, A$31,335, A$19,724 and A$25,206, respectively.
The
future minimum lease payments in respect of the four leases that were in place and had remaining non-cancellable lease terms as of June
30, 2023 were A$551,879.
Item
5.C Research and Development, Patents and Licenses, etc.
Our
principal business industry is biotechnology, with a historical emphasis on genomics and genetics, the licensing of our non- coding patents,
reduction to practice of our fetal cell patents and expansion of the related service testing business. Research and development expenditure
as below is reflective of the intense focus by the scientific and laboratory team to develop and market a suite of world-leading predictive
genetic tests.
The
following table details historic R&D expenditure by project.
2023
A$
2022
A$
2021
A$
Polygenic Risk Testing
3,679,139
4,204,919
986,622
Total R&D expense
3,679,139
4,204,919
986,622
Other expenditure
18,973,214
12,572,667
7,833,906
Total expenditure
22,652,353
16,777,586
8,820,528
R&D as a % of total expenditure
16.7
%
25.1
%
11.19
%
38
Item
5.D Trend Information
See
Item 5.A. "Operating Results" and Item 5.B. "Liquidity and Capital Resources" above.
Item
5.E Critical Accounting Estimates
Not
applicable
Item
6. Directors, Senior Management and Employees
(Start
of the Remuneration Report (Audited) for
Australian Disclosure Requirements
)
The
Genetic Technologies Limited Board of Directors ("the Board") presents the 2022/2023 Remuneration Report, which has been
prepared in accordance with the relevant Corporations Act 2001 and accounting standards requirements. The remuneration report sets out
remuneration information for our company's key management personnel ("KMP") as defined in the International Accounting
Standards 24 'Related Party Disclosures' and the Australian Corporations Act 2001 for the financial year ended June 30, 2023.
The remuneration report which complies with s300A of the Corporations Act 2001 has been audited as required by s308 (3C) of the Corporations
Act 2001.
Item
6.A Directors and Senior Management
The
Directors of the Company as of the date of this Annual Report are:
Mr.
Peter Rubinstein
, BEc. LLB
(Independent Non-Executive and Chairman)
Mr.
Rubinstein was appointed to the Board on January 31, 2018 and appointed as Chairman in April 2020. He has over 20 years' experience
in early-stage technology commercialization through to public listings on the ASX. He is a lawyer, having worked at a large national
firm prior to moving in-house at Montech, the commercial arm of Monash University.
Mr.
Rubinstein has had significant exposure to the creation, launch and management of a diverse range of technology companies in biotech,
digital payments and renewable energy. Mr. Rubinstein is also a Non-Executive Director of DigitalX Limited (ASX: DCC).
Dr.
Jerzy (George) Muchnicki
, MBBS
(Non-Independent Non-Executive)
Dr.
Muchnicki was appointed to the Board on January 31, 2018 and acted as Interim Chief Executive Officer from September 2019 till the appointment
of Mr. Simon Morriss to the role. Dr. Muchnicki graduated from Monash University and has held positions in private practice for over
25 years and was Head of Student Health at The University of Melbourne. For the past 14 years, he has been involved in commercialization
and funding R&D in the biotechnology sector from gene silencing to regenerative medicine.
Dr.
Muchnicki brings with him strong commercial and medical skills, including broad interests in software development, blockchain and sustainable
building materials. He is a co-founder and Non-Executive Director of Speed Panel Holdings a world leader in fire rated and acoustic wall
solutions. He is also the co-founder of Candlebets, a software development company that is creating blockchain enabled platforms for
the gaming industry.
Dr.
Lindsay Wakefield
, MBBS
(Independent Non-Executive)
Dr.
Wakefield was appointed to the Board on September 24, 2014. He started Safetech Pty Ltd in 1985 and over the next 25 years, Safetech
became a force in the Australian material handling and lifting equipment market, designing and manufacturing a wide range of industrial
products. In 1993, he left medicine to become the full-time CEO of Safetech. In 2006, Safetech was awarded the Telstra Australian National
Business of the Year. In 2013, Safetech merged and ultimately acquired Tiemen Materials Handling.
Dr
Wakefield continues as the CEO of Safetech. It is Australia's largest manufacturer and supplier of dock equipment, freight hoists
and custom lifting solutions. Safetech employs approximately 100 people. Dr Wakefield has been a biotech investor for more than 20 years.
Mr.
Nick Burrows
, B.Com. FAICD, FCA, FGIA, FTIA, F Fin
(Independent Non-Executive)
Mr.
Burrows has over 30 years' commercial experience and was appointed to the Board on September 1, 2019. He is a contemporary independent
Non-Executive Director across the Listed, government and private sectors with significant expertise in corporate governance, and strategic,
commercial, financial and risk management oversight, underpinned by his background as a chartered accountant.
39
Mr.
Burrows was Chief Financial Officer and Company Secretary of Tassal Group Limited for 21 years from 1988 to 2009, and accordingly brings
to the Board strong independent C-suite commercial experience and the benefits of an extensive and contemporary senior executive ASX200
listed entity background. Mr. Burrows current and past Board and advisory portfolio encompasses listed and regulated entities, government
business enterprises, state-owned and local government entities and authorities, large private/ family companies community organizations,
membership-based bodies and Not-for-Profits.
Mr
Burrows' expertise spans a raft of industry sectors encompassing water and sewerage, infrastructure, renewable energy, forestry,
agribusiness, public transport, tourism and hospitality, education and the vocational education sector, aquaculture, civil engineering,
construction, and finance and valuations.
Mr
Burrows is a Fellow of the Australian Institute of Company Directors, Institute of Chartered Accountants Australia, Governance Institute
of Australia Ltd, Taxation Institute of Australia and the Financial Services Institute of Australasia and is also a Chartered Accountant.
Mr Burrows also served as National President of the Governance Institute of Australia in 2002 and served on their National Board for
6 years.
Senior
Management
The
Company has a professional team of qualified and experienced personnel, including a number of research and development scientists and
technicians. The Company currently has 60 full-time-equivalent employees in addition to the four Non-Executive Directors listed above.
Mr.
Simon Morriss,
GAICD
(Chief Executive Officer)
Mr.
Morriss was appointed as Chief Executive Officer on February 1, 2021 and brings over 20 years' experience within the Pharmaceutical,
Healthcare and FMCG industries having held senior executive positions at Sanofi and Blackmores. He brings a wealth of experience in managing
teams and successfully executing across sales, marketing and brand building.
Additionally,
Mr. Morriss has been critical in leading commercialization across these industries and understands the unique pressures and opportunities.
He has led companies through strategic adaptation to execution and will be driving Genetic Technologies commercialization strategy and
continue to drive innovation across the business.
Mr.
Tony Di Pietro,
BComm, CA, AGIA, MAICD
(Company Secretary/Chief Financial Officer)
Mr
Tony Di Pietro was appointed Company Secretary & Chief Financial Officer November 28, 2022. Mr Di Pietro is a Chartered Accountant
with significant corporate accounting experience, gained both in Australia and the UK. He holds a Graduate Diploma of Applied Corporate
Governance from the Governance Institute of Australia and is a member of the Australian Institute of Company Directors. Tony is a finance
executive with extensive technical accounting, corporate tax, and company secretarial experience. Mr Di Pietro has held senior roles
within the Biotechnology/MedTech industry for the past 20 years including INOVIQ Ltd (ASX:IIQ), BARD1 Life Sciences Ltd (ASX:BD1), Sienna
Cancer Diagnostics Ltd (SDX), and Acrux Ltd (ASX:ACR). Tony played a significant role in the ASX listing of both Sienna and Acrux and
the merger between Sienna and BARD1. He has also gained valuable experience in other industry sectors, employed by companies such as
BHP Ltd, ExxonMobil Ltd, HSBC Ltd and Wilson Group.
Dr.
Richard Allman
, PhD
(Scientific Advisor, former Chief Scientific Officer)
Dr.
Allman joined the Company in December 2004 and was appointed as Scientific Director in December 2012 and Chief Scientific Officer in
2016. He has over 20 years of scientific and research experience in both the academic arena in the UK and the commercial sector in Australia.
He has wide experience in research leadership, innovation management, and intellectual property strategy, covering oncology, diagnostics,
and product development. Prior to entering the biotech sector, Dr. Allman's academic career encompassed oncology research, drug
development, and assay design. Dr. Allman ceased full-time employment with the Company on October 6, 2022. Dr. Allman has continued his
association with the Company as a consulting Scientific Advisor.
Mr.
Carl Stubbings
(Chief Commercial Officer)
Mr
Stubbings joined the Company in 2021 and was appointed as Chief Commercial Officer on September 1, 2021. Mr Stubbings is an experienced
senior leader in the biotechnology and diagnostics industry with a focus on commercialization, sales, marketing and business development.
He
has considerable experience commercializing diagnostic products, both locally and globally. Based in the USA for 13 years, he served
as Senior Vice President for Panbio USA Ltd and Vice-President of Sales and Marketing for Focus Diagnostics, a subsidiary of Quest Diagnostics
(NASDAQ:DGX), one of the world's largest pathology laboratories.
40
In
July 2012, Mr Stubbings moved back to Australia where he was appointed Chief Business Officer at Benitec Biopharma Limited (ASX: BLT,
NASDAQ: BNTC). More recently he has assisted several Australian biotech companies with their commercialization strategies. These companies
include BCAL Diagnostics, a start-up company developing a blood test for breast cancer, Minomic, an Immuno Oncology company with a test
for prostate cancer, and Biotron (ASX: BIT), a listed company that is developing and commercializing anti-viral small molecule therapies.
In 2019 Mr Stubbings was appointed CEO and Managing Director of Sienna Cancer Diagnostics Ltd (ASX: SDX). In that role, he helped lead
the successful merger between Sienna and BARD1 Life Sciences (ASX:BD1). Following the merger, Mr Stubbings was appointed Chief Operating
Officer of the merged entity BARD1 Life Sciences.
Mr
Stubbings has a Bachelor of Applied Science (Medical Technology) from the Queensland University of Technology.
Mr.
Kevin Camilleri
(Chief Executive Officer of EasyDNA)
Mr
Camilleri joined the Company in 2021 and was appointed as Chief Executive Officer of EasyDNA on August 16, 2021. He was founder member
of the EasyDNA brand in 2001 and grew the business over time into a leading international online provider of genetic testing services.
A business graduate from the University of Bath in the UK, Mr. Camilleri has over the years accumulated a broad range of skills covering
most aspects of business management including strategic, financial, organizational, operational and commercial skills. He brings to the
company the ability to manage a cross-border organization in line with Genetic Technologies strategy for international expansion.
Mr.
Mike Tonroe, BSc, FCA, MAICD
(former Company Secretary/Chief Financial Officer)
Mr.
Tonroe joined the company on June 15, 2021, resigning November 28, 2022. Mike has over 25 years of experience with private and listed
companies in Australia, UK, US and Canada.
Mike
held the role of Chief Financial Officer and Company Secretary at dual-listed Opthea and was Chief Financial Officer and Company Secretary
at the Australian Synchrotron in Melbourne and he also has extensive accounting expertise having worked for both Deloitte and KPMG in
the UK and Hong Kong.
Mr.
Tonroe is a fellow of the Institute of Chartered Accountants in England and Wales, a member of the Australian Institute of Company Directors
and holds a graduate degree in Business Studies from Buckingham University, UK.
Item
6.B Compensation
Elements
of compensation
Independent
external advice is sought from remuneration consultants when required, however no advice has been sought during the period ended June
30, 2023, or comparative period. The board aims to ensure that remuneration practices are:
●
competitive and reasonable, enabling the Company to attract and retain key
talent
●
aligned to the Company's strategic and business objectives and the creation of shareholder
value
●
transparent and easily understood,
and
●
acceptable to
shareholders.
Element
Purpose
Performance
    metrics
Fixed
    annual remuneration (FR)
Provide
    competitive market salary including superannuation and non-monetary benefits
Nil
Short-Term
    Incentive (STI)
Reward
    for in-year performance and retention
Company
    and individual performance goals
Long-Term
    Incentive (LTI)
Alignment
    to long-term shareholder value
Share
    price, capital raised, company and individual performance goals
(i)
Fixed
    annual remuneration (FR)
Objective
The
Remuneration Committee oversees the setting of fixed remuneration on an annual basis. The process consists of a review of Company, divisional
and individual performance, relevant comparative remuneration in the market and internally and, where appropriate, external advice on
policies and practices. The members of the Committee have access to external advice independent of Management.
41
Structure
Fixed
remuneration consists of some or all of the following components:
●
base
    salary;
●
non-monetary
    benefits, for example health insurance; and
●
superannuation
    benefits, which includes employer contributions,
With
the exception of the employer contributions to superannuation, Executives are given some flexibility to decide the composition of their
total fixed remuneration and the allocation between cash and other benefits. It is intended that the manner of payment chosen will be
optimal for the recipient without creating any additional cost for the Company.
Fixed
remuneration is reviewed annually with reference to individual performance, market benchmarks for individual roles and the overall financial
performance of the Company. Any changes to the fixed remuneration of Executives are first approved by the Remuneration Committee.
All
employee remuneration is evaluated on a regular basis using a set of variables and taking into account the addition of the statutory
superannuation contribution. An assessment of existing base salaries is made annually using comparisons against independent market data
which provides information on salaries and other benefits paid for comparable roles within the biotech and pharmaceutical industries,
using third party salary survey data. Annual performance reviews with each employee are based on a rating system which is used to assess
his or her eligibility for salary increases. Other qualitative factors, including the specialized knowledge and experience of
the individual and the difficulty of replacing that person, are also taken into account when considering salary adjustments.
Remuneration
Committee membership
As
at the date of this Report, the composition of the committee is as follows:
●
Dr.
    Lindsay Wakefield – Chairman of the Committee
●
Mr.
    Nicholas Burrows (Member)
●
Mr.
    Peter Rubinstein (Member)
(ii)
Short-Term
    Incentives (STI)
Short
Term Incentive (STI) is an annual plan that applies to Executives and other senior employees that is based on the performance of both
the Company and the individual during a given financial year. STI ranges vary depending on the role, responsibilities and deliverables
achieved by each individual. Actual STI payments granted to the relevant employee will depend on the extent to which the pre-agreed specific
targets are met within a financial year. Specific targets are quantifiable with the agreed method of measurement defined at the beginning
of the financial year. The ongoing performance of the Executive or senior employee is evaluated regularly during the performance cycle.
Company
objectives, and their relative weighting, vary depending on the position and responsibility of the respective individual, but in respect
of the year ended June 30, 2023 include, amongst other things, the achievement of:
●
achieving
    targets for cost reduction or efficiency gains;
●
contributing
    to business growth and expansion; and
●
performance
    or the delivery of results which exceed agreed targets.
These
measures are chosen as they represent the key drivers for the short-term success of the business and provide a framework for delivering
long term value. Personal and operating objectives vary according to the role and responsibility of the Executive and include objectives
such as service delivery to customers, project delivery, compliance outcomes, intellectual property management and various staff management
and leadership objectives.
Achievement
of an individual's targets or objectives is documented and assessed by both the individual and his or her direct manager. The individual
will participate in an annual performance review and must provide evidence of the objectives that he or she has delivered during the
period under review. Each objective is then rated on an achievement scale. Depending on the aggregate of the ratings, the individual
may be eligible to receive an STI payment.
42
STI
payments, if any, are generally paid in August or September of each year subject to the completion of the performance review process
and the receipt of a satisfactory rating. The Remuneration Committee conducts this process in the case of the CEO. During the financial
year ended June 30, 2023, no Short-Term Incentive payments were made to Executives and other senior employees.
(iii)
Long-Term
    Incentives (LTI)
The
objective of the Company's LTI arrangements is to reward Executives and senior employees in a manner that aligns their remuneration
with the creation of shareholder wealth. As such, significant LTI grants are generally only made to Executives who are able to influence
the generation of shareholder wealth and have an impact on the Company's long-term profitability. There are share price targets
to be met before performance rights vest in respect of the LTI grants made to Executives. Options with a vesting period also serve as
a retention tool and may reduce the likelihood of high performing Executives and senior employees being targeted by other companies.
Long
Term Incentive (LTI) grants to Executives and senior employees are delivered in the form of options over unissued ordinary shares in
the Company which are granted under the terms and conditions of the Company's Employee Option Plan. Selected Executives who contribute
significantly to the long-term profitability of the Company are invited to participate in the Employee Option Plan. The remuneration
value of these grants varies and is determined with reference to the nature of the individual's role, as well as his or her individual
potential and specific performance.
In
cases where an Executive ceases employment prior to the vesting of his or her options, the options are forfeited after a prescribed period
if they have not been exercised. The prescribed period ranges from two to six months, depending on the circumstances under which they
left the Company, e.g. resignation, retirement, termination or death. In the event of a change of control of the Company, the performance
period end date will be brought forward to the date of the change of control and awards will vest over this shortened period.
Link
between remuneration and performance
Statutory performance indicators
The
Company aims to align executive remuneration to the Company's strategic and business objectives and the creation of shareholder
wealth. The table below shows measures of the Company's financial performance over the last five years as required by the Corporations
Act 2001. However, these are not necessarily consistent with the measures used in determining the variable amounts of remuneration to
be awarded to KMPs. As a consequence, there may not always be a direct correlation between the statutory key performance measures and
the variable remuneration awarded.
2023
2022
2021
2020
2019
Loss for the year attributable to owners (A$)
11,750,923
7,130,998
7,077,619
6,294,775
6,425,604
Basic earnings per share (cents)
(0.1
)
(0.1
)
(0.1
)
(0.1
)
(0.2
)
Share price at year end (A$)
0.003
0.003
0.009
0.005
0.006
The
Company's earnings have remained negative since inception due to the nature of the business. Shareholder wealth reflects this speculative
and volatile market sector. No dividends have ever been declared by the Company. The Company will continue its research and development
activities, leading to an expansion of its intellectual property portfolio, as well as continued growth of product revenues from its
three key brands; geneType, EasyDNA and AffinityDNA. The overall objective is to achieve key development and commercial milestones in
order to add further shareholder value.
43
Remuneration
expenses
Details
of the nature and amount of each major element of the compensation of each director of the Company and each of the named officers of
the Company and its subsidiaries, for services in all capacities during the financial year ended June 30, 2023 are listed below. All
figures are stated in Australian dollars (A$).
Short-term benefits
Post-
employment
Superannuation
Other long-term benefits
Share- based payments Equity
Percentage (%)
Name and title
Salary/fees
STI
#
Other**
***
****
*****
Totals
Fixed
Variable
Non-Executive Directors
Year
A$
A$
A$
A$
A$
A$
A$
Rem.
Rem.
Dr. Lindsay Wakefield
2023
67,462
-
-
7,084
-
-
74,546
100
-
Mr. Peter Rubinstein
2023
154,769
-
-
9,951
-
-
164,720
100
-
Mr. Nicholas Burrows
2023
67,462
-
-
7,084
-
-
74,546
100
-
Non-Independent Non-Executive Director
Dr. Jerzy Muchnicki
2023
58,330
-
-
6,125
-
-
64,455
100
-
Management
Dr. Richard Allman
2023
48,162
21,707
3,007
7,336
7,071
-
87,283
75
25
Mr. Mike Tonroe
(3)
2023
63,584
17,031
4,192
6,444
-
-
91,251
81
19
Mr. Simon Morriss
(2)
2023
330,565
24,188
13,985
25,375
2,285
191,346
587,744
63
37
Mr. Tony Di Pietro
(6)
2023
158,958
-
10,131
15,028
313
-
184,430
100
-
Mr. Carl Stubbings
(4)
2023
223,444
14,205
(1,335
)
24,953
1,309
34,368
296,944
84
16
Mr. Kevin Camilleri
(5)
2023
233,276
14,725
1,276
4,131
-
27,739
281,147
85
15
Totals
2023
1,406,012
91,856
31,256
113,511
10,978
253,453
1,907,066
82
18
Referencing
the table above:
#
Represents the payment of short-term incentives for the 2022 financial year, no short-term incentive was payable for the 2023 financial
year
**
Other includes movement in Annual Leave component
***
Post-employment benefits as per Corporations Regulation 2M.3.03 (1) Item 7
****
Other long-term benefits as per Corporations Regulation 2M.3.03 (1) Item 8
*****
Equity settled share-based payments as per Corporations Regulation 2M.3.03 (1) Item 11
44
Details
of the nature and amount of each major element of the compensation of each director of the Company and each of the named officers of
the Company and its subsidiaries, for services in all capacities during the financial year ended June 30, 2022 are listed below. All
figures are stated in Australian dollars (A$).
Short-term benefits
Post-
employment
Superannuation
Other long-term benefits
Share- based payments Equity
Percentage (%)
Name and title
Salary/fees
STI
*
Other**
***
****
*****
Totals
Fixed
Variable
Non-Executive Directors
Year
A$
A$
A$
A$
A$
A$
A$
Rem.
Rem.
Dr. Lindsay Wakefield
2022
67,462
-
-
6,746
-
4,010
78,218
95
5
Mr. Peter Rubinstein
2022
154,769
-
-
9,477
-
5,347
169,593
97
3
Mr. Nicholas Burrows
2022
67,462
-
-
6,746
-
-
74,208
100
-
Non-Independent Non-Executive Director
Dr. Jerzy Muchnicki
2022
145,117
-
-
8,194
-
6,684
159,995
96
4
Management
Dr. Richard Allman
2022
195,365
-
8,683
17,366
3,231
-
224,645
100
0
Mr. Mike Tonroe
(3)
2022
289,531
-
10,400
27,500
472
101,043
428,946
76
24
Mr. Simon Morriss
(2)
2022
346,688
43,750
18,606
27,500
780
191,346
628,670
63
37
Mr. Stanley Sack
(1)
2022
107,188
-
-
-
-
35,438
142,626
75
25
Mr. Carl Stubbings
(4)
2022
201,850
-
3,205
18,765
314
26,459
250,593
89
11
Mr. Kevin Camilleri
(5)
2022
211,982
-
22,355
3,528
-
16,719
254,584
93
7
Totals
2022
1,787,414
43,750
63,249
125,822
4,797
387,046
2,412,078
Referencing
the table above:
*
Represents the payment of short-term incentives for the 2021 financial year
**
Other includes movement in Annual Leave component
***
Post-employment benefits as per Corporations Regulation 2M.3.03 (1) Item 7
****
Other long-term benefits as per Corporations Regulation 2M.3.03 (1) Item 8
*****
Equity settled share-based payments as per Corporations Regulation 2M.3.03 (1) Item 11 Notes pertaining to changes during the year:
During
the financial year ended June 30, 2020, the Board approved to obtain consulting services in relation to capital raises, compliance, NASDAQ
hearings and investor relations from its Non-Executive director and current Chairman, Mr. Peter Rubinstein. The services procured were
through Mr. Peter Rubinstein's associate entity, ValueAdmin.com Pty Ltd, and amounted to A$60,000 for the year ended June 30, 2023
(2022: A$60,000).
(1)
Mr. Sack was appointed as Chief Operating Officer (COO) on May 18, 2020. He resigned on April 30, 2022.
(2)
Mr. Morriss was appointed as Chief Executive Officer (CEO) on February 1, 2021.
(3)
Mr. Tonroe was appointed as Chief Financial Officer (CFO) on June 15, 2021. He resigned on November 28, 2022.
(4)
Mr Stubbings was appointed as Chief Commercial Officer (CCO) on September 1, 2021.
(5)
Mr Camilleri was appointed as Chief Executive Officer of EasyDNA on August 16, 2021.
(6)
Mr Di Pietro was appointed as Company Secretary & Chief Financial Officer on November 28, 2022.
45
Contractual
agreements with the directors and other key management personnel
Name:
Dr.
    Jerzy Muchnicki
Position:
Non-Independent
    Non-Executive Director
Fixed
    remuneration:
A$64,455
    (inclusive of superannuation)
Name:
Mr.
    Peter Rubinstein
Position:
Non-Executive
    Director and Chairman
Fixed
    remuneration:
A$104,720
    (inclusive of superannuation)
Consulting
    fee:
A$60,000
    (excluding GST)
Name:
Dr.
    Lindsay Wakefield
Position:
Non-Executive
    Director
Fixed
    remuneration:
A$74,546
    (inclusive of superannuation)
Name:
Mr.
    Nicholas Burrows
Position:
Non-Executive
    Director
Fixed
    remuneration:
A$74,546
    (inclusive of superannuation)
Name:
Mr.
    Simon Morriss
Position:
Chief
    Executive Officer
Fixed
    remuneration:
A$365,274
    (inclusive of superannuation)
Name:
Mr.
    Mike Tonroe
Position:
former
    Chief Financial Officer
Fixed
    remuneration:
A$300,000
    (inclusive of superannuation)
Name:
Mr.
    Tony Di Pietro
Position:
Company
    Secretary & Chief Financial Officer
Fixed
    remuneration:
A$300,000
    (inclusive of superannuation)
Name:
Dr.
    Richard Allman
Position:
Chief
    Scientific Officer until October 6,2022/Scientific Advisor (Consultant)
Fixed
    remuneration:
A$200,530
    (inclusive of superannuation) when employed as Chief Scientific Officer/Remains on call and invoices the company for his time on
    a project by project basis.
Name:
Mr.
    Carl Stubbings
Position:
Chief
    Commercial Officer
Fixed
    remuneration:
A$257,415
    (inclusive of superannuation)
Name:
Mr.
    Kevin Camilleri
Position:
Chief
    Executive Officer, EasyDNA
Fixed
    remuneration:
A$233,276
46
Key
Terms and Conditions:
The
key provisions contained in the agreements of the directors of the Company include the following:
●
The
    Company does not have a set tenure for directors, and under the Corporations Act 2001 and the Constitution, the directorship can
    cease under prescribed circumstances (example, bankruptcy, conviction of an offence). In addition, the director may resign by providing
    notice in writing at any time.
●
No
    form of remuneration linked to short term incentives has been issued to any of the directors.
●
The
    following are the key provisions contained in the agreements of the other Key Management Personnel:
Mr.
Simon Morriss
●
Genetic
    Technologies or Mr. Morriss may terminate the employment agreement by providing two weeks written notice within the first six months
    of employment. Thereafter the notice period is 4 months written notice. Genetic Technologies may, at its own election, make payment
    in lieu of notice.
●
Mr.
    Morriss shall be subject to restrictions on competing with Genetic Technologies Limited and its related bodies corporate during the
    employment and for a period of up to 24 months after the employment ends. Mr. Morriss is also prevented from soliciting Genetic Technologies
    employees' customers or suppliers to cease employment or conducting business with the Company.
●
Mr.
    Morriss' CEO employment agreement otherwise contains standard terms and conditions for agreements of its nature, including
    confidentiality, retention of intellectual property and leave.
Mr.
Mike Tonroe (resigned on November 28, 2022)
●
Genetic
    Technologies or Mr. Tonroe may terminate the employment agreement by providing two weeks written notice within the first six months
    of employment. Thereafter the notice period is 4 months written notice. Genetic Technologies may, at its own election, make payment
    in lieu of notice.
●
Mr.
    Tonroe shall be subject to restrictions on competing with Genetic Technologies Limited and its related bodies corporate during the
    employment and for a period of up to 24 months after the employment ends. Mr. Tonroe is also prevented from soliciting Genetic Technologies
    employees' customers or suppliers to cease employment or conducting business with the Company.
●
Mr.
    Tonroe's CFO employment agreement otherwise contains standard terms and conditions for agreements of its nature, including
    confidentiality, retention of intellectual property and leave.
Mr.
Tony Di Pietro (appointed November 28, 2022)
●
Genetic
    Technologies or Mr. Di Pietro may terminate the employment agreement by providing two weeks written notice within the first six months
    of employment. Thereafter the notice period is 4 months written notice. Genetic Technologies may, at its own election, make payment
    in lieu of notice.
●
Mr.
    Di Pietro shall be subject to restrictions on competing with Genetic Technologies Limited and its related bodies corporate during
    the employment and for a period of up to 24 months after the employment ends. Mr. Di Pietro is also prevented from soliciting Genetic
    Technologies employees' customers or suppliers to cease employment or conducting business with the Company.
●
Mr.
    Di Pietro's CFO employment agreement otherwise contains standard terms and conditions for agreements of its nature, including
    confidentiality, retention of intellectual property and leave.
Dr.
Richard Allman
●
Towards
    termination, the agreement states that the Company or the employee may terminate at any time by providing a 30-day notice to the
    other party or the agreement will be terminated on the expiration of that notice.
●
On
    termination of this agreement the Company will pay the employee the salary package due up to and including the date of termination.
Mr.
Carl Stubbings
●
Genetic
    Technologies or Mr. Stubbings may terminate the employment agreement by providing two weeks written notice within the first six months
    of employment. Thereafter the notice period is 4 months written notice. Genetic Technologies may, at its own election, make payment
    in lieu of notice.
●
Mr.
    Stubbings shall be subject to restrictions on competing with Genetic Technologies Limited and its related bodies corporate during
    the employment and for a period of up to 24 months after the employment ends. Mr. Stubbings is also prevented from soliciting Genetic
    Technologies employees' customers or suppliers to cease employment or conducting business with the Company.
●
Mr.
                                                         Stubbings's CCO employment agreement otherwise contains standard terms and conditions for agreements of its nature, including
                                                         confidentiality, retention of intellectual property and leave.
47
Mr.
Kevin Camilleri
●
Genetic
    Technologies or Mr. Camilleri may terminate the employment agreement by providing two weeks written notice within the first six months
    of employment. Thereafter the notice period is 4 months written notice. Genetic Technologies may, at its own election, make payment
    in lieu of notice.
●
Mr.
    Camilleri shall be subject to restrictions on competing with Genetic Technologies Limited and its related bodies corporate during
    the employment and for a period of up to 12 months after the employment ends. Mr. Camilleri is also prevented from soliciting Genetic
    Technologies employees' customers or suppliers to cease employment or conducting business with the Company.
●
Mr.
    Camilleri's EasyDNA CEO employment agreement otherwise contains standard terms and conditions for agreements of its nature,
    including confidentiality, retention of intellectual property and leave.
The
details of those Executives nominated as Key Management Personnel under section 300A of the
Corporations Act 2001
have been disclosed
in this Report. No other employees of the Company meet the definition of "Key Management Personnel" as defined in
IAS
24 Related Party Disclosures
, or "senior manager" as defined in the
Corporations Act 2001.
Executive
officers are those officers who were involved during the year in the strategic direction, general management or control of the business
at a company or operating division level. The remuneration paid to Executives is set with reference to prevailing market levels and comprises
a fixed salary, short-term incentives (which are linked to agreed key performance indicators), and an option or performance share component
(long term incentive). Options/Performance shares are granted to Executives in line with their respective levels of experience and responsibility.
Share
Based Payments
Option
holdings and details of options exercised, granted, and forfeited, as part of remuneration
No
options were issued under employee incentive scheme during the financial year ended June 30, 2023 and June 30, 2022. On December 21,
2020, the Company issued 5,000,000 options to Executives and 7,850,000 to other employees, under an employee incentive scheme. The
options have an exercise price of A$0.008 (0.8 cents) per option and expire on December 1, 2023. During the financial year ending
June 30, 2023 250,000,000 options lapsed due to expiry (2022: 10,000,000, 2021: 5,000,000). No options were exercised during the
financial years ending June 30, 2023, 2022 and 2021.
Details
of the options held by the Executives and Directors nominated as Key Management Personnel at the year ended June 30, 2023 are set out
below.
Option
holdings of Key Management Personnel June 30, 2023
Options
Balance at start of the year
Granted as remuneration
Granted as part of cost of capital
Exercised
Lapsed
Balance at end of the year
Vested
and exercisable
Dr. Lindsay Wakefield
-
-
-
-
-
-
-
Mr. Peter Rubinstein
125,000,000
-
-
-
(125,000,000
)
-
-
Dr. Jerzy Muchnicki
125,000,000
-
-
-
(125,000,000
)
-
-
Dr. Richard Allman
5,000,000
-
-
-
-
5,000,000
5,000,000
Mr. Stanley Sack
-
-
-
-
-
-
-
Mr. Mike Tonroe
-
-
-
-
-
-
-
Mr. Carl Stubbings
-
-
-
-
-
-
-
Mr. Kevin Camilleri
-
-
-
-
-
-
-
Total
255,000,000
-
-
-
(250,000,000
)
5,000,000
5,000,000
48
The
Company introduced a Staff Share Plan on November 30, 2001. On November 19, 2008, the shareholders of the Company approved the introduction
of a new Employee Option Plan. Collectively, these Plans establish the eligibility of our employees and those of any subsidiaries, and
of consultants and independent contractors to a participating company who are declared by the Board to be eligible, to participate. Broadly
speaking, the respective Plans permits us, at the discretion of the Board, to issue traditional options (with an exercise price). The
Plans conform to the IFSA Executive Share and Option Scheme Guidelines and, where participation is to be made available to staff who
reside outside Australia, there may have to be modifications to the terms of grant to meet or better comply with local laws or practice.
As
of June 30, 2023, there was one executive and 7 employees who held options that had been granted under the Company's respective
option plans. Options issued under the Plan carry no rights to dividends and no voting rights.
As
of the date of this Annual Report, there was a total of 8,000,000 unlisted employee options outstanding.
Options
granted under the Employee Option Plan carry no rights to dividends and no voting rights and generally have an expiry date of five years
from the date of the offer to grant options.
During
the year ended June 30, 2023, the Company did not record a share-based payments expense in respect of the options granted (2022: Nil).
The
following is additional information relating to the options granted under the Employee Share Option Plan as of June 30,
2023:
Options outstanding
Options exercisable
Range of exercise prices
Number of
options
Weighted average
exercise price
A$
Remaining weight- ed average contrac- tual life (years)
Number of
options
Weighted average
exercise price
A$
A$0.008
8,400,000
0.008
0.42
8,400,000
0.008
Unlisted
performance rights holdings and details of performance rights exercised, granted, and forfeited, as part of remuneration
Performance
Rights are not currently quoted on the ASX and as such have no ready market value. The Performance Rights each grant the holder a right
of grant of one ordinary Share in the Company upon vesting of the Performance Rights for nil consideration. Accordingly, the Performance
Rights may have a present value at the date of their grant. Various factors impact upon the value of Performance Rights including:
●
the
    period outstanding before the expiry date of the Performance Rights;
●
the
    underlying price or value of the securities into which they may be converted;
●
the
    proportion of the issued capital as expanded consequent upon conversion of the Performance Rights into Shares (i.e. whether or not
    the shares that might be acquired upon exercise of the options represent a controlling or other significant interest); and
●
the
    value of the shares into which the Performance Rights may be converted.
Key
management personnel, being the recipients of the performance rights, must remain employed by the Company for the relevant performance
right to vest.
No
new performance rights were issued during the financial year. (2022: 80,000,000). The performance rights issued to Mr Michael Tonroe,
40,000,000, in the prior financial year lapsed upon his resignation in November 2022 (2022: 15,000,000). No performance rights were exercised
during the financial year (2022: 3,937,500).
Valuation
of performance rights granted in the year ended June 30, 2022
During
the year ended June 30, 2022, the Board has approved for the following Performance Rights to be issued to the Key Management Personnel
below:
●
40,000,000
    Performance Rights to Mr. Michael Tonroe
●
20,000,000
    Performance Rights to Mr. Carl Stubbings
●
20,000,000
    Performance Rights to Mr. Kevin Camilleri
49
Performance
hurdles
Key
management personnel, being the recipients of the performance rights, must remain engaged by the Company at the time of satisfaction
of the performance hurdle in order for the relevant Performance Right to vest.
The
performance rights for key management personnel vest and are exercisable upon the Share price reaching A$0.016 while or greater for more
than 15-day consecutive ASX trading days.
There
are various formulae which can be applied to determining the theoretical value of performance rights (including the formula known as
the Black-Scholes Model valuation formula and the Binomial model).
The
Company commissioned an independent valuation of these performance rights. The independent valuer has applied the Binomial model in providing
the valuation of the performance rights.
Inherent
in the application of the Binomial model are a number of inputs, some of which must be assumed. The data relied upon in applying the
Binomial model was:
a)
exercise
    price being 0.0 cents per Performance Right for all classes;
b)
VWAP
    hurdle for key management personnel (15 days consecutive share price hurdle) equaling A$0.016 for Performance Rights;
c)
sales
    and market cap hurdles as listed above for Performance Rights;
d)
the
    continuously compounded risk-free rate is as per table below (calculated based on yield of Australian government bonds, as at the
    grant dates for a 2 or 3 year period matching the expected life of Performance Rights);
e)
the
    expected option life of 3 years for key management personnel and 2 years for others; and
f)
a
    volatility measure between 149% to 161%.
Based
on the independent valuation of the performance rights, the Company agrees that the total value of these performance rights to be issued
to each member of key management personnel (depending on the share price at issue) is as follows:
Performance
rights issued during prior year, vested during the year
Number of Performance Rights issued
Valuation (cents)
Total fair value of Performance Rights
A$
Expense accounted for in 2022
A$
Expense accounted for during the year
A$
Mr. Carl Stubbings
20,000,000
0.52
103,104
26,459
34,368
Mr. Kevin Camilleri
20,000,000
0.42
83,216
16,719
27,739
Total
40,000,000
186,320
43,178
62,107
Performance
rights issued during prior year, lapsed during the financial year ending June30, 2023
Number of Performance Rights issued
Valuation
(cents)
Total fair value of Performance Rights
A$
Expense accounted for in 2022
A$
Expense accounted for during the year
A$
Mr. Michael Tonroe
40,000,000
0.73
291,428
101,043
-
Total
40,000,000
291,428
101,043
-
50
Valuation
of performance rights granted in prior years
Based
on the independent valuation of the performance rights, the Company agrees that the total value of the outstanding performance rights
issued to key management personnel (depending on the share price at issue) is as follows:
Valuation
of Class A Performance Rights granted prior to the year ended June 30, 2022
Performance
hurdles
The
Class A Performance Rights vest and are exercisable upon the Share price reaching A$0.012 or greater for more than 10- day consecutive
ASX trading days.
The
Class B Performance Rights vest and are exercisable upon the Share price reaching A$0.014 or greater for more than 10-day consecutive
ASX trading days and sales commence on the Consumer Initiated Testing (CIT) platform in either Australia or the United States of America.
The
Class C Performance Rights vest and are exercisable upon a minimum of 4,000 tests being processed in any 12-month period or the market
cap of GTG reaching A$100 million or above and being sustained for more than 10 consecutive ASX trading days, whichever happens sooner.
The
Class D Performance Rights vest and are exercisable upon the Share price reaching A$0.016 or greater for more than 15- day consecutive
ASX trading days.
The
Class E Performance Rights vest and are exercisable upon the first commercial sale of the Company's COVID-19 risk test with IBX
(Infinity BioLogix).
The
Company commissioned an independent valuation of these performance rights. The independent valuer has applied the Binomial model in providing
the valuation of these performance rights. Inherent in the application of the Binomial model are a number of inputs, some of which must
be assumed. The data relied upon in applying the Binomial model was:
a)
exercise
    price being 0.0 cents per Performance Right for all classes;
b)
VWAP
    hurdle (10 days consecutive share price hurdle) equaling A$0.012 for Class A and A$0.014 for Class B, and (15 days consecutive share
    price hurdle) equaling A$0.016 for Class D Performance Rights;
c)
sales
    and market cap hurdles as listed above for Class C and Class E Performance Rights;
d)
the
    continuously compounded risk-free rate being 0.111% for all classes of Performance Rights (based on a 3 year Australian Government
    yield as at December 21, 2020);
e)
the
    expected option life of 2 years for Class E Performance Rights and 3 years for all other classes of Performance Rights; and
f)
a
    volatility measure of 158.23%.
The
values calculated are set out below and are recognized as a share-based payment expense is included within general and administrative
costs in the statement of profit or loss and other comprehensive income. Performance rights issued during prior years, lapse during the
year
Valuation
of class A performance rights granted in prior years, and held by key management personnel at June 30, 2023
Number of Performance Rights issued
Valuation per Class A (cents)
Total fair value of Class A Performance Rights
A$
Expense
accounted in
2021
A$
Expense
accounted for during the
year
A$
Dr. Lindsay Wakefield
5,000,000
0.6702
33,512
33,512
-
Mr. Nicholas Burrows
5,000,000
0.6702
33,512
33,512
-
Dr. Jerzy Muchnicki
7,500,000
0.6702
50,268
50,268
-
Mr. Peter Rubinstein
7,500,000
0.6702
50,268
50,268
-
Total
25,000,000
167,560
167,560
-
51
Valuation
of class B performance rights granted in prior years, and held by key management personnel at June 30, 2023
Number of Performance Rights issued
Valuation
per Class B (cents)
Total fair value of Class B
Performance
Rights A$
Expense accounted in 2021
A$
Expense accounted for during the year
A$
Dr. Jerzy Muchnicki
25,000,000
0.6646
166,158
166,158
-
Mr. Peter Rubinstein
25,000,000
0.6646
166,158
166,158
-
Total
50,000,000
332,316
332,316
-
Valuation
of class C performance rights granted in prior years, and held by key management personnel at June 30, 2023
Number of Performance Rights issued
Valuation per Class C (cents)
Total
fair value of Class C Performance Rights
A$
Expense
accounted in 2021
A$
Expense accounted for during the year
A$
Dr. Jerzy Muchnicki
25,000,000
0.6702
167,541
-
-
Mr. Peter Rubinstein
25,000,000
0.6702
167,541
-
-
Total
50,000,000
335,082
-
-
Valuation
of class D performance rights granted in prior years, and held by key management personnel at June 30, 2023
Number
of Performance Rights issued
Valuation
per Class D (cents)
Total fair value of Class D Performance Rights
A$
Expense
accounted in 2022
A$
Expense
accounted for during the year
A$
Mr Simon Morriss
60,000,000
0.96
574,037
191,346
191,346
Valuation
of class E performance rights granted in prior years and exercised in the financial year ending June 30, 2022
Number
of Performance Rights issued
Valuation
per Class E (cents)
Total fair value of Class E Performance Rights
A$
Expense
accounted in 2021
A$
Expense
accounted for during the year
A$
Mr Stanley Sack
3,937,500
0.90
35,438
4,622
-
Class
A performance rights issued in prior years, that lapsed during the financial year ending June 30, 2022
Number
of
Performance
Rights issued
Valuation
per Class A (cents)
Total fair value of Class A
Performance Rights
A$
Expense
accounted in
2022
A$
Expense
accounted for during the
year
A$
Dr. Lindsay Wakefield
3,750,000
0.77
28,875
4,010
-
Dr. Jerzy Muchnicki
6,250,000
0.77
48,125
6,684
-
Mr. Peter Rubinstein
5,000,000
0.77
38,500
5,347
-
Total
15,000,000
115,500
16,041
-
52
The
values calculated as set out above are recognized as a share-based payment expense is included within general and administrative costs
in the statement of profit or loss and other comprehensive income for the relevant period.
The
following is the reconciliation of Performance Rights for the year ended June 30, 2023 held by Key Management Personnel:
Performance Rights
Balance at start of the year
Granted as remuneration
Exercised
Lapsed/ Forfeited
Balance at the end of year
Dr. Lindsay Wakefield
5,000,000
-
-
-
5,000,000
Mr. Peter Rubinstein
57,500,000
-
-
-
57,500,000
Mr. Nicholas Burrows
5,000,000
-
-
-
5,000,000
Dr. Jerzy Muchnicki
57,500,000
-
-
-
57,500,000
Dr. Richard Allman
-
-
-
-
-
Mr. Tony Di Pietro
-
-
-
-
-
Mr. Mike Tonroe
40,000,000
-
-
(40,000,000
)
-
Mr. Simon Morriss
60,000,000
-
-
-
60,000,000
Mr. Carl Stubbings
20,000,000
-
-
-
20,000,000
Mr. Kevin Camilleri
20,000,000
-
-
-
20,000,000
Total
265,000,000
-
-
(40,000,000
)
225,000,000
Performance
rights included in the balance at start of the financial year
The
unlisted performance rights granted and outstanding as of June 30, 2023 are as follows:
2023
Fair
                                                                                                 Value
A$
Expiration Date
Director
Mr. Peter Rubinstein (Class A)
7,500,000
50,268
21-Dec-2023
Mr Nick Burrows (Class A)
5,000,000
33,512
21-Dec-2023
Dr. Jerzy Muchnicki (Class A)
7,500,000
50,268
21-Dec-2023
Mr. Lindsay Wakefield (Class A)
5,000,000
33,512
21-Dec-2023
Mr. Peter Rubinstein (Class B)
25,000,000
166,158
21-Dec-2023
Dr. Jerzy Muchnicki (Class B)
25,000,000
166,158
21-Dec-2023
Mr. Peter Rubinstein (Class C)
25,000,000
167,541
21-Dec-2023
Dr. Jerzy Muchnicki (Class C)
25,000,000
167,541
21-Dec-2023
Mr. Simon Morriss (Class D)
60,000,000
574,037
4-Feb-2024
Mr. Carl Stubbings
20,000,000
103,104
22-Sep-2024
Mr. Kevin Camilleri
20,000,000
83,216
22-Nov-2024
Balance at the end of the financial year
225,000,000
1,595,315
53
The
following is additional information relating to the performance rights granted, as of June 30, 2023:
Performance rights outstanding
Performance rights exercisable
Range of exercise prices
Number of Performance Rights
Weighted average
exercise price
A$
Remaining Weighted average contractual life (years)
Number of Perf.
rights
Weighted average
exercise price
A$
A$0.00 - A$0.00
225,000,000
0.000
0.66
225,000,000
0.00
Australian
disclosure requirements: ordinary shares of Genetic Technologies Limited held by key management personnel at the date of this Directors'
report are as follows:
Ordinary Shares
Balance at start of the year
1
Granted as remuneration
Received on exercised options
Other Changes
2
Balance at the end of year
Dr. Lindsay Wakefield
9,418,104
-
-
-
9,418,104
Mr. Peter Rubinstein
308,132,009
-
-
-
308,132,009
Mr. Nicholas Burrows
1,670,000
-
-
-
1,670,000
Dr. Jerzy Muchnicki
263,085,885
-
-
(38,400,000
)
224,685,885
Dr. Richard Allman
553,338
-
-
-
553,338
Mr. Tony Di Pietro
-
-
-
500,000
500,000
Mr. Mike Tonroe
-
-
-
-
-
Mr. Simon Morriss
-
-
-
-
-
Mr. Carl Stubbings
-
-
-
750,000
750,000
Mr. Kevin Camilleri
-
-
-
-
-
Total
582,859,336
-
-
(37,150,000
)
545,709,336
1.
Balance may include shares held prior to individuals becoming KMP. For individuals who became KMP during the period, the balance
is as at the date they became KMP.
2.
Other changes incorporate changes from acquisition and disposals of ordinary share transactions.
Indemnification
and Insurance with respect to Directors
We
are obligated pursuant to an indemnity agreement, to indemnify the current Directors and executive officers and former Directors against
all liabilities to third parties that may arise from their position as Directors or officers of the Company and our controlled entities,
except where to do so would be prohibited by law. In addition, the Company does currently carry insurance in respect of Directors'
and officers' liabilities for current and former Directors, Company Secretary and executive officers or employees under certain
circumstances as specified in the insurance policy.
Loans
to Key Management Personnel
There
have been no loans to KMP's during the financial year or prior financial year.
Voting
and comments at the Company's 2022 Annual General Meeting
The
Company received 84.49% of the vote in favor of its Remuneration Report for the 2022 financial year. The Company did not receive any
specific feedback at the AGM on its remuneration policies.
(End
of the Remuneration Report (Audited) for
Australian Disclosure Requirements
)
Other
Australian Disclosure Requirements
Auditor's
Independence Declaration
There
were no former partners or directors of Grant Thornton Audit Pty Ltd, the Company's auditor, who were or were at any time during
the financial year, an officer of the Company.
A
copy of the auditor's independence declaration under Section 307C of the Corporations Act 2001 in relation to the audit for the
year ended June 30, 2023 is included in Exhibit 15.4 of this annual report on Form 20-F.
Directors'
resolution
The
components of our directors' report are incorporated in various places within this annual report on the Form 20-F. A table charting
these components is included within 'Exhibit 15.3 Appendix 4E'.
This
report is made in accordance with a resolution of directors.
/s/
Peter Rubinstein
Director Melbourne
August
30, 2023
54
Item
6.C Board Practices
The
Board of Directors
Under
the Company's Constitution, its Board of Directors is required to comprise at least three Directors. As of the date of this Annual
Report, our Board comprised four Directors.
The
role of the Board includes:
(a)
Reviewing
    and making recommendations in remuneration packages and policies applicable to directors, senior executives and consultants.
(b)
Nomination
    of external auditors and reviewing the adequacy of external audit arrangements.
(c)
Establishing
    the overall internal control framework over financial reporting, quality and integrity of personnel and investment appraisal. In
    establishing an appropriate framework, the board recognized that no cost-effective internal control systems will preclude all errors
    and irregularities.
(d)
Establishing
    and maintaining appropriate ethical standards in dealings with business associates, suppliers, advisers and regulators, competitors,
    the community and other employees.
(e)
Identifying
    areas of significant business risk and implementing corrective action as soon as practicable after a risk is identified.
(f)
Nominating
    audit and remuneration committee members.
The
Board meets to discuss business regularly throughout the year, with additional meetings being held when circumstances warrant. Included
in the table below are details of the meetings of the Board and the sub-committees of the Board that were held during the 2023 financial
year.
Directors' meetings
Audit & Risk Committee meetings
Remuneration Committee meetings
Attended
Eligible
Attended
Eligible
Attended
Eligible
Dr. Lindsay Wakefield
11
12
6
6
3
3
Dr. Jerzy Muchnicki
9
12
-
-
-
-
Mr. Peter Rubinstein
12
12
6
6
3
3
Mr. Nicholas Burrows
12
12
6
6
3
3
Committees
of the Board
The
Board has established an Audit & Risk Committee which operates under a specific Charter approved by the Board. It is the Board's
responsibility to ensure that an effective internal control framework exists within the Company. This includes internal controls to deal
with both the effectiveness and efficiency of significant business processes, the safeguarding of assets, the maintenance of proper accounting
records, and the reliability of financial information as well as non-financial considerations such as the benchmarking of operational
key performance indicators.
The
Board has delegated the responsibility for the establishment and maintenance of a framework of internal control and ethical standards
for the management of the Company to the Audit & Risk Committee. The Audit & Risk Committee also provides the Board with assurance
regarding the reliability of financial information for inclusion in the financial reports. As at date of this report, all of the members
of the Audit & Risk Committee are independent Non-Executive Directors.
The
Remuneration Committee is, amongst other things, responsible for determining and reviewing remuneration arrangements for the Directors,
the Chief Executive Officer and the Senior Leadership Team. The Chairman of the Committee is an independent non- executive director.
The
Remuneration Committee assesses the appropriateness of the nature and amount of remuneration paid to Directors and Executives on a periodic
basis by reference to relevant employment market conditions, with the overall objective of ensuring maximum shareholder benefit from
the retention of a high-quality Board and senior leadership team.
55
Committee
membership
As
at the date of this Report, the composition of these two Sub-Committees are:
Audit
    & Risk Committee:
Mr.
    Nicholas Burrows — Chairman of the Committee
Mr.
    Peter Rubinstein
Dr.
    Lindsay Wakefield
Remuneration
    Committee:
Dr.
    Lindsay Wakefield — Chairman of the Committee
Mr.
    Peter Rubinstein
Mr.
    Nicholas Burrows
Compliance
with NASDAQ Rules
NASDAQ
listing rules require that the Company disclose the home country practices that we will follow in lieu of compliance with NASDAQ corporate
governance rules. The following describes the home country practices and the related NASDAQ rule:
Majority
of Independent Directors
: The Company follows home country practice rather than NASDAQ's requirement in Marketplace Rule 4350(c)
(1) that the majority of the Board of each issuer be comprised of independent directors as defined in Marketplace Rule 4200. As of the
date of this Annual Report, with there were three independent Directors namely Mr. Nick Burrows, Mr. Peter Rubinstein and Dr. Lindsay
Wakefield which led to our Board of Directors being comprised of a majority of independent directors.
Compensation
of Officers
: The Company follows home country practice rather than NASDAQ's requirement in Marketplace Rule 4350(c) (3) that
chief executive compensation be determined or recommended to the Board by the majority of independent directors or a compensation committee
of independent directors. Similarly, compensation of other officers is not determined or recommended to the Board by a majority of the
independent directors or a compensation committee comprised solely of independent directors. These decisions are made by the Company's
remuneration committee.
Nomination
:
The Company follow home country practice rather than NASDAQ's requirement in Marketplace Rule 4350(c)(4) that director nominees
be selected or recommended by a majority of the independent directors or by a nominations committee comprised of independent directors.
These decisions are made by the Company's full Board which is comprised of a majority of independent directors which constitute
Mr. Nick Burrows, Mr. Peter Rubinstein, Dr. Jerzy Muchnicki and Dr. Lindsay Wakefield.
The
ASX does not have a requirement that each listed issuer have a nominations committee or otherwise follow the procedures embodied in NASDAQ's
Marketplace Rule. Furthermore, no law, rule or regulation of the ASIC has such a requirement nor does the applicable corporate law legislation.
Accordingly, selections or recommendations of director nominees by a committee that is not comprised of a majority of directors that
are not independent is not prohibited by the laws of Australia.
Quorum
:
The Company follows home country practice rather than NASDAQ's requirement in Marketplace Rule 4350(f) that each issuer provides
for a quorum of at least 33 1/3 percent of the outstanding shares of the issuer's ordinary stock (voting stock). Pursuant to the
Company's Constitution it is currently required to have a quorum for a general meeting of three persons. The practice followed
by the Company is not prohibited by Australian law.
Shareholder
Approval for Capital Issuance
: The Company has elected to follow certain home country practices in lieu of NASDAQ Marketplace Rule
5635. For example, the Company is entitled to an annual 15% of capital placement capacity under ASX Listing Rule 7.1 without shareholder
approval. If this amount of annual entitlement is aggregated with an additional placement of Ordinary Shares, including through the grant
of options over Ordinary Shares, that exceeds 20% of the outstanding share capital, only the excess over the 15% annual allowance requires
shareholder approval under Australian law. Such home country practice is not prohibited by the laws of Australia.
56
Board
diversity matrix
Board
    Diversity Matrix (As of June 30, 2023)
Country
    of Principal Executive Offices
Australia
Foreign
    Private Issuer
Yes
Disclosure
    Prohibited under Home Country Law
No
Total
    Number of Directors
4
Female
Male
Non-Binary
Did
    Not Disclose Gender
Part
    I: Gender Identity
Directors
-
4
-
-
Part
    II: Demographic Background
Underrepresented
    Individual in Home Country Jurisdiction
1
LGBTQ+
-
Did
    Not Disclose Demographic Background
-
As
at 7th August 2023 the Company has less than 5 Directors and at that date does not have a diverse director on the Board. Accordingly,
we are not in compliance with Nasdaq Rule 5605(f) as we did not meet the applicable board diversity objective by the end of the phase-
in period on that date.
The
Company's Directors acknowledge the importance of board diversity and this is considered as part of the Company's regular
director skills assessment process. In considering the output from this skills assessment process, the Board has formally identified
the need to address and prioritize Board diversity. Accordingly, one of the key People and Culture strategic pillar initiatives from
the Company's current strategic plan, is to identify and appoint a suitable female director over the course of the financial year
ended June 30, 2024. The Company's Remuneration Committee will oversee this process, consistent with its Charter, and will provide
a formal recommendation to the Board.
Item
6.D Employees
As
of the date of this Annual Report, the Company comprising the Company and its subsidiaries, employed 60 full-time equivalent employees.
The number of full-time equivalent employees as of the end of each respective financial year ended June 30 are as follows:
2023
60
2022
52
2021
18
Item
6.E Share Ownership
The
relevant interest of the directors in the share capital of the Company as notified by them to the Australian Securities Exchange in accordance
with section 205G(1) of the
Corporations Act 2001
as of the date of this Annual Report is as follows:
Director
Ordinary
shares
Percentage of Capital held
Dr. Lindsay Wakefield
9,418,104
0.10
%
Dr. Jerzy Muchnicki
224,685,885
2.85
%
Mr. Peter Rubinstein
308,132,009
3.34
%
Mr. Nicholas Burrows
1,670,000
0.02
%
57
Item
7. Major Shareholders and Related Party Transactions
Item
7.A Major Shareholders
As
at the date of this Annual Report, no shareholders hold a beneficial ownership of 5% or more of our voting securities.
The
number of Ordinary Shares on issue in Genetic Technologies Limited as of the date of this Annual Report was 11,541,658,143. The number
of holders of Ordinary Shares in Genetic Technologies Limited as of the date of this Annual Report was approximately 4,846 (August 21,
2023).
The
Company is not aware of any direct or indirect ownership or control of it by another corporation(s), by any foreign government or by
any other natural or legal person(s) severally or jointly. Principal shareholders do not enjoy any special or different voting rights
from those to which other holders of Ordinary Shares are entitled. The Company does not know of any arrangements, the operation of which
may at a subsequent date result in a change in control of the Company.
Record
Holders
As
of August 21, 2023, there were 4,846 holders of record of our ordinary shares, of which 33 record holders, holding approximately 0.02%
of our ordinary shares, had registered addresses in the United States. These numbers are not representative of the number of beneficial
holders of our shares nor are they representative of where such beneficial holders reside, since many of these ordinary shares were held
of record by brokers or other nominees. The majority of trading by our U.S. investors is done by means of ADSs that are held of record
by HSBC Custody Nominees (Australia) Ltd., which held 70.35% of our ordinary shares as of such date.
Item
7.B Related Party Transactions
During
the year ended June 30, 2023, 2022 and 2021, the only transactions between entities within the Company and other related parties occurred,
are as listed below. Except where noted, all amounts were charged on similar to market terms and at commercial rates.
Transactions
within the Company and with other related parties
During
the year ended June 30, 2023, other than compensation paid to directors and other members of key management personnel, see "Item
6.B Compensation", the only transactions between entities within the Company and other related parties are as listed below. Except
where noted, all amounts were charged on similar to market terms and at commercial rates.
Mr.
Phillip Hains (Former Chief Financial Officer)
On
July 15, 2019, the Company announced that it had appointed Mr. Phillip Hains (MBA, CA) as the Chief Financial Officer who has over 30
years of extensive experience in roles with a portfolio of ASX and NASDAQ listed companies and provides CFO services through his firm
The CFO Solution. Prior to this point the Company had a similar arrangement with The CFO Solution, where it would engage and provide
services of overall CFO, accounting and other finance related activities.
In
the prior reporting period, the Company paid A$91,615 to The CFO Solution towards provision of overall CFO, accounting and other finance
related activities. During the reporting period, the Company did not transact with The CFO Solution.
Mr.
Stanley Sack (former Chief Operating Officer)
On
May 18, 2020, the Company appointed Mr. Stanley Sack who provides consulting in the capacity of Chief Operating Officer. Mr. Sack had
spent 15 years in large listed entities in executive positions managing large business divisions. He has worked with a high-net-worth
family managing all their operating businesses and private equity activities. Mr. Sack built an Allied Health Business in the aged care
and community care space which became the biggest Mobile Allied Health Business in Australia, and was recently sold to a large medical
insurance company.
During
the reporting period, the Company had no transactions (2022: A$107,188) with Mr. Stanley Sack's entity Cobben Investments Pty Ltd
towards provision of consulting services in relation to provision of duties related to Chief Operating Officer of the Company.
Mr.
Peter Rubinstein (Non-Executive Director and Chairman)
During
the financial year ended June 30, 2020, the Board approved to obtain consulting services in relation to capital raises, compliance, NASDAQ
hearings and investor relations from its Non-Executive Director and current Chairman, Mr. Peter Rubinstein. The services procured were
through Mr. Peter Rubinstein's associate entity ValueAdmin.com Pty Ltd and amounted to A$60,000 (2022: A$60,000), which is included
as part of the cash salary and fees in the remuneration report as at June 30, 2023.
58
There
were no transactions with parties related to Key Management Personnel during the year other than that disclosed above.
Dr.
Jerzy Muchnicki (Non-Independent Non-Executive Director)
During
the financial year ended June 30, 2022, the Board approved to obtain consulting services in relation to PRS and Germline Integration;
Epigenetics; Somatic Testing; NIPT; Carrier testing and related marketing advice from its Non-Independent Non- Executive Director, Dr.
Jerzy Muchnicki. The services procured were through Dr. Jerzy Muchnicki's private consultancy and amounted to A$50,000 (2021: Nil)
that is included as part of the cash salary and fees in the remuneration report as at June 30, 2022.
There
were no transactions with parties related to Key Management Personnel during the year other than that disclosed above.
Performance
Rights Issuance
After
receiving another requisite shareholder approval on December 10, 2020, the Company issued additional 125,000,000 Performance Rights to
Directors of the Company as follows:
●
5,000,000
    Class A Performance Rights to Dr. Lindsay Wakefield
●
7,500,000
    Class A Performance Rights, 25,000,000 Class B Performance Rights and 25,000,000 Class C Performance Rights to Dr. Jerzy Muchnicki
●
7,500,00
    Class A Performance Rights, 25,000,000 Class B Performance Rights and 25,000,000 Class C Performance Rights to Mr. Peter Rubinstein
●
5,000,000
    Class A Performance Rights to Mr. Nicholas Burrows
During
the year ended June 30, 2021, the Board has approved for the following Performance Rights to be issued to the Chief Executive Officer
and Chief Operating Officer:
●
60,000,000
    Class D Performance Rights to Mr. Simon Morriss
●
3,937,500
    Class E Performance Rights to Mr. Stanley Sack
During
the year ended June 30, 2022 the Board has approved for the following Performance Rights to be issued to the Key Management Personnel
below:
●
40,000,000
    Performance Rights to Mr. Michael Tonroe
●
20,000,000
    Performance Rights to Mr. Carl Stubbings
●
20,000,000
    Performance Rights to Mr. Kevin Camilleri
The
Company has accounted for these Performance Rights in accordance with its accounting policy for share-based payment transactions, recording
A$125,500 (2022: A$437,508, 2021: A$622,725) of associated expense in the current reporting period. During the financial year ending
June 30, 2023 the Performances Rights issued to Mr. Michael Tonroe were forfeit as Mr. Tonroe resigned from his position as CFO.
Item
7.C Interests of Experts and Counsel
Not
applicable.
Item
8. Financial Information
Item
8.A Consolidated Statements and Other Financial Information
The
information included in Item 18 of this Annual Report is referred to and referenced into this Item 8.A.
Legal
Proceedings
We
are not currently a party to any legal proceedings. From time to time, we may be a party to litigation or subject to claims incident
to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe
that the final outcome of these ordinary course matters will not have a significant effect on our financial position or profitability.
Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management
resources and other factors.
59
Dividends
Until
our businesses are profitable beyond our expected research and development needs, our Directors are unlikely to be able to recommend
that any dividend be paid to our shareholders. Our Directors will not resolve a formal dividend policy until we generate profits. Our
current intention is to reinvest our income in the continued development and expansion of our businesses.
Item
8.B Significant Changes
There
have been no significant changes in the operational or financial condition of the Company since June 30, 2023.
Item
9. The Offer and Listing
Item
9.A Offer and Listing Details
The
Company's Ordinary Shares have been listed on the Australian Securities Exchange (the "ASX") since July 1987 and trade
there under the symbol GTG. The Company's securities are also listed on NASDAQ's Capital Market (under the ticker GENE) in
the form of American Depositary Shares, each of which represents 600 Ordinary Shares.
Item
9.B Plan of Distribution
Not
applicable.
Item
9.C Markets
See
"Item 9.A Offer and Listing Details."
Item
9.D Selling Shareholders
Not
applicable.
Item
9.E Dilution
Not
applicable.
Item
9.F Expenses of the Issue
Not
applicable.
Item
10. Additional Information
Item
10.A Share Capital
Not
applicable.
Item
10.B Our Constitution
Our
registration number is 009 212 328. Our Constitution has been posted on the Company's website and has been filed with the
SEC.
Purposes
and Objects
Our
Constitution does not specify any purposes or objects of the Company.
The
Powers of the Directors
Under
the provisions of our Constitution our Directors may exercise all of the powers of our company, other than those that are required by
our Constitution or the Corporations Act 2001 of Australia to be exercised at a general meeting of shareholders. A director may participate
in a meeting and vote on a proposal, arrangement or contract in which he or she is materially interested, so long as the director's
interest is declared in accordance with the Corporations Act 2001. The authority of our directors to enter into borrowing arrangements
on our behalf is not limited, except in the same manner as any other transaction by us.
60
Rights
Attached to Our Ordinary Shares
The
concept of authorized share capital no longer exists in Australia and as a result, our authorized share capital is unlimited.
All our outstanding Ordinary Shares are validly issued, fully paid and non-assessable. The rights attached to our Ordinary Shares are
as follows:
Dividend
rights.
If our board of directors recommends a dividend, registered holders of our Ordinary Shares may declare a dividend by ordinary
resolution in a general meeting. The dividend, however, cannot exceed the amount recommended by our board of directors. Our board of
directors may declare an interim dividend.
Voting
rights.
Holders of Ordinary Shares have one vote for each Ordinary Share held on all matters submitted to a vote of shareholders.
Such voting rights may be affected by the grant of any special voting rights to the holders of a class of shares with preferential rights
that may be authorized in the future.
The
quorum required for an ordinary meeting of shareholders consists of at least three shareholders represented in person or by proxy. A
meeting adjourned for lack of a quorum generally is adjourned to the same day in the following week at the same time and place or any
time and place as the directors designate in a notice to the shareholders. At the reconvened meeting, the required quorum consists of
any two members present in person or by proxy.
An
ordinary resolution, such as a resolution for the declaration of dividends, requires approval by the holders of a majority of the voting
rights represented at the meeting, in person, by proxy or by written ballot and voting thereon. Under our Constitution, a special resolution,
such as amending our Constitution, approving any change in capitalization, winding-up, authorization of a class of shares with special
rights, or other changes as specified in our Constitution, requires approval of a special majority, representing the holders of no less
than 75% of the voting rights represented at the meeting in person, by proxy or by written ballot, and voting thereon.
Pursuant
to our Constitution, our directors are elected at our annual general meeting of shareholders by a vote of the holders of a majority of
the voting power represented and voting at such meeting.
Rights
in our profits.
Our shareholders have the right to share in our profits distributed as a dividend and any other permitted distribution.
Rights
in the event of liquidation.
In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be
distributed to the holders of Ordinary Shares in proportion to the nominal value of their holdings. This right may be affected by the
grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized
in the future.
Changing
Rights Attached to Shares
According
to our Constitution, in order to change the rights attached to any class of shares, unless otherwise provided by the terms of the class,
such change must be adopted by a general meeting of the shareholders and by a separate general meeting of the holders of the affected
class with a majority of 75% of the voting power participating in such meeting.
Annual
and Extraordinary Meetings
Our
Board of Directors must convene an annual meeting of shareholders at least once every calendar year, within five months of our last fiscal
year-end. Notice of at least 28 days prior to the date of the meeting is required. An extraordinary meeting may be convened by the board
of directors, it decides or upon a demand of any directors, or of one or more shareholders holding in the aggregate at least five percent
of our issued capital. An extraordinary meeting must be called not more than 21 days after the request is made. The meeting must be held
not later than two months after the request is given.
Limitations
on the Rights to Own Securities in Our Company
Neither
our Constitution nor the laws of the Commonwealth of Australia restrict in any way the ownership or voting of our shares. However, acquisitions
and proposed acquisitions of securities in Australian companies may be subject to review and approval by the Australian Federal Treasurer
under the Takeovers Act as described under Item 10.D below.
Changes
in Our Capital
Pursuant
to the Listing Rules of the ASX, without shareholder approval, we may not issue more than 25% of our outstanding Ordinary Shares in any
twelve month period other than by a pro rata rights offering or a share purchase plan offer (of shares with a value at the issue price
of up to A$30,000 per shareholder to a maximum of 30% of our outstanding shares) in each case to the then existing shareholders.
61
Takeovers
Act
There
are no limitations, either under the laws of Australia or under the Company's Constitution, to the right of non-residents to hold
or vote our Technologies Ordinary Shares other than the Commonwealth Foreign Acquisitions and Takeovers Act 1975 (the "Takeovers
Act"). The Takeovers Act may affect the right of non-Australian residents, including U.S. residents, to hold Ordinary Shares but
does not affect the right to vote, or any other rights associated with, any Ordinary Shares held in compliance with its provisions. Acquisitions
of shares in Australian companies by foreign interests are subject to review and approval by the Treasurer of the Commonwealth of Australia
under the Takeovers Act. The Takeovers Act applies to any acquisition of outstanding shares of an Australian company that exceeds, or
results in a foreign person or persons controlling the voting power of more than a certain percentage of those shares. The thresholds
are 15% where the shares are acquired by a foreign person, or Company of associated foreign persons, or 40% in aggregate in the case
of foreign persons who are not associated. Any proposed acquisition that would result in an individual foreign person (with associates)
holding more than 15% must be notified to the Treasurer in advance of the acquisition. There are statutory limitations in Australia on
foreign ownership of certain businesses, such as banks and airlines, not relevant to the Company. However, there are no other statutory
or regulatory provisions of Australian law or Australian Securities Exchange requirements that restrict foreign ownership or control
of the Company.
Corporations
Act 2001
As
applied to the Company, the
Corporations Act 2001
prohibits any legal person (including a corporation) from acquiring a relevant
interest in Ordinary Shares if after the acquisition that person or any other person's voting power in the Company increases from
20% or below to more than 20%, or from a starting point that is above 20% and below 90%.
This
prohibition is subject to a number of specific exceptions set out in section 611 of the
Corporations Act 2001
which must be strictly
complied with to be applicable.
In
general terms, a person is considered to have a "relevant interest" in a share in the Company if that person is the holder
of that share, has the power to exercise, or control the exercise of, a right to vote attached to that share, or has the power to dispose
of, or to control the exercise of a power to dispose of that share.
It
does not matter how remote the relevant interest is or how it arises. The concepts of "power" and "control" are
given wide and extended meanings in this context in order to deem certain persons to hold a relevant interest. For example, each person
who has voting power above 20% in a company or a managed investment scheme which in turn holds shares in the Company is deemed to have
a relevant interest in those shares. Certain situations (set out in section 609 of the
Corporations Act 2001
) which would otherwise
constitute the holding of a relevant interest are excluded from the definition.
A
person's voting power in the Company is that percentage of the total votes attached to Ordinary Shares in which that person and
its associates (as defined in the
Corporations Act 2001
) holds a relevant interest.
Item
10.C Material Contracts
During
the financial years ending June 30, 2021, 2022, and 2023, the Company entered into agreements with H.C. Wainwright & Co, to act as
placement agents to the share offerings made on multiple occasions the Company raised a total of A$22,881,958 before costs of the transactions.
Towards the cost of these transactions, the Company issued the following securities:
●
156,000,000
    warrants issued to H.C. Wainwright & Co. LLC on December 21, 2020 exercisable at US$0.004166 expiring on December 21, 2025, amounting
    to A$1,462,442. The warrants are exercisable for fully paid ordinary shares.
●
39,975,000
    warrants issued to H.C. Wainwright & Co. LLC on December 21, 2020, exercisable at US$0.0104 expiring on December 21, 2025,
    amounting to A$360,017. The warrants are exercisable for fully paid ordinary shares.
●
48,750,000
    warrants issued to H.C. Wainwright & Co. LLC on November 24, 2021, exercisable at US$0.00109375 expiring 5 years after date of
    issue, amounting to A$476,297. The warrants are exercisable for fully paid ordinary shares.
●
250,000
    warrants to be issued to H.C. Wainwright & Co. LLC, subject to shareholder approval scheduled for the 2023 Annual General Meeting
    (AGM), exercisable at US$1.625 expiring 5 years after date of issue, amounting to A$134,956. The warrants are exercisable for fully
    paid ordinary shares.
As
at June 30, 2023, the following warrants remain outstanding and exercisable and relate to capital raising activities prior to June 30,
2021.
●
40,114,200
                                            warrants issued to H.C. Wainwright & Co. LLC on April 3, 2020, exercisable at US$0.00365
                                            each and expiring on
April
    1, 2025, amounting to A$175,137. The warrants are exercisable for fully paid ordinary shares.
●
28,177,578
                                                                              warrants issued to H.C. Wainwright & Co. LLC on April 22, 2020, exercisable at US$0.00417 each and expiring on April 19, 2025,
                                                                              amounting to A$149,693. The warrants are exercisable for fully paid ordinary shares.
62
The
Company executed an acquisition agreement ("Acquisition Agreement") on July 19, 2021 to acquire the direct-to- consumer eCommerce
business and distribution rights associated with General Genetics Corporation and its associated brands trading as EasyDNA, from BelHealth
Investment Fund LP. The Acquisition Agreement provides for the acquisition of all brands, websites and agency reseller agreements associated
with EasyDNA. This includes over 70 websites in 40 countries and six brand identities. Under the terms of the Acquisition Agreement,
the Company acquired 100% of EasyDNA's brands and assets within the General Genetics Corporation business for a purchase price
of US$4 million, comprising cash consideration of US$2.5 million and US$1.5 million of ADSs.
The
Company executed an asset purchase agreement ("APA") on July 14, 2022 to acquire the direct-to-consumer eCommerce
business, laboratory testing and distribution agreements associated with AffinityDNA. The APA provides for the acquisition of all
brands and websites associated with AffinityDNA. This includes the AffinityDNA Amazon sales channel rights. Under the terms of the
APA, the Company acquired 100% of AffinityDNA's brands and assets for a purchase price of GBP555,000, comprising cash
consideration of GBP227,500 on completion and GBP227,500 payable in July 2023 subject to the AffinityDNA business attaining certain
financial performance parameters. The second payment was payable on the achievement of a gross profit target for the 12-month period
from the acquisition date. This target was not achieved and therefore no further payment is to be made in respect of the acquisition
of AffinityDNA.
There
were no other material contracts entered into during the two years preceding the date of this Annual Report which were outside the ordinary
course of business.
Item
10.D Exchange Controls
Under
existing Australian legislation, the Reserve Bank of Australia does not inhibit the import and export of funds, and, generally, no permission
is required to be given to the Company for the movement of funds in and out of Australia. However, payments to or from (or relating to)
Iraq, its agencies or nationals, the government or a public authority of Libya, or certain Libyan undertakings, the authorities in the
Federal Republic of Yugoslavia (Serbia and Montenegro) or their agencies, the Taliban (also referred to as the Islamic Emirate of Afghanistan),
or the National Union for the Total Independence of Angola (also known as UNITA), its senior officials or the adult members of their
immediate families, may not be made without the specific approval of the Reserve Bank of Australia.
Accordingly,
at the present time, remittances of any dividends, interest or other payment by the Company to non-resident holders of our securities
in the U.S. are not, subject to the above, restricted by exchange controls or other limitations.
Item
10.E Taxation
The
following summary is based on the tax laws of the United States (including the Internal Revenue Code of 1986, as amended, or the Code,
its legislative history, existing and proposed regulations thereunder, published rulings and court decisions) and on the Australian tax
law and practice, in each case as in effect on the date hereof. In addition, this summary is based on the Convention between the Government
of the United States of America and the Government of Australia for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion
with Respect to Taxes on Income, signed on August 6, 1982, as amended and currently in force, or the. The foregoing laws and legal authorities
as well as the Treaty are subject to change (or changes in interpretation), possibly with retroactive effect. Finally, this summary is
based in part upon the representations of our ADS Depositary and the assumption that each obligation in the Deposit Agreement and any
related agreement will be performed in accordance with its terms.
The
discussion does not address any aspects of U.S. taxation other than federal income taxation or any aspects of Australian taxation other
than federal income taxation, stamp duty and goods and services tax. This discussion does not necessarily address all aspects of U.S.
or Australian federal tax considerations that may be important to particular investors in light of their individual investment circumstances.
Prospective
investors are urged to consult their tax advisers regarding the U.S. and Australian federal, state and local tax consequences and any
other tax consequences of owning and disposing of ADSs and Ordinary Shares.
Australian
Tax Consequences
In
this section, we discuss Australian tax considerations that apply to non-Australian tax residents who are residents of the United States
with respect to the ownership and disposal by the absolute beneficial owners of ADSs. This summary does not discuss any foreign or state
tax considerations, other than stamp duty.
63
Nature
of ADSs for Australian Taxation Purposes
ADSs
held by a U.S. holder will be treated for Australian taxation purposes as being held under a "bare trust" for that holder.
Consequently, the underlying Ordinary Shares will be regarded as owned by the ADS holder for Australian income tax and capital gains
tax purposes. Dividends paid on the underlying Ordinary Shares will also be treated as dividends paid to the ADS holder, as the person
beneficially entitled to those dividends. Therefore, in the following analysis, we discuss the tax consequences to non-Australian resident
holders of Ordinary Shares which, for Australian taxation purposes, will be the same as to U.S. holders of ADSs.
Taxation
of Dividends
Australia
operates a dividend imputation system under which dividends may be declared to be "franked" to the extent of tax paid on
company profits. Fully franked dividends are not subject to dividend withholding tax. Dividends payable by our company to non-Australian
resident stockholders will be subject to dividend withholding tax, to the extent the dividends are unfranked. Dividend withholding tax
will be imposed at 30%, unless a stockholder is a resident of a country with which Australia has a double taxation agreement. Under the
provisions of the Treaty, the Australian tax withheld on unfranked dividends paid by us to which a resident of the United States is beneficially
entitled is generally limited to 15% if the U.S. resident holds less than 10% of the voting rights of our company, unless the shares
are effectively connected to a permanent establishment or fixed base in Australia through which the stockholder carries on business or
provides independent personal services, respectively. Where a U.S. corporate resident holds 10% or more of the voting rights of our company,
the withholding tax rate is reduced to 5%.
Tax
on Sales or other Dispositions of Shares - Capital Gains Tax
Non-Australian
resident stockholders who hold their shares in us on capital account will not be subject to Australian capital gains tax on any gain
made on a sale or other disposal of our shares, unless they hold 10% or more of our issued capital and the Company holds real property
situated in Australia, the market value of which is 50% or more of the market value of the Company. The Australian Taxation Office maintains
the view that the Treaty does not limit Australian capital gains tax. Australian capital gains tax applies to net capital gains charged
at a taxpayer's marginal tax rate but, for certain stockholders, a discount of the capital gain may apply if the shares have been
held for 12 months or more. For individuals, this discount is 50%. For superannuation funds, the discount is 33%. There is no discount
for a company that derives a net capital gain. Net capital gains are calculated after deducting capital losses, which may only be offset
against such gains.
Tax
on Sales or other Dispositions of Shares - Stockholders Holding Shares on Revenue Account
Some
non-Australian resident stockholders may hold shares on revenue rather than on capital account, for example, share traders. These stockholders
may have the gains made on the sale or other disposal of the shares included in their assessable income under the ordinary income provisions
of the income tax law, if the gains are sourced in Australia. Non-Australian resident stockholders assessable under these ordinary income
provisions in respect of gains made on shares held on revenue account would be assessed for those gains at the Australian tax rates for
non-Australian residents, which start at a marginal rate of 32.5%. Some relief from the Australian income tax may be available to non-Australian
resident stockholders under the Treaty, for example, because the stockholder derives business profits not through a permanent establishment
in Australia. To the extent an amount would be included in a non- Australian resident stockholder's assessable income under both
the capital gains tax provisions and the ordinary income provisions, the capital gain amount would generally be reduced, so that the
stockholder would not be subject to double tax on any part of the income gain or capital gain.
Dual
Residency
If
a stockholder were a resident of both Australia and the United States under the respective domestic taxation laws of those countries,
that stockholder may be subject to tax as an Australian resident. If, however, the stockholder is determined to be a U.S. resident for
the purposes of the Treaty, the Australian tax would be subject to limitation by the Treaty. Stockholders should obtain specialist taxation
advice in these circumstances.
Stamp
Duty
Any
transfer of shares through trading on the Australian Securities Exchange, whether by Australian residents or foreign residents, is not
subject to stamp duty within Australia.
Australian
Death Duty
Australia
does not have estate or death duties. Further, no capital gains tax liability is realized upon the inheritance of a deceased person's
shares. However, the subsequent disposal of the shares by beneficiaries may give rise to a capital gains tax liability.
64
Goods
and Services Tax
The
issue or transfer of shares will not incur Australian goods and services tax and does not require a stockholder to register for Australian
goods and services tax purposes.
United
States Federal Income Taxation
The
following discussion is a summary of U.S. federal income tax considerations generally applicable to the ownership and disposition of
the ADSs or Ordinary Shares by a U.S. holder (as defined below). This summary applies only to U.S. holders that hold such ADSs or Ordinary
Shares as capital assets (generally, property held for investment) for U.S. federal income tax purposes. This summary does not address
all U.S. federal income tax considerations that may be relevant to a particular U.S. holder and does not represent a detailed discussion
of all of the U.S. federal income tax considerations applicable to a holder of our ADSs or Ordinary Shares that may be subject to special
tax rules including, without limitation:
●
banks, financial institutions or insurance companies;
●
brokers, dealers or traders in securities, currencies, commodities,
or notional principal contracts;
●
tax-exempt entities or organizations, including an "individual
retirement account" or "Roth IRA" as defined in Section 408 or 408A of the Code (as defined below), respectively;
●
real estate investment trusts, regulated investment companies
or grantor trusts;
●
persons that hold ADSs or Ordinary Shares as part of a "hedging,"
"integrated," "wash sale" or "conversion" transaction or as a position in a "straddle"
for U.S. federal income tax purposes;
●
S corporations, partnerships, or other entities or arrangements
classified as passthrough entities for U.S. federal income tax purposes, or U.S. holders who hold the ADSs or Ordinary Shares through
such an entity;
●
certain former citizens or long-term residents of the United
States;
●
persons that received ADSs or Ordinary Shares pursuant to the
exercise of any employee share option or otherwise as compensation for the performance of services;
●
persons who have elected mark-to-market accounting;
●
holders that own or have owned directly, indirectly, or through
attribution 10% or more of the voting power or value of ADSs or Ordinary Shares; and
●
holders that have a "functional currency" other
than the U.S. dollar.
Each
holder of the ADSs or Ordinary Shares who fall within one of the categories above is advised to consult their tax advisers regarding
the specific tax consequences which may apply to their particular situation.
If
a partnership (or any other entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds the ADSs or Ordinary
Shares, the tax consequences relating to an investment in such ADSs or Ordinary Shares will depend in part upon the status of the partner
and the activities of the partnership. Such a partner or partnership should consult its tax advisers regarding the U.S. federal income
tax considerations of owning and disposing of the ADSs or Ordinary Shares in its particular circumstances.
The
discussion in this section is based on the Code, existing, proposed and temporary U.S. Treasury Regulations promulgated thereunder, administrative
and judicial interpretations thereof, and the Treaty, in each case as in effect and available on the date hereof. Such authorities are
subject to change, which change could apply retroactively, and to differing interpretations, all of which could affect the tax considerations
described below. There can be no assurance that the U.S. Internal Revenue Service, or the IRS, will not take a position concerning the
tax consequences of the ownership and disposition of ADSs or Ordinary Shares or that such a position would not be sustained by a court.
U.S. holders should consult their own tax advisers concerning the U.S. federal, state, local and non-U.S. tax consequences of owning
and disposing of ADSs or Ordinary Shares in their particular circumstances.
This
summary does not address the estate or gift tax considerations, alternative minimum tax considerations, the potential application of
the Medicare contribution tax on net investment income, the special tax accounting rules under Section 451(b) of the Code, or any U.S.
state, local, or non-U.S. tax considerations applicable to the acquisition, ownership and disposition of ADSs or Ordinary Shares.
65
As
used herein, a "U.S. holder" is a beneficial owner of an ADS that is, for U.S. federal income tax purposes, (i) an individual
who is a citizen or resident of the United States, (ii) a corporation (or an entity taxable as a corporation) created or organized in
or under the laws of the United States, any State thereof or the District of Columbia, (iii) an estate the income of which is subject
to U.S. federal income tax without regard to its source or (iv) a trust if (1) a court within the United States is able to exercise primary
supervision over the ad- ministration of the trust, and one or more United States persons have the authority to control all substantial
decisions of the trust, or (2) the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a
United States person.
GIVEN
THE COMPLEXITY OF THE TAX LAWS AND BECAUSE THE TAX CONSEQUENCES TO ANY PARTICULAR INVESTOR MAY BE AFFECTED BY MATTERS NOT DISCUSSED HEREIN,
ALL CURRENT AND PROSPECTIVE HOLDERS OF ORDINARY SHARES AND THE ADSs ARE URGED TO CONSULT THEIR OWN TAX ADVISORS WITH RESPECT TO THE SPECIFIC
TAX CONSEQUENCES OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF ADSs, INCLUDING THE APPLICABILITY AND EFFECT OF U.S. FEDERAL, STATE
AND LOCAL TAX LAWS, AS WELL AS AUSTRALIAN AND OTHER NON-U.S. TAX LAWS.
Nature
of ADSs for U.S. Federal Income Tax Purposes
In
general, for U.S. federal income tax purposes, a holder of an ADS will be treated as the owner of the underlying Ordinary Shares. Accordingly,
except as specifically noted below, the tax consequences discussed below with respect to ADSs will be the same as for Ordinary Shares.
Exchanges of Ordinary Shares for ADSs, and ADSs for Ordinary Shares, generally will not be subject to U.S. federal income tax.
Distributions
In
general, subject to the passive foreign investment company rules discussed below, a distribution on an ADS or Ordinary Share will constitute
a dividend for U.S. federal income tax purposes to the extent that it is made from our current or accumulated earnings and profits as
determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, it generally
will be treated as a non-taxable reduction of basis to the extent of the U.S. holder's tax basis in the ADS or Ordinary Share on
which it is paid, and to the extent it exceeds that basis it generally will be treated as capital gain. The Company has not maintained
and does not plan to maintain calculations of earnings and profits under U.S. federal income tax principles. Accordingly, it is unlikely
that U.S. holders will be able to establish that a distribution by the Company is in excess of its current and accumulated earnings and
profits (as computed under U.S. federal income tax principles). Therefore, a U.S. holder should expect that a distribution by the Company
will generally be treated as taxable in its entirety as a dividend to U.S. holders for U.S. federal income tax purposes even though the
distribution may be treated in whole or in part as a non-taxable distribution for Australian tax purposes.
The
gross amount of any dividend on an ADS or Ordinary Share (which will include the amount of any Australian taxes withheld) generally will
be subject to U.S. federal income tax as foreign source dividend income, and will not be eligible for the corporate dividends received
deduction. In general, the amount of a dividend paid in Australian dollars will be its value in U.S. dollars based on the prevailing
spot market exchange rate in effect on the day the U.S. holder receives the dividend or, in the case of a dividend received in respect
of an ADS, on the date the Depositary receives it, whether or not the dividend is converted into U.S. dollars at that time. A U.S. holder
will have a tax basis in any distributed Australian dollars equal to its U.S. dollar amount on the date of receipt, and any gain or loss
realized on a subsequent conversion or other disposition of Australian dollars generally will be treated as U.S. source ordinary income
or loss. If dividends paid in Australian dollars are converted into U.S. dollars on the date they are received by a U.S. holder, the
U.S. holder generally should not be required to recognize foreign currency gain or loss in respect of the dividend.
Subject
to certain exceptions, a dividend that a non-corporate holder receives on an ADS or Ordinary Share may qualify for the preferential
rates of taxation with respect to dividends on the ADSs or Ordinary Shares applicable to long-term capital gains (i.e., gains from
the sale of capital assets held for more than one year) and "qualified dividend income" (as discussed below). A dividend
on an ADS or Ordinary Share will be a qualified dividend if (i) either (a) the ADSs or Ordinary Shares, as applicable, are readily
tradable on an established market in the United States or (b) we are eligible for the benefits of a comprehensive income tax treaty
with the United States that the Secretary of the Treasury determines is satisfactory for purposes of these rules and that includes
an exchange of information program, and (ii) we were not, in the year prior to the year the dividend was paid, and are not, in the
year the dividend is paid, a passive foreign investment company ("PFIC"). The ADSs are listed on the NASDAQ Capital
Market, which should qualify them as readily tradable on an established securities market in the United States. In any event, the
Treaty satisfies the requirements of clause (i)(b), and we believe we qualify as a resident of Australia entitled to the benefits of
the Treaty (though there can be no assurance in this regard). However, based on our audited financial statements and relevant market
and shareholder data, we believe we were a PFIC for U.S. federal income tax purposes for our taxable year ended June 30, 2023.
Therefore, in light of the discussion in the section entitled "Passive Foreign Investment Company Rules," you should
assume that dividends generally will not constitute qualified dividend income eligible for reduced rates of taxation.
66
Any
Australian withholding tax imposed on dividends received with respect to the ADSs or Ordinary Shares will be treated as a foreign income
tax eligible for credit against a U.S. holder's U.S. federal income tax liability, subject to generally applicable limitations
under U.S. federal income tax law. Alternatively, any Australian withholding tax may be taken as a deduction against taxable income,
provided the U.S. holder takes a deduction and not a credit for all foreign income taxes paid or accrued in the same taxable year. The
rules relating to the determination of the foreign tax credit are complex and subject to numerous limitations that must be applied on
an individual basis. In addition, the creditability of foreign taxes could be affected by actions taken by intermediaries in the chain
of ownership between the holders of the ADSs and our company if, as a result of such actions, the holders of the ADSs are not properly
treated as beneficial owners of the underlying Ordinary Shares. U.S. holders are urged to consult with their own tax advisers to determine
whether and to what extent they will be entitled to foreign tax credits as well as with respect to the determination of the foreign tax
credit limitation.
Sale,
Exchange or Other Taxable Disposition
Subject
to the passive foreign investment company rules discussed below, on a sale, exchange or other taxable disposition of an Ordinary
Share or ADS, a U.S. holder generally will recognize capital gain or loss in an amount equal to the difference between the U.S.
holder's adjusted tax basis in the Ordinary Share or ADS and the amount realized on the sale, exchange or other taxable
disposition, each determined in U.S. dollars. The adjusted tax basis in the ADSs or Ordinary Shares generally will be equal to the
cost of such ADSs or Ordinary Shares. Capital gain from the sale, exchange or other taxable disposition of the ADSs or Ordinary
Shares by a non-corporate U.S. holder is generally eligible for a preferential rate of taxation applicable to long-term taxable
capital gains if the non-corporate U.S. holder's holding period determined at the time of such sale, exchange or other taxable
disposition for such securities exceeds one year. Capital gains recognized by corporate U.S. holders generally are subject to U.S.
federal income tax at the same rate as ordinary income. The deductibility of capital losses is subject to limitations. Any gain or
loss a U.S. holder recognizes generally will be U.S. source for U.S. foreign tax credit purposes. The rules relating to the
determination of the foreign tax credit are complex, and U.S. holders are urged to consult with their own tax advisers regarding the
application of such rules.
For
a cash basis taxpayer, units of foreign currency paid or received are translated into U.S. dollars at the spot rate on the settlement
date of the purchase or sale. In that case, no foreign currency exchange gain or loss will result from currency fluctuations between
the trade date and the settlement date of such a purchase or sale.
An
accrual basis taxpayer may elect the same treatment required of cash basis taxpayers with respect to purchases and sales of our Ordinary
Shares or ADSs that are traded on an established securities market, provided the election is applied consistently from year to year.
Such election may not be changed without the consent of the IRS. For an accrual basis taxpayer who does not make such election, units
of foreign currency paid or received are translated into U.S. dollars at the spot rate on the trade date of the purchase or sale. Such
an accrual basis taxpayer may recognize exchange gain or loss based on currency fluctuations between the trade date and the settlement
date. Any foreign currency gain or loss a U.S. holder realizes will be U.S. source ordinary income or loss.
Passive
Foreign Investment Company Rules
A
special set of U.S. federal income tax rules applies to a foreign corporation that is a PFIC for U.S. federal income tax purposes. As
noted above, based on our audited financial statements and relevant market and shareholder data, we believe that we were a PFIC for U.S.
federal income tax purposes for our taxable year ended June 30, 2023. There can be no assurance that we will not be considered a PFIC
in any past, current or future taxable year. However, our PFIC status is based on an annual determination and may change from year to
year. Our status as a PFIC will depend on the composition of our income (including with respect to the R&D Tax Credit) and the composition
and value of our assets, which may be determined in large part by reference to the market value of the ADSs and Ordinary Shares, which
may be volatile, from time to time. Our status may also depend, in part, on how quickly we utilize the cash we raise in any offering
of our securities. Our U.S. counsel expresses no opinion regarding our conclusions or our expectations regarding our PFIC status.
In
general, a non-U.S. corporation is a PFIC if at least 75% of its gross income for the taxable year is passive income (the "income
test") or if at least 50% of the average quarterly value of its total gross assets for the taxable year (which would generally
be measured by fair market value of our assets, and for which purpose the total value of our assets may be determined in part by the
market value of the ADSs and Ordinary Shares, which are subject to change) produce passive income or are held for the production of passive
income (the "asset test"). Passive income for this purpose generally includes dividends, interest, royalties, rents, gains
from commodities and securities transactions, the excess of gains over losses from the disposition of assets which produce passive income,
and includes amounts derived by reason of the temporary investment of funds raised in offerings of our securities. If a non-U.S. corporation
owns directly or indirectly at least 25% by value of the stock of another corporation or the partnership interests in a partnership,
the non-U.S. corporation is treated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation
or partnership and as receiving directly its proportionate share of the other corporation's or partnership's income.
67
If
we are classified as a PFIC in any year with respect to which a U.S. holder owns ADSs or Ordinary Shares, we will continue to be treated
as a PFIC with respect to such U.S. holder in all succeeding years during which the U.S. holder owns the ADSs or Ordinary Shares, regardless
of whether we continue to meet the tests described above unless we cease to be a PFIC and the U.S. holder has made a "deemed sale"
election under the PFIC rules. If the "deemed sale" election is made, a U.S. holder will be deemed to have sold the securities
the U.S. holder holds at their fair market value as of the date of such deemed sale and any gain from such deemed sale would be subject
to the rules described below. After the deemed sale election, so long as we do not become a PFIC in a subsequent taxable year, the U.S.
holder's securities with respect to which such election was made will not be treated as shares in a PFIC and the U.S. holder will
not be subject to the rules described below with respect to any "excess distribution" the U.S. holder receives from us or
any gain from an actual sale or other disposition of the securities. U.S. holders should consult their tax advisors as to the possibility
and consequences of making a deemed sale or other "purging" election if such election becomes available.
If
we are a PFIC, and you are a U.S. holder that does not make one of the elections described herein, a special tax regime will apply to
both (a) any "excess distribution" by us to you (generally, your ratable portion of distributions in any year, other than
the taxable year in which your holding period in the Ordinary Shares or ADSs begins, which are greater than 125% of the average annual
distribution received by you in the shorter of the three preceding years or the portion of your holding period for the ADSs or Ordinary
Shares that preceded the year of the distribution) and (b) any gain realized on the sale or other disposition of the ADSs or Ordinary
Shares. Under this regime, any excess distribution and realized gain will be treated as ordinary income and will be subject to tax as
if (a) the excess distribution or gain had been realized ratably over your holding period, (b) the amount deemed realized in each year
had been subject to tax in each year of that holding period at the highest marginal rate for such year (other than income allocated to
the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. holder's regular ordinary
income rate for the current year and would not be subject to the interest charge discussed below) and (c) the interest charge generally
applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those years. In addition, dividend distributions
made to you will not qualify for the lower rates of taxation applicable to qualified dividends discussed above under "Distributions."
Certain
elections may alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment of our Ordinary
Shares or ADSs. If a U.S. holder makes a mark-to-market election with respect to their Ordinary Shares or ADSs, the U.S. holder
generally will recognize as ordinary income any excess of the fair market value of such Ordinary Shares or ADSs at the end of each
taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis
of such Ordinary Shares or ADSs over their fair market value at the end of the taxable year (but only to the extent of the net
amount of income previously included as a result of the mark-to-market election). If a U.S. holder makes the election, the U.S.
holder's tax basis in their Ordinary Shares or ADSs will be adjusted to reflect these income or loss amounts. Any gain
recognized on the sale or other disposition of Ordinary Shares or ADSs in a year in which we are a PFIC will be treated as ordinary
income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a
result of the mark-to-market election). The mark-to-market election is available only if we are a PFIC and the Ordinary Shares or
ADSs are "regularly traded" on a "qualified exchange." Our Ordinary Shares or ADSs will be treated as
"regularly traded" in any calendar year in which more than a de minimis quantity of our Ordinary Shares or ADSs are
traded on a qualified exchange on at least 15 days during each calendar quarter (subject to the rule that trades that have as one of
their principal purposes the meeting of the trading requirement are disregarded). The NASDAQ Capital Market is a qualified exchange
for this purpose and, consequently, if the ADSs are regularly traded, the mark-to-market election will be available to a U.S.
holder. It should be noted that it is intended that only the ADSs and not the Ordinary Shares will be listed on the NASDAQ Capital
Market. Consequently, the Ordinary Shares may not be marketable if the ASX (where the Ordinary Shares are currently listed) does not
meet the applicable requirements. U.S. holders should consult their tax advisors regarding the availability of the mark-to-market
election for Ordinary Shares that are not represented by ADSs.
However,
a mark-to-market election generally cannot be made for equity interests in any lower-tier PFICs that we own, unless shares of such lower-tier
PFIC are themselves "marketable." As a result, even if a U.S. holder validly makes a mark-to-market election with respect
to our Ordinary Shares or ADSs, the U.S. holder may continue to be subject to the PFIC rules (described above) with respect to its indirect
interest in any of our investments that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. U.S. holders
should consult their tax advisors as to the availability and desirability of a mark-to-market election, as well as the impact of such
election on interests in any lower-tier PFICs.
We
do not currently intend to provide the information necessary for U.S. holders to make qualified electing fund elections if we were treated
as a PFIC for any taxable year. U.S. holders should consult their tax advisors to determine whether any of the other elections described
above would be available and if so, what the consequences of the alternative treatments would be in their particular circumstances.
If
we are determined to be a PFIC, the general tax treatment for U.S. holders described in this section would apply to indirect distributions
and gains deemed to be realized by U.S. holders in respect of any of our subsidiaries that also may be determined to be PFICs. U.S. holders
should consult their tax advisors regarding the application of the PFIC rules to our subsidiaries. If a U.S. holder owns Ordinary Shares
or ADSs during any taxable year in which we are a PFIC, the U.S. holder may be required to file an IRS Form 8621 (Information Return
by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund) with respect to the company, generally with the
U.S. holder's federal income tax return for that year. You should consult your tax advisor concerning any filing requirements arising
from the PFIC rules.
68
The
U.S. federal income tax rules relating to PFICs are complex. Prospective U.S. investors are urged to consult their own tax advisors with
respect to the acquisition, ownership and disposition of our Ordinary Shares or ADSs, the consequences to them of an investment in a
PFIC, any elections available with respect to Ordinary Shares and ADSs and the IRS information reporting obligations with respect to
the acquisition, ownership and disposition of Ordinary Shares and ADSs.
Information
Reporting and Backup Withholding
U.S.
holders generally will be subject to information reporting requirements with respect to dividends on the Ordinary Shares or ADSs and
on the proceeds from the sale, exchange or disposition of the Ordinary Shares or ADSs that are paid within the United States or through
U.S.-related financial intermediaries, unless the U.S. holder is an "exempt recipient." In addition, U.S. holders may be
subject to backup withholding on such payments unless the U.S. holder provides a taxpayer identification number and a duly executed IRS
Form W-9 or otherwise establishes an exemption. Backup withholding is not an additional tax, and the amount of any backup withholding
will be allowed as a credit against a U.S. holder's U.S. federal income tax liability and may entitle such holder to a refund,
provided that the required information is timely furnished to the IRS.
Reporting
Obligations of Individual Owners of Foreign Financial Assets
Subject
to certain exceptions (including an exception for property held in accounts maintained by U.S. financial institutions), Section 6038D
of the Code generally requires certain individual U.S. holders (and certain entities that are closely held by U.S. individuals) to report
information relating to an interest in the Ordinary Shares or ADSs by filing IRS Form 8938 (Statement of Specified Foreign Financial
Assets) with their U.S. federal income tax return. Such U.S. holders (or entities) who fail to timely furnish the required information
may be subject to penalties. Additionally, if any such U.S. holder (or entity) does not report the required information, the statute
of limitations with respect to tax returns of the U.S. holder (or entity) to which the information relates may not close until three
years after such information is reported. U.S. holders are urged to consult their tax advisors regarding their information reporting
obligations, if any, with respect to their ownership and disposition of the Ordinary Shares or ADSs.
THE
DISCUSSION ABOVE IS NOT INTENDED TO CONSTITUTE A COMPLETE ANALYSIS OF ALL TAX CONSIDERATIONS APPLICABLE TO AN INVESTMENT IN ORDINARY
SHARES OR ADSs. EACH CURRENT AND POTENTIAL HOLDER IS URGED TO CONSULT THEIR OWN TAX ADVISERS CONCERNING THE TAX CONSEQUENCES RELEVANT
TO THEM IN THEIR PARTICULAR SITUATION.
Item
10.F Dividends and Paying Agents
No
dividends were declared or paid to members for the year ended June 30, 2023 (2022: nil). The Company's franking account balance
was nil at June 30, 2023 (2022: nil).
Item
10.G Statement by Experts
Not
applicable.
Item
10.H Documents on Display
The
documents concerning the Company which are referred to in this Annual Report may be inspected at the offices of the Company at 60-66
Hanover Street, Fitzroy, Victoria 3065 Australia. As a "foreign private issuer" we are subject to the information requirements
of the U.S. Securities Exchange Act of 1934, as amended, and, in accordance therewith, we are required to file reports, including annual
reports on Form 20-F, and other information with the U.S. Securities and Exchange Commission in electronic form. Any filings we make
electronically are available to the public over the Internet at the Commission's website at http://www.sec.gov. We also maintain
a website at www.genetype.com. Information on our website and websites linked to it do not constitute a part of this Annual Report.
Item
10.I Subsidiary Information
Not
applicable.
Item
10.J Annual Report to Security Holders
Not
applicable.
Item
11. Quantitative and Qualitative Disclosures about Market Risk
Our
market risk relates primarily to exposure to changes in foreign currency exchange rates and interest rates. Refer Note 31 of the attached
financial statements for further analysis surrounding market risk.
69
Interest
Rate Risk
. As of June 30, 2023, we had A$7,851,197 in cash and cash equivalents of which A$6,216,646 was subject to interest
rate risk. Interest income earned on the cash balances is affected by changes in the levels of market interest rates. We invest excess
cash in interest-bearing, investment-grade securities and time deposits in high-quality institutions. We do not utilize derivative financial
instruments, derivative commodity instruments, positions or transactions in any material matter.
Accordingly,
we believe that, while the investment-grade securities and time-deposits we hold are subject to changes in financial standing of the
issuer of such securities, the principal is not subject to any material risks arising from changes in interest rates, foreign currency
exchange rates, commodity prices, equity prices or other market changes that affect market risk sensitive instruments. Since we hold
cash and cash equivalents in Banks which are located outside Australia, we are subject to certain cross-border risks, though due to the
size of the holdings these risks are not generally significant.
Foreign
Currency Exchange Rate Risk
. We operate in Australia with active operations in the U.S.A., United Kingdom and Europe, and are
accordingly subject to certain foreign currency exposure. This includes foreign-currency denominated receivables, payables, and other
balance sheet positions as well as future cash flows resulting from anticipated transactions including intra-company transactions. Historically,
currency translation gains and losses have been reflected as adjustments to stockholders' equity, while transaction gains and losses
have been reflected as components of income and loss. Transaction gains and losses could be material depending upon changes in the exchange
rates between the Australian dollar and the U.S. dollar. A significant amount of our current revenue is denominated in U.S. dollars which
provides us with a limited natural hedge against exchange rate movements.
Item
12. Description of Securities Other Than Equity Securities
Item
12.A Debt Securities
Not
applicable.
Item
12.B Warrants and Rights
Not
applicable.
Item
12.C Other Securities
Not
applicable
Item
12.D American Depositary Shares Fees and Charges Payable by ADS Holders
The
table below summarizes the fees and charges that a holder of our ADSs may have to pay, directly or indirectly, to our depositary, The
Bank of New York Mellon, or BNYM, pursuant to the Deposit Agreement, which was filed as Exhibit 2.1 to our Registration Statement on
Form F-6 filed with the SEC on January 14, 2002, and the types of services and the amount of the fees or charges paid for such services.
The disclosure under this heading "Fees and Charges Payable by ADS Holders" is subject to and qualified in its entirety by
reference to the full text of the Deposit Agreement. The holder of an ADS may have to pay the following fees and charges to BNYM in connection
with ownership of the ADS:
Persons
Depositing or Withdrawing Shares Must
Pay:
For:
●
    US$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)
●
    Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property
●
    Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates
●
    US$0.02 (or less) per ADS
●
    Any cash distribution to you
●
    A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been
    deposited for issuance of ADSs
●
    Distribution of securities distributed to holders of deposited securities which are distributed by the depositary to ADS
    holders
●
    US$1.50 (or less) per ADR
●
    Transfers, combination and split-up of ADRs
●
    Expenses of the depositary
●
    Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement)
●
    Converting foreign currency to U.S. dollars
The
depositary collects its fees for issuance and cancellation of ADSs directly from investors depositing shares or surrendering ADSs
for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to
investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees.
The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing
investors or by charging the book-entry system accounts of participants acting for them. The depositary may generally refuse to
provide fee-attracting services until its fees for those services are paid.
70
PART
II
Item
13. Defaults, Dividend Arrearages and Delinquencies
Not
applicable.
Item
14. Material Modifications to the Rights of Security Holders and Use of Proceeds
Not
applicable.
Item
15. Controls and Procedures
Item
15.A Disclosure controls and procedures
We
maintain disclosure controls and procedures as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934 (the "Exchange Act"), as amended, that are designed to ensure that information required to be disclosed in the reports
that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods
specified in the rules and forms of the Securities and Exchange Commission. Disclosure controls and procedures include, without limitation,
controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities
Exchange Act of 1934 is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer,
as appropriate, to allow timely decisions regarding required disclosure.
Our
Management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures or
our internal control over financial reporting are designed and operated to be effective at the reasonable assurance level. However, our
Management does not expect that our disclosure controls and procedures and our internal control over financial reporting will prevent
all error and fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the control system are met. Additionally, the design of a control system must reflect the fact that there are
resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in
all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any,
have been detected or that our control system will operate effectively under all circumstances. Moreover, the design of any system of
controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design
will succeed in achieving its stated goals under all potential future conditions.
Our
Management has carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial
Officer, of the effectiveness of our disclosure controls and procedures as of June 30, 2023. Based on that evaluation, the Chief Executive
Officer and the Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective as of June
30, 2023.
Item
15.B Management's annual report on internal control over financial reporting
Our
Management is responsible for establishing and maintaining adequate internal control over financial reporting. The Securities Exchange
Act of 1934 defines internal control over financial reporting in Rules 13a-15(f) and 15d-15(f) as a process designed by, or under the
supervision of, the Company's Chief Executive Officer and Chief Financial Officer effected by the Company's Board of Directors,
Management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies
and procedures that:
●
Pertain
    to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets
    of the Company;
●
Provide
    reasonable assurance that transactions are recorded as necessary to permit the preparation of financial statements in accordance
    with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance
    with authorizations of Management and directors of the Company; and
●
Provide
    reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's
    assets that could have a material effect on the consolidated financial statements.
Our
Management, under the supervision and with participation of our Chief Executive Officer and Chief Financial Officer, has assessed the
effectiveness of the Company's internal control over financial reporting as of June 30, 2023. Based on that evaluation, the Chief
Executive Officer and the Chief Financial Officer concluded that the Company's internal control over financial reporting was effective
as of June 30, 2023. In making this assessment, Management used the criteria set forth by the Committee of Sponsoring Organizations of
the Treadway Commission, or COSO, in Internal Control-Integrated Framework (2013).
71
This
Annual Report does not include an attestation report of the Company's registered public accounting firm regarding internal control
over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting
firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only Management's report in
this Annual Report.
Item
15.C Attestation report of the registered public accounting firm
Not
applicable.
Item
15.D Changes in Internal Control over Financial Reporting
There
were no changes in the internal control over financial reporting during the year ended June 30, 2023.
Item
16. Reserved
Reserved.
Item
16.A Audit Committee Financial Expert
On
September 2, 2019, the Company appointed Mr. Nick Burrows to the Board as an independent Non-Executive Director. Mr. Burrows is a financial
expert and hence the Company subsequently appointed Mr. Burrows as the Chairman of the Audit & Risk Committee replacing Mr. Peter
Rubinstein, former Chairman of the Audit & Risk Committee.
Item
16.B Code of Ethics
We
have adopted a Code of Ethics (styled "Code of Conduct") that applies to all of our Directors and employees, including our
principal executive officer, principal financial officer and principal accounting officer or controller. The Code can be downloaded at
our website (www.genetype.com). Additionally, any person, upon request, can ask for a hard copy or electronic file of the Code. If we
make any substantive amendment to the Code or grant any waivers, including any implicit waiver, from a provision of the Code, we will
disclose the nature of such amendment or waiver on our website. During the year ended June 30, 2023, no such amendment was made, or waiver
granted.
Item
16.C Principal Accountant Fees and Services
The
following table sets forth the fees billed to us by our Independent Registered Public Accounting Firms, Grant Thornton Audit Pty Ltd
and PricewaterhouseCoopers, during the financial years ended June 30, 2023 and 2022, respectively:
2023
A$
2022
A$
Services rendered
PricewaterhouseCoopers in respect of:
Audit fees
(1)
-
20,000
Audit-related fees
(2)
-
-
All other fees
(3)
-
-
Grant Thornton Audit Pty Ltd in respect of:
Audit fees
(1)
320,569
241,882
Audit-related fees
(2)
-
-
All other fees
(3)
-
30,000
(1)
Audit fees consist of services that would normally be provided in connection with statutory, half year review and regulatory filings
or engagements, including services that generally only the independent accountant can reasonably provide such as comfort letters.
(2)
Audit-related
fees consist of fees billed for assurance and related services that generally only the statutory auditor could reasonably provide to
a client.
(3)
All other fees consist of fees billed for financial and information technology due diligence services in respect of the Company's
acquisition of the business and assets associated with the EasyDNA brand that completed on August 13
th
, 2021
72
Audit
Committee Pre-Approval Policies and Procedures
Our
Board of Directors has established pre-approval and procedures for the engagement of its Independent Registered Public Accounting Firm
for audit and non-audit services. The Board of Directors reviews the scope of the services to be provided, before their commencement,
in order to ensure that there are no independence issues and the services are not prohibited services, as defined by the Sarbanes-Oxley
Act of 2002. The Board of Directors has considered advice received from the Audit & Risk Committee and is satisfied that the provision
of the non-audit services is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001.
The directors are satisfied that the provision of the non-audit services as set out above, did not compromise the auditor independence
requirements of the Corporations Act 2001 because the services are not deemed to undermine the general principles relating to auditor
independence as set out in APES 110 Code of Ethics for Professional Accountants.
Item
16.D Exemptions from the Listing Standards for Audit Committees
Not
applicable.
Item
16.E Purchases of Equity Securities by the Issuer and Affiliated Purchasers
Not
applicable.
Item
16.F Change in Registrant's Certifying Accountant
Not
applicable.
Item
16.G Corporate Governance
Refer
to Item 6C regarding the Company's Corporate Governance practices and the key differences between the Listing Rules of the Australian
Securities Exchange and NASDAQ's Marketplace Rules as they apply to us.
Item
16.H Mine Safety Disclosure
Not
applicable.
Item
16.I Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not
applicable.
Item
16.J insider Trading Policies
The
Company has adopted a Securities Trading Policy which covers insider trading. Refer to exhibit 4.13 for further details.
PART
III
Item
17. Financial Statements
The
Company has responded to Item 18 in lieu of responding to this Item.
Item
18. Financial Statements
The
full text of the Company's audited financial statements for the fiscal years ended June 30, 2023 and 2022 begins on page F-1 of
this Annual Report on Form 20-F.
Australian
Disclosure Requirements
Directors' Declaration
In
the directors' opinion:
(a)
the financial statements and Notes set out on pages F-4 to F-56 are in accordance with the Corporations Act 2001, including:
(i)
Complying with Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements,
and
(ii)
Giving a true and fair view of the consolidated entity's financial position as at June 30, 2023 and of its performance for the
fiscal year ended on that date, and
(b)
There are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and
payable.
Note
1 'Basis of preparation' confirms that the financial statements also comply with International Financial Reporting Standards
as issued by the International Accounting Standards Board.
The
directors have been given the declarations by the chief executive officer and chief financial officer required by section 295A of the
Corporations Act 2001.
This
declaration is made in accordance with a resolution of the directors.
/s/ Peter Rubinstein
Chairman
Melbourne,
August 30, 2023
73
Item
19. Exhibits
The
following documents are filed as exhibits to this Annual Report on Form 20-F:
1.1
Constitution of the Registrant (incorporated by reference to Exhibit 1.1 to the Company's Registration Statement on Form 20-F filed with the Commission on December 21, 2010)
2.1
Deposit Agreement, dated as of January 14, 2002, by and among Genetic Technologies Limited, The Bank of New York Mellon, as Depositary, and the Owners and Holders of American Depositary Receipts (such agreement is incorporated herein by reference to the Registration Statement on Form F-6 relating to the ADSs (File No. 333-14270) filed with the Commission on January 14, 2002).
2.2
Description of Securities (incorporated by reference to Exhibit 4.1 to the Company's Annual Report on Form 20-F filed with the Commission on October 22, 2020)
2.5
Form of Compensation Warrant issued on April 3, 2020 (incorporated by reference to Exhibit 10.3 of the Company's Report on Form 6-K filed with the Commission on April 2, 2020)
2.6
Form of Pre-funded Warrant (incorporated by reference to Exhibit 4.5 to the Company's registration statement on Form F-1/A filed on May 12, 2020)
2.7
Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.6 to the Company's registration statement on Form F-1/A filed on May 12, 2020)
2.8
Staff Share Plan 2001 dated November 30, 2001 (incorporated by reference to Exhibit 4.2 to the Company's Registration Statement on Form 20-F filed with the Commission on August 19, 2005)
4.5
Placement Agent Agreement effective March 30, 2020 (incorporated by reference to Exhibit 10.2 of the Company's Report on Form 6-K filed with the Commission on April 2, 2020)
4.6
Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.9 to the Company's registration statement on Form F-1/A filed on May 12, 2020)
4.7
Renewal of Lease over premises in Fitzroy, Victoria, Australia with an effective date of September 1, 2018 (incorporated by reference to 20-F filed October 3, 2019)
4.8
Form of Securities Purchase Agreement dated July 16, 2020 (incorporated by reference to Exhibit 10.1 of the Company's Report on Form 6-K filed with the Commission on July 20, 2020)
4.9
Form of Securities Purchase Agreement dated January 21, 2021 (incorporated by reference to Exhibit 10.1 of the Company's Report on Form 6-K filed with the Commission on January 5, 2021)
4.10
Registration Rights Agreement dated August 12, 2021 (incorporated by reference to Exhibit 4.11 of the Company's Annual Report on Form 20-F filed with the Commission on August 31, 2021)
4.11
Non-Solicitation Agreement dated July 18, 2021 (incorporated by reference to Exhibit 4.12 of the Company's Annual Report on Form 20-F filed with the Commission on August 31, 2021)
4.12
Sale of Business Agreement dated July 14, 2022 (incorporated by reference to Exhibit 4.12 of the Company's Annual Report on Form 20-F filed with the Commission on August 30, 2022)
4.13
Securities Trading Policy
4.14
Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company's Report on Form 6-K filed with the Commission on February 7, 2023)
74
12.01
Section 302 Certification of the Chief Executive Officer
12.02
Section 302 Certification of the Chief Financial Officer
13.01
Section 906 Certification of the Chief Executive Officer
13.02
Section 906 Certification of the Chief Financial Officer
15.1
Appendix 4E
15.2
Auditor's Independence Declaration
15.3
Independent Auditor's Report
101.
                                                         INS
Inline
    XBRL Instance Document
101.
    SCH
Inline
    XBRL Schema Document
101.
                                                         CAL
Inline
    XBRL Calculation Linkbase Document
101.
    DEF
Inline XBRL Definition Linkbase Document
101.
    LAB
Inline
    XBRL Labels Linkbase Document
101.
    PRE
Inline
    XBRL Presentation Linkbase Document
104
Cover
    Page Interactive Data File (embedded within the Inline XBRL document)
*Certain
information which constitutes a clearly unwarranted invasion of personal privacy pursuant to Item 601(a)(6) of Regulation S-K has been
omitted.
75
SIGNATURES
The
registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized
the undersigned to sign this Annual Report on its behalf.
GENETIC
    TECHNOLOGIES LIMITED
Dated:
    August 30, 2023
By:
/s/
    Simon Morriss
Name:
Simon
    Morriss
Title:
Chief
    Executive Officer
76
2023
Financial Report
GENETIC
TECHNOLOGIES LIMITED
INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS
Page
Genetic Technologies Limited - Report of Independent Registered Public Accounting Firm (PCAOB ID 0
2233
).
F-1
Genetic Technologies Limited - Consolidated Statements of Profit or Loss and Other Comprehensive Income/(Loss) for the years ended June 30, 2023, 2022 and 2021.
F-4
Genetic Technologies Limited - Consolidated Statements of Financial Position as of June 30, 2023 and 2022.
F-5
Genetic Technologies Limited - Consolidated Statements of Cash Flows for the years ended June 30, 2023, 2022 and 2021.
F-6
Genetic Technologies Limited - Consolidated Statements of Changes in Equity for the years ended June 30, 2023, 2022 and 2021.
F-7
Genetic Technologies Limited - Notes to Consolidated Financial Statements.
F-8
77
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Board
of Directors and Shareholders
Genetic
Technologies Limited
Opinion
on the financial statements
We
have audited the accompanying consolidated balance sheets of Genetic Technologies Limited and subsidiaries (the "Company")
as of June 30, 2023 and 2022, the related consolidated statement of profit or loss and other comprehensive income, changes in shareholders'
equity, and cashflows for the three years ended June 30, 2023, and the related notes (collectively referred to as the "financial
statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the
Company as of June 30, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period
ended June 30, 2023, in conformity with International Financial Reporting Standards, as issued by the International Accounting Standards
Board.
Basis
for opinion
These
financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.
Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence supporting
the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe
that our audits provide a reasonable basis for our opinion.
Going
concern
The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
2(a)(iv) to the financial statements, the Company incurred a total comprehensive loss of A$11,650,334 (2022: A$7,103,134) and net cash
outflow from operations of A$9,723,095 (2022: A$5,659,456). As at June 30, 2023, the Company held total cash and cash equivalents of
A$7,851,197 and total net current assets of A$7,185,750. These conditions, along with other matters as set forth in Note 2(a)(iv), raise
substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters
are also described in Note 2(a)(iv). The financial statements do not include any adjustments that might result from the outcome of this
uncertainty.
Critical
audit matters
The
critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated
or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated
financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit
matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical
audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Research
and Development Tax Incentive
As
described further in Note 5 and Note 12 of the financial report, Genetic Technologies Limited determines the eligibility of the research
and development ("R&D") activities under the Australian government tax incentive scheme. The R&D receivable for the
period was A$1,616,064 and the income recognized in the consolidated statement of profit or loss and other comprehensive income
was A$1,616,064 for the year then ended.
F-
1
There
is inherent subjectivity involved in the Company's judgements in relation to the calculation and recognition of the R&D tax
incentive income and receivable, with several assumptions made in determining the eligibility of claimable expenses.
Our
procedures included, amongst others:
●
Obtained
                                            an understanding of the process undertaken to calculate the research and development tax
                                            incentive;
●
Utilized
                                            an internal research and development tax specialist to:
○
Review
                                            the methodology used by the Company for consistency with the R&D tax offset rules; and
○
Consider
                                            the nature of the expenses against the eligibility criteria of the R&D tax incentive
                                            scheme to assess whether the expenses included in the estimate were likely to meet the eligibility
                                            criteria;
●
Inspected
                                            supporting documentation for a sample of expenses claimed to assess validity of the claimed
                                            amount and eligibility against the R&D tax incentive scheme criteria;
●
Validated
                                            the approval process for a sample of expenses;
●
Compared
                                            the nature of R&D expenditure included in the current year estimate to the prior year
                                            claim;
●
Considered
                                            the Company's history of successful claims;
●
Inspected
                                            copies of relevant correspondence with Aus Industry and the Australian Taxation Office related
                                            to the claims; and
●
Assessed
                                            the adequacy of the Company's disclosures in relation to the R&D tax incentive.
Impairment
of goodwill and other long-lived assets impairment assessment
As
described further in Note 15 of the financial report, goodwill amounted to A$3,116,893 at June 30, 2023, as a result of the acquisitions
of EasyDNA and AffinityDNA and the impairment loss of A$1,845,000 for EasyDNA that was recognized in the period. At June 30, 2023,
Genetic Technologies Limited also has other intangibles assets of A$520,472 made up of brands, trademarks, trade names, and domain
names acquired via the EasyDNA and AffinityDNA acquisitions.
In
accordance with AASB 136 Impairment of Assets, goodwill and other intangible assets acquired in a business combination must be allocated
to the Group's cash generating units ("CGUs"). For each CGU to which goodwill has been allocated, the Group is required
to assess if the carrying value of the CGU is in excess of the recoverable value.
The
Goodwill and other long-lived assets impairment assessment has been assessed as a critical audit matter due to the judgement required
by management in preparing a value in use model to satisfy the impairment test as prescribed in IFRS 36 Impairment of Assets, including
significant estimation involved in forecasting of future cash flows and applying an appropriate discount rate which inherently involves
a high degree of estimation and judgement by management.
Our
procedures included, amongst others:
●
Assessed
                                            management's determination of the Company having two CGUs and their allocation of goodwill;
●
Assessed
                                            whether management has the requisite expertise to prepare the impairment model;
●
Reviewed
                                            the impairment model for compliance with IFRS 36 Impairment of Assets;
●
Assessed
                                            the reasonableness and appropriateness of inputs and assumptions to the model, with involvement
                                            of our internal valuation specialist;
●
Evaluated
                                            management's future cash flow forecasts and obtained an understanding of the process
                                            by which they were developed, including:
○
Assessed
                                            management's key assumptions for reasonableness and obtaining available evidence to
                                            support key assumptions;
○
Considered
                                            the reasonableness of the revenue and cost forecasts against current period actuals;
○
Performed
                                            a sensitivity analysis on the key assumptions;
○
Tested
                                            the underlying calculations for mathematical accuracy of the model; and
●
Evaluated
                                            the disclosures in the financial statements for appropriateness and consistency with accounting
                                            standards.
F-
2
Business
combination
As
described further in Note 17 to the financial statements, on July 14, 2022, the Company completed the acquisition of AffinityDNA's
direct-to-consumer eCommerce business and distribution rights. This transaction was accounted for as a business combination using the
acquisition method.
Accounting
for these transactions is a complex and judgmental exercise requiring management to determine the fair value of acquired assets and liabilities
as well as the goodwill arising on acquisition and as a result has been assessed as a critical audit matter.
Our
procedures included, amongst others:
●
Read
                                            the executed acquisition agreement and evaluated the Company's acquisition accounting
                                            against the requirements of International Financial Reporting Standards;
●
Tested
                                            the accuracy of the purchase consideration against the executed acquisition agreements;
●
Assessed
                                            the fair values of the acquired assets and liabilities recognized, with involvement
                                            of our valuations specialist, including:
○
Evaluated
                                            the competence, capabilities and objectivity of management's expert who assisted the
                                            Company in estimating fair values;
○
Assessed
                                            the valuation of identified intangible assets recognized as part of the purchase price
                                            allocation calculations;
○
Assessed
                                            the completeness of identified intangible assets through discussions with management and
                                            with the internal valuation specialist;
○
Evaluated
                                            the mathematical accuracy of the Company's calculation of the resulting goodwill arising
                                            on the PPA calculations;
○
Reviewed
                                            the work of the independent valuers engaged by the Group to assist with the PPA calculations;
○
Utilized
                                            an internal valuation specialist to review the work performed by management's expert;
                                            and
●
Assessed
                                            the adequacy of the Company's disclosures in relation to business combination.
/s/
GRANT THORNTON AUDIT PTY LTD
We
have served as the Company's auditor since 2021.
Melbourne,
Australia
August
30, 2023
F-
3
CONSOLIDATED
STATEMENT OF PROFIT OR LOSS AND COMPREHENSIVE INCOME
For
the year ended June 30, 2023
(in
Australian dollars, except number of shares)
Year ended
June 30, 2023
Year ended
June 30, 2022
Year ended
June 30, 2021
Note
A$
A$
A$
Revenue
4A
8,686,118
6,794,816
120,554
Finance income
8
220,161
36,256
62,394
Other income
5
1,836,822
2,783,391
1,559,961
Changes in inventories
72,257
(
321,223
)
14,463
Raw materials
(
4,407,522
)
(
2,692,311
)
(
184,920
)
Commissions
(
236,019
)
(
156,625
)
-
Employee benefits expenses
6
(
6,208,066
)
(
5,868,655
)
(
3,868,331
)
Advertising and promotional expenses
(
2,712,353
)
(
1,885,402
)
(
436,274
)
Professional fees
(
1,360,640
)
(
1,835,444
)
(
1,461,401
)
Research and development expenses
(
1,281,157
)
(
705,507
)
(
1,165,531
)
Depreciation and amortization
(
676,583
)
(
578,668
)
(
386,277
)
Impairment expenses
(
2,125,725
)
(
564,161
)
(
32,048
)
Other expenses
7
(
3,687,030
)
(
2,154,375
)
(
1,283,871
)
Finance costs
8
(
29,515
)
(
15,215
)
(
16,338
)
Loss from operations before income tax
(
11,909,252
)
(
7,163,123
)
(
7,077,619
)
Income tax credit
9
158,329
32,125
-
Loss for the year
(
11,750,923
)
(
7,130,998
)
(
7,077,619
)
Other comprehensive income/(loss)
Exchange gains/(losses) on translation of con- trolled foreign operations
100,589
27,864
(
37,468
)
Other comprehensive income/(loss) for the year, net of tax
100,589
27,864
(
37,468
)
Total comprehensive loss attributable to the members of Genetic Technologies Ltd
(
11,650,334
)
(
7,103,134
)
(
7,115,087
)
Loss per share (cents per share)
Basic and diluted net loss per ordinary share
10
(
0.012
)
(
0.08
)
(
0.08
)
Weighted-average shares outstanding
10
10,138,075,003
9,220,348,281
8,544,157,979
The
above consolidated statement of profit or loss and comprehensive income should be read in conjunction with the accompanying notes.
F-
4
CONSOLIDATED
STATEMENT OF FINANCIAL POSITION
As
at June 30, 2023
(in
Australian dollars)
Note
2023
A$
2022
A$
ASSETS
Current assets
Cash and cash equivalents
11
7,851,197
11,731,325
Trade and other receivables
12
1,921,657
2,421,238
Inventories
325,893
398,150
Other current assets
13
399,048
166,087
Total current assets
10,497,795
14,716,800
Non-current assets
Right-of-use assets
20
509,553
647,150
Property, plant and equipment
14
89,623
306,175
Goodwill
15
3,116,893
4,506,653
Other intangible assets
16
520,472
624,920
Other non-current assets
-
-
Deferred tax asset
9
121,901
-
Total non-current assets
4,358,442
6,084,898
Total assets
14,856,237
20,801,698
LIABILITIES
Current liabilities
Trade and other payables
18
1,617,333
2,122,379
Contract liabilities
4C
849,212
814,150
Provisions
19
541,930
611,060
Lease liabilities
20
303,570
264,130
Total current liabilities
3,312,045
3,811,719
Non-current liabilities
Provisions
19
30,439
22,499
Lease liabilities
20
229,276
388,396
Deferred tax liability
9
121,901
148,013
Total non-current liabilities
381,616
558,908
Total liabilities
3,693,661
4,370,627
Net assets
11,162,576
16,431,071
EQUITY
Contributed equity
21
161,342,707
155,138,636
Reserves
22
6,535,556
11,498,651
Accumulated losses
23
(
156,715,687
)
(
150,206,216
)
Total equity
11,162,576
16,431,071
The
above consolidated statement of financial position should be read in conjunction with the accompanying notes.
F-
5
CONSOLIDATED
STATEMENT OF CASH FLOWS
For
the year ended June 30, 2023
(in
Australian dollars)
Note
2023
A$
2022
A$
2021
A$
Cash flows from/(used in) operating activities
Receipts from customers
8,771,325
5,745,162
121,190
Payments to suppliers and employees
(
20,453,567
)
(
13,802,170
)
(
7,747,186
)
R&D tax incentive and other grants received
1,959,147
2,397,552
1,330,067
Net cash flows (used in) operating activities
11
(
9,723,095
)
(
5,659,456
)
(
6,295,929
)
Cash flows from/(used in) investing activities
Purchases of plant and equipment
(
17,552
)
(
63,926
)
(
748,706
)
Purchases of intangible assets
-
(
32,868
)
-
Interest received
191,803
36,256
-
Payment for purchase of business, net of cash acquired
17
(
486,188
)
(
3,400,625
)
-
Net cash flows (used in) investing activities
(
311,937
)
(
3,461,163
)
(
748,706
)
Cash flows from/(used in) financing activities
Proceeds from the issue of shares
7,172,399
-
15,897,629
Equity transaction costs
(
916,060
)
(
10,474
)
(
1,956,691
)
Principal elements of lease payments
(
336,396
)
(
268,590
)
(
236,893
)
Interest paid
-
-
(
14,049
)
Net cash flows from/(used in) financing activities
5,919,943
(
279,064
)
13,689,996
Net (decrease)/ increase in cash and cash equivalents
(
4,115,089
)
(
9,399,683
)
6,645,361
Cash and cash equivalents at beginning of year
11,731,325
20,902,282
14,214,160
Net foreign exchange difference
234,961
228,726
42,761
Cash and cash equivalents at end of year
11
7,851,197
11,731,325
20,902,282
The
above consolidated statements of cash flows should be read in conjunction with the accompanying notes.
F-
6
CONSOLIDATED
STATEMENT OF CHANGES IN EQUITY
For
the year ended June 30, 2023
(in
Australian dollars)
Contributed equity
Reserves
Accumulat- ed losses
Total equity
A$
A$
A$
A$
Balance at June 30, 2020
140,111,073
9,928,571
(
136,047,037
)
13,992,607
Loss for the year
-
-
(
7,077,619
)
(
7,077,619
)
Other comprehensive loss
-
(
37,468
)
-
(
37,468
)
Total comprehensive loss
-
(
37,468
)
(
7,077,619
)
(
7,115,087
)
Transactions with owners in their capacity as owners
Contributions of equity, net of transaction costs and tax
11,764,379
-
-
11,764,379
Exercise of options/warrants
1,699,522
(
973,467
)
-
726,055
Issue of performance rights
-
622,725
-
622,725
Options expired
-
(
49,438
)
49,438
-
Issue of options/warrants
-
1,542,356
-
1,542,356
13,463,901
1,142,176
49,438
14,655,515
Balance at June 30, 2021
153,574,974
11,033,279
(
143,075,218
)
21,533,035
Loss for the year
-
-
(
7,130,998
)
(
7,130,998
)
Other comprehensive income
-
27,864
-
27,864
Total comprehensive loss
-
27,864
(
7,130,998
)
(
7,103,134
)
Transactions with owners in their capacity as owners
Contributions of equity, net of transaction costs
1,563,662
-
-
1,563,662
Issue of performance rights
-
437,508
-
437,508
1,563,662
437,508
-
2,001,170
Balance at June 30, 2022
155,138,636
11,498,651
(
150,206,216
)
16,431,071
Loss for the year
-
-
(
11,750,923
)
(
11,750,923
)
Other comprehensive income
-
100,589
-
100,589
Total comprehensive loss
-
100,589
(
11,750,923
)
(
11,650,334
)
Transactions with owners in their capacity as owners
Contributions of equity, net of transaction costs
6,256,339
-
-
6,256,339
Valuation of warrants
(
134,956
)
134,956
-
-
Exercise of performance rights
82,688
(
82,688
)
-
-
Options/warrants expired
-
(
5,241,452
)
5,241,452
-
Issue of performance rights
-
125,500
-
125,500
6,204,071
(
5,063,684
)
5,241,452
6,381,839
Balance at June 30, 2023
161,342,707
6,535,556
(
156,715,687
)
11,162,576
The
above consolidated statements of changes in equity should be read in conjunction with the accompanying notes.
F-
7
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
For
the year ended June 30, 2023
1.
CORPORATE INFORMATION
Genetic
Technologies Limited (the "Company") is a molecular diagnostics company that offers predictive genetic testing and risk assessment
tools. These consolidated financial statements comprise the Company and its subsidiaries (together referred to as the "Group").
The Financial Report of the Company for the year ended June 30, 2023 was authorized for issue in accordance with a resolution
of the Directors dated on August 30, 2023. Genetic Technologies Limited is incorporated in Australia and is a company limited by shares.
The Directors have the power to amend and reissue the financial statements.
The
Company's Ordinary Shares are publicly traded on the Australian Securities Exchange under the symbol GTG and, via Level II American
Depositary Receipts, on the NASDAQ Capital Market under the ticker GENE.
2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(a)
Basis of preparation
(i)
Compliance with International Financial Reporting Standards as issued by the International Accounting Standards Board
The
general purpose financial statements of Genetic Technologies Limited and its subsidiaries have been prepared in accordance with International
Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board and Australian equivalent
International Financial Reporting Standards, as issued by the Australian Accounting Standards Board. Genetic Technologies Limited is
a for-profit entity for the purpose of preparing the financial statements.
(ii)
Historical cost convention
These
financial statements have been prepared under the historical cost convention except for financial assets and liabilities (including derivative
instruments) which are measured at fair value.
(iii)
Critical accounting estimates
The
preparation of financial statements requires the use of certain critical accounting estimates. It also requires Management to exercise
its judgement in the process of applying the Company's accounting policies. The areas involving a higher degree of judgement or
complexity, or areas where assumptions and estimates are critical to the financial statements, are disclosed in Note 3.
(iv)
Going concern
For
the year ended June 30, 2023, the Company incurred a total comprehensive loss of A$
11,650,334
(2022: A$
7,103,134
) and net cash outflow
from operations of A$
9,723,095
(2022: A$
5,659,456
). As at June 30, 2023, the Company held total cash and cash equivalents of A$
7,851,197
and total net current assets of A$
7,185,750
.
The
company expects to continue to incur losses and cash outflows for the foreseeable future as it continues to invest resources in research
and development activities for geneType risk assessment tests and to invest in the commercialization activities for geneType,
EasyDNA and AffinityDNA, via marketing, sales and distribution channels.
The
continuing viability of the company and its ability to continue as a going concern, and meet its debts and commitments as they fall due,
is dependent on the satisfactory completion of an equity raising forecast for the early part of the 2024 calendar year. The Company does
not currently have binding commitments from any party to subscribe for shares and any raise will be subject to maintaining active listing
on the NASDAQ exchange as well as compliance with the Group's obligations under ASX Listing Rule 7.1.
On
July 17, 2023, the company received notification from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price
requirement of Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market, since the closing bid price for the
company's American Depositary Shares (ADS) on the Nasdaq Capital Market was below US$1.00 for 34 consecutive trading days.
Under
Nasdaq Listing Rule 5810(c)(3)(A), the company has a period of 180 calendar days from the date of Notification to regain compliance with
the minimum bid requirement, during which time the ADS will continue to trade on the Nasdaq Capital Market. If at any time before January
15, 2024, the bid price of the ADS closes at or above US$1.00 per ADS for a minimum of 10 consecutive business days, the Company will
regain compliance with the Minimum Bid Requirement.
F-
8
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
(a)
Basis of preparation (cont.)
(iv)
Going concern (cont.)
Due
to the uncertainty surrounding the timing, quantum or the ability to raise additional equity, there is a material uncertainty that may
cast significant doubt on the Group's ability to continue as a going concern and therefore, that it may be unable to realize
its assets and discharge its liabilities in the normal course of business. However, the Directors believe that the Company will be
successful in its equity raising endeavours, and has a strong track record in this regard, and accordingly, have prepared the financial
report on a going concern basis. As such no adjustments have been made to the financial statements relating to the recoverability and
classification of the asset carrying amounts or classification of liabilities that might be necessary should the Group not be able to
continue as a going concern.
(v)
New standards and interpretations
The
Group has applied the following standards and amendments for the first time for its annual reporting period commencing 1 July 2022:
●
Onerous
                                            Contracts – Cost of Fulfilling a Contract –
Amendments to IAS 37
●
Annual
                                            Improvements to IFRS Standards 2018–2020
●
Property,
                                            Plant and Equipment: Proceeds before Intended Use –
Amendments to IAS 16
●
Reference
                                            to the Conceptual Framework –
Amendments to IFRS 3
The
amendments listed above did not have any impact on the amounts recognized in prior periods and are not expected to significantly affect
the current or future periods.
(vi)
New standards and interpretations not yet adopted.
There
are no standards that are not yet effective and that would be expected to have a material impact on the Company in the current or future
reporting years and on foreseeable future transactions.
(b)
Principles of consolidation
(i)
Subsidiaries
Subsidiaries
are all entities (including structured entities) over which the Company has control. The Company controls an entity when the Company
is exposed to, or has rights to, variable returns from its involvement with the Company and has the ability to affect those returns through
its power to direct the activities of the Company. Subsidiaries are fully consolidated from the date on which control is transferred
to the Company. They are deconsolidated from the date that control ceases.
The
acquisition method of accounting is used to account for business combinations by the Company.
Intercompany
transactions, balances and unrealized gains on transactions between Group companies are eliminated. Unrealized losses are also eliminated
unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed
where necessary to ensure consistency with the policies adopted by the Company.
(ii)
Loss of control
When
the Group loses control over a subsidiary, it derecognizes the assets and liabilities of the subsidiary, and any related NCI and other
components of equity. Any resulting gain or loss is recognized in profit or loss. Any interest retained in the former subsidiary is measured
at fair value when control is lost.
F-
9
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
2.
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
(c)
Business combination
The
Group accounts for business combinations using the acquisition method when the acquired set of activities and assets meets the
definition of a business and control is transferred to the Group (Note 2(b)(i)). In determining whether a particular set of
activities and assets is a business, the Group assesses whether the set of assets and activities acquired includes, at a minimum, an
input and substantive process and whether the acquired set has the ability to produce outputs.
The
Group has an option to apply a 'concentration test' that permits a simplified assessment of whether an acquired set of activities
and assets is not a business. The optional concentration test is met if substantially all of the fair value of the gross assets acquired
is concentrated in a single identifiable asset or group of similar identifiable assets.
The
consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Any goodwill
that arises is tested annually for impairment (Note 2(k)). Any gain on a bargain purchase is recognized in profit or loss immediately.
Transaction costs are expensed as incurred, except if related to the issue of debt or equity securities (Note 2(u)).
The
consideration transferred does not include amounts related to the settlement of pre-existing relationships. Such amounts are generally
recognized in profit or loss.
Any
contingent consideration is measured at fair value at the date of acquisition. If an obligation to pay contingent consideration that
meets the definition of a financial instrument is classified as equity, then it is not remeasured and settlement is accounted for within
equity. Otherwise, other contingent consideration is remeasured at fair value at each reporting date and subsequent changes in the fair
value of the contingent consideration are recognized in profit or loss.
If
share-based payment awards (replacement awards) are required to be exchanged for awards held by the acquiree's employees (acquiree's
awards), then all or a portion of the amount of the acquirer's replacement awards is included in measuring the consideration transferred
in the business combination. This determination is based on the market-based measure of the replacement awards compared with the market-based
measure of the acquiree's awards and the extent to which the replacement awards relate to pre-combination service.
(d)
Segment reporting
Operating
segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The acquisition
of EasyDNA in the 2022 financial year changed how the Company reports segment information as compared to the prior year. Therefore, the
2021 financial year period presentation of segment information was recast to conform with the current segment reporting structure.
(e)
Foreign currency translation
(i)
Functional and presentation currency
Items
included in the financial statements of each of the Company's entities are measured using the currency of the primary economic
environment in which the company operates ('the functional currency'). The consolidated financial statements are presented
in Australian dollar ($), which is Genetic Technologies Limited's functional and presentation currency.
(ii)
Transactions and balances
Foreign
currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign
exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities
denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss.
All
foreign exchange gains and losses are presented in the consolidated statement of profit or loss on a net basis, within other expenses
or other income, respectively.
Non-monetary
items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was
determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss.
For example, translation differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss
are recognized in profit or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities
classified as at fair value through other comprehensive income are recognized in other comprehensive income.
F-
10
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
2.
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
(e)
Foreign currency translation (cont.)
(iii)
Group companies
The
results and financial position of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional
currency different from the presentation currency are translated into the presentation currency as follows:
●
assets
    and liabilities for each consolidated statement of financial position presented are translated at the closing rate at the date of
    that consolidated statement of financial position;
●
income
    and expenses for each consolidated statement of profit or loss and other comprehensive income are translated at average exchange
    rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in
    which case income and expenses are translated at the dates of the transactions); and
●
all
    resulting exchange differences are recognized in other comprehensive income.
On
consolidation, exchange differences arising from the translation of any net investment in foreign entities, and of borrowings and other
financial instruments designated as hedges of such investments, are recognized in other comprehensive income. When a foreign operation
is sold or any borrowings forming part of the net investment are repaid, the associated exchange differences are reclassified to profit
or loss, as part of the gain or loss on sale.
(f)
Revenue recognition
Under
IFRS 15, revenue is recognized based on contract with customers when performance obligations were satisfied. The following recognition
criteria must also be met before revenue is recognized:
(i)
Revenue from sale of goods - Genetic testing revenues
Genetype
Revenues
from the provision of genetic and clinical risk testing for cancer and other serious diseases under the geneType brand are recognized
at a point time when the Company has provided the customer with their test results, the single performance obligation. Invoices are usually
payable within 30 days. Where consideration is received in advance of performance, it is initially recorded as contract liabilities and
then revenue is recognized as the performance obligations are satisfied. Revenue is recognized where consideration for collection
is probable and is above 50%. The geneType brand have more than 75% probability of being collected.
EasyDNA
and AffinityDNA
Revenue
from provision of genetic test direct to consumer under the EasyDNA and AffinityDNA brand is recognized at a point in time when the Company
has provided the customer with their test results, the single performance obligation. Where consideration is received in advance of performance,
it is initially recorded as contract liabilities and then revenue is recognized as the performance obligations are satisfied. Revenue
recognized under the EasyDNA and AffinityDNA brands are mainly upfront, hence, no issue in collectability.
(ii)
Revenue from services - license fees
Revenue
from contracts with service providers is recognized when the contracted sales parameters are met, the single performance obligation.
Revenue is recognized over time based on the higher of actual sales incurred or minimum fees requirement on a quarterly basis. The Company
did not recognize or receive any license fee revenue in the current financial year. Fixed license fee revenue recognized in the prior
period have been fully impaired as it is unlikely that these amounts will be recovered.
(iii)
Contract liabilities
The
Group recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these
amounts as deferred income in its consolidated statement of financial position. Similarly, if the Group satisfies a performance obligation
before it receives the consideration, the Group recognizes either a contract asset or a receivable in its consolidated statement
of financial position, depending on whether something other than the passage of time is required before the consideration is due.
F-
11
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
(g)
Other income
(i)
Research and development tax incentive income
The
Australian government replaced the research and development tax concession with research and development (R&D) tax incentive from
July 1, 2011. The R&D tax incentive applies to expenditure incurred and the use of depreciating assets in an income year commencing
on or after July 1, 2011. A refundable tax offset is available to eligible companies with an annual aggregate turnover of less than A$
20
million. A new legislation subsequently came into place, where for the first income year commencing on or after 1 July 2021, for companies
with an aggregated turnover below A$
20
million, the refundable R&D tax offset will be a premium of
18.5
percentage points above the
claimant's company tax rate.
Management
has assessed the Company's activities and expenditure to determine which are likely to be eligible under the incentive scheme.
The Company accounts for the R&D tax incentive as a government grant. The grant is recognized as other income over the period in
which the R&D expense is recognized.
(ii)
Government Grants
Income
from government grants is recognized in the consolidated statement of profit or loss and comprehensive income on a systematic basis
over the periods in which the Company recognizes as expense the related costs for which the grants are intended to compensate in accordance
with IAS 20 Accounting for Government Grants and Disclosure of Government Assistance.
The
receivable for reimbursable amounts that have not been collected is reflected in trade and other receivables on our consolidated statement
of financial position.
(h)
Finance income and finance costs
The
Group's finance income and finance costs include interest income and interest expenses. Interest income or expense is recognized
using the effective interest method.
(i)
Income tax
The
income tax expense or credit for the period is the tax payable on the current period's taxable income based on the applicable income
tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to
unused tax losses.
The
current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period
in the countries where the Company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates
positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes
provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.
Deferred
income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities
and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise
from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset
or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable
profit or loss.
Deferred
income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period
and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.
Deferred
tax assets are recognized only if it is probable that future taxable amounts will be available to utilize those temporary differences
and losses.
F-
12
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
2. SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
(j)
Leases
For
any new contracts entered into on or after July 1, 2019, the Group considers whether a contract is, or contains a lease. A lease is defined
as 'a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange
for consideration'. To apply this definition the Company assesses whether the contract meets three key evaluations which are whether:
●
the
    contract contains an identified asset, which is either explicitly identified in the contract or implicitly specified by being identified
    at the time the asset is made available to the Group,
●
the
    Company has the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period
    of use, considering its rights within the defined scope of the contract,
●
the
    Company has the right to direct the use of the identified asset throughout the period of use. The Company assess whether it has the
    right to direct 'how and for what purpose' the asset is used throughout the period of use.
Leases
are recognized as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the
Group. Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the
lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The right-of-use
asset is depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis.
Assets
and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value
of the following lease payments:
●
fixed
    payments (including in-substance fixed payments), less any lease incentives receivable,
●
amounts
    expected to be payable by the lessee under residual value guarantees,
●
the
    exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and
●
payments
    of penalties for terminating the lease, if the lease term reflects the lessee exercising that option.
The
lease payments are discounted using the interest rate implicit in the lease, if that rate can be determined, or the Group's incremental
borrowing rate.
Right-of-use
assets are measured at cost comprising the following:
●
the
    amount of the initial measurement of lease liability,
●
any
    lease payments made at or before the commencement date, less any lease incentives received,
●
any
    initial direct costs, and
●
restoration
    costs.
Payments
associated with short-term leases and leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss.
Short-term leases are leases with a lease term of 12 months or less.
Short-term
leases and leases of low-value assets
The
Group has elected not to recognize right-of-use assets and lease liabilities for leases of low-value assets and short-term leases, including
IT equipment. The Group recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease
term.
F-
13
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
(k)
Impairment of assets
Non-financial
asset
The
Group assesses at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists, the
Group makes an estimate of the asset's recoverable amount. An asset's recoverable amount is the higher of its fair value
less costs of disposal or its value in use and is determined for an individual asset, unless the asset does not generate cash inflows
that are largely independent of those from other assets or group of assets and the asset's value-in-use cannot be estimated to
be close to its fair value. In such cases, the asset is tested for impairment as part of the cash-generating unit to which it belongs.
Cash generating unit is the smallest group of assets that generates cash inflows from continuing use that are largely independent of
the cash inflows of other assets or CGUs. When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount,
the asset or cash-generating unit is considered impaired and is written down to its recoverable amount.
In
assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects
current market assessments of the time value of money and the risks specific to the asset. Impairment losses relating to operations are
recognized as a separate line in the statement of profit or loss unless the asset is carried at its revalued amount, in which case the
impairment loss is treated as a revaluation decrease.
An
assessment is made at each reporting date as to whether there is any indication that previously recognized impairment losses may no longer
exist or may have decreased. If such indication exists, the recoverable amount is estimated. A previously recognized impairment loss
is reversed only if there has been a change in the estimates used to determine the asset's recoverable amount since the last impairment
loss was recognized. If so, the carrying amount of the asset is increased to its recoverable amount. The increased amount cannot exceed
the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior
years. Such reversal is recognized in profit or loss unless it reverses a decrement previously charged to equity, in which case the reversal
is treated as a revaluation increase. After such a reversal, the depreciation charge is adjusted in future periods to allocate the asset's
revised carrying amount, less any residual value, on a systematic basis over its remaining useful life. An impairment loss in respect
of goodwill is not reversed.
Financial
asset
The
Group records the impairment losses for financial assets as lifetime expected credit losses. These are the expected shortfalls in contractual
cash flows, considering the potential for default at any point during the life of the financial instrument. In calculating, the Group
uses its historical experience, external indicators and forward-looking information to calculate the expected credit losses using a provision
matrix.
(l)
Cash and cash equivalents
For
the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held
at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that
are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts.
Bank overdrafts are shown within borrowings in current liabilities in the consolidated statement of financial position.
(m)
Trade and other receivables
Trade
receivables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method, less
loss allowance.
Refer
Note 31 for details of management of interest rate, foreign exchange and liquidity risks applicable to trade and other payables for which,
due to their short-term nature, their carrying value approximates their fair value.
(n)
Inventories
(i)
Raw materials and stores, work in progress and finished goods
Raw
materials and stores, work in progress and finished goods are stated at the lower of cost and net realizable value. Cost comprises direct
materials, direct labor and an appropriate proportion of variable and fixed overhead expenditure, the latter being allocated on the basis
of normal operating capacity. Costs are assigned to individual items of inventory on the basis of weighted average costs. Costs of purchased
inventory are determined after deducting rebates and discounts. Net realizable value is the estimated selling price in the ordinary course
of business less the estimated costs of completion and the estimated costs necessary to make the sale.
F-
14
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
(o)
Property, plant and equipment
Property,
plant and equipment is stated at historical cost less accumulated depreciation. Historical cost includes expenditure that is directly
attributable to the acquisition of the items.
Subsequent
costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that
future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying
amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged
to profit or loss during the reporting period in which they are incurred.
Depreciation
is calculated using the straight-line method to allocate their cost or revalued amounts, net of their residual values, over their estimated
useful lives or, in the case of leasehold improvements and certain leased plant and equipment, the shorter lease term as follows:
Plant
    and equipment
3
-
5
years
Furniture,
    fittings and equipment
3
-
5
years
Leasehold
    improvements
1
-
3
years (lease term)
Leased
    plant and equipment
3
years (lease term)
The
assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.
An
asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than
its estimated recoverable amount (Note 2(k)).
Gains
and losses on disposals are determined by comparing proceeds with carrying amount. These are included in profit or loss. When revalued
assets are sold, it is Company policy to transfer any amounts included in other reserves in respect of those assets to retained earnings.
(p)
Intangible assets and goodwill
(i)
Goodwill
Goodwill
arises on the acquisition of a business combination. Goodwill is calculated as the excess sum of:
●
the
                                            consideration transferred;
●
any
                                            non-controlling interest; and
●
the
                                            acquisition date fair value of any previously held equity interest; over the acquisition
                                            date fair value of net identifiable assets acquired.
Goodwill
is not amortized. Instead, goodwill is tested annually for impairment, or more frequently if events or changes in circumstances indicate
that it might be impaired, and is carried at cost less accumulated impairment losses. Impairment losses on goodwill are taken to profit
or loss and are not subsequently reversed.
Goodwill
is allocated to the Group's cash-generating units representing the lowest level at which goodwill is monitored.
(ii)
Brand name and customer contracts
Brand,
trademark, trade names and domain names acquired in a business combination that qualify for separate recognition are recognized as intangible
assets at their fair values.
Brand,
trademark, trade names and domain names are amortized on a straight-lined basis over their estimated useful lives of
5
years.
(q)
Trade and other payables
Trade
payables and other payables are carried at amortized cost and represent liabilities for goods and services provided to the Company prior
to the end of the financial year that are unpaid and arise when the Company becomes obliged to make future payments in respect of the
purchase of these goods and services. Trade payables and other payables generally have terms of between 30 and 60 days.
F-
15
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
2.
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
(r)
Provisions
Provisions
for legal claims, service warranties and make good obligations are recognized when the Company has a present legal or constructive obligation
as a result of past events, it is probable that an outflow of resources will be required to settle the obligation and the amount can
be reliably estimated. Provisions are not recognized for future operating losses.
Where
there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering
the class of obligations as a whole. A provision is recognized even if the likelihood of an outflow with respect to any one item included
in the same class of obligations may be small.
Provisions
are measured at the present value of management's best estimate of the expenditure required to settle the present obligation at
the end of the reporting period. The discount rate used to determine the present value is a pre-tax rate that reflects current market
assessments of the time value of money and the risks specific to the liability. The increase in the provision due to the passage of time
is recognized as interest expense.
(s)
Employee benefits
(i)
Short-term obligations
Liabilities
for wages and salaries, including non-monetary benefits, annual leave and accumulating sick leave that are expected to be settled wholly
within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees'
services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled.
The liabilities are presented as current employee benefit obligations in the consolidated statement of financial position.
(ii)
Other long-term employee benefit obligations
In
some countries, the Company also has liabilities for long service leave and annual leave that are not expected to be settled wholly within
12 months after the end of the period in which the employees render the related service. These obligations are therefore measured as
the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting
period using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee
departures and periods of service. Expected future payments are discounted using market yields at the end of the reporting period of
high-quality corporate bonds with terms and currencies that match, as closely as possible, the estimated future cash outflows. Remeasurements
as a result of experience adjustments and changes in actuarial assumptions are recognized in general and administrative expenses in profit
or loss.
The
obligations are presented as current liabilities in the consolidated statement of financial position if the Company does not have an
unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement
is expected to occur.
(t)
Fair value measurement
When
an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is
based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal
market, in the most advantageous market.
Fair
value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in
their economic best interests. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximizing the
use of relevant observable inputs and minimizing the use of unobservable inputs.
Assets
and liabilities measured at fair value are classified into three levels, using a fair value hierarchy that reflects the significance
of the inputs used in making the measurements. Classifications are reviewed at each reporting date and transfers between levels are determined
based on a reassessment of the lowest level of input that is significant to the fair value measurement.
F-
16
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
2.
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
(t)
Fair value measurement
Fair
value hierarchy levels 1 to 3 are based on the degree to which the fair value is observable:
●
Level
    1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities;
●
Level
    2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for
    the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
●
Level
    3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not
    based on observable market data (unobservable inputs).
For
recurring and non-recurring fair value measurements, external valuers may be used when internal expertise is either not available or
when the valuation is deemed to be significant. External valuers are selected based on market knowledge and reputation. Where there is
a significant change in fair value of an asset or liability from one period to another, an analysis is undertaken, which includes a verification
of the major inputs applied in the latest valuation and a comparison, where applicable, with external sources of data.
(u)
Contributed equity
Issued
and paid-up capital is recognized at the fair value of the consideration received by the Company. Transaction costs arising on the issue
of Ordinary Shares are recognized directly in equity as a deduction, net of tax, of the proceeds received. The Company has a share-based
payment option plan under which options to subscribe for the Company's shares have been granted to certain executives and other
employees.
(v)
Loss per share
(i)
Basic loss per share
Basic
loss per share is calculated by dividing:
●
the
    loss attributable to owners of the Company, excluding any costs of servicing equity other than ordinary shares,
●
by
    the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares
    issued during the year and excluding treasury shares.
(ii)
Diluted loss per share
Diluted
loss per share adjusts the figures used in the determination of basic loss per share to take into account:
●
after
    income tax effect of interest and other financing costs associated with dilutive potential ordinary shares, and
●
the
    weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential
    ordinary shares.
On
the basis of the Company's losses, the outstanding options and performance rights as at June 30, 2023 are considered to be anti-
dilutive and therefore were excluded from the diluted weighted average number of ordinary shares calculation.
(w)
Goods and services tax (GST) and other sales taxes
Receivables
and payables are stated inclusive of the amount of GST and other sales taxes receivable or payable. The net amount of GST and other taxes
recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated statement
of financial position.
Cash
flows are presented on a gross basis. The GST and other sales taxes components of cash flows arising from investing or financing activities
which are recoverable from, or payable to the taxation authority, are presented as operating cash flows.
(x)
Parent entity financial information
The
financial information for the parent entity, Genetic Technologies Limited, disclosed in Note 33 has been prepared on the same basis as
the consolidated financial statements. Loans to subsidiaries are written down to their recoverable value as at balance date.
F-
17
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
3.
CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS
Estimates
and judgements are evaluated and based on historical experience and other factors, including expectations of future events that may have
a financial impact on the Company and that are believed to be reasonable under the circumstances.
Share-based
payments transactions
The
Company has determined that the fair value of the equity instruments is a critical judgement. The Company measures the cost of equity-settled
transactions with employees and service providers by reference to the value of the equity instruments at the date on which they are granted.
Management has determined the fair value by engaging an independent valuer for more complex equity instruments, such as warrants and
performance rights, by using a Black-Scholes or Binomial model, and utilized internal resources to perform fair value by straight forward
equity instruments by using Black-Scholes model.
Goodwill
The
Group tests annually, or more frequently if events or changes in circumstances indicate impairment, whether goodwill and other indefinite
life intangible assets have suffered any impairment, in accordance with the accounting policy stated in Note 2(k). The value-in-use calculation
used in assessing potential impairment of goodwill incorporates a number of key estimates and assumptions which is a critical judgement.
CGUs are identified by determining the smallest identifiable group of assets that generate largely independent cash inflows from other
assets or groups of assets. Identifying those largely independent cash inflows requires significant judgement in assessing the Group's
sources of revenue and how assets are utilized in generating those revenues. Goodwill is required to be allocated to the CGUs or groups
of CGUs that are expected to benefit from the synergies of the combination acquired where goodwill cannot be allocated to individual
CGUs on a reasonable and consistent basis. Significant judgement is required to assess which CGUs or groups of CGUs benefit from the
synergies and thus determine how the goodwill is allocated.
Impairment
of non-financial assets other than goodwill and other indefinite life intangible assets
The
Group assesses impairment of non-financial assets other than goodwill and other indefinite life intangible assets at each reporting date
by evaluation conditions specific to the Group and to the particular asset that may lead to impairment. If an impairment trigger exists,
the recoverable amount of the asset is determined. This involves fair value less costs of disposal or value-in-use calculation which
incorporate a number of key estimates and assumptions.
Business
combination and the contingent consideration
Business
combination are initially accounted for on a provisional basis. The fair value of assets acquired and liabilities assumed are initially
estimated by the Group taking into consideration all available information at the reporting date. Fair value adjustments on the finalization
of the business combination accounting is retrospective, where applicable, to the period the combination occurred and may have an
impact on the assets and liabilities, depreciation and amortization reported.
For
the AffinityDNA acquisition, a second payment of A$
486,188
(£
277,500
) would be due to the prior owners of the business if a pre-determined
gross profit target for the 12-month period from the acquisition date is achieved. Management used judgement by not including the second
payment in the calculation of fair value of consideration transferred.
F-
18
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
4.
REVENUE AND DEFERRED INCOME
4A.
REVENUE
2023
A$
2022
A$
2021
A$
Sales of EasyDNA branded test - point in time
7,698,605
5,989,782
-
Sales of AffinityDNA branded test - point in time
944,058
-
-
Sales of geneType branded test - point in time
43,455
7,551
25,347
License fees - over time
-
797,483
95,207
Total revenue from contract with customers
8,686,118
6,794,816
120,554
4B.
DISAGGREGATION OF REVENUE FROM CONTRACTS WITH CUSTOMERS
The
Group's revenue disaggregated by primary geographical markets is as follows:
2023
A$
2022
A$
2021
A$
America and Canada
2,242,169
2,274,551
120,554
Europe Middle East and Africa
4,494,626
2,501,302
-
Latin America
322,033
128,840
-
Asia Pacific
1,627,290
1,890,123
-
Total revenue
8,686,118
6,794,816
120,554
4C.
CONTRACT BALANCES
Note
2023
A$
2022
A$
Receivables, which are included in 'net trade receivables'
12
1,049,393
390,587
Contract liabilities
849,212
814,150
Contract
liabilities arises from revenue for all business units, which is the consideration received in respect of unsatisfied performance obligation.
There are
no
contract assets as at 30 June 2023 (2022:
Nil
).
The
amount of A$
814,150
included
in deferred income (contract liabilities) at 30 June 2022 has been recognized as revenue in 2023 (2022:
Nil
).
No
revenue was recognized in 2023 from performance obligations satisfied (or partially satisfied) in previous periods (2022:
Nil
,
2021:
Nil
).
5.
OTHER INCOME
2023
A$
2022
A$
2021
A$
Research and development tax incentive income
(1)
1,616,064
2,397,552
997,908
Export Marketing & Development Grant
-
-
100,000
Other income
45,724
25,955
116,271
Government grant income – COVID-19 relief
(2)
-
-
287,883
Net unrealized foreign exchange gain
152,963
244,762
-
Net realized foreign exchange gain
22,071
115,122
57,899
Total other income
1,836,822
2,783,391
1,559,961
F-
19
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
5.
OTHER INCOME
(1)
R&D tax incentive
The
Company's research and development activities are eligible under an Australian government tax incentive for eligible expenditure.
Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts
are recognized when it has been established that the conditions of the tax incentive have been met and that the expected amount can be
reliably measured. For the year ended June 30, 2023, the Company has included an item in other income of A$
1,616,064
, (2022: A$
2,397,552
,
2021: A$
997,908
) to recognize income over the period necessary to match the grant on a systematic basis with the costs that they are
intended to compensate.
On
December 5, 2019, the Treasury Laws Amendment (R&D Tax Incentive Bill 2019) was introduced into Parliament. The draft bill contains
proposed amendments to the R&D tax incentive regulations. Under the proposed amendments, the refundable tax offset rate for companies
with an aggregated turnover of less than A$
20
million would become
41
%. In lieu of that bill, the below legislation came into place.
During
the 2022 financial year new legislation came into place, where for the first income year commencing on or after 1 July 2021, for companies
with an aggregated turnover below A$
20
million, the refundable R&D tax offset will be a premium of
18.5
percentage points above the
claimant's company tax rate. The Company has therefore calculated the R&D tax incentive for 2022 and 2023 by applying the legislation
brought into effect during the 2022 financial year.
(2)
Government Grant income – COVID-19 Relief
The
COVID-19 relief relates to government assistance received during the year, from the Australian Government (at both federal and state
level) and the U.S. Small Business Administration, in response to the economic and financial challenges in the current economy.
6.
EMPLOYEE BENEFITS EXPENSE
2023
A$
2022
A$
2021
A$
Salaries and wages
4,938,516
4,490,186
2,480,336
Director fees
288,024
288,024
288,024
Superannuation contribution
415,128
347,018
203,242
Share-based payments
125,500
437,508
714,577
Other employee costs
440,898
305,919
182,152
Total employee benefits expenses
6,208,066
5,868,655
3,868,331
7.
OTHER EXPENSES
2023
A$
2022
A$
2021
A$
Buildings and facilities costs
695,844
748,580
345,624
Insurance
403,167
345,450
302,722
Investor relations and shareholder maintenance
469,151
344,355
273,187
Net unrealized foreign exchange loss
13,521
-
47,896
Net realized foreign exchange loss
-
-
-
Bank and credit card merchant charges
426,589
296,883
14,582
IT and communication
670,008
84,133
75,311
Travel and entertainment
366,920
67,298
12,318
Administrative
370,571
121,184
82,264
Other expenses
271,259
146,492
129,967
Total other expenses
3,687,030
2,154,375
1,283,871
F-
20
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
8.
FINANCE INCOME / (FINANCE COSTS)
2023
A$
2022
A$
2021
A$
Interest income
220,161
36,256
62,394
Total finance income
220,161
36,256
62,394
Lease interest
(
29,515
)
(
15,215
)
(
16,338
)
Total finance costs
(
29,515
)
(
15,215
)
(
16,338
)
9.
INCOME TAX CREDIT/(EXPENSE)
2023
A$
2022
A$
2021
A$
Reconciliation of income tax expense to prima facie tax payable
Loss before income tax credit
(
11,909,252
)
(
7,163,123
)
(
7,077,619
)
Tax at the Australian tax rate of
25
% (2022:
25
% and 2021:
26
%)
(2,977,313
)
(1,790,781
)
(1,840,181
)
Tax effect amounts which are not deductible/(taxable) in calculating taxable income
Share-based payments expense
31,375
109,377
185,790
Research and development tax incentive
919,785
1,116,714
588,659
Impairment of goodwill
461,250
-
-
Other assessable items
-
-
-
Income tax expenses before unrecognized tax losses
(
1,564,903
)
(
564,690
)
(
1,065,732
)
Difference in overseas tax rates
53,673
(
79,604
)
16,688
Over provision in prior years
(
454,928
)
(
348,607
)
(
235,653
)
Temporary differences not recognized
29,979
(
301,694
)
(
419,965
)
Research and development tax credit
(
404,016
)
(
599,388
)
(
275,631
)
Tax losses not recognized
2,543,441
1,861,858
1,980,293
Utilization of tax losses not previously recognized
(
361,575
)
-
-
Income tax credit
(
158,329
)
(
32,125
)
-
F-
21
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
9.
INCOME TAX CREDIT/(EXPENSE) (cont.)
2023
A$
2022
A$
2021
A$
Net deferred tax assets
Deferred tax liabilities recognized
Brands and trademarks
(
121,901
)
(
148,013
)
-
Total deferred tax liabilities
(
121,901
)
(
148,013
)
-
Deferred tax assets recognized
Tax losses
121,901
-
-
Total deferred tax assets
121,901
-
-
Deferred tax assets not recognized
Property, plant and equipment
-
-
8,004
Trade debtor
222,144
58,041
-
Capital raising costs
582,168
661,863
975,270
Intangible assets
1,407,570
1,456,225
1,701,477
Provisions
342,252
442,383
297,907
Total deferred tax assets
2,554,134
2,618,512
2,982,658
Deferred tax liabilities not recognized
Right-of-use assets
(
127,388
)
(
161,787
)
(
34,735
)
Total deferred tax liabilities
(
127,388
)
(
161,787
)
(
34,735
)
Net deferred tax assets on temporary differences not brought to account
(
2,426,746
)
(
2,456,725
)
2,947,923
Total net deferred tax assets/(liabilities)
-
(
148,013
)
-
2023
A$
2022
A$
2021
A$
Tax losses
Unused tax losses for which no deferred tax asset has been recognized
119,096,654
105,287,311
100,694,696
Potential tax benefit @
26
% (Australia)
21,897,732
19,020,914
19,025,063
Potential tax benefit @
21
% (USA)
6,568,458
5,950,299
5,665,976
Potential tax benefit @
35
% (Malta)
65,895
304,115
-
Potential tax benefit @
19
% (UK)
7,427
-
-
Subject
to the Company continuing to meet the relevant statutory tests, the tax losses are available for offset against future taxable income.
F-
22
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
9.
INCOME TAX CREDIT/(EXPENSE) (cont.)
At
June 30, 2023, the Company had a potential tax benefit related to tax losses carried forward of A$
28,539,512
(2022: A$
25,275,328
, 2021:
A$
24,691,039
). Such amount includes net losses of A$
6,568,458
(2022: A$
5,950,299
, 2021: A$
5,665,976
) related to subsidiaries in the United
States (U.S.). The Tax Cuts and Jobs Act (TCJA) enacted by Congress in the U.S. on December 22, 2017 cut the top corporate income tax
rate from 35% to 21%. For tax years beginning after December 31, 2017, the graduated corporate tax rate structure is eliminated and corporate
taxable income will be taxed at 21% flat rate. Additionally, the previous
20
-year limitation on carry forward net operating losses (NOL's)
has been removed, allowing the NOL's to be carried forward indefinitely. The remaining tax losses carried forward of A$
21,897,732
(2022: A$
19,020,914
, 2021: A$
19,025,063
) are indefinite and are attributable to the Company's operations in Australia, as well
as A$
65,895
(2022: A$
304,115
, 2021:
Nil
) and A$
7,427
(2022:
Nil
) tax losses attributable to Company's operations in Malta and UK,
respectively. As such the total unused tax losses available to the Company, equal A$
28,539,511
(2022: A$
25,275,328
, 2021: A$
24,691,039
).
As
at balance date, there are unrecognized tax losses with a benefit of approximately A$
28,539,511
(2022: A$
25,275,328
, 2021: A$
24,691,039
)
that have not been recognized as a deferred tax asset to the Company. These unrecognized deferred tax assets will only be obtained if:
(a)
The
    Company derives future assessable income of a nature and amount sufficient to enable the benefits to be realized;
(b)
The
    Company continues to comply with the conditions for deductibility imposed by the law; and
(c)
No
    changes in tax legislation adversely affect the Company from realizing the benefit.
Management
has assessed the tax position of the Company and concluded that any potential uncertainty does not have a material impact on the financial
statements.
Tax
consolidation legislation
Genetic
Technologies Limited and its wholly owned Australian subsidiaries implemented the tax consolidation legislation as from July 1, 2003.
The accounting policy in relation to this legislation is set out in Note 2(i).
The
entities in the tax consolidated Company have entered into a Tax Sharing Agreement which, in the opinion of the Directors, limits the
joint and several liabilities of the wholly owned entities in the case of a default by the head entity, Genetic Technologies Limited.
The
entities have also entered into a Tax Funding Agreement under which the wholly owned entities fully compensate Genetic Technologies Limited
for any current tax payable assumed and are compensated by Genetic Technologies Limited for any current tax receivable and deferred tax
assets relating to unused tax losses or unused tax credits that are transferred to Genetic Technologies Limited under the tax consolidation
legislation. The funding amounts are determined by reference to the amounts recognized in the respective subsidiaries' financial
statements.
The
amounts receivable or payable under the Tax Funding Agreement are due upon receipt of the funding advice from the head entity, which
is issued as soon as practicable after the end of each financial year.
As
at June 30, 2023, there are
no
unrecognized temporary differences associated with the Company's investments in subsidiaries, as
the Company has no liability for additional taxation should unremitted earnings be remitted (2022: Nil, 2021: Nil).
10.
LOSS PER SHARE
The
following reflects the income and share data used in the calculations of basic and diluted loss per share:
2023
A$
2022
A$
2021
A$
Loss for the year
(
11,750,923
)
(
7,130,998
)
(
7,077,619
)
Weighted average number of Ordinary Shares used in calculating loss per share (number of shares)
10,138,075,003
9,220,348,281
8,544,157,979
Note:
None
                                                                     of the
233,400,000
(2022:
757,400,000
and 2021:
725,787,500
) options/performance rights over the Company's Ordinary Shares
                                                                     that were outstanding as at the reporting date are considered to be dilutive for the purposes of calculating diluted earnings per
                                                                     share.
F-
23
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
11.
CASH AND CASH EQUIVALENTS
2023
A$
2022
A$
2021
A$
Reconciliation of cash and cash equivalents
Cash at bank and on hand
7,851,197
11,731,325
20,902,282
Total cash and cash equivalents
7,851,197
11,731,325
20,902,282
Reconciliation of loss for the year
Reconciliation of loss for the year after income tax to net cash flows used in operating activities is as follows:
Loss for the year after income tax
(
11,750,923
)
(
7,130,998
)
(
7,077,619
)
Tax credit
158,329
32,125
-
Loss for the year before income tax
(
11,909,252
)
(
7,163,123
)
(
7,077,619
)
Adjust for non-cash items and non-operational items
Amortization and depreciation expenses
380,409
343,427
265,748
Depreciation of right-of-use of assets
296,174
235,241
212,474
Impairment of receivables
280,725
564,161
-
Impairment of goodwill
1,845,000
-
-
Share-based payments expense
125,500
437,508
714,577
Inventory written-off
-
30,214
54,523
Finance costs
29,515
15,215
16,338
Finance income
(
220,161
)
(
36,256
)
(
62,394
)
Net foreign exchange (gains) / losses
(
152,963
)
(
244,762
)
9,755
(
9,325,053
)
(
5,818,375
)
(
5,866,598
)
F-
24
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
11.
CASH AND CASH EQUIVALENTS (cont.)
2023
A$
2022
A$
2021
A$
Reconciliation of cash and cash equivalents (cont.)
Adjust for changes in assets and liabilities
Decrease / (Increase) in trade and other receivables
256,213
(
1,889,124
)
(
284,971
)
(Increase) / Decrease in other operating assets
(
232,961
)
16,493
(
182,602
)
Decrease / (Increase) in inventories
72,257
(
351,437
)
14,463
Decrease / (Increase) in other non-current assets
-
97,868
-
(Decrease) / Increase in trade and other payables
(
432,361
)
2,178,301
(
14,991
)
(Decrease) / Increase in provisions
(
61,190
)
106,818
38,770
Net cash flows used in operating activities
(
9,723,095
)
(
5,659,456
)
(
6,295,928
)
Financing facilities available
As at June 30, 2023, the following financing facilities had been nego- tiated and were available:
Total facilities
Credit cards
188,630
190,020
190,020
Facilities used as at reporting date
Credit cards
(
16,029
)
-
(
9,511
)
Facilities unused as at reporting date
Credit cards
172,601
190,020
180,509
The
Company's main interest rate risk arises in relation to its short-term deposits with various financial institutions. If rates were
to decrease, the Company may generate less interest revenue from such deposits. However, given the relatively short duration of such
deposits, the associate risk is relatively minimal.
The
Company has a Short-Term Investment Policy which was developed to manage the Company's surplus cash and cash equivalents. In this
context, the Company adopts a prudent approach that is tailored to cash forecasts rather than seeking high returns that may compromise
access to funds as and when they are required. Under the policy, the Company deposits its surplus cash in a range of deposits over different
time frames and with different institutions in order to diversify its portfolio and minimize risk.
12.
TRADE AND OTHER RECEIVABLES (CURRENT)
2023
A$
2022
A$
Trade receivables
1,080,479
1,036,998
Less: impairment loss
(1)
(
888,576
)
(
594,798
)
Net trade receivables
191,903
442,200
Other receivables
(2)
1,729,754
1,979,038
Total net current trade and other receivables
1,921,657
2,421,238
(1)
Provision
  of impairment losses against trade receivables relate to license fees from IBX contract in the prior year. The Company did not
  recognize or receive any license fee revenue in the current financial year.
(2)
Other
  receivables includes the R&D tax incentive refund accrued for the 2023 financial year A$
1,616,064
(2022: A$
1,943,083
).
F-
25
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
13.
OTHER CURRENT ASSETS
2023
A$
2022
A$
Prepayments
381,608
147,854
Bonds and deposits
17,440
13,257
Other
-
4,976
Total current prepayments and other assets
399,048
166,087
14.
PROPERTY, PLANT AND EQUIPMENT
2023
A$
2022
A$
Laboratory equipment, at cost
975,619
960,872
Less: cost written-off during the year
(
8,243
)
-
Add: additions during the year
6,402
14,747
Less: accumulated depreciation
(
941,545
)
(
744,615
)
Add: accumulated depreciation written-off during the year
8,243
-
Net laboratory equipment
40,476
231,004
Computer equipment, at cost
292,817
251,852
Less: cost written-off during the year
(
3,099
)
-
Less: cost transferred
(
11,603
)
Add: additions during the year
11,150
40,965
Less: accumulated depreciation
(
261,580
)
(
230,186
)
Add: accumulated depreciation transferred
11,897
Add: accumulated depreciation written-off during the year
3,099
-
Net computer equipment
42,681
62,631
Office equipment, at cost
18,709
10,495
Less: cost written-off during the year
-
-
Add: cost transferred
11,603
Add: additions during the year
8,214
Less: accumulated depreciation
(
11,949
)
(
6,169
)
Less: accumulated depreciation transferred
(
11,897
)
Add: accumulated depreciation written-off during the year
-
-
Net office equipment
6,466
12,540
Total net property, plant and equipment
89,623
306,175
Reconciliation of property, plant and equipment
Opening gross carrying amount
1,284,395
1,220,469
Add: additions purchased during the year
17,552
63,926
Less: cost written-off during the year
(
11,342
)
-
Closing gross carrying amount
1,290,605
1,284,395
Opening accumulated depreciation and impairment losses
(
978,220
)
(
763,291
)
Add: accumulated depreciation written-off during the year
11,342
-
Less: cost written-off during the year
(
234,697
)
(
214,929
)
Add: foreign currency translation
593
-
Closing accumulated depreciation and impairment losses
(
1,200,982
)
(
978,220
)
Total net property, plant and equipment
89,623
306,175
F-
26
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
14.
PROPERTY, PLANT AND EQUIPMENT (cont.)
Reconciliation
of movements in property, plant and equipment by asset category for the year ended June 30, 2023
Asset category
Opening net carrying Amount
A$
Additions during year
A$
Transfer during year
A$
Depreciation
expense
A$
Foreign currency translation
A$
Closing net carrying amount
A$
Laboratory equipment
231,004
6,402
-
(
196,928
)
(
2
)
40,476
Computer equipment
62,631
11,150
294
(
31,394
)
-
42,681
Office equipment
12,540
-
(
294
)
(
6,375
)
595
6,466
Totals
306,175
17,552
-
(
234,697
)
593
89,623
Reconciliation
of movements in property, plant and equipment by asset category for the year ended June 30, 2022
Asset category
Opening net carrying Amount
A$
Additions during year
A$
Disposals during year A$
Depre- ciation expense
A$
Closing net carrying amount
A$
Laboratory equipment
412,889
14,747
-
(
196,632
)
231,004
Computer equipment
34,917
40,965
-
(
13,251
)
62,631
Office equipment
9,372
8,214
-
(
5,046
)
12,540
Totals
457,178
63,926
-
(
214,929
)
306,175
15.
GOODWILL
The
following table shows the movements in goodwill:
2023
2022
A$
A$
Gross carrying amount:
Balance at beginning of period
4,506,653
-
Acquired through business combination - AffinityDNA (Note 17)
455,240
4,506,653
Balance at end of period
4,961,893
4,506,653
Accumulated impairment:
Balance at beginning of period
-
-
Impairment loss recognized
(
1,845,000
)
-
Balance at end of period
(
1,845,000
)
-
Carrying amount at the end of the period
3,116,893
4,506,653
Management
has determined that the acquisition of AffinityDNA in the current year is a single cash generating unit. The total goodwill acquired
though business combination for AffinityDNA amounted to $
455,240
. Further details of net assets acquired and of goodwill is disclosed
in Note 17.
F-
27
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
15.
GOODWILL (cont.)
(i)
Impairment testing for CGUs containing goodwill
For
the purpose of impairment testing, goodwill has been allocated to the Group's CGUs as follows:
2023
2022
A$
A$
Net carrying amount at the end of the period:
EasyDNA
2,661,653
4,506,653
AffinityDNA
455,240
-
Goodwill allocation at 30 June
3,116,893
4,506,653
(ii)
Key assumptions used for value-in-use calculations
The
estimates below were used in the goodwill impairment assessment for the acquired EasyDNA and AffinityDNA businesses:
EasyDNA
AffinityDNA
Revenue growth (FY2025 to FY2028)
4.3
%
4.5
%
Gross margin
47.5
%
45.0
%
Pre-tax discount rate
22.7
%
22.7
%
Post-tax discount rate
17
%
17
%
Growth rate beyond FY2027
4.3
%
4.5
%
The
key assumptions in the value-in-use impairment tests are estimated post-tax cash flows, revenue growth rates, gross margins and the discount
rate. Management is aware that reasonably possible negative changes in the estimated post-tax cash flows or the discount rate could cause
the recoverable amount to fall below the carrying amounts of the acquired EasyDNA and AffinityDNA businesses.
(iii)
I
mpairment
charge for goodwill
EasyDNA
Based
upon the impairment testing undertaken by management for the financial year ending June 30, 2023 an impairment loss of A$
1,845,000
(2022:
Nil
) was recorded for the goodwill asset recorded as part of the EasyDNA business acquisition indicating that the carrying value exceeded
the recoverable amount of the CGU as at 30 June 2023. Although significant revenue was recorded in the financial year for EasyDNA, revenue
did not meet forecast expectations. Management believes there were a number of contributing factors, including increased competition
for the genetic tests offered by EasyDNA and slowing economic activity in key markets following the actions of central banks to bring
down inflation.
Following
the impairment loss recognized in the Group's EasyDNA CGU, the recoverable amount was equal to the carrying amount. Therefore,
any adverse movement in a key assumption would lead to further impairment.
AffinityDNA
Management's
assessment of impairment for AffinityDNA did not result in an impairment for AffinityDNA as the recoverable amounts exceeds it's
carrying value by A$
78,000
.
Sensitivity
analysis undertaken on the key impairment model assumptions indicates that in order for the recoverable amount to be equal to their carrying
value for AffinityDNA, the discount rate would need to increase to 17.5% and revenue growth rate would need to decrease by 0.5%. Management
is not aware of any events that are expected to have an adverse effect on revenue growth
F-
28
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
16.
OTHER INTANGIBLE ASSETS
The
following table shows the movements in other intangible assets:
2023
2022
A$
A$
Other intangible assets:
Gross carrying amount
Balance at beginning of period
753,418
-
Brands, trademark and trade names, acquired through business combination
41,264
720,550
Domain names
-
32,868
Balance at end of period
794,682
753,418
Accumulated amortization:
Balance at beginning of period
(
128,498
)
-
Amortization for the period
(
145,712
)
(
128,498
)
Balance at end of period
(
274,210
)
(
128,498
)
Carrying amount at the end of the period
520,472
624,920
Brand,
trademark, trade names and domain names acquired in a business combination that qualify for separate recognition are recognized as intangible
assets at their fair values. Brands, trademarks and trade names acquired through business combination for EasyDNA and AffinityDNA have
been recognized a one category of intangible asset for each segment as they are interconnected elements that collectively
contribute to a company's image, recognition, and legal protection. They are essential components for establishing a strong market
presence, building consumer trust, and safeguarding a company's intellectual property.
The
Brand, trademark, trade names and domain names acquired in respect of the purchase of the EasyDNA business and its assets have been valued
using the 'relief from royalty method'. The projected royalty cashflows were discounted to their present value assuming a
weighted average cost of capital of
16
%. A net royalty rate of
1.5
% of projected EasyDNA revenues has been assumed.
The
Brand, trademark, trade names and domain names acquired in respect of the purchase of AffinityDNA's business and its assets have
been valued using the 'relief from royalty method'. The projected royalty cashflows have been discounted to their present
value assuming a weighted average cost of capital of
48
%. A net royalty rate of
1.5
% of projected AffinityDNA revenues has been assumed.
Brand,
trademark, trade names and domain names are amortized on a straight-line basis over their estimated useful lives of five years.
F-
29
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
17.
BUSINESS ACQUISITION
On
14 July 2022, the Company completed the acquisition of AffinityDNA's direct-to-consumer eCommerce business and distribution rights.
The purchase consideration has two parts, A$
486,188
(£
277,500
) on the acquisition date (which has been paid) and a further A$
486,188
(£
277,500
) as contingent consideration. The second payment is payable on the achievement of certain financial targets and remained
unpaid at June 30, 2023. The second payment was payable on the achievement of a gross profit target for the 12-month period from the
acquisition date. This target was not achieved and therefore no further payment is to be made in respect of the acquisition of AffinityDNA.
Costs
incurred in respect of acquisition were A$
40,625
, these have been recognized through profit or loss for the period.
The
acquisition of AffinityDNA provides the Group with an additional and complimentary platform to further build its existing direct-to-consumer
offerings and lifestyle division. The acquisition also expands the Group's portfolio of tests, geographic (including the UK and
US markets) and demographic access. The acquisition provides the group with operational, supply chain, distribution and commercial
synergies with its existing EasyDNA direct-to-consumer business that represents goodwill, which cannot be separately measured and identified.
Intangible
assets arising on acquisition were valued by an independent valuer. Details of net assets acquired and of goodwill are as follows:
A$
Fair value of consideration transferred
Amount settled in cash
486,188
Total consideration
486,188
Recognized amounts of identifiable net assets
Intangible assets
(1)
41,264
Deferred tax liabilities
(
10,316
)
Identifiable net assets
30,948
Goodwill on acquisition (Note 15)
455,240
The
total fair value of the contingent consideration transferred was on the basis that the probability of achieving the earn-out payment
at acquisition date was 0%.
Goodwill
arises on the acquisition of a business combination. Goodwill is calculated as the excess sum of:
●
the
                                            consideration transferred;
●
any
                                            non-controlling interest; and
●
the
                                            acquisition date fair value of any previously held equity interest; over the acquisition
                                            date fair value of net identifiable assets acquired.
Goodwill
is not amortized. Instead, goodwill is tested annually for impairment, or more frequently if events or changes in circumstances indicate
that it might be impaired, and is carried at cost less accumulated impairment losses. Impairment losses on goodwill are taken to profit
or loss and are not subsequently reversed.
(1)
Intangible assets
relate to brand, trademark, trade names and domain names acquired as part of the business acquisition amounted to A$
41,264
(refer to
Note 16 for further details). The useful life of these intangibles are amortized on a straight-line basis over their estimated useful
lives of
five years
.
AffinityDNA
reported revenue of A$
944,058
and incurred an operating loss of A$
89,618
from July 14, 2022 to the June 30, 2023. Given
that the acquisition date was fairly close to the start of the year, the impact to consolidated revenue and loss for the year would be
immaterial, even if the acquisition had occurred on 1 July 2022.
F-
30
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
17.
BUSINESS ACQUISITION (cont.)
Prior
year's business acquisition
On
13 August 2021, the Company completed the acquisition of EasyDNA's assets and business. The purchase was settled by A$
3,400,625
in cash and A$
1,574,136
in GTG shares. Costs incurred in respect of acquisition were A$
116,682
, these have been recognized through profit
or loss for the period. The acquisition provides the foundation for the Company to grow its portfolio of serious disease test through
direct-to-consumer market and additional platform for growth and expansion into lifestyle testing. The acquisition will provide the Group
with operational and sales channel synergies that represents goodwill, which cannot be separately measured and identified.
Intangible
assets arising on acquisition were valued by an independent valuer. Details of net assets acquired and of goodwill are as follows:
Number of shares
A$
Fair value of consideration transferred
Amount settled in cash
3,400,625
Amount settled in shares
209,363,400
1,574,136
Total consideration
4,974,761
Recognized amounts of identifiable net assets
Right-of-use asset
42,289
Intangible assets
(1)
720,550
Other payables
(
19,193
)
Lease liability
(
42,289
)
Employee benefit provisions
(
53,111
)
Deferred tax liability
(
180,138
)
Identifiable net assets
468,108
Goodwill on acquisition (Note 15)
4,506,653
Goodwill
arises on the acquisition of a business combination. Goodwill is calculated as the excess sum of:
●
the
                                            consideration transferred;
●
any
                                            non-controlling interest; and
●
the
                                            acquisition date fair value of any previously held equity interest; over the acquisition
                                            date fair value of net identifiable assets acquired.
Goodwill
is not amortized. Instead, goodwill is tested annually for impairment, or more frequently if events or changes in circumstances indicate
that it might be impaired, and is carried at cost less accumulated impairment losses. Impairment losses on goodwill are taken to profit
or loss and are not subsequently reversed.
(1)
Intangible assets
relate to brand, trademark, trade names and domain names acquired as part of the business acquisition amounted to A$
720,550
(refer to
Note 16 for further details).
EasyDNA
reported revenue of A$
5,989,782
and incurred an operating loss of A$
165,000
from August 13, 2021 to the June 30, 2022. The revenue and
operating loss as at June 30, 2023 for EasyDNA CGU are A$
7,698,605
and A$
2,871,259
, respectively (see Note 25).
There
are no contingent consideration arrangements related to the acquisition.
F-
31
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
18.
TRADE AND OTHER PAYABLES (CURRENT)
2023
A$
2022
A$
Trade payables
837,952
1,153,856
Accrued expenses
618,163
953,439
Other payables
161,218
15,084
Total current trade and other payables
1,617,333
2,122,379
19.
PROVISIONS (CURRENT AND NON-CURRENT)
2023
A$
2022
A$
Current provisions
Annual leave
328,924
312,665
Long service leave
121,416
206,805
Make good
(1)
91,590
91,590
Total current provisions
541,930
611,060
Non-current provisions
Long service leave
30,439
22,499
Total non-current provisions
30,439
22,499
Total provisions
572,369
633,559
(1)
Make good provision
in respect of the lease of the Melbourne office and laboratory
2023
A$
2022
A$
Reconciliation of annual leave provision
Balance at the beginning of the financial year
312,665
171,398
Add: obligation accrued during the year
400,780
366,816
Less: utilized during the year
(
388,457
)
(
225,549
)
Less: FX on translation
3,936
-
Balance at the end of the financial year
328,924
312,665
Reconciliation of long service leave provision
Balance at the beginning of the financial year
229,304
210,642
Add: obligation accrued during the year
21,723
18,662
Less: reversal during the year
(
472
)
-
Less: paid off during the year
(
98,700
)
-
Balance at the end of the financial year
151,855
229,304
F-
32
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
20.
RIGHT-OF-USE ASSET / (LEASE LIABILITIES)
(a)
Amounts recognized in the statement of financial position
The
statement of financial position shows the following amounts relating to leases:
2023
2022
A$
A$
Right-of-use assets
Right-of-use assets
509,553
647,150
Lease Liabilities
Lease liabilities - Current
(
303,570
)
(
264,130
)
Lease liabilities - Non-Current
(
229,276
)
(
388,396
)
Total
(
532,846
)
(
652,526
)
(b)
Amounts
recognized in the statement of profit or loss
The
statement of profit or loss under general and administrative expenses includes the following amounts relating to leases:
2023
2022
A$
A$
Depreciation charge of right-of-use assets
Depreciation Expense (for Leased Assets)
296,174
235,241
Interest expense (included in finance costs)
29,515
15,215
Low value leases
32,094
26,408
During
the financial year ended June 30, 2023, the total cash outflow was A$
336,396
(2022: A$
268,590
).
21.
CONTRIBUTED EQUITY
2023
A$
2022
A$
Issued and paid-up capital
Fully paid Ordinary Shares
161,342,707
155,138,636
Total contributed equity
161,342,707
155,138,636
F-
33
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
21.
CONTRIBUTED EQUITY (cont.)
Movements
in shares on issue
Year ended June 30, 2023
Number of
Shares
A$
Balance at the beginning of the financial year
9,233,965,143
155,138,636
Shares issued during the year
2,307,693,000
7,172,399
Add: Exercise of performance rights
-
82,688
Less: transaction costs arising on share issue
(i)
-
(
916,060
)
Less: valuation of warrants to be issued
-
(
134,956
)
Balance at the end of the financial year
11,541,658,143
161,342,707
Year ended June 30, 2022
Number of
Shares
A$
Balance at the beginning of the financial year
9,016,726,743
153,574,974
Shares issued during the year
217,238,400
1,574,136
Less: transaction costs arising on share issue
(i)
-
(
10,474
)
Balance at the end of the financial year
9,233,965,143
155,138,636
(i)
The
    details of securities arising on shares issued for the year ended June 30, 2023 and June 30 2022 are as below:
●
On
    July 19, 2021, the Company issued
209,363,400
new ordinary shares, at fair value of A$
1,574,136
in part consideration for the acquisition
    of
100
% of EasyDNA.
●
On
    November 3, 2021, the Company issued
7,875,000
new ordinary shares pursuant to the Company's Employee Performance Rights Plan.
●
On
    February 7, 2023, the Company issued
3,846,155
ADSs, each representing six hundred (
600
) of the Company's ordinary shares,
    totaling
2,307,693,000
ordinary shares, at a purchase price of United States Dollars (US$) US$
1.30
per ADS. The gross proceeds for
    this offering were approximately US$
5
million. Against the offering, the Company agreed to issue
250,000
warrants exercisable at
    US$
1.625
each,
expiring in 5 years from issue date
, to H.C. Wainwright & Co which would form part of cost of raising capital.
    The said warrants are subject to shareholder approval at the Company's 2023 annual general meeting.
Terms
and conditions of contributed equity
Ordinary
shares have the right to receive dividends as declared and, in the event of winding up the Company, to participate in the proceeds from
the sale of all surplus assets in proportion to the number of and amounts paid up on shares held. Ordinary shares, which have no par
value, entitle their holder to one vote, either in person or by proxy, at a meeting of the Company.
F-
34
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
22.
RESERVES
2023
A$
2022
A$
Foreign currency translation
847,408
746,819
Share-based payments
5,688,148
10,751,832
Total reserves
6,535,556
11,498,651
Reconciliation of foreign currency translation reserve
Balance at the beginning of the financial year
746,819
718,955
Add: net currency translation gain / (loss)
100,589
27,864
Balance at the end of the financial year
847,408
746,819
Reconciliation of share-based payments reserve
Balance at the beginning of the financial year
10,751,832
10,314,324
Add: share-based payments expense
-
-
Add: Issue of performance rights
125,500
437,508
Add: Valuation of warrants
134,956
-
Less: Options/warrants expired
(
5,241,452
)
-
Less: Exercise of performance rights
(
82,688
)
-
Balance at the end of the financial year
5,688,148
10,751,832
Share
Based Payments Reserve
Nature
and Purpose
The
share-based payment reserve records items recognized as expenses on valuation of warrants, share options, and performance shares issued
to capital raising agents, key management personnel, other employees, and eligible contractors.
Warrants
During
the financial year ended June 30, 2023, the following warrants were issued to as a part of capital raising costs.
2023
Valuation date
December 20, 2022
Grant Date
December 20, 2022
Warrants issued
250,000
Underlying asset price
A$
1.525
Risk free rate
4.1
%
Volatility
75
%
Exercise price presented in United States Dollar
US$
1.625
Exchange rate at valuation date
A$
1 to USD$0.669
Exercise price presented in Australian Dollar
A$
2.429
Time to maturity of underlying warrants (years)
5.12
Value per warrant in Australian Dollar
A$
0.5398
Model used
Black Scholes
Valuation amount
A$
134,956
F-
35
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
22.
RESERVES (cont.)
No
warrants were issued for the financial year ended June 30, 2022. During the financial year ended June 30, 2021, the following warrants
were issued to as a part of capital raising costs.
2021
Valuation date
July 21, 2020
Grant Date
June 1, 2020
Warrants issued
39,975,000
Underlying asset price
A$
0.0070
Risk free rate
0.42
%
Volatility
148.66
%
Exercise price presented in United States Dollar
US$
0.00417
Exchange rate at valuation date
A$
1 to US$0.7127
Exercise price presented in Australian Dollar
A$
0.0146
Time to maturity of underlying warrants (years)
5
Value per warrant in Australian Dollar
A$
0.009
Model used
Binomial
Valuation amount
A$
360,017
2021
Valuation date
January 25, 2021
Grant Date
January 25, 2021
Warrants issued
48,750,000
Underlying asset price
A$
0.0110
Risk free rate
0.414
%
Volatility
147.29
%
Exercise price presented in United States Dollar
US$
0.0109
Exchange rate at valuation date
A$
1 to US$0.7708
Exercise price presented in Australian Dollar
A$
0.0142
Time to maturity of underlying warrants (years)
5
Value per warrant in Australian Dollar
A$
0.0098
Model used
Binomial
Valuation amount
A$
476,297
Share
Options
No
share options were issued during the financial year ending June 30, 2023 or June 30, 2022. The following information relates to options
granted and issued against under the Employee Option Plan for the year ended June 30, 2021;
Options issued to
Grant date for
options issued
Number of options
issued
Employee Option Plan
December 21, 2020
12,850,000
F-
36
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
22. RESERVES
(cont.)
2021
Grant Date
December 21, 2020
Options issued
12,850,000
Dividend yield
-
Historic volatility and expected volatility
155.34
%
Option exercise price
A$
0.008
Fair value of options at grant date
A$
0.007
Weighted average exercise price
A$
0.008
Risk-free interest rate
0.111
%
Expected life of an option
3
years
Model used
Binomial
Valuation amount
A$
72,439
Performance
Rights
No
Performance Rights were issued for financial year ended June 30, 2023. The following information relates to issued Performance Rights
for the year ended June 30, 2022;
Performance rights issued to
Grant date for
performance rights issued
Number of performance rights
issued
Adam Kramer
March 3, 2021
3,937,500
Mike Tonroe
June 15, 2021
40,000,000
Carl Stubbings
September 22, 2021
20,000,000
Kevin Camilleri
November 22, 2021
20,000,000
2022
Grant Date
March 3,
2021
June 15,
2021
September 22,
2021
November 22,
2021
Performance rights issued
3,937,500
40,000,000
20,000,000
20,000,000
Dividend yield
-
-
-
-
Historic volatility and expected volatility
161
152
149
150
%
Performance rights exercise price
A$
0.009
0.0069
0.0047
0.0038
Fair value of performance rights at grant date
A$
0.012
0.0073
0.0052
0.0042
Weighted average exercise price
A$
0.008
0.008
0.008
0.008
Risk-free interest rate
0.110
0.085
0.160
0.960
%
Expected life of the performance rights
2.02
years
3
years
3
years
3
years
Model used
Binomial
Binomial
Binomial
Binomial
Valuation amount
A$
47,250
291,428
103,104
83,216
Foreign
currency translation reserve
Nature
and Purpose
Exchange
differences arising on translation of the foreign controlled entities are recognized in other comprehensive income as described in Note
2(e) and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the net investment
is disposed of.
F-
37
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)
23.
ACCUMULATED LOSSES
2023
A$
2022
A$
Balance at the beginning of the financial year
(
150,206,216
)
(
143,075,218
)
Add: net loss attributable to owners of Genetic Technologies Limited
(
11,750,923
)
(
7,130,998
)
Less: Options/warrants expired
5,241,452
-
Balance at the end of the financial year
(
156,715,687
)
(
150,206,216
)
24.
SHARE OPTIONS
Employee
Option Plan
The
fair value of options granted under an Employee Option Plan is recognized as an employee benefit expense with a corresponding increase
in equity. The fair value is measured at grant date and recognized over the vesting period over which the service vesting conditions
are to be satisfied. Employee Option Plan options have no other vesting conditions. The fair value at grant date is determined by management
with the assistance of an independent valuer, using a Black-Scholes option pricing model or a Binomial model simulation analysis. The
total amount to be expensed is determined by reference to the fair value of the options granted;
●
including any market performance
    conditions (e.g. the entities share price)
●
excluding the impact of any service and non-market
    performance vesting conditions (e.g. remaining an employee over a specified time period)
The
cumulative employee benefits expense recognized at each reporting date until vesting date reflects (i) the extent to which the vesting
period has expired; and (ii) the number of awards that, in the opinion of the Directors of the Company, will ultimately vest. This opinion
is formed based on the best information available at balance date.
Where
the terms of an equity-settled award are modified, as a minimum an expense is recognized as if the terms had not been modified. In addition,
an expense is recognized for any increase in the value of the transaction as a result of the modification, as at the date of modification.
Where appropriate, the dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted
earnings per share. The Company's policy is to treat the options of terminated employees as forfeitures if termination occurs prior
to vesting conditions being reached.
On
November 30, 2001, the Directors of the Company established a Staff Share Plan. On November 19, 2008, the shareholders of the Company
approved the introduction of a new Employee Option Plan. Under the terms of the respective Plans, the Directors may, at their discretion,
grant options over the ordinary shares in the Genetic Technologies Limited to executives, consultants, employees, and former Non-Executive
Directors, of the Company. The options, which are granted at nil cost, are not transferable and are not quoted on the ASX. As at June
30, 2023, there were 1 executive and 7 employees who held options that had been granted under the Plans. Options granted under the Plans
carry no rights to dividends and no voting rights.
F-
38
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)
24. SHARE OPTIONS (cont.)
(i)
Fair value of options granted
During
the year ended June 30, 2023, there were
no
options granted (2022:
Nil
). The Company, however issued various unlisted options to underwriters
and sub-underwriters as a part of capital raising costs in 2021. For valuations on the unlisted options issued please refer to Note 22.
Set
out below are summaries of all and unlisted options, including ESOP which were issued in prior periods:
2023
2022
Average
exercise price
per share
option A$
Number
of
options
Average
exercise price
per share
option A$
Number
of
options
Opening balance
0.008
492,400,000
0.008
521,850,000
Lapsed during the year
0.008
(
481,500,000
)
0.012
(
29,450,000
)
Forfeited during the year
0.008
(
2,500,000
)
-
-
Closing balance
0.008
8,400,000
0.008
492,400,000
The
movements in the number of options granted under the Employee share plans are as follows:
2023
2022
Average
exercise price
per share
option A$
Number
of
options
Average
exercise price
per share
option A$
Number
of
options
Balance at the beginning of the financial year
0.008
10,900,000
0.011
27,850,000
Add: options granted during the year
-
-
-
-
Less: options lapsed during the year
-
-
0.010
(
16,950,000
)
Less: options forfeited during the year
0.008
(
2,500,000
)
-
-
Balance at the end of the financial year
0.008
8,400,000
0.008
10,900,000
F-
39
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
24. SHARE OPTIONS (cont.)
The
number of options outstanding as at June 30, 2023 by ASX code, including the respective dates of expiry and exercise prices, are tabled
below. The options tabled below are not listed on ASX.
2023
2022
Unlisted options
Average
exercise price
per share
option
A$
Number
of
options
Average
exercise price
per share
option
                                                                                 A$
Number
of
options
Options to various underwriters (expiring October 30, 2022)
-
-
0.008
229,000,000
Options to directors (expiring December 20, 2022)
-
-
0.008
250,000,000
Options issued Lodge Corporate Pty Ltd (expiring March 6, 2023)
-
-
0.008
2,500,000
ESOP options (expiring December 1, 2023)
0.008
8,400,000
0.008
12,850,000
Total
0.008
8,400,000
0.008
494,350,000
Exercisable at the end of the financial year
0.008
8,400,000
0.008
494,350,000
The
weighted average remaining contractual life of options outstanding as at June 30, 2023 was
0.42
years (2022:
0.43
years).
25.
SEGMENT INFORMATION
(a)
Identification of reportable segments
The
Company has identified three reportable segments as reported that is consistent with the internal reporting provided to the chief operating
decision maker, Chief Executive Officer.
As
of June 30, 2022, the Company changed its reportable operating segments from two geographical segments, previously Australia and USA,
to two business unit segments, EasyDNA and geneType/Corporate as a result of integrating the EasyDNA acquisition in fiscal 2022. The
Company changed its reporting structure to better reflect what the chief operating decision maker is reviewing to make organizational
decisions and resource allocations. As a result, the 2021 presentation of segment information has been recast to conform with the current
segment reporting structure. In July 2022, a new business unit was created as a result of AffinityDNA acquisition.
Management
considers the business from a business unit perspective and has identified three reportable segments:
EasyDNA:
relates to EasyDNA branded test sales and expenses.
AffinityDNA:
relates to AffinityDNA branded test sales and expenses.
GeneType
/ Corporate:
relates to geneType branded test sales and expense, includes corporate charges.
F-
40
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)
25. SEGMENT INFORMATION (cont.)
(b)
Business unit segments
The
segment information for the reportable segments is as follows:
2023
AffinityDNA
EasyDNA
geneType/
Corporate
Total
A$
A$
A$
A$
Segment revenue & other income
Revenue from contracts with customers
944,058
7,698,605
43,455
8,686,118
Other income
-
17
1,836,805
1,836,822
Finance income
-
-
220,161
220,161
Total segment revenue & other income
944,058
7,698,622
2,100,421
10,743,101
Segment expenses
Depreciation and amortization
(
22,310
)
(
30,074
)
(
624,199
)
(
676,583
)
Finance costs
(
2,693
)
(
2,132
)
(
24,690
)
(
29,515
)
Raw materials and change in inventories
(
404,660
)
(
3,896,000
)
(
34,605
)
(
4,335,265
)
Commissions
(
42,727
)
(
193,292
)
-
(
236,019
)
Employee benefits expenses
(
209,219
)
(
1,593,699
)
(
4,405,148
)
(
6,208,066
)
Advertising and promotional expenses
(
35,926
)
(
1,681,875
)
(
994,552
)
(
2,712,353
)
Professional fees
(
62,522
)
(
18,414
)
(
1,279,704
)
(
1,360,640
)
Research and development expenses
-
-
(
1,281,157
)
(
1,281,157
)
Impairment expenses
-
(
2,125,725
)
-
(
2,125,725
)
Other expenses
(
253,619
)
(
1,028,670
)
(
2,404,741
)
(
3,687,030
)
Total segment expenses
(
1,033,676
)
(
10,569,881
)
(
12,513,521
)
(
22,652,353
)
Income tax credit
-
-
158,329
158,329
Loss for the period
(
89,618
)
(
2,871,259
)
(
10,254,771
)
(
11,750,923
)
Total Segment Assets
625,421
3,320,967
10,909,849
14,856,237
Total Segment Liabilities
(
208,468
)
(
1,308,206
)
(
2,176,987
)
(
3,693,661
)
F-
41
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
25. SEGMENT INFORMATION (cont.)
2022
AffinityDNA
EasyDNA
geneType/
Corporate
Total
A$
A$
A$
A$
Segment revenue & other income
Revenue from contracts with customers
-
5,989,782
805,034
6,794,816
Other income
-
-
2,783,391
2,783,391
Finance income
-
-
36,256
36,256
Total segment revenue & other income
-
5,989,782
3,624,681
9,614,463
Segment expenses
Depreciation and amortization
-
-
(
578,668
)
(
578,668
)
Finance costs
-
-
(
15,215
)
(
15,215
)
Raw materials and change in inventories
-
(
2,951,815
)
(
61,719
)
(
3,013,534
)
Commissions
-
(
156,625
)
-
(
156,625
)
Employee benefits expenses
-
(
1,235,657
)
(
4,632,998
)
(
5,868,655
)
Advertising and promotional expenses
-
(
1,079,291
)
(
806,111
)
(
1,885,402
)
Professional fees
-
(
21,685
)
(
1,813,759
)
(
1,835,444
)
Research and development expenses
-
-
(
705,507
)
(
705,507
)
Impairment expenses
-
-
(
564,161
)
(
564,161
)
Other expenses
-
(
721,226
)
(
1,433,149
)
(
2,154,375
)
Total segment expenses
-
(
6,166,299
)
(
10,611,287
)
(
16,777,586
)
Income tax credit
-
-
32,125
32,125
Loss for the period
-
(
176,517
)
(
6,954,481
)
(
7,130,998
)
Total Segment Assets
-
2,668,618
18,133,080
20,801,698
Total Segment Liabilities
-
(
1,969,878
)
(
2,400,749
)
(
4,370,627
)
F-
42
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
25. SEGMENT INFORMATION (cont.)
2021
AffinityDNA
EasyDNA
geneType/
Corporate
Total
A$
A$
A$
A$
Segment revenue & other income
Revenue from contracts with customers
-
-
120,554
120,554
Other income
-
-
1,559,961
1,559,961
Finance income
-
-
62,394
62,394
Total segment revenue & other income
-
-
1,742,909
1,742,909
Segment expenses
Depreciation and amortization
-
-
(
386,277
)
(
386,277
)
Finance costs
-
-
(
16,338
)
(
16,338
)
Raw materials and change in inventories
-
-
(
170,457
)
(
170,457
)
Commissions
-
-
-
-
Employee benefits expenses
-
-
(
3,868,331
)
(
3,868,331
)
Advertising and promotional expenses
-
-
(
436,274
)
(
436,274
)
Professional fees
-
-
(
1,461,401
)
(
1,461,401
)
Research and development expenses
-
-
(
1,165,531
)
(
1,165,531
)
Impairment expenses
-
-
(
32,048
)
(
32,048
)
Other expenses
-
-
(
1,283,871
)
(
1,283,871
)
Total segment expenses
-
-
(
8,820,528
)
(
8,820,528
)
Income tax credit
-
-
-
-
Loss for the period
-
-
(
7,077,619
)
(
7,077,619
)
Total Segment Assets
-
-
22,971,688
22,971,688
Total Segment Liabilities
-
-
(
1,438,653
)
(
1,438,653
)
(c)
Geographic information
In
presenting the geographic information, segment revenue has been based on geographic location of customers. The geographic information
for the reportable segments is as follows:
2023
AffinityDNA
EasyDNA
geneType/
Corporate
Total
A$
A$
A$
A$
America and Canada
15,056
2,190,352
36,761
2,242,169
Europe Middle East and Africa
766,040
3,728,586
-
4,494,626
Latin America
144,727
177,306
-
322,033
Asia Pacific
18,235
1,602,361
6,694
1,627,290
Total revenue
944,058
7,698,605
43,455
8,686,118
F-
43
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)
25. SEGMENT INFORMATION (cont.)
(c)
Geographic information (cont.)
2022
AffinityDNA
EasyDNA
geneType/
Corporate
Total
A$
A$
A$
A$
America and Canada
-
2,267,474
7,077
2,274,551
Europe Middle East and Africa
-
2,501,302
-
2,501,302
Latin America
-
128,840
-
128,840
Asia Pacific
-
1,092,166
797,957
1,890,123
Total revenue
-
5,989,782
805,034
6,794,816
2021
AffinityDNA
EasyDNA
geneType/
Corporate
Total
A$
A$
A$
A$
America and Canada
-
-
120,554
120,554
Europe Middle East and Africa
-
-
-
-
Latin America
-
-
-
-
Asia Pacific
-
-
-
-
Total revenue
-
-
120,554
120,554
26.
SHARE BASED PAYMENTS
(a)
Employee option plan
On
December 21, 2020, the Company issued
12,850,000
options with an exercise price of A$
0.008
(0.8cents) per option, expiring December 1,
2023 issued under an employee incentive scheme (2020: Nil). The Company, also issued various unlisted options to underwriters and sub-underwriters
as a part of capital raising costs in financial year ended June 30, 2021. Please refer to further details on options on Note 23.
There
were no new options issued under the Employee Option Plan during the financial years ending June 30, 2022 and June 30, 2023.
(b)
Performance Rights Issuance
After
receiving requisite shareholder approval on December 10, 2020, the Company issued performance rights to Directors of the Company as follows:
●
5,000,000
Class A Performance Rights
    to Dr. Lindsay Wakefield
●
7,500,000
Class A Performance Rights,
25,000,000
Class
    B Performance Rights and
25,000,000
Class C Performance Rights to Dr. Jerzy Muchnicki
●
7,500,000
Class A Performance Rights,
25,000,000
Class
    B Performance Rights and
25,000,000
Class C Performance Rights to Mr. Peter Rubinstein
●
5,000,000
Class A Performance Rights to Mr. Nicholas
    Burrows
These
performance rights remain available to Directors to exercise at June 30, 2023, if vesting conditions are met.
During
the financial year ending June 30, 2021, the Board has approved the issue of the following performance rights to the Chief Executive
Officer and Chief Operating Officer:
●
60,000,000
Class D Performance Rights
    to Mr. Simon Morris
●
3,937,500
Class E Performance Rights to Mr. Stanley
    Sack
F-
44
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
26.
SHARE BASED PAYMENTS
(b)
Performance Rights Issuance (cont.)
Mr.
Stanley Sack exercised his performance rights during the financial year ending June 30, 2022. The performance rights issued to Mr. Simon
Morriss remain exercisable at June 30, 2023, if vesting conditions are met.
During
the financial year ending June 30, 2022, the Board has approved for the following performance rights to be issued to the Key Management
Personnel below:
●
40,000,000
Performance
    Rights to Mr. Michael Tonroe
●
20,000,000
Performance Rights
    to Mr. Carl Stubbings
●
20,000,000
Performance Rights
    to Mr. Kevin Camilleri
The
performance rights issued to Mr. Michael Tonroe were forfeit during the 2023 financial year following his resignation. The performance
rights issued to Mr. Carl Stubbings and Mr. Kevin Camilleri remain exercisable at June 30, 2023, if vesting conditions are met.
The
Company has accounted for these performance rights in accordance with its accounting policy for share-based payment transactions and
has recorded a share-based payments expense of A$
125,500
in the Statement of Profit or Loss and Other Comprehensive Income for the current
reporting period (2022: A$
437,508
& 2021: A$
622,725
).
Valuation
of Performance Rights
The
Performance Rights are not currently quoted on the ASX and as such have no ready market value. The performance rights each grant the
holder a right of grant of one ordinary Share in the Company upon vesting of the performance rights for nil consideration. Accordingly,
the performance rights may have a present value at the date of their grant. Various factors impact upon the value of performance rights
including:
●
the period outstanding before the
    expiry date of the performance rights;
●
the underlying price or value of the securities into
    which they may be converted;
●
the proportion of the issued capital as expanded consequent
    upon conversion of the performance rights into Shares (i.e. whether or not the shares that might be acquired upon exercise of the
    options represent a controlling or other significant interest); and
●
the value of the shares into which the performance
    rights may be converted.
There
are various formulae which can be applied to determining the theoretical value of performance rights (including the formula known as
the Black-Scholes Model valuation formula and the Binomial model).
The
Company commissioned an independent valuation of the performance rights. The independent valuer has applied the Binomial Model in providing
the valuation of the performance rights.
Valuation
of Performance Rights
The
Performance Rights are not currently quoted on the ASX and as such have no ready market value. The performance rights each Inherent in
the application of the Binomial model are a number of inputs, some of which must be assumed. For the performance rights issued in the
year ended June 30, 2021, the data relied upon in applying the Binomial model was:
a)
exercise price being
0.0
cents per
    performance right for all classes;
b)
VWAP hurdle (
10
days consecutive share price hurdle)
    equaling A$
0.012
for Class A and A$
0.014
for Class B, and (
15
days consecutive share price hurdle) equaling $
0.016
for Class D performance
    rights;
c)
sales and market cap hurdles as listed above for Class
    C and Class E performance rights;
d)
the continuously compounded risk-free rate being
0.111
%
    for all classes of performance rights (calculated with reference to Refinitiv – closing share price as at December 21, 2020,
    and 3 year Australian Government yield as at December 21, 2020);
e)
the expected option life of
2
years for Class E performance
    rights and
3
years for all other classes of performance rights; and
f)
a volatility measure of
158.23
%.
F-
45
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)
26. SHARE BASED PAYMENTS (cont.)
Valuation
of Performance Rights (cont.)
For
the performance Rights issued during the financial year ending June 30, 2022, the data relied upon in applying the Binomial model was:
a)
exercise price being
0.0
cents per
    performance right for all classes;
b)
VWAP hurdle for key management personnel (
15
days consecutive
    share price hurdle) equaling A$
0.016
for performance rights;
c)
sales and market cap hurdles as listed above for performance
    rights;
d)
the continuously compounded risk-free rate is as per
    table below (calculated based on yield of Australian government bonds, as at the grant dates for a 2 or 3 year period matching the
    expected life of performance rights);
e)
the expected option life of
3
years for key management
    personnel and
2
years for others; and
f)
a volatility measure between
149
% to
161
%.
Performance
hurdles
Key
management personnel, being the recipients of the performance rights, must remain engaged by the Company at the time of satisfaction
of the performance hurdle in order for the relevant performance right to vest.
There
were no performance rights issued for the year ended June 30, 2023.
Performance
rights issued during the year ended June 30, 2022
The
performance rights for key management personnel vest and are exercisable upon the Share price reaching A$0.016 while or greater for more
than 15-day consecutive ASX trading days
.
Performance
rights issued during the year ended June 30, 2021
The
Class A Performance Rights vest and are exercisable upon the Share price reaching A$0.012 or greater for more than 10-day consecutive
ASX trading days.
The
Class B Performance Rights vest and are exercisable upon the Share price reaching A$0.014 or greater for more than 10-day consecutive
ASX trading days and sales commence on the Consumer Initiated Testing (CIT) platform in either Australia or the United States of America.
The
Class C Performance Rights vest and are exercisable upon a minimum of 4,000 tests being processed in any 12-month period or the market
cap of the Company reaching A$100 million or above and being sustained for more than 10 consecutive ASX trading days, whichever happens
sooner.
The
Class D Performance Rights vest and are exercisable upon the Share price reaching A$0.016 or greater for more than 15-day consecutive
ASX trading days.
The
Class E Performance Rights vest and are exercisable upon the first commercial sale of the Company's COVID-19 risk test with IBX
(Infinity BioLogix)
.
Performance
rights issued prior to the year ended June 30, 2021
The
Class A Performance Rights vest and are exercisable upon the Share price reaching A$0.02 or greater for more than 10-day consecutive
ASX trading days.
F-
46
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)
26. SHARE BASED PAYMENTS (cont.)
Performance
rights issued during prior year
Number of
Performance
Rights
issued
Valuation
(cents)
Total fair
value of
Performance
Rights
A$
Expense
accounted
for in 2022
A$
Expense
accounted
for during
the year
A$
Mr. Carl Stubbings
20,000,000
0.52
103,104
26,459
34,368
Mr. Kevin Camilleri
20,000,000
0.42
83,216
16,719
27,739
Total
40,000,000
186,320
43,178
62,107
Performance
rights issued during prior year, that lapsed during the financial year ending June 30, 2023
Number of
Performance
Rights
issued
Valuation
(cents)
Total fair
value of
Performance
Rights
A$
Expense
accounted
for in 2022
A$
Expense
accounted
for during
the year
A$
Mr. Michael Tonroe
40,000,000
0.73
291,428
101,043
(
101,043
)
Total
40,000,000
291,428
101,043
(
101,043
)
Number of
Performance
Rights
issued
Valuation
per
Class D
(cents)
Total
fair
value of
Class D
Performance
Rights
A$
Expense
accounted
for in 2022
A$
Expense
accounted
for during
the year
A$
Mr Simon Morriss
60,000,000
0.96
574,037
191,346
191,346
Number of
Performance
Rights
issued
Valuation
per
Class E
(cents)
Total fair
value of
Class E
Performance
Rights
A$
Expense
accounted
for in 2022
A$
Expense
accounted
for during
the year
A$
Mr Stanley Sack
3,937,500
0.90
35,438
35,438
-
Performance
rights issued during prior years, that lapsed during the financial year ending June 30, 2022
Number of
Performance
Rights
issued
Valuation per
Class A
(cents)
Total fair
value of
Class A
Performance
Rights
A$
Expense
accounted
for in 2021
A$
Expense
accounted
for during
for in 2022
A$
Dr. Lindsay Wakefield
3,750,000
0.77
28,875
9,625
4,010
Dr. Jerzy Muchnicki
6,250,000
0.77
48,125
16,042
6,684
Mr. Peter Rubinstein
5,000,000
0.77
38,500
12,833
5,347
Total
15,000,000
115,500
38,500
16,041
No
Performance Rights were cancelled/forfeited during the years ended June 30, 2023 and June 30, 2022.
F-
47
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)
26. SHARE BASED PAYMENTS (cont.)
Performance
rights issued during prior years, that lapsed during the financial year ending June 30, 2022
Number of
Performance
Rights
issued
Valuation
per
Class A
(cents)
Total
fair
value of
Class A
Performance
Rights
A$
Expense
accounted
for in 2021
A$
Expense
accounted
for during
for in 2022
A$
Dr. Lindsay Wakefield
3,750,000
0.77
28,875
9,625
4,010
Dr. Jerzy Muchnicki
6,250,000
0.77
48,125
16,042
6,684
Mr. Peter Rubinstein
5,000,000
0.77
38,500
12,833
5,347
Total
15,000,000
115,500
38,500
16,041
No
Performance Rights were cancelled/forfeited during the years ended June 30, 2023 and June 30, 2022.
(c)
Expenses arising from share-based payment transactions
Total
expenses arising from share-based payment transactions recognized during the period as part of employee benefit expense and equity raising
expenses were as follows:
2023
2022
2021
A$
A$
A$
Kentgrove options issued
-
-
16,667
Warrants to be issued H.C. Wainwright, subject to shareholder approval
134,956
-
-
Performance rights issued
125,500
436,119
622,725
Reversal of forfeited Performance Rights
-
-
-
Options issued under employee option plan
-
1,389
75,186
Total expenses arising from share-based payments
260,456
437,508
714,578
27.
CAPITAL COMMITMENTS
There
were no significant contracted capital expenditures at the end of the reporting periods ending June 30, 2021, 2022 & 2023.
28.
AUDITORS' REMUNERATION
2023
A$
2022
A$
2021
A$
Audit and assurance services
PricewaterhouseCoopers in respect of:
Audit
(1)
-
20,000
72,500
Audit related fees
(2)
-
-
-
All other fees
(3)
-
-
-
Grant Thornton Audit Pty Ltd in respect of:
Audit
(1)
320,569
241,882
168,333
Audit related fees
(2)
-
-
-
All other fees
(3)
-
30,000
65,000
Other audit firms in respect of:
Audit of the Financial Reports of subsidiaries
-
-
-
Total remuneration in respect of audit services
320,569
291,882
305,833
F-
48
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)
28.
AUDITORS' REMUNERATION (cont.)
(1)
Audit fees consist of services that
    would normally be provided in connection with statutory, half year review, and regulatory filings or engagements, including services
    that generally only the independent accountant can reasonably provide.
(2)
Audit related fees consist of fees billed for assurance
    and related services that generally only the statutory auditor could reason- ably provide to a client.
(3)
All other fees consist of fees billed for financial
    and information technology due diligence services in respect of the Company's acquisition of the business and assets associated
    with the EasyDNA brand that completed on August 13
th
, 2021.
29.
RELATED PARTY DISCLOSURES
Ultimate
parent
Genetic
Technologies Limited is the ultimate Australian parent company. As at the date of this Report,
no
shareholder controls more than 50%
of the issued capital of the Company.
Transactions
within the Company and with other related parties
During
the financial years ended June 30, 2023, 2022 and 2021, other than compensation paid to directors and other members of key management
personnel, see "Item 6.B Compensation", the only transactions between entities within the Company and other related parties
are as listed below. Except where noted, all amounts were charged on similar to market terms and at commercial rates.
Performance
Rights Issuance
After
receiving shareholder approval on December 10, 2020, the Company issued additional
125,000,000
Performance Rights to Directors of the
Company as follows:
●
5,000,000
Class A Performance Rights
    to Dr. Lindsay Wakefield
●
7,500,000
Class A Performance Rights,
25,000,000
Class
    B Performance Rights and
25,000,000
Class C Performance Rights to Dr. Jerzy Muchnicki
●
7,500,000
Class A Performance Rights,
25,000,000
Class
    B Performance Rights and
25,000,000
Class C Performance Rights to Mr. Peter Rubinstein
●
5,000,000
Class A Performance Rights to Mr. Nicholas
    Burrows
During
the financial year ending June 30, 2021, the Board has approved for the following Performance Rights to be issued to the Chief Executive
Officer and Chief Operating Officer:
●
60,000,000
Class D Performance Rights
    to Mr. Simon Morris
●
3,937,500
Class E Performance Rights to Mr. Stanley
    Sack
Mr.
Stanley Sack exercised his performance rights during the financial year ending June 30, 2022.
During
the financial year ending June 30, 2022, the Board has approved for the following Performance Rights to be issued to the Key Management
Personnel below:
●
40,000,000
Performance
    Rights to Mr. Michael Tonroe
●
20,000,000
Performance Rights
    to Mr. Carl Stubbings
●
20,000,000
Performance Rights
    to Mr. Kevin Camilleri
The
performance rights issued to Mr. Michael Tonroe were forfeit during the 2023 financial year following his resignation.
The
Company has accounted for these Performance Rights in accordance with its accounting policy for share-based payment transactions and
has recorded A$
125,500
(2022: A$
437,508
& 2021: A$
622,725
) of associated expense in the reporting period.
F-
49
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)
29. RELATED PARTY DISCLOSURES (cont.)
Mr.
Phillip Hains (Former Chief Financial Officer)
On
July 15, 2019, the Company announced that it had appointed Mr. Phillip Hains (MBA, CA) as the Chief Financial Officer who has over 30
years of extensive experience in roles with a portfolio of ASX and NASDAQ listed companies and provides CFO services through his firm
The CFO Solution. Prior to this point the Company had a similar arrangement with The CFO Solution, where it would engage and provide
services of overall CFO, accounting and other finance related activities.
During
the reporting period, the Company had not transacted with The CFO Solution towards provision of overall CFO, accounting and other finance
related activities (2022: A$
91,615
& 2021: A$
224,971
).
Mr.
Stanley Sack (former Chief Operating Officer)
On
May 18, 2020, the Company appointed Mr. Stanley Sack who provides consulting in the capacity of Chief Operating Officer. Mr. Sack has
spent 15 years in large listed entities in executive positions managing large business divisions. He has worked with a high-net- worth
family managing all their operating businesses and private equity activities. Mr. Sack built an Allied Health Business in the aged care
and community care space which became the biggest Mobile Allied Health Business in Australia, and was recently sold to a large medical
insurance company.
During
the reporting period, the Company had not transacted with Mr. Stanley Sack's entity Cobben Investments towards provision of consulting
services in relation to provision of duties related to Chief Operating Officer of the Company (2022: A$
107,187
& 2021: A$
143,172
).
Mr.
Peter Rubinstein (Non-Executive Director and Chairman)
During
the financial year ended June 30, 2020, the Board approved to obtain consulting services in relation to capital raises, compliance, NASDAQ
hearings and investor relations from its Non-Executive Director and current Chairman, Mr. Peter Rubinstein. The services procured were
through Mr. Peter Rubinstein's associate entity ValueAdmin.com Pty Ltd and amounted to A$
60,000
(2022: A$
60,000
& 2021: A$
60,000
)
that is included as part of the cash salary and fees in the remuneration report as at June 30, 2023.
Dr.
Jerzy Muchnicki (Non-Independent Non-Executive Director)
During
the financial year ended June 30, 2022, the Board approved to obtain consulting services in relation to PRS and Germline Integration;
Epigenetics; Somatic Testing; NIPT; Carrier testing and related marketing advice from its Non-Independent Non-Executive Director, Dr.
Jerzy Muchnicki. The services procured were through Dr. Jerzy Muchnicki's private consultancy and amounted to A$
50,000
(2021:
Nil
)
that is included as part of the cash salary and fees in the remuneration report.
There
were no transactions with parties related to Key Management Personnel during the year other than that disclosed above.
F-
50
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)
29. RELATED PARTY DISCLOSURES (cont.)
Details
of Directors and Key Management Personnel as at balance date
Directors
●
Mr. Peter Rubinstein (Independent
    Non-Executive & Chairman)
●
Dr. Jerzy Muchnicki (Non-Independent Non-Executive)
●
Dr. Lindsay Wakefield (Independent Non-Executive)
●
Mr. Nicholas Burrows (Independent Non-Executive)
Key
Management Personnel (KMPs)
●
Mr. Simon Morriss (Chief Executive
    Officer) (appointed 1 February 2021)
●
Dr. Richard Allman (Chief Scientific Officer) (ceased
    full-time employment 6 October 2022, then appointed consulting Scientific Advisor)
●
Mr. Tony Di Pietro (Chief Financial Officer) (appointed
    28 November 2022)
●
Mr. Mike Tonroe (Chief Financial Officer) (appointed
    15 June 2021, resigned on 28 November 2022)
●
Mr. Phillip Hains (Chief Financial Officer) (July 15,
    2019 to 15 June 2021)
●
Mr. Stanley Sack (former Chief Operating Officer) (May
    18, 2020 to April 30, 2022)
●
Mr. Kevin Camilleri (Chief Executive Officer of EasyDNA)
    (appointed August 16, 2021)
●
Mr. Carl Stubbings (Chief Commercial Officer) (appointed
    September 1, 2021)
2023
A$
2022
A$
2021
A$
Remuneration of Key Management Personnel
Short-term employee benefits
1,529,124
1,894,413
1,035,302
Post-employment benefits
113,511
125,822
79,042
Share-based payments
253,453
387,046
650,911
Other long-term benefits
10,978
4,797
4,589
Termination benefits
-
-
-
Total remuneration of Key Management Personnel
1,907,066
2,412,078
1,769,844
F-
51
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)
30.
SUBSIDIARIES
The
following diagram is a depiction of the Company structure as at June 30, 2023.
Incorporation
Company interest (%)
Net carrying value (A$)
Name of Company
details
2023
2022
2023
2022
Entities held directly by parent
GeneType Pty. Ltd. (Dormant)
September 5, 1990 Victoria, Australia
100
%
100
%
-
-
Genetic Technologies Corporation Pty. Ltd. (Genetic testing)
October 11, 1996 NSW, Australia
100
%
100
%
2
2
Gene Ventures Pty. Ltd.
(1)
(Dormant)
March 7, 2001 NSW, Australia
100
%
100
%
10
10
GeneType Corporation (Dormant)
December 18, 1989 California, U.S.A.
100
%
100
%
-
-
geneType Inc.
(2)
(formerly Pheno- gen Sciences Inc.)
June 28, 2010 Delaware, U.S.A.
100
%
100
%
11,006
11,006
Hainan Aocheng Genetic Technolo- gies Co Ltd
March 18, 2019 Hong Kong, China
100
%
100
%
-
-
Genetic Technologies HK Ltd
March 18, 2019 Hong Kong, China
100
%
100
%
-
-
Helix Genetics Limited
July 7, 2021 Malta
100
%
100
%
1,910
-
Genetype UK Limited
April 26, 2022 United Kingdom
100
%
100
%
176
-
Total carrying value
13,104
11,018
(1)
On 26 April 2018, the name of RareCellect
    Pty Ltd (ACN 096 135 9847) was changed to Gene Ventures Pty Ltd (ACN 096 135 947)
(2)
On 3 April 2023, the name of Phenogen Sciences Inc.
    was changed to geneType Inc.
31.
FINANCIAL RISK MANAGEMENT
This
note explains the Company's exposure to financial risks and how these risks could affect the Company's future financial performance.
The
Company's risk management is predominantly controlled by the board. The board monitors the Company's financial risk management
policies and exposures and approves substantial financial transactions. It also reviews the effectiveness of internal controls relating
to market risk, credit risk and liquidity risk.
(a)
Market risk
(i)
Foreign exchange risk
The
Company undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange
rate fluctuations.
Foreign
exchange rate risk arises from financial assets and financial liabilities denominated in a currency that is not the Company's functional
currency. Exposure to foreign currency risk may result in the fair value of future cash flows of a financial instrument fluctuating due
to the movement in foreign exchange rates of currencies in which the Company holds financial instruments which are other than the Australian
dollar (AUD) functional currency of the Company. This risk is measured using sensitivity analysis and cash flow forecasting. The cost
of hedging at this time outweighs any benefits that may be obtained.
The
consolidated financial statements are presented in Australian Dollar ($), which is Genetic Technologies Limited's functional and
presentational currency.
F-
52
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)
31. FINANCIAL RISK MANAGEMENT (cont.)
Exposure
The
Company's exposure to foreign currency risk at the end of the reporting period, expressed in Australian dollar, was as follows:
June 30, 2023
June 30, 2022
USD
CAD
EUR
GBP
USD
CAD
EUR
A$
A$
A$
A$
A$
A$
A$
Cash at Bank / on hand
1,296,082
10,766
100,369
41,858
3,299,787
3,318
199,758
Trade and other receivables
611,193
11,252
17,690
26,376
606,075
-
16,033
Trade and other payables
(
455,167
)
(
3,795
)
(
151,327
)
(
31,441
)
(
412,511
)
(
1,652
)
(
46,790
)
Sensitivity
As
shown in the table above, the Company is primarily exposed to changes in USD/AUD exchange rates. The sensitivity of profit or loss to
changes in the exchange rates arises mainly from USD denominated financial instruments.
The
Company has conducted a sensitivity analysis of its exposure to foreign currency risk. Based on the financial instruments held as at
June 30, 2023, had the Australian dollar weakened/strengthened by
3.65
% (2022:
8.3
%) against the USD with all other variables held constant,
the Company's post-tax loss for the year would have been A$
52,988
lower/higher (2022: A$
289,607
lower/higher).
●
USD:
3.65
% (2022:
8.3
%)
The
Company is less sensitive to movements in the AUD/USD exchange rates in 2023 than 2022 because of the reduced amount of USD denominated
cash and cash equivalents. The Company's exposure to other foreign exchange movements is not material.
(b)
Credit risk
Exposure
to credit risk relating to financial assets arises from the potential non-performance by counterparties of contract obligations that
could lead to a financial loss to the Company.
(i)
Risk management
Credit
risk is managed through the maintenance of procedures (such as the utilization of systems for the approval, granting and renewal of credit
limits, regular monitoring of exposures against such limits and monitoring the financial stability of significant customers and counterparties),
ensuring to the extent possible that customers and counterparties to transactions are of sound credit worthiness. Such monitoring is
used in assessing receivables for impairment. Credit terms are normally 30 days from the invoice date.
Risk
is also minimized through investing surplus funds in financial institutions that maintain a high credit rating.
(ii)
Security
For
some trade receivables the Company may obtain security in the form of guarantees, deeds of undertaking or letters of credit which can
be called upon if the counterparty is in default under the terms of the agreement.
(iii)
Impairment of financial assets
The
Company has one type of financial asset subject to the expected credit loss model:
●
trade receivables for sales of inventory
While
cash and cash equivalents are also subject to the impairment requirements of IFRS 9, the identified impairment loss was immaterial.
F-
53
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)
31. FINANCIAL RISK MANAGEMENT (cont.)
(b)
Credit risk (Cont.)
(iii)
Impairment of financial assets (Cont.)
Trade
receivables
The
Company applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for
all trade receivables.
To
measure the expected credit losses, trade receivables assets have been grouped based on shared credit risk characteristics and the days
past due.
(c)
Liquidity risk
Liquidity
risk arises from the possibility that the Company might encounter difficulty in settling its debts or otherwise meeting its obligations
related to financial liabilities. The Company manages this risk through the following mechanisms:
●
preparing forward looking cash flow
    analyses in relation to its operating, investing and financing activities;
●
obtaining funding from a variety of sources;
●
maintaining a reputable credit profile;
●
managing credit risk related to financial assets;
●
investing cash and cash equivalents and deposits at
    call with major financial institutions; and
●
comparing the maturity profile of financial liabilities
    with the realization profile of financial assets.
(i)
Maturities of financial liabilities
The
tables below analyze the Company's financial liabilities into relevant maturity groupings based on their contractual maturities.
The amounts disclosed in the table are the contractual undiscounted cash flows.
Contractual maturities of
Less than
6 months
6
– 12
months
Between 1 and 2 years
Between 2 and 5 years
Over
5
years
Total contrac- tual cash flows
Carrying amount (assets)/ liabilities
financial liabilities
A$
A$
A$
A$
A$
A$
A$
At June 30, 2023
Trade and other payables
1,617,333
-
-
-
-
1,617,333
1,617,333
Lease liabilities
158,316
161,154
208,957
21,636
1,817
551,880
532,846
Total
1,775,649
161,154
208,957
21,636
1,817
2,169,213
2,150,179
Contractual maturities of
Less than 6 months
6
                                            – 12
months
Between 1 and 2 years
Between 2 and 5 years
Over
                                            5
years
Total contrac- tual cash flows
Carrying amount (assets)/ liabilities
financial liabilities
A$
A$
A$
A$
A$
A$
A$
At June 30, 2022
Trade and other payables
2,122,379
-
-
-
-
2,122,379
2,122,379
Lease liabilities
133,507
136,250
255,601
163,896
-
689,254
652,526
Total
2,255,886
136,250
255,601
163,896
-
2,811,633
2,774,905
F-
54
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(cont.)
31. FINANCIAL RISK MANAGEMENT (cont.)
(d)
Interest rate risk
The
Company's main interest rate risk arises in relation to its short-term deposits with various financial institutions. If rates were
to decrease, the Company may generate less interest revenue from such deposits. However, given the relatively short duration of such
deposits, the associate risk is relatively minimal.
The
Company has a Short-Term Investment Policy which was developed to manage the Company's surplus cash and cash equivalents. In this
context, the Company adopts a prudent approach that is tailored to cash forecasts rather than seeking high returns that may compromise
access to funds as and when they are required. Under the policy, the Company deposits its surplus cash in a range of deposits / securities
over different time frames and with different institutions in order to diversify its portfolio and minimize risk.
On
a monthly basis, Management provides the Board with a detailed list of all cash and cash equivalents, showing the periods over which
the cash has been deposited, the name and credit rating of the institution holding the deposit and the interest rate at which the funds
have been deposited.
At
June 30, 2023, if interest rates had changed by +/- 50 basis points from the year-end rates, with all other variables held constant,
the Company's loss for the year would have been A$
31,083
lower / higher (2022: loss A$
40,369
lower / higher), as a result of higher
/ lower interest income from cash and cash equivalents and deposits in place.
The
exposure to interest rate risks and the effective interest rates of financial assets and liabilities, both recognized and unrealized,
for the Company is as follows:
Floating rate
Fixed rate
Carrying amount
Weighted ave. effective rate
Ave. maturity Period
Year
A$
A$
A$
%
Days
Financial assets
Cash at bank / on hand
2023
1,516,646
6,334,551
7,851,197
4.46
At call
2022
1,971,827
9,759,498
11,731,325
1.31
At call
Bonds / deposits
2023
-
17,440
17,440
At call
2022
-
13,257
13,257
-
At call
Totals
2023
1,516,646
6,351,991
7,868,637
2022
1,971,827
9,772,755
11,744,582
Financial liabilities
Borrowings
2023
-
-
-
-
-
2022
-
-
-
-
-
Leases
2023
-
532,846
532,846
4.77
%
-
2022
-
652,526
652,526
4.55
%
-
Totals
2023
-
2022
-
652,526
652,526
F-
55
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (cont.)
32.
CAPITAL MANAGEMENT
(a)
Risk management
The
Company's objectives when managing capital are to:
●
safeguard their ability to continue
    as a going concern, so that they can continue to provide returns for shareholders and benefits for other stakeholders, and
●
maintain an optimal capital structure to reduce the
    cost of capital.
In
order to maintain or adjust the capital structure, the Company may issue new shares or reduce its capital, subject to the provisions
of the Company's constitution. The capital structure of the Company consists of equity attributed to equity holders of the Company,
comprising contributed equity, reserves and accumulated losses. By monitoring undiscounted cash flow forecasts and actual cash flows
provided to the board by the Company's management, the board monitors the need to raise additional equity from the equity markets.
(b)
Dividends
No
dividends were declared or paid to members for the year ended June 30, 2023 (2022:
nil
). The Company's franking account balance
was
nil
at June 30, 2023 (2022:
nil
).
33.
PARENT ENTITY FINANCIAL INFORMATION
The
individual financial statements for the parent entity show the following aggregate amounts:
2023
A$
2022
A$
2021
A$
Statement of Financial Position
Current assets
10,035,224
5,022,689
21,809,918
Non-current assets
4,237,344
5,815,118
2,011,338
Total assets
14,272,568
10,837,807
23,821,256
Current liabilities
2,841,919
2,270,626
1,317,378
Non-current liabilities
314,999
589,745
7,694,668
Total liabilities
3,156,918
2,860,371
9,012,046
Shareholders' equity
Share Capital
161,342,707
155,138,636
153,574,974
Other reserves
(
117,131
)
(
117,131
)
(
117,131
)
Share-based payment
3,917,101
8,937,157
8,499,649
Accumulated losses
(
154,027,027
)
(
155,981,226
)
(
147,148,282
)
Total Equity
11,115,650
7,977,436
14,809,210
Loss for the year
(
3,697,316
)
(
8,833,064
)
(
1,601,672
)
For
the year ended June 30, 2023, A$
30,956,037
impairment loss previously recognized on intercompany loan balances between the parent and
its subsidiaries was reversed (2022:
Nil
, 2021: A$
4,482,965
recognized as impairment loss reversal). The parent entity forgave loan balances
with subsidiaries representing A$
26,072,596
during the year.
34.
CONTINGENT LIABILITIES AND CONTINGENT ASSETS
The
Company is not aware of any contingent liabilities as at June 30, 2023 (2022: There were
no
contingent liabilities or assets).
35.
SUBSEQUENT EVENTS
At
the date of this report there have been no matters or circumstances that have arisen since the end of the period which significantly,
or may significantly affect:
–
The Company's operations
    in future years;
–
The results of those operations
    in future years; or
–
The Company's state
    of affairs in future years.
Australian
Disclosure Requirements
All
press releases, financial reports and other information are available using the stock code GTG on the Australian Securities Exchange
website: www2.asx.com.au
F-
56